<SEC-DOCUMENT>0001193125-25-338281.txt : 20251231
<SEC-HEADER>0001193125-25-338281.hdr.sgml : 20251231
<ACCEPTANCE-DATETIME>20251231160127
ACCESSION NUMBER:		0001193125-25-338281
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20251231
DATE AS OF CHANGE:		20251231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galecto, Inc.
		CENTRAL INDEX KEY:			0001800315
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				371957007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292175
		FILM NUMBER:		251617435

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		45-70-70-52-10

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galecto Inc.
		DATE OF NAME CHANGE:	20200116
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d98130d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR> Registration No. 333-292175 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00z03.jpg" ALT="LOGO" STYLE="width:2.57669in;height:0.453987in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Galecto, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>60,513,309 Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;), of
up to (i) 265,309 shares (&#8220;Merger Common Shares&#8221;) of our common stock, par value $0.00001 per share (&#8220;Common Stock&#8221;), (ii) 16,366,000 shares of Common Stock (&#8220;Merger Conversion Series B Shares&#8221;) issuable upon the
conversion of 16,366 shares (&#8220;Merger Series B Preferred Shares&#8221;) of our Series B Preferred Stock, par value $0.00001 per share (&#8220;Series B Preferred Stock&#8221;), (iii) 4,241,000 shares of Common Stock (&#8220;Merger Conversion
Series C Shares&#8221; and, together with the Merger Conversion Series B Shares, the &#8220;Merger Conversion Shares&#8221;) issuable upon the conversion of 4,241 shares (&#8220;Merger Series C Preferred Shares&#8221; and together with the Merger
Series B Preferred Shares, the &#8220;Merger Preferred Shares&#8221;) of our Series C Preferred Stock, par value $0.00001 per share (&#8220;Series C Preferred Stock&#8221;), and (iv) 39,641,000 shares of Common Stock (the &#8220;Private Placement
Conversion Shares&#8221;) issuable upon the conversion of 39,641 shares of our Series C Preferred Stock (the &#8220;Private Placement Preferred Shares&#8221;). Subject to receiving approval by our stockholders of the issuance of shares of Common
Stock upon conversion of Series B Preferred Stock and Series C Preferred Stock in accordance with Nasdaq rules (the &#8220;Conversion Approval&#8221;) and certain beneficial ownership limitations set by each preferred stockholder, each share of
Series B Preferred Stock may, at the option of the holder, convert into 1,000 shares of Common Stock, and each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock. The shares of Common Stock registered by
this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The Merger Common Shares and Merger Preferred Shares were issued and sold to
former stockholders of Damora Therapeutics, Inc., a Delaware corporation (&#8220;Damora&#8221;), in connection with our acquisition (the &#8220;Asset Acquisition&#8221;) of Damora, which closed on November&nbsp;10, 2025. The Private Placement
Preferred Shares were issued and sold to accredited investors in a private placement (the &#8220;PIPE&#8221; and, together with the Asset Acquisition, the &#8220;Transactions&#8221;), which closed on November&nbsp;12, 2025. We are not offering or
selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at
the time of sale, on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or
using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#8220;Plan of
Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling
Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">You
should carefully read this prospectus and any applicable prospectus supplement, as well as any documents incorporated by reference herein or therein, before you invest in any of the securities being offered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Our Common Stock is traded on the Nasdaq Capital Market under the symbol &#8220;GLTO.&#8221; On December&nbsp;15, 2025, the last reported sales price for our
Common Stock was $31.60 per share. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading &#8220;<A HREF="#tx98130_4">Risk
 Factors</A>&#8221; beginning on page 51 of this prospectus and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is December 23, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_5">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_9">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx98130_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC using a &#8220;shelf&#8221;
registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell the securities described in this prospectus in one or more offerings. Information about the Selling Stockholders may change
over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities the Selling Stockholders may offer. Each time the Selling
Stockholders sell shares of Common Stock using this prospectus, to the extent necessary and required by law, we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the number of
shares of Common Stock being offered, the manner of distribution, the identity of any underwriters or other counterparties and other specific terms related to the offering. The prospectus supplement may also add, update or change information
contained in this prospectus. To the extent that any statement made in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the
prospectus supplement. You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an investment in shares of our Common Stock. See &#8220;Where You Can Find
More Information&#8221; for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference information that you should consider when making
your investment decision. Neither we nor the Selling Stockholders have authorized anyone to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. The Selling Stockholders are
offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not
constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any
circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference herein and any related free writing prospectus is
accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise requires, the terms &#8220;Galecto,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and
&#8220;our&#8221; refer to Galecto, Inc., a Delaware corporation, and, where appropriate, its consolidated subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains trade
names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the
<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to &#8220;our product candidates,&#8221; &#8220;our
programs&#8221; and &#8220;our pipeline&#8221; in this prospectus include the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to that certain antibody discovery and option
agreement by and among Damora, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paramora Holding LLC (&#8220;Paramora&#8221;), dated October&nbsp;7, 2025 (the &#8220;Paragon Option Agreement&#8221;), which we assumed pursuant to the Asset
Acquisition. As of the date of this prospectus, we have exercised the option for <FONT STYLE="white-space:nowrap">DMR-001.</FONT> We have not exercised the option for <FONT STYLE="white-space:nowrap">DMR-002</FONT> or
<FONT STYLE="white-space:nowrap">DMR-003</FONT> or entered into a license agreement for <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> or <FONT STYLE="white-space:nowrap">DMR-003.</FONT> We expect to
finalize the <FONT STYLE="white-space:nowrap">DMR-001</FONT> license agreement in the first quarter of 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors outside of the United States,
neither we nor the Selling Stockholders have done anything that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are
required to inform yourselves about and to observe any restrictions relating to the offering and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_2"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains <FONT STYLE="white-space:nowrap">&#8220;forward-looking</FONT>
statements&#8221; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements involve a number of risks and uncertainties. We caution readers that any <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement is not a guarantee of future performance and that
actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements, other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: the Conversion
Approval; our ability to achieve the expected benefits or opportunities and related timing with respect to the Asset Acquisition of Damora, our future results of operations and financial position, business strategy, the length of time that we
believe our existing cash resources will fund our operations, our market size, our potential growth opportunities, our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential
therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials, the expected impact of adverse macroeconomic conditions, including inflation, slower growth or recession, new or
increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), volatility in financial markets and other challenges in the global economy,
and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking
statements generally relate to future events or our future financial or operating performance. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions
that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly
changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference include those discussed in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed
or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement. You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by
the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to
reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect
to those or other forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus and the
information incorporated by reference in this prospectus carefully, including &#8220;Risk Factors&#8221; and the financial data and related notes and other information incorporated by reference herein, before making an investment decision. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this prospectus include the research
programs with respect to which we have the option to acquire intellectual property license rights to pursuant to that certain antibody discovery and option agreement by and among Damora, Paragon and Paramora, dated October&nbsp;7, 2025 (the
&#8220;Paragon Option Agreement&#8221;), which we assumed pursuant to the Asset Acquisition. As of the date of this prospectus, we have exercised the option for <FONT STYLE="white-space:nowrap">DMR-001.</FONT> We have not exercised the option for <FONT
STYLE="white-space:nowrap">DMR-002</FONT> or <FONT STYLE="white-space:nowrap">DMR-003</FONT> or entered into a license agreement for <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> or <FONT
STYLE="white-space:nowrap">DMR-003.</FONT> We expect to finalize the <FONT STYLE="white-space:nowrap">DMR-001</FONT> license agreement in the first quarter of 2026. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company
developing therapies for the treatment of hematological malignancies. In our recently announced Asset Acquisition, we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms
(&#8220;MPNs&#8221;), a group of related, chronic cancers of the bone marrow. Our lead product candidate, <FONT STYLE="white-space:nowrap">DMR-001,</FONT> targets mutant forms of the calcium binding protein calreticulin (&#8220;CALR&#8221;) which
are collectively known as mutCALR. We have the option to license exclusive worldwide development and commercialization rights to <FONT STYLE="white-space:nowrap">DMR-001</FONT> from Paragon pursuant to the Paragon Option Agreement. We intend to
develop <FONT STYLE="white-space:nowrap">DMR-001</FONT> for the treatment of essential thrombocythemia (&#8220;ET&#8221;), an MPN associated with the overproduction of platelets, and myelofibrosis (&#8220;MF&#8221;), an MPN involving the
overproliferation of blood cells in the bone marrow. In contrast to marketed therapies for ET, <FONT STYLE="white-space:nowrap">DMR-001</FONT> is designed to selectively target cells that express mutCALR while avoiding the adverse effects associated
with <FONT STYLE="white-space:nowrap">non-specific</FONT> cytoreductive drugs. We believe that the potential combination of increased<I> </I>clinical activity and improved pharmacokinetics of <FONT STYLE="white-space:nowrap">DMR-001</FONT> positions
it as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapy for ET, MF and other mutCALR-related diseases. In addition to two other mutCALR-targeting product candidates, <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003,</FONT> for which we also have the option to license exclusive worldwide development and commercialization rights from Paragon pursuant to the Paragon Option
Agreement, our portfolio includes GB3226, a small molecule inhibitor of <FONT STYLE="white-space:nowrap">ENL-YEATS</FONT> and FLT3 for the treatment of acute myeloid leukemia (&#8220;AML&#8221;). Based on our preclinical results, we believe that
GB3226 has the potential to treat a broad portion of the AML patient population, including those patients who have high-risk genetic mutations. We intend to initiate clinical development of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and GB3226 in 2026, and <FONT STYLE="white-space:nowrap">DMR-003</FONT> in 2027. Pursuant to the Paragon Option Agreement, we have engaged Paragon to execute a mutually agreed research plan for <FONT
STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> aimed at producing potential product candidates to be licensed for further development, manufacture and
commercialization by us. The research plan activities performed by Paragon for us primarily include preclinical studies and are overseen by a joint development committee comprised of our employees and employees of Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MPNs are caused by excessive proliferation of myeloid cells. In some patients, including ET patients, MPNs are considered chronic diseases that lead to
significant decreases in quality of life, but are not associated with increased mortality. MPNs also include MF, which is associated with poor prognosis and increased mortality. One feature that makes MPNs attractive indications for drug development
is that mutations in just a small number of genes are responsible for a significant percentage of cases, which enables the opportunity to develop targeted therapies. Our ultimate goal is to develop a portfolio of targeted mutation-directed
candidates to address the full spectrum of MPN disease. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMR-001</FONT> is a monoclonal antibody that targets mutations in CALR,
including the two major forms referred to as Type 1 and Type 2 mutCALR. CALR mutations are the drivers of about a quarter of all cases of ET, a disease with a prevalence in the United States of about 140,000 patients. ET is characterized by
excessive production of platelets, leading to symptoms that range from tingling or burning in the hands and feet to headache, visual problems, weakness, dizziness and vascular problems such as heart attacks and stroke. Approximately 17% of ET
patients progress to MF, a disease with a prevalence in the United States of about 20,000 patients. CALR mutations are also the driver of about 35% of all cases of MF. MF is characterized by scarring of the bone marrow, which interferes with the
body&#8217;s ability to produce healthy blood cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary goal in the treatment of ET is to lower platelet counts. Current treatments, including
drugs such as hydroxyurea and anagrelide, are not designed to be selective for platelets affected by mutCALR. <FONT STYLE="white-space:nowrap">DMR-001</FONT> is designed to specifically block proliferation of platelets containing mutCALR, without
impairing normal platelets and other types of blood cells. Third-party Phase 1 data from INCA033989, an antibody therapy in development by Incyte Corporation (&#8220;Incyte&#8221;), demonstrated clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for the potential of targeting mutCALR with an antibody therapy. In this Phase 1 trial, INCA033989 treatment led to a rapid and sustained reduction of mutCALR platelets and no reported cases
of thrombocytopenia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">DMR-001</FONT> has the potential to become a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> anti-mutCALR therapy due to two differentiating features compared to marketed therapies and therapies in development, including INCA033989. First, our preclinical studies demonstrated that <FONT
STYLE="white-space:nowrap">DMR-001</FONT> is a more potent inhibitor of mutCALR-dependent cell proliferation compared to a reference mutCALR targeted monoclonal antibody. This is especially relevant with regard to patients with Type 2 mutCALR, which
represent about a third of mutCALR patients. Whereas Type 1 mutations are characterized by a deletion of 52 base pairs in the gene for CALR, Type 2 mutations have an insertion of 5 base pairs. Our preclinical assays demonstrated that <FONT
STYLE="white-space:nowrap">DMR-001</FONT> has approximately <FONT STYLE="white-space:nowrap">ten-fold</FONT> higher potency on Type 2 mutCALR than a reference mutCALR antibody with the same mechanism of action as INCA033989. Second, <FONT
STYLE="white-space:nowrap">DMR-001</FONT> was engineered to have an increased half-life in circulation through the incorporation of sequence modifications that have previously been shown to improve pharmacokinetics in humans. Our preclinical data
generated in <FONT STYLE="white-space:nowrap">non-human</FONT> primates (&#8220;NHPs&#8221;), confirmed the improved half-life of <FONT STYLE="white-space:nowrap">DMR-001</FONT> compared to a reference antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected combination of increased clinical activity and longer half-life is predicted to enable the delivery of sufficient amounts of <FONT
STYLE="white-space:nowrap">DMR-001</FONT> via subcutaneous injection to match and potentially exceed the reported efficacy of the highest dose of INCA033989 that was intravenously administered in Incyte&#8217;s Phase 1 trial. We believe such a
subcutaneous formulation is critically important for the treatment of ET patients because it provides a more convenient dosing option for such patients, some of whom have a life expectancy of at least 35 years after diagnosis and thus require
long-term treatment. We intend to file an Investigational New Drug application (&#8220;IND&#8221;), or equivalent, for <FONT STYLE="white-space:nowrap">DMR-001</FONT> in <FONT STYLE="white-space:nowrap">mid-2026</FONT> and initiate a Phase 1 trial
in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are developing <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003,</FONT> both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. We intend to file an IND or Clinical
Trial Notification, or equivalent, for <FONT STYLE="white-space:nowrap">DMR-002</FONT> in the second half of 2026 and for <FONT STYLE="white-space:nowrap">DMR-003</FONT> in 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GB3226 is a small molecule product candidate which we intend to develop to treat AML, a highly aggressive leukemia. Firstline therapy for AML typically
involves cytotoxic chemotherapy, a treatment regimen that has tolerability issues and that especially older patients cannot tolerate. These patients and those in whom the disease is not otherwise controlled are treated with a number of targeted
therapies that address specific genetic alterations that lead to AML. Unfortunately, these therapies fail to result in long-term disease suppression in the majority of patients. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that GB3226 can overcome some of these limitations through its ability to simultaneously inhibit
two targets that are key drivers of AML. The first of these is ENL YEATS, a transcription regulator that is implicated in AML pathogenesis through genetic alterations. The second is FLT3, a clinically validated target. We believe that GB3226 has the
potential to limit the ability of AML cells to develop resistance by requiring changes in two independent pathways. The superior anti-tumor activity of GB3226 compared to approved AML therapies has been demonstrated preclinically. We intend to file
an IND for GB3226 in AML patients in the first quarter of 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our product candidates and programs and their current stage of development. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g98130g00z10.jpg" ALT="LOGO" STYLE="width:6.29in;height:3.73667in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to develop potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies to treat a range of
hematologic malignancies, including AML and MPNs such as ET and MF. Our strategy to achieve this is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiate clinical development of <FONT STYLE="white-space:nowrap">DMR-001.</FONT> </B>Our preclinical results
have shown that <FONT STYLE="white-space:nowrap">DMR-001</FONT> has improved potency and pharmacokinetics compared to a reference antibody with the same mechanism of action as INCA033989, a molecule for which impressive Phase 1 clinical results in
the treatment of ET and initial data in MF have been reported. We plan to file an IND or equivalent for <FONT STYLE="white-space:nowrap">DMR-001</FONT> for the treatment of ET and MF patients in <FONT STYLE="white-space:nowrap">mid-2026</FONT> and
initiate a Phase 1 trial in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Invest early in preparation for late-stage development of <FONT STYLE="white-space:nowrap">DMR-001.</FONT></B>
Although <FONT STYLE="white-space:nowrap">DMR-001</FONT> is not the first anti-mutCALR antibody to enter the clinic, we believe that it has the potential to be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class.</FONT></FONT> We intend to be in a position to execute additional clinical trials for <FONT STYLE="white-space:nowrap">DMR-001</FONT> in response to both the results
that we generate and to those of our competitors, with the intent of minimizing unnecessary delays. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT>
into clinical development. </B>We are developing mutCALR targeted therapies that are designed to be even more potent than <FONT STYLE="white-space:nowrap">DMR-001</FONT> with the goal of addressing the full spectrum of mutCALR-driven MPNs. We
anticipate filing an IND or equivalent for <FONT STYLE="white-space:nowrap">DMR-002</FONT> in the second half of 2026 and for <FONT STYLE="white-space:nowrap">DMR-003</FONT> in 2027. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiate clinical development of GB3226.</B> We believe that the dual action of GB3226 provides an opportunity
to demonstrate improved and more durable anti-tumor activity than current therapies. We intend to file an IND for GB3226 in patients with AML in the first quarter of 2026. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MPNs &#8211; a spectrum of diseases with high unmet medical need </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MPNs are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. The three most common
MPNs are MF, ET, and polycythemia vera (&#8220;PV&#8221;). Common symptoms of MPNs include fatigue, itching, weight loss, night sweats, fever, difficulty breathing, abdominal swelling and discomfort due to spleen enlargement, bruising and stroke,
all of which can be devastating and debilitating. Patients with ET and PV can progress to MF, and all MPN patients have a risk that their cancer progresses into AML, a hematological malignancy with a five-year survival rate of 33% . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MPNs generally arise from mutations in the blood-forming stem cells of the bone marrow. The most commonly mutated genes observed in MPNs are Janus-associated
kinase 2 (&#8220;JAK2&#8221;), CALR, and myeloproliferative leukemia virus oncogene (&#8220;MPL&#8221;). These mutations lead to constitutive or <FONT STYLE="white-space:nowrap">always-on</FONT> activation of signaling pathways that, when
over-activated, drive the aberrant production of blood cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">DMR-001,</FONT> a product candidate designed to treat
mutCALR-driven MPNs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMR-001</FONT> is a monoclonal antibody that targets mutCALR, a mutant protein that is believed
to be a critical driver of approximately 25% of ET cases and 35% of MF cases. Third-party phase 1 clinical data for INCA033989, an anti-mutCALR antibody, demonstrated that direct targeting of mutCALR can lead to rapid and sustained reduction in
excess platelets, the key pathology in ET. <FONT STYLE="white-space:nowrap">DMR-001</FONT> is designed to improve on the clinical activity and pharmacokinetics of INCA033989, which we believe will provide the opportunity to capture a sizable portion
of the mutCALR ET market. We anticipate filing an IND, or equivalent, for <FONT STYLE="white-space:nowrap">DMR-001</FONT> in <FONT STYLE="white-space:nowrap">mid-2026</FONT> and initiating a Phase 1 trial in ET and MF patients with a subcutaneous
formulation thereafter, subject to regulatory approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ET background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ET, an MPN with excessive platelet production, is associated with an increased risk of thrombosis and bleeding. The annual incidence of ET in the United States
is 1.5/100,000 persons. The prevalence in the United States is approximately 140,000 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Excessive levels of platelets in ET are associated with
increased risk of serious conditions such as arterial thrombosis, venous thrombosis and hemorrhagic complications. In addition, patients with ET can experience symptoms that include tingling or burning in the hands and feet, headache, visual
problems, weakness and dizziness. These symptoms and others result from excessive numbers of platelets causing blockages in small or large blood vessels in different parts of the body that can reduce patients&#8217; quality of life. More serious
potential complications include an increased risk of blood clots, causing heart attacks and strokes, as well as an increase in the risk of hemorrhage that rises with the platelet count. The median age at diagnosis of ET is 59 years. ET is considered
a chronic disease in most patients with a median overall survival that exceeds 35 years in those diagnosed at 40 years or younger. A significant fraction of ET patients, progress to more aggressive cancers, including 17% who develop MF and 3% who
develop AML. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 90% of individuals with ET have genetic variants that upregulate the <FONT
STYLE="white-space:nowrap">JAK-STAT</FONT> signaling pathway, including JAK2, CALR or MPL, which encodes the thrombopoietin (&#8220;TPO&#8221;) receptor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t12.jpg" ALT="LOGO" STYLE="width:5.92in;height:4.88333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 1. Mutations that drive JAK/STAT signaling, including those in JAK2, CALR and MPL are the primary
causes of ET </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main treatment objective for patients with ET is to lower platelet levels to the normal range. About 30% to 40% of ET patients are
classified as lower-risk patients who have elevated platelet counts without a history of clotting events. These patients are often treated with aspirin alone. The remaining ET patients carry a higher risk of clotting and bleeding. These patients are
generally treated with hydroxyurea, which is not approved for the treatment of ET in the United States. Hydroxyurea does not alter the underlying disease process and, as a result, disease progression may continue in some patients. Long-term use of
hydroxyurea is also associated with the development of mucosal ulcers, actinic keratosis and an increased risk of skin cancer. Anagrelide, an inhibitor of the maturation of megakaryocytes to platelets, is approved to treat ET but is associated with
cardiotoxicity. Although 59% of ET patients have mutations in JAK2, inhibitors of JAK kinase, such as ruxolitinib, are not routinely used. Ruxolitinib is not approved to treat ET, as it failed to improve response rates and is associated with a
number of toxicities that are barriers to widespread use. Interferon has also been reported to reduce platelet counts in ET patients in a small number of clinical trials, but it has not been approved for this indication. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MF disease overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MF is a MPN characterized by abnormal myeloid cell proliferation leading to inflammation and a fibrotic response in the bone marrow. This results in bone
marrow scarring, splenomegaly, elevated cytokine levels, and marrow dysfunction. Symptoms include fatigue, easy bruising and bleeding, night sweats and fever. At the time of diagnosis, 35% to 54% of patients with MF have anemia. Within a year of
diagnosis, 60% of patients develop anemia and 46% of all patients require treatment with red blood transfusions. Anemia is the disease feature most consistently associated with poor prognosis in MF. Up to 20% of MF patients will ultimately develop
AML. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the median age of MF diagnosis is around 65 years, disease-associated complications are often compounded by concurring medical conditions
such as diabetes, hypertension, atherosclerotic or pulmonary disease, and obesity. Patients with intermediate-risk disease have a median overall survival of about five years which decreases to two years in those with high-risk disease. Common fatal
complications include transformation into AML, thrombohemorrhagic events, organ failure, and infections. The prevalence of MF in the United States is estimated at 20,000 patients. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t13.jpg" ALT="LOGO" STYLE="width:6.19333in;height:4.11333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 2. Median overall survival for patients with MF </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current treatments for MF </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The only current
curative treatment for MF is allogeneic hematopoietic stem cell transplantation (&#8220;HSCT&#8221;); however, this procedure has both significant morbidity and a high mortality rate. Because many patients diagnosed with MF are elderly and have
other comorbidities, only a minority are eligible for this treatment. In other patients, inhibitors of cell proliferation are used such as JAK kinase inhibitors or chemotherapy agents. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These therapies, however, increase the risk of anemia, reduce platelet counts causing increased risk of bleeding and bruising, and reduce white blood cell counts, a condition known as
neutropenia, resulting in increased risk of serious infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management of anemia can be one of the most challenging aspects of treating patients with
MF. In patients with mild anemia, erythropoiesis stimulating agents, are used to stimulate red blood cell formation. Other patients are treated with steroids, including danazol, which lead to increases in hemoglobin (&#8220;Hb&#8221;), levels with a
mean response time of five months in 30% of patients. Patients with more serious anemia are treated with blood transfusions, but over time, repeated transfusions lead to the development of iron overload, alloantibodies, and other toxicities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there remains a substantial unmet need for new therapies that can reduce disease symptoms and slow progression for MF patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential of targeting mutCALR </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that mutCALR
is a highly desirable target in oncology given its clear role as a disease driver. CALR normally functions as a calcium-binding chaperone that is active in three areas: intracellularly, on the cell surface, and extracellularly. However, in patients
who have deleterious mutations, the gene for CALR is mutated so that the DNA transcription machinery does not stick to the normal reading frame. This <FONT STYLE="white-space:nowrap">so-called</FONT> frameshift occurs in the protein-coding region of
the gene and it results in the synthesis of mutCALR proteins that contain an amino acid sequence at the <FONT STYLE="white-space:nowrap">C-terminal</FONT> end of the protein that is not present in normal CALR. In response to this additional
sequence, these mutCALR proteins begin to drive abnormal cell proliferation by gaining the ability to bind to and stimulate signaling through a receptor known as the TPO receptor. TPO activation, in turn, activates the JAK/STAT pathway, a well-known
pathway leading to cell proliferation. It is this JAK/STAT pathway activation which, in turn, drives the unhealthy proliferation of myeloid cells. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t14.jpg" ALT="LOGO" STYLE="width:5.94667in;height:4.98333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 3. mutCALR leads to <FONT STYLE="white-space:nowrap">TPO-independent</FONT> activation of JAK/STAT
signaling </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of CALR mutations associated with ET are classified as Type 1 mutations (52 bp deletion) or Type 2 mutations (5 bp insertion)
depending on the size and location of the frameshift causing genetic changes. Both Type 1 and Type 2 mutations result in a novel, shared mutant <FONT STYLE="white-space:nowrap">C-terminal</FONT> domain. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t15.jpg" ALT="LOGO" STYLE="width:4.03337in;height:4.04004in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 4. Two types of mutCALR account for 85% of CALR mutations in ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the critical role of mutCALR in stimulating cell proliferation, several other factors make mutCALR an especially attractive drug target. First,
the frameshift mutations that create mutCALR lead to the expression of a protein domain that is not present in wild-type (&#8220;WT&#8221;) CALR, thereby providing an opportunity to specifically target mutCALR and avoid potential consequences of
binding to CALR on healthy cells. Second, due to the deletion of the <FONT STYLE="white-space:nowrap">ER-localization</FONT> signal that occurs when mutated, mutCALR localizes to the cell surface while WT CALR does not. Third, the pathology of
mutCALR appears to be limited to its ability to activate the TPO receptor which is primarily expressed on platelets and hematopoietic progenitor cells that give rise to platelets, providing the ability to selectively and specifically target the root
cause of the pathological cell proliferation. Fourth, mutations in CALR are mutually exclusive with other driver mutations, providing an opportunity to block oncogenic signaling through selective mutCALR inhibition with less potential for
resistance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A recent third-party advancement in the treatment of ET </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2025, Incyte announced results from two Phase 1 clinical trials of INCA033989 which included ET patients resistant or intolerant to prior cytoreductive
therapy. Incyte reported that intravenous doses of INCA033989 led to a rapid and sustained reduction in platelets. Furthermore, biweekly doses greater than 400 mg were associated with a trend towards improved responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INCA033989 was well tolerated with no dose-limiting toxicities in this trial. There was only one discontinuation out of 49 patients treated due to a
treatment-emergent adverse event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Single cell sequencing in clinical responders showed that INCA033989 reduced the percentage of cells carrying mutCALR
including early blood-forming cells and cells in the myeloid-lineage. At the same time, there was a </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clear increase in cells expressing normal CALR, suggesting that the treatment supports the return of normal blood production. Bone marrow biopsies further confirmed these effects and demonstrated
fewer megakaryocytes expressing mutCALR protein and a notable increase in megakaryocytes not expressing mutCALR protein. Together, these findings demonstrated that INCA033989 led to a rapid decrease in platelets as well as a trend towards
normalization of healthy hematopoiesis. Further, deep reductions in the frequency of mutCALR alleles, also known as variant allele frequency (&#8220;VAF&#8221;), were reported at the higher doses tested, with 47% and 21% of evaluated patients
achieving greater than 20% and greater than 50% VAF reductions, respectively. These findings are consistent with our belief that an anti-mutCALR antibody has the potential to trigger a rapid hematologic response and to result in long-term disease
modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results reported from the Phase 1 trials of INCA033989 showed an overall response rate of 83%, however the response to treatment was lower
in patients with Type 2 mutCALR compared to those with Type 1 mutations. We believe that these results demonstrate both the clinical potential of anti-mutCALR therapy in ET and the need for more potent therapies against Type 2 mutations, which
represent a third of mutCALR patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, <FONT STYLE="white-space:nowrap">DMR-001</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMR-001</FONT> is an anti-mutCALR monoclonal antibody designed to improve the ability to treat all patients that have either
Type 1 or Type 2 mutCALR. <FONT STYLE="white-space:nowrap">DMR-001</FONT> is engineered to have improved potency against both Type 1 and Type 2 mutCALR, which we believe will provide the potential to treat patients with both classes of mutations at
lower doses than may be required using INCA033989. Furthermore, <FONT STYLE="white-space:nowrap">DMR-001</FONT> contains modifications that are known to increase the half-life of antibodies in circulation. We believe that the increased potency and
associated improvements in the half-life of <FONT STYLE="white-space:nowrap">DMR-001</FONT> will enable infrequent subcutaneous dosing and result in more convenience for patients compared to treatment with INCA033989, which is currently dosed by
intravenous infusion every two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our preclinical studies, <FONT STYLE="white-space:nowrap">DMR-001</FONT> demonstrated approximately three-fold
greater inhibition of cell proliferation of a cell line that is dependent on Type 1 mutCALR than a reference mutCALR antibody with the same mechanism of action as INCA033989. In this<I> in vitro </I>assay, the proliferation of Ba/F3 cells was
engineered to be dependent on Type 1 mutCALR and the TPO receptor. At 72 hours, <FONT STYLE="white-space:nowrap">DMR-001</FONT> led to more potent inhibition of proliferation than the reference antibody. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t16.jpg" ALT="LOGO" STYLE="width:5.41333in;height:4.45in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 5. <FONT STYLE="white-space:nowrap">DMR-001</FONT> was more potent than a reference mutCALR
antibody in a Type 1 mutCALR-dependent cell assay </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a similar assay in which the Ba/F3 cells were engineered to be dependent on a Type 2 mutCALR, <FONT
STYLE="white-space:nowrap">DMR-001</FONT> had an approximately <FONT STYLE="white-space:nowrap">ten-fold</FONT> greater inhibition of cell proliferation than the reference antibody. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t17.jpg" ALT="LOGO" STYLE="width:5.44in;height:4.46in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 6. <FONT STYLE="white-space:nowrap">DMR-001</FONT> was more potent than a reference mutCALR
antibody in a Type 2 mutCALR-dependent cell assay </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">High-molecular-weight biologics, such as antibodies, are routinely dosed via intravenous or
subcutaneous administration. Subcutaneous administration has certain advantages in that patients can be dosed either during a clinic visit or via self-administered dosing at home, e.g., with an auto-injector, instead of receiving an hours-long
intravenous administration in a hospital or infusion center. Subcutaneous administration is not only more convenient and desirable to patients, it also reduces the burden on healthcare facilities by lowering the cost of administration and increasing
the number of patients who can be treated in a given time. The ability to administer treatment by subcutaneous injection is especially important for the treatment of chronic diseases, such as ET, for which patients may require treatment over years
or even decades. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">DMR-001</FONT> has been engineered to have an extended half-life based on specific modifications that
have been shown to extend the half-life of antibodies by three- to four-fold in other third-party therapies. In our preclinical studies, <FONT STYLE="white-space:nowrap">DMR-001</FONT> had a five-fold longer half-life in NHPs compared to a reference
mutCALR antibody that lacked these modifications. We believe that the extended half-life observed in NHPs with <FONT STYLE="white-space:nowrap">DMR-001</FONT> has the potential to carry over into clinical development, as the half-life of other
antibodies in NHPs, including those engineered to have extended half-lives, has been shown to correlate with that observed in humans. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t18.jpg" ALT="LOGO" STYLE="width:5.43667in;height:3.98333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 7. <FONT STYLE="white-space:nowrap">DMR-001</FONT> had a five-fold longer half-life in <FONT
STYLE="white-space:nowrap">non-human</FONT> primates than a reference mutCALR antibody </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the potential combination of the increased
potency of <FONT STYLE="white-space:nowrap">DMR-001</FONT> combined with its longer half-life provides the opportunity to gain a competitive advantage to existing anti-mutCALR antibodies in development, such as INCA033989. We believe the combination
of these enhancements provides the opportunity for low doses of <FONT STYLE="white-space:nowrap">DMR-001</FONT> to be administered subcutaneously using an autoinjector and for <FONT STYLE="white-space:nowrap">DMR-001</FONT> potentially to be
administered less frequently than INCA033989. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To estimate the potential impact of the increased potency and the improved half-life of <FONT
STYLE="white-space:nowrap">DMR-001,</FONT> we modeled the pharmacokinetics of <FONT STYLE="white-space:nowrap">DMR-001</FONT> and compared that to the maximum dose of 2500 mg INCA033989 that was tested and led to clinical responses in Incyte&#8217;s
Phase 1 trials. We believe that it is feasible for subcutaneous doses administered approximately every four weeks or less frequently to deliver sufficient <FONT STYLE="white-space:nowrap">DMR-001</FONT> to match what is known as the C<SUB
STYLE="font-size:75%; vertical-align:bottom">trough</SUB>, the lowest concentration of drug substance before administration of the subsequent dose, of 2500 mg of INCA033989 when INCA033989 is delivered intravenously biweekly. We note that this
analysis is based on an improvement in activity against Type 2 mutCALR for <FONT STYLE="white-space:nowrap">DMR-001</FONT> of only <FONT STYLE="white-space:nowrap">two-fold,</FONT> which is substantially lower than the
<FONT STYLE="white-space:nowrap">ten-fold</FONT> improvement that we observed in our <I>in vitro</I> experiments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the increased potency
and improved pharmacokinetics of <FONT STYLE="white-space:nowrap">DMR-001</FONT> as well as the anticipated subcutaneous doses have the potential for <FONT STYLE="white-space:nowrap">DMR-001</FONT> to match doses of INCA033989 that have demonstrated
meaningful clinical results in ET in third party clinical trials. We believe that the improved properties of <FONT STYLE="white-space:nowrap">DMR-001</FONT> may provide the opportunity to not only simplify dosing, but also to increase the response
rates in ET patients with Type 2 mutCALR mutations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98130g00t19.jpg" ALT="LOGO" STYLE="width:5.42333in;height:4.08in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 8. Pharmacologic modeling suggests that subcutaneous doses of
<FONT STYLE="white-space:nowrap">DMR-001</FONT> can match the clinical activity of the highest dose of INCA033989 tested in the clinic </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate
filing an IND, or equivalent, in <FONT STYLE="white-space:nowrap">mid-2026</FONT> and initiating a Phase 1 trial of a subcutaneous formulation in ET and MF patients thereafter, subject to regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although ET is a chronic disease that typically requires lifelong management, about 17% of patients with mutCALR ET progress to MF, a life-threatening
condition. In addition, primary MF can occur, where patients are newly diagnosed with MF without any contributing progression from ET. Primary MF has an incidence in the United States of 3,700 to 3,900 new patients per year. Third-party clinical
data of INCA033989 demonstrated promising activity as a monotherapy and as a combination therapy in reducing anemia and spleen volume, as well as improving symptoms in mutCALR MF patients. We anticipate that some MF patients with mutCALR may also
respond to <FONT STYLE="white-space:nowrap">DMR-001</FONT> treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are developing two additional anti-mutCALR product candidates: <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003,</FONT> a bispecific CD3 x anti-mutCALR T cell engager. We plan to disclose specifics about both of these product candidates as they advance into formal clinical
development. We anticipate filing an IND, or equivalent, for <FONT STYLE="white-space:nowrap">DMR-002</FONT> in the second half of 2026 and for <FONT STYLE="white-space:nowrap">DMR-003</FONT> in 2027. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GB3226 for the treatment of AML </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GB3226 is a dual
inhibitor of two drivers of AML progression: ENL YEATS and FLT3. GB3226 has been shown to have potent anti-tumor activity in animal models. We plan to submit an IND to evaluate GB3226 in AML in the first quarter of 2026. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AML disease background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AML is a hematologic malignancy characterized by excessive proliferation of myeloid stem cells and their failure to properly differentiate into mature blood
cells. AML is the second most common subtype of leukemia in adults. There are an estimated 22,000 new diagnoses of AML each year in the United States. AML is generally a disease of older people, with more than 60% of diagnosed patients older than 60
years. The average five-year survival rate for patients with AML is 32.9%, but there are significant differences in prognosis depending on several factors including the age of the patient at diagnosis and the genetic driver of disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recommended treatment for AML for patients younger than 60 years and for older patients who can tolerate intensive chemotherapy is a regimen referred to
as 7+3. Patients undergoing this regimen are dosed continuously for seven days with cytarabine along with short infusions of daunorubicin on days one through three. This is a very toxic and taxing treatment. Patients who cannot tolerate this therapy
can be treated with a combination of venetoclax, marketed as Venclexta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by AbbVie Inc., and chemotoxins such as azacytidine, decitabine, or <FONT STYLE="white-space:nowrap">low-dose</FONT>
cytarabine. A subset of patients can be treated with one of several targeted therapies approved for the treatment of AML: enasidenib for patients with mutations in IDH2, marketed as Idhifa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by
Bristol Myers Squibb Company and Servier Pharmaceuticals (&#8220;Servier&#8221;); ivosidenib for patients with mutations in IDH1, marketed as Tibsovo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Servier; revumenib for patients with
KMT2A rearrangements or nucleophosmin-1 gene (&#8220;NPM1&#8221;) mutations (&#8220;NPM1m&#8221;), marketed as Revuforj<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Syndax Pharmaceuticals Inc.; ziftomenib for patients with NPM1m,
marketed as Komzifti<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Kura Oncology, Inc. and Kyowa Kirin Co., Ltd.; and a series of drugs approved for patients with genetic alterations in FLT3 including gilteritinib, marketed as Xospata<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Astellas Pharma Inc., and quizartinib, marketed as Vanflyta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Daiichi Sankyo, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither intensive chemotherapy nor targeted therapies are curative in most patients. The primary goal of these therapies is to induce disease remission,
allowing the patient to undergo a potentially curative HSCT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite these advances, for patients who do achieve remission, five-year survival is only
30% to 40% because the majority of patients relapse. Patients in the elderly population have a far worse prognosis with a <FONT STYLE="white-space:nowrap">five-year</FONT> survival rate of less than 10%. There remains a significant need for safe,
durable and broadly effective AML treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global AML therapy market is estimated at over $3&nbsp;billion currently and is projected to grow
significantly to over $6&nbsp;billion by 2030 driven by sales of existing and new targeted agents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic potential of inhibitors of ENL YEATS
and FLT3 in AML </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Epigenetics is a central mechanism of gene regulation. Whereas DNA code holds the instructions for making RNA and protein,
epigenetics controls which sections of the DNA are read in specific cells. Points of epigenetic intervention include the <FONT STYLE="white-space:nowrap">so-called</FONT> histones, the backbone proteins that DNA is wrapped around in the nucleus, as
well as regulatory proteins such as transcription factors. Intervening at the level of transcription factors or histones can bring powerful control to cell proliferation. The chromatin reader eleven&#8211;nineteen leukemia (&#8220;ENL&#8221;)
protein, acts as a transcription factor, binding to acetylated histone through a protein domain called the YEATS domain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The human genome encodes four
YEATS domain-containing proteins: ENL, AF9, GAS41 and YEATS2. These proteins have been found in nuclear complexes with a variety of molecular functions spanning chromatin remodeling, histone modification and transcription, and they have been
increasingly implicated in various cancers. In leukemia, ENL and its paralog, AF9, are frequently fused with the mixed lineage leukemia protein, MLL1, also known as KMT2A, as a result of chromosomal translocations. Once bound to acetylated histones,
ENL can stabilize transcription machinery on target genes, leading to increased gene expression and the growth </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of leukemia cells. Deletion of ENL or disruption of its binding to acetylated histones has been shown to decrease leukemia burden and increase survival in mouse models of leukemia. By contrast,
loss of ENL has minimal effects on the survival of normal hemopoietic stem cells in culture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another drug target found in leukemias, <FONT
STYLE="white-space:nowrap">Fms-like</FONT> tyrosine kinase 3 (&#8220;FLT3&#8221;), is a receptor tyrosine kinase that plays a role in early hematopoiesis. Upon binding to the FLT3 ligand, FLT3 receptors activate and dimerize, leading to
conformational change, cellular proliferation, and inhibition of apoptosis and differentiation. Activating mutations in FLT3 are found in approximately 30% of AML patients, representing the most frequent genetic alteration in the disease. Small
molecule inhibitors of FLT3 have been approved by the Food and Drug Administration (&#8220;FDA&#8221;), but their impact is limited due to the development of resistance mutations and poor tolerability that limits their potential as a combination
partner in earlier line settings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, GB3226 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GB3226 is a small molecule that inhibits both ENL YEATS and FLT3. We believe that the combination of these two mechanisms in one molecule provides an advantage
over other therapeutic approaches to treat AML. We anticipate that the rapid anti-tumor activity of FLT3 will be complemented by the long-term anti-tumor activity offered by ENL YEATS inhibition. In addition, we believe that simultaneously
inhibiting both pathways will reduce the likelihood that resistance to GB3226 will arise through single point mutations in either target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our mouse
xenograft model using human <FONT STYLE="white-space:nowrap">MV4-11</FONT> leukemia cells, treatment with doses as low as 25 mg/kg twice daily (&#8220;BID&#8221;), led to reductions in tumor size. Tumors were no longer measurable after seven days of
treatment with 50 mg/kg BID or higher GB3226 with reductions sustained after dosing ended. Treatment with GB3226 led to a dose-dependent reduction in key genetic drivers of leukemogenesis and maintenance such as HOXA9 and MEIS1. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g98130g01t21.jpg" ALT="LOGO" STYLE="width:6.29in;height:2.50667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 9. GB3226 had anti-tumor activity in an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MV-4-11</FONT></FONT> xenograft model </I></P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with GB3226 led to significant improvements in survival in a separate <FONT
STYLE="white-space:nowrap">MV4-11</FONT> mouse model compared to existing therapies approved to treat AML. In this model treatment with GB3226 led to significant improvement in survival compared to gilteritinib, a small molecule FLT3 inhibitor, and <FONT
STYLE="white-space:nowrap">SNDX-5613,</FONT> a <FONT STYLE="white-space:nowrap">third-party</FONT> menin inhibitor now known as revumenib. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g98130g02t21.jpg" ALT="LOGO" STYLE="width:6.29in;height:3.21667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure 10. Treatment with GB3226 led to statistically significant improvements in survival in a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MV-4-11</FONT></FONT> model compared to gilteritinib and revumenib </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No statistically
significant changes in QTc prolongation in dogs have been observed with GB3226 at a dose of 100 mg/kg. Changes in QTc are common side effects of some kinase inhibitors such as FLT3 inhibitors as well as with revumenib. We intend to file an IND for
GB3226 with the FDA in the first quarter of 2026. The proposed Phase 1 trial is designed as an open-label, dose-escalation and expansion trial to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of GB3226, as well as
biomarker analyses, including MYC, MEIS1, HOXA9 and FLT3 to further characterize the therapeutic potential of GB3226 in adults with relapsed or refractory AML. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that an <FONT STYLE="white-space:nowrap">ENL-YEATS</FONT> and FLT3 inhibitor such as GB3226 may have the potential to address a broad portion of
the AML patient population, including those patients with high-risk genetic mutations. Our preclinical models have demonstrated that GB3226 is active against AML driven by rearrangement of mixed lineage
<FONT STYLE="white-space:nowrap">leukemia-1</FONT> gene (&#8220;KMT2A&#8221;), mutation of NPM1 and FLT3-driven AML. We believe that GB3226 is also <FONT STYLE="white-space:nowrap">well-positioned</FONT> to address the menin-resistant population
within AML. Acute leukemias driven by KMT2A or NPM1, require the chromatin adapter protein menin, encoded by the MEN1 gene, to sustain aberrant leukemogenic gene expression programs. Somatic mutations in MEN1 have been identified in patients with
acquired resistance to menin inhibition. Consistent with the genetic data in patients, inhibitor-menin interface mutations represent a conserved mechanism of therapeutic resistance in xenograft models and in an unbiased <FONT
STYLE="white-space:nowrap">base-editor</FONT> screen. These mutants attenuate drug-target binding by generating structural perturbations that impact small-molecule binding but not the interaction with the natural ligand MLL1 and prevent
inhibitor-induced eviction of menin and MLL1 from chromatin. Inhibition of ENL and the subsequent decrease of target gene expression occurs independent of presence of menin and is not negatively impacted by MEN1 mutations, which suggests that this
therapeutic resistance could potentially be addressed by GB3226. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2025, we announced the completion of the Asset Acquisition with the focus on advancing a pipeline of next-generation antibodies targeting
mutCALR with respect to which we have the option to acquire intellectual property license rights pursuant to the Paragon Option Agreement. The antibodies subject to the Paragon Option Agreement were discovered and developed by Paragon, a
biotechnology company applying cutting-edge science and technology to shape the next generation of novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> complex biologics for major medical needs.
Paragon&#8217;s scientific founders&#8217; discoveries have also led to the creation of five other successful, publicly traded biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the closing of the Asset Acquisition, we completed a $285&nbsp;million private placement of our Series C Preferred Stock with a syndicate of
healthcare investors led by Fairmount Funds Management LLC, with participation from Viking Global Investors, Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson Investors, Wellington Management, RA Capital Management, TCGX,
Forbion, BB Biotech, Blackstone Multi-Asset Investing, Perceptive Advisors, Vestal Point Capital, Balyasny Asset Management, Andreessen Horowitz (a16z Bio + Health), and a leading life sciences investment firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a strong management team, board of directors and group of employees with diverse backgrounds and significant experience in developing novel treatments
for patients at biopharmaceutical companies such as CRISPR Therapeutics, Cogent Biosciences, Jade Biosciences, Oruka Therapeutics, Apogee Therapeutics, Spyre Therapeutics, Ultragenyx, Roche/Genentech, Arena Pharmaceuticals, Maxygen, Spring Bank, and
Bridge Medicines. Together, our team has a proven track record in the discovery, development, and commercialization of numerous approved therapeutics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2025, we
effected the Asset Acquisition to acquire Damora in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), by and among the Company, Daylight Merger Sub I, Inc., a Delaware corporation and a wholly
owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Daylight Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and Damora. Pursuant to the Acquisition
Agreement, First Merger Sub merged with and into Damora, pursuant to which Damora was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, Damora
merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Asset Acquisition was structured as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> transaction pursuant to which all of Damora&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1.6366,</FONT></FONT> for consideration of a combination of 265,309 shares of Common Stock, 16,366 shares of Series B Preferred Stock (or 16,366,000&nbsp;shares on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis), and 4,241 shares of Series C Preferred Stock (or 4,241,000&nbsp;shares on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis), in addition to the assumption of outstanding and unexercised stock options to purchase 434,508
shares of Common Stock from the Damora 2025 Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Asset Acquisition, we determined that Galecto was the acquiror for
accounting purposes under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-10-25-4</FONT></FONT></FONT> and ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">805-10-55-11.</FONT></FONT></FONT> The primary factors considered were (a)&nbsp;the relative voting rights in the combined entity not resulting in a change of control, (b)&nbsp;legacy members of our board of directors
maintained control of the board, and (c)&nbsp;the composition of senior management remained the same at the closing of the Transactions. Next, we considered whether the Asset Acquisition should be defined as a business under ASC 805. ASC <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-10-55-5A</FONT></FONT></FONT> through <FONT STYLE="white-space:nowrap">55-5C</FONT> describe a screen test to determine whether an acquired set of
assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, Damora&#8217;s Option to license intellectual property rights related to <FONT
STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> pursuant to the Paragon Option Agreement. Accordingly, we
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated the Asset Acquisition as an asset acquisition for accounting purposes. Even if the transaction would have failed the screen test, Damora lacked the financial resources to have inputs,
processes, and outputs to constitute a business under ASC 805. Following the Asset Acquisition, we will need to invest in infrastructure and the continuing research and development being conducted under the Paragon Option Agreement to be able to
have any measurable outputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Asset Acquisition, we entered into a securities purchase agreement (the &#8220;Securities Purchase
Agreement&#8221;) for a PIPE investment with existing and new investors (the &#8220;Investors&#8221;) to raise approximately $285&nbsp;million in which the Investors were issued 39,641 shares of Series C Preferred Stock (or 39,641,000 shares on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis) at a price of $7,186.90 per share (or $7.1869&nbsp;per&nbsp;share on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis). The PIPE transaction closed on November&nbsp;12, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transactions were approved by our board of directors and the board of directors and stockholders of Damora. The closings of the Transactions were not
subject to the approval of Galecto stockholders. Subject to the Conversion Approval and certain beneficial ownership limitations set by each holder, each share of Series B Preferred Stock will be convertible at the option of the holder into 1,000
shares of Common Stock and each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock. We expect to file a proxy statement with the SEC to solicit such Conversion Approval, among other matters, at a special
meeting of Galecto stockholders (the &#8220;Special Meeting&#8221;). Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series B Preferred Stock or the rights of such shares as required by Delaware General
Corporation Law) and the Certificate of Designation of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#8220;Series B Certificate of Designation&#8221;), the Series B Preferred Stock does not have voting
rights. Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series C Preferred Stock or the rights of such shares as required by Delaware General Corporation Law) and the Certificate of Designation of Series C <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#8220;Series C Certificate of Designation&#8221;), the Series C Preferred Stock does not have voting rights. For more information on the Series B Preferred Stock and the
Series C Preferred Stock, please refer to the Series B Certificate of Designation and the Series C Certificate of Designation, respectively, which are incorporated by reference herein and attached as Exhibit 3.1 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;10, 2025 and as Exhibit 3.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K/A</FONT> filed with the SEC on December&nbsp;9, 2025, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Acquisition Agreement, Galecto and Damora entered into stockholder support agreements (the &#8220;Support
Agreements&#8221;) with certain of Galecto&#8217;s officers and directors (together with affiliated entities), which collectively own an aggregate of approximately 3.0% of the outstanding shares of Common Stock. The Support Agreements provide that,
among other things, each of the parties thereto has agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the Conversion Approval at the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Acquisition Agreement, certain Damora stockholders as of immediately prior to the Asset Acquisition,
and certain of the directors and officers of Galecto as of immediately prior to the Asset Acquisition entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with Galecto and Damora, pursuant to which each such stockholder will be
subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> lockup on the sale or transfer of shares of Common Stock held by each such stockholder at the closing of the Asset Acquisition, including those shares received by such Damora stockholders
in the Asset Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Transactions, you should refer to our Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;10, 2025, which is incorporated by reference herein. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporation Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded as Galecto Biotech AB, a Swedish company, in 2011 and incorporated in Delaware as Galecto, Inc. in October 2019. On November&nbsp;10, 2025, we
completed the Asset Acquisition, pursuant to which we assumed the rights and obligations of Damora under the Paragon Option Agreement, and all of Damora&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 1 to
1.6366 for consideration from Galecto of 265,309 shares of Common Stock, 16,366 shares of Series B Preferred Stock (or 16,366,000 shares on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis), and 4,241 shares of Series C Preferred Stock (or 4,241,000 shares on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis), in addition to the assumption of outstanding and unexercised stock options to purchase 434,508
shares of Common Stock from the Damora 2025 Equity Incentive Plan. In addition, in October 2024, we acquired the global rights to Bridge Medicines LLC&#8217;s (&#8220;Bridge Medicines&#8221;) GB3226 (formerly
<FONT STYLE="white-space:nowrap">BRM-1420)</FONT> program, a novel dual <FONT STYLE="white-space:nowrap">ENL-YEATS</FONT> and FLT3 inhibitor for multiple genetic subsets of AML, and assumed certain of Bridge Medicines&#8217; liabilities associated
with the acquired assets. Our principal executive offices are located at Ole Maaloes Vej 3s, <FONT STYLE="white-space:nowrap">DK-2200</FONT> Copenhagen N, Denmark and 75 State Street, Suite 100, Boston, MA 02109, and our telephone number is (+45) 70
70 52 10. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Relationship with Fairmount, Paragon and Paramora </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, we assumed the rights and obligations of Damora under the Paragon Option Agreement. Paragon and Paramora each
beneficially own more than 5% of a class of our voting securities through their respective holdings of our Common Stock, although neither are expected to own more than 5% following the Conversion Approval. Fairmount beneficially owns more than 5% of
Paragon, appointed Paragon&#8217;s board of directors, and has the contractual right to approve the appointment of any executive officers of Paragon. Paramora is an entity formed by Paragon as a vehicle to hold equity in Damora (and as a result of
the Asset Acquisition, us) in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement other than to receive warrants expected to be granted to Paramora under the Paragon
Option Agreement. Three of our directors are affiliated with Fairmount (Peter Harwin, Christopher Cain, Ph.D., and Julianne Bruno) and were appointed in accordance with the Acquisition Agreement. We consider Paragon, Paramora, and Fairmount to be
related parties. See the section titled &#8220;<I>Paragon</I> <I>Option Agreement</I>&#8221; below for more information on the Paragon Option Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paragon Option Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;7, 2025, Damora
entered into the Paragon Option Agreement with Paragon and Paramora. In connection with the Asset Acquisition, we assumed the rights and obligations of Damora under the Paragon Option Agreement. Under the terms of the Paragon Option Agreement,
Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest (each, a &#8220;Research Program&#8221;). The
Paragon Option Agreement includes mutCALR as the selected target for <FONT STYLE="white-space:nowrap">DMR-001</FONT> and <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and mutCALR and CD3 as the selected targets for
<FONT STYLE="white-space:nowrap">DMR-003.</FONT> From time to time, we may choose to add additional targets to the Paragon Option Agreement by mutual agreement with Paragon and Paramora. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Paragon Option Agreement requires us, Paragon, and Paramora to develop a research plan for each target that includes design, modeling, synthesis,
evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities primarily include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth
in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two of our employees and two employees from Paragon, with us and Paragon
each having one vote with respect to decisions of the committee. When Paragon and Paramora have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Paramora will deliver to us a data package
that includes sequence information for all then-existing antibodies and information directed to such </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
target. We, Paragon, and Paramora have developed a Research Plan for each of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT
STYLE="white-space:nowrap">DMR-003</FONT> consistent with the foregoing, and Paragon and Paramora have delivered an antibody against mutCALR with respect to <FONT STYLE="white-space:nowrap">DMR-001</FONT> in accordance with the applicable Research
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Paragon Option Agreement, we have an option (an &#8220;Option&#8221;), on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, to enter into a separate agreement with Paragon consistent with a set of <FONT STYLE="white-space:nowrap">pre-negotiated</FONT> terms (a &#8220;License Agreement&#8221;).
Each License Agreement will include (a)&nbsp;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and
commercialize the antibodies and products directed to the selected target(s), and (b), for <FONT STYLE="white-space:nowrap">DMR-001</FONT> and <FONT STYLE="white-space:nowrap">DMR-002,</FONT> a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable monospecific Research Program to develop, manufacture, and commercialize multispecific antibodies and products
directed to the selected target(s). Additionally, each License Agreement under the Paragon Option Agreement will include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide license to certain patents controlled by Paragon or its
affiliates that (i)&nbsp;include a claim that expressly recites the sequence of the monospecific or bispecific antibody, as applicable, or the derived antibodies applicable to the Research Program, and (ii)&nbsp;are necessary to develop, manufacture
or commercialize the monospecific or bispecific antibody, as applicable, or the derived antibodies applicable to the Research Program, but exclude any patents owned or otherwise controlled by Paragon or its affiliates that cover (x)&nbsp;that
antigen-binding portion of any antibody or moiety that is directed to a target other than the target(s) of the Research Program (e.g., a second binder in a multispecific antibody), (y) any portion of any multispecific antibody other than an antibody
directed to the target(s) of the Research Program, and (z)&nbsp;the composition of matter of, or any method of specifically making or using, a multispecific antibody directed to targets other than the target(s) of the Research Program that is
developed, manufactured, commercialized or otherwise exploited by Paragon or its affiliate or sublicensee (other than us and our affiliates and sublicensees). The Option with respect to each Research Program is exercisable at our sole discretion at
any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of days following the delivery of the data package from Paragon related to the results of the Research Program
(an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreement. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. We have
exercised our Option with respect to <FONT STYLE="white-space:nowrap">DMR-001</FONT> and are negotiating the related License Agreement, but our Options with respect to <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT
STYLE="white-space:nowrap">DMR-003</FONT> currently remain unexercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercise of an Option with respect to a Research Program, the parties are
obligated to use reasonable efforts to finalize and execute a License Agreement within 90 days. Under the terms of a License Agreement, we expect that we will have sole authority over and control of the development, regulatory approval,
manufacturing and commercialization of such <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property worldwide. In addition, we expect to have sole authority over and control of the application for and issuance of all regulatory
approvals related to such <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the
Research Program. Following entry into a License Agreement, we expect to control prosecution, defense, maintenance and enforcement of patents <FONT STYLE="white-space:nowrap">in-licensed</FONT> under such License Agreement. However, there is no
assurance that we will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis until the later of: (i)&nbsp;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by
us; (ii)&nbsp;if we exercise our Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 90 days, the expiration of such <FONT STYLE="white-space:nowrap">90-day</FONT> period (subject
to any mutually agreed extension of such period); and (iii)&nbsp;the expiration of the applicable Research Term (as defined under the applicable Paragon Option Agreement). We may terminate any Paragon Option Agreement or any Research Program at any
time for any or no reason upon </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
30 days&#8217; prior written notice to Paragon; provided, that we must pay certain unpaid fees due to Paragon upon such termination, as well as any
<FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or any Research Program
immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a
period of four consecutive months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i) 30 days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the <FONT
STYLE="white-space:nowrap">30-day</FONT> period and (ii)&nbsp;the other party&#8217;s bankruptcy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon signing of the Paragon Option Agreement, Damora
became obligated to reimburse Paragon $10.6&nbsp;million for research and development costs related to <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and
<FONT STYLE="white-space:nowrap">DMR-003,</FONT> other general and administrative costs incurred by Paragon though September&nbsp;30, 2025, and certain additional development costs incurred between October&nbsp;1, 2025 and October&nbsp;7, 2025 (the <FONT
STYLE="white-space:nowrap">&#8220;Pre-Development</FONT> Costs&#8221;). The <FONT STYLE="white-space:nowrap">Pre-Development</FONT> Costs reflect the actual historical costs incurred by Paragon, including a 20%
<FONT STYLE="white-space:nowrap">mark-up</FONT> on certain direct costs to approximate the indirect costs incurred by Paragon from inception of the programs to the entry into the Paragon Option Agreement. Such direct costs incurred by Paragon were
related to development activities. Paragon&#8217;s cash flows related to <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> are operating cash flows.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also required to pay Paragon for certain development fees and costs on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis. Under the Paragon Option Agreement, we are required to pay Paragon a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-refundable</FONT> research initiation fee within 30 days following finalization of a Research Plan in the amount of $1.25&nbsp;million for each of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT STYLE="white-space:nowrap">DMR-003.</FONT> The Research Plans for each of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT
STYLE="white-space:nowrap">DMR-003</FONT> were completed in December 2025, and we expect to pay the related fees in January 2026. Under the Paragon Option Agreement, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, we are required to make <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT>
milestone payments to Paragon of up to a total of $22.0&nbsp;million for each of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> upon the
achievement of certain clinical development and regulatory milestones. We recognized research and development expense of $1.5&nbsp;million related to the milestone payment due to Paragon in connection with the achievement of a development candidate
for <FONT STYLE="white-space:nowrap">DMR-001</FONT> in December 2025. As of the date of this prospectus, we have not paid Paragon the <FONT STYLE="white-space:nowrap">DMR-001</FONT> development candidate milestone payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercise of the Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License
Agreement within 30 days. Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the applicable Paragon Option Agreement, provided that any milestone set in such Paragon
Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of such Paragon Option Agreement and shall only be achievable under the terms of the License
Agreement. For the avoidance of doubt, if a milestone is achieved and paid by us pursuant to a Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a
subsequently executed License Agreement for such Research Program. Further, under a License Agreement, we would also be required to make royalty payments to Paragon in the low single-digit percentage range based on net sales of products, subject to
certain reductions. The royalty term will terminate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid
claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as part of
the Paragon Option Agreement, on each of December&nbsp;31, 2025 and December&nbsp;31, 2026, we will grant Paramora warrants to purchase a number of shares equal to 1.00% of our outstanding capital stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares of our Common Stock on each respective grant date. If the Research Term with respect to all Research Programs ends prior to the end of a calendar year, the warrant
grant for such calendar year shall be <FONT STYLE="white-space:nowrap">pro-rated.</FONT> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the closing of the Asset Acquisition, Damora had incurred total expenses of $15.2&nbsp;million under
the Paragon Option Agreement since its inception. No payments were made by Damora to Paragon prior to the closing of the Asset Acquisition. Through November&nbsp;30, 2025, we have recognized $16.4&nbsp;million of expense pursuant to the Paragon
Option Agreement, of which $15.6&nbsp;million is research and development expense and $0.8&nbsp;million is general and administrative expense. Of the research and development expense, $5.1&nbsp;million related to
<FONT STYLE="white-space:nowrap">DMR-001,</FONT> $1.5&nbsp;million related to <FONT STYLE="white-space:nowrap">DMR-002,</FONT> $1.3&nbsp;million related to <FONT STYLE="white-space:nowrap">DMR-003,</FONT> and $7.7&nbsp;million was for shared program
costs supporting all three programs. As of the date of this prospectus, we have paid Paragon an aggregate of $10.6&nbsp;million, including $2.5&nbsp;million related to <FONT STYLE="white-space:nowrap">DMR-001,</FONT> $0.7&nbsp;million related to <FONT
STYLE="white-space:nowrap">DMR-002,</FONT> $0.7&nbsp;million related to <FONT STYLE="white-space:nowrap">DMR-003,</FONT> and $6.7&nbsp;million related to shared program costs supporting all three programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining patent
protection intended to cover the composition of matter of our programs, our methods of use and manufacture, and other inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragon has filed
provisional patent applications directed to antibodies that bind to mutCALR, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies. A provisional patent application is an application
filed in the USPTO for the purpose of securing an early date of priority for the applicant&#8217;s invention. The provisional application must include a written description of what the inventor has discovered, along with a drawing of the invention,
but need not include patent claims, statements concerning or disclosing the prior art, or certain other formalities. A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a
provisional patent application is filed, either a <FONT STYLE="white-space:nowrap">corresponding&nbsp;non-provisional&nbsp;patent</FONT> application or a petition to convert the provisional patent application into
<FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;patent</FONT> application must be filed within 12 months or such effective filing date will be lost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum term of a U.S. patent, excluding extensions and adjustments, begins on the effective filing date of the
<FONT STYLE="white-space:nowrap">first&nbsp;non-provisional&nbsp;application</FONT> claiming the patented invention and ending 20 years from that date. In essence, a provisional patent application provides a patent applicant two principal advantages
over filing <FONT STYLE="white-space:nowrap">a&nbsp;non-provisional&nbsp;application.</FONT> First, it allows the applicant to secure an earlier priority date for its invention than that of an
<FONT STYLE="white-space:nowrap">equivalent&nbsp;non-provisional&nbsp;application&#8212;up</FONT> to one year earlier than the filing date of a <FONT STYLE="white-space:nowrap">related&nbsp;non-provisional&nbsp;application.</FONT> Second, since the
term of a patent runs from the effective filing date of the <FONT STYLE="white-space:nowrap">first&nbsp;non-provisional&nbsp;application</FONT> but does not begin upon filing a provisional application, filing a provisional application provides the
applicant an additional year&#8217;s time to refine that invention before filing a <FONT STYLE="white-space:nowrap">related&nbsp;non-provisional&nbsp;application</FONT> without surrendering the earlier priority date. Securing an earlier priority
date both ensures that later inventors cannot obtain a patent to the same invention and provides protection against certain arguments that developments in the field arising after the priority date should prevent or invalidate the applicant&#8217;s
invention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">the&nbsp;non-provisional&nbsp;patent</FONT> applications filed for
<FONT STYLE="white-space:nowrap">DMR-001</FONT> result in issued patents, such patents are expected to expire in 2046, without taking potential patent term adjustment or patent term extension into consideration. If we or Paragon timely <FONT
STYLE="white-space:nowrap">file&nbsp;non-provisional&nbsp;patent</FONT> applications in the United States and in countries outside of the United States with regard to Paragon&#8217;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DMR-002-related</FONT></FONT> provisional patent applications and these <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications result in issued patents, such
patents are expected to expire in 2046, without taking potential patent term adjustment or patent term extension into consideration. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as part of the agreement with Bridge Medicines, we assumed an
<FONT STYLE="white-space:nowrap">in-license</FONT> from Rockefeller University of a patent portfolio directed to a series of selective inhibitors of ENL/AF9 YEATS. As of December&nbsp;1, 2025, the <FONT STYLE="white-space:nowrap">in-licensed</FONT>
portfolio includes 18 pending U.S. and foreign applications and one allowed Chinese application, covering compositions of matter for various <FONT STYLE="white-space:nowrap">N-linked</FONT> compounds and methods of treatment using such compositions.
If the <FONT STYLE="white-space:nowrap">in-licensed</FONT> applications were to issue as one or more patents, these patents would expire in 2040. We also own two additional patent families relating to claims covering compositions of matter for
various <FONT STYLE="white-space:nowrap">C-linked</FONT> inhibitors of ENL/AF9 YEATS and various inhibitors of ENL/AF9 YEATS and FLT3, combinations with various therapeutic agents, methods of treatment, and methods of administration. As of
December&nbsp;1, 2025, these two families collectively include two pending U.S. patent applications and multiple pending foreign counterpart patent applications. If the applications were to issue as one or more patents, these patents would expire in
2042. We currently, and expect that we will continue to, file for patents in the United States with counterparts in major market countries in Europe and other key markets in the rest of the world. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other IP Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely
upon unpatented trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can
be difficult to protect. We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and
collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are
developed through our relationship with the respective counterparty. We cannot guarantee, however, that we have executed such agreements with all applicable counterparties, that such agreements will not be breached, or that these agreements will
afford us adequate protection of our intellectual property and proprietary rights. For more information, please see the section titled &#8220;<I>Risk Factors&#8212;Risks Related to Our Intellectual Property</I>&#8221; in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of our product candidates be
approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial
value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution capabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate, and currently
have no plans to establish, any manufacturing facilities. All of our preclinical and clinical drug supply development, manufacturing, storage, distribution and testing are outsourced to third-party manufacturers and facilities. Our manufacturing
strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities. As our programs advance
through development, we expect to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure our supply needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to face intense competition from
other biopharmaceutical companies that are developing agents for the treatment of mutCALR-driven MPNs, including ET and MF. If approved for the treatment of patients with mutCALR-driven MPNs, our portfolio of products would compete with hydroxyurea,
which is not approved for </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the treatment of ET in the United States, anagrelide, ruxolitinib, and interferon, which has not been approved for ET, and well as ruxolitnib, momelotinib, pacritinib and fedratinib in MF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of several companies with product candidates in development for the treatment of patients with mutCALR-driven MPNs, including Incyte&#8217;s
INCA033989 and INCA035784, Janssen Pharmaceuticals, Inc.&#8217;s <FONT STYLE="white-space:nowrap">JNJ-88549968,</FONT> Meiji Seika Pharma&#8217;s mutCALR TCE, Prelude Therapeutics, LLC&#8217;s mCALR CDK9d DAC, Alethio Therapeutics&#8217; <FONT
STYLE="white-space:nowrap">AT-02,</FONT> PharmaEssentia Corporation&#8217;s ropeginterferon <FONT STYLE="white-space:nowrap">alfa-2b,</FONT> Merck&nbsp;&amp; Co., Inc&#8217;s bomedemstat, Novartis AG&#8217;s pelabresib, Geron Corporation&#8217;s
imetelstat, and Kartos Therapeutics, Inc.&#8217;s navtemadlin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there are a number of large biotechnology and biopharmaceutical companies
that are currently pursuing the development of products for the treatment of the biological processes that drive certain cancers. Companies that we are aware of targeting the treatment of AML include large companies with significant financial
resources, such as Kyowa Kirin Co., Ltd., Syndax Pharmaceuticals, Inc., Crescent Biopharma, Inc. and Actinium Pharmaceuticals, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government
Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring
and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory
authorities of the countries in which we conduct studies or seek approval or licensure of our product candidates. Generally, before a new therapeutic product can be marketed, considerable data demonstrating a biological product candidate&#8217;s
quality, safety, purity and potency, must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. For biological product candidates, potency is similar to efficacy
and is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a
given result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biologics Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the United States, biological products (or &#8220;biologics&#8221;) are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local,
and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process
required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s
current Good Laboratory Practices (&#8220;GLP&#8221;) regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated
annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical
site before the trial is commenced; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture of the proposed biologic candidate in accordance with current good manufacturing practices
(&#8220;cGMPs&#8221;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice
(&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;), after completion
of all pivotal clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60&nbsp;days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity
and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use
in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning any clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to
support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the <FONT
STYLE="white-space:nowrap">30-day</FONT> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on partial or full clinical hold and the IND sponsor, and the FDA must resolve any
outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance
with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the
trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any
subsequent protocol amendments. Furthermore, an independent IRB representing each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at
that site, and must monitor the trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk
or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides
authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical trial results to public registries. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that
may overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;1. The investigational product is initially introduced into healthy human subjects or patients with
the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible,
to gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;2. The investigational product is administered to a limited patient population with a specified
disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&nbsp;2 clinical trials may be conducted to obtain information prior to
beginning larger and more expensive Phase&nbsp;3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;3. The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or
companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase&nbsp;4 studies may be made a condition to approval of
the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in
commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity,
strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate
does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical
trial under an IND. When a foreign clinical trial is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain
FDA regulatory requirements in order to use the trial as support for an IND or application for marketing approval or licensure, including that the trial was conducted in accordance with GCP, including review and approval by an independent ethics
committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the trial through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both
ethical and data integrity standards for clinical studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical
trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a
substantial application user fee to the FDA, unless a waiver or exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60&nbsp;days following submission of the application, the FDA
reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has
been accepted for filing, the FDA&#8217;s goal is to review standard applications within 10&nbsp;months after the filing date, or, if the application qualifies for priority review, six&nbsp;months after the FDA accepts the application for filing. In
both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the
facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review
questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA
will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission
and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be
produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe
all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting
required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including
requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance
to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and
may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its
risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the
development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur
after the product reaches the marketplace. The FDA may require one or more Phase&nbsp;4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is
required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official
release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on
the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the
safety, purity, and potency or effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user
fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state
authorities, and are subject to periodic unannounced inspections by the FDA and certain state authorities for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to
the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and
impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with
cGMPs and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or
other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and
efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other governmental regulatory authorities </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other
things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from
those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best
treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <FONT
STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Reference Product Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BPCIA created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety,
purity, and potency, is generally shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be
expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has
been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost
and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant
hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. The FDA has issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and
interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA,
an application for a biosimilar product may not be submitted to the FDA until four&nbsp;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by
the FDA until 12&nbsp;years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference
product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The
BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by
pharmacies, which are governed by state pharmacy law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reference biologic is granted 12&nbsp;years of exclusivity from the time of first licensure of
the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval
pathway for the lesser of (i)&nbsp;one year after the first commercial marketing, (ii)&nbsp;18&nbsp;months after approval if there is no legal challenge, (iii)&nbsp;18&nbsp;months after the resolution in the applicant&#8217;s favor of a lawsuit
challenging the biologics&#8217; patents if an application has been submitted, or (iv)&nbsp;42&nbsp;months after the application has been approved if a lawsuit is ongoing within the <FONT STYLE="white-space:nowrap">42-month</FONT> period. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric
exclusivity, if granted, adds six&nbsp;months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be
granted based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#8220;Written Request&#8221; for such a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July&nbsp;2018, the FDA announced an action plan to encourage the
development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&nbsp;20, 2020, Congress amended the PHSA as part of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to
be a requirement of the application. In addition, government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA
exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant law that intends to foster generic and biosimilar competition and
to lower drug and biologic costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Extension </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, after a BLA is approved, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term
restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as <FONT STYLE="white-space:nowrap">one-half</FONT> the time between (1)&nbsp;the later of
(a)&nbsp;the effective date of an IND and (b)&nbsp;issue date of the patent for which extension is sought, and (2)&nbsp;the submission date of a BLA, plus the time between BLA submission date and the BLA approval date, up to a maximum of
five&nbsp;years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14&nbsp;years from the date of product licensure. Only one
patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted
prior to the expiration of the patent in question. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable
deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms
that may be more or less stringent and comprehensive than those of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the
states and foreign jurisdictions in which they conduct their business that may restrict certain general business and marketing practices. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False
Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or
in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything
of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the
remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may
be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a
statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the
arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. In 2025, the Department of Justice continued to apply the Supreme Court&#8217;s 2023 scienter framework in United States ex rel. Schutte v. SuperValu
Inc. for FCA matters, focusing on a defendant&#8217;s subjective understanding and beliefs at the time of claim submission, thus expanding the use of the FCA against recipients of federal funds that allegedly misrepresented compliance with federal
civil rights laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil
whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false
or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for
example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional
federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not
need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and
prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is
available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&nbsp;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other
transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership
and investment interests held by physicians and their immediate family members. Beginning on January&nbsp;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established
under the federal Physician Payments Sunshine Act. In 2025, CMS continued incremental Open Payments program updates, published updates to data publication timelines, and expanded taxonomy lists for covered recipients, which may increase reporting
and validation burdens for manufacturers and expand public transparency regarding transfers of value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to additional similar U.S.
state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in
violation of any of such laws or any other </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded
healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement,
individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data
Privacy and Security </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security
of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state
consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes privacy, security, and breach notification obligations on certain health care providers, health plans, and
health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually
identifiable protected health information for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates
protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health
or condition or information about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created,
received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals
and regulators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties
and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA <FONT
STYLE="white-space:nowrap">non-compliance.</FONT> A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business
associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil
actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that do
not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied. In addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical
Information Act and Washington&#8217;s My Health My Data Act, govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even when HIPAA and state health information privacy laws do not apply, according to the FTC and state Attorneys General, violating consumers&#8217; privacy
rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act and state
consumer protection laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain state laws, such as the California Consumer Privacy Act of 2018, as amended by the California Privacy
Rights Act of 2020 (&#8220;CCPA&#8221;), govern the privacy and security of personal information, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including health-related information in certain circumstances, some of which are more stringent than HIPAA in various ways. Numerous other states have passed similar laws, but many differ from
each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do
business in California, including to provide specific disclosures in privacy notices and affords rights to California residents in relation to their personal information. Health information falls under the CCPA&#8217;s definition of personal
information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household&#8201;unless it is subject to HIPAA&#8201;and is
included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The numerous
other comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels also exempt some data processed in the context of clinical trials; but others exempt covered entities and business
associations subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for us and the third parties upon whom we rely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are also an increasing number of, and continuous change within, foreign laws regulating data privacy and security, such as Canada&#8217;s Personal
Information Protection and Electronic Documents Act, Australia&#8217;s Privacy Act 1988, New Zealand&#8217;s Privacy Act 2020 and South Korea&#8217;s Personal Information Protection Act. In particular, when we conduct clinical trials, including in
New Zealand, we need to comply with the applicable country data privacy and security laws with respect to the processing of clinical data, which impose obligations similar to those described below in the section titled &#8220;<I>&#8212; Other
Government Regulation</I><I></I><I>&nbsp;Outside of the United States</I><I>&#8201;</I><I>&#8212;</I><I>&#8201;</I><I>Regulation in the European Union</I><I>&#8201;</I><I>&#8212;</I><I>&#8201;</I><I>European Data Laws</I>&#8221; of this prospectus.
Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or
criminal penalties and restrictions on data processing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to government activity, privacy advocacy groups and technology and other industries
are considering various new, additional or different self-regulatory standards that may place additional burden on us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain
regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed
healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be
provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can
differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare
determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly
challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety
and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could
reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companion diagnostic tests require coverage and reimbursement separate and apart
from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls,
restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be
able to directly negotiate prescription drug prices and to cap <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and
biologics that are covered under Medicare Part&nbsp;B and Part&nbsp;D that do not have generic or biosimilar competition. On August&nbsp;15, 2024, CMS announced the agreed-upon reimbursement prices of the first 10 drugs that were subject to price
negotiations. In January 2025, CMS announced a list of 15 additional drugs Medicare Part&nbsp;D drugs that will be subject to price negotiations. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect
in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&nbsp;B
and Part&nbsp;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&nbsp;2022, qualifying biosimilars may receive a Medicare Part&nbsp;B payment increase for a period of five&nbsp;years. Separately,
if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&nbsp;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding
these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these
efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded
health care programs, and increased governmental control of drug pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the ACA, which was enacted in March&nbsp;2010, substantially
changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and
biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are
inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain
aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA
marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&nbsp;D program beginning in 2025 by significantly lowering the beneficiary maximum <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost and creating a new manufacturer discount program. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic
aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April&nbsp;2013 and, due to subsequent
legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts that manufacturers must agree to offer under the Medicare Part&nbsp;D coverage discount program from 50% to 70% off negotiated prices of applicable
brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&nbsp;D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has
resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&nbsp;2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for
Part&nbsp;B drugs, permitting Medicare Part&nbsp;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&nbsp;D beneficiaries to disclose drug price
increases and lower cost therapeutic alternatives, which went into effect on January&nbsp;1, 2021. In response to the Biden administration&#8217;s October&nbsp;2022 executive order, on February&nbsp;14, 2023, HHS released a report outlining three
new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform
measures in the future. Further, on December&nbsp;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of <FONT STYLE="white-space:nowrap">march-in</FONT> rights under the Bayh-Dole
Act. On December&nbsp;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of <FONT STYLE="white-space:nowrap">March-In</FONT> Rights which for the
first time includes the price of a product as one factor an agency can use when deciding to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights. While <FONT STYLE="white-space:nowrap">march-in</FONT> rights have not previously been
exercised, it is uncertain if that will continue under the new framework. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the IRA, continued legislative and enforcement interest exists
in the United States with respect to specialty drug pricing practices. We expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and
manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Government Regulation&nbsp;Outside of the
United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among
other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other
promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use
may be restricted in some countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory
authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial
application much like the IND prior to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials,
including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an
appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In
certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such
product, which would make launch of such products commercially unfeasible in such countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>European Data Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collection and use of personal
health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (GDPR), which came into force in May&nbsp;2018, and related data protection laws in individual member states
of the EU (&#8220;EU Member States&#8221;). The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to
health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the
individuals prior to processing their personal data, the notification obligations to the national data protection authorities and data subjects, the measures to be taken when engaging processors, and the security and confidentiality of the personal
data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area (&#8220;EEA&#8221;)) that are not considered by the
European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard
contractual clauses (&#8220;SCCs&#8221;). When relying on SCCs, data exporters are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the
SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary
measure is suitable, the data exporter should avoid, suspend or terminate the transfer With regard to the transfer of data from the EEA to the United States, on July&nbsp;10, 2023, the EC adopted its adequacy decision for the <FONT
STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. With regard to the transfer of data from EU to the
United Kingdom (&#8220;UK&#8221;), personal data may freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8220;sunset clause&#8221; which entails that the
decisions will automatically expire four years after their entry into force, unless renewed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with the requirements of the GDPR and the
related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#128;20&nbsp;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other
administrative penalties and a number of criminal offenses for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from
the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal
data in the EU. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, are specific requirements relating to processing health data from clinical trials, including
public disclosure obligations provided in the EU Clinical Trial Regulation No.&nbsp;536/2014 (&#8220;CTR&#8221;), EMA disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government
enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;11, 2025, the European Union adopted Regulation (EU) 2025/327 establishing the European Health Data Space, which imposes new obligations and liabilities on companies that handle electronic health data in the EU, including mandatory
interoperability, logging, security and cross-border exchange requirements for electronic health record systems, expanded individual rights of access and control, and conditions and prohibitions on secondary uses of health data (e.g., for research
or regulatory purposes), with staged implementation beginning in late 2025 and 2026. Compliance may require significant investments in technology, processes and governance, as well as engagement with national health data access bodies, and could
limit companies&#8217; ability to collect, process, transfer, or commercialize health data or delay product development and post-market activities. Failure to comply&#8212;or differing national implementations, enforcement actions or evolving
guidance&#8212;could result in audits, restrictions, fines, litigation, reputational harm, interruption of operations and increased costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally,
following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act
2018 (the DPA 2018)), the DPA 2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &pound;17.5&nbsp;million or 4% of global turnover.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companies are subject to specific transfer rules under the UK regime which broadly mirror the GDPR rules. On February&nbsp;2, 2022, the UK Secretary of
State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (the &#8220;IDTA
Addendum&#8221;) and a document setting out transitional provisions. The IDTA and IDTA Addendum came into force on March&nbsp;21, 2022 and replaced the old SCCs for the purposes of the UK regime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States (the <FONT
STYLE="white-space:nowrap">&#8220;UK-US</FONT> Data Bridge&#8221;), which came into force on October&nbsp;12, 2023. The <FONT STYLE="white-space:nowrap">UK-US</FONT> Data Bridge recognizes the United States as offering an adequate level of data
protection where the transfer is to a U.S. company participating in the <FONT STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework and the UK Extension to the <FONT STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Drug and Biologic Development Process </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of
where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials
conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international
good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&nbsp;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC (&#8220;Clinical
Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
former regime, which will expire after a transition period of three&nbsp;years, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more ethics committees. The
NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent ethics committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU
member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and ethics committees. Under
the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the ethics committees of the EU member state where they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a
centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate
with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States.
However, a concerned EU member state may in limited circumstances declare an <FONT STYLE="white-space:nowrap">&#8220;opt-out&#8221;</FONT> from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims
to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period.
EU Member States will work in CTIS immediately after the system has gone live. Since January&nbsp;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and CTIS serves as the single entry point for submission of clinical
trial-related information and data. By January&nbsp;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July&nbsp;19, 2023, the EC published
guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&nbsp;documentation which was previously assessed will not be reassessed, (ii)&nbsp;templates that were developed and endorsed by the
EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&nbsp;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct
of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the
development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A
fee is incurred with each scientific advice procedure but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls
testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Drug Marketing Authorization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, after
completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a
centralized or decentralized procedure. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through
EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;)
Submissions Portal. The process from application to authorizations generally takes up to 210&nbsp;days, excluding time taken to provide any additional information or data required by the MHRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;30, 2023, the MHRA published detailed guidance on its new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since
January&nbsp;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other
jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK. Applicants can submit initial MAAs to the IRP, but the procedure can also be used throughout the lifecycle of a product for
post-authorization procedures including line extensions, variations and renewals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Centralized Authorization Procedure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that
is valid for all EU Member States as well as in the three additional EEA member states (Norway, Iceland and Liechtenstein). The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means
of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy, or tissue engineered medicines) and medicinal products with a new active substance
indicated for the treatment of certain diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&nbsp;20,
2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of
public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the centralized
procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions
to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&nbsp;days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written
or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might
be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to
150&nbsp;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is
then transmitted to the EC, which has the ultimate authority for granting MA within 67&nbsp;days after receipt of the CHMP opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Decentralized
Authorization Procedure </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&nbsp;they
can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&nbsp;they can be authorized under a
decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&nbsp;they can be authorized in an EU member state in accordance with that state&#8217;s national
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member
States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The
competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are
subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public
health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk Management Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All new MAAs must include a RMP
describing the risk management system that a company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new
information becomes available. An updated RMP must be submitted: (i)&nbsp;at the request of EMA or a national competent authority, or (ii)&nbsp;whenever the risk-management system is modified, especially as the result of new information being
received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition
of the MA. Since October&nbsp;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MA
Validity Period </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAs have an initial duration of five&nbsp;years. After these five&nbsp;years, the authorization may subsequently be renewed on the
basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one
additional five-year renewal. Applications for renewal must be made to the EMA at least nine&nbsp;months before the five-year period expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&nbsp;years after authorization ceases to be valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the UK, the period of three&nbsp;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a
Great Britain MA. Conversion refers to the procedure by which, as of January&nbsp;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations
have all been automatically converted into UK MAs effective in Great Britain only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the other hand, for the EU, in the case the drug has been marketed
in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&nbsp;31, 2020 and ending on December&nbsp;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after
the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of the Brexit
Transition Period. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advanced Therapy Medicinal Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, medicinal products, including advanced therapy medicinal products (&#8220;ATMP&#8221;) are subject to extensive
<FONT STYLE="white-space:nowrap">pre-</FONT> and post-market regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are
genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to Regulation (EC) No 1394/2007,
the Committee for Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance
on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance
with them is often necessary to gain and maintain approval for product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the mandatory RMP, the holder of a MA for an ATMP must
put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing,
packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exceptional Circumstances/Conditional
Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A
conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&nbsp;the benefit/risk
balance of the product is positive, (ii)&nbsp;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&nbsp;unmet medical needs will be fulfilled by the grant of the MA and (iv)&nbsp;the benefit to
public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfil specific
obligations within defined timelines. A conditional MA must be renewed annually, but it can be converted into a standard MA once the MA holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue
to outweigh its risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Market Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry
into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological
and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&nbsp;years of data
exclusivity and 10&nbsp;years of marketing exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An additional <FONT STYLE="white-space:nowrap">non-cumulative</FONT> <FONT
STYLE="white-space:nowrap">one-year</FONT> period of marketing exclusivity is possible if during the data exclusivity period (the first eight&nbsp;years of the <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period), the MA
holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight&nbsp;years, a generic product application may be
submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&nbsp;years later (or a total of 10&nbsp;years after the first MA in the EU of the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovator product), or three&nbsp;years later (or a total of 11&nbsp;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant
clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative <FONT STYLE="white-space:nowrap">one-year</FONT> period of data exclusivity can be added to the eight&nbsp;years of data exclusivity where an
application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the
eight&nbsp;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant <FONT STYLE="white-space:nowrap">pre-trial</FONT> tests or clinical trials (when examining an application by another
applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory
authorities to include an NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if
such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages, e.g., a shortening
of the periods of data exclusivity; however, there is currently neither a final version of this draft nor a date for its entry into force. While the European Parliament adopted its approving position on the reform on April&nbsp;10, 2024, no further
required legislative steps have been taken since. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a pediatric improvement plan
(&#8220;PIP&#8221;) together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP
approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA.
The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the
pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a
<FONT STYLE="white-space:nowrap">six-month</FONT> extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a
<FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and
submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU
system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&nbsp;1, 2021 have been adopted as UK PIPs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PRIME
Designation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March&nbsp;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which
few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representing substantial innovation reviewed under the centralized procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier
entry into the PRIME scheme than larger companies on the basis of compelling <FONT STYLE="white-space:nowrap">non-clinical</FONT> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with
PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization
application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased
understanding of the product at EMA&#8217;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance
on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United States,
both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of
manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and
distribution, recordkeeping, importing and exporting of medicinal products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure by us or by any of our third-party partners, including suppliers,
manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before
and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the
conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating
restrictions, injunctions, suspension of licenses, fines and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of MA for a medicinal product must also comply with EU
pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of
marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a
medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an
individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports
(&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has
varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase&nbsp;4 safety studies. If the EC agrees with the
opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More generally, <FONT STYLE="white-space:nowrap">non-compliance</FONT> with pharmacovigilance obligations
can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
manufacturing process for pharmaceutical products in the European Union is highly regulated, and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing
authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC (repealed by Directive 2017/1572 on
January&nbsp;31, 2022), Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing pharmaceutical products and active
pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Amendments or replacements of at
least Directive 2001/83/EC and Regulation (EC) No 726/2004 are part of the reform proposal for European pharmaceutical legislation Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance
with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified
person who is responsible for certifying that each batch of product has been manufactured in accordance with cGMPs, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing
facilities are subject to periodic inspections by the competent authorities for compliance with cGMPs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sales and Marketing Regulations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading
and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These
laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s summary of product characteristics (&#8220;SmPC&#8221;) as approved by the competent regulatory authorities. The SmPC is the
document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore
all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription-only medicines is also prohibited in the
EU. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our
products to the general public and may also impose limitations on our promotional activities with healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EU regulation with regards to
dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations&nbsp;2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following
Brexit, the requirements to display the common logo no longer apply to <FONT STYLE="white-space:nowrap">UK-based</FONT> online sellers, except for those established in Northern Ireland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-Corruption Legislation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, interactions
between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The
provision of benefits or advantages to physicians to induce or </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to
physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of
prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry
codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery
Act 2010. Due to the Bribery Act 2010&#8217;s <FONT STYLE="white-space:nowrap">far-reaching</FONT> territorial application, the potential penalized act does not have to occur in the UK to come within its scope. If the act or omission does not take
place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. The Bribery Act 2010 is comprised of four offenses
that cover (i)&nbsp;individuals, companies and partnerships that give, promise or offer bribes, (ii)&nbsp;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&nbsp;individuals, companies and partnerships
that bribe foreign public officials, and (iv)&nbsp;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and
culpability and penalties range from unlimited fines to imprisonment for a maximum term of 10&nbsp;years and in some cases both. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations in the
UK and Other Markets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK formally left the EU on January&nbsp;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as
laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation
agreement, which includes provisions affecting the life sciences sector (including on customs and tariffs) specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal
products and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK government has adopted the Medicines and Medical Devices Act 2021 (&#8220;MMDA&#8221;) to enable the existing regulatory frameworks to be updated
following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been
consulting on future regulations for medicines and medical devices in the UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MMDA supplements the UK Medical Devices Regulations&nbsp;2002 (the
&#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU
Medical Devices Regulation (EU) 2017/745, which has gained full application in all EU Member States since May&nbsp;26, 2021, but is not applicable in the UK as &#8220;retained law&#8221;. Additionally, the MHRA launched a comprehensive consultation
in 2021 with proposals to amend the regulatory framework for medical devices in the UK. The stated objectives of the proposals include expansion of the scope of the UK Regulations (for example, by expanding the in vitro diagnostic medical device
definition to include software and other products, including products without an intended medical purpose but with similar functioning and risk profiles) and potentially through use of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internationally recognized definitions (for example, by excluding products that contain viable biological substances and excluding food), remove trade barriers, further the availability of
medical devices and improve the favorability of the UK market. The consultation period closed on November&nbsp;25, 2021 and on June&nbsp;26, 2022, the MHRA published a response to its consultation, which sets out the proposed new UK regulatory
framework for medical devices and in vitro diagnostic medical devices. The proposals are intended to improve patient safety and public health through appropriate regulatory oversight, improve the traceability of medical devices, improve the
regulation of the rules governing software and AI as medical devices and introduce alternative routes to market to ensure the UK aligns with any superior international best practices. Core aspects of the new framework are expected to apply from
July&nbsp;1, 2025 with appropriate transitional measures and the introduction of secondary legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the European
Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be
conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation
of Medical Products in New Zealand </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials in New Zealand are regulated under the Medicines Act 1981 (&#8220;Medicines Act&#8221;) and
Medicines Regulations 1984. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical trial requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Zealand Medicines and Medical Devices Safety Authority (&#8220;Medsafe&#8221;) is the regulatory authority that administers the application and
approval process for medicines and clinical trials in New&nbsp;Zealand (under delegation from the Director-General of Health). Approval from Medsafe is required in the following two circumstances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before a medicine can be distributed in New Zealand&#8201;&#8212;&#8201;see &#8220;Approval for
distribution&#8221; below; however, there is an exemption from this approval requirement for medicines that are imported or manufactured for the sole purpose of use in a clinical trial (including pharmacokinetic, bioequivalence and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for all clinical trials involving unapproved medicines carried out in New Zealand; however, if a medicine is
already approved by Medsafe for distribution in New Zealand, then there is no separate requirement to obtain approval for clinical trials with that medicine (including if the medicine is being tested for a use not provided for under its existing
authorization). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medsafe also expects all clinical trials to be carried out in accordance with internationally accepted standards for
good clinical practice as published by the EMA in its Guideline for Good Clinical Practice, to the extent that these standards are compatible with the Medicines Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical trial approval process </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical trial
approval process requires submission of an online application to Medsafe. The application must include information about the nature of the medicine, the purpose of the trial, details of the investigators conducting the trial, written consent to
nomination from each investigator, copies of information supplied to the investigators, a protocol of the trial, and details of the sites and facilities used. The application must be made by the actual or intended importer, manufacturer, packer, or
supplier of the medicine in New Zealand. Once </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved, the applicant becomes the &#8220;sponsor&#8221; and assumes responsibility and legal liability for the trial in New Zealand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once an application is received, Medsafe provides it to the Health Research Council of New Zealand (&#8220;HRC&#8221;). One of two HRC standing committees
will consider the application and make a recommendation to Medsafe as to whether the clinical trial should be approved (with or without conditions) or declined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Standing Committee on Therapeutic Trials considers pharmaceutical medicine trial applications, while the Gene Technology Advisory Committee considers
applications for trials involving gene and other biotechnology therapies. Both standing committees undertake a similar scientific assessment process, and consider factors such as trial protocol and design, data collection, and general compliance
with the Guideline for Good Practice before making a recommendation to Medsafe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ethical requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medsafe expects all clinical trials to be approved by the Health and Disability Ethics Committee (&#8220;HDEC&#8221;), regardless of whether Medicines Act
approval is required. HDEC reviews and approves applications and provides ongoing oversight of clinical trials to ensure alignment with good ethical practice. HDEC approval can be sought before, during, or after Medicines Act approval is sought from
Medsafe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A clinical trial&#8217;s
sponsor may register a trial with the Australian New Zealand Clinical Trials Registry (&#8220;ANZCTR&#8221;), an online public registry of clinical trials undertaken in New Zealand, Australia, and elsewhere. While not mandatory, the ANZCTR is a
recognized part of the World Health Organisation Registry Network and registration is encouraged by the World Health Organisation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Approval for
distribution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a sponsor decides to distribute the new medicine product in New Zealand after the clinical trial, the sponsor must apply for
distribution approval. This is separate to the approval process for clinical trials and involves submitting an application to Medsafe for consideration. Medsafe assesses the safety, efficacy, quality and risk profile of the medicine, and makes a
recommendation to the Minister of Health as to whether the medicine should be approved for distribution (in practice, the Minister follows Medsafe&#8217;s recommendation). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;15, 2025, we had seven employees, all of whom were employed full time. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be
good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may
be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this prospectus include the research
programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreement, which we assumed pursuant to the Asset Acquisition. As of the date of this prospectus, we have exercised
the option for <FONT STYLE="white-space:nowrap">DMR-001.</FONT> We have not exercised the option for <FONT STYLE="white-space:nowrap">DMR-002</FONT> or <FONT STYLE="white-space:nowrap">DMR-003</FONT> or entered into a license agreement for <FONT
STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> or <FONT STYLE="white-space:nowrap">DMR-003.</FONT> We expect to finalize the <FONT STYLE="white-space:nowrap">DMR-001</FONT> license agreement in the first
quarter of 2026. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no guarantee that our acquisition of Damora will increase stockholder value. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2025, we acquired Damora. We cannot guarantee that implementing the Asset Acquisition and related transactions will not impair stockholder value
or otherwise adversely affect our business. The Asset Acquisition poses significant integration challenges between our businesses which could result in management and business disruptions, any of which could harm our results of operation, business
prospects, and impair the value of the Asset Acquisition to our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical stage biotechnology company with a limited
operating history on which to assess our business; we have no products approved for commercial sale, which may make it difficult to evaluate our current business and likelihood of success and viability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical stage biotechnology company with limited operating history. Since our inception, we have incurred operating losses with no corresponding
revenue and have utilized substantially all of our resources to identify, license and develop our product candidates, organize and staff our company and provide other general and administrative support for our operations. We have limited experience
as a company in initiating, conducting and completing preclinical studies and clinical trials. In part because of this lack of experience, we cannot be certain that our preclinical studies or clinical trials will begin or be completed on time, if at
all. In addition, we have not yet demonstrated an ability to obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary
for successful product commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown
factors. We will need to transition at some point from a company with an early research and development focus to a company capable of supporting larger scale clinical trials and eventually commercial activities. We may not be successful in such a
transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when
needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research programs or future commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing biotechnology products is a long, time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase
in connection with our ongoing activities, particularly as we conduct preclinical studies and clinical trials of, and seek regulatory approval for our product candidates, advance discovery efforts with respect to our research and research programs,
and advance any future programs and product candidates that we may develop or license. Even if one or more of the programs that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing,
manufacturing and distribution activities to launch any such product. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to or more
expansive than those that we currently anticipate. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of funding that will be necessary to successfully complete the development and commercialization of any program we develop. Our future capital requirements depend on many factors, including but
not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, design, progress, results and costs of discovery, preclinical and clinical development for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of clinical and commercial-scale manufacturing activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining, defending and
enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of the regulatory review of our product candidates and obtaining the requisite
regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of our future commercialization activities, either on our own or in collaboration with others,
including product sales, marketing, manufacturing, and distribution for any product candidate for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of product candidates for which we receive regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our current or future collaborations, including our collaboration with Paragon pursuant to the
Paragon Option Agreement and any future license agreements we enter into with Paragon; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, intellectual
property and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operational, financial and management information systems and associated personnel; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we will require substantial additional funding to continue our operations. As of November&nbsp;30, 2025, we had $274&nbsp;million of cash and
cash equivalents. We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. We will still need to raise additional capital to continue to fund our
operations in the future. If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing
arrangements or other sources, and adequate additional financing may not be available to us on acceptable terms, or at all. Such financing may dilute our stockholders or the failure to obtain such financing may restrict our operating activities. Any
additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our business. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect
the rights of our stockholders. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone
payments pursuant to current or future collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be
adversely impacted by global macroeconomic conditions and volatility in the credit and financial markets in the United States and worldwide. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our
financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our product candidates, clinical trials or future commercialization efforts or cease our
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to continue to incur losses for the foreseeable future and may not be able to achieve or
sustain profitability in the future. We have no products approved for sale, have not generated any revenue from our product candidates and may never generate revenue or become profitable.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks
that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale, have not generated any revenue from
product sales to date, and continue to incur significant research and development and other expenses related to our ongoing operations. We do not expect to generate product revenue unless or until we successfully complete preclinical and clinical
development and obtain regulatory approval of, and then successfully commercialize, at least one of our product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough
to achieve profitability. If we are unable to raise sufficient additional capital to advance a product candidate to commercialization or generate sufficient revenue through the sale of any approved products, we may be unable to continue operations
without additional funding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses in each period since our inception in 2011. For the three and nine months ended
September&nbsp;30, 2025, we had net losses of $3.1&nbsp;million and $9.1&nbsp;million, respectively. As of September&nbsp;30, 2025, we had an accumulated deficit of $286.6&nbsp;million. We expect to continue to incur losses for the foreseeable
future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our existing and future product candidates through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek, obtain and maintain regulatory and regulatory approvals for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, establish and maintain additional collaborations and license agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone payments to Paragon under the Paragon Option Agreement and under any additional future
collaboration or license agreements that we enter into; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any drug products for
which we may obtain regulatory approval, either on our own or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">generate revenue from commercial sales of product candidates for which we receive regulatory approval, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional personnel including research and development, clinical and commercial personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> products, intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish clinical and commercial-scale cGMPs capabilities through a third-party or our own manufacturing
facility; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrate Damora into our operations following the Asset Acquisition. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our expenses will increase if, among other things, we are required by the FDA or other regulatory authorities to perform clinical trials or
studies in addition to, or different than, those that we currently anticipate, there are any delays in completing our clinical trials or the development of any of our product candidates, or there are any third-party challenges to our intellectual
property or we need to defend against any intellectual property-related claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for, and are successful in commercializing, one or more of our product
candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter unforeseen
expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our failure to become profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts,
expand our business and/or continue our operations. A decline in the value of our stock could also cause stockholders to lose all or part of their investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Discovery, Development and Commercialization</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from entities that have developed or may develop product candidates for the diseases addressed by our product candidates.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure
to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies. If approved for
the treatment of patients with mutCALR-driven MPNs, our portfolio of products would compete with hydroxyurea, which is not approved for the treatment of ET in the United States, anagrelide, ruxolitinib, and interferon, which has not been approved
for ET, and well as ruxolitnib, momelotinib, pacritinib and fedratinib in MF. In addition, we are aware of several companies with product candidates in development for the treatment of patients with mutCALR-driven MPNs, including Incyte&#8217;s
INCA033989 and INCA035784, Janssen Pharmaceuticals, Inc.&#8217;s <FONT STYLE="white-space:nowrap">JNJ-88549968,</FONT> Meiji Seika Pharma&#8217;s mutCALR TCE, Prelude Therapeutics, LLC&#8217;s mCALR CDK9d DAC, Alethio Therapeutics&#8217; <FONT
STYLE="white-space:nowrap">AT-02,</FONT> PharmaEssentia Corporation&#8217;s ropeginterferon <FONT STYLE="white-space:nowrap">alfa-2b,</FONT> Merck&nbsp;&amp; Co., Inc&#8217;s bomedemstat, Novartis AG&#8217;s pelabresib, Geron Corporation&#8217;s
imetelstat, and Kartos Therapeutics, Inc.&#8217;s navtemadlin. Companies that we are aware of targeting the treatment of AML include large companies with significant financial resources, such as Kyowa Kirin Co., Ltd., Syndax Pharmaceuticals, Inc.,
Crescent Biopharma, Inc. and Actinium Pharmaceuticals, Inc. We also compete with academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or
will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and regulatory approved
products than we do, and are further along in the clinical development and/or commercialization process. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and
retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, patient registration for clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies
complementary to, or necessary for, our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors have developed or are developing, and may in the future develop, product
candidates or products competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any potential new treatments, including those currently under
clinical development. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or
eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or biosimilars that enter the
market more quickly than we do and are able to gain market acceptance. Conversely, the lack of commercial success of other competing therapies may raise concerns about the financial viability of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because of the competitive landscape for MPNs and AML indications, we may also face competition
for establishing trial sites and clinical trial enrollment. Patient enrollment will depend on many factors, including if potential clinical trial patients choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing
clinical trials for product candidates that are under development for the same indications as our product candidates. An increase in the number of approved products for the indications we are targeting with our product candidates will likely further
exacerbate this competition. Our inability to enroll a sufficient number of patients could, among other impacts, delay our development timeline, which may further harm our competitive position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our programs are in the preclinical stages of development and may fail in development or suffer delays that materially and adversely affect our
viability. If we or our current or future collaborators are unable to complete development of or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no commercially approved products. Our programs are in the preclinical stages of development, and we have not completed any clinical trials for these
product candidates. As a result, we expect it will be many years before we commercialize any product candidate, if ever. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully
commercializing, our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have not yet demonstrated our ability to obtain regulatory
approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the
commercial distribution of any product candidate, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators may experience delays in initiating or completing preclinical studies or clinical trials. We or our collaborators also may experience
numerous unforeseen events during, or as a result of, any future preclinical studies or clinical trials that we could conduct that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, such as the FDA, institutional review boards (&#8220;IRBs&#8221;) or comparable foreign regulatory
authorities may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial
sites and prospective clinical research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites may deviate from the trial protocol, fail to conduct trials in a compliant manner or drop
out of a trial, which may require that we add new clinical trial sites or investigators or otherwise negatively impact the timing or integrity of our clinical trial(s); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or
inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon a product research program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate,
and enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all, or may deviate from the clinical trial protocol or suffer other quality or performance issues that negatively impact the timing or integrity of our clinical trial(s); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or
terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality of our product candidates or other materials necessary to conduct clinical trials of our product
candidates may be inadequate to initiate or successfully complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to manufacture sufficient quantities of our product candidates for use in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical
data for such product candidates as well as data emerging from other therapies in the same class as our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology
studies, or impose other requirements before permitting us to initiate a clinical trial. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United
States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA. Commencing clinical trials in jurisdictions outside of the United States is similarly subject to acceptance by the applicable
regulatory authority of clinical trial documentation following discussions with such authority. In the event that the FDA or other applicable regulatory authority requires us to complete additional preclinical studies or we are required to satisfy
other FDA or foreign regulatory authority requests, respectively, prior to commencing clinical trials, the start of our first clinical trial for a product candidate may be delayed. Even after we receive and incorporate guidance from these regulatory
authorities, the FDA or other regulatory authorities could disagree as to whether we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints
selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are analogous processes and risks
applicable to clinical trial applications in other countries, including but not limited to Canada, New Zealand, Australia, countries in the EU and countries in Asia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory
approval of, or our ability to commercialize, our product candidates. We or our current or future collaborators&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a
material and adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the
success of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> and our anticipated future clinical trials of such product candidate may not be successful. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success is substantially dependent on our ability to timely obtain regulatory approval for, and then successfully commercialize, <FONT
STYLE="white-space:nowrap">DMR-001.</FONT> We are initially investing a majority of our efforts and financial resources into the research and development of this program. We intend to file an IND, or equivalent, for
<FONT STYLE="white-space:nowrap">DMR-001</FONT> with the FDA in <FONT STYLE="white-space:nowrap">mid-2026</FONT> and initiate a Phase 1 trial in ET and MF patients with a subcutaneous formulation thereafter, subject to regulatory approval. The
success of <FONT STYLE="white-space:nowrap">DMR-001</FONT> is dependent on observing rapid and sustained reduction in excess platelets, the key pathology in ET, compared to other anti-mutCALR antibody product candidates in clinical development. This
is based in part on the assumption that the increased <I>in vitro</I> potency and improved pharmacokinetics observed in NHPs will translate into a inhibition of Type 1 and Type 2 mutCALR-dependent cell proliferation and improved pharmacokinetic
properties of <FONT STYLE="white-space:nowrap">DMR-001</FONT> in humans, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resulting in a more convenient dosing regimen. To the extent we do not observe this inhibition of Type 1 and Type 2 mutCALR-dependent cell proliferation or improved pharmacokinetic properties in
our Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">DMR-001</FONT> or in additional clinical trials, it would significantly and adversely affect the clinical and commercial potential of <FONT STYLE="white-space:nowrap">DMR-001.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, regulatory
approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote these product candidates, or any other product candidates,
before we receive regulatory approval from the FDA and comparable foreign regulatory authorities, and we may never receive such regulatory approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our
intellectual property rights, potential threats from the intellectual property rights of third parties and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, we cannot assure you that we
will ever be able to generate revenue through the sale of these product candidates, even if approved. If we are not successful in obtaining regulatory approval and commercializing <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002,</FONT> <FONT STYLE="white-space:nowrap">DMR-003,</FONT> GB3226 or future product candidates, or are significantly delayed in doing so, our business will be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB3226 is currently in preclinical development and we may fail to show that the drug is generally safe and well tolerated and that it may provide
clinical benefit for patients. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical models have demonstrated that GB3226 is active against mixed-lineage leukemia-rearranged
(&#8220;MLLr&#8221;), NPM1m and FLT3+ driven AML, and we believe that GB3226 has the potential to be further developed to become a treatment option for other tumor types. However, we have not yet sufficiently demonstrated a favorable risk-benefit of
GB3226 in patients, and we may be unable to establish sufficient efficacy to warrant continued development in this indication and we may fail to show that the drug is generally safe and well tolerated and that it may provide clinical benefit for
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development objectives in the time frames we announce and expect, the commercialization of our product
candidates may be delayed which may harm our reputation and prospects, increase our expenses and cause our stock price to decline.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to
time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of
scientific studies and clinical trials, such as the expected timing for the initiation of our Phase 1 clinical trials of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT>
<FONT STYLE="white-space:nowrap">DMR-003</FONT> and GB3226, the timing for receipt of clinical data, and the timing for the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these
milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these
milestones as publicly announced, or at all, our prospects and reputation may be adversely affected and our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may
require us to raise additional capital sooner than expected and prior to achieving targeted development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The target patient population
for the treatment of MPNs is small and has not been definitively determined, and if estimates of the number of treatable patients is lower than expected, our potential revenues from sales of our product candidates, if approved, and our ability to
achieve profitability would be compromised. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimates of both the number of patients who have MPNs, as well as the subset of patients with
the disease in a position to receive treatment from <FONT STYLE="white-space:nowrap">DMR-001</FONT> (i.e., those with mutCALR proteins &gt; 42,000 patients in the United States), if approved, may prove to be incorrect. These estimates have been
derived from a variety of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sources, including scientific literature, input from physicians that treat patients with the diseases we are targeting, patient foundations and secondary market research databases. For example,
estimates of the prevalence of MPNs in certain geographies are based in part on the published prevalence of MPNs among patient populations in the United States split across ethnicities, and our own analyses of prevalence in Europe, and on published
disease incidence rates for certain geographies and estimated for the populations of such geographies. Further, new studies may change the estimated incidence or prevalence of MPNs, and any regulatory approvals that patient population. Similar
considerations would apply to estimates of patient population for target indications we select for <FONT STYLE="white-space:nowrap">DMR-002,</FONT> <FONT STYLE="white-space:nowrap">DMR-003</FONT> and any future product candidates. Accordingly, our
target patient populations may turn out to be lower than expected, in which case the potential revenues from sales of our product candidates, if approved, would be lower than expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the discovery and development of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT
STYLE="white-space:nowrap">DMR-003</FONT> is unproven, and we may not be successful in our efforts to build a pipeline of product candidates with commercial value.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to the discovery and development of our product candidates leverages well-established mechanisms of action and incorporates advanced antibody
engineering to optimize half-life and other properties designed to overcome limitations of existing therapies, including increased binding affinity. Our product candidates are purposefully designed to improve upon existing product candidates and
products while maintaining the same, well-established mechanisms of action. However, the scientific research that forms the basis of our efforts to develop <FONT STYLE="white-space:nowrap">DMR-001,</FONT>
<FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> using half-life extension technologies and to enhance efficacy through improved binding affinity, including monoclonal antibodies, is ongoing and may
not result in viable product candidates. We have limited clinical data on product candidates utilizing monoclonal antibody half-life extension technologies, especially in autoimmune indications, demonstrating whether they are safe or effective for
long-term treatment in humans. We also have no clinical data to indicate whether our modifications to enhance binding affinity translate into improved efficacy in humans. The long-term safety and efficacy of
<FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> compared to currently approved products is unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may ultimately discover that utilizing half-life extension technologies for our specific targets and indications and any product candidates resulting
therefrom do not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data regarding the increased half-life properties of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003,</FONT> and the same results may not be seen in humans. In addition, product candidates using half-life extension technologies may demonstrate different chemical
and pharmacological properties in patients than they do in laboratory studies. This technology and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human
biological systems in unforeseen, ineffective or harmful ways. Many product candidates that appeared highly promising in preclinical studies or in early-stage clinical trials have failed when advanced into, or further in, clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other companies are developing drug products that utilize half-life extension technology in other targets and indications. The failure of those
companies to demonstrate the safety and efficacy of their product candidates may be harmful to our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may in the future seek to discover and develop product candidates that are based on novel targets and technologies that are unproven. If our
discovery or business development activities fail to identify novel targets or technologies for drug development, or such targets or technologies prove to be unsuitable for treating human disease, we may not be able to develop viable additional
product candidates. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for
targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from our product
candidates prove to be ineffective, unsafe or commercially unviable, our product candidates and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development involves a lengthy and expensive process that is subject to
delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our
product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct
extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical
study or clinical trial process. For example, we depend on the availability of NHPs to conduct certain preclinical studies that we are required to complete prior to submitting an IND and initiating clinical development. There is currently a global
shortage of NHPs available for drug development. While we currently do not anticipate that this shortage will materially impact our costs or timelines, a continuing or future shortage could cause the cost of obtaining NHPs for our future preclinical
studies to increase significantly or result in delays to our development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, enrolling patients in clinical trials for cancer therapies
is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care therapy (and thus do not enroll in clinical trials) are believed to have tumor types that may have
responded well to our product candidates. This may limit the number of eligible patients able to enroll in our clinical trials and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to
the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However, these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the
prior administration of checkpoint inhibitors. Either of these prior treatment regimens may render our therapies less effective in clinical trials. We have sought and may continue to seek to mitigate these effects in the future through modification
of enrollment eligibility criteria. Additionally, patients who have failed approved therapies will typically have more advanced cancer and a poorer long-term prognosis. If we are unable to initiate or adequately enroll our clinical trial sites, our
clinical trials may be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, a failure of one or more clinical trials can occur at any clinical trial phase. The outcome of preclinical
studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. In addition, we expect to rely on patients to provide feedback on measures such
as measures of disease and quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control and can vary widely from day to day for a particular patient, and from patient
to patient and from site to site within a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that the FDA or comparable foreign regulatory authorities will agree with our
clinical development plans. However, there is no guarantee the data from such Phase 1 trial will support additional trials. If the FDA or comparable foreign regulatory authorities require us to conduct additional trials or enroll additional
patients, our development timelines may be delayed. We cannot be sure that submission of an IND or similar foreign application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a
timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical
trials include: inability to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I> data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on
study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical investigators; delays in obtaining required IRB approval or positive ethics committee opinions at each clinical trial site; delays in manufacturing, testing, releasing, validating or
importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to
perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s GCP requirements or regulatory guidelines; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes
in regulatory requirements, guidance or clinical trial plans that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of
manufacturing processes to new or larger-scale facilities and delays or failure by our contract manufacturing organizations (&#8220;CMOs&#8221;) or us to make any necessary changes to such manufacturing process; and third parties being unwilling or
unable to satisfy their contractual obligations to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs
or ethics committees of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend
or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the
FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to
successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations would be adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll patients in our clinical trials, particularly given the relatively small patient population. If we encounter
difficulties enrolling patients in our future clinical trial of <FONT STYLE="white-space:nowrap">DMR-001</FONT> or our other programs, our clinical development activities could be delayed or otherwise adversely affected.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience difficulties in patient enrollment in our current or future clinical trials for a variety of reasons. The timely completion of clinical
trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until our conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, cancer therapies are sometimes characterized by line of therapy (first, second, third, fourth, etc.), and the FDA often initially approves new
therapies only for use in a particular line or lines of therapy. For example, we may initially seek approval of our product candidates as a third-line therapy for patients who have failed other approved treatments. We may subsequently seek approval
as a second- and first-line therapy. There is no guarantee that our product candidates, even if initially approved, would be subsequently approved as a second or first line therapy, which may further reduce the number of patients available to us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, most ET patients are often treated with aspirin alone. However, the remaining ET patients carry a higher risk of clotting and bleeding and are
generally treated with hydroxyurea, which is not approved for the treatment of ET in the United States, anagrelide and interferon. In addition, there are several targeted therapies approved for the treatment of AML: enasidenib for patients with
mutations in IDH2, marketed as Idhifa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Bristol Myers Squibb Company and Servier Pharmaceuticals, or Servier; ivosidenib for patients with mutations in IDH1, marketed as Tibsovo<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Servier; revumenib for patients with KMT2A rearrangements or NPM1m , marketed as Revuforj<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Syndax Pharmaceuticals Inc.; ziftomenib
for patients with NPM1m, marketed as Komzifti<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Kura Oncology, Inc. and Kyowa Kirin Co., Ltd.; and a series of drugs approved for patients with genetic alterations in FLT3 including
gilteritinib, marketed as Xospata<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Astellas Pharma Inc., and quizartinib, marketed as Vanflyta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Daiichi Sankyo, Inc. Patients may
decide, or physicians may recommend, to use such treatments instead of enrolling in clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enrollment of patients in future trials for any of our product candidates will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved drugs for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient eligibility and exclusion criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#8217; and clinicians&#8217; perceived risks and benefits of the product candidate under study;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if patients choose to enroll in clinical trials, rather than using approved products, or if our competitors have
ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients instead enroll in such clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued enrollment of prospective patients by clinical trial sites. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the number of patients required for clinical trials of our product candidates may be larger than we anticipate. Even if we are able to enroll a
sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Our inability to enroll or maintain a sufficient number of patients would result in significant delays in completing
clinical trials or receipt of regulatory approvals and increased development costs or may require us to abandon one or more clinical trials altogether, which could cause our value to decline, limit our ability to obtain additional financing and
otherwise harm our prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary, &#8220;topline&#8221; or interim data from our clinical trials that we announce or publish from time to
time may change as more patient data become available and are subject to audit and verification procedures.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly
disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a more
comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or
topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit
and verification procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available
or as patients from our clinical trials continue other treatments. Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the
importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and of us as a company. In addition, the information we choose to publicly
disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our
disclosure. As a result, you or others may have reached different conclusions based on such extensive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information in comparison to our publicly disclosed conclusion regarding a particular preclinical study or clinical trial. If the preliminary, topline or interim data that we report differ from
actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results,
prospects or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future clinical trials or those of our current or future collaborators may reveal significant adverse events
or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a high or unacceptable severity and prevalence of side effects, adverse events or unexpected
characteristics. If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to such trials, patients may drop out of our trials, or we may be required to abandon
the trials or our development efforts of one or more product candidates altogether. For example, although anti-mutCALR monoclonal antibodies have been generally well tolerated in clinical trials to date, four discontinuations out of 55 patients, one
of which was due to a treatment-emergent adverse event (&#8220;TEAE&#8221;), were was reported by Incyte in its Phase 1 trial investigating INCA033989 in ET patients resistant or intolerant to prior cytoreductive therapy. The most frequent grade
&#8805; 3 TEAEs were neutropenia, amylase increase, anemia and lipase increase. Because <FONT STYLE="white-space:nowrap">DMR-001</FONT> will have a similar mechanism of action, it is possible that patients in our future clinical trials could exhibit
similar grade TEAEs as well. We, the FDA or other applicable regulatory authorities, or an IRB or ethics committee, may suspend any clinical trials of any product candidate at any time for various reasons, including a belief that subjects or
patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later
been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects
do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to our tolerability versus other therapies. In addition, an extended
half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. TEAEs could also affect patient recruitment or the ability of enrolled subjects to complete our clinical trials or could result in
potential product liability claims. Potential side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally
encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the anticipated clinical trials of GB3226 will include cancer patients who are critically ill and whose health is deteriorating, and we expect
that additional clinical trials of GB3226 and our other product candidates will include similar patients with deteriorating health. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events
due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if we
successfully advance our product candidates or any future product candidate through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be
assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the
effect and safety consequences of using our product candidates over a multi-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the foregoing events occur or if one or more of our
product candidates prove to be unsafe, our entire pipeline could be affected, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular program and fail to capitalize on programs
that may be more profitable or for which there is a greater likelihood of success.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we
focus our research and development efforts on certain selected programs. For example, we are focused primarily on <FONT STYLE="white-space:nowrap">DMR-001.</FONT> As a result, we may forgo or delay pursuit of opportunities with other programs that
later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development of
product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to
that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we
select product candidates amongst a variety of potential product candidates from Paragon, and the product candidates we select may fail to be viable commercial products or the product candidates we do not select may have a greater likelihood of
success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among
clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, we may not gain market acceptance among
physicians, healthcare professionals, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it
will otherwise be accepted in the market. Market acceptance will depend on many factors, including factors that are not within our control. There are two recently approved products and additional product candidates in later stages of development for
the treatment of MPNs, including momelotinib (approved in 2023) and pacritinib (approved in 2022) as well as late-stage ropeginterferon <FONT STYLE="white-space:nowrap">alfa-2b,</FONT> imetelstat, pelabresib, bomedemstat, and navtemadlin. However, <FONT
STYLE="white-space:nowrap">DMR-001</FONT> is designed to have improved potency against both Type 1 and Type 2 mutCALR and contain modifications that are known to increase the half-life of antibodies in circulation; to date, no such disease-modifying
therapy that reduces platelet counts in ET patients with high risk of clotting and bleeding has been approved by the FDA for the treatment of MPNs, though several such agents are in advanced clinical development and close to approval. Market
participants with significant influence over acceptance of new treatments, such as clinicians and <FONT STYLE="white-space:nowrap">third-party</FONT> payors, may not adopt a biologic that incorporates anti-mutCALR antibodies and half-life extension
for our targeted indication, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. In
addition, there are several targeted therapies approved for the treatment of AML: enasidenib for patients with mutations in IDH2, marketed as Idhifa<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Bristol Myers Squibb Company and
Servier Pharmaceuticals, or Servier; ivosidenib for patients with mutations in IDH1, marketed as Tibsovo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Servier; revumenib for patients with KMT2A rearrangements or NPM1m, marketed as
Revuforj<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Syndax Pharmaceuticals Inc.; ziftomenib for patients with NPM1m, marketed as Komzifti<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Kura Oncology, Inc. and Kyowa
Kirin Co., Ltd.; and a series of drugs approved for patients with genetic alterations in FLT3 including gilteritinib, marketed as Xospata<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Astellas Pharma Inc., and quizartinib, marketed as
Vanflyta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> by Daiichi Sankyo, Inc. Market acceptance of our product candidates may be negatively impacted by potential poor performance of our competitors, including the occurrence of serious
adverse events in such competitors&#8217; clinical trials or failure by such competitors to obtain and maintain regulatory approval for their product candidates. Additionally, although we believe that the improved dosing and convenience we expect
our product candidates to provide will improve market acceptance of such product candidates and that our candidates will have a competitive efficacy profile, our predictions may not be accurate and other competitive products may instead gain and
hold the applicable market. Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing
treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain
profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future
revenue.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">DMR-001</FONT> for the treatment of ET and MF and intend to develop <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> for other MPNs, and we may in the future develop programs for additional MPNs. However, developing multiple product candidates for MPNs may negatively
impact our business if the product candidates compete with each other. For example, if multiple product candidates are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple product
candidates are approved for the same indication, they may compete for market share, which could limit our future revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We plan to conduct
clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are planning to conduct our Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">DMR-001</FONT> in several geographies, including potentially the
United States and Australia, and we may choose to conduct one or more of our future clinical trials outside the United States in whole or in part. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance
of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately
represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA
acceptance of the data will depend on our determination that the trials also complied with all applicable U.S. laws and regulations. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective
jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will
accept data from trials conducted outside of the United States or the relevant jurisdiction, as applicable. If the FDA or any comparable foreign regulatory authority does not accept such data, it would likely result in the need for additional
trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates or delay or prevent regulatory approval for commercialization in the applicable jurisdiction. Even if the FDA
or any comparable foreign regulatory authority accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or the relevant jurisdiction, as applicable, or to
continue such trials once initiated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, conducting international clinical trials presents additional risks that may delay completion of our
clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our
clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic
risks relevant to foreign countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on collaborations and licensing arrangements with third parties, including Paragon. If we are unable to maintain these collaborations or
licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
rely on our collaboration with a third party, Paragon, for a substantial portion of our discovery capabilities and for the rights necessary to develop and commercialize our product candidates. In the future, we could also rely on additional
licensing arrangements with third parties. For example, we have entered into the Paragon Option Agreement. However, Paragon could terminate the Paragon Option Agreement under certain circumstances, including our failure to make any payments owed to
Paragon under the agreement or any uncured material breach of the agreement by us, in which event we may lose intellectual property rights and may not be able to develop or commercialize the product candidates covered by that agreement, including <FONT
STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> or <FONT STYLE="white-space:nowrap">DMR-003,</FONT> as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to our acquisition of Bridge Medicines, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> rights to GB3226 from Rockefeller
University. This license agreement provides that we are subject to various obligations and conditions, including diligence obligations relating to the commercialization and development of GB3226. If we fail to comply with any of the conditions or
obligations or otherwise breach the terms of our license agreement with Rockefeller University, Rockefeller University may have the right to terminate the applicable agreement in whole or in part and thereby extinguish our rights to the licensed
technology and intellectual property and/or any rights we have acquired to develop and commercialize GB3226 or other product candidates. The loss of the rights licensed to us under our license agreement with Rockefeller University would eliminate
our ability to further develop GB3226. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend
heavily on the efforts and activities of such collaborators or licensors. If any of our collaborators or licensors experiences delays in performance of, or fails to perform, our obligations under our agreement with us, disagrees with our
interpretation of the terms of such agreement or terminates their agreement with us, our pipeline and product candidates and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations
or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture,
market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by
our agreement with them, leading to the potential invalidation of our intellectual property, or they may even infringe upon our intellectual property rights, any of which could subject us to litigation or arbitration, which would be time-consuming
and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and
products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or add development or
commercialization capabilities. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges,
increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may face
significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a
competitive advantage over us due to their size, financial resources and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater clinical development and commercialization capabilities. In addition, companies may be unwilling to assign or license rights to us, whether they perceive us to be a competitor or for
other reasons. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the
number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and does not have sufficient funds or expertise to
undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks associated with the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of product candidates could cause substantial delays in
the preclinical and clinical development of our product candidates.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied and continue to rely on Paragon, and expect to rely on our
future licensing partners, to (i)&nbsp;conduct research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, (ii)&nbsp;accurately report the results of all preclinical trials conducted prior to our
licensing or acquisition of the relevant product candidates and (iii)&nbsp;correctly collect and interpret the data from these trials. If the research and development processes or the results of the research programs prior to our licensing or
acquisition of our product candidates prove to be unreliable, this could result in increased costs and delays in the development of our product candidates, which could adversely affect any future revenue from such product candidates, if approved.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates for preclinical or clinical development in the
future as we continue to build our pipeline. The risks associated with acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates could result in delays in the commencement or completion of our preclinical studies and
clinical trials, if they are ever commenced or completed, and our ability to generate revenues from our product candidates may be delayed. Please see the section titled &#8220;<I>Risk Factors&#8212;Risks Related to Our Intellectual Property&#8212;If
we are unable to obtain or maintain necessary rights to our programs through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses,</FONT> our business may be materially harmed</I>&#8221; below for additional information regarding such
risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If
these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract
testing labs and strategic partners, to conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we
control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies
and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory
and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP, which are regulations and guidelines enforced by
the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials
may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials comply with GCP. In addition, our clinical trials must be conducted with products manufactured in accordance with cGMPs. Our failure to comply with these
requirements may require us to repeat </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false
claims laws and regulations or healthcare privacy and security laws, and foreign equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third parties conducting our clinical trials will not
be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may encounter challenges hiring and
retaining sufficient qualified personnel or they may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our current or future product candidates. If
these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully
commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we plan to rely on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited (&#8220;WuXi
Biologics (Hong Kong)&#8221;), for formulation and manufacturing of our Phase 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi Biologics (Hong Kong) is a subsidiary or affiliate of WuXi
Biologics, which was previously identified in the U.S. legislation proposed in 2024 known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The BIOSECURE Act as it was introduced in the House of Representatives in 2024 would
have prohibited federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering
provision allowing biotechnology equipment and services provided or produced by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until January&nbsp;1, 2032. The pathway and
timing for the BIOSECURE Act or its provisions to become law is uncertain. Depending on whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could
be potentially restricted from pursuing U.S. federal government business or grants in the future if we continue to use WuXi Biologics (Hong Kong) and if WuXi Biologics (Hong Kong) or other parties we contract with are identified as
&#8220;biotechnology companies of concern&#8221; beyond the grandfathering period. Foreign CMOs may be the target of U.S. legislation, including a new version of the BIOSECURE Act, trade restrictions and other foreign regulatory requirements which
could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material, restrict or even prohibit our ability to work with such CMOs, or have an adverse effect on our ability to secure significant
commitments from governments to purchase potential therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry in China is strictly regulated by the Chinese government.
Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial
condition, results of operations and prospects. In addition, the United States government has imposed significant tariffs on imports from China and other countries and may impose more restrictions on goods, including biologically derived substances,
manufactured in or imported from China or other countries or impose other restrictions on companies&#8217; ability to work with Chinese or other foreign counterparties. Evolving changes in China&#8217;s public health, economic, political, and social
conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an
adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical research programs. Furthermore, if a version of the BIOSECURE Act becomes law, and one or more of our
collaborators or vendors in China, including WuXi Biologics (Hong Kong), is deemed to be a biotechnology company of concern, our operations and financial condition may be negatively impacted as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while we have established
relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the research program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on the use of third-party CMOs to manufacture our product candidates, and we expect to continue to rely on third-party CMOs to produce our
products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must rely on CMOs to manufacture our
product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. We currently have a single source for our supply of our product
candidates and recently entered into an agreement with a second supplier. If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, or if we experience delays or difficulties in
transferring, or are unable to successfully transfer, our manufacturing processes, it could have a negative effect on the clinical development of our product candidates and other operations while we work to identify and qualify an alternate supply
source. We have limited control over the manufacturing process of, and may be dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory
authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or another applicable
regulatory authority does not approve these facilities for the manufacture of our product candidates or withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant
additional costs and delays and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. We, or our future contract manufacturers, any current or future collaborators and their
contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of the EU Member States or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMPs. Despite our
efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to
be noncompliant with cGMP regulations. Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension, variation or
withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or products,
if approved, and harm our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, our CMOs may experience manufacturing difficulties due to resource constraints,
supply chain issues, intellectual property disputes or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet
regulatory requirements and at a scale sufficient to meet anticipated demand at a commercially reasonable cost, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for
transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications.
We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially
adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the
approval of any of our product candidates by the FDA or comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Operations</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in
managing this growth.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in
the areas of preclinical and clinical drug development, technical operations, clinical operations and regulatory affairs. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial
personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such
anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly
qualified personnel, we may not be able to successfully implement our business strategy.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive
biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our managerial, scientific and medical personnel. Although we have
entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the
services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore,
replacing executive officers and key personnel may be difficult and may take an extended period of time. If we do not succeed in attracting and retaining qualified personnel, it could materially adversely affect our business, financial condition and
results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and
other risks and uncertainties.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates, if
approved, in foreign markets for which we may rely on collaboration with third parties. Recent and ongoing changes in the United States trade policy with foreign countries, including the continued uncertainty surrounding U.S. tariffs and potential
retaliatory measures by foreign governments, may disrupt the global supply chain for biopharmaceutical products. For example, in September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals,
unless the importing company is building U.S. manufacturing capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical
trials and not for commercial sale, which could increase the costs of materials for our clinical trials. Any direct tariffs, if imposed on pharmaceutical products, may result in increased costs for raw materials and contract manufacturing services,
reduced ability to source critical CMOs, and a delay in our development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market or promote any of our product
candidates before we receive regulatory approval from the applicable foreign regulatory authority, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries,
we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, if
approved, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be harmed and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to
the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the
forecasted growth, our business may not grow at similar rates, or at all.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our market opportunity estimates and growth forecasts are subject to
significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we
compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and
uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the
accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by
regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. Misconduct by these parties
could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing
standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are
subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales
commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of
clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third party service
providers, or existing or future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which
could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, &#8220;Process&#8221;) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively,
&#8220;Sensitive Information&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures in an effort to protect systems that store our information, given
their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials), third party service
providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and
electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may
compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some actors now engage and
are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and
the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations. In particular, severe ransomware attacks are becoming
increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may
be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any
disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and
reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure
or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations.
Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated
entities&#8217; systems and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no
assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be
detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may
require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party service providers and technologies to operate critical business systems to Process Sensitive Information in a variety of contexts. Our
ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or
other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our
damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217;
supply chains have not been compromised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we (or a third party upon whom we rely) experience a security incident or are perceived to have
experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight;
restrictions on Processing Sensitive Information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including
availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products,
and negatively impact our ability to grow and operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there
can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate
or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and
data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could
negatively affect our operating results and business.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, and third parties we work with, are or may become subject to numerous domestic and
foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other
rules. In addition, we are and may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us
or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of
customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on the success of our business.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and
radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or
commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules governing U.S.
federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (&#8220;IRS&#8221;) and the U.S. Treasury Department. Changes to tax laws (which changes may have
retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect
on our business and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals
would have on our business if they were to be enacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the United States enacted the Inflation Reduction Act of 2022, which implements,
among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and JOBS Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize
them generally over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside the United States. July&nbsp;4, 2025, the U.S. Congress enacted the One Big Beautiful Bill Act,
which includes a provision restoring the immediate deductibility of domestic research and development expenditures. The impact of this newly enacted law on our tax position will depend on how the provision is implemented and interpreted by the IRS
and other regulatory authorities. In addition, we have no assurance as to whether, when and how this provision may be subject to further amendment or repeal. Such changes, among others, may adversely affect our effective tax rate, results of
operation and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses, product candidates or products, or form strategic alliances, in the future, and may
not realize the benefits of such acquisitions.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances, or create joint
ventures with third parties that believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to
successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition
that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in
a material adverse effect on our business and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We maintain our cash at financial institutions, often in balances that exceed
federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash held in <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> and interest-bearing accounts exceeds the FDIC insurance limits. If such banking
institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank in March 2023. The Federal Reserve subsequently announced that account
holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217;
access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse
effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Intellectual Property</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our intellectual property portfolio is at an early stage. Therefore, our ability to obtain and protect our patent rights,
and protect other proprietary rights, is uncertain, exposing us to the possible loss of competitive advantage.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will rely upon a combination of
patents, trademarks, trade secret protection, copyrights and confidentiality agreements, licenses and the Paragon Option Agreement to protect the intellectual property related to our programs and technologies and to prevent third parties from
competing unfairly with us. Our success depends in large part on our ability to obtain and maintain patent protection for our product candidates and their uses, as well </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as our ability to operate without infringing on or violating the proprietary rights of others. We do not currently own or license any patents with respect to
<FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> <FONT STYLE="white-space:nowrap">DMR-003.</FONT> Paragon has filed patent applications directed to anti-mutCALR monoclonal antibodies, including
applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including <FONT STYLE="white-space:nowrap">DMR-001,</FONT> which we have the option to license pursuant to the Paragon Option Agreement.
In addition, with respect to GB3226, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Rockefeller University a patent portfolio directed to a series of selective inhibitors of ENL/AF9 YEATS. We also own two additional patent families
relating to claims covering composition of matter for various <FONT STYLE="white-space:nowrap">C-linked</FONT> inhibitors of ENL/AF9 YEATS and various inhibitors of ENL/AF9 YEATS and FLT3, combinations with various therapeutic agents, methods of
treatment, and methods of administration. In the future, we expect to prosecute underlying intellectual property for <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT>
<FONT STYLE="white-space:nowrap">DMR-003,</FONT> GB3226 and some or all of the <FONT STYLE="white-space:nowrap">in-licensed</FONT> or owned product candidates that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to obtain or protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor
enforcement or protection of at least certain patents, trade secrets or other intellectual property. Filing, prosecuting, maintaining and defending patents on product candidates and other related inventions worldwide would be expensive and our
intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, we may not have patents in all countries or all major markets and may not be able to obtain
patents in all jurisdictions even if we or our licensor files patent applications to obtain such rights. Our competitors may operate in countries where we do not have patent protection and may be able to freely use our technologies and discoveries
in such countries, at least to the extent not forbidden by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our intellectual property portfolio is at an early stage. Except as described above, we
do not currently own or license any issued patents or pending patent applications. Our future optioned, <FONT STYLE="white-space:nowrap">in-licensed</FONT> or owned patent applications may not result in patents being issued. Any issued patents may
not afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties, or effectively
prevent others from commercializing competitive technologies, products or product candidates. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our product candidates
could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. If we do not obtain patent coverage for the work we are conducting, or if we obtain such
rights but they are invalidated or rendered unenforceable, we may be unable to exclude competitors from pursuing and marketing the same or similar product candidates. Other risks we face if we are not able to obtain and maintain patent coverage for
our product candidates are the reduction in valuation of our product candidates, and ultimately of us as a company, by potential investors, and our inability to assert claims for infringement against third parties or counterclaim against such third
parties or negotiate more advantageous settlement parameters. Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent
protection would be reduced. Thus, the patents that we may own or license may not afford us any meaningful exclusivity period or competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share
our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary
information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality
agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including
through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake reasonable efforts to protect our trade secrets and other confidential information from disclosure,
others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine
the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain or maintain necessary rights to our programs through acquisitions
and <FONT STYLE="white-space:nowrap">in-licenses,</FONT> our business may be materially harmed.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our research programs currently do and may
in the future require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We
may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our programs. The
licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider
attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a
competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are
unable to successfully obtain rights to required third-party intellectual property rights or maintain intellectual property rights we obtain in the future, we may have to abandon development of the relevant program, which could have a material
adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have the right to control prosecution, defense,
maintenance and enforcement of patents <FONT STYLE="white-space:nowrap">in-licensed</FONT> under the Paragon License Agreements once the trigger for transfer of prosecution control is met, there may be times when rights for patents and patent
applications relating to our product candidates are controlled by our future licensors or collaboration partners. For example, Paragon currently has the right to file patent applications and control prosecution with respect to any other inventions
that may fall within the Paragon Option Agreement, including those that may apply to <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003.</FONT> If we, Paragon
or any of our future licensors or collaboration partners fail to prosecute, defend, maintain and enforce such patents and patent applications in a manner consistent with our best interests, including by payment of all applicable fees for patents
covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be
able to prevent competitors from making, using and selling competing products. In addition, even if we have the right to control prosecution of patents and patent applications we have licensed to and from third parties, including under future
license agreements with Paragon following the point at which such control is assumed, we may still be adversely affected or prejudiced by actions or inactions of Paragon, additional licensees, or licensors and their counsel prior to the date upon
which we assume control over patent prosecution. For example, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to <FONT STYLE="white-space:nowrap">DMR-001,</FONT>
<FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003.</FONT> Subsequent to entering into such license agreements, we expect to control patent prosecution over <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003</FONT> following the trigger for transfer of prosecution control for the applicable program to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future licensors may not be the sole and exclusive owners of all rights in the patents we may <FONT STYLE="white-space:nowrap">in-license.</FONT> If other
third parties have rights to our future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial condition, results of
operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are
able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to
redesign our product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or
commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced
against our product candidates, manufacturing methods or future products or methods resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties
and/or other forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our future licensors regarding
intellectual property subject to a license agreement, including (but not limited to): the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes
infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of
inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology. If we or our
future licensors breach the terms of our license agreements, such breach may have a material adverse effect on our business and the commercialization efforts for our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to intellectual property lawsuits or may need to file lawsuits to protect our intellectual property, which could result in substantial
costs and liability and prevent us from commercializing our potential products.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the intellectual property landscape in the biotechnology
industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third party rights. If certain of our product candidates are
ultimately granted regulatory approval, patent rights held by third parties could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, and our rights are not held invalid or
unenforceable, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret
misappropriation) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that future patents, if
filed and issued, owned or licensed by us will not be challenged by others, whether in the course of litigation or in agencies like the USPTO. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more
effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our future patents, trademarks, copyrights or other intellectual property. To counter infringement or other
violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual
property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or
refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we
have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be
forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we may be required to protect our future patents, if filed and issued, through procedures created to attack the validity of a patent at the USPTO. An
adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO
proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even
though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if our product
candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees or customers and other parties with whom we have business relationships and we may be
required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees or other parties regardless of the merits of such claims.
If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating
to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success will depend in part on our and our current and future licensors&#8217; ability to obtain, maintain and enforce patent protection for our
licensed intellectual property.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our and our current and future licensors&#8217; (including Paragon&#8217;s)
ability to obtain, maintain and enforce patent protection for our licensed intellectual property. Currently, Paragon controls the prosecution, maintenance, enforcement and defense of <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT
STYLE="white-space:nowrap">DMR-002</FONT> and <FONT STYLE="white-space:nowrap">DMR-003.</FONT> After entry into license agreements with Paragon for <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002</FONT> and <FONT
STYLE="white-space:nowrap">DMR-003,</FONT> and once the trigger for transfer of prosecution control is met, we expect to hold such rights. We, Paragon and our future licensors may not successfully prosecute the patent applications that cover our
product candidates. In addition, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> rights to GB3226 from Rockefeller, and we depend on Rockefeller University to prosecute and maintain patents and otherwise protect the licensed intellectual
property related to GB3226. Even if patents are issued in respect of these patent applications, we and our future licensors (including Paragon) may fail to maintain these patents, may determine not to pursue litigation against other companies that
are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for any <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property, other companies might be able to offer substantially
identical products for sale, which could adversely affect our competitive business position and harm our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to
claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product
candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our
competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors.
Although </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in
their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we
or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we may litigate to defend against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to
management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such
technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to
form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if
we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to
patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America
Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the maintenance, enforcement or
defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent
applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to
March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act,
the United States transitioned to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a
patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation increased the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally,
there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.
Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts.
For example, the United States Supreme Court in <I>Amgen, Inc. v. Sanofi</I> (&#8220;<I>Amgen</I>&#8221;) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were
invalid for lack of enablement where the patent specification provided 26 exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated
that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be
granted U.S. patents with composition of matter claims as broad as Amgen&#8217;s directed to antibodies functionally defined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge our patents, when issued,
relying on the reasoning in <I>Amgen</I> or other precedential court decisions. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.
Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights
in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory
agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. Geopolitical instability in the United States and in foreign
countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. In addition, the Unified Patent Court (&#8220;UPC&#8221;) entered
into force on June&nbsp;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single
proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not
currently own any European patents or applications, if we obtain or license such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to
commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We
may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be
challenged for <FONT STYLE="white-space:nowrap">non-compliance</FONT> and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if
we decide to opt out of the UPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions,
fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the
USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment
and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in
abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly
legalize and submit formal documents. If we fail to maintain any future patents and patent applications, if filed and issued, covering our product candidates, our competitive position would be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might
adversely affect our ability to develop and market our products.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our patent searches or analyses, including the
identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, the patent&#8217;s prosecution history and in some cases certain extrinsic evidence of the meaning of
terms in a claim. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict
whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and
correctly interpret relevant patents may negatively impact our ability to develop and market our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications
in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific
literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our future issued patents or our pending applications, if filed, or that we were the first to invent the
technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our future patent applications or patents, if filed
and issued, which could require us to obtain rights to issued patents covering such technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the
inventorship or ownership of our patents, if issued, and other intellectual property.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our future patents, if filed and issued, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a
patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws
where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding
<FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements
to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use,
valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the
U.S. government, such that our licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-licensed.</FONT> If other third parties have ownership rights or other rights to our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our
competitive position, business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our
competitive position of our product candidates for an adequate amount of time.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all
maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from our earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and
the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of
time required for the development, testing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and
licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our technology licensed from various third parties may be subject to retained rights.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future licensors may retain certain rights under the relevant agreements with us, including the right to use or license the licensed technology outside of
the scope of our license, use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of
information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of
misuse. In addition, while there are certain restrictions on Paragon&#8217;s ability to develop products that could be competitive with ours, these restrictions may not prevent the possible future license or development by Paragon of certain
technology that could lead to product candidates competitive with ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals
for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following
commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize product candidates in
the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities.
Before obtaining regulatory approvals for the commercial sale of our product candidates, including <FONT STYLE="white-space:nowrap">DMR-001,</FONT> <FONT STYLE="white-space:nowrap">DMR-002,</FONT> <FONT STYLE="white-space:nowrap">DMR-003</FONT> and
GB3226, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the
submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective, may prove to
have undesirable or unintended side effects, toxicities or other characteristics, or may fail to improve on the applicable standard of care, any of which may preclude our obtaining regulatory approval. The FDA and comparable foreign regulatory
authorities have discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be
delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to
the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance required by the
FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be
unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh our safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable
foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of
third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data
insufficient for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA or applicable foreign
regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would
significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were to obtain approval, regulatory authorities may approve any of our
product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may
approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required
regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, this could have a material adverse effect on our competitive position, business, financial condition, results of
operations, and prospects. In addition, the FDA and foreign regulatory authorities may undergo leadership changes, change their policies, issue additional regulations or revise existing regulations, or take other actions, such as those implemented
by the recently established Department of Government Efficiency, which may impact our clinical development plans or prevent or delay approval of our product candidates under development on a timely basis. Such policy or regulatory changes could
impose additional requirements upon us that could delay our ability to obtain approvals and increase the costs of compliance. Since the start of President Trump&#8217;s administration in 2025, U.S. policy changes have been implemented at a rapid
pace and additional changes are likely. It is difficult to predict how executive actions that may be taken under the current administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If any actions impose constraints on
the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, our business may be negatively impacted. Additionally, federal government could adopt legislation, regulations or policies that adversely
affect our business or create a more challenging and costly environment to pursue the development, approval and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing
partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug
product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. Meeting these chemistry, manufacturing and control
requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval as biologics may face competition from biosimilars sooner than anticipated.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a highly similar or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a
biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety,
purity and potency of their product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as biologics under a BLA should qualify for the <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet
clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of our
product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory
requirements or experience unanticipated problems with our product candidates.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our product
candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups,
warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy, or REMS, in order to approve our product
candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
Comparable foreign regulatory authorities may impose similar requirements. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their
development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation
by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as <FONT
STYLE="white-space:nowrap">on-going</FONT> compliance with cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic,
unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. If we or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or
problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension
of manufacturing, delays or restrictions on our ability to conduct clinical trials or delays or refusal to grant a marketing authorization, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing
process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, suspension, withdrawal or variation of any marketing authorization that has been granted, voluntary or mandatory publicity
requirements and imposition of restrictions on operations, including costly new manufacturing requirements. Similar penalties may apply in case of failure by us or by any of our third-party partners, including suppliers, manufacturers and
distributors, to comply with FDA and EU laws and the related national laws of individual EU Member States and other applicable regulatory authorities governing the conduct of clinical trials, manufacturing approval, marketing authorization of
medicinal products and marketing of such products, both before and after grant of a marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements, including administrative, civil or criminal penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and
generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at
the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from
being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review regulatory filings and our ability to commence human clinical trials can be affected by a variety of factors, including
government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In
addition, government funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and approval of
applications for clinical trial or marketing authorization, which would adversely affect our business. For example, in recent years, including in 2018, 2019 and 2025, the U.S. government shut down several times and certain regulatory agencies, such
as the FDA and the SEC, had to furlough critical employees and stop critical activities. Additionally, action by the Trump administration to limit federal agency budgets or personnel may result in reductions to the FDA&#8217;s budget, employees, and
operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. If a prolonged government
shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability
to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown
occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face
difficulties from healthcare and regulatory legislative reform measures.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change, and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action,
either in the United States or abroad. For example, the Trump administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making
and ultimately the cost and availability of prescription drugs. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may
lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and
future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient
organizations and customers may expose us to broadly applicable fraud </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations and future business arrangements with
third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be
subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions
can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement
policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to seek
approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those
jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health
administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and
establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access
policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and
regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to export
control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets
Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering
laws in the countries in which we conduct activities. Governmental regulation of the import or export of our drug candidates, or our failure to obtain any required import or export authorization for our candidates, when applicable, could harm
international operations. Furthermore, export control laws and economic sanctions prohibit the provision of certain items, technology, and services to countries, governments, and persons targeted by sanctions programs. Anti-corruption laws are
interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from
recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.
We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our
employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal
fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governments outside the United States tend to impose strict price controls, which may adversely affect
our revenue, if any.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, particularly EU Member States, the pricing of prescription drugs is subject to governmental control. In
these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices
and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained.
Reference pricing used by various EU Member States and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. To obtain coverage and reimbursement
or pricing approvals in some countries, we or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain
reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any
product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we seek and are unable to obtain accelerated approval, the amount, size and duration of our clinical trials could be greater than planned, which
could increase the expense, reduce the likelihood, and/or delay the timing of obtaining necessary regulatory approvals. Even if we receive accelerated approval, if confirmatory trials do not verify clinical benefit, or if we do not comply with
rigorous post-approval requirements, such authorities may withdraw accelerated approval.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek accelerated approval, or other expedited
development, review or approval status, for our product candidates. Even if granted, there is no guarantee that receiving an expedited development, review or approval status from the FDA will lead to a faster development or regulatory review or
approval process, and such status does not increase the likelihood that our product candidates will ultimately receive marketing approval. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition
that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. If we choose to pursue accelerated
approval, there can be no assurance that the FDA will agree that our proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that we will continue to pursue accelerated
approval or any other form of expedited development, review, or approval, even if we initially decide to do so. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or
that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA&#8217;s
requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. Accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent
manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require,
as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA may require that any such confirmatory study be initiated or
substantially underway prior to the submission of an application for accelerated approval. Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-approval requirements, including submission to the FDA of all
promotional materials prior to their dissemination. The FDA could withdraw accelerated approval for multiple reasons, including our failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the
drug&#8217;s predicted clinical benefit relative to its risks. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such
product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate, increase the cost of development of such product candidate, and harm our competitive position in the marketplace. Comparable considerations apply outside of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to
costly and damaging liability claims, when testing a product candidate in the clinical stage or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and
use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to
liability claims. These claims may be made by patients that use the product or product candidate, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against us, regardless of their merit, could be difficult
and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance for our future clinical trials, it is
possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may
arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be
impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation costs and the outcome of litigation could have a material adverse effect on our business.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities
litigation, employment matters, security of patient and employee personal information, contractual relations with collaborators and licensors and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to
enforce any rights that we may have against third parties, could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be adversely affected by economic downturns, inflation, fluctuating interest rates, natural disasters, public health crises,
political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, fluctuating interest rates, and uncertainty about economic stability. Adverse macroeconomic
conditions, including inflation, slower growth or recession, new or increased tariffs imposed by the U.S. government and potential retaliatory measures by foreign governments and other barriers to trade, especially in light of recent comments and
executive orders made by the Trump administration, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), government shutdowns, tighter credit, higher interest rates, volatility in
financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, we and our business partners and
suppliers. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. In addition, the U.S. has imposed and taken action to pause,
resume or adjust tariffs on imports from a number of countries. Since February 2025, the United States government has imposed various tariffs on imports from most countries, including tariffs on imports from China and South Korea. In September 2025,
President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical
trials and not for commercial sale, which could increase the costs of materials for our clinical trials. There still remains substantial uncertainty about the duration of existing tariffs and whether additional tariffs may be imposed, modified or
suspended. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Uncertainty and political tensions as a result of trade policies could
reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. The
Federal Reserve has raised interest rates multiple times in recent years in response to concerns about inflation and it may raise them again. High interest rates, coupled with reduced government spending and volatility in financial markets, may
increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and
may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets
deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates
can adversely affect us by increasing our costs, including labor and employee benefit costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future experience disruptions as a result of
such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our
results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Ownership of Our Common Stock</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our Common Stock has been and is expected to continue to be volatile.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our Common Stock has been and is expected to continue to be subject to significant fluctuations. Some of the factors that may cause the
market price of our Common Stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our
existing or future collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial and development projections we may provide to the public;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed the financial and development projections of the investment community;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we do not achieve the perceived benefits of our recent merger as rapidly or to the extent anticipated by
financial or industry analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us
or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing
process or sales and marketing terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts do not publish research or reports about our business, or if they issue
adverse or misleading opinions regarding our business and stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of securities by us or our securityholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to raise an adequate amount of capital to fund our operations or continued development of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by competitors of new commercial products, clinical progress or lack thereof, significant
contracts, commercial relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity relating to precision medicine product candidates, including with respect to other products in
such markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of technological innovations or new therapies that compete with our products and services; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in
our financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to
the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our Common Stock. In addition, a recession, depression or other sustained adverse market event could materially and
adversely affect our business and the value of our Common Stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such
companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic
direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are governed by Delaware law and our Certificate of Incorporation and Bylaws, provisions of which have anti-takeover implications. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions that are included in our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger, acquisition or other change in control
of the Company that our stockholders may consider favorable, including transactions in which holders of Common Stock might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be
willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock. In addition, because the Board of Directors is responsible for appointing our management team, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for our stockholders to replace members of the Board of Directors. Among other things, these provisions will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the use of a classified board of directors such that not all members of our Board of Directors are
elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of directors to be changed only by resolution of the Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which our stockholders can remove directors from the Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for advance notice requirements for nominations for election to the Board of Directors or for proposing
matters that can be acted on at stockholder meetings </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call a special meeting of stockholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the Board of Directors to issue preferred stock without stockholder approval, which could be used to
institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 66 2&#8725;3% of the voting rights to amend or repeal certain
provisions of the Certificate of Incorporation or Bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the affirmative vote of not less than 66 2/3% of the outstanding shares of capital stock entitled to vote
on the matter to amend or repeal the Bylaws if the Board of Directors does not recommend the same. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we and our organizational
documents are governed by Delaware law. Section&nbsp;203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;) contains provisions that may enable our board of directors to discourage, delay or prevent a change in our ownership or in our
management. The business combinations with interested stockholders provisions of the DGCL, subject to certain exceptions, restrict our ability to engage in any business combination with an interested stockholder for a three year period following the
time that this stockholder becomes an interested stockholder, unless (i)&nbsp;before the stockholder became an interested stockholder, our board of directors approved either the business combination or the transaction which resulted in the
stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation
outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding
voting stock owned by the interested stockholder; or (iii)&nbsp;at or after the time the stockholder became an interested stockholder, the business combination was approved by our board of directors and authorized at an annual or special meeting of
the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. For purposes of the foregoing provisions, &#8220;interested
stockholder&#8221;, with certain exceptions is any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person at
any time in the last three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Series B Certificate of Designation may delay or prevent a change in control of the Company. At
any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock,
(i)&nbsp;consummate (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y)&nbsp;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in
which our stockholders immediately before such transaction do not hold at least a majority of our capital stock of immediately after such transaction, (ii)&nbsp;increase the size of the Board of Directors, (iii)&nbsp;adopt, amend or repeal any
written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Board of Directors, or (iv)&nbsp;retain or replace
our registered independent public accounting firm, independent compensation consultant or corporate counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because our Certificate of
Incorporation and Bylaws limit the court in which you may bring an action against us, you may have difficulty obtaining a more favorable judicial forum or you may incur more expense enforcing any rights which you may claim as compared to another
forum. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and our Bylaws provide that, to the extent permitted by law, any person who acquires equity in our
company shall be deemed to have notice and consented to the forum selection provision of our bylaws, which require actions to be brought only in the Court of Chancery of the State of Delaware, which may inhibit or deter stockholders&#8217; actions
(i)&nbsp;brought in the name of our company or on our behalf; (ii)&nbsp;asserting a claim for breach of any fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders; (iii)&nbsp;arising or asserting a claim
arising pursuant to any provision of Delaware General Corporation Law or any provision of our Certificate of Incorporation or Bylaws; (iv)&nbsp;to interpret, apply, enforce or determine the validity of any provision of our Certificate of
Incorporation or Bylaws; or (v)&nbsp;asserting a claim governed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the internal affairs doctrine. This exclusive forum provision may limit our stockholders&#8217; ability to obtain what they believe to be a favorable judicial forum for disputes with us and our
officers and directors. This provision does not apply to claims brought under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person or entity purchasing or
otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its
choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either exclusive-forum provision in our bylaws to be
inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public
companies.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will incur significant legal, accounting and other expenses as a public company, including costs associated with public company
reporting obligations under the Exchange Act. Our executive officers and other personnel need to devote substantial time to comply with public company reporting requirements and additional applicable laws and obligations. Any changes we make to
comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation
exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the Board of Directors or on board committees or to serve as executive officers, or to obtain certain types
of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Once we are no longer a smaller reporting company or
otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash
flows.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC, annual,
quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, in at least the near term, we may take advantage of exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements. In addition, as a smaller reporting company with less than $100.0&nbsp;million in annual revenue, we are not required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act. Once we
are no longer a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal,
accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our Common Stock may be harmed. For example, if we or our independent auditor
identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to
sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act
requires, among other things, that we maintain effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to
allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement
of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the
control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues
and instances of fraud will be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, or if we are
unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our Common Stock could decline and we could be subject to sanctions or
investigations by Nasdaq, the SEC or other regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate that we will pay any cash dividends in the foreseeable
future.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying
dividends. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain, if any, for our stockholders for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares by existing stockholders could cause our stock price to decline.</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If existing securityholders sell, or indicate an intention to sell, substantial amounts of our Common Stock in the public market after legal restrictions on
resale in connection with our recent merger lapse, the trading price of our Common Stock could decline. In addition, shares of Common Stock that are subject to outstanding options will become eligible for sale in the public market to the extent
permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of our Common Stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our
stockholders for approval.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers, directors and principal stockholders, in the aggregate, beneficially own a significant portion
of our outstanding shares of common stock (on a fully-diluted basis), subject to beneficial ownership limitations. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all
matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any
merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of interest may arise between us and Paragon or us and Fairmount. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, we assumed the rights and obligations of Damora under the Paragon Option Agreement. See the section titled
&#8220;<I>Paragon Option Agreement</I>&#8221; for more information on the Paragon Option Agreement. Paragon and Paramora each beneficially own more than 5% of a class of our voting securities through their respective holdings of our Common Stock,
although neither are expected to own more than 5% following the Conversion Approval. Fairmount beneficially owns more than 5% of Paragon, appointed Paragon&#8217;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors, and has the contractual right to approve the appointment of any executive officers of Paragon. Paramora is an entity formed by Paragon as a vehicle to hold equity in Damora
(and as a result of the Asset Acquisition, us) in order to share profits with certain employees of Paragon. Fairmount beneficially owns 19.99% of our Common Stock assuming conversion of the Series B Preferred Stock and Series C Preferred Stock into
common stock (in each case, subject to beneficial ownership limitations and based on the number of shares of common stock outstanding as of December&nbsp;1, 2025, and assuming no exercise of outstanding options). Three of our directors are
affiliated with Fairmount (Peter Harwin, Christopher Cain, Ph.D., and Julianne Bruno) and were appointed in accordance with the Acquisition Agreement. The remaining four members of the Board of Directors, constituting a majority of the Board of
Directors, are not affiliated with Fairmount or Paragon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our relationship with Paragon, Paramora, Fairmount and our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors may create, or may create the appearance of, conflicts of interest when we are faced with decisions that could have different implications for Paragon or Paramora than the decisions have
for us. For example, such conflicts may arise in connection with the selection of additional targets, the exercise of options under the Paragon Option Agreement, the negotiation of the terms of any future license agreements, the allocation of
resources and expenses, the enforcement or defense of intellectual property rights, the pursuit of strategic partnerships or transactions, or the resolution of any disputes that may arise between us and Paragon or Paramora. We expect that the
decision to amend the Paragon Option Agreement or enter into any similar agreements or license agreements with Paragon will be subject to the approval of the Board of Directors. All directors of the Board of Directors owe fiduciary duties pursuant
to Delaware law, and directors of the Board of Directors are expected to comply with their respective fiduciary duties under Delaware law relevant to related party transactions. We have previously adopted a related party transaction approval policy
and our audit committee will be responsible for the review, consideration and approval or ratification of related party transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore,
because Paragon and Fairmount have interests in other biotechnology companies that may compete with us or pursue similar or complementary product candidates or technologies, they may have an incentive to favor or support such other companies over
us. These potential conflicts of interest may make it more difficult for us to favorably advance our business interests and may adversely affect our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, then
our stock price and trading volume could decline.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock is influenced by the research and reports that equity
research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our Common Stock, and such lack of research coverage may adversely affect the market price of our Common Stock. In addition,
we do not have any control over the analysts or the content and opinions included in their reports. The price of our Common Stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or
research. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, demand for our Common Stock could decrease, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use net operating loss (&#8220;NOL&#8221;) carryforwards and other tax attributes may be limited, including as a result of our recent
merger.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to become profitable in the near future and may never achieve profitability. As of December&nbsp;31, 2024, we had federal
and state NOL carryforwards and federal and state research and development credits that may be used to offset future taxable income. Under current law, our U.S. federal NOLs incurred in tax years beginning after December&nbsp;31, 2017 may be carried
forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of
the Internal Revenue Code (the &#8220;Code&#8221;), U.S. federal NOL carryforwards and other tax attributes may become subject to an annual limitation in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&nbsp;382 of the Code generally occurs if one or more stockholders or groups of
stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our net operating loss
carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with our recent merger or other transactions. Similar rules may
apply under state tax laws. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The class structure of our capital stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain
transactions.</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The class structure of our capital stock may limit your ability to influence corporate matters. Holders of Common Stock are entitled
to one vote per share, while holders of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock are not entitled to any votes. Nonetheless, each share of Series A Preferred Stock, and, following approval of the Conversion
Proposal, each share of Series B Preferred Stock and Series C Preferred Stock, may be converted at any time into 1,000 shares of Common Stock at the option of the holder by providing written notice to us, subject to beneficial ownership limitations
and the limitations provided for in our Certificate of Incorporation and the related certificates of designation. Consequently, if holders of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock exercise their option
to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, respectively, and correspondingly decreasing
the voting power of the holders of Common Stock, which may limit your ability to influence corporate matters. On the third business day following approval of the Conversion Proposal, each share of Series C Preferred Stock will automatically convert
into shares of Common Stock, subject to certain limitations, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Series B Preferred Stock does not have voting rights on proposals presented to our
holders of common stock, at any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the
Series B Preferred Stock, (i)&nbsp;consummate (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y)&nbsp;any merger or consolidation of the Company with or into another entity or any stock sale to, or other
business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, (ii)&nbsp;increase the size of the Board of Directors, (iii)&nbsp;adopt,
amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Board of Directors, or
(iv)&nbsp;retain or replace our registered independent public accounting firm, independent compensation consultant or corporate counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally,
stockholders who hold, in the aggregate, more than 10% of Common Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, but 10% or less of Common Stock, and are not otherwise an insider, may not be required to report
changes in their ownership due to transactions in the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock pursuant to Section&nbsp;16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of
Section&nbsp;16(b) of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_5"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with the SEC, which means that we can disclose important information to
you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report
(or portion thereof) furnished, but not filed, on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make
with the SEC under Section&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except, in each
case, as to any portion of any future report or document that is not deemed filed under such provisions, prior to the termination of any offering of securities made by this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000095017025041981/glto-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;
19, 2025, including certain information incorporated by reference therein from our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000095017025060552/glto-20250429.htm">Definitive Proxy Statement on Schedule
 14A</A> for our 2025 annual meeting of stockholders filed with the SEC on April&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2025, June&nbsp;30, 2025 and September&nbsp;30, 2025 and filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000095017025066884/glto-20250331.htm">May<U></U>&nbsp;
8, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000095017025102963/glto-20250630.htm">August<U></U>&nbsp;
5, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000119312525269426/glto-20250930.htm">November<U></U>&nbsp;6, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (except for information contained therein
which is furnished rather than filed) filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000095017025088168/glto-20250618.htm">June<U></U>&nbsp;
20, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000119312525273342/d53983d8k.htm">November<U></U>&nbsp;
10, 2025</A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001800315/000119312525312912/glto-20251110.htm">December<U></U>&nbsp;9, 2025</A>); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Common Stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1800315/000119312520275442/d49896d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on October&nbsp;23, 2020 under Section&nbsp;12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference
(other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). Written or oral requests for copies should be directed Galecto, Inc., Attn: Investor
Relations, 75 State Street, Suite 100, Boston, MA 02109, telephone number (+45) 70 70 52 10. See the section of this prospectus entitled &#8220;Where You Can Find More Information&#8221; for information concerning how to read and obtain copies of
materials that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus, or in a document all or a portion of which is incorporated by reference,
shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such
statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net
proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, the
Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of
any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our
counsel and our independent registered public accounting firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of
60,513,309 shares of Common Stock, which represents the total number of shares of Common Stock issued to the Selling Stockholders pursuant to the Acquisition Agreement or issuable upon the conversion of the Series B Preferred Stock and Series C
Preferred Stock issued pursuant to the Acquisition Agreement and the Securities Purchase Agreement. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any
accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2025, we entered into the Securities Purchase Agreement, pursuant to which we sold an aggregate
of 39,641 shares of Series C Preferred Stock, which are convertible into 39,641,000 shares of Common Stock pursuant to the Series C Certificate of Designation, at an aggregate purchase price of approximately $285&nbsp;million. Also on
November&nbsp;10, 2025, we completed our acquisition of Damora in accordance with the Acquisition Agreement, pursuant to which we issued an aggregate of 265,309 shares of Common Stock, 16,366 shares of Series B Preferred Stock, which are convertible
into 16,366,000 shares of Common Stock pursuant to the Series B Certificate of Designation, and 4,241 shares of Series C Preferred Stock, which are convertible into 4,241,000 shares of Common Stock pursuant to the Series C Certificate of
Designation, to certain of the Selling Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees,
transferees or other <FONT STYLE="white-space:nowrap">successors-in</FONT> interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of
Distribution&#8221; herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any
position, office or other material relationship with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of the Selling Stockholders, the number of shares of
our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders
assuming all of the shares registered for resale hereby are sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell some, all or none of their Resale Shares. We do not
know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale
Shares, except for <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with certain Damora stockholders as of immediately prior to the Asset Acquisition, pursuant to which each such Selling Stockholder is subject to a <FONT
STYLE="white-space:nowrap">180-day</FONT> lockup on the sale or transfer of shares of Common Stock held by each such Selling Stockholder at the closing of the Transactions. The Resale Shares covered hereby may be offered from time to time by the
Selling Stockholders, provided that Resale Shares issued upon conversion of Series B Preferred Stock and Series C Preferred Stock may only be offered after such shares of Series B Preferred Stock and Series C Preferred Stock, respectively, are
converted to Common Stock pursuant to the terms of the Series B Certificate of Designation and Series C Certificate of Designation, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Series B Preferred Stock, Series C Preferred Stock, and Merger Common Shares in
connection with the Transactions. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 1,595,161 shares of Common Stock outstanding as of December&nbsp;1, 2025, and, for each Selling Stockholder,
assumes the conversion of only the Series B Preferred Stock and Series C Preferred Stock owned by such Selling Stockholder but not the Series B Preferred Stock and Series C Preferred Stock owned by any other Selling Stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling<BR>Stockholders(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Beneficially<BR>Owned<BR>Before<BR>Offering (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock&nbsp;that&nbsp;May<BR>Be Offered<BR>Pursuant to<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Beneficially<BR>Owned After<BR>Offering (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Fairmount Funds Management LLC (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,801,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,801,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paragon Therapeutics, Inc. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paramora Holding LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Health Care Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Select Health Care Portfolio (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable Insurance Products Fund IV: VIP Health Care Portfolio (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,298,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,298,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Small Cap Growth Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolio (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Life Sciences Fund LLC (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,478,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,478,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Viking Global Investors LP (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,782,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,782,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Venrock Healthcare Capital Partners (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital Master LP (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,739,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,739,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,739,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,739,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Biomedical Innovation Master Investors (Cayman) II L.P. (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P. (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with TCG Crossover Management (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ForGrowth III PA B.V. (15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotech Growth N.V. (16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Associates, LLC (18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Vestal Point Capital, LP (19)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Private Holdings (Cayman) Ltd. (20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AH Bio Fund IV, L.P, as nominee (21)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CDK Associates, L.L.C. (22)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spruce Street Aggregator L.P. (23)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP (24)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with ADAR1 Capital Management, LLC (25)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling<BR>Stockholders(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Beneficially<BR>Owned<BR>Before<BR>Offering (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock&nbsp;that&nbsp;May<BR>Be Offered<BR>Pursuant to<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Beneficially<BR>Owned After<BR>Offering (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trails Edge Biotechnology Master Fund, LP (26)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackwell Partners LLC&#8212;Series A (27)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kalehua Capital Partners LP (28)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nantahala Capital Partners Limited Partnership (29)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Healthcare Partners 2025 Fund, LLC (30)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NCP RFM LP (31)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Street Holdings, LLC (32)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julianne Bruno (33)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Crutcher (34)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice (35)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin DiMartino (36)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and
investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 75 State Street, Suite 100, Boston, MA 02109. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect
ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus
without taking into account certain limitations, including that a holder of Series B Preferred Stock and Series C Preferred Stock is prohibited from converting shares of Series B Preferred Stock and Series C Preferred Stock into shares of Common
Stock (i)&nbsp;prior to the Conversion Approval, or (ii)&nbsp;if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0.00% and 19.99%)
(the &#8220;Beneficial Ownership Limitation&#8221;) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 16,366,000 shares of Common Stock issuable upon the conversion of 16,366 shares of Series B
Preferred Stock held by Fairmount Healthcare Fund II LP (&#8220;Fund II&#8221;), (ii) 6,957,000 shares of Common Stock issuable upon the conversion of 6,957 shares of Series C Preferred Stock held by Fund II and (iii) 3,478,000 shares of Common
Stock issuable upon the conversion of 3,478 shares of Series C Preferred Stock held by Fairmount Healthcare <FONT STYLE="white-space:nowrap">Co-Invest</FONT> V L.P. <FONT STYLE="white-space:nowrap">(&#8220;Co-Invest&#8221;).</FONT> Fairmount Funds
Management LLC (&#8220;Fairmount Funds Management&#8221;) serves as investment manager for Fund II and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> and may be deemed a beneficial owner of any securities of the Company held by Fund II and <FONT
STYLE="white-space:nowrap">Co-Invest.</FONT> Fund II and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> have delegated to Fairmount Funds Management the sole power to vote and the sole power to dispose of all securities held in Fund II&#8217;s
and <FONT STYLE="white-space:nowrap">Co-Invest&#8217;s</FONT> portfolio. Because Fund II and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> have divested themselves of voting and investment power over the securities they hold and may not revoke
that delegation on less than 61 days&#8217; notice, Fund II and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> disclaim beneficial ownership of the securities they hold. As managers of Fairmount Funds Management, Peter Harwin and Tomas Kiselak
may be deemed beneficial owners of any securities of the Company beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Mr.&nbsp;Harwin and Mr.&nbsp;Kiselak disclaim beneficial ownership of securities held by Fund II and <FONT
STYLE="white-space:nowrap">Co-Invest,</FONT> except to the extent of their pecuniary interest therein. The address for the beneficial owners is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock and Series C Preferred Stock held by each of Fund II and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> are each subject to a Beneficial Ownership Limitation of 19.99%. At such time as
Fairmount Funds Management and its affiliates beneficially own 9.0% or less of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the shares of common stock, the beneficial ownership limitation applicable to the shares of the Series B Preferred Stock and Series C Preferred Stock will automatically reduce to 9.99%.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 120,473 shares of Common Stock and (ii) 1,925,000 shares of Common Stock issuable upon the
conversion of 1,925 shares of Series C Preferred Stock. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak, and Keri Lantz. Paragon&#8217;s address is 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453.
The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Paragon are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 120,473 shares of Common Stock and (ii) 1,925,000 shares of Common Stock issuable upon the
conversion of 1,925 shares of Series C Preferred Stock held. Paramora is managed by its board of managers, consisting of Mary Beth DeLena and Keri Lantz. Paramora&#8217;s address is 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453. The
shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Paramora are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a
Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of
the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form
a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by each of these funds
and accounts are subject to a Beneficial Ownership Limitation of 14.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,478,000 shares of Common Stock issuable upon the conversion of 3,478 shares of Series C Preferred
Stock held by Avoro Life Sciences Fund LLC. Avoro Capital Advisors LLC (&#8220;Avoro&#8221;) is the investment advisor for Avoro Life Sciences Fund LLC. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro and may be
deemed to have investment discretion and voting power over the shares held by Avoro. Mr.&nbsp;Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of Avoro Life
Sciences Fund LLC is 110 Greene Street, Suite 800, New York, NY 10012. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Avoro Life Sciences Fund LLC are subject to a Beneficial Ownership
Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,947,000 shares of Common Stock issuable upon the conversion of 1,947 shares of Series C
Preferred Stock held by Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP (the &#8220;Opportunities Fund&#8221;) and (ii) 835,000 shares of Common Stock issuable upon the conversion of 835 shares
of Series C Preferred Stock held by Viking Global Opportunities Vintage IV (Aggregator) LP (the &#8220;Vintage IV Fund&#8221;). The Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be
exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (&#8220;Opportunities GP&#8221;), and by Viking Global Investors LP (&#8220;VGI&#8221;), which provides managerial services to Opportunities Fund. O. Andreas Halvorsen,
David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC, the sole member of Viking Global Opportunities GP LLC (which is the sole member of
Opportunities GP), have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Opportunities GP. The Vintage IV Fund has the authority to dispose of and vote the shares directly owned by it, which power
may be exercised by its general partner, Viking Global Opportunities Vintage IV Portfolio GP LLC (&#8220;Vintage IV GP&#8221;), and by VGI, which provides managerial services to the Vintage IV Fund. O. Andreas Halvorsen, David C. Ott and Rose
Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities Parent GP LLC, the sole member of Viking Global Opportunities Vintage IV GP LLC (which is the sole member of Vintage IV
GP), have shared authority to direct the voting and disposition of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
investments beneficially owned by VGI and Vintage IV GP. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by each of the Opportunities Fund and
the Vintage IV Fund are subject to a Beneficial Ownership Limitation of 9.90%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,767,000 shares of Common Stock issuable upon the conversion of 1,767 shares of Series C
Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;), (ii) 480,000 shares of Common Stock issuable upon the conversion of 480 shares of Series C Preferred Stock held by Venrock Healthcare Capital Partners III,
L.P. (&#8220;VHCP III&#8221;) and (iii) 48,000 shares of Common Stock issuable upon the conversion of 48 shares of Series C Preferred Stock held by VHCP <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Holdings III, LLC (&#8220;VHCP III
Co&#8221;). VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. Dr.&nbsp;Bong Koh and
Nimish Shah are the voting members of VHCPM and VHCPM EG. The address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred
Stock held by each of VHCP EG, VHCP III and VHCP III Co are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,739,000 shares of Common Stock issuable upon the conversion of 1,739 shares of Series C Preferred
Stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson
are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The
address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Commodore Capital Master LP
are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,468,000 shares of Common Stock issuable upon the conversion of 1,468 shares of Series C
Preferred Stock held by Janus Henderson Biotech Innovation Master Fund Limited and (ii) 271,000 shares of Common Stock issuable upon the conversion of 271 shares of Series C Preferred Stock held by Janus Henderson Biotech Innovation Master Fund II
Limited. Such shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for Janus Henderson
Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation Master Fund II Limited (the &#8220;Janus Funds&#8221;) and has the ability to make decisions with respect to the voting and deposition of the shares subject to the
oversight of the board of directors of the Janus Funds. Under the terms of its management contract with the Janus Funds, Janus has overall responsibility for directing the investments of the Janus Funds in accordance with the Janus Funds&#8217;
investment objective, policies and limitations. The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure of Janus who make decisions with respect to the disposition of the shares of Common Stock offered hereby.
The address for Janus is 151 Detroit Street, Denver, CO 80206. The portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred
Stock held by each of Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation Master Fund II Limited are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,391,000 shares of Common Stock issuable upon the conversion of 1,391 shares of Series C Preferred
Stock held by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. (the &#8220;Wellington Selling Stockholder&#8221;). Wellington Management Company LLP (&#8220;WMC&#8221;) has the power to vote and dispose of the securities pursuant
to WMC&#8217;s capacity as investment advisor on behalf of the Wellington Selling Stockholder. WMC is a subsidiary of Wellington Management Group LLP (&#8220;WMG&#8221;). WMG is a Massachusetts limited liability partnership, privately held by 181
partners (as of July&nbsp;1, 2025). There are no external entities with any ownership interest in the firm. No single partner owns or has the right to vote more than 5% of WMC&#8217;s capital. Additional information about WMC is available in its
Form ADV filed with the SEC. The address of the Wellington entities is 280 Congress Street, Boston, MA 02210. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by the Wellington Selling Stockholder
are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,391,000 shares of Common Stock issuable upon the conversion of 1,391 shares of Series C Preferred
Stock held by RA Capital Healthcare Fund, L.P. (&#8220;RACHF&#8221;). RA Capital Management, L.P. is the investment manager for RACHF. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky,
Ph.D. and Rajeev Shah are the managing members. Each of RA Capital Management, L.P., RA Capital Management GP, LLC, Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah may be deemed to have voting and investment power over the securities held by RACHF. RA Capital
Management, L.P., RA Capital Management GP, LLC, Mr.&nbsp;Kolchinsky and Mr.&nbsp;Shah disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The principal business address of the persons and
entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by RACHF are subject to a Beneficial Ownership Limitation of 9.99%.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 696,000 shares of Common Stock issuable upon the conversion of 696 shares of Series C Preferred
Stock held by TCG Crossover Fund II, LP (&#8220;TCGX II&#8221;) and (ii) 695,000 shares of Common Stock issuable upon the conversion of 695 shares of Series C Preferred Stock held by TCG Crossover Fund III, LP (&#8220;TCGX III&#8221;). TCG Crossover
GP II, LLC (&#8220;TCGX II GP&#8221;) is the general partner of TCGX II and may be deemed to have voting, investment, and dispositive power with respect to the securities held by TCGX II and TCG Crossover GP III, LLC (&#8220;TCGX III GP&#8221;) is
the general partner TCGX III and may be deemed to have voting, investment, and dispositive power with respect to the securities held by TCGX III. Chen Yu is the sole managing member of TCGX II GP and TCGX III GP and may be deemed to share voting,
investment and dispositive power with respect to these securities. Each of TCGX II GP, TCGX III GP and Chen Yu disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. The
principal business address for TCGX II, TCGX III, TCGX II GP, TCGX III GP and Chen Yu is c/o TCG Crossover Management, LLC, 245 Lytton Ave., Suite 350, Palo Alto, CA 94301. The shares of Common Stock issuable upon conversion of the shares of Series
C Preferred Stock held by each of TCGX II and TCGX III are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,391,000 shares of Common Stock issuable upon the conversion of 1,391 shares of Series C Preferred
Stock held by ForGrowth III PA B.V. (&#8220;ForGrowth III&#8221;). Forbion Growth Opportunities Fund III Cooperatief U.A. (&#8220;Forbion Growth III COOP&#8221;), the sole shareholder of ForGrowth III, and Forbion Growth III Management B.V.
(&#8220;Forbion Growth III&#8221;), as director of each of ForGrowth III and Forbion Growth III COOP, may be deemed to have voting and investment power over the securities held directly by ForGrowth III. The address of the principal business and
principal office of each of the entities referenced in this footnote is c/o Forbion Capital Partners, Gooimeer <FONT STYLE="white-space:nowrap">2-35,</FONT> 1411 DC Naarden, The Netherlands. The shares of Common Stock issuable upon conversion of the
shares of Series C Preferred Stock held by ForGrowth III are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 973,000 shares of Common Stock issuable upon the conversion of 973 shares of Series C Preferred
Stock held by Biotech Growth N.V. Biotech Growth N.V. is a wholly owned subsidiary of BB Biotech AG, a publicly held investment company, the shares of which are traded on the Swiss and German stock exchanges. The address of the principal business
and principal office of each of the entities referenced in this footnote is Ara Hill Top Building, Unit <FONT STYLE="white-space:nowrap">A-5,</FONT> Pletterijweg Oost 1, Willemstad, Cura&ccedil;ao, Dutch Caribbean. The shares of Common Stock
issuable upon conversion of the shares of Series C Preferred Stock held by Biotech Growth N.V. are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 973,000 shares of Common Stock issuable upon the conversion of 973 shares of Series C Preferred
Stock held by Perceptive Life Sciences Master Fund, Ltd (&#8220;Perceptive Fund&#8221;). Perceptive Advisors LLC (&#8220;Perceptive Advisors&#8221;) is the investment advisor of Perceptive Fund and may be deemed to have beneficial ownership of the
shares beneficially owned thereby. Joseph Edelman is the controlling person of Perceptive Advisors and, accordingly, may be deemed to have beneficial ownership of the shares beneficially owned by each of Perceptive Fund and Perceptive Advisors.
Perceptive Advisors, Perceptive Fund and Mr.&nbsp;Edelman disclaim beneficial ownership of all such shares except to the extent of his or its pecuniary interest therein. The address of Perceptive is 51 Astor Place, 10th Floor, New York, NY 10003.
The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Perceptive Fund are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 973,000 shares of Common Stock issuable upon the conversion of 973 shares of Series C Preferred
Stock held by Point72 Associates, LLC (&#8220;Point72 Associates&#8221;). Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates.
Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr.&nbsp;Steven&nbsp;A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen may be deemed to beneficially own the securities held by Point72 Associates reflected herein.
Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen disclaims beneficial ownership of any such securities. The address for Point72 Associates is c/o Point72 Asset Management, L.P., 72 Cummings Point Road,
Stamford, CT 06902. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Point72 Associates are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 494,000 shares of Common Stock issuable upon the conversion of 494 shares of Series C Preferred
Stock held by Vestal Point Master Fund, LP (&#8220;Vestal Point Master Fund&#8221;) and (ii) 479,000 shares of Common Stock issuable upon the conversion of 479 shares of Series C Preferred Stock held by accounts separately managed by Vestal Point
Capital, LP (&#8220;Vestal Point Capital&#8221;). The sole general partner of Vestal Point Master Fund, LP is Vestal Point Partners GP, LLC. The managing member of Vestal Point Partners GP, LLC is Ryan Wilder. The sole general partner of Vestal
Point Capital, LP is Vestal Point Capital, LLC. The managing member of Vestal Point Capital, LLC is Mr.&nbsp;Wilder. As a result, Mr.&nbsp;Wilder may be deemed to have voting and investment power over the securities held by Vestal Point Master Fund,
LP and the accounts separately managed by Vestal Point Capital, LP. Mr.&nbsp;Wilder disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of the foregoing entities and Mr.&nbsp;Wilder
is c/o Vestal Point Capital, LP, 632 Broadway, Suite 602, New York, NY 10012. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by each of Vestal Point Master Fund and the accounts separately managed
by Vestal Point Capital are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 973,000 shares of Common Stock issuable upon the conversion of 973 shares of Series C Preferred
Stock held by Atlas Private Holdings (Cayman) Ltd. (&#8220;APHC&#8221;). Balyasny Asset Management L.P. (&#8220;BAM&#8221;) is the investment manager of APHC. Dmitry Balyasny indirectly controls the general partner of BAM and shall be deemed to have
voting and investment control over the shares held by APHC and may be deemed to beneficially own the shares beneficially owned by APHC. The business address of APHC is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town,
Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands, and the business address of BAM and Dmitry Balyasny is 444 W. Lake Street, 50th Floor, Chicago, IL 60606. The shares of Common Stock issuable upon conversion of the
shares of Series C Preferred Stock held by APHC are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 973,000 shares of Common Stock issuable upon the conversion of 973 shares of Series C Preferred
Stock held by AH Bio Fund IV, L.P. (&#8220;AH Bio Fund IV&#8221;), for itself and as nominee for AH Bio Fund <FONT STYLE="white-space:nowrap">IV-B,</FONT> L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual
<FONT STYLE="white-space:nowrap">Fund-B,</FONT> L.P., AH 2022 Annual <FONT STYLE="white-space:nowrap">Fund-QC,</FONT> L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. (&#8220;AH EP Bio IV&#8221;) is the general partner of AH Bio Fund
IV and may be deemed to have sole voting and dispositive power over the shares held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz, and each of them may be deemed to hold shared
voting and dispositive power over the shares held by AH Bio Fund IV for itself and as nominee. Shares held by AH Bio Fund IV include shares that may be subsequently sold by each of the entities for which AH Bio IV holds as nominee, these
entities&#8217; respective general and limited partners, Mr.&nbsp;Andreessen and Mr.&nbsp;Horowitz following <FONT STYLE="white-space:nowrap">in-kind</FONT> distributions of shares by these entities. The address for the persons and entities set
forth herein is 2865 Sand Hill Road, Suite 101, Menlo Park, CA 94025. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by AH Bio Fund IV for itself and as nominee are subject to a Beneficial
Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 499,000 shares of Common Stock issuable upon the conversion of 499 shares of Series C Preferred
Stock held by CDK Associates, LLC (&#8220;CDK&#8221;). Bruce Kovner has voting and/or dispositive power </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
over the holdings of CDK. The address of CDK is c/o CAM Capital 731 Alexander Road, Bldg 2, Suite 500, Princeton, NJ 08540. The shares of Common Stock issuable upon conversion of the shares of
Series C Preferred Stock held by CDK are subject to a Beneficial Ownership Limitation of 4.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(23)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 443,000 shares of Common Stock issuable upon the conversion of 443 shares Series C Preferred Stock
held by Spruce Street Aggregator L.P. (&#8220;Spruce Street Fund&#8221;). Blackstone Alternative Asset Management Associates LLC is the general partner of Spruce Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative
Asset Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C. Blackstone Group Management L.L.C. is the sole holder
of the Series II preferred stock of Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities and Mr.&nbsp;Schwarzman
may be deemed to beneficially own the securities beneficially owned by Spruce Street Fund directly or indirectly controlled by it or him, but each (other than Spruce Street Fund to the extent of its direct holdings) disclaims beneficial ownership of
such securities. The address of each of the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Spruce Street Fund
are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(24)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 278,000 shares of Common Stock issuable upon the conversion of 278 shares of Series C Preferred
Stock held by Affinity Healthcare Fund, LP (the &#8220;Fund&#8221;). Affinity Asset Advisors, LLC (the &#8220;Advisor&#8221;) is the investment manager of the Fund and exercises investment discretion with regard to the shares of Common Stock owned
by the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of such shares of Common Stock owned by the Fund. The Advisor may be deemed to be the beneficial owner of such shares
of Common Stock owned by the Fund by virtue of its position as investment manager of the Fund. The principal business address of each of the Fund and the Advisor is 450 Park Avenue, Suite 1403, New York, NY 10022. The shares of Common Stock issuable
upon conversion of the shares of Series C Preferred Stock held by the Fund are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(25)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 234,000 shares of Common Stock issuable upon the conversion of 234 shares of Series C Preferred
Stock held by ADAR1 Partners, LP (&#8220;ADAR1&#8221;) and (ii) 44,000 shares of Common Stock issuable upon the conversion of 44 shares of Series C Preferred Stock held by Spearhead Insurance Solutions, LLC&#8212;Series ADAR1
(&#8220;Spearhead&#8221;). ADAR1 Capital Management, LLC acts as an investment adviser to ADAR1, acts as <FONT STYLE="white-space:nowrap">sub-advisor</FONT> to Spearhead, and manages investment and trading accounts of ADAR1 and Spearhead. ADAR1
Capital Management GP, LLC (&#8220;ADAR1 General Partner&#8221;) acts as the general partner of ADAR1. ADAR1 Capital Management may be deemed to indirectly beneficially own securities held by ADAR1 and Spearhead, and ADAR1 General Partner may be
deemed to indirectly beneficially own securities held by ADAR1. Mr.&nbsp;Daniel Schneeberger is the Manager of ADAR1 Capital Management, LLC and ADAR1 General Partner. Mr.&nbsp;Schneeberger may be deemed to indirectly beneficially own securities
held by ADAR1. Mr.&nbsp;Schneeberger disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of ADAR1 Capital Management, LLC is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by each of ADAR1 and Spearhead Insurance Solutions, LLC&#8212;Series ADAR1 are subject to a Beneficial Ownership Limitation of 9.99%.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(26)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 278,000 shares of Common Stock issuable upon the conversion of 278 shares of Series C Preferred
Stock held by Trails Edge Biotechnology Master Fund, LP (&#8220;Trails Edge Biotechnology&#8221;). Trails Edge Capital Partners, LP (&#8220;Trails Edge Capital&#8221;), as the investment manager to Trails Edge Biotechnology, may be deemed to
beneficially own these securities. Mr.&nbsp;Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own such securities.
The address of these funds and persons is 3455 Peachtree Road NE, Atlanta, GA 30326. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Trails Edge Biotechnology are subject to a Beneficial
Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(27)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 144,000 shares of Common Stock issuable upon the conversion of 144 shares of Series C Preferred
Stock held by Blackwell Partners LLC&#8212;Series A (&#8220;Blackwell&#8221;). Each of Wilmot B. Harkey and Daniel Mack may be deemed to be beneficial owners of securities held by Blackwell as the managing members of Nantahala Capital Management,
LLC, which is the general partner or investment manager of Blackwell. The address for Blackwell is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock
held by Blackwell are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(28)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 139,000 shares of Common Stock issuable upon the conversion of 139 shares of Series C Preferred
Stock held by Kalehua Capital Partners LP. Kalehua Capital Partners LP is a Delaware limited partnership whose general partner is Kalehua Capital Management LLC. <FONT STYLE="white-space:nowrap">Tai-Li</FONT> Chang serves as the Managing Member of
Kalehua Capital Management LLC and is the Initial Limited Partner of Kalehua Capital Partners LP. The address of this person and fund is 3819 Maple Avenue, Dallas, Texas 75219. The shares of Common Stock issuable upon conversion of the shares of
Series C Preferred Stock held by Kalehua Capital Partners LP are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(29)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 101,000 shares of Common Stock issuable upon the conversion of 101 shares of Series C Preferred
Stock held by Nantahala Capital Partners Limited Partnership (&#8220;Nantahala&#8221;). Each of Wilmot B. Harkey and Daniel Mack may be deemed to be beneficial owners of securities held by Nantahala as the managing members of Nantahala Capital
Management, LLC, which is the general partner or investment manager of Nantahala. The address for Nantahala is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840. The shares of Common Stock issuable upon conversion of the shares of Series C
Preferred Stock held by Blackwell are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(30)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 69,000 shares of Common Stock issuable upon the conversion of 69 shares of Series C Preferred Stock
held by Wedbush Healthcare Partners 2025 Fund, LLC. The address for Wedbush Healthcare Partners 2025 Fund, LLC is 225 S Lake Ave, Penthouse, Pasadena, CA, 91101. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred
Stock held by Wedbush Healthcare Partners 2025 Fund, LLC are subject to a Beneficial Ownership Limitation of 9.90%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(31)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 33,000 shares of Common Stock issuable upon the conversion of 33 shares of Series C Preferred Stock
held by NCP RFM LP (&#8220;NCP&#8221;). Each of Wilmot B. Harkey and Daniel Mack may be deemed to be beneficial owners of securities held by NCP as the managing members of Nantahala Capital Management, LLC, which is the general partner or investment
manager of NCP. The address for NCP is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by each of NCP are subject to a Beneficial Ownership
Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(32)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 31,000 shares of Common Stock issuable upon the conversion of 31 shares of Series C Preferred Stock
held by Third Street Holdings, LLC (&#8220;Third Street&#8221;). Peter P. D&#8217;Angelo has voting and/or dispositive power over the holdings of Third Street. The address of Third Street is c/o Pelican Management, LLC 731 Alexander Road, Bldg 2,
Suite 500, Princeton, NJ 08540. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Third Street are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(33)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 8,032 shares of Common Stock and (ii) 129,000 shares of Common Stock issuable upon the
conversion of 129 shares of Series C Preferred Stock held by Julianne Bruno. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Julianne Bruno are subject to a Beneficial Ownership Limitation of
4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(34)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 8,032 shares of Common Stock and (ii) 129,000 shares of Common Stock issuable upon the
conversion of 129 shares of Series C Preferred Stock held by Patrick Crutcher. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Patrick Crutcher are subject to a Beneficial Ownership Limitation of
4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(35)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 6,693 shares of Common Stock and (ii) 107,000 shares of Common Stock issuable upon the
conversion of 107 shares of Series C Preferred Stock held by Michelle Pernice. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Michelle Pernice are subject to a Beneficial Ownership Limitation of
4.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(36)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,606 shares of Common Stock and (ii) 26,000 shares of Common Stock issuable upon the
conversion of 107 shares of Series C Preferred Stock held by Justin DiMartino. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by Justin DiMartino are subject to a Beneficial Ownership Limitation of
4.99%. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relationship with the Selling Stockholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Securities Purchase Agreement, on November&nbsp;10, 2025, in connection with the PIPE, we entered into a registration rights agreement (the
&#8220;RRA&#8221;) with the Investors. Julianne Bruno serves on our board of directors. Wedbush PacGrow served as lead financial advisor to Damora with respect to the Asset Acquisition. We consider Paragon, Paramora, and Fairmount to be related
parties. See the section titled &#8220;<I>Prospectus Summary</I>&#8212;<I>Our Relationship with Fairmount, Paragon and Paramora</I>&#8221; for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of
our RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition of the Investors&#8217; shares of Common Stock issued upon conversion of the Series C Preferred Stock issued to such Investors
pursuant to the Securities Purchase Agreement and, subject to certain exceptions, use commercially reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such
securities registered for resale thereunder retain their character as Registrable Securities (as defined in the RRA). We are filing this prospectus to satisfy our obligations under the RRA, as well as register for resale or other disposition the
other Selling Stockholders&#8217; shares of Common Stock issued upon conversion of the Series B Preferred Stock and Series C Preferred Stock issued to such Selling Stockholders pursuant to the Acquisition Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed, among other things, to indemnify the Investors and each of their respective officers, directors, members, employees, partners, managers,
stockholders, affiliates, investment advisors and agents, each person who controls any such Investor and the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such
controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the RRA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling
Stockholders or their donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> of Common Stock or interests in shares of Common Stock received after the date of
this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other transfer. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Resale Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the case of
the Private Placement Conversion Shares and Merger Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the terms of the Series B Certificate of Designation and Series C Certificate of Designation, as
applicable, directly or through one or more underwriters, broker-dealers or agents. The Resale Shares may be sold on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be
at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may
involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when disposing of shares or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the Selling Stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and settlement of short sales entered into after the effective date of the registration statement of
which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of Common Stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act, amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer the
shares of Common Stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the Selling Stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of Common Stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of Common Stock in the course of hedging the positions they assume. The Selling Stockholders may also sell shares of Common Stock short and deliver these securities to close out their
short positions, or loan or pledge shares of Common Stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such
broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the Selling Stockholders from the sale of shares of Common Stock offered by them will be the purchase price of the Common Stock less
discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of Common Stock to be made directly or through
agents. We will not receive any of the proceeds from this offering. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders also may resell all or a portion of the shares in open
market transactions in reliance upon Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements
under the Securities Act. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any underwriters, broker-dealers or agents that participate in the sale of shares of Common Stock
or interests therein may be &#8220;underwriters&#8221; within the meaning of Section&nbsp;2(a)(11) of the Securities Act (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their
participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#8220;underwriters&#8221;
within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
extent required, the shares of Common Stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the Common Stock may be sold in these jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the Common Stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. We have
advised the Selling Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the Selling Stockholders and their affiliates. In addition, to the extent
applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling
Stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the RRA, we have agreed to indemnify the Investors against liabilities, including liabilities under the Securities Act and state securities laws,
relating to the registration of the shares offered by this prospectus. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the RRA, we have agreed with the Investors to use commercially
reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&nbsp;the date on which the Investors shall have resold or otherwise
disposed of all the shares covered by this prospectus and (ii)&nbsp;the date on which the shares covered by this prospectus no longer constitute &#8220;Registrable Securities&#8221; as such term is defined in the RRA, such that they may be resold by
the Investors without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations and without current public information pursuant to Rule 144 or any
other rule of similar effect. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the
registration statement of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_9"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 300,000,000 shares of Common Stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, of which
200 shares have been designated as Series A Preferred Stock, par value $0.00001 per share, 16,366 shares have been designated as Series B Preferred Stock, par value $0.00001 per share, and 43,882 shares have been designated as Series C Preferred
Stock, par value $0.00001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Common Stock are entitled to one vote for each share of Common Stock held of record for the election of directors and on all matters submitted to a
vote of stockholders. Except as described under &#8220;<I>Anti-takeover Effects of Delaware Law and Provisions of our Certificate of Incorporation and Bylaws</I>&#8221; below, a majority vote of the holders of Common Stock is generally required to
take action under our amended and restated certificate of incorporation, as amended (the &#8220;Certificate of&nbsp;Incorporation&#8221;), and amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> as amended (the
&#8220;Bylaws&#8221;). Holders of Common Stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then
outstanding. Upon our dissolution, liquidation or winding up, holders of Common Stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights of
any preferred stock then outstanding. Holders of Common Stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to Common Stock. The rights, preferences and privileges of holders of
Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we have designated or may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2025, 1,595,161 shares of Common Stock were outstanding and held by 20 holders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the
authority, without action by the stockholders, to designate and issue up to an aggregate of 10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each
series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of
Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on
Common Stock, diluting the voting power of Common Stock, impairing the liquidation rights of Common Stock, or delaying, deferring or preventing a change in control of us, which might harm the market price of our Common Stock. See also
<I>&#8220;&#8212;Anti-Takeover Effects of Delaware Law and Provisions of Our Certificate of Incorporation and Bylaws&#8212;Provisions of our Certificate of Incorporation and Bylaws&#8212;Undesignated preferred stock</I>&#8221; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors will make any determination to issue such shares of preferred stock based on its judgment as to our best interests and the best
interests of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2025, our board of directors had authorized the issuance of up to 200 shares of Series A
<FONT STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;), of which 158.361 shares were issued and outstanding. The terms of the Series A Preferred Stock are as set forth in the
Certificate of Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;), attached as Exhibit 3.1 to our
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on October&nbsp;7, 2024. On June&nbsp;18, 2025, our stockholders approved, for purposes of the Nasdaq Stock Market Rules, the issuance of shares of Common Stock
upon conversion of the Series A Preferred Stock (the &#8220;Series A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholder Approval&#8221;). On the third business day following the Series A Stockholder Approval, certain shares of Series A Preferred Stock were, subject to certain beneficial ownership
limitations, automatically converted into 1,000 shares of Common Stock upon the conversion terms set forth in the Series A Certificate of Designation. Each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock at the
election of the holder of such Series A Preferred Stock, subject to certain beneficial ownership limitations. Except as required by law, the Series A Preferred Stock shall have no voting rights, provided that we may not, without the affirmative vote
or written consent of the holders of majority of then outstanding Series A Preferred Stock, among other things, alter or change adversely the power, preferences&nbsp;or rights given to the Series A Preferred Stock, amend the Series A Certificate of
Designation, issue additional shares of Series A Preferred Stock or fail to comply with certain provisions of the Asset Purchase Agreement between us and Bridge Medicines LLC, dated October&nbsp;7, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1,
2025, our board of directors had authorized the issuance of up to 16,366 shares of Series B Preferred Stock, of which 16,366 shares were issued and outstanding. The terms of the Series B Preferred Stock are as set forth in the Certificate of
Designation of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#8220;Series B Certificate of Designation&#8221;), attached as Exhibit 3.1 to our Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;10, 2025. Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT> basis, and in the same form as dividends actually paid on shares of Common Stock. Except as
provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the
affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock: (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B
Certificate of Designation, amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any
series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions
will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&nbsp;issue further shares of Series B Preferred Stock or increase or decrease (other than
by conversion) the number of authorized shares of Series B Preferred Stock, (c)&nbsp;or at any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, (i)&nbsp;consummate (x)&nbsp;any Fundamental
Transaction (as defined in the Series B Certificate of Designation) or (y)&nbsp;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company
immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, (ii)&nbsp;increase the size of the board of directors of the Company, (iii)&nbsp;adopt, amend or repeal any
written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the board of directors of the Company, or
(iv)&nbsp;retain or replace the Company&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel, or (d)&nbsp;enter into any agreement with respect to any of the foregoing. The Series B
Preferred Stock does not have a preference upon any liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Conversion Approval, each share of Series B Preferred Stock may, at the option of the holder, be converted into 1,000 shares of Common Stock,
subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its
affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2025, our board of directors had authorized the issuance of up to 43,882 shares of Series C Preferred Stock, of which 43,882 shares were
issued and outstanding. The terms of the Series C Preferred Stock are as set forth in the Certificate of Designation of Series C <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#8220;Series C Certificate of
Designation&#8221;), attached as Exhibit 3.2 to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on November&nbsp;10, 2025, as corrected by Exhibit&nbsp;3.3 to our Current Report on Form 8-K filed with the
SEC on December&nbsp;9, 2025. Holders of Series C Preferred Stock are entitled to receive dividends on shares of Series C Preferred Stock equal to, on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT> basis, and in the same form as dividends actually paid on shares of Common Stock. Except as provided in the Series C Certificate
of Designation or as otherwise required by law, the Series C Preferred Stock does not have voting rights. However, as long as any shares of Series C Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a
majority of the then outstanding shares of the Series C Preferred Stock: (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series C Preferred Stock, or alter or amend the Series C Certificate of Designation, amend or
repeal any provision of, or add any provision to, the Certificate of Incorporation or Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such
action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series C Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to
the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&nbsp;issue further shares of Series C Preferred Stock or increase or decrease (other than by conversion) the number of
authorized shares of Series C Preferred Stock, or (c)&nbsp;enter into any agreement with respect to any of the foregoing. The Series C Preferred Stock does not have a preference upon any liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the third business day following the Conversion Approval, each share of Series C
Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series C Preferred Stock is prohibited from converting shares of Series C Preferred Stock into shares of Common
Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and
outstanding immediately after giving effect to such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no current plan to issue any additional shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the holders of our Series
C Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under the heading &#8220;<I>Selling Stockholders&#8212;Registration Rights Agreement</I>.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Provisions of Our Amended and Restated Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of the DGCL, and of our Certificate of Incorporation could have the effect of delaying, deferring or discouraging another party from
acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the
market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors.
These provisions might also have the effect of preventing changes in our board of directors or management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in
their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced
above the then-current market value of our Common Stock, because, among other reasons, the negotiation of such proposals could improve their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware takeover statute </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the DGCL (&#8220;Section&nbsp;203&#8221;). In general, Section&nbsp;203 prohibits a publicly held
Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder
of 10% or more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity
or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions of our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws include a number of provisions that may have the effect of delaying, deferring or discouraging another party from
acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover
attempts. These provisions include the items described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Board composition and filling vacancies</I></B><I>.</I> In accordance with our Certificate of
Incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year. Our Certificate of Incorporation also provides that directors may be removed only for cause and then only by the
affirmative vote of the holders of not less than two thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an
increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>No written consent of stockholders</I></B><I>.</I> Our Certificate of Incorporation provides that all
stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to
take stockholder actions and would prevent the amendment of our Bylaws or removal of directors by our stockholder without holding a meeting of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Meetings of stockholders</I></B><I>.</I> Our Bylaws provide that only a majority of the members of our
board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our Bylaws limit the business
that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance notice requirements.</I></B> Our Bylaws establish advance notice procedures with regard to
stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing
to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the first anniversary date
of the annual meeting for the preceding year. The notice must contain certain information specified in our Bylaws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Amendment to Certificate of Incorporation and Bylaws</I></B><I>. </I>As required by the DGCL, any amendment
of our Certificate of Incorporation must first be approved by a majority of our board of directors, and if required by law or our Certificate of Incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on
the amendment, and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, directors, limitation of liability and the amendment of our
Certificate of Incorporation must be approved by not less than two thirds of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class
entitled to vote thereon as a class. Our Bylaws may be amended by the affirmative vote of a majority vote of the directors then in office, subject to any limitations set forth in the Bylaws; and may also be amended by the affirmative vote of at
least two thirds of the outstanding shares entitled to vote on the amendment, voting together as a single class. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Undesignated preferred stock</I></B><I>.</I> Our Certificate of Incorporation provides for 10,000,000
authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender
offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors
could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder
group. In this regard, our Certificate of Incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease
the amount of earnings and assets available for distribution to holders of shares of Common Stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring
or preventing a change in control of us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusive forum</I></B><I>.</I> Our Bylaws provide that the Court of Chancery of the State of Delaware
shall be the sole and exclusive forum for any state law claims for: (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to
us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL or our Certificate of Incorporation or Bylaws, (iv)&nbsp;any action to interpret, apply, enforce, or determine the validity of
our Certificate of Incorporation or Bylaws, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(v)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision will not apply to any causes of action arising under the Securities Act
or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternate forum, the United States District Court for the District of Delaware shall be the sole and
exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, as we are a Delaware corporation. Although our Bylaws contain the choice of forum provision described above, it is possible that a court could
rule that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer
Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is
250 Royall Street, Canton, MA 02021, and its telephone number is (800) <FONT STYLE="white-space:nowrap">962-4284.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;GLTO.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco,
California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Galecto, Inc. appearing in Galecto, Inc.&#8217;s Annual Report
<FONT STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2024, have been audited by EY Godkendt Revisionspartnerselskab, independent registered public accounting firm, as set forth in their report thereon (which
contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note&nbsp;1 to the consolidated financial statements), included therein, and
incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx98130_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other
information with the SEC. The SEC maintains an Internet site (<I>http://www.sec.gov</I>) that contains reports, proxy and information statements, and various other information about us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at <I>https://galecto.com</I>. However, the information on our website is not a part of this prospectus
and is not incorporated by reference into this prospectus. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g98130g00t12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t12.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[25*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )2T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H_\  $0@%N0;P P$B  (1 0,1 ?_$ !T  0 " P$! 0$
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MN";68<\;5)CYY/N*F ZC9\/4[?SO/Z0MGSLP=EJD^M3[CWSLP?LN7ZU/N*E
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M\4\(1N\7*HN]?+5U;MY[UY=B)[#" /H(B(C2'YO75575-54ZS( "O(
M                            "
M
M                                         $
M
M                                      ?J)[HI&R1N5KVKE')V*?D!
M>2[]FVJ_AJD6DJW8K(43_P R=Y.#F>Q7.2TW6GJXE5-QZ*Y.].TZ0MU6RMHH
M:F)45DC4<F%.'G6(M5[U/*7WVPMH3EVIMW)^]3ZP^%]JO(K355'ZD:J<UU$K
MIZF69Z^F]RN7Z5.@-H<JP:/N3TYHQ/M0Y[0VMFT_<JJ<G[3W)F[1;[HC7]Y_
MX  =)\L
M            'H'@
M              !
M
M                                                         !>>
MR>O=5Z7CC?Q="JMSGLR486UL2E5U'<(NQCFFEGTZV9GP=W[.W)HS(I\8F/[2
M7:9^1-S_ '4_J0Y_3DAT!M,_(FY_NI_4AS^G(\;-_+GXL_VF_4T_X_W+T '0
M?-@                      @                            #T\
M
M
M                   "
M                                    @                 %J[#_B
M[I^\TJHM78?\7=/WFFIF_DR[&P?UU'S_ (E*MIGY$W/]U/ZD.?TY(= ;3/R)
MN?[J?U(<_IR,6S?RY^+<^TWZFG_'^Y>@ Z#YL
M                               !E$[0H#S>3O/0@   &4SS   9QS7
M4 1<\N("  RG> !YO)WC>3O ]!YE#T                 !D          $
M4 #T\     @             #Q%XA7H " &> R@                 !%&0
M                            !5QSY   %  $    '?[  /-Y.\]10H >
M90(]!YO)WA')]/<!Z >;R9QD#T!%SRX@ #S)Z       @   93O  (J<DY@
M!G',\1R=X5Z#S>3O&\G>!Z BY3)YO)WA'H/-Y.\;R=X'H/-Y.\]0
M                                 @             6KL/^+NG[S2JB
MU=A_Q=T_>::F;^3+L;!_74?/^)2K:9^1-S_=3^I#G].7T'0&TS\B;G^ZG]2'
M/Z<C%LW\N?BW/M-^II_Q_N7H .@^;
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MAWE1<?[N575NC=53.A3$2N56IW)G@?((;]JS%K729^;YW+SJ\J(WJ8C3PC0
M!F:0                                                  !:NP_X
MNZ?O-*J+5V'_ !=T_>::F;^3+L[!_74?/^)2K:9^1-S_ '4_J0Y_3E]!T!M,
M_(FY_NI_4A0"<OH,6S?RY^+;^TWZFG_'^Y  =!\V
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M&?RAJ?F?[F-MA_+)/X=G]S2C]7/P=^K_ -FC_+ZH2 #>?.@
M                                        6KL/^+NG[S2JBU=A_P 7
M=/WFFIF_DR[.P?UU'S_B4JVF?D3<_P!U/ZD.?TY?0= ;3/R)N?[J?U(<_IR^
M@Q;-_+GXMO[3?J:?\?[EZ #H/FP
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MS*\$4U(Q[^[T>_P]78G:.!TG6(M3O\]->&OBLK;:N]9[>Y.77+_2IJ-B:_\
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ME[M&].=1.!&+I.NNNO<Q0 ;+E@           ]/
M                    !:NP_P"+NG[S2JBU=A_Q=T_>::F;^3+L[!_74?/^
M)2K:9^1-S_=3^I#G].1T!M,_(FY_NI_4AS^G(Q;-_+GXMO[3?J:?\?[EZ #H
M/FP                              /0/
M              'IX         "
M                                                          #T
M#P
M                           "                             +5V
M'_%W3]YI51:NP_XNZ?O--3-_)EV-@_KJ/G_$I5M,_(FY_NI_4AS^G)#H#:9^
M1-S_ '4_J0Y_3E]!BV;^7/Q;GVF_4T_X_P!R] !T'S8                >
MG@                              /3P
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MBV;^7/Q;?VF_4T_X_P!R] !T'S8            0
M                   ]/
M  -CIVV+>+Q3T2.5B2/])R=B%NZ@OMJT32LI:.E8ZK5N\V-$QE.]5*7HFU,E
M4QE#UOE#UPU(N:E@T.S6X5L*3WBX+'*O)'+OJB>*FEE4T35$W:M(\'>V3<OT
MVZZ<6WK7/^[PCYLFCVJO?4,;64#6P.5$<YKN+4-GM&L]%==-I=Z%C>N:B.:]
M.&\U>>3"@V?V*VMDENMU22-$3UE1J-)'J:*FAT')'0.1U*R)$B5%RBH:DU6J
M;E,V=8X_)V;=O*N8]VC.F)X:QRUC]E:[)N.MJ;YJ3["QM5UUHTQ52W.HAZVX
MU+<1M7CG=[NXKC9)^6M-\U)]BFSVSRK)>Z6-4X1L7'TF>];BYDQ3/+1H861.
M-LNJ[3$;T5<->Z>'%L[9M32:K9'<*)L5.]<*]KLX/WM8L-,^W1WBC:UCTPCD
M:F$<U>TJ=W)/%"[MHG#03/W(_L)<M4V+M$V^&IBY5S/Q+].3][=C6)_?Z(-L
MRTTR^5\E35MWJ.F5,IGUG=Q,-3:\I=/5*VZUTC)G1<'HGHM:I]MF<24^BI96
M^L]CGKA,<D4IB=SGU$KGN5SE<N57CGCVEIHC)O5;_*GN>:[U6S,.W%CA77QF
M5T:3U5;]4SMBKZ9D-P8N8TYY3V*:?;A\7:_WG$&T5,M-JFWRM1-Y'X]_ G.V
M_P"+M7[SCST,6LFF*>3+UVO+V7=FY^*)B-?'C"K#T\!TWR@J(IN],Z9KM0R2
M)0I&C8U]-7NQA#2&ULFH+C962MMT_5I+ZW#)XN;V[.YS;&--F+D=/KN^[FM?
M1^E(-)4\]PK)72U.ZJ+N\4:WN0JK5=W=>KY4U:YZM7*D:+S1";:%UY55%P9;
M[RB3MG=ADOZJ]RH8>UG3U+;*B&X4:=6E2]4?&B<,\\H:-F:J+\Q>_%/*7T&;
M%N_@15A\**)XQWZ^*2;(:9(--3S3*C>M>Y<Y_1/A-J'1MIJ)8FP^4/5<N?U>
M^BKXJ57"^N;3JZ%]2D"<%5JJC3%3AR,G4XJKJJJJY^#5C;4VK%NU;MQK3'.>
M/[+K@H=,ZTMDR4$21R,[6MW',5>2X[BI=166IL5REHJKFWBUR<G)WFSV=U;Z
M35=&K'.:V1=QR(O/Q)9MNC1)+:]$3>=O(O#G@\V]ZQ>Z+76)9<CH\_!G*FF*
M:Z)TG3O;.-GX8;.$@IO2GBW6HU5QZ337[-]+7"SW*:Y71K8(HXU;C//VE=6F
M[UUIJ$FH*AT3D[$7@OT&==M67FZ4_45=6Y8\\F>CGQ+.-<B*J*9C=EYIVGC5
M31?NTS-RB-.'*=.6K;^2LUAM$J%IT5U*]^\]>2HQO!3*VHWI:RXPV>@<Y:>F
M1&N8B<WIR\>!N=/P-T9HN:YU&XM?5)Z#'IA?8F?YF'LJMU-4PU]\KTZR:"1<
M;W''#.3QOQ$S<YTT\(^+/%BNNF,?72N[]ZKW1ST05UDNC(ED=;ZAL:)E7*S@
MB=YKTXEG46TB:IOS*>:FB2@DDZM<]V<9-5M5L,%JN3*RC:D<-2O%B<D=[#/1
M?JWXHN1I,\G-OX%GH9OXU>]%,Z3K&GS^"# 'B\C:<E:6S32M(EM6\W=F45';
MC)/5:U.:JA^KEM1935;X;70LDI6<&O5=W/T&^ODRTFS:-8D3TJ=K,>*%&M3T
M4]B'.L6XR:JJ[G'CP?49V35LRW;L8W"9C69[Y798[[:=<4<M#7TR,JE;Z3.W
M'>U2$U"S;/M6S/B@2:%[%2%'.YM4T^A:A]-JVV.8JM1\S6NQVIDF^VZ!.HH9
M^&_O;G+LXB+<6KW1?[:NXG(JR\*<N>%VW,<?%-+3?'UNEDNKH4:_JU?U:+P*
MGU9K>?4-"M))2,A:UV4<CLE@:83_ +-6_,N*/7UG>*GG#LT;]4Z<IX/6V<V]
M%BU3%7"NGC[^0AX_U%/3\O\ 4<=-\JO#42JW9I YJJBI31JBIV>B:^\HS4FS
M""IC>Y'4[4<JN3BJMRBFPU)^;*+^%C_I-%L=N#:BCK+34R-<S&]'&[N7F<:B
M-+<W(YTU/N+M<59-.-5RN6]/GW*M1<MR6QIAOX-[.JNXHF[453%>Q'=_)" 5
M-EG;JEUJ<F[*^;=3'<J\/Y$SVMU3:6WVNSPNQU;-YR)[.&#=OS%V:+<<IX_)
MPMGT3BT7LBKG3&['QGAZ)1I-[I-G#'O<JN=$]55?%2DK?_CJ?YYO]1=>C_S:
M1?,O_N4I;_\ '4_SS?ZCQB?BN?'ZMC:_Y>-_C]%Y;0;'6WZRP4]N:Q9&KE4>
M[=*Z\VFHO^'2_6H6%M&O%99;)3SV^1(Y'+A55,\,%:)M U%\L;_T&'$Z?H__
M !Z:>]N;7G C(_\ 415O:1RTT9#]FVH6M5RQTV$X_&H1"6-T4LD3TP]CE:[Q
M0DSM?:A<U6NK&X7AZA&)'NDD?(]<O>N\Y?:IOVNEX])I\GSV7.).G58J]^NC
M\GK?C&?O)]IX>IZ[/WD^TS-)T/=**W3VJAJ;MCJ*-K9O27AE&]O>0>IVII#5
M/CH;>QU&U<,55W55/ V&U:JF@TC;XXG;K)E:U_M3=*?3@G!5.7B8U-RC>KX^
M#ZO;&T[N->Z.Q]V=(UG3C*[ZJFM6M].2U%-$UM2B91R)AR.[E*EL=GDK]0Q6
MV1=U5DW7X[$1>)-]B4S_ "RXP;WXM&(_=]N>9&-74TC-:UD5M1Z32RKCJUXY
M7P,MB)MUUV8GASCW-;.FG)L6<VJGC,Z3$=ZR[U=K/H>BAIZ>F1]0YN&-1O%?
M:JD=I]J\JU#$J;>QL"JF\K795$,>AV;7*NA9-=:]8WKV.7>5$-A#L]L5O;(^
MY7;K&)^LJ-P8(C&B-*YWI^;?JKVG75%5FF+='=$Z>K9;0;-0WC3+[O2M1DK&
M=>CT3"N3N4AFS/4TEJK&6]E.V1E7*F7JN-TLG4L=/#H*M91.1U.VF5&.1<Y3
M',I;1WY1VSYU#WC1%RQ735RAAVG5./G6KEOA5,1KIW\=%Q:\U;+IKJ$AIFS+
M*F5RN,%8Z/K'5^T.BJY&[KIIU<J)V+A23[;?7H?W?[J0_9]^6EJ^<_L>L:W3
M&/-41QF)8MI9%RO:--JJ?NQ53I'[-UMCX:HCSV4Z?:;79SI6GCHOAR[IZ+45
MT;'>JC<>LIK-K[$DU=3L7DZ)J+]*EES4UOI]*QTM?,V*A2)K'.<['T&.Y<FC
M'HICO;.-BTW=H7[M<1.YRUY:^]"KAM2;3U4D-NH6/IV*J->JXS]!MK+>+5KR
MADHZ^!L=:B*N[VHG>U3#^ =!X7_?H?KC-LE-HVS5Z5=%<*=LZ-5J+UJ<E/%4
M6HI_\=,Q5XL]F<N;G_J+M%5$\XUCE[N"I]26E]DN\]!([?6-45%]B\B]*VDH
M)]-T$]V3--2QQSKW<&IS*SVM5MOK[I1S6Z>&?\7B1T:YXYX9)QK658MGK43]
M.G8U?^E#)?FJY3:UX3+6P*+>-<RHITJIIB-.^.^81VHVIL@J716^W,=2-7#%
MSNJJ>!)VOMNN],S/2-&R8W554]*-R<>91#?50M_8O^35R^?7^E#UDX]%FC?H
MX3#'LK:-_-OS8OSO4U1/#3^$!TS>9]+7J9S(FRKO=4YJKV9+CO\ J)]MTHV[
M,@1[W(W\6J]Y15VX7RJ^?7[2UM;_ )L8?"/^XRK=-5=N9CGS>=DY-VU9R**:
MN%,3,>Z>*O[C7R:RU52R20MA61&Q.:B_HIS4LK4-VM^A+=30T=&CZB5N&</6
M1.:JO>4U:ZQ]ON%/5QXWHGH[Z"YXKQIO6-OCAKWQMD1>$<B[KD7V*7*HW9IX
M:T1X)LF_TM-V8KB+U7*9:>Q[38Z^O92W.C;%#)P1[?2X]F4-;M9T[34+HKG1
M,;&R7T9&IRSWH;:Z[,**?,EJK'P]K6*B*GO()JFQ7JRHUMT?++3N7@_?5S?8
M2Q%F;D569T]SUG3F4XU5O,HWO"J-.'[?\(\ #I/E@          #T\
M
M      " >G@       +5V'_%W3]YI51:NP_XNZ?O--3-_)EV=@_KJ/G_ !*5
M;3/R)N?[J?U(<_IR0Z VF?D3<_W4_J0Y_3DG@8MF_ES\6W]IOU-/^/\ <O0
M=!\V
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MCJE&QPL]2-O+Q,71UWKE-4T[NC<C)LX./<MTW>DFJ-(CNAH4Y  Z#YD
M
M                            "U=A_P 7=/WFE5%J[#_B[I^\TU,W\F79
MV#^NH^?\2E6TS\B;G^ZG]2'/Z<CH#:9^1-S_ '4_J0Y_3E]!BV;^7/Q;?VF_
M4T_X_P!R] !T'S8                  /3P
M   >@>'IX        @                                    , !0
M.WF.P (  *#Z0 @     #  #  "@P $   &       *  (     H  @
M       "@ "!ZWUV?O)]IX.\*N3:1402:,A9'-$]Z(W@UR*O(II$X'Z555,*
MYRX[U53PPV+/0T[NNK>VAFSFW>DF-.&AW@ S-   4  0P       *  (   A
MZ> *!  @.\                        (
M                                                !:NP_P"+NG[S
M2JBU=A_Q=T_>::F;^3+L[!_74?/^)2K:9^1-S_=3^I#G].7T'0&TS\B;G^ZG
M]2'/Z<D,6S?RY^+;^TWZFG_'^Y>@ Z#YL
M
M                                              #T\
M
M
M                       M78?\7=/WFE5%J[#_ (NZ?O--3-_)EV-@_KJ/
MG_$I5M,_(FY_NI_4AS^G(Z VF?D3<_W4_J0H!.2>!BV;^7/Q;GVF_4T_X_W(
M #H/FP       !                        >G@              @
M
M   >G@
M                                                       #T#P
M               !
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M=/8^SLJQETUW*)B(U_A,YD_%.,,S)OBG>!AG%?;@ *
M                 ?2                  "       0@! "@$   =@ #Z
M0                    ?2       @  H          @  H
M                       .\       =XP       /I
M           8  ?2 @                                    ,
M                   ?2                @       "        R*7DXQ
MS(I>3O$A#Z3?%.\##,R;XIW@898
M
M 0
M                                                           "
M
M                    R*7DXQS(I>3@0^DWQ3O PS,F^*=X&&0  4
M                                 =@                     @
M                          @
M                                   $
M                                                   (
M                                              #(I>3O$QS(I>3O
M$$/I-\4[P,,S)OBG>!AD  %                    :Z^WVU6"D2JOE?#0T
MRKA))<XR1[SJ:#_YJH/>[[@)D"(P;3M#SOW(=3T#W<\97[B26VXT5TIVSVVK
MAJH7<G1N10,H'XJ)HZ:"2>H>D<,;=Y[W<FH1RV:_TC=*]M#;=04=16/7#86*
MN\J^X"3 ]Y*J+S/     ^-95T]%"LU9/'!$GZ4CD3W=Y](I&2Q,DB<CHWHCF
MN3M0#]   ".WO7.EK%6.H[U?:2BJF\5BD5<H;FDKZ2LM[:^EJ&2T3F*])F^J
MK4YJ!D@C%NVA:0N5?'0V_4-%/62.W61-5<N7NY$G        54:U7.<C6IS5
M5PB?2 !CT-=2U\;Y**HCGC8[=<YBY1%[C3W[6VF-/5OD=]O=+0U2M1Z1RJN<
M+V@2 &-;:^DNE#%6VVH94TDJ9CE9R<G>AD@               )Q  C=XU[I
M.RUCJ2[:@HJ6I;SC<Y55/<9]BU'9M01N?8[E!7-:F56)5X(!M0  !ZU,KA"*
MQ[1=&R5Z4,>HZ)U8K^K2%%7.]G&.7>!*0$7*(J<EXH?F65D,3Y97(R-B;SG+
MR1 /T"'+M2T(CE:NJ:!')PQE?N)70U=/7T<-713-GI9FH^.5G)S>] /L#QRH
MUCG.7#43*KW(15FTC1;ZQ*-NI*%:IS^K2/*Y5V<8Y 2L'O+F:;4.J+%IML2W
M^Z4] DOQ?6JOI ;@$8M6T+2-WKHZ*UZ@I*JKD7#(H\JJ_P B1U,\5+&Z2IEC
MAC;S<]R-3^8'T!%)MH^C(:MU++J2@;4-7"LWEX*;ZTW:WWBG6HM5;#5PHNZK
MXW9PH&:   /'*C&N<Y41K4RJKV&AMNL]-72KJ*6VWFFJ:FG15ECCRJL1.>?<
M!OP1)FTO1+ZE*=FI:%9U=N(Q55%SW<B6-5'-1S5RBIE%[T ] RB(JJN$1,JO
M<A%)MI&C(*QU)+J2B;5-?N+'E57>[N" 2L'BN1&;ZJB-PBY5<)CQ(S<=H6C[
M94/@N&HJ&"9CE:YJN5<*G-. $G!@6>\VR\TZ3VBN@K(53*.B=G@9X 'QKJNG
MH**>LKIFP4L#%?+*[DUJ<U4U&G]8Z;U'4OIK!>::OJ&-WW1Q9RB=X&]"&#>;
MO;K'0NK;Q61T=(W@LLG)"-^=30?_ #50>]WW 3($-\ZF@_\ FJ@][ON-OIW5
MNG]2RRQ:>NU/<)(F[TC8E7+4[^(&[!&+KM TC:*U]'=-04=+51KAT3U7*&)Y
MU-!_\U4'_P"U]P$R!#?.IH/_ )JH/>[[C>.U+9&V-+RMRA^"53>2J3.[CO V
MP-78-0V?4-,^>PW&"OA8N'.B7DIM     $=OFN=+6"O=0WN^4E%6-1'+%*JY
M1%Y*!(@1VQ:XTMJ"O2AL=\I*VL5JO2*-5RJ)S7B2).8 $8NVT#2-GKY:&ZZ@
MHZ6LB7$D+U7+5]IDZ>UEIO4=6^EL%YIJ^I8S?='%G*-[^7M0#? CEZUUI6QU
MKJ.\WVDHZIJ96*3.4_D8'G4T%_S50>]WW 3($9H-H&D;@]C*'4-#,]Z[K41V
M,K]))D5%:BM5%1>2HN<@ 1R]Z[TK8J]U#>;[24=8U$5T4BKE,\C=VVNI;G11
MUEOG944LJ99(WDY ,@                 )SP !&KQK[2=DKY**[W^DI*QB
M(KHI%7*9-]15=/7TD=513,FIY$WF2-Y.3V ?< =X &%=KM;K/!U]VK8:2+.-
MZ5R)_(CKMI^AFR]4[5% DF<8RO/W 2\&/05U)<8$FH*F*IB7CO1N1W#Z#(
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MOH;S?:2CK&(BNBD5<ID"1@CUAUOI?4-?Y%8KY25U9NJ_JHU7.ZG->)(>/T@
M1BZ[0=(6BOFH;IJ&BIJR%V[)"]5RU>Y3*T]K'3FI*J2FT_>::OJ(V[[XXLY:
MWED#>@C=YUYI2R5KJ.\7ZDHZIJ9=%(JY3^1@^=30?_-5![W?<!,@1JWZ^TC<
M7L90ZAH9G/7=:B.QE?I)*F%1%:J*B\45%RB@ 1N\Z\TI8Z^2AO-^I*.LCQO1
M2*N4R;>S76@O=NCK[/5Q5E%(JHV6->"XY@9H/C6U=/04<U76S-AIH4WI)'<F
MI[306C7VDKQ7,H;3?Z.KK)%PR*/.7+[@)*#W&,G@
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MV-F7*BKA%<J)Q.N]F&G*C2>B;?:*R7K:F)JND7.<*O8!*  5
M       #)I>3O$QC)I>3@0_<WQ3O PS,F^*=X&&0  4
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M=QM !J+CIFQW.I6HN%II*F=4PLDC,JILZ:"*FIV04T;8H8TPQC>"-3N/H
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MRIE62HL=!)(O-SHS> #7VVR6JV/1]NMU+3/1,(Z-F%P;
M        &32\G>)C&12\G>((?2;XIW@89F3?%.\##(  *       "  "@
M                                                0
M                            (                       !V
M
M
M                                     9-+R=XF,9%+R<"'TF^*=X&&
M9DWQ3O PR0  *                    (
M
M                                  $
M                                   $
M            !V
M   ( !D4O)QCF32\G A^YOBG>!AF9-\4[P,,@  H    $
M                                           ($
M                           !
M
M                                                        !
M                               !DTO)WB8QD4O)WB"'TF^*=X&&9DWQ
M3O PR  "@ $Y@?I&JJ<.1^3D_I,7^[6S:"V.WW*JIXDA149'(K4SGN+KV':^
MBUOI6-)Y6K=J)C8ZEN,;W#@Y.\@L7O/UNKC/8&>NU.S*'-=MO-R=TG8:%U?4
MK1+.]%@5Z[F-UW#!1TD#U>;CP !WY  #![@#P'N#P  0C:OM#H=GUFCJ*B-9
MZVHRE/"G)V.:JH$X1JKR0]W%[CFBVTFU#:G2I73UC;5:)'[T2L7JW8SPY<53
MVG[N>S/:3IVGDKK+?Y;@Z!>LZI\N5<B<\(O/P(.D@4]L4VL3:LJ9;'J.*.GO
M-.F-[U>M5."ICL4N'QYE'N%7*8[ K5;S*>Z2NJ9K)I:FMEMG=%<*^1&HK'8<
MUN>:*0SH]:GN5HUO<=,ZLJZB2LG:UM.V1RO_ !G/&>[!!TF>M:JYQV!4PJH4
M!TL[K7VNAT^ZW5D]*KW2(Y8GJW/N*+_Q[SPT.SZ62?0>GI9WNDE?11.>]RY5
MR[O-3? $YX/UN+W&JU2]T>F;I)&Y6O; Y6N3FAR=LTL6I-H%SNL-/J:MIG4S
MUX+*[BF5(.QMQ>X*U415QP.>O,EJ_P#YRJOK7$?U+:-HVRF)M[I[N^X4$;L2
M.D=UB-[.**!U&$0BFS#6--K?2=-=(?1J$1&5+,81DF.*)[#*VA7A;!HRZW%J
M(KF1.:U<XPJHN%*)$J*WF>%8='2"K79^VON=7/55=7,YV](]78;A,(G<6@@!
M&JJ91#PYPVV7>Y4>V&S4U)7U,-.][$=&QZHU>*=AT>SU&]^$(/<'NZJ(N4--
MJ^[Q6#2]TNDRINT\#G)GM7"X./\ 3&K-1VJ_VO5%TKZMUHEJU3"R*YKN?#=[
M@.USU$SR/E25,572Q5,#MZ*9J/:OL4C.U.>6FT!>9J:5\4K855KV+A47'842
MM6JWF>%'=%6YUUSL-Q?<:R>I<CL-65ZNQQ]I;NI[_;],6:HNEWF2*FA3Z7+V
M(B=X&U1JJF408PO$Y2I;OJ_;/KA4M%146^R4S\*^)ZL1D:KS7O=@Z&KJNAV>
MZ'=+435%1344:X?*[??([VKXD$G:U5Y(>JU4YH<N:?;M$VP2SUS+C\'6:*56
MMDC7JU]B(B<5X=I[J&R[0]E757N*ZR7.VQR9EZQV^B(G>B\D Z@/<9Y$:V>:
MLIM::7I;O2,6-TB;LL:_H/[40UNVF]S:=V;7>OI78J4:V-BYPJ;RHF4*)ONK
MG& K51%54*6MD-;;.CO)7.KZF2LJZ;RKKGR*KFJY.Q>PHO99KN^V?65JK*ZX
M5<M'-)U*]<]7,7>7"\^X@[< RU<+&J*U>*+V*ABW>NBM=IK;A4+B*EB=(Y5[
MD*,Q&*O8?E.?+B<-7O7%_N^M%KVU];34M54HL;&2*C=U%QP.Q=82R1: KI8I
M',E2C:Y'M7"HN.9!(MQW<-QW<<;[-M-:RU\ROFH-0544=-)N+OU#DRJ_231-
MC&OL_E/4?_,. Z35%3F@1,KA#E7\*-?;']04U)J21*VU3NSEZ[^^SEP=V*77
MM(O*5FR.LN]JG=&D],DL<C%PK<ID"?JBIS0\*6Z+5QK;EI.LDN%5-4O21<+*
M[>5/2]I=)0
M
M                 @   .P                     "
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MF ('T2?R.K?G%_J+T*+Z)/Y'5OSB_P!1>@0 !0
M                                  0
M             0                                             "
M
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MP<BIPSX%AU$,53!+!41LEAE:K7L<F4<B]A4M]V Z7N59+44535VM7KZE-C"
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MMMU;'4N9ZR,7D; @.S39?;] 5-5/07.LK73M1JI.B(B>&"?%
M             (                    !
M
M                               0   @      "
M                 #)I>3C&,BEY.!#Z3?%.\##,R;XIW@89  !0
M     .\               !!V@    />P\              @       0
M               @    .\   $
M                       !
M
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M!Z&5')')\6]KO!<GB8F.;9IKIJ_#.K] 84$>@
M
M
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MB:FY:CM5O;FIK(M[]5%RI#[KM-A9OMMU*LJ]CGK@"QD0^-55T](F:F>.)/\
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MQ-T                                            (
M
M                                                @
M        #(I>3O$QS)I>3O$$/W-\4[P,,S)OBG>!AB
M         !   *RV\:!NFT"TV>ELTU-%)1SOE>L[E1%14PF"S0!J='VV:S:6
MMELJG,=44L*1O<SDJY["M]L.S.\:TU5:;G:YZ2."D5N^V9RHJX=G@6\.\#YT
MK%AI8(G>M&QK5QWE/:HV6WN[;96:MIIZ-MN:L:[CW+O^BF%X%R@#6:ML=)J>
MPUMIKT_$5+=W>QQ:O>A1<&QG7.FIY&:*U+''12>LDKU:J<>[B=#]@(.>+IL"
MNMRLT]3<KPVX:CF_2F>O5L\%+AV>:>GT]H.W6*Y.C?-!"Z*58URU<YY$G/.T
MHYYFV*ZNL6I:JXZ'OE/20U$BNP]VZN[G*(J8+%UQLY;KG1UOH-0U2)>J5F\E
M7&G!9.WZ%+!"?S(.=K7LIVH6B-M';M54\=%C"_C556I[$5#*N_1]DJ;%5N==
MW7&_2JBQR5+U1D7-5QXE_H (KLIL%?I70]#9[N^&2KIU=ET2JK=U5X<5[<%4
MWW8GJ.AU947G0MX@HUF<KL/=NJF>?>=  "*-TL^^:&BLVMUAN%<L*LFG:GZ>
M/6:I4L&QW76FUEAT9J>.*C>J_BY'JW"?S.A1]H% 6+8-<KA<F5VOKXM:K';W
M4QN5R.]G$OBDHZ>DM\5#3PM9211]4V).6YRP?<)Q**0UAL3JF7Q][V>7-+77
M2.RZ!R[K$[U1?[&%!L>U=?I577FHVU=,U,MIXY%5KG)RSR+\Y)E5QW^PC]]U
M?:[0QR2S=;,G*-G%2"&[#-G5RT Z_I<I*9\5;(U8$A<KMUJ*[G]"H6)=+M0V
MR/?K:F./N3/%2J[WM#N-:CHZ)K:>)>&<<2&U-1-4R*^HE=(Y>UR@6C>=I=/%
MOQVVG=(['!S^1"+OJV[W/*353V1_J,X&@ 5Z]SGKF1RO7O<N3P    @
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MN3/- +(W5QR7!X<\ZNUQJ*CZ05'8::YRQVE\\35IT1,*BIQ0Z'>GI+XE'@
M   $                                             9%+R<8YDTO)
MWB"'[F^*=X&&9DWQ3O PQ
M              GVFEO^IK?9(U6HE1\O8QB\0-TJHB9<J(U.U>!&=1:SMMG8
MK6R-J:CLC8O(KG46N;C=5='3N6FIUX;K>:D3<JO<KGJKG+S52"47_6]SNJN9
M&]::!>36+A2+N57.5SE5SE[5XGB<5PB955PB=Y^Y898E1)HI(E7DCVJW('X
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M$UU_ZTM!_$P?8=6/]=QRGKK_ -:6@_B8/L.K'^NX(_( *
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M5;,J*LCUW51,>CV$]VHW6&@HX-.6_P!%K&-=*J<.'9]A6:<OL"        H
M CZTO^)9XGX=ZSO$_=+_ (EGB?AWK..KLSE4^1^U'.W\_P"G@ .J^1
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MT!$W<AB8JY5C$9GOPG,(_0 *
M          9%+R<8YD4O)Q"'TF^*=X&&9DWQ3O PP  *
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M9XGX=ZSO$ZNS.53Y'[4<[?S_ *>  ZKY$
M  #]T\TE/*DD#UCD;Q16\#\ +$Z<86;I#7Z*D=+>E7*<$FX?S+)BD9+&U\3D
M>QR91S>**AS3C.24Z1U?5V25(IEZVC5>+5XJB>PYN3@Q/WK?/P?4;+V_51I:
MRN,>/A\5W@PK1<Z6ZTK9Z.1'M5$54[4,TY,Q,3I+[&BJFNF*J9UB0 $>@YVZ
M6FJY*:FHM-TLSV).Q)YVMY.;E<(OTH=%)S.0.EC^<&G_ (5/M4A#?=';91;+
MY;I+]J2%*B'>;Y-$CEQXN0N^\[,=(W>W>136:EA:C51DD+-UR+C&57M-3T>E
MC79;:DC5,HQ-['?[2Q\ <:4>R?6-IURK+'3O_P!UGWH:E55C7-1>'''<=B6]
M:E;?3?"&ZE;U;>NW>6_CC@^$E]ML56M#+<(&5283J5=A3.X-15<J(UJ95<]@
M%$=+/4246EZ*R12/;-5RI,[=7]%N4PI3]IV?-JMB5RU.D3GU;*E%C<B+Z$;>
M#OM-?MIU&_5NT:O>V;%.R3J(]_@UN."J=)V:_P"A*?9ZS3C]16^..6F2.5&N
MY.5/2_F%55T3-4LH+U7V*IEW8JW=?&B]KTX8.J7<&2IV[BG\^;-</P;UW3UM
M#,U[*.MWHY&\4<U'<%]QW[;:R.X6J&LA>U\<\&^CDY*JIQ X*U)^<>I_C4_J
M.^:3_!T_S3/Z4.!M2?G'J?XU/ZCOJD_P=/\ -,_I0(^A!]MOYL+U^XGVDX(/
MMN_-A>OW$^THYPZ,-LH;IKR6&Y4D%7#U*KN3,1R)[>)U6[1>F6-5SK!:D1.:
MK TX*TU07JOKW1:>BJY*K'%*951V/H,N^/U19:CR6\3W.EE5,]7+*Y%7^9%3
MSI*6?3MEU914^F(XHE= KJID3LHC][AX<"[^C"Z5VS9G6N>K&OPS>Y(GL*$V
M6;*J_:))Y;+<X&4:.W9W];O3-[O14[#TO9*73EAH[30?$4K$8CEYN[U4#9@
MJ        ':.'$    "#O            !W@  @          =X[
M    [P     #U%/   [     =X     .S             $
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M9'P@"  "@ "   ^M+_B6>)^'>L[Q/W2_XEGB?AWK..MLSE4^1^U'.W\_Z>
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MZYW.LHI8%C5F["Y5=DO- C@C3EYO6S;6>]^.IZBFDW)X55421O)<H=PZ4O\
M1:FL%)=+=(U\4[$5R(OJNQQ0K/;9L=_#BLAN5C=34ESQNSNE5421._Q,G8=H
M+5&@G5=)=Z^CJ+3*W>9'"Y55K^_BG(*MD %0
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M42P%.6SI#Z4K*ID-11W"B8Y41)ID3=3^9;-KN%'=J"&MMM1'4TLR;S)&+E%
MR@:^_P!ZM^G[9)<+Q51TU+'S<]>:]R%3S](S2L54^-EON4D37;O7-1-U?:!L
MMI>U2LT=K&VV6FME-4Q5>-Z61RHYN5[,%JQKO1QO7])J.]YR;M>U+:]5;1--
MW"S5#9H';J+QXM7*<%.L8/\ #P_-M^P@_0 *   (
M                                     $         &12\G>)CF12\G
M$(?2;XIW@89F3?%.\##+                                       ^
MP=^>2$(UGJA(6OHJ!V7KE'O1>0#6NJ$C8^AM\F)%7#Y$[/ J.LCECF=UZJYS
MN.\O:;ASG.<KG*JN7FJ\S\R1LGC6.3Z%[B*T8/I40O@D5KTY<E[SY@ @
M  $  %  $  %  $  %  $  %  $  %  $  %?6D_Q+/$_#O6=XG[I?\ $L\3
M\.]9QU=F<JGR'VHYV_G_ $\ !U7R(
M      ^E/-)33-E@>K)&KE'(7!H;6$5VB;25KD95L1$3*8WRFS]PR/AE9)$]
M62-7*.1<*A@OX]-ZG2>;H[.VC<P;F]3QB><.E>T$(T#J]ETB;15[D;5M3".<
MOKH3<X%RW5:JW:GZ'BY5O*MQ=M3P  >&P  !V   @          (
M                             'ZB]=OB?D_47QC?$#C;3>F8=5[?:ZW5
MJ*ZC6LEDE1%PCD:JJB+])TQJ?1>GY]'72@2V01PI3OW58WBU43@J*47LB_\
M6,NOS\_]SI:__P"0W/\ AW_817)W1ZT71ZBUC<:>[-?4VJB1WXESE1KG9PU5
M0N_;+HVP>:^]2QVV&*2B@62!S$PK5RA7_15_*74_[R_U%P;8OS4ZH_A%^U (
M-T5JV:JV>UT$JY93/W8_8BHI#-C'';[J']Q_]B4]$S\A;Q\XGV*1+8[*R'I
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M<X5790Z6A_P\/S;?L"/T "@                @
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M_=+_ (EGB?AWK+XG5V9RJ?(?:CG;^?\ 3P '5?(@
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M\,\X\72?($9T/J6*^T*,>J)61(B/;W^TDQP*Z)MU335S?H=B_1D6XN6YUB0
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M_6U]0Y^$14=P1,^PZ=B3=AB:O-K$1?<?I/Y   "@
M                               '8                 !DTO)QC&12
M\G$(?2;XIW@89F3?%.\##   H                              '88=V
MKXK;0R5,SD1&IP3M50,'5%\BL]$J[R+4/1=QN>.2HZNHDJZA\T[E<]RY7)][
MQ<9;I7/J)W*N5]%%[$,)"*        _%3 VJ9V)*G)>\T[VJQSFN145."F[/
ME54Z5+%5.$K>2]X&G!ZYJM54<F%3L/   "  "@    (  *  (  *  (  *
M(     KZTO\ B6>)^'>L[Q/W2_XEGB?AWK.\3K;,Y5/D/M1SM_/^G@ .H^1
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MK_!//W>]?P,>@JXJZCCJ:=R.C>F4PID'!F-)TE^A4S%41,<@ !0
M $                        "                              /?<
M!X#%GN%%3YZ^JA9C]9R&FJ]:V2E<J.J>LQ^IQ()&GB"#5&TRT,54ABG?XM-?
M/M2C3>ZB@5W[SL 62.PJEVU"K5/1H6)_YCXNVFW!<[M.Q/I MSLY J!-I%UW
M%7<;P#=I5U1?2B8XVK>)<NT[U/)RLG;.-BW9M7-=8]RWP5/%M.KF?&44;_\
MS8,R+:BB_&V[=_=>>IP;T=SQ3M[!J_WZ?*5F @E/M+M;D_WB"=G[J9-I1ZZL
M=5C=G='G_B)@Q58UVGG3+9HVGB7/PW(2<&#3W>W5*?B*V!^>YZ&<G%$5%147
MEA3#,3'-NTUTUQK3.H $#T
M  #L                       !D4O)QCF12\G>((?2;XIW@89F3?%.\##$
M                               ! /'O;&QSWKAC4RJE3:QOKKM6.CB7
M%-'P1.]3?:_U#NYMU&_TD7\8Y%_D5^10            !\*RE\H:KV)^-3G[
M34\4547@IO4X<E,:NIDF:LD:8D3FU.T#5@<LHO# "     *  (     H  @
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MT3H#(.4^N
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MGF?;E<[=1:A>'\BTXI&31,EA>V2)Z(K7-7**B]J%'Z
M      ,FEY.\3&,BEY.!#Z3?%.\##,R;XIW@89  !0
M         U&J;NRTVR23/XYZ*C$]IM9)&Q1NDD<B,:F54I_5EW==KF]R+^)C
M548A"&HFE=/,^61<O>N55>\_  4         0    /47"Y3F> #%KJ5)$66%
M/23UD[S6&^1<+E.9@UU+G,T2?O-[O:!KP    0  4  0    !0    $
M   ?6E_Q+/$_#O6=XG[I?\2SQ/P[UG>)U=F<JGR/VHYV_G_3P '5?(@
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MB9XE7HJIG#G)X*J'GCQ\3!3BS$Q%56L1RAOW=KQ537-NW%-=<:3.O[\.[40
M&VXH9%NK);?6Q54#E:^-R*F.TQP)C6-)>J:IIF*J>;H73EWBO5JBJXU])R8<
MWN5#9E);/=0K9[HD4S\4LWHNSV*78UR.1%:J*B\45.X^>R;'0UZ=T\GZ/LK/
MC-L15/XHX3]?F] !KNF                                 !
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M;++-Z,,<G+V+P"( WXMWB>'[5V^CWJU&[SL[J<D/P=_!_)A^=[>_75_+^(
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MAWOJ(TM].[#WIEZHO+V%<F3<:R2OK9:B5RJYZ]O<8Q%
M  /6KA<G@ P:ZDPBS0IZ/Z2=Q@&^1<9RF47@J=YKJZD2-.MB^+7FG<!A
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MEQ*QS%_U)@V*:Z:N-,ZN9<LW+4Z7*9CXOR #TQ
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M5$5%YIWG@ UM=3=2N^SC$O\ (Q#>\%14<B*U>:&KK*58';S>,:\E[@,8  $
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M;N<)X2^9S=@Y&/K51]ZGW<_V0D'[ECDA>YDK',>W@K7)C!^#<<28TX2  (
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M6ZE1<OCB7@[W$3.ULZWNT37XOAOM)D])?BS$?A_L !T'S8
M     3@J*F45%RB@ 371^N*BV;M-7KUM)R153+FEN457#6TS*BE>DD3DRBH<
MW?0A(]'ZHJ;#4HU5=)1N7TXU7E[4.?E845_>M\_Y?2;)VY58F+61.M/CX?\
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M[TV47#O65"T['IZWV:)&TD#=_M>J953;)P1$1,(G8"AW@
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MLO:].(&"@ "     *_3?BW>)X?IOQ;O$_)W\'\F'YUM[]=7\OX@ !MN.
M               @    #=:9U#56*K22%SG0JJ;\?>A=MBN]->J!E52N];UF
MJO%ISP;K2M^GL5>DL:JL3N#V=Z&EE8L78WJ?Q.[LC:]6'5T=R=:)]/?"_@8=
MJN$%SHF5-*Y',=_(S#B3$Q.DOO::HKB*J9UB0 $>@
M                     R*7DXQS(I>3@0^DWQ3O PS,F^*=X&&0  4
M                 @NTNYK'%%;XU5-]-YY.5>C&N>[U43*J4OJ.N=<;O/.J
MY:B[K?!"$-8  H                      !       >/8R6-8Y$]%?Y'HS
MSP!IZF!U/)NNY=B]BFTTUI^KOM6D<#')"BIOR*G!#?:>TY)?I$9(BMIFKES^
MWZ"U[7;J:UTC*:BB;&QJ87"<_$(Q-.6&DLE&D5.Q%DQZ4BIQ4VP!0
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M1$RJJ5MKK43JN9:*D<J0,7TE3](@U6K+[)>*Y=U<4\?!K47@OM-$ %
M             /E61];2/1OK-]+/L/J>MPN4=R7@H&A0'[E8L<KVJF,+_(_
M  !   ?IOQ;O$\/6_%N\3P[^#^3#\[V]^NK^7\0  VW'
M      ]/    $CT9J6:PUK4>KGT;U]-B]GM0NZBJX:VECJ*9Z/B>B*BH<W$V
MV<ZG6V5:4-6]5I)5PW_2IS\S%WXWZ>;Z38>UIL51CW9^[/+W3]%Q \:YKFHK
M516KQ14/3C/N          (        @ !                  0  #(I>3
MO$QS(I>3@0^DWQ3O PS,F^*=X&&                        !JM45K:"R
MU$CL9<FXB+[2F,YRJ\U)UM-N&]-#0L5,,])^""D4
M            ,VTVZ>YU;8*=N5[5[$0^5!22UU5'! U7/>J)X%OZ=LT%GHVQ
MQIF94]-_>!][);F6J@;3,<KL<7*O>9P!4
M  !           -%K"Q)?K6M.C]R5OI,7O4WH0]45315%5/.&.[:IO43;KC6
M)<WUU'-05<E/5,5DC%5%13'+NUQI:*^4;IH$:RMC15:J)ZWL4I6>&2GF?%.Q
M62,7"M7L._C9%-^G7O?G6T]FUX%S=GC3/*?^][Y@ V',
M             'ZC?U<C)$YM5%.A=/US;C9J2J9CTXTRB=BG/'86OLAN:S4-
M30O5-Z)4>U%7L-#:%O>M[W@^C^S>3T>1-J>54>L+! !Q7W(
M         !        8]?5Q4-))43.1K6)GCV@:36E[CMEO="WTIY45J(O85
M.Y5<YRKS5<F=>KA)<[A+42+E%5=U.Y# (H   0                    -=
M=&JE1O\ 8]$PAAFUN$>_3*J)E[5Y]R&J   (  *_3?BW>*'AZWXMWBAX=_!_
M)A^=;>_75_+^  &VXX      ]/   [% _43'RR(R)CGO7DC4RJDBBT/J*2-'
MMMZ[JIE,O1"<;-;/1VNP27NL6.25S5>U7?\ =M3LSWFAK]IUU?6JZBABBIT7
M",<F\JIDTYOW*ZYILQR[Y=RC9^-8LTW,RJ8FKC$1X>]#KI:JZU3=5<*9T+O;
MQ3WF$A>.G;I2:YLL\5?2,29G!R+QPO8J%+W.E6AN-52JN>ID5ADL7YN3-%<:
M50U\_ HQZ:;UFK>HJY>/S9%ELEPO<DC+9!USH\*_BB8R;7\ ]2_L_P#_ 'C2
M9;&*+J*"X5[G(K9<-1N.*;N<FEN.TB]0U]3%"VFZMDBM:BM55PGTF*;UVJY5
M1;B.#:MX.':QJ+V5-435KRT:C\ ]2?L__P#>(1^MI9J&KDIJIG5SQKA[<\E)
MAYS;]^K2_P#0OWD2N-;+<KC+5U.[UTST5VZG#F9K4WM?_)$?)HY=.%%,=6FJ
M9]^C[6>RW"\2NCMM,Z9S4RO'"(GB9-TTO>;5 LU=1.CC3BKD5%Q[BRKU6_@5
MH>B;;8_QTRHU'NYHJIE54Q=FNH:J_2UEMN^[4,5N^BO3/T&"<FY-,W*8C=C]
MW2IV7C173C7*YZ6J/E$^"IDXF3;:"IN58REH8^MG?ZK<XSCF9.IJ5E#J"XTL
M>$CBF<U,<.!/-G-!3V2QU&HK@U-Y6JD6_P!WL\3/=O;EO>COY.;B84WLB;-4
MZ13KK/A$<U>W6V5=IJ_);A%U4^ZCMW.>"F(U5:J*G-%13)N==+<J^>JG5SG2
M.54WESA.XQ3-3KI][FT[FYOST?+NU79L^U#%=[6RG=AM5"F'-[T[%)8<ZV:Y
MSVBOCJZ95WFKZ29X*A?EEN<-VMT=53N16N3TD1>2G$S,?HJMZGE+[O8>TNMV
MNBK_ !T^L,X &D[H                                     &12\G&.
M9-+R=X@A^YOBG>!AF9-\4[P,,0         [P            'BN1C7/7U6I
ME3TUFIJSR*QU4F<*K%:GT@5/J*J\MO55-V*[=3P-<,JN5<N57B"*(
M      (                >L:KW(UJ*KE7"(>$UV>V/RB?R^I8JQL7#$7M4
M#?Z(L#;;2I4U"(M3*B+Q_10E ^P%0
M              $X%>;3=,)40NNM"U.M9CK6HG-.\L,\<U'-<UZ(Y%3"HJ=A
MDLW:K56]2U<S$HR[4VJ__J7-"*"7;0M.+9[AY13-7R29<I_I7N(CD^BMW(N4
MQ52_-<G'KQKDVKG.  'MK@!Z!X                        2+0-R6W:DI
MU7XN5R,<1T_<,BQ31R)P5CD<GT*>:Z(KIFF>]FQ[LV;M-RGNG5TJ# L-6E=9
MZ2I1V=]B97VF>?,S$Q,Q+]4HJBNF*HY2  CT
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M);9+I<(Z>-JJBKERHG)"YJ&ECHZ6.GA;AC$P1S9]:4HK;Y5(W$TZ<U[B5%0
M                                                 &MU#:X[Q:IJ
M21/63+5QR4H&X4DM#6S4TS5:^-RMXI_,Z0*WVKV%)(X[K3,]-O";'=V*;^!?
MW*NCGE+YS[08'36NL41]ZGG\/^%7@ [3X8
M   7%LGK_*;"ZF<J*^!R^[)-BH=D56L-]FI\\)H^7@6\<#,HW+T^]^C;$O\
M38=&O..'[  -5U@                        \54:U7.X(B95?8>D;US=D
MMMJ6-CL33Y:F%Y(!!M9W9;I=G[BY@B]%OB:  B@           (
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M-G6(N1\WU?V:S=*IQJIY\8_M,  <E]B
M      9%+R<8YD4O)P(?2;XIW@89F3?%.\##$                      _
M,S^KAD?GU6[Q1USF6HN-5*JYWY%4M[5-1Y+8*N1%PN[CWE,$6
M           0        V^EK:ZZ7>*/'XMCD<_P-1V9+0V=6U*6U+4O;^,FX
MHN.P"5QL;$QK&)AK4PB'H!4
M              /A74K*VBFII4RR5JM/N!'#BDQ%4:2YUO=O?:[I/2/3BQW#
MP,$M#:W9T6&*YQ-])%W'X3L*O[#Z/'N]+;BI^9[2Q)Q,BJUW=WP  9F@
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ME-20PM3T8V(A76S2B2:XRU3TRD2>BOM+*"  *                    (
M                               ,"_4+;E:*FF<F=YJJGB<\R1.AE?$Y
M,.8Y6J=*IP4I':1;?@[4<CFI^+F3?3Q[3I;-N:3-$OEOM-C;U%-^.[A/](J
M#KOC                           >+R4O+9O4^4Z5@7.58Y6>XHXM;8[4
M*^V5=.OZ#]['B:.T*=;6O@[_ -G+FYF;OC$_580 .(^]
M      (#\R/;%&][N#415 KG:5<>MK8Z*-WH1IE_B0LR[K4K67&HG5<[SE,0
MB@                   &104DM=5QT].W>D>O #[V.US7:N93P)P7UG=B(6
M[9+33VBD2&!OI*B;[N\^6G+-%9J%(F)^-7B]W;DVH0 !0
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MN%BR2L8WFYR)_,"T]GM&E+8^L5N'RNWN/<28^%! E+1PP-QAC4P?<J
M @                                            $     5]M?HNLM
MU/6-;\4NZJI[2P32ZRH_+M-5L*(F\C=]/%#-CU[EVF6CM&QT^+<H]W\<5 @8
M5%5%YHN ?1OS(  0                    ] \   L+8[/NW&LASZ[4X>!7
MI+]E<W5:KB8J\)&.^PP94:V:H=+9->YF6Y]_\\%T@ ^=?I0      !
M         :36=;Y%8)W(J(Z3T$4W97VT^MWI(*-%X)Z:I[2$((G'BH "@
M               (F>"<U7"(6?H.P^04J5M2Q$J)4X(J>JA$]#VCX3NB22MS
M!"N\N>U2V41$1$1,(@  %0                             $(9M&TXVZ
M6_RNF9_O4"*J[J>LA,SQ4145%1%14P>[=R;=454M?*QZ,FU5:N<I<TX5%5%1
M45.Q3PF&TFP?!5U6I@;_ +K4<L=CNTAY]';N1<IBJ'YGE8]>-=JM5\X  >VN
M                =BET;+J_RO3J0N=E\"[N,]A2Y/MD-<L-TJ*1R^C,U,)[
M34SJ-ZS/N=K8-_H<RF.ZK@MH '!?H0
M  9%+R=XF.9%+R<"'TF^*=X&&9DWQ3O PP                   'CN#'+W
M(JGI^95_W>1>YCOL I"[NW[I5.[WJIB(?6I=OU,SN]RGR(H
M             !L],TZU-[I8T3**[B:PE.SB!9;^YV/BV;P%I\N'=P 7B$*@
M                                                  "     !^)(
MTEA?&O)R*A^SUJX4#G"ZQ+#=*R)4QNRN3^9BF]UQ3K3:HKF*F,OWO>:(^GMS
MO4Q+\JR*.CNU4>$R  ],                         ;_0<G5:JHW9PN53
M^1H#::6DZO4- [E^,1#Q=C6BJ/<V,2K=OT5>^/Y="=H/3P^9?J@
M            ]0I[6U3Y3J.J5/5;A$+<GD2&GED=R:U5*.N$JSUT\KN*N>OV
MD(?  !0                ]8USWM8U,N<N$0\0DN@[9Y?>&R/;F*'TESW@6
M#I:V,MEHAC1N)7-1SU[U-L/#@@*@
M  -/JNTMO5DGIG)EZ)O,7N5"@I8GPROBD3=>U514]ITJG,I?:=:DM]_ZZ-N(
MJAN]P3AGM.ELZ[I,VY?+?:7#BJBG)IYQPG^D/ !UWQ@                ;
MC2-6M%J*AESA.L1%^DTY^X7K'-%(GZ+T4E5.]3,,MFY-NY37'=,2Z55>X&'9
MYO*+3239SOQHN3,/EYC2='ZK35%5,51W@ #T
M     !DTO)QC&32\G A^YOBG>!AF9-\4[P,,                   !\:YV
MY0U"_P"AWV*?8Q+LN+;4K_H7^X%'(N57Q4'B?W4](H
M        !.-EK/\ ?ZN3_P!W@@Y8.RYGXJJDQVX G8 *@
M                    0      [                 *:VJQ(S4JO3F]O$
MAA/-K[=V\TKOUF*0,^BQ9ULT_!^:;6IW<RY'O  9W.     !
M       ,RS+NW>C5.R9OVF&9-L7%RI5_]XW[25<I9+7"N/BZ.8N\QJ]Z(>GS
MI^-/$O\ H3[#Z'R[]7CD  *                  #5:IJ?);#6/3FYBM0I=
M%RF5YJ6IM&FZJP(W/%S\%6)RP18                   +3V=T/DME69[</
MF=DJ^GB6:>.)/TG(A>=#"VGHX8F)A&L3@!]@ 5
M             "([3K:E;IN29K46:G5'-\.TEQCU].VJHIX'IO)(Q6X/=JO<
MKBKP:^58C(LUVI[X<WIV@^]?3K25]33N3"QR*U/>? ^FB=>+\MJB:9TD  >0
M]/           " #Q>1Z +TV>5'E&E*157.YEGN)(0?9'/OZ>?#G.Y(JH3@^
M<R*=V[5'O?IVS:^DQ+=7N@ !A;P                             &12\
MG>)CF12\G A])OBG>!AF9-\4[P,,@  H                &#>UQ:*K]PSC
M"O29M52G^A0*03M!XG]STB@                          %C[+_\ +ZI/
M_>%<%B[+E_W.J3_4!-P 5              0
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M'$:1H                     (1M1DQ24L?ZRY*Z)WM4D_'4$:?JN4@A%
M                !NM'4OE=_IV*F49Z?N+C7F5ELQBWKS+(J>K&J%F"$  4
M                                   /6\%\#P 47M"I?)=4528PCUW_
M 'D;)_M@@W+K23(GQC%15\" 'T>-5O6J9?F6U+719=RGW_SQ  9F@
M         L[8W+EMPBSR1'8^DLHJ?8Y)NW6N9G@Z-/M+8.#FQI>E^B;!JWL&
MCW:_R  U'8                              R*7DXQS(I>3O$$/I-\4[
MP,,S)OBG>!A@                   ,6ZIFVU/M8OV*91\JMN_1U#>^-?L4
M"B$[?%0%3#G(O8J@B@                          %@;+I$W*J/MYE?DR
MV7S;MUJ8U7@Z+^X%E  J
M                   BVJG9JXT[D4T9MM2N1UR<B?HFI(H
M   >GA&]?:MI='V=*RHC;/,]<10*["O[\ 20$;T#JE-7V/X12D\E3?5O5[V]
MR7',D-1-'3P233.1D4:;SG+V(!]#PJBNVRL2X3P62Q3W*GB7"S-54_DB$MT1
MKBV:LBD;2KU-5'Z\#U]("5'H1,D'U)KY;7JREL-MMS;E4S;N^YDF.KRO;X 3
M<^U)QJH4_P!:'RP?:@3-9 G^M )ZU,,1/9@]/3PJ 0             "
M   K?:@O_I&D3N:I"R8[3?\ -8/W5(<10                  3W98Q%=7/
M[4P3\@NRQ,05Z]ZH3HJ          0    0           @
M *UVS1YCMDG:BN0K$M3;+PHK<G^IQ59WL'\F'YYMZ-,ZOY?Q  #;<8
M         !.=D*XU!.G_ +LM\IW9*J_A&]$Y=6I<1P\_\[]GW_V=G_T4?&0
M&D[H                             &32\G>)C&12\G>((?2;XIW@89F3
M?%.\##     $              !^9.,,B?Z50_0QE%3O3 %$UK=RLG;W.4^)
MFWMG57BL9CE(IA$4           (               "1[/YNJU#&BKC?;@C
MAF6>?R6Z4TV<;KT O%3P(N6M5.2HB@J
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M9"W-^G7NC+?*FV.MS=ZY>Z-/M+9.%G_G3\GZ!]GHTPH^,@0 TW<
M                     R*7DXQS(I>3@0^DWQ3O PS,F^*=X&&0  4
M           #UO/Z3P 4_K2+J=0U"8QO>D:,EFTJ'J[^QZ>JZ)/>1,B@
M                      'J+A47N5%/!V 7;8:E*JSTLJ.SEO'V&>0_9I7+
M-;)J9Z^E&[*>!,"H
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M\_FDLWB_[0+% !4     $$VILRRB?C@B*F2OBS-IL6]9XI$3U7X*S0B@
M    0         "1:!GZC43%SA'-5I;7(HVU5"TMQIYD7&Z]%7P+QC=UD;'\
MT<U%"/0 4                                    /'/:QKGN]5J97P
MI7:A5)4ZF>Q%RV)J(A$C8ZAJ5J[[739RCI78\,FN/I;-.Y;BE^6YMWILBNYX
MS( #(U0               %D[&8/Q]RG7DK&M3WEGD#V0P;MDFGQZSU;[B>'
MS^9.MZI^C[%HW,*W'CQ_>0 &LZH  "             "           .P  9
M%+R=XF.9%+R=X@A])OBG>!AF9-\4[P,,0                     "![4:=
M=RDJ$3V*I7Y:VT.G673LDB)GJG(O\RJ4(H $            @        "
M     D6@ZU*2^QM>N&2INJ6U@H:&1T,S)&*J.8N>!=5CKFW"U05#5RJM3>\0
MC/ !0                                                     %<
MC4<YWJHF54I?4]=\(7FHFSZ*+NI]!9^KJ]+?9)I-[#W^BWVY*<XKG/-2+
M   ]:Y6KE%5%]AE0W&JB<BI(JHG8IB #=P7UV/Q\:?\ E,V&[4LB)O/W%7L5
M"+@":LD8],M>U?I/W@A+'N8N6N5%[\F7!=*J+_O%>G^H"5 TD-]X?CHLK_I,
MV*Z4LBHG6(BKW@9P/RU['^H]KO!3]X 9(]KVPS:DTS46VFECBEE5,/?R0D
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M"G2;;-+CU59)0O=Z,B;S<]X%C  J
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M6H]JM=R7@4E?J=:6\UD2IA$D7'@188
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MJ*BE)W^F\DO-7#C"(_./$NQ"K]I%)U-Z2=$]&9,J0A$P %      !
M   ,JV5;Z"X0U,:\8W(O#M,4 7K;ZIE;1Q5$:HJ/:BGW(#LWO"(C[?.[N6/)
M/BH                                 ! /A75<=%22U,KL,C;E5.>KO
M7ON=RGJI,JLCEQGN+"VL7W#&6JG?Z6=Z54[NQ"L>\[.S[.Y1OSSE\/\ :+-B
M[=BQ1RIY_'_@ !T'S8                ;#3U/Y7?**'GF5JX^DUY,-EE"M
M5J-LV,LIV[RF.]7N6ZJFUA6IO9%%N.^870C48U&MX(B80#F$/FGZD
M                         &12\G&.9%+R<"'TF^*<89F3?%.\##( 0 H
M   $         (     (N"K]H]'U%Y;,B>C*G\RT");2:/RBT1U"-RZ%>:>T
MA"L $ 4                           =@ $YV<7A(YG6Z=WH.]*-57M+#
M*'IYGT\[)8E5'L7**A<>FKNR\6]LR<)4X/0#:@ J            !
M                            0!XX0J[:!>/+[@E)"[\3 JHN%YJ3'6=Y
M2U6US(E_WB5,-]G>5(Y5<Y7.7+E7*JO:18>
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M3M$EOL='3HF',C3>]JFAM"YNV]WQ?1_9K'W\B;L_[8]9;( '%?<@      @
M                        &32\G&,9%+R<0A])OBG>!AF9-\4[P,,H
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M "I==6_R&^2.:U4CF3>0CI:.T6W^56E*AB9DA7/#N*N["*
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M'80;91:_)+/)5R-_&3N]%53]$G)P<VYTEV8[H?H6P<7H,2*IYU<?H  U':
M                      $        ,BEY.,<R*7DX$/I-\4[P,,S)OBG>!
MAD  %                     !"MIE!UE#%6,8JK&[=54YE<%Y76D;6V^>G
M>BKO-7'B4C40N@GDB<BHK'*WB17S                0              0
M >HJHN47"IR+%T+J1*AC:"M?B1J>@Y>TKD]:Y6/1S%5KDXHJ 7VN4!#M':I;
M6-;25[D;4)P:[]8F)4                                        !X
MXP$[>[O('K356$?0VY^55,/D3^P'RUSJ;?<Z@H'KA,I(]""?2.>57BJKD$4
M            $                  #DBEK: H$I+*V5R8?/Z7T%:6FD=77
M&"F:BKON[.XNVFA;3TT4+.#6-1J(!]  5
M?.HA944\D4B9:],*A2=XHG6^Y5%.]%3=<N/:F2\"";2K5O1QW")JY;Z+_#O(
M0KX !0                    !O]-:EJ;/)NN59:9>"L7L+/M%TI;I3I)32
M(O>U>:%(F105M103I+2R*QR+GV*!>@(9I_6\-2K8;FB12<M]$X*3""6.>-'P
MO1[%[4*C]@                'YFDC@C629Z,8G:H'Z/C5545+&KY7(F.SM
M4C5VUI1T\W44?XURKA7XX(:NIJ)*F3?E<KE_D09MUNLE8Y6M56Q=W>:Q  H
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MO'71M5(I4SG':6H:'6ML2XV656)F6+TFK["$*A 7@JHO-."@*     "
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M";;-+=OU$M<].$?HM54X9+$\36:;H$MEHA@_3QO.]JFS*@
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MRA]W]GL'H+,WZ^=7\?\ ( #0?0@
M &12\G>)CF12\G A])OBG>!AF9-\4[P,,                         >*
MU'-5KDRB]AZ *<U=;EMUYF9C$;U5S33%JZ^M25]J6>-N9H/2RB<50JKCW$4
M                                " #:62^5EHE1:=^8NUB\4-6 +>T_
MJ:CNS$;OI%4(F'-=PROL-\4+&]T;T?&Y6N3DJ<,$ML.M:FC:D-<WKXOUL\4
MLT&NM5ZH;FQ%IIV;_P"HJX4V6"H\           !             #L-3>+_
M $-J8O72M=*B<(VKQ VW)%5>"(1O46JZ6V-6.G<V:I[D3*(0N^ZNK;BYS(56
M"GY;K5XJA'%57*JN555>:J169=;G572=9*N17=S4Y(80
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M<Y3^97VS974.N;O1P*C87.5JM]B*H%LHA%*35KZW53K10T;9HF>O4([@W_\
M,&5KR^,L5@EEWD\HE_%Q-[5SW&NV7V);79G5=3O>65B[[E7GCL F0
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M,IJ>."),,C:C4^@^@!P'Z+$:1I   H
M    !D4O)QCF12\G>((?2;XIW@89F3?%.\##
M   #Q[4DC>QZ9:Y,*A3FJ[8ZUW>:+=Q&Y=YG@7(1W6]H2Y6M9(VYGA])OM0A
M"I0.]%Y@*                                     /W!+)!)OPO=&].
MUJX)79M;UM(U(ZU/*(T[>U"(@"W[3JJVW!$1)>ID7]&3@;UJHYN6JBHO:A0:
M>Y>]#9VV^W"W82FJ'(WN=Q ND=Y7%!KZJ8J)64['M_6:G$D=#K2TU*)UDCH%
M_P!:!$D!AP72@J/B:J-WTF6U4=ZKFKX*4>@]P,+W > 'N / >X7VC"@> \54
M3.7-3Z3"J+Q;Z9%6>KC9CV@9W8/>1>KUO:H,[G62KV*U.9';AKRME<J4<3(F
M=CEYD%DO<V-JN>YK6IS55(]=]76ZWY:U_7R]S.*%95UTK:YZNJ:A[E[D7"&%
MCG[0J37C6-PKE5L#O)X>YO,C<LCY7J^5[GO7M<N5/R
M     @                !^F,=(]K&(KGN7"(G:H$AT-:5N5V;*]J+! J.=
MGO+9Y<$X)R0T^D[4EJM,<:_&R(CWFX"  *         0   $         !
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MO+1/S#&R&)L<;4:QO!$0_1+UZ;U<U2]X&%1A68M4?.?&0 &)N
M                 !         !D4O)WB8YDTO)P(?N;XIW@89F3?%.\##(
M  *                         X+G*(J+W@ 5-KBS_  9=%?"W_=YO214Y
M(O<1PNG45K9=K9+ Y$ZS&6+W*4W4P/IJB2&5%1['*U2*^0  =@
M                                ]:YS?5>Y/!<&737.MIOB:J5O_F4P
MP!NHM47EG#RZ14[E,F/65V9ZTN]XD< $I_#>Z=S/>>+K:Z*G#=0BZ "1OUE=
MG-PDNZO>AARZDN\N=ZNEP:@ 9<UQK9OC:J5W_F4Q557>LYSO%<G@ (
M                   @                    3'9Y9?*ZQ:Z=OXJ%<-14
MYJ1>WT<M?5LIX4RYZX\"Z+301VZACIHFX1J<?'M R^8 *@
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MN_N\<<4+:1NZB-[DQP(GI31L-GJGUM;+Y9<'HF95[%[<$L
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M)E?L _=NHWUE0D;$7=SQ7N)M24[*:%L<:81$X^T^-LHF44"-:GI+ZR^TRP@
M"@                        @               !D4O)WB8YDTO)P(?N;
MXIW@89F3?%.\##(  *                           ]R0+:)9%<B7&F:J
MKE>L1/M)X?B:)DT+XI&HYCTPJ+V@4,@-WJNS/M-RD:U/]W>N8U_L:0B@
M  $                                                     .P
M                                    #B"1Z*L;KI<$EE3_ '>)<KPY
MJ!*MG]D\CH_+JAJI/*G!%[$)>>-:UK4:U,(B83V'I4 $
M         !                #5W^S07BD=',F)$3T')V*;0 4A=K;/:ZMT
M%0U4QZKNQ3"0NJ_6:GO%(L4Z(DGZ+\<44J6\6FJM-2Z&I8J-['HG!2*UX"
M                                        ?J-RL>U[5PJ+E#\@"84%
M0E33-D1>/)4[E/N1BS5?DU3NO5>K?P\"4> '@     >GAD45)+5RHR)JKWKV
M(!Y1TTE5*C(DRO:O<3*V4$=%"B-3+\<5/;;01T42-:B*]>:X,L(  H
M                                     9-+R=XF,9%+R<"'TF^*=X&&
M9DWQ3O PR  "@                             UFH;1%=[>^%Z)UB)EB
M]RE-U5-)25#X)V[LC>:%[D2UU8$N%-Y92L_WB-.*)^DA"%8 ]5%1514PJ+A4
M/ H          "                                   $
M                                      !^HV.D>UD;5<YRX1$ R;30
M2W*NCIH4RKEXKW(7+:;?%;**.GA:B83TE[U-3HRQ):*+?F3_ 'J3BJ]R=Q(@
M@ "@            0                                 G Q+G;J:Y4
MSH:J-'(J81>U#+ %1:ETU46B57L3K*9556N3L3VF@+YFC9/$Z.5J/8[@J*5Y
MJC1TD+W5%K:KXE7+H\^J14)!Z]KF.5KVJUR=BG@
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MU!K[->K9>HGR6BOIZQC/6=$[*(;
M 9%+R<8YDTO)P(?N;XIW@89F3?%.\##(  *
M     /8N%  KC7>G%IY75]&S\4[B]K4Y$*0OJ6-DL3XY&HYCTPJ*51J^P.M-
M4LD+<TKU]%4[%(J.
M  "                          $              @      ">PL/06G.
MJ8EPK8_2<GXMCDY>TU6BM-K7RI5U;/\ =V*BM1?TBSD1&HB-1$1."(@  %0
M                                                  ]0\ $?O^EZ
M.ZL5[&I#48X.1.96MXLU7:IE;41NW,X1Z)P4NH^-72P5<3HJF-)(UYHI!1()
MY?="N17RVMZ;JK\6[FA":NFFI)5CJ8W1N3O0*^(
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M]A;=UM"V+8!\'O:K9H:!$D1?UL 1'HB_D]<U[5=_<OTH+HB_D[<OWO[E^A!
M 4                              R:7D[Q,8R:7DX$/W-\4[P,,S)OBG
M>!AB                                    ^%;20UU,^"H:CF.3W'W
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M .\
M      D>D-//N]3ULR*E)&[TE[U/GI73TMXJ=YZ*RF;Q5RIP7V%KT=-%1T[8
M:=B,8G8G:!^X8F0Q,BB:C6-3"(A^P"H    @    $
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MAD1S[=,L;_U7)P(=<[#<;:Y4GIWJSL<U,HH5JP%RU<.147N4     "
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M"1    "             0
M  =B@#?Z7T]/=ZEKW)N4S%17JO#*>P^NE--2W:1)JA%CHVKQ7M4M.EIXJ6!D
M,#$:QJ(B(@'YH:2&AIFP4S4;&U.1]P"H
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MM!_/[R: #1:=T=IS3<TDU@L]/02R)A[HLY<GTF]              $
M           &32\G>)C&12\G>((?2;XIW@89F3?%.\##$
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ML  ]R>  ,@  ,@
M                           #(I>3O$QS)I>3@0_<WQ3O PS,F^*=X&&
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M&T6FBM%.L-O@;$Q>?>OTF<   0                   @
M                !ZB*JX3BJ\D)3IK2%1<'-FK,PTZ<>*<5 T5JME3<YTBI
M8U=WN[$+1TWINFM$;7*G65/-7+V&TMU!3V^G;%2Q-8B=J)Q4R@CT\ *
M                                         /$  /I            !
MGP'T             "
M                                                #)I>3O$QC(I>
M3O$$/I-\4[P,,S)OBG>!AB                   &!>+-;;U3+!=J.&JCPJ
M)OMRJ(O/CV$6MVR70]OJFU%)886RMY*KW.1/H4G" #QK&,9N,:UC43"(U,80
MB]JV>Z6M5_=>[?:V1717ND6??<J[SN:X4E(   "*ZDV>:6U+<$KKW:F556B8
M217JU?Y'MRV>:6N=SI[A76IDM9 UK8Y-]4W4;R)2 ")A$3L1$1 J9:YJ\45,
M*B]J  0^GV9:0IKU\+TUG9%<$?UB2LD<F'=^,X,>Y;)=$7*NGK:ZR,EJ9WJ^
M1ZRN3>5>:\R< "OO,OL__P"7V?6O^\_<.QS04,K)8[!&CV*CFKUKN"I])/@!
MXQJ,8UC.#6(C43N1#T         #QS6O:K7HBHO-%(9J+1450CY[9B*3FK%7
M@JDT" 456T<]#.Z&IC<QZ=Z'P+PN5LI;E"Z.KB1V4PCNU"O;]HNIHMZ6@59X
M4[,\4(J(@]>UT;U:]JM<G-%3B>          $   (
M                          ^E/#)42)' QTCU[$ ^9FVJUU5SFZJDC5R]
MJ]B$IL6AY)MV:YN6)O!=Q%XJ3^BHX**%(J6-L;43'#M CNGM'TMO5DU6B3U"
M<4[D)2F$1$1,(G)$ *@      !
M                                             $
M                                    !         $
M            &12\G&.9%+R<"'TF^*=X&&9DWQ3O PR  "@ @
M                                      TUXTW073>=)$D<WZ[4XE?W
MK2-?;E<^)JU$.>"M3DA;)[V8[ *#<U6N5KT5KDYHIXA<-VTQ;;EO.?"D<J_I
M,X$&N^C*^B1TD.)XD[N:$5%P?J1CHWJV1JM<G8J8/R
M                     $      @  ^E/#+42(R"-TCE[&ID#YGZBC?*]&1
M,<]Z]C4RI++/HBLJE;)6.;!%VHO-2<VBP6^UIFGA:LG:]W%0('8]%UE;NOJU
M\GAYJBIQ4G]HLE#:F8IH6[W:]4XJ;(=A4
M
M      !
M                              ,BEY.,<R:7DXA#]S?%/\##,R;XIW@8
M8@  4            0                                         #
MW..1X -?<K+07%%\I@:KE_23@I#KKH)[5<^VS*YOZCN98( I"NM5;0.5*JG>
MQ$[>PPD7)?,T,4[=V>-DC>YR9-#<](6RMRYL?4/[V<$(JI$!,;EH2L@WG4<C
M9FYY*F"-55KKJ5RMGI94QV[O ## [<*G$
M     )QX(BJH! 9U'::^L>C8*6547])6X0D]MT#4R*CJV=(F_JHF0(5R-E;K
M'<+@J>3T[MU?TG<$+,MFE+9087J4F>G:],F]C8V-F[&UK6IV-3 $%M&@FHY'
MW*95XYW&$OMUMI+=&C:2%C%_6QQ,P%1Z>
M                                                           0
M
M                                   R*7D[Q,<R*7DX$/I-\4[P,,S)
MOBG>!AB
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M)JYK:CK$_5:A(Z+3EKHL=32L54[7<3; H\C8V-N(VHU.Y#T       (
M
M
M                                                 (       9-+
MR<8QDTO)P(?N;XIW@89F3?%.\##
M                                             "'J*O>> #W*]ZC/
M:IX '!>:(OB$1$Y(B  >Y&\O:JG@ ]RO>>  #U/Y'@          (
M    0
M           $             $  !
M
M    9%+R=XF.9%+R=X@A])OBG>!AF9-\4[P,,
M                                             /4:J\D4]W7=R@?D
M'ZW7=RGBHJ<T4#P                   >HG,(G'"<P/ >[JIS13P    "?
M_B'NZJ=B@>
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MW0&%47:UTLSH:NZ4%/,WG'+.UKD\453,8YKV(YCFN:J916KE%3V >@
M       !A3W>UT\JQ5-TH(94YLDG:UR?0J@9H/&.:]B/C<CV.3+7-7*.3V*>
M@                                                      R*7D[
MQ,<R*7D[Q!#Z3?%.\##,R;XIW@89  !0
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M>%0
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M-:Y\W7,SW<SHS8OK"X:RTKY3>*.2GKJ=6L>]T>XV7*<%:!/4 !0
M                "                  $    #(I>3C',FEY.!#]S?%.\
M##,R;XIW@88              "  $
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MBXZ7V8?F#3_PN7^AQS3L _.A:_\ S =RN]93P]=ZRGA4
M
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M#4;&QW!9%[T Z* !4
M     #)I>3C&,BEY.\00^DWQ3O PS,F^*=X&&
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MX8VHUC&IA&I[#]@      !
M       &12\G>)CF32\G$(?N;XIW@89F3?%.\##   H
M                             !2^WW:G>]GUZM5'9H:.2.JIEF>L[%<J
M.WE3AQ(+H!R+_M*:O^26KZE?O'^TIK#Y):OJ5^\&CKH',.A]OVJ+YJNV6RKI
MK:V"IE2-ZLB5%1/9Q,G4VW?4]LU_66.GIK:M+#6^3-5T2J[=WL<\\P:.E0?*
MDD6:C@E=C?>Q'+CED^J8[R@      =@       [P?IB;SD10/R#FW7.W74UB
MVA7.Q4=-;G4M-5^3L5\:JY6Y3FN3HFV3OJK;35$B(DDL:.=CEQ R0   "
M  ^D       %?[3]J=DT) L,[O*;JY$5E(SGA>U5)1I*ZRWK3%'=)VM9+/%U
MNZWDG#* ;CL!S/=MO6J*/6TUGCI;:M.RI2%%6-=[&4XYR=+L7,<;EYN:CE]P
M'H   !   [       "G-M6TC5&C;Q3TNGK=#502,WG/? Y^%^@G&RZ_W'4VC
MJ:Z7JG;3UTCU:Z-K%:B(G+@I!*P, H                    @
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MW'8]5< ?D'O;CM/>K?\ JK[@/R!A4RB\%/TC'+R:ON _("IC**>M:JIE$5?
M#P'JM5.:*GB>HURIE$50/R#]=6_]5?<>,]=$]H'Q?54L;U;+5TT;_P!5\J(J
M?0?5JHY,M<CD[%1<H<4=(>1[=J=P1LCT15;^DIUWH3\B[+Q7/DS2#> ]:U79
MPF<'O5O_ %5]Q1^0#]-8Y>357Z /R#U&JN<(J_0%:Y.:+[@/ / ]:BNY)Q[@
M/ ?K<=CU7>X_( 'J<S]=6[]5WN _ /514SE#P  @
M                9%+R=XF.9-+R<"'[F^*=X&&9DWQ3O PP
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M7M.9]?1+4;0[G"F562JW>'/C@Z_TGLCTC:[-34TUHIZR9\:=9-,W><JJG9W
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MJ$D2-=V2-?68N,\B1G(/11K9X=H$E/'(J02P/WV=B^TZ_P"\J/
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MYOBG>!AF9-\4[P,,H
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MY+?F'_8=CKV^)SELDV2:NT7KJGN<\5&MORYDJI+ER1KVHG>=&JN57 1X "@
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MQ3O PS,F^*=X&&0  4           0
M       [P%[0 &0    !   "#ES    $  !.&0  [ $ !        .T  $
MBFU*>_4VBJN;2*O2\-<WJ]UN\Y6YXHB*<NU>B=I6T*^Q+?J:H2;&$FJV[C&I
M]"'9J91>"JA^E<Y4PKE5/$@C6SO2M-HW2E':*5J(]B(Z=R+G?E5.*HO<2, H
M   $     .8 #P ^D .P       !!V  >G@        "
M                          $     $                    .P
M          %4[3=C%'KS47PO4W::D?U38NK;'O)P[2?Z0LC--Z<H;1#.L[*5
MB,21R85QMP0  4                /
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MR2.8K(O5PG:?':CM&M>S^W1R5K5J*V9/Q-,QR(Y?:OL0TW1E3>V542+VS/\
MM.<-N-WJ=3[3ZQJX18W-IHVYX)A50"<.Z35Y\L16V:B\FWDRF5WMW[RZ=E6T
MZU[0*>9M/&M)7PIET$CT57)WH:&T[$])3:!IZ62V1_"LU&CEK7*N^V16YSX9
M.<]E]QGTGM3IF0.X-J5IGYX;S=["_8!U/MLUQ6Z"TQ3W.W4T%1)+.D2MFSC&
M%XFHV%[3;EM!=<4N5'34R4R)NK#GCGOR:OI;JB[/*%4Y.JVJGN4A717NM'9+
M;J2XW.9L-+3L1SU5>?#DGM Z4O5THK+;)[A<ZB.GI8FJJO>N,^Q#FFIZ2%^F
MNDM/:K-131.D5L*>DKG)G@0K;!M-N&T&\>1T/6QV>-^*>F1.+UY97'-2Y=@V
MQV+3\,5]U)"V2ZN]*"%>*0HJ<U3O M#0=9?[C88:S5%)34E7,F^V"'.6(O8[
M/:2,]R>%16VV[7]=H"TTE5;:6GJ'3.PY)LX3C[!L.U_7[0+3<*JY4E/3/IGM
M:U(<X7/B0[I<_DS;OWT^T=$'\F+U\ZS^Y%7VWB['T'.^T?;O>]+ZVN5EI+90
MRP4TB,8^15WG)CM.B&>LB^TX9V[?G>OGSZ?8@2':>F;@^ZZ=H+C4-;&^HA25
MZ-]5O#)5&T';[:--W*HMMII%N-3"F%F:].K1W<2Z.IFI-BJ34V>M;;<)A,\-
MTXVT$ZROU?1KJK>6U.>O7*G'(5;$/2:OZ2(LMGMZL[=U79+)V;;=[/JBLAMU
MU@^#:^14:QZN162.7L3VFULN@-E=]MR/M=KMLS'IN(])523/?C/,KB?HW7>D
MU#Y=9;U0PTT4Z34[94=OM1%RF>',#I945%5%YH>'QH65#*&G962-FJ6L1LDB
M<G.3FI]BH)RX @^U':10[/(*.6X4%16)4JJ(D+D;C'?DC\6W?2_X-LNU3%/!
M+(JHRD54<]V/:BX M@%&V[I*Z;JJIL51:*^EC7_O'/:Y$^A%+HM%PI+Q;J>O
MML[)Z6H:CF/:O?W]R@90*FUEMRM.E=4RV.JL]9//&YK5E9(U&\>WB:^_](K3
M=JJ_)X;;5URHGINC>U$:O=Q(+I!'+'K"W7/2,.HZC>M]#(S?Q.J91.?TE:7?
MI(Z:H*Q\%+;*VN8U<=:Q[6HOO4HN[' (5OL^VQZ=UI5LHX&R4%:_*MBJ')Q1
M/;R,G:GM.I=G<E&E?9ZNMAJFJK9H7(UK53L7/:!/P1+9KKRW:_LTMPMD$M/U
M3]R2&145S5^@_6TG7-#H*R,N5QII:EKW]6R.-4157Z0)6"O]E>U"CVBSUT=O
MM-71-I&(Y9)G(YKU5<83':?3:%M5T]H:I92W![ZFM7BZ&'"JQ/:!/ 4+_M.6
M#K=WX N&YGUNM;R[\%JZ&UO9=:T+ZFR3JYT2)UL3DPZ-5[ (-MUVI7/9Y7VN
M"VT5-4LJHE>YTRKE%1<<,$KV1:LJ]::/BN]?!%!,Z1S=R+U<)R*3Z8_^<:>_
MAW_:63T9?S74_P \[[2*M8$3UWM L.B8&.O%3F>1%5D$>%<N._N*RBZ3>GWR
MHQ]AN#&*O%ZR-7'T%1?(-%H[5=JU?:6W"RU#98^3V*OI,7N5"+[4-J]NV>UE
M+2U]LJJQT[=Y'0N1J)[P+%!5M5MQTQ2:=I+I4-F;-4M5S*-%1TB(G?QX&DL_
M20TQ75;8:RVUM!&J_&O<CT3Z$ NT&-;*^FNE!!6T$J34T[4?&].U%([KG:!8
M-%,C^&JK$\B99"SBY?'N E80H:/I-Z?=,C'6&X-9G&_UC>"=^"U]$ZSLVLJ#
MRFRU&^YJ9DB7UF>($B!B7:Y4=HM\U;<JAE/31IESW+_).]2FKKTD]-456Z&D
MM5=6QHGQK'HU%^A0+P[ 5UL\VOZ<UM5+24V_0UJHBMAJ')Z7L1>\L94QS \
M                "                                       !
M       0
M                                              #(I>3O$QS(I>3@
M0^DWQ3O PS,F^*=X&&(
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M23;#:[54>I;3#22W5++UOI-C1W4\^.>PUNV"C73>UBLD2!T:-F2H1O+>RN>
M';U&U&T4#4X(V%$1.Y,'"5XSYV9^'_MR?:=7V[:II=NA8KM)<X.LBI4WZ=9$
MZQ7[OJX\3E'0].[5&U2D5&2RQ3UG6OQS1F]S^A 0Z Z5WYL[7_$,_I4Y4I*F
MLEIDME+ON;-(B]6SF]W)$]IU?TM6I'L[H8V^JRK:U/!$4@71.T];;E=[A<:Z
MF;/44B(L.^F48O>GM J"Z6:]Z(O-(ZY4TE'5HC9XT7'%.9V]LTUA3ZVTK3W2
M#=;,F(YXT_0>B<2)](30*:NTL^NHHLW6A3K&83B]B)Q3Z$XG/6P;7:Z,U=$V
MNF>VTU*]7.W/HHO8[ ';8/Q3SQU5-%44[D?#*U'L<WBBHO:?LJ*%Z7/Y,V[]
M]/M/.B%^2]Z^=9_<VG2KMBU6SUE<S><^FG8S=:F>"KQ4K+HS;0K7I2:YVR^2
MK##6N8Z.97>BU4SP5/I(KK5GK)XG#6W5-[:_>T[ZA$_DAV#7ZZTO;Z%U9-?;
M>Z)K=[=9,USE^A%.)M9WA=7[0:RXTD+U6KJ,L8U,JJ?_ (@(=Q:-ID9HNU4T
MN'L=2-:[N<BM3*'/6U?8#7)<);CHMB5%/,[>=2*Y&NBX<<*O9["Z]7UEVTWL
MN6KLBM=<**DC<C7,WL^BF>!3>S+I"5U3?UI];.@2AD9ADL3-SJWYYKWH!1[K
M9J33=6Z3R:OHYHERKVM<B)]*<"TMFVWV]6B>GH-1HVOH%?NNE=\:W*\\]J(=
M)5&JM(UMNS57:T34LJ(JQR2L7/BAQWMMJ].UFNJAVD(HV4:8:[JDPQS^W=0#
MM^W5M/<:""MI)&R03M1[')VF20O8O334NS2S1U#%8_J][==SPO(FA4<\],'_
M "RR?O.(AT;]FELU=Y;=K[O2TM(Y(V4_8]R\<K["7],#_*[)^\X_71*U%;_@
M:OL<L[(J_K.LC8]V.L3V>WB17UV_[*K!3Z-JK_9*:.W3V]B;\<289(U78]_$
MT?1%U*YEQN5CJYW=4]K9(&+Q3?SQ3V%E=(Z^4-NV972WU$\?E=:C61Q;R;WK
M(N<=W IWHDVN2IUE6UG5/ZJGA:O68]'.>60(KTBN&U"Y>S=^POG8]LHTQ%HJ
M@K;I017*JKHTG<Z9,HQ%3DA1'2&3.U6XY[VG8&A6M9HRRM8B-:E*S")RY <W
M=*?43X[K1:4H6M@M]#&B]6Q,)Q3@GN/WLKK]D=GTS%^$KTJ[M+QF2:!SD9QX
M(F$-1TK+9/3;1O+I&KU%7$W<7'/=3"DRV6;(]"ZRTA17))ZM:IR*V>-LR(K7
M(N%X=B 5%M4ETG!J:&KV>U4RT[F[[\M5O5OSR;["_KJQ=I'1Z;4I"LUQI:??
M8Q>*J]J8S[D/7["MG4=;Y')<9F5F-[J%J6H_'?@L_1NF+;I>PLM-I<]]$F41
M7NWE7/!0.;>B?J%UOU;66:I<UL-5$NZU>:R(J?VR?OI::B2MU/166FF5\-+'
MOO;V-D553[$(IKN*79SMGGK*>GQ#!4)/ UOHHYJH?G2T;]IFVB":I3\55SK+
M)E,HUJ)G&.[('2FP/3;=/;.+>JHB5%<Q*B3"<6JJ<B&ZSV"VZOU!)>:F^+!#
M/-ULJ5+TXIVHBEV5CX[59:F6%C6145,Y[&(G!$8W*?8<2U%^O^TG6?D,MYFA
M@JYEW&R2JD<;?#(%R;6+7LMH-,55%1K1175D.] ZF7>5RIWJG K+HQU]12;3
M::*!ZI%-&YKV9X.)EJO8=8]'Z,K[G>+TL]5''^)W?01SNS"$#Z-_YTJ#'+==
M_8"==,C_ #G3_P##O^TG_1YK66W8VZMD]2!TC^! .F3_ )SI_P#AW_U$WV$T
M;[AL.J*2)<23)(UO\@.;JN\4^J=I*UVK:I\-!45:K421HJ[D>5]5/H+MNMTV
M&U=F?1,5(GM9ALT5.Y'JJ)P7."B]+6ZVRZ_@MVI5DAH7U:Q3/1=U6)E>)TVG
M1\T*Z!*AE16.IU3>21)TW<=^>X"@]B>I?P8VETCJ:61;=/(L,C<^NU<XS_(G
M?2^5%OEH5.2Q*I86G]BN@$KH*RT7"6JEA>CV]74M>F4\"O>EZF+Y:$[HE0#8
M='+9?8[YIAU_OL"U;WRNA9"_U6[J\R.=*+1]HTU>;5/9*5E)'5PKO11IAJ*B
MXR73T:_S3T/SS_M*WZ9'^*TY\U)_4!,NC/>)G;,*A*E4=%0;SH\\\<5PON.=
MKE55>T+:HK;B_,M;5]3Z'!&M1<)CZ"]^C-2+7[,;S2-?N+,CF(_'+**4'IE\
M>FMJ](^[/6**DK\RN7L3>Y@=4:GV-Z6K=*S6^@M4<%<R)$CGCX/<].]?:0#8
MOLCU;I34])=JJH91T^_NU-,CLJ^/*\,IP[B_JZZT5+:9;I+4PMHFQ]:DJO3=
M5,<.)5NB=O%FU+?8+7)034E5/-U46';Z.7/ "K^E=JNIK=316")R-H*1J2*B
M915>J+G)D[,Z_9!:-*P1ZA>E7=)DWY^NIW.6-WZK51.1'.E#;9Z/:3+/*U>J
MJ(FO:['#P\2?[-=C^A-7Z2HKE'45;ZES$2HC9,GH/[4QV 4UM,FTO2ZKBK-
M5,RTR*DN7-5NX]%RF,IR.Q-ENH':GT):[F]SG3.CZN5SN:N3FI7C]A6SF.K6
MDDN4S*I.*PNJ6H]/H+4T?IRATI88;3:5D6CB57,61=Y>(&Y !4
M                            (
M                        $         0
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MVNV4]##)))' Q&HZ5V\Y?%3+[P4
M     (               $   #L                        0       #
ML        0                                         $
M                   R*7DXQS)I>3@0_<WQ3O PS,F^*=X&&0  4
M          $                                          (
M              'J.5 JJO-5/        $
M                      0            0
M                 (
M                                                       ,BEY.
M,<R*7DX$/I-\4[P,,SU]53PBL$&< FC!!G &C!!G &C!!G &C!!G &C!!G &
MC!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &
MC!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!X S@
M#1@\ 9P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09
MP!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09
MP!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09
MP!HP09P!HP09P!HP1P,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(
M,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(,X T8(
MR9P!HP09P!HP0AG &C!!G &C!!G &C!!G &C!!G &C!!G &C!!G &C!"&< :
M,$&< :,$&< :,$&< :,$&< :,$&< :,$(9P!HP09P!HP09P!HP09P!HP09P!
MHP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!HP09P!
>HP09P!HP09P!HP09P!HP09P!HP3(I>3C['J!7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g98130g00t13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t13.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1WH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '<L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H_\  $0@$T@=" P$B  (1 0,1 ?_$ !T  0 " @,! 0
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M !($$@@ 202 ()  @D 0"0!!( $$@@ 2  ()( $@   ! ) $$@  02!!(
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M @$D 2""0(!( @$@ 02 (!( $$@" "0!!(   ""00!(!  D " "0   @D
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M!I@QG&=/RF7SZ[/T-,'/K-/]U7\H=-?!(!!N5(   $ 2   (  D$ 2 0!(!
M$@ ""2 !(   @ 2   !  D$ 2 0!(  @D@D ""0()() $$@  0!(()  $ 2"
M"0 ()   ""00!(   $ "2"0!  $@@D  0!(() @D   0!(()  $ 20"0   @
MD$ 2"  )(0D  0!(   $ 2" !(   $ 20A) $@$ 2   () !" !(     " !
M)!(  @D""00!(()  $ 202     $ 2"   )  @D    ()  @D  0!(   @D
M   ! $@@D 0 !(! $@$ 2020!(() $$D 2     $$@    ()  @ 2"  !) $
M@@ 2 0!(     $( $@     ! $@ ""2 !( Y@ ! $D$D 2""0 ( $@$ 2""0
M   $$D 2""0!!(    >S@MRMQ=9%:NB]V1;_ /N0\4]G!GQNLO\ .1?J0PR?
M))+>"/X-OH0"/X-OH0'R#E:?9T_*9?/M&?H:809OG3\IE\^T9^AIA!]9I_NJ
M_E#HKX  -S(   @D@"002    @D 02             $$@            0
M      $$@ 02   $$D$@ " )   @D   !!(   @"0     @D      $ D 02
M     @D   !!(( $@  " )     ""0  0  02   $$@      $ $@ " )
M @ "0!!)  D        @D 02   ( D   02 ()( D       !         "
M)             ""0 !!( (       02        " !(  @D    ()
M    @D            ()( D       $$@  " )!!($$D$@      @D    !!
M( @D   !![.#?C=9?YR+]2'CGL8-^-UE_G(OU(89/DDEO!'\&WT(!'\&WT(#
MY!RM/LZ?E-OGUV?H:8.9QG3\IE\^T9^AI@Y]9I_NJ_E#HKX) !N9 () $$D
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M0U:)SJL+O8=<WKO:(EEN"HB?\/)S?]*FBG.[TJ<FCU<ZG?IMLPI;B - =K,
MTW! "(JJB(BJJ\FG.=A*"M5-4HJI4Z>)=["X>#CA>WW:LK[I<(TG?2*D<<;T
MU:BKOVBYL9XTL6#88/=A[FK+NCCBCVE5/1T'G9M?-,G*I7>6NU]IVAIKW-.D
MB1K!-QJ\C-A=I?0A]/HJN-JNDI*EC$Y7.B<B)]^A<F(<P\/U69^'L04W&I;J
M6!S)5;%H_5=>5OWGM9@9M87OF$;E;:!:SNFHCV6;4"(FNO3J9_$Y=Z_]OQ]E
MXI:^Q123.V88WROZK&JY?4AR24=7$Q7RTE1&Q.5SXG(B??H6#P>OE.HD7YO+
MR_5+SSQ1$RTN^Y$U:WF_ZD)FUDX\T8MO'8F^T[-1.0@E.0:'>S -!H ()T&@
M$$@: 0"=     #0(!]PPRS.5L$4DKDWZ1M5R_P!#[EI*F%FW-2SQ,Y-I\:M3
MUJ9SDQBNV81Q'55MY65()*?BF\5'MKM;2+_8S'.#,W#V*\'/MEH=5=U+.R3]
MY#LIHFNN_4Y+Y\E<L4BF\>;";3OLH\ '6S02-  ()( D^X8)IET@ADE<G-&U
M7?D?&NB*J\B&T60^$V8>PHZ\5K$[KKHTE5===F)-Z>A=#FU.HC3TXO&6-K;0
MU@EAEA=LSQ21.ZLC5:O]3E2@K51%2BJE1=Z*D+M_]#W\S\2.Q3BVNK]?W"+Q
M4";.RJ,3DU\YN!AM$7#UK543_A8N;_H0TZC66P4K::]98S>8:/2TE3"W:GII
MXFZZ;4D:M3^IPFY6;%K2Z8#NT3*=LTK(5DC;IOVDYT\YIMHK=SD5%3<J*;-)
MJOB*S.VVS*EN)]PP33JJ00RRJG-&Q7:>HY?<^N^8U?8N]AL%P8;5)%8[I<9F
M-1D\R,B73>J(F_\ ,NS933Q4]1RY^TN5DFD5WV_%A.3:6A+V/C>K9&.8].5K
MDT5/N.6*CJI6(^&DJ)&+R.9$KD7[T0RC-Q?_ ,2+]K_&_LAL+D FN6=OU1%]
M_)^HZ,^KG%BC)MXLK6VAJK[GUWS&K[%WL'N?7?,:OL7>PW4N^*;#9ZON6YW*
MEIJC9VMB1VBZ=)TN_P"PIY;H?QG+':628WC'_G[,>.6FTE%5QM5TE)4L8F]7
M.B<B)]^A\PTU1.BK!3S2HG*L;%=IZC:'-#&6'+A@"^4E#=J2:IE@V8XV.U5R
MZIN0K+@YXC6UXEDM,R(M/<$1$5?\KTY-/3J=%-7>V*V3@VF/HRBT[;JH>Q\;
MU9(QS'IRM<FBI]Q\EX\(["#:6KBQ'1L78J%2.I:U-R.TW._L4<=.GS1FI%X9
M5G>-T$HBJN[E4'8MO^(TGVK?S0VS.T*^9*2JB9MRTM1&SK/C5$]9PFUV=^[*
MNH71-52/F-4$Y#FTNHG44FTQLQI;>$@(@T.ID$$Z ""0.D !S#0 .8:#F4#F
M925+V+(RFG?'UFQJJ>LX3:++3Y&)ET35(9.;S&L-3_Q,WUU_,YL&HG+:U=MM
MI8UMONXB1H#I9(!( !.0&;9281I<8XE6BKYGQTT4?&/1FYSTUY$7F,,F2,=9
MM;PA)G:-V$@LC/*PV_#N(Z2@M-.D-.RG;SZJY>E5*W)BR1EI%X^I$[QN@D(B
M@V*@D: ""2"=   0""1IH  &@T @D:*G*  "(     :#0""00!(&@ $$H@ @
MD: ""1H-.4 !H ()&@Y@  TW*!S)25*Q<8VFG6+37;2-=G3IU.$O"QYFX>H\
MK76"=:KW06C?!HD**W:5%TWZ^<HYK51J)T(:,.2]YMQ5VV]V,3,RD (;V2"0
M- !!.@T 'W#!-,JI!#)*O.C&J[\CX+CX,?QHN2:(NM.G+Z35GR\K'-_))G:-
MU/RPRPNV9HGQ.Z'M5J_U/@M'A%K_ ./W)N1$A9R)YBKAAR<RD7\RL[P  VJ@
MD   -  &G* ()&@ (3&Q\CD;&QSWKR-:FJK]Q&AF&46[,:R[M_')RF&2_!6;
M>1,[0Q.:GG@TX^":+7DXQBMU]9QE]\*--&V--$1/?E"&O39N=CB^VVZ5G>-P
M@D(;U -!H 0YDI*E8N-2FG6+KI&NSZSA5-45"[K?F9AZ#*M</R+5>Z/<KH=T
M*;.TJKSZFC-DM3;AKOO*3,PI$@E$W WJ (@T @$C0 !H- "(JKHB*JKR(G.<
MLM-40M1T]/-$U>19&*U%]9SV:I927:BJ9M>+AE:]VB:KHBEJYT9A6+%]CH:2
MS+4K-#+MNXV+9333TFB^2];UK%=XGZ^3&9G=3QSQT-7(FL=)4N:O(K8G*B_T
M,NRAPU#BC&E-25;D[FA3CY&==$5/>E_8YS)LF!JUEJ=1RNJ$B:]K(F(C$:NO
M/]QISZNU+QCI7BE+6Z[0U2;252R+&VEG61-ZL2-=I/N..2.2)ZLEC>QZ<K7I
MHJ?<758<U[3X1*^^76.2&BDIFP0-BB1SMRZKM>TKW,V^T>(\85MRMBR+2RZ;
M/&-V5Y.@V8\V2U^&U=NG^0L3._5BA(&ATL@ :  !H  "(    !$"  7XS+6R
MV7+.JO$C75=RDID=QCU]ZW5>9I0:)N-&'/7-OP_1(G<()!O4 T '+#35$Z+Q
M%/-+IR\6Q7:>HXW-<URM<U6N3<J*FBH6QDGCVR8/HZ^*]+4(Z9Z.9Q46WNT]
M)76)ZV&Y8CNE;2Z\145#Y8]I-%V5<JIN-%,E[9)K->D?5C$SN\L#3E"(;V0?
M4<;Y'HR)CGO7D:U-57[CY,VR8^4>T<B^_P!-YADOP5FWDDSM&[#9H)H%TGAE
MB5=Z)(Q6JOK.-"[.%"G^_K.FY$[F7F_ZG%)Z&&GR\['%YC;<K.\(!.B@W*
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M^+H$L%34.DFWROGT5K&Z>8[$63V$J1&T]TQ-LUJ[E:V5C?Z+O,XS=Q)4X;P
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M+OYTYS":G-G&51 Z)]VT:NY59&UKO6AV,ZL66O%M]I:NS/F?%'%L.61FSO\
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MS]#3"#-\Z?E,OGUV?H:80?6:?[JOY0Z*^  0;F24    @"0     @D@"002
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M-K5KXR;O ()!D()!  DA"0 ! $@  -0 !!( @D@D  3LJC4=HNRO(JIN4"
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M  '2 !*M5$15141>153E(      !!(  $ "2 !(   @D       @D   !!(
M      ()      ()             >Q@WXW67^<B_4AXQ[.#?C=9?YR+]2&&
M3Y));P1_!M]" 1_!M]" ^0<K3[.GY3;Y]HS]#3"#-\Z?E,OGVC/T-,(/K-/]
MU7\H=-?  !N5 ) $ D@"0 ! )   @ 2   ( D  0202 ()( $@  02 () $
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M[HIYV+)#(J:*J(NBHIB!VX[UR5BU?!E$[A!)!FJ0   ( D@D 02 !!(( D
M02 ! )    ""0! )    ""2 )()  ]C!OQNLO\Y%^I#QSV,&_&ZR_P Y%^I#
M#)\DDMX(_@V^A (_@V^A ?(.5I]G3\IE\^NS]#3"#-\Z?E,OGUV?H:80?6:?
M[JOY0Z:^ 0"3<J"2"0!!(  $ 2" !(     02  () $$@           ()
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M,6X+_P 8KK]@GYH95PF/B9:OYE/TJ8KP7_C%=?L$_-#CQ_R-O\^K#_:\K/\
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M3A"W06J"_P!NIDBJ.,1DW%IHUR+R*J=)K^=NDR4R8XM2-H9UG> @D'2R 02
M   @D  0@ D@D   !!)!($$D$@ 02 "     !!( $$@   /8P9\;K+_.1?J0
M\<]C!OQNLO\ .1?J0PR?))+>"/X-OH0"/X-OH0'R#E:?9T_*9?/KL_0TP@S?
M.GY3+Y]HS]#3!SZS3_=5_*'37P2 #<H""0   $$@      @D@D    ! $@$
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M 2"#<R "0!!) $@$ "00 )     02  ! $@@D 020!(  @D   0 )() $$D
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M @D"$)() $$@   ()( $@  ""0 ! $@   0!)!( @D$ 2" !(() @D@D""2
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M\@Y6GV=/RF7S[1GZ&F$&;YT_*;>_M&?H:80?6:?[JOY0Z*^  #<R
M""2 )  $$@ ""0   $$@ " 2 !!( (            $ $@ " )   @D ""0
M   @D@ 202!!(( D@D    ()( D @"0             $$@      A  )()
M   " 2       0 )    @"0     @D 02        02              " 2
M      ""2 )!!(         @D    !!( @D  " )     02 !!)!(  @ 2
M      02       " )  $$@ ""2 ) ( D            ! )   @"0
M 0202 !!(  @ 2   ( D   " )  $$D$@      @ "0      @"0 !![.#?C
M=9?YR+]2'CGL8-^-UE_G(OU(89/DDEO!'\&WT(!'\&WT(#Y!RM/LZ?E,OGUV
M?H:8.9QG3\IE\^T9^AIA!]9I_NJ_E#HKX() -S)!)!( @D@ "0 ()  @$@
M ()  @D 020 )(!(   ""0 () $$@ 0"2 !( $$D$@""0!!(  @D ""0! )
M  @ 2 !!(    0"2  )( D   0 )  !""0 (0D   ! )  @D " 2!!(( D@D
M   !!(( D@D ""0 ()  (  ()( $@    () $ D 02"  ) $ D@ 202 () $
M D ""0! !($ D   ! )  @D ""0!!(  @D ""2 )   @D 0202 ()( $@ 02
M02! )( D@D    ()( D$$@" 2 () $$D$@ " !(  @D 02 !!( $ D@ "0!!
M(  $$@        0 2! ) $$D$@0"0! ) $$H02 ()    0"0!!(( $@ ""0
M  $$@ 02     @D ""0    @D ""0!![.#/C=9?YR+]2'CGL8-^-UE_G(OU(
M89/DDEO!'\&WT(!'\&WT(#Y!RM/LZ?E,OGVC/T-,(-G<8Y-T&(\25MUGO-53
MR5+D<L;(D5&Z-1.7[CQOV?[7](*SL&^T]_#VA@K2M9GPB/I+=6\1#7L&PG@
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M<R&O8-A/ !:_I!6]@WVCP 6OZ05G8-]H[RP>?M)S(:]@V$\ %K^D%9V#?:/
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M.9#7L&PG@ M?T@K>P:/ !:_I!6]@WVCO+!Y^TG,AKV#83]G^U_2"M[!OM'@
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MDYD->P;"> "U_2"M[!OM'@ M?T@K.P:.\L'G[2<R&O8-A/ !:_I!6]@WVCP
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M9#7L&PG@ M?T@K>P;[1X +7](*WL&^T=Y8//VDYD->P;"> "U_2"M[!OM'@
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M&_M)QPNB/X-OH0$M31J)T(#YYH=6?X5QQG)-\*XXRH     "    @
M                                   (
M                $
M                               !
M      0             0
M                                                   2SQV^D@EG
MCM]('> !%=2;X5WI0XSDF^%<<94
M              (                                         "
M                                  "                        !
M                         @
M                                            0
M                                   "8_';Z2#Z9X[?2!W0 174F^%<
M<9R3?"N])QE0
M
M                                 $
M                 (                                   0
M
M                  )9X[?20?4?CM]* =T $5U)OA7'&<DWPKCC*@
M
M                                         0
M                                      (
M
M         "                                   @            @
M $Q^.WTD'TSQV^D#N@ BNI-\*XXSDF^%<<94
M                                                 $
M
M         "                                        (
M
M                                          "8_';Z2"8_';Z0.\ "
M*ZDWPKCC.2;X5QQE0           (   0          @
M  !                                     !
M                                                '2
M     $
M
M    @                      )9X[?203'X[?2!W@ 174F^%<<9R3?"N.,
MJ                 "
M       !       @
M               (
M                     "                      "
M
M         !+/';Z2#ZC\9OI [H (KJ3?"N^XX^DY)OA7'&5
M
M                 $  %
M
M                                                   0
M                        (         0  4                #Z9X[?
M2?)+/';Z0.\ "*ZDWPKCC.2;X5QQE0
M     &-8XQM9<%4<%1?:C8X]^Q%&W>YR^@]^BJ8ZRC@JH5UBF8DC/0N] .8'
MQ4314U/)/4RLA@C17/D>NC6IYU*PNF?&![?7.I5KWSJU=E9(6ZM3[P+2!XF%
M,56;%=!W78:^&J8GC-:OOF>E#V]-4W:?> "%>8JSDP;ANN?1U=Q2HJ&*K7MI
M_?;*IS*>M@K,3#6,M662XQOJ$358'KH_3T 9:!T@
M        0
M
M
M                            (                          "   2
MSQV^D@^F>.WT@=T $5U)OA7?<<?2<DWPKON.,J
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M55;J2=%FB-]O<X978"53153H(.5B
M                                               (  *
M                      @
M
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M]6KTIM'N3-IB=_#;^[PNP\]LL9(O;>8GZ^3<%_CN/D^G^.I\GSSV
M
M
M                                                     @
M                                                        )9X[
M?202SQV^D#O  BNI-\*XXSDF^%<<94
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MH8(M4CCK-ENO1J;A/\=WI->MQ4QVB*1MO"6C9\@(#B8@"
M
M
M                   >??+W;+#1+5WJLCHZ;73C'ZZ:_<>@4MPM$1<L]_\
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M/=;RKZ#4K+A$_:HK>G;E_0A"&V@)YU/A)(U71LC'+T(Y%*/H
M                                    ^F>.WTGR2SQV^D#O  BNI-\*
M\XSDF^%<<94        .8                                     "
M  !T@:R\-'QL-^AQS80L5QOF1V&V6NF=.Z.>17(WF0X>&EXV&_JN++X-/R/V
MGZ[_ ,S&:\4;2ZM%JK:/-7/2-YCS5K%@;%L3=F*AJF-Y=&NT0\2ZP7:T5JTM
MQ?40SIHJM=(O)ZS;5%5%Y37/.U?_ !O+YHVG-DQ12N\2^Y[$[<R]HZF<.6E8
MC:9Z,QQ78[G>[%AZ2@@6?8IDVUVN<QYF$<4L:C64\[6IR(DBHA9^5]Z2]81I
M7MBXI8$XE4Z=.<RW53U<.MM2D5B(F'Y?VIV'2^LRVR3,6WG?;90J83Q5K\#4
M:_:J=/#DE9#BJB@J)ID>R=&N:KUY>@V&1R[]_,:[UE:EOQK4U;FJ](:E7*WI
M.W3Y[9XM68^CY_7Z&FAG'>MIZS]6PY\2_ 3?9N_(K9<V(-5_V!?7_J?+\UH'
M12)W"Y-6JG]/2</P>;TO;[XT?K]I4CA#Y7:;^>7\S;Z3QW>DTHM5];;,;-O*
MQ;;8ZA9>+Z=_(7$O"$@U7_<W_P!1VZW3Y,EHFD>$/5G^+K"\P47^T'!Y&_\
MJ'[0<'D;_P"HX_@LWDG"O0%&IP@Z;3_!G?B_U'[05-Y'7\0^"S^DX5Y Q?+G
M%S,:6!]SBIUID;*L>QR\G.90<UJS29K;QACL  @
M                            <P
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M4+L-FG]\L,BZ[U])N=R[T75%WHO2!"<@ *
M                    2SQV^D@^F>.WT@=T $5U)OA7'&<DWPKON.,J
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M:OD^E_FW_P!BUBJ>#5\GTO\ -O\ [%K'%JOOK?FZY  :$
M                  $W@
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M\315U5OH"+.!*[U5>37F(*
M        2SQV^D@F/QV^D#O  BNI-\*XX^<Y)OA7G&5
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M  ',@
M          $                     $             "  "@
M                    (      !
M                 !,?CM])!,?CM]('> !%=2;X5QQG)-\*XXRH!
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M+YXV39( -8
M
M
M         3'X[?202SQV^D@[P "NI-\*XXSDF^%=]QQE0
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MU'J;*6Z^6VYSNBH*N*:1$U5K7:[C7@GI,2][[5Z??+3-CIXUWF?[O1 !O?(
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MG,0                                       !
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M-15SK^Z@8LC].71 .?0%<96YG19@7R[P4-(Z"AHVZL<_QGKJGM+'
M #TGB8XKJNV80NU=;M>[(('/BT35=I$W;C N#SBW$6+;)<)\4I)QT4J-CVX]
MA=-$\Q!; )T(* T4EB:N1#7Z',S$3L]HL,+4-]R73\6L>RG)JJ<H&P /IR:.
M=ITGR                    ^F>.WTGR2SQV^D#O  BNI-\*[TG&<DWPKSC
M*@$                                    "H>$M@REQ)A!ESDKXJ*LM
MJZPOF=HUZ:\GI*TP5PBJ^UX;BM]QLRU\U&SBF5$2+LO1NY-?4<G"1J*G$F<%
MBPC).^&VN2-%:BZ(JNWJIL3A["5BL%G@MM%:Z-(8XT8Y71(JOT3>JD&MN4M+
M)FQFI+BJ_5M-#W.NVRA8[1Z[.B(B)T&1<,VJ?[EV"E1?>3/553T+N,<X0=@@
MP!CZRXBPJO<#ZI[=N*+WJ(NN_DYMQ[?"WXRXX3PQ>-A6L1$<_=R*NGM"KVR_
M@;38$L$+$1&MI(UT]*%:<+>G;-E;&Y4WQU37(OW*65EY4LJ\!V":-R.:ZC8F
MJ>9$0K/A<53:?*^*-7>_EJVM1.?D4(R[(:I=5Y5V9TBZJQJQIZ#U\P<94&!K
M&VZ76.:2!S]A$B35=3RLBZ1]%E99F/16K(SC$U\YZ>8F"Z''=B;:[E4300-?
MM[<7+J!6O[3&$?F=P[)1^TSA'YG<>S4XOV8\+>5;AZD'[,>%O*MP_H!47"#S
M-M&8BVGW&BJ(^Y$5'\<S9Y>@V%X-"ZY/6GZ\GYFO'" RQM>7*VE+355%1W6C
MMOC=-VG0;#\&A-,G[5]H_P#,*L\ %0"<H &OF+<M;U2NNMU>ZF6F:]\ZHDGO
MME55>30Y<@T3ONGU^;N_-"W<PMV"+S]@I0>6%YJ+/BNF6F8Q_=*I Y'="KRH
M<UJUI>)A^@:+5ZCM3LO/7)MO'2/I](;.IR <G.GK!TOS\             5U
MCG ]ROUZ6LI'P)$K43WSM%*TOUEJ+#=$HZMS'2)HNK%U0V0Z2D<UT_\ &"^A
MIZ>BSWM;ESX1#YCMO08<>.<]=^*97#8TTLU%]DAW3IV/5;-1?9(=S13S;>,O
MI,?R5_*  $9@                               !+/';Z2"6[E1>@#4+
M-N1(<U;G*]-4CG8Y?0FA;\6?.&FPQM6EKM6M1%]XGM/1Q1DW9L17ZJNM5<*N
M*:H5%<QB)HBZ><\M,@;!Y4K_ %-/3MFT^2E8R;](9.7P]X9^:UWX/]1X>\,_
M-:[\'^IQ> &P>5*_U-'@!L'E2O\ 4TP_T?XHY?#WAGYK7?@_U'A[PS\UKOP?
MZG%X ;!Y4K_4T> &P>5*_P!31_H_Q'+X>\,_-:[\'^H\/>&?FM=^#_4XO #8
M/*E?ZFCP V#RI7^IH_T?XCE\/>&?FM=^#_4>'O#/S6N_!_J<7@!L'E2O]31X
M ;!Y4K_4T?Z/\1R^'O#/S6N_!_J/#WAGYK7?@_U.+P V#RI7^IH\ -@\J5_J
M:/\ 1_B.7P]X9^:UWX/]1X>\,_-J[\'^IQ> &P>5*_U-'@!L'E2O]31_H_Q'
M+X>\,_-:[\'^H\/>&?FM=^#_ %.+P V#RI7^IH\ -@\J5_J:/]'^(Y?#WAGY
MK7?@_P!1X>\,_-:[\'^IQ> &P>5*_P!31X ;!Y4K_4T?Z/\ $<OA[PS\VKOP
M?ZCP]X9^:UWX/]3B\ -@\J5_J:/ #8/*E?ZFC_1_B.7P]X9^:UWX/]1X>\,_
M-:[\'^IQ> &P>5*_U-'@!L'E2O\ 4T?Z/\5<OA[PS\UKOP)[0F?6&OFM=^!/
M:<7@!L'E2O\ 4TJ#-C"-)@W$4=!05$L\3F([:E1-=?N-F+%I<MN&NY$;ML[/
M<(KK:J6OIT<D-0Q)&([<NBG<,?R^^(]D_EF_W,@/-O&UIB$GQ  8H
M            @                              =*\UCZ"UU-5%$LKXF
M:M:G.(C>=H8VM%8FT_1W4U!2C\T+XKETBID37DT4CPH7S^'3?A4[/@,WX/'[
M^TGX_LNQ 4GX4+[_  Z7\*CPH7W^'3?A4? 9OP._M)^/[+L^X?<I2?A0OO\
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MI/D^F>.WT@=T $5U)OA7'&?<WPKCX*@
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M+589I)JAZR2N;O<O*I[ICN7OQ3HOJF1'G9?GM^;Z+23,X*3/E  #!T
M                $          :   -        -     :#0       :
M  !K'PDOCO#]DALX:Q\)+X[P_9(=O9_WWZ,JK]R^^(]D_EFGOG@9??$>R?RS
M?[GOG+D^>?S2?$ !@@
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MEGCM]('> !%=2;X5QQG)-\*XXRH
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M^#9]5/R.C6UI'#:L;;O/[%RY9G)BRVWX=HCW2 #A>Z
M                 $                      $    :Q\)+X[P_9(;.<Q
MK;PBK?65.,HGTU+/*U(M-IC%<G]#M[/^^_1E1>>7R*N"+)HG)3-,@V7=!IW2
M8AQO1TT=/35%SC@C398U(W:(GJ..HQUC"FDXNHNM;$]-^R_<O]3=;L^UK3,6
MAE-6X^FG+R@PS)VX5=UR_H*NX3NGJ7JY'2.Y5WF9GG7KP6FL_1K  8@
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MY%5 BZ:JUK6JO.B:*0 )5=5U7>-I=--I2  /I'.1--I3Y
M     "8_';Z2"8_';Z0.\ "*ZD_PKCC.2;X1QQE0     $
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M7RSX-GU4_([M9\F/\G@]C_?:C\_[I "'"]X"     0
M           "                          !NYVM7TIJ !*(W7Q&?A0U5
MX0_RB2Z(B?N6\B>DVJ;RH:J\(?Y1)?LF_P!SN[.^]_1E5=F17R9VWTN_,STP
M+(KY,[;Z7?F9Z<^H^]M^<I( #2@  "      "
M
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M'P^O_P"MB/2#Z?XR\G*?)Y3ZL
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MXKG7P4TLF]C9%T5WH.\QS7M1S%1S7)JBIR*!(
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M +5!VB$=U4WSJ#M$.E\%PV\G,#A[JIOG4':(?4<T4BZ12QO7_I<BD.&?)R
MK$     %\1_U5-=:NM6WXNFJT:CUAGVD1><V*7D5.9>4QV?!.'ZB=\TU#M2/
M75R[2[U.K2YZXM^+ZO*[4T.75Q3E3$36=^K"ES8F55_W<S\1G&"\0.Q%;'U;
MX$A5';.B*8/F?AJTV>S036ZFXF5TNRJZZ[CW,G/BY)]=3;EIAG#S,<;=7)H\
MVKIK/A]1??IO_G1G8 .!]                    $
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MG(UOF-E$1&M1K>1$T0  "@
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M         GFWG#/64E,[9JJVF@>O^625&J!S ACV21I)$]DD:\CF.1R+]Y(
M'%45--2Z=UU=/3Z\B2R(W7UGW%)'-'QE/+'-&O\ FC<CD]: ?0   #F UDX:
M7C8;^JXLW@T_(_:?KO\ S*RX:7C8;^JXLS@T_(_:OKO_ #(+/Z0 4
M   !#TU8].EJZ><UTN^7>)9KM5S146K'RN<U4>G(J[C8PG?TJ87I%XVEZG9G
M:V7LV;3BB)XO/\&M7@\Q9\T?VJ#P=XL^:/[5#977SJ-5Z5-?P]7K?]7:OT5_
M:?[M8J[ N)J&CFJJFF>V&)NT]>-3<AW,I\145AOLU1=JB1D+H]E-$5V\V!OU
MO]UK-5T'&<6M1&K-OJE&8PRQDPY8)[DZXLFXI6IL(S375=#"V*:3Q5^CU=#V
MUA[4Q6TVMF*VM.T1$3UW_?ZKGPWBBUXC2;W)F=)Q.FWM-TTU/;*<X._)>?\
ML_N7(O*IOQVXJQ,ODNU])31:N^#'X1MX_D@! 9O-   " (!@&<WQ=IM/XQY&
M6V*+59K(^"X3N9*K]=$;J9MC3#O?+;XJ;NCB.+?MZZ:ZF!7?++W/ME56>Z*/
MXEBOV=GETYCT,%L5L7*O/U?/:W%J\6KG4X*[QM]??ZK#LN)K7>JA\%OG=)(U
M-516Z;CVD*:R6^,53]B7*AS:G%&+)PU>EV9JKZO!&6_CO( #0[P
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MK#LO=W,Z9538?U-YL\J*B[^4(@ %
M           "6>.WTD$Q^.WT@=X $5U)OA7'&<DWPKCC*@
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M                                      @
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MKF^TUOO7/XMFNT]/\Q;-OBF@H*>&KJ.Z9XXVL?-IIMJB<NAS@
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MWV^AIXXHH6HJ\6FKETWJJ\Y2_"HP=<*MEOQA9(EDJ+=HD[6(JNT1=RZ=![N
M\^<*W+#E.MZJ7T%QIXFLFC>GC.1--4]1%5KPF+)385QY8[[8F-HYJE[%>V)-
ME-K7EW>@];A=+)6X<PI<7-79V4<_TKI[3'L4W2?//-:WT=A@E;9J%4_>O3=L
MHNJN70O'/G!:XKRTJ:"W1HM91(V2!--[D;RHGJ RO 4K9L#V&1BHJ+1QIN]"
M%:<+6=L.5C4735]4UJ>I3&\B\Y;3;,-18<Q>^2AK;:G%,D>W<Y$Z?.8UG!C%
MV;^)[9A7"$,L]##*CGRJW<Y>==W(F@%XY"4[J;*JSM>BHKT5Z:IS'9S=P1)C
M["[;3#6,I'->K]MZ:F46&V166R4-L@^#I86QIY]$.\$:N?LLUOTBI_P!."S6
M_2*G_ IM(1S%&B><65LV6WN<DUQ96]V:Z;+=-G0V<X,Z:9/VK[23\RM>&EXV
M&_0XLO@T_(_:?KO_ #(JSP 5                 PC.7X@UWUV?J,W,(SE^
M(%;]=GZC"_RR[^ROYW%_]H_JQ3@[>+>O^S^Y<13O!W\6]?\ 9_<N(QP_=P[?
MM'_ZCD_3^D  -KPP     );RIZ2"6^,GI H7'_Q]J?M6EZT__"P?9M_(HK'_
M ,?:G[5I>U-_PL'V;?R._5_=X_R>!V1_,ZC\_P#S+[ !P/?
M
M
M      "  3M.Z2/2
M         (               #ZC\=OI/D^H_';Z0.Z "*ZDWPKCC.2;X5QQ
ME0                   <B*J\B;U!#DVHWMY-IJM]: 8])CG"\<CXY+[0M>
MQ=ES5DY%/GO\PKY?H.T*@N'!FH:ROJ:IV()FK-(KU3BTW:J==."Y0KN3$,ZK
M]G_J07/W^85\OT':#O\ ,*^7Z#M"F?V6J+Z05'9_ZC]EJB\OU'9I[0+VL^(K
M/>I)([3<J>KDC35S8G:JB'J%892924N7-SK:J"ZOK'U,:,6-R(FFA9Z%
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M3,;3L^KI/%6)  &0          "           @              $
M
M
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MF79V=JXU6&+Q&VW3]@ &AW
M
M
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M'S_V?U%)QSA^L=7J@ \Y]$                           @     @
M                                              !
M
M                                     !               3'X[?2A
M!+/';Z4 [P (KJ3?"N.,Y)OA7?<<94                 $    #CJ8(:J!
MT-7!%/$J*BMD:CDT.5"E<U\\6X.O<MDM=I=6W%K>5RKL[^31$W@>KC#(7!N)
M4DFCII+=4JNTKZ==RKYT*#Q1AR]93U+JK#V,:>=K%U2&.;:<G-HJ'N-ES<S/
MD]XE7;K<_D=OC8U/3RJ9OA/@WV^"1M5BNZ37&?E=$WQ5^]2*[_!VS4O6/)Z^
M@OD,"NI(FN;/&W17<V\NX\G#V'+/AVFXBRV^"D;HB*Z-J(YWI7G/6*@
M                UDX:7C8;]#BS.#3\C]I^N_\ ,K/AI>-AOZKBS.#3\C]I
M^N_\R"SP 4                   )3E( &MV/;#=YL8W*>FH*ES%EVF/8U=
M/2=%*?%Z)\'<MWI-GT)U]!IY,;S.\OJ\?VJO3'7'.&L\,1'5J=77*^T,ZP5E
M35PRHB*K'N5%T-F<)5\%QP_134\[9](FM>Y%U]]IOU*>SXLU1#?8[NYS%IZA
MK8FHG*BM13,,AOBA/_,*8X]ZWFLNWMSE:WLS'K*Q$3OX1YSXQ^FRR  =#X<
M  AS4>U6N35J[E120!3F<-'34=;0I20,A1S7*NRG*6'E]\3;9]1?S,#SK_XZ
MW_5<=G"^85NM5@HZ&>GG=)"W15;R<IZ5Z7R::D5C=\WAS8M-VCEG),5C;^RT
MP8 F:5I^;5/]"?"E:OFU3ZSD^%S>EZO>>D_Y(9\# ?"E:?FM3ZT'A2M7S:I]
M:#X7-Z3O/2?\D,^!@'A2M/S6I]8\*5I^:U(^%S>D[STG_)#/P8!X4K3I_P -
M4^LR/"N)*7$<,TE'&^-(E1%VS&V#)2.*T=&S%KM/FMP8[Q,O< !J=8
M                                                        (
M
M@
M            !],\=OI/D^H_';Z0.Z "*ZDWPKD]!QG)-\*[[CC*@
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M4WXSM4M3#51\932LE9R;3%U0<,QXPM<E+=(F', ",P
M
M
M                        $                             "6>.WT
MD'TSQV^D#N@ BNI-\*XXSDF^%<<94                     $H5YF#E'AO
M&\[ZJOC?!<%33NB/E7TISEA)SZ&/XHQEA_"\+I+W<X8%1->*VD5Z_<!KS<\C
M\;80F6KP3?)ZF-BZMBC>K7KZ4UT.:T9W8TPE*E)CFP33QMW.F>U6.1/-S'K8
MIX35&DCJ;!]IJ:J;D;+*W_[><Q5;'FQFVU4NRMHK8Y=Z2L2-NG+R:;R*V RZ
MS(L6/(I?<>1S:F)J.D@?XS44S0J_)K*6GRY6IJ'5W=E=4L1DBHBHUJ)T%H%0
M         , SJQ]!@+"4M0CD6Y5;5CI&(J:H[K>A + 5%3E0@HG@M8JO>)Z6
M]R7^X35BL<BLXQ?$W\Q;V+\0TF%<-UUZN.O<]*S791=%<[F1 /91JKR)J@5%
M3E135JQW/-7-NIJ[EA^Y>X]IC>J1?Y$5.9/.=JQ9B8TRTQE!8<QY%K;?.J-;
M4)OTUY'([G(-F@0QS7L:]CD<QR(YKDY%124*  Y@-9.&EXV&_JN+-X-/R/VG
MZ[_S*RX:7C8;^JXLS@T_(_:?KO\ S(+/ !0                        ]
M7WE'\(7_ !FU_8._47@4=PA?\9M7\N[]1JR_)+Z'[+_^HT_*?Z+$RH^(MN^J
M9:8EE1\1;=]4RTSKX0\OM+^;R_\ VG^H #)Q   (          ,=QY9ZB^V!
MU'2*U)>,1WON3<5KX,KUUH/678@.C%JLF*O#5YVJ[+P:J_,R;[^"D_!C>NM!
MZQX,;UUH/678#9\?E_!S]PZ3\?W:^8EPC7X?IHIJUT:LD56ILKO++R@3_P +
MN^T4ZF=7^#4/VBG<RA^+#OM%-V;);+IN*WFXM)IJ:;M.<>/PBO\ 9FX /-?3
M
M                 @  H                           $
M                        !     (
M               $L\=OI(/IGCM]('= !%=2;X5QQG)-\*XXRH
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M\ $@0   "                                     "
M   (
M                             !
M                 ?3/';Z3Y)9X[?2!W@ 174F^%<<9R3?"N.,J
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M(G]#-<FL27>[XBG@N5=+40MAVD:[3EU-E<T6G9X6J^S.?38+9YR5F*^6ZYT
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M^Q0],\RT;6F(?2XIFU*S/E  "-@
M                               @
M
M                               !+/';Z2"6>.WT@=X $5U)OA7'&<DW
MPKON.,J "                    !"O8BZ.>Q%Z%<B'TG*G04'FKE[F)?<7
MU%=AFY<3;7M389QZ-T7T$%\\9'_$B_&AQ5592TU-++55,$<+&JKW.>FFFGI-
M6_!)F]Y93_\ B4.*;)3-*Y-XBXW=CJ=VYVU4:H!Z?!]JV5&=>*7VC_"YGN=[
MSQ53:70V=*ZR9RQILNK7.CI6U-SJD3CYFIN33F0L4H      "
M  Z0.8#63AI>-AOT.+,X-/R/VGZ[_P RL^&EXV&_JN+,X-/R/VGZ[_S(+/ !
M0                          'RL<:KJL;%7I5J$<5%_"C_"A]@+O+'<?Q
MQI@V[*D;$_<\S4*=R-JXJ?%[V2KHZ:-6M].I>&**-+AAVXTKG["/A=[[HTWF
MOV4[-G'E*WEV7*G]31DZ7K+Z_L3AR=EZK'/Y^W_XV53< O*H-[X\
M             "ELY/C+']DA=)AV+L$,Q%<FU;JKBE1NSLZ:G3I,E<63BMX/
M,[6TV34Z:<>.-YWAU+%CJRTEDHJ>:5W&11HUVG29Q3RMG@CE8NK)&HY%\QKS
MC"R-L%Y6B;+QJ(U';6FA?UFW6>B^Q;^1GJL-*1%Z?5H[*U>;->^'-$?P;0[@
M .-[0   "
M
M                     "           @ 0                    "
M            'TSQV^D^26>.WT@=X $5U)OA7'&<DWPKCC*@        $
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M;K:G[G:-FB7EB?SH9(:N\%BJFLV/\1X>5ZK Y51&JNY%:J[]#:+F   H
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M)Z-?:W8%]/,9--O>+;STCPCZ,V!#5U:BIR+O0DVOF
M G* G*!1N;?QO?\ 9H7!9JB#W*HV\?#JD34TVTZ"O,P\*W6[8C?4T-.KXE8C
M44P1L-707N*DJGR,ECE:BMVEW;SU>5748JUBW6(?)QJ<G9^JRWFDS%I_+ZMD
M$!#?$;Z$_(D\I]8
M                                  0
M                                                @
M                    !]1^.WTGR2SQV^D#O  BNG-\*[[CXYSDF^%<<94
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M'!;BDO&9&([VC5XINKM?K.70VF0PO*; 5+@###+?"[C:R71]5+UGZ<B>8S0
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M:I'0R2(US=C3<7-SJ<^;#;#.UGI:+6X]96;XXGITZ@ -+L
M                                           @       "   @
M
M                               0                  "6>.WTD$Q^
M.WT@=X $5U)OA7'&<DWPKCC*@                     )NY%)U54WJOK(0
M "=I=-$Y/-N(     @                  <P &LG#2\;#?U7%F<&GY'[3]
M=_YE9\-+QL-_5<69P:?D?M/UW_F06> "@
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MPN5-2-H)&+,]&;2N3<6$:LF*^.=KQLZM/JL6IB;8IWV  8.@
M    0
M
M                                          )C\=OI(/IGCM]('= !
M%=2;X5QQGW-\*X^"H                                      !.B]
M$    B:\F\     ',!K)PTO&PW]5Q9G!I^1^T_7?^96?#2\;#?U7%F<&GY'[
M3]=_YD%G]( *                                 \X &'77+C#USN$]
M950S+/,Y7O5LBHBJ5'FUAJW8;N=)#:VR-9)'M.1SMK>;&E%\(#=>Z#[)31FK
M$4F=GUGV;UVIRZVF*^29KM/3?ITA9&5/Q$MOH4RQ>4K3+K&%@MV#Z&EKKG#%
M4,14<QR[T,C3'V%U71+Q3^OE-M9C;Q>5K]#J;:K+:,=MIM/TGS90#CIIHZB!
MDT#D?$]-6N3D5#D,GDS$Q.T@ "              0J:HJ+R+N) &*3Y?V">9
M\TL$BO>NTY=M>4X_!UA[YO)^-3+P;>?D]4N2=#IIZ\N/V8CX.L/?P)/QJ1X.
ML/?P)/QJ9>!S\OJD^ TW_''[,0\'6'OX$GXU'@ZP]\WD_&IEX'/R^J2-!IO^
M./V:_6RGCI<>P00HJ11U>RU%Z-38$U_X^*FQ^LT[T9$RKVG.7D1-2X>_##Z_
M_ND'K.O6UM::S$;]'D=BY<6*,M;6B/XGO@\#OPP_Y4@]8[\,/^5(/6<7*OZ9
M>W\5@]<?O#W]0>!WX8?\J0>L=^&'_*D'K'*OZ9_8^*P>N/WA[X/ [\,/^5(/
M6._##_E2#UCE7],GQ6#UQ^\/?!X'?AA_RI!ZQWX8?\J0>L<K)Z9/BL'KC]X>
M^#P._##_ )4@]8[\,/\ E2#UCE7],_L?%8/7'[P]\'@=^&'_ "I!ZQWX8?\
M*D'K'*OZ9_8^*P>N/WA[X/ [\,/^5(/6._##_E2#UCE7],GQ6#UQ^\/?!X'?
MAA_RI!ZQWX8?\J0>L<J_IG]CXK!ZX_>'O@\#OPP_Y4@]8[\,/^5(/6.5?TR?
M%8/7'[P]_4'@=^&'_*D'K'?AA_RI!ZQRK^F?V/BL'KC]X>^#P._##_E2#UG)
M!BNQSS,BAN4+Y'KHUJ+RJ.5?RDC58)Z1>/WA[8 ,&\
M                           !S
M
M     (  )C\=OI()9X[?2!W@ 174F^%<<9R3?"N.,J
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MLW@T_(_:?KO_ #*RX:"M<[#FRYKM$=R+J69P:?D?M/UW_F06> "@
M                          !7F96 ZO%E?3U%+5PP)$S95)$5=?46&#&:
MQ:-I=.DUF71Y8S89VM"B_ K=-/\ $Z3\+C!L7X<GPO>>X*F:.9^RU^VQ%1-_
MI-K37C/+=C=_2D+/R.?+BK6N\0^S^S_;6KUVKY6:T3&TSX1^"\L)?%FW)_\
M"0]4UKHLS<1T=)%303PI%&U&MUCWZ>LYO"MB?YQ!V7^ILC-2'!F^R>MODM:)
MKUGSG^S8X'G8:JY:_#UNJZC3CIH6O?IR:J>B;GREZ32TTGZ=  !B(
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MJ  4                                      (
M  0                            ',
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MM+2T<\#V-V]J145%3[C+'EBWCXN7M?[/Y-%:;88FU(C>9G;HS, &U\X
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MGC*9><62O!::Q]'N:?+.7%7)/UC< !@W         "
M           "
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M &LG#2\;#?U7%F<&GY'[3]=_YE9\-+QL-_5<69P:?D?M/UW_ )D%G@ H
M                                               ?$\39H)8GZ[,C
M5:OH4^P%B9CK"H<7Y866TX9N=PII:E9J>)7L1SMVIX.07QGJOL?[EN8^@EJL
M&7BGIHWRS20*C&-357+KR(:T2P7:PS-=)'64$DB;E7:C5R'-DVI:+1#[WL?)
ME[4T&;!FR;VF=HW\MH^C;<&)943S5.!:":IE?-*Y7:O>NJKO7G,M.BL[QN^'
MU.&=/FOAF=^&9C]@ %:0!
M              K'.W_AK;]=?R4LXK'.W_A;;]=?R.G1_?5>;VO_ "=_T_JR
M#*OXH4_UG&7&(Y5_$^G^LXRXUY_O+?FWZ#^6Q_E  #4ZP
M
M                                                  /IGCM])\DL
M\=OI [P (KJ3?"N./I.2;X5QQE0
M               ',!T@:R\-+QL-_5<67P:?D?M/UW_F5GPTO&PW]5Q9G!I^
M1^T_7?\ F06> "@                                         @
M        !R;REN$,J]U6A%ZC_P T+I,6QG@JAQ9)3/KIY8E@14;Q?/J:\E9M
M68AZO8NKQZ/65S9?EC?^C!<LLP+=06>W6.6FG6H1RMVTTV=574N-><U*F<MC
MQ%(M(NTM+,J,5W/HO.6K@7,J[7[$U);ZN*G2&5515:FBFO'E_P!MGT/;G8,W
MF=7I8_AF)M;>?UZ+@0#D5?4#H?$@          !
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M% 0QVW&UVFFTU%T7F).-[(
M                                    "            @
M       $Q^.WTD$L\=OI [P (KJ3?"N.,Y)OA7'&5
M                                :R<-+QL-_5<69P:?D?M/UW_F5IPT
MO&PW]5Q9?!I^1^T_7?\ F06> "@
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M .&5C ^8GI)$Q[?%>U')]Y]&;R@
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M;CT0..WF<G'Z8_:  &+8
M                                   @                      $
M     !+/';Z2"6>.WT@=X $5U)OA7'&?<WPKSX*@
M                             .8#63AI>-AOZKBS.#3\C]I^N_\ ,K/A
MI>-AOZKBS.#3\C]I^N_\R"SP.D%
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M[W/E? U7.=RJILQY(O.VSP.U>Q<G9U:Y+7BT6GZ/3 !M>(
M                0
M     #F
M                                            'TSQV^D^28_';Z0.
M\ "*ZDWPKCC.2;X5QQE0                                0 <P
M          ',!S :R<-+Q\-^AQ9G!I^1^T_7?^96?#2\;#?U7%F<&GY'[3]=
M_P"9!9_2 "@                                         $
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M?]=O?^SU_"]ASJU7X!X7L.=6J_ >1X%:+RK4=F@\"M%Y5J.S0;Y?*%Y/V?\
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MI&B] !
M
M                            EGCM])!,?CM]('> !%=2;X5QQG)-\*XX
MRH                                (         <=1/%34TM14R-B@B
M:KWO=R-1.=0.0% XAX1<?NK-180L-3<VPN5KYE9JURISIIR(>[EIGI:\579E
MFO%%+:+J_P 5)4V6.7HW\B@7""514547U$ !S <R@:R<-+QL-_5<69P:?D?M
M/UY/S*SX:7C8;^JXLS@T_(_:?KO_ #(+/ !0
M                                             $
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MFLSY@ *YP
M                                                    !
M                       F/QV^D@^F>.WT@=T $5U)OA7?<<9R3?"N.,J
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M)O5%1"#5C@\YAXIQ'CZ.@O-VGJJ56*JLD75#:<H
M              @                               "
M                   $Q^.WTH0?3/';Z0.Z "*ZDWPKCC/N;X5Q\%0 ',
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M_P"5C[G?FIN<AICP8/E97T._,W.   H
M            !                                       $
M        !+/';Z2#Z9X[?2!W0 174F^%<<9R3?"N.,J            !
M                          "473D(       * X5N%;UB5UB6R6^6K2%'
M<8L:*NR9]D%::ZR97VVANM.^FJXWOVHWIHJ;RPVN5-=E53T$.555=5U4@CI
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MM4?2O<NJ*Y3Y                       "
M                                                    !],\=OI/
MDEGCM]('> !%=2;X5QQG)-\*XXRH
M                 &+YFXPI\#8.K;U4-222/1D$2KIMO7D RA?>^,K4]*Z$
MHF[5-Z=*&J^$,)8^S:IIL07+$=1:J&9RNIF*KM'(O,FG,<MLQ)B[)[&U/:<6
M5DMRL=2J-9*]5V=%_P S=>@@VB!$;VR1LDC5'1O:CFJG.BDE
M                                @*;X4>)JW#N"J%MJJY*:LJJA&(Z-
M=':(!<J)YT]8T]'W*:LVK+_-BXVREK8L1SMCJ(VR-19%U1%37?O,IP)@+,FV
M8IH:N^7V6>WQOUEC5ZJCDU(+\!+E17*J<FNX@H
M              $     0YS6-5TCFL8W>KG+HB)YU E-_(-VFY45/,NI0.?&
M==%;+?4V#"=0VJN$S=B6JB?JV%.A%3G,CX+]94UN6S9:VHDGE69WOY'*Y>50
M+;0E=V]51/2NAXV+\04N%L.5MXKE3BJ=FJ-5=-MW,AK;A6VX]SJGJ[Q-?9K/
M9V2*R)J*J-Z=&H@&U::*FY47T+J0:KXJPWC[*#B+W0W^>[6UK_W[=7;*)T.1
M>8V&R]Q13XQPG17JF1&\<W21B+KL/3E0@R( %
M     $           ^)IHJ>%\M1+'%$U-7/D=LM1/.H'WT_W&[F77T;S6;A!
M9UPRT=1AW!]0KE7_ (BMB=NT3_*U4+;R&GFJ<KK7+52OFE7E>]=57<G.09\G
M*2B;N5/6>3BVN]S,+7:MV]AT-,]S7=#M-QJAE_;\R<?T%5<K3?ZJ.!DFSHZ1
M>7S;P-Q43T>L@UD\&>;6[_Q)/S?^8OM-C,/4]326*@IZ^3C*N*%K97K_ )G(
MF]0.^ @*
M     0                                    !],\=OI/DEGCM]('>
M!%=2;X5QQG)-\*XXRH
M      &N/#)K)5H</6UCU2*=ZN>WIW[C8XUIX8[%;6X5G7Q-I4U^\"^\#44=
MNP18:6)J-:RCC71.E6HJE1<,"B8_ MNKT1..AJT8CNA%15+GPS(V7"]ED9HK
M744*HO\ V(5%PO)6LRSIHU5-IU:W1/N4@L+*>O?<<N;#42JKI%IT1RKSJAEA
MA.2D+H,KK UZ:*Z':T\QFW2  !0
M       -7>%K=X5Q78+=5.5:6GV:B5$Y4Y=3:)-W(8#B_*/#.+<1PWR\I5/J
MH]/>-D1&.1.94(0JR;A'NI(8([)A:LEMD$;8VRR1KJJ(FA9F56;=CS"VZ>D1
M]'<XVHKZ>7=M>=IGL-#104B4D5%3-IFMV4B2---.C0U,S>L<& ,[K/<; BTT
M55,R98VKHB*JIJB>8#;L'S!+Q]/%-IIQC$?IZ4/HH              "
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M[5Z=.<SG@_WF>\Y5V:6K<KYHHTC5Z\JZ<@%B  H
M
M            !],\=OI0^26>.WT@=X $5U)OA7'&<DWPKCC*@
M                           (         !4O":PC-B?+V2HH(UDKK>Y)
M&M:FJJW7?H6T.945-47<J+R*!2&2&;MCJ\'TEJO]8R@N=OC2%Z3KIMHG/O,$
MSLQ6S-#%=JPMA-'5E-#*BR3,35KEYU]"%QXDR4P/?ZY]956M8:AZ[3UA>K4<
MJ^8]W!67V&L&-<N'[<V&9R:+,]RN?IYEYB#W;';H[19J*W0^)31-C3[DWG=
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M-8ZVK<L\C531S47D1?4=G"^3."<.5K*RBM:RU3%U:Z9ZN1%]!8@  %
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M6F%,'2\=8K6UE2G)-*Y7N3T:\AF.]5557>H$  H                 (
M
M             'U'X[?2?),?CM]('> !%=2;X5QQG)-\*XXRH
M                                                        @
M
M
M
M                                                      2SQV^D
M@^F>.WT@=T $5U)OA7'&<DWPSCC*@                @
M       $                     @           &.7['.&;!6K1WF[14U4
MB:\6[74#(P84F:N!_I!!ZE)\*N!OI!!ZE S0&'TV9^"ZFHC@@OT#I9'(UK=^
M]5Y#TJ'&6'[A?9++1W.*6Z,UVH$Y=W*![P                !YF(,06K#M
M&VJO=8VD@<[91[N15Z /3!U+3<J.[V^&NMD[:BCF36.1O(Y#M@
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M-%35.1=Z><
M  0
M           !+/';Z2"6>.WTD'>  5U)OA''&<DWPKCC*@
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M-B1:>KJDXV*!'+HUJ[T3=R<H&RD4D<S-N&1DK%Y',75%^\^DW\AJ;E1B'$>
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M0
M                             0                             /
MIGCM])\DL\=OI [P (KJ3?"N.,Y)OA7'&5       !  !0
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M!]/75[EYM3Y*
M       $
M          !+/';Z2"6>.WT@=X $5U)OA7>E#C.2;X5QQE0
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M9KZ#%J?@R61LFU4W:HECZNBH7_S @P? 65N&,%*DUJHMNM^<2JKG)Z->0S@
MH&/Y@8?CQ1@VZVF1J*^:%W%JO,[3<9 $W;^@#7S@IWJ2DCNV#KAJRJHI'2L8
M[E7?O-A$37=JFO-JNA3>-\N;U3YE4.,\#LC6J<Y&UL#W(U%;SK]YV\],(8MQ
M.RW5.#JIU/4Q,V)XDD1O+Z2"J>$FZCQ7FQ8K%:6-DKT<V&HD:NJ.U5-R_=N-
MH+!;(;+9**VTS4;%31I&B)_7^I3V1^3%1A*ZRX@Q5.E1>')^[CVD<D:JNJN5
M>DN_IUY0..I@AJJ:6GJHVS4\K=E\;TU1R%-8EX.V%[G6R5-KEGMKY'*YS6N5
M4U\R<Q=(**:PMP>\+6BL957%\MRD8NK4>Y4;KYT+B;#$VF[G;$Q*?8XOB]/>
M[/)IIT'V *8Q5P>L,W>Y2UMMEFMDLKE>]L:JK=5Z$YCM82R#PO9*QE7<%FNE
M0Q=6\<Y=A%\Z%N\PZ2"O+=E+8K;C=F)[>LM/5L?MI&UR['HTZ#EQOE99,88E
MI;W<W3-JJ;381CE1-W_\C/@41&U&1L8WD8U&I]QBF/< 6#'%(D=]I=N9B:1S
M,56O;]YE@ H%>#/9^/U;>*E(-?@]_)T%G9?Y<8=P+"[W$I-*EZ:/J)%5SU3H
M\R&8( /#QU?(<-X1NMVJ'(UM/ Y4Z=531-"D^"KAR:IK+UC2Y,UDK)%;3N7E
MWKJJ^HS/.S".)<<U%JLUL9%%A_;VZV=9$1VY>33GW%C6"TTMBLE%:J!FQ34D
M;8V[N73G(.^ "@
M
M           $L\=OI()9X[?2!W@ 173F^%>?!R3?"N.,J
M
M              Y@
M            $              '($  !                  ',
M            "
M                                   !S                    !+/
M';Z2"8_';Z0.\ "*Z<WPKCX.2;X5QQE0                           (
M
M
M                                                    !
M
M                                     "8_';Z2"6>.WT@=X $5QN:U
M7+JB>HC8;U4]0 0V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&
M]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53
MU#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V
M&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO5
M3U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0
M #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V
M&]5/4-AO53U  -AO53U#9;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO5
M3U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0
MV&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO
M53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]
M0 #8;U4]0V&]5/4  V&]5/4-AO53U  -EO53U#8;U4]0 #9;U4]0V&]5/4
MV&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO
M53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]
M0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-A
MO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4
M]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#9;U4]0 #8;U4]0V&]5/4
M V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -A
MO53U#8;U4]0 #8;U4]0V6]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4
M]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-
MAO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U
M4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4
M  V&]5/4-AO53U  -AO53U#9;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -
MAO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U
M4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4
M-AO53U  -AO53U#9;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;
MU4]0 #8;U4]0V&]5/4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/
M4  V&]5/4-AO53U  -AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4-AO53U
H-AO53U#8;U4]0 #8;U4]0V&]5/4  V&]5/4$:W5/>IR]  '*  K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g98130g00t14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t14.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[28L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )@\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*/_  !$(!=<&^ ,!(@ "$0$#$0'_Q  =  $  04! 0$
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MAWX#Y1-._/%^P[\"!0/=V+SD^\VK^6OI/U3U\HFG?GB_8=^ ^433OSQ?L._
M@4#W=B\Y/O-J_EKZ3]4]?*)IWYXOV'?@/E$T[\\7[#OP(% ]W8O.3[S:OY:^
MD_5/7RB:=^>+]AWX#Y1-._/%^P[\"!0/=V+SD^\VK^6OI/U3U\HFG?GB_8=^
M ^433OSQ?L._ @4#W=B\Y/O-J_EKZ3]4]?*)IWYXOV'?@/E$T[\\7[#OP(%
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M-I_#'2  &=S@
M
M
M
M                                                       J9Z@
M;AH'5DMDK6P5+U=0RN1'9WY?<3I33,J(&31.1T;T1S53O0Y;)?X0W]:FF?:Y
MW9DA3FCSWH<S7Z>)CO:_R]7]GNTK1;V7)/*>GT22 @.0]D$:\9[CV=OI:%N<
MRN578\$)*(8XRS<U]IHD7U8LX^LV]#7BS1^CC]NY9QZ*^WCM"/DZ J4.^^=
M
M
M
M
M                                               !G=$7!;;J2DFR
MJ->Y&.]RJ8(^M*_LJJ&3]5Z+_,K>O%6:SXLN#).+)6\=8EU$Q4<W*=%W0'RH
MG<U)"[Q8U?Y \N^KQ.\;OLI"'&'\ZV?N$^\F]2$.,/YUL_<(;W9_];^'"^T?
M]G_,-& !W'@
M
M
M
M
MJG5/>A0JG5/VD"8=/VW^[Z;]TS[@+;_=]-^Z9]P/+3U?6J?AA<*0AQA_.MG[
MA";U(0XP_G6S]PAN]G_U?X</[1_V?\PT8 '<>
M
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MDDC6K[LF_P"OM'6NQV9*JA699>9$])R*GW%+YJTM%)ZRS8-%DSXKYJ=*=4<
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M7^XH;MQ(TS0:>=2?!ZR_E$7FYUR:21BR1EKQ5Z+ZK37TN6<63K  "[7
M
M                          *IU3]I"A5.J?M($PZ?MO\ =]-^Z9]P%M_N
M^F_=,^X'EIZOK5/PPN%(0XP_G6S]PA-ZD(<8?SK9^X0W>S_ZO\.']H_[/^8:
M, #N/
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MC-:G.CIKG$S*,]"5W@G<4I'<:C@CI9ESS/:'9O?3SOCF=_VE%?XDI<#_ /\
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M;Z->269.R8F,IRHFY"B)A#%I\LYJ\<QM#<[2T=-%EC%6V\[<P &=S@
M
M                   *IU3]I"A5.J?M($PZ?MO]WTW[IGW 6W^[Z;]TS[@>
M6GJ^M4_#"X4A#C#^=;/W"$WJ0AQA_.MG[A#=[/\ ZO\ #A_:/^S_ )AHP .X
M\
M                              )U.@K9^8L?^67[CGU.IT%:_P Q8_\
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M,ULL^,@ +M<
M                                    "J=4_:0H53JG[2!,.G[;_=]-
M^Z9]P%M_N^F_=,^X'EIZOK5/PPN%(0XP_G6S]PA-ZD(<8?SK9^X0W>S_ .K_
M  X?VC_L_P"8:, #N/
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MJ+L:6/%6VJF:](Y_R[VHU>3%V52E^5K<H_;_ /&"[@ =-Y,
M
M               *IU3]I"A5.J?M($PZ?MO]WTW[IGW 6W^[Z;]TS[@>6GJ^
MM4_#"X4A#C#^=;/W"$WJ0AQA_.MG[A#=[/\ ZO\ #A_:/^S_ )AHP .X\
M
M
M
M          (2#PWU#9K50U%/=T:U[G\[7N;G/L(_*&/+CC+7AELZ357TF6,M
M(B9_5*FLN(%+);W4=B5561,.D1,(U"*T&Q4C#AKAKM5?6Z[+K;\>6>G3RA0
M&5I@
M                               !5.J?M(4*IU3]I F'3]M_N^F_=,^X
M"V_W?3?NF?<#RT]7UJGX87"D(<8?SK9^X0F]2$.,/YUL_<(;O9_]7^'#^T?]
MG_,-& !W'@
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M;L9%3EYDW,5;WG)-9CEYMV^##735RUOO>9YU\NK# %3*TE 5*  5 % 5 %
M !4H /O24=36*Y*2GEG5OK=FU78/B27P._VZ[?L,^]3%GR=UCF\>#<T&FC5Z
MBN&9VW^B.*BGFII5CJ8GQ2)U:],+_ ^T%MKJB+M:>CGEBZ<[&*J&R<5OSRJ/
MW;?N,UH?6EJLNF6T%:LW;HYZ^@W*;]-\E)S7[J+UKO,MC'HL/M5\&7)PUKOS
M_9&ZHK55%V5%PJ+W%#[5<B2U4TC?5>]7)GP53XFQ#F3RG:  J$* J4  JFX
MH"I0
M                   !5.J?M(4*IU3]I F'3]M_N^F_=,^X"V_W?3?NF?<#
MRT]7UJGX87"D(<8?SK9^X0F]2$.,/YUL_<(;O9_]7^'#^T?]G_,-& !W'@
M
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MZBV+PCI^RC_54Z"ID_\ 9ZW_ ""_]ASZ[U5.@Z;_  \;_D%_[#5U_2G[NO\
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M#
M             "J=4_:0H53JG[2!,.G[;_=]-^Z9]P%M_N^F_=,^X'EIZOK5
M/PPN%(0XP_G6S]PA-ZD(<8?SK9^X0W>S_P"K_#A_:/\ L_YAHP .X\
M
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MG
M              JG5/VD*%4ZI^T@3#I^V_W?3?NF?<!;?[OIOW3/N!Y:>KZU
M3\,+A2$.,/YUL_<(3>I"'&'\ZV?N$-WL_P#J_P .']H_[/\ F&C  [CP
M
M           ,_H[44VGKDDS$YX)-I69ZIXDF5&KM(W:%OPFL+E3HV6-55"%
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M$[S;] ZIM%KTFE%75;8JCG>O(J+W]"+ 3?3UOCC'/2%,':67#J+:FL1O;?\
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M*>FM3;-12<LRJWF1B[-:G<I$IL:"DUQS,^,N;]H<U;ZBM(G>:QM/[J  W7
M
M           "J=4_:0H53JG[2!,.G[;_ '?3?NF?<!;?[OIOW3/N!Y:>KZU3
M\,+A2$.,/YUL_<(3>I"'&'\ZV?N$-WL_^K_#A_:/^S_F&C  [CP
M
M
M                                                  +NVW&JMM2V
M>BF=%(U<[+LOO-G;Q)U"W_>4R^^)#308[XJ7YVC=LX=9GP1PXKS$?I+9;KK>
M^7.!T-14-8QR87LF\N36D3 !:E*TC:L;*9L^3//%EM,S^H "S"
M        "J'NGFDIIF34[W1RM7*.1>A\P$Q.T[PV^FXBZ@@CY&S0O1.]\>5/
M-5Q"O]3"^-\T+&N3"JQF%0U(&'V?%UX8;GO+5[</>3M^[W)(^1ZOE>Y[UZN5
M<JIX ,S3  $
M                       !5.J?M(4*IU3]I F'3]M_N^F_=,^X"V_W?3?N
MF?<#RT]7UJGX87"D(<8?SK9^X0F]2$.,/YUL_<(;O9_]7^'#^T?]G_,-& !W
M'@
M
M
M
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M>KZC3\,/NJ9+2I54>F%[B[+2I]=/<0L^65\1E?$H *Y7Q&5\2@ KE?$97Q*
M"N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N
M5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\
M1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E
M?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$
MH *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H
M*Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y
M7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q
M&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5
M\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2
M@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@
MKE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE
M?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$
M97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97
MQ* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q*
M "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "
MN5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5
M\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1E?$H *Y7Q&5\2@ KE?$97Q* "N5\1
ME?$H *Y7Q&5\5* #(,3#4]P#?53W "I:5/KI[B[+2I]=/<!\0
M
M
M
M
M                                         &0;ZJ>X!OJI[@!4M*GU
MT]Q=EI4^NGN ^(
M
M
M
M
M      #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
M
M
M
M
M                               !D&^JGN ;ZJ>X 5+2I]=/<79:5/KI
M[@/B                                          !1[V1M5TKV1L3J
MYZX1/K*F-U+11W+3URI)8UD22G>B-3KG&V +R&KI)W\D%932R?J1RM<O\$4^
MQQ'PEN,NG>*%N<]TB.;.M,Y'+E4SL=J7>I2@ME;5X3\A"Z3?ILA$3NM-=E9*
MZBC>K):ZD8].K73-14^K)]8Y(Y6(^*1DC%Z.8O,B_6A^?FH;A-<+Y7U<T[WO
MEF<[/-W9.G/)4N\M=HROHIY.;S.H1L:*N5PJ94B)W3--HW3-++%"WFGFCB;^
MM(Y&I_%3Q'54LK5=#5T\C$ZN9(BHGOP03Y6=T?%:+1;HW\G/(LKL+A53!;^3
MWI6JN'#Z]O658GW#,43G.54QXD[\]D</+=/T5923/Y(*RFE?W-9*URK]63U-
M404^/.:B&!%Z=J]&Y]V2%^&'!2Z:,U;3WFLNT%1#%S9C9S97*>U#%>5\JI;M
M,X<Y/RLO1<=R#<VWG9/T,T,[>:GFBF9^M&]')_(]D,^2PJKH.;*JOY9W5<]Y
M,Z(KEVW7V$QS1,;2H?"2MHHWJR6NI8WIU:Z9J*GU9+KD<B*JM7IU.'N-*N3B
M?>L/>B=LW;F7P(F=BL;NWD5'(BM<CD7HJ+D&)TC^:]K_ '#?N0RQ* H]S6)F
M1[6)XN7!55Y6/?A51K5=A._!R3KOB;>=4:UH[<CO-;=3UK&-BCV5V'?I+WD3
M*:UW=; ]I&[#=E5.5/N/+FJWJF"4* JB97"=2JL<B;M5/>!Y!Z1CE3*-54#6
MN=T15 \@]*QR=45/>>0 *HU5]5,^XKV;M]EP!Y 4  @" ?.:>"!J.J)XH6JN
M$61Z-1?XE89X9VJZGGBF:G58WHY$_@0=Y6RJFD[(J*J?Z4O1<=P\DU573-U5
M7.7\NG5<]Q&_/9;AY;IT0^4U33P8\XJ8(<].TD1N?XGW;NJ'&W'G5,NJ==OI
M:1RN@HU\WB:S**K\[^\3.Q6N[L&&JI9W*VGJZ>9R=T<J.7^2GV.*>"M]GTUQ
M(M_:N<U)9?-96O551,KC<[77"*O*N4[E$3N6KL^4U1! B+45$,*+T61Z-S_$
M03P5#5=3SPS-395B>CD3^! ?E9JJ4%IPYR;]RX\2[\D57.TMJ'*JJ^=L3=<_
MHC?GL</+=.O<6RW"@:JHZX42*G7\NW;^9%G&[BM!I.DEM-G>R:]2HK7IC*0M
M5.J^T@#A?H*Z:^OF&OD90-<KJFI<Y<-]B>T3)%>6\NV(98IF<T$T<K/UHW(Y
M/XH>9ZFGI\><U,$&>G:R(W/\2QTS8J'3=H@MEJC5E/$B)E555<J=54YO\HJX
M?#'$VVV6'M')$Z-KDRJ-578R@F=D1&\NHF*CVHYCD<U4RBMW1?<>)JBG@VJ*
MF"%?"21&_>1CQ@UC+P\T1145O:U+C-$V&)5W1B)U4YQM]HUMQ$G?/3I57)R=
M7ND1J(-UHKOS=M15=),N(:RFE7P9*UR_R4^ZICJ</WG2&MM"4S;C74]301.=
MRI*R3FW]N";O)TXCUNI9*BRWRI;-5Q,62%V,.<Q,9RO>(DFO+>$V355+ Y&U
M%73PN7=$DD1JK_$^?PC;_I&B_P"NW\2#/*(T!J;5NIK;5Z>H'U-/#3=F]S94
M;AW-G'4A34W#G5>F+=Y]?*"2FI5=R\_;9W^I2)G8BL2[>^$;?](T7_7;^)6.
MNHI'(V.NI'O7HULS55?YG".DM)7W5T]1#I^FDJI(&H^1.UY<)]:DE<.>%&M;
M1K.V5MPM<D5+#*CI'+,BX3W9&YP1'BZL541%5RHU$ZJNV"V^$;?](T7_ %V_
MB:3QSU8W2VAZI\>'558BT\;5\%145?J.+G15"4[9W]KV3UPC\KA5$SL5KO#]
M#VJCFHYCD<U>BM7**?.:IIJ=42IJJ>%R[HDLB-S_ !(]X :@6_</:5LST=4T
M?Y)^.Y/T34/**T'J35M^M=1IZA?4PPP*Q[FR(W"Y)WY(VY[2FSX1M_TC1?\
M7;^)7X1M_P!(T7_7;^)Q'J3AKJW35L=<+S;Y*>D:J(K^VSA?J4QFD=*7S5U5
M/3:?IWU4T+$>]O:\N$7;O4CB6X/U=X,KJ&1R-CKZ1[UZ-;,U57^9<')NA.$N
MM[9JRW5E;:I(Z:*5'/<LZ+A/XG6:KG'N)B=U)C90 $H
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MTC7<SE7\LO5<C?GL</+=-H!5OK(2JMY:VCB>K)JVDC>G5KYFHJ?5D\_"-O\
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M4!9V)J_%^UJN?]EBRJ_LH7J(J]$)0H#WV;_U7?P/*ICKL!0%43)Z2-^/57^
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MYU7S_)M_[AXIC\+J'*^*E"JE"S&
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M4]P J6E3ZZ>XNRTJ?73W ?$
M      @ $6>4E9X+APWJ*IS%6II)&K&Y.Y,[H<D66A?<[O14,:X?4S,B3ZUP
M?H#<J&FN=OJ**NB26FG:K'M7O131[9P=T7;+A35M);YFU--(DL;EE541R+LO
M0K,;KUMM&S<=.6UEGL5!;V)A*>)K%]J]YRSY3]GFH-?MK9&IV5="CV*GLVW.
MMU55555>IK>L-%6+6#84O]*Z;L?45KN54)F-X16VT[N:O)DL[Z_7BU?9HL5'
M'VBO5.B^SVG2W$=<Z*NZ_P#PE_J>-'Z'L6CUG6P4SX5G]?F?S9,Y<J&"Y4,U
M'6-5]/,WE>U%QE"(CD3;>=W(7DW+_P"U.@]S_N)%\L#^[M-?O9?N0DW3'##2
MNF;M'<K/1215D>>5[I,]3):ST79-914L>H*=\[:9RNBY7\N%7J(CDF;1ONCO
MR66-?H"HCD3F8Z9Z*GBF2$.(^G+GP]U]YVC/0[?SJFE7=J[JN/J.NM)Z6M.D
M[>ZBL<#X:=SE<K7.SO[RYO\ 8[;J"A6DO%)'4PYRG,U,M]R]PVY$6VE$5'Y1
M-A^+L<E73U/PVD>'0MC_ ":O\<Y\3G'5UPK[MJ.JN5VB6*JJGI(K5;R^CW;>
MX[ MG"'15MKDJZ>U<TJ+E$D=S-_A@N-1<+=)ZAN2UUSM[WU*HC<L?RIA.B8P
M-I3%HAF]-00U6D+=!51,FA?3L1T;TRUVR=4/7Q6L'T);_P#HH9*CIHJ*DBIJ
M=JMAB:C6M\$0^Q;93=94=IH:*":*VT=/2K*U6_DF<N57Q.&[^R2R\0:GSUN'
MTU;SO1-]D=G8[Q-5U1P]TSJB=9KQ;6/FQA7QX:J^]<$3&Z:VVZK;A]Q(LFN:
MBJ@LRS(^EC8Y_:LY<YVV\>A"/E3Z=2@U)27VFC5OGB<KW-Z(YJ;>Y2=;!I+2
M^@Z6:JH(F4$*;R32N[O:I#OE):^L5XL5-9;-/!7RK*DKJB)V4C1.Y/?DB>G-
M->O)&/#VBKM<<1+6VO62JY7-[9W?V;3MR&-L+8XHTQ'&B,:G@B="!?)4TXZE
MM5PO=3 ]LDS^2![DQEN-\$]M]9!6"\\W%''S/RNZ@QU[5F/LH2KP[XW45DL3
M+7K>"J@K:9$2-8XL\[<;9WV(KX\[<8;[^^C_ .U#IR;0FG=6Z<M3KY;VR2LA
M8J2QX:]=DZKWD1U6G;;FYCXGZSJN)>K*9M%3*V)%[&FB:F[LKU4Z(L'#A(>#
M[M-54B^=3Q+*Y%7I)NJ(;/I?0>F],.Y[/;(F2]TDB(YR>U%QLIL^=R8CS5FW
MA#BG0&H;CPKUV[X4IGL:W,=3!C=R=RH3A>/*,TU!;'26F.LJ:_;$,L7(WV[Y
M)&U/HZPZG8B7JW13O3;M$:B/_B:U2\%M#TL[98[6]7-W1'R93^&!M,&\3U?3
MAEQ2I]>O6"FHJB&2-G-,Y6_DV+X9[R0"VMUOHK9 D-NI(*:+"(K8F(W/OQU+
MDM"LM(XS::DU/H*OI:;F6J@:LT+$_3<G<<J<-M=W+A[?)IJ>%LK'(L<]._;/
MU]RG<2;&G:DX9:3U%4^<7*UL[;JKH?0S[\(5F%JVB.4N6.)_$>X\1*VEC?2,
MIX(L)% S=5=XY.C>!.FJC1O#^1]U:D<T^:Q[5ZL;RYPIG=-<-]*Z<?VEMM<:
MR9YD=-AZHOLRAM%=2Q5]%44M2BK#,Q8WHBX54794$03:)C:'$FMKI4:XXFSR
MHJSMGJ6P1<B?[O.$.C*?@%HAD$;:BFK73(U.=4J5PJF<L/"?2%BN<5PMU!(R
MJB7+%?)S(GU8-ZR(CS)MY(EN' +1CJ"I2@IJU*OLW=DKJA<([&V3FG3==/H[
M7L$KU5KJ.J[.5,]6H[<[P0T&\<(=&W>Y3UU;;Y'5,[N9ZMDPBK[L":^16WFC
MGRK9DJ;/8ZAJ>C,ULB?7E2^\D1?_  KJ'_-L_P"TDJ_</M/7ZVT=!=*:6:FI
M$Q"G:;HGO+S1ND+-HZDJ:;3].Z"*H>CY$<[FRJ;((CGN<4;;+/BAI2+6&D*J
MWOC1T[$66G7..5Z(IQSI*_7/0FK65<"]E44[UCF8Y,HJ=%14.\D7!HE\X3:/
MO=SGN%PM[W54R\SU8_E15]V!,;E;;<I:3Y0.KJ2OX4T+Z.1KXKOA6X\4PJI[
MS9_)YM2VKAA0<SD<ZI<L^43HB]Q=2\']'S6Z&AEHZEU+"]7QL69?15>N-C=;
M3;Z:T6RFM]!&D=+3L2.-O@A,1*)F-MH0=Y36A*R[,AU%;(>V\W9R5+4];'<N
M.\C'AQQBO.C*#X/[*.NH6KEL<FRM]F3LAR-<U6O:CF.3"M<F45/::7?.%FC[
MS(LE9:F->JYS#AGW(1,>28M&VTH,U1Y0MXNELDI;;;H*!9$5KY,\ZX7WF,\G
M;2E;>M<4MYDBD;143UF694PCG^'\R>Z+@[HFC=S1VM7+E%_*.YOZ&]4=+34-
M.D%%3PT\*=&1,Y4]^$&T^)Q1$;0^ZKERK[<D1>4]MP\9^^3[B7<[F&U5IJUZ
MIMJ4%[@=-3([F1J+C<F><*UG:=W/WDB_W_?O\LW_ +D-N\J'4\EJTS26BEE:
MCZ]525O54:A(>CM Z>T?45$]@I7P23LY)%<_FRA\M7<.]-ZMKF5E]I9)IV-Y
M$<U_+A!MRV3Q1ON@7@%PNM.L+777#4<%0^FRC*=8I.3=%W)5^030?S2O_P#Y
ME3?]-V&WZ;M$=LL\*P4<;E<UF<[KU4R8B";3,N2O* X;6[1<EMJ=/13-H)VN
M27M9.=4?G;J25Y+6H77#2M3:)U].A=^3[\M7=24=6Z7M.K+<VAOM.L].UZ/:
MC5PJ+[S&Z/X=Z<TC7R5MBII8)Y(^S<KI,HJ>XC;FGBWC:6L^4G_AM4?O&D8^
M2+^=5\_R;?O.BM3:>MNI[6ZWWF%TU*Y<JUJXW,7H[A_IW1]9/4V"EDAFG8D;
MU<_FRTG;GNB+?#LVH $J@
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MRC>DE-5=43?9%7Q-VL?E'7BEH6Q72V05L[4QVJ+R9^HZ;KJ2FKZ5U/74T-3
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MIV1R8[E1.ACM,Z(T]IE[9+/;HHI6HJ)(Y,N3ZS8R8C9%K;B'+WE=+_XMLO\
MDE_[E.H35=8\/].ZQK(*K4%(^>:!G9L5K^7#<Y$QNBL[2T[@A;.WX-S0([*U
M43]E39%Y3E"ZT4M'=ZJBFPDS)E8N%VZG>^G;%0:>M++;:HEBI&)AK7+E35:[
MA#HVNNLEQJ+?(ZJDD25RI)A.;.>F".%:+;;L0VRMM' 1:2!%=(ZG[1ZYSE<_
M@03Y./\ BO:O^?\ [5.P:R@IJVW24,\?^BO9V:L;LG+X&IZ:X7:4TU=XKI:*
M*6*MBSR.=)E$RF.@V(MRE!_E7?G71?N_Z(3'Y/\ _A;;OWC_ +S+ZNX>Z<U=
M5QU-]I'S3,3"*U_*9K3MDH=.VJ.VVJ)8J2-55K57/41&T[HFV\;,D40!"RKE
MKRMOSUM.?F/_ -2F,X=\:YM&Z>9:H[/'4HUW-VBR*F3HS6'#S3FL*^&LOU))
M/40Q]FQS7\N&Y,%\A^A?HV;_ *J_@5VGP9(M&VTHW_\ Q+U/_P"KL/\ UE)+
MX/<29.(+:[MK<RB\V3/HOYN;_P!9/'R'Z$^C9O\ JK^!LNCM$V+1Z3I8*9T/
M;>OS.YLDQNK,UVY-D !*H                       #(-]5/< WU4]P J6
ME3ZZ>XNRTJ?73W ?$                                     !5&N5-
MD"HJ+N!0     "        %6HKEPFZA6JG5%0"@*HU53*(JI[@J87?8"G<
M     #%ZHLL.HK#66JI<K(JEBL5R)E6^TB*V>3C8J6H:^KNE151HY%6-8^3*
M>'4G$$;)B9CHMK904MJH(:*W0M@I84PR-O1"Z1<*4/7(['1?X$H0_K7@;0:J
MU577R>\ST\M4]KUB;%E&X1$ZY]A*UNI4H;?3TC7*]L+$8CE3JB)@N -D[@ "
M    "J)E<)U H"JM<G5%*  "J(JKA.H%$V!56N3JBE    ?4   ]X
M *HU5Z(J^X"@"HJ;+LH          ]<COU5_@.S?^JO\ /(/7([]5?X%.5>B
MHN0* ]<COU5_@.1WZJ_P \@JJ8ZE  ";]#TC'+^BO\ /(*\JIU12@
M                                     "J-<J91%4"@"I@
M    "(JKA$R !56JG5%"-5>B*H% 55%1<*4            "J-=C.%Q[B@
M 5R4   %4:J]$50* KA4Z[%                     (>D8Y4RB+CW >0%^
ML    &0     JB%        51%7HFX% >N1R)E44\@
M      9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
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M8^*GB8K(.9OKJO54(GG*8CAKS=,OZ]YY"@NQ
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M/!;QEU1P[PF@=/81N5HH]\>PV U_AW^8&G?\C']QL!:.C'/4 !*
M            !D&^JGN ;ZJ>X 5+2I]=/<79:5/KI[@/B
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MX((TPR.-,-:GL0^N03$;$S,]0 !
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M/< WU4]P J6E3ZZ>XNRTJ?73W ?$
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MQ\W9N:G7ZANK$;QNZ2!5>JE"4
M                                  !D                     'N
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M4BIB1>]6DC%M]U-M@
M                    &0;ZJ>X!OJI[@!4M*GUT]Q=EI4^NGN ^(
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M0'&:".EX.WVGA:C8HJ5K&HG@BHAS_P"3%_B&W]R3**])=>KU4H57JI0LQ@
M
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M5J,(J>\[$X?120Z)LT<S5:](&Y1?<5JO?HV  %V,
M                                         9!OJI[@&^JGN %2TJ?7
M3W%V6E3ZZ>X#X@
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MZAN+K[!*VFE;*K$C5%7"].@WDVJZ!5,*J*4/3UYER>2R@
M
M                     $ 0""/*Q_-^W?MI]ZGP\D'^YM3?OX_N) XN</I=
M?V^FIHJ]E&L+L\SVY13Y\'.'<O#RBN=/-7QUJUDC7HK&JG+A"-N:^\<.R0E]
M23]E?N.&KW_BA/\ YM/O.Y>K7)XHJ9]Y ]=P#J:K5<EW^'(6M=,DO9K&N?<1
M:-RDQ'5.D#(_-H?R4?\ 9MZL3P/HF$]5&M3V)@I&G+%&SKRM1N?'"%2RBCF-
MD:YDB98Y,.3Q0XIXO:3K=&:TGE8U[*::59Z:=J;)OG&?%#M<Q.I].VS4]JEM
M]YITF@>F$5-G,]J+W$3&ZU;;(;X=<>[7\"04>JVS15M.UK%J43F25/''B7VN
M^/=DI+/(S2SWU=PD3#7N;RMC]JYZF.O?DWT$KU6R79].S.R3IS[?P/E9?)NI
MHJIKKS>?.*?.[($Y55/?@CFM\/5#O#K3U=KC6\$:HKT?/VU3*J*J(F<KD[A@
MB2"GA@:J*V)C6)CP1,?T,/I+2MHTE;DHK)2I#'^D]V[W_M*9LF(V5M;< !*H
M
M R#?53W -]5/< *EI4^NGN+LM*GUT]P'Q
M                                                  5;UW1%3P7O
M.?N(7 )]PN-7=--UJ)-.]TRTSTQZ2KG9>XZ  F-TQ,PY4BX5\5/-_-5K)V4R
MIRK&E;Z./#&3=^$_ YVG[O!>=0U*255.Y714[$3".[E52= 1PIXY55<JJ^)0
M E4  #(  )L          &2N2@
M
M
M                                    ,@WU4]P#?53W "I:5/KI[B[+
M2I]=/<!\0
M
M
M
M
M &0;ZJ>X!OJI[@!4M*GUT]Q=EI4^NGN ^(
M
M
M
M
M                          #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
M
M
M
M
M                                                   !D&^JGN ;
MZJ>X 5+2I]=/<79:5/KI[@/B
M
M
M
M
M                 R#?53W -]5/< *EI4^NGN+LM*GUT]P'Q
M
M
M
M
M                                          9!OJI[@&^JGN %2TJ?
M73W%V6E3ZZ>X#X@
M
M
M
M
M       ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
M
M
M
M
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M:DLRXJZ=*F).JN):T5KNW:II=G)%5MPCHU\38QZBF3I*U;19M(*J4,ZX
M
M
M
M                                                          ,@
MWU4]P#?53W "I:5/KI[B[+2I]=/<!\0
M    !CM452T.GZRH:OIMC56^_!S+2PNN5TJ*ZM<LKE=E$=N=+ZNI_.].5<3>
MJQKC^!S-;7/I;C4TLB[M=@YW:'%P[PPY>C-HO*F&)RIX(4RY?TE4 XC74*]X
M3H$W JF_1%&_1%4UC6>H'6>D<D/]HJ?P(WHM<71M5S22N<U5Z&WAT>3+7BAD
MKCFT;IOV7*.1')[3%Q2.M%\IJBE<L?,].9J+A%W/.G+G\*43953"]Y\Y6.KK
M_2T\>^)$3^97#6U<G"BN\2Z>L%;Y_:H)U9RY:F2^+2Q4ZTEHIH51/18A=GHH
MZ-J  $I                                                   ![
M8SF1=\>\IVD+55JR,YNY.9 /(*JGM3V%
M
M                $
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MYN6>DGBA145 *   !@  ,#
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M2^736QQNFP%=E:CF+EJ[HI0V&N
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ML8;S&^SH!4PN"AJFA=<4>IJ5J.Y8:I$PZ-5[S:S*Q;;
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M53*8R!TYA? H:SH36$&J[:V>-J-EPG,U$QN;,
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M",^!%6LECEA=^B]235ZG;CHX<]5  $
M                                                >HV\RX1<'D*_
MLVN=X(!$_&*YNFJ(;<QR^DJ(J?6932E"RAL\+$:B.5,J:5J";X2URQJ^DC7X
M_F233M1D#&IT1$.;J[[VV=31TVKN^B;&J<0Z-DUJ67ERYB9R;68[4$23VBH;
MU7D4U:SM.[;M&\3#QPDN*SVQ:=7>HF,$@$.\(ZE(+G4Q.ZYQ_,F->IVJ3O7=
MPKQM:84 !94     50CGBY?%IK>M%&N'OV)$5W(USNY$R0?KNH2ZZIC@3TD:
M_!6]N&LROCKQ6V9CAY:6T-M[=S4[61<Y-KD8V:-T<R(]CDQA3XV^)(*..-$P
MB(7"G%M.\[NY6L1&R*KU1NTMJ>.MHD5D+WIE$Z$ZV6N9<+;'.SO3<C#B/2))
M:DEQNQ<FQ<(ZU:JQ\CERK54Z6DOQ5VER]73AMO#>0/8#::@
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MU(GX!0XM]1(O17J2P[KL=ND;0X5_Q2H "RH
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M?K?!*SDPO7)Y/3U15V/)ON<
M                   R#?53W -]5/< *EI4^NGN+LM*GUT]P'Q
M                                                 #WF*?IVV25G
MG3X,SIOS9,J *,1&,Y4]7H8M=.VQ:_SU8?\ 2<YY\F5 !-FX3H$7  &&O6F+
M3>O[QI4D]RX/A9]#:>M,G;4-(K)4[U7)L  JOAA,)X%
M              "SO$"U%MG9C.6D#Z?E2AUE/"[;+\?S.A'(KXW-[E3!S_KV
MG6RZQCG1O*QSLY^LQ9J\5)9L%N&\)41<IE.@+2U5+:JWPRM7**U"[.,[</C6
M)_H<W[*D<:#_ #WG_:_J215HKJ29$_54C?0[DBUQ.UW57+]YMZ3\33UGX$^*
MK5;LFYX*JFR*4.FY0     &C\67\MA=OU14-Y0C[C(]K=/KOAW<GB)Z)CJP7
M#)G+847.ZJOWFX-Z&J<-6*S3T?,F%4VQ#B7_ !2[N/\ #!W*:7Q3J4BT^K%7
M"N<ANA%G$VJ\_O%+;8EYE5R*J(3AKQ7A7-;AI,I"X+TRTVF>94PKE53?E,5I
M6WMMUAIXD1$7E3.#*':APP
M                                          K)A].]KDSL4/I%A<HH
M'/%Q;YGKS+MD63^I*D+D=$QR=Z$=\5:5U%J2*J1,-5V<X]IN]@J6U5K@D:N?
M10YFKKM;=U=';>NS('E^\;T]AZ/+O4?[C4;B&-17F"P:I?55"[([.# ZPU]=
M]52)!12+%28QE-E/CQ5@;-?7(_..8Q]'"R&%&L1$3'<>H[,PQ?'%I:$8.\O,
MVZ+.EM$3%YZA5FD7=5=ON7\<<<7]FQK?<>UR$W3<[,1$=&[6E:\HA5'+XJ4=
ME4!1JKGH2LMI:&GGSVL355>_!;0,KK).E5:*F1KFKGD1=C*#NPI6U(MUACOB
MK>.<-TH.+DEUT]);+LO)4<O+G'4V3A=&BQ2RINCN\@N^6YCT2:/T7(N5QL3+
MP8N,$UM2!')VC4PNYY_M3332O%7HU<.'NLFR3?$ 'GV\U;B%+V=E<F<9V,CP
M8@5EH<]4V55W-3XH5G.L-(Q<N<Y,HBDE<.J)U!I^)JIA5WZ'2T=?AW<O6VWM
MLV8!>H-QI
M     ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0          /2-]!7=QY16M
MRLCN5J;JO@0AJC7%^U%J2IL^DHVK!3N5LDR;9P5M:*QO*U:S:=H3@B9Z*B_6
M55CD3*HN" (J37]L<LL,RS*FZHYR*92V<6+S:)DAU51-;&GHJ]K5_B4KFI;I
M*]L%ZQO,)I!@M/:NL]_A9YA5-=(Y,\J[*; Z-6JF>\RL3P
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ME;B65N553>TF/_*7/UF3_&&\(U&-1C=D0#JJJ#?<\
M
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MWD &1C
M  9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@         #7^(E4ZBT3=9XU5'
MLC7"H1AP3IFML556JB=M4/YG.[^I*FN*);AI.Y4J=9(UQ_ AC@?<>P^$+/4.
MQ-&]>5%VV134U<3P-O1S''S2LW*9])=RWK:&DKH71U=/'(U>]6HJEQWJ#F.M
MMNCB^<-^SE6LTU524U0B\W+G"?R/OIKB7=M-SI;]6TLDD><).N<(A(";+GO,
M?>[/0WNE=3W&!LC53"*J;H;.+4VIUYPU<NFK?HW&T7*DO%&RIH)XY6/3.&NS
M@O,8ZG/,UGU!H*M\]L%1)/0(N70HJ[)[B5-$<0K;J:G9&]W87!$P^-VV5]AT
M<>6N2-X<W)BMCG:6X@].:K=E0\F1B
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M5J&J<,M/QV*QLYF(DST157VFV.7*Y.S2O#&SBWMQSO*@ +*
M
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MX.BY@
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M7>WW-C5HJJ&553HUR*IM1,2U)B8ZKD'MS'-V5#PJ8ZDH
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M;Z+43;W'5TV+@KO+D:K+QVVA>JN54H.X&RU0
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MD@@<C4<C4SA,'9TN+ACBETM5EWG@CI#+*J-:C&IA$V/(4&VTP
M
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M?%^@5*M622O1R.SOU4Z;9$Z&&.-[U>YK417+W@
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MYM8\U;]&GDP6IU3X# Z8U;:M01)YG4M63&>1>IL#F*U<.3!F87D
M       'MD:JF5V1.JF*O.H+5:(U?5U<;<=V<J!DT3)[[-&MYI'HU$\5(EO'
M&6C:JPVBG[>;N54V-7J;GK35+L-B6G@=WM7N,=LM:]99*XK6Z0F6]:NL5GC?
MYW6,1Z?HHY"-[SQ<?4.6#3]+-(Y>CT;DQ5OX9),Y)KS6R3/ZJQ3=[58K=:F(
MVBIFM5/TNIK7UD?XMO'HI_R:"M)K/4ZYK:UT-._JUVVRFPV+0-MMRI+5M6HJ
M.]7+E#<,JO4H:=\U[]9;E,%*=(>8XV1L1L3&L:B81$0]E,E3$S 0\2S10M5T
MKVM1/%32M3:^H;:UT5,[MIUZ-1"U:S;E"MKQ6-Y;3=[I36NF=-4O1J-3.%7J
M15<KK<-:W3S*VM>E-GJB;*>+=9K_ *ZN#7U+7QTBNSA.F"<-(:1HM.43&0M1
M9<>DXW\&FX>=G.SZKB^&JWT!HVDT[1(YS4=4.3TEP;8[V= JY*&ZT0
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MW4R7"N8CJB5,Y5-T)/<[.R="C&MBC2.-,-1,%#I1&S!,[\Y
M
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MB=K+:C31:.*J<?=DH:3PRUG#?[:D%0JI71(C9$7Q-V.E'-R]MN0
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M/U4P%<J]>ILUQUKTAK6R6OUE\J&EIJ")(Z.%D;$3&&H?55R4!90
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MYSP
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MDK=1?#-OK74D_/S<C&I@E<9 ^%OA=34,,,DBR.8W"N7JI]P
M                         #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
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M#]*Z#3W.Y,<^%_D;NBCE,M#6SSB&^+U4H ;S0
M
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M<=<[ 4!\J>LI:ARLBGC>]-E1KLGU4
M                    ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
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M33;%=9*>1SN95;WEZI9:8:_X"I\+Z/*F"^<U47<"@
M               &$UE1)76.HCQE>5?N,V4F8DE.^-4SS)@#GWAI6.I+O/12
M+A%>N$)7(?OM._3^N$?A6L5V?XDM44J3TD4B+E%:BG)U-.&[L:6_%1[G:CX9
M&KT5#G6]VS/$!C$V;S'1J[HJ$-ZJ@2#6T3T3JJ%<-MIE;-7>(2U:XNQH(6>#
M4+I#X4*YI8E_X4/I-(V*)[W+ZJ9,+/TA&?%"L6IN--0Q+E7*F4)BT52)1:=I
MHUV56)M]1!UKB=?^(;53+HXWG1,4*001QI^BW!U]/7AHXVIOQ75 !G:X
M
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M'MD<F538#X
M#(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
M  *IL4 &'U;9X;Q;7Q/:U55/ YYIWU>A-3\K^;S*1V_<FYT\F-T5,H1YQ3TE
M'=;;(^-C>T1,HN"MZ1>-I7QWFEMX7UMK(J^CCJ('(YCVHNQ<]"'N&FH)K3<)
M+-<7.Y4=RL528&JBIE.AQLE)I;:7:Q9(O7>$><2;>M-4TMWIVJDD+T550E70
M]U9=M/4\[GHZ56IE,]#6=2T*7"RU,&$559L8+@M<4IYJZWU#UYXG\K6_Q-[1
MWWCAEHZS'M/$E[N!54WZ%#=: G>8G5EU;:+)/4.<B+C";F7;U(AXWW57NIK;
M3N7+G8<B$3.T;IK&\[-?X>V]]RO-1=JA%7TUY54E'V&%TA;VV^RPQHW#L(JF
M:[ERIQLEN*TR[F*G!79\JB=E-"^65R(UJ=Y$EQFJ=:ZGCHZ3F6G:[&VZ;&2X
MCZ@?43MM5N<JR.7#L&_<*=)1V*VLJJAB+5/WRO5#:TN'?XI:>JS;?##:]-6J
M&RV>*EA:B8:G-MC<R2[ARJJJJE#H.<   $  ^%VIUGME1'$N7N8J(A"FE-%W
M*CUO/6547^CJXG(HC&(N48W/B!8)IBT)4>=>:Q]OCUN5,D(ZST-=*S6L5731
M?D$ESGV9)_SMU4*R)4RYB*[Q B;BCI*X7/25)3TS4=(Q$RB>XS?![3]19+(V
M*NB:R3W&_(V-4P]J+[RF&MV:F$\ /HKL\R*N45-CG+BUI&]U>IOA"V0*]$<B
MH=$A&1.5>TC:[WH!SS0:AU_1T\<$=N=RMV3TE)BT-77:NMS)+U!V4RINF<FQ
M=A3\W]BS'N/>&-VC1$0"@                                  'IB[]
M#R.@$0\;K4J<E<U$YMLJA?Z$K_/+)'OE6(B&T<2+<E;IFJ]%%<UN4(NX4U:Q
MRU%(]?5=LAIZNN\;M[17VG9):=2)>(:+#J2GD]J$M]Y$_%!%;=Z=4\4-'%^)
MO9H^%)=FD[6W0N\6H6>KZQ**R3ORB.5JHA]]-KFT4_CRI]QJ/%:K5*.&F8[T
MGO1%0BE=[;)O;:NZYX(6M99IKA*U<JJX4F5ZY7J:APNMZ4.F8<MPYVYMIVJQ
MM#AVG>=P $H
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M>KY*1CE7J>FV*U1O1T-)&QR=Z!"YM\[JFACFD8K7N1,HI]@WT6HU.B )
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M"(UK4[D+@Z]8VC9QIF9G>0 $H
M                     ?&Y1)46R>!4SSMP<^6O-FUO+#NC7/Q_,Z*:JHBX
MZX(&XIT2VO4\%6U%1'.YE7ZS%FKQ4F&7!;AO"2V*CD1R=%(CXF2<]^IX^N%0
MDZQ5C:NTPSHJ*G+E2&]:72";6D4:N394[SF88^)U<L_"F+3[59:H<I^@A&VK
MI%N>L8*1N[6O39"1:6H9!8DFYD1J1YS]1H7#^C=>M;352HKF-RN?K,FFKO?=
MCU5MJ;)UM5.E+;((D3&&IL7)Z<G*B-3HAY.HY(
M
M              4J&-EII&*F<IT*GN/&=^@'.UPC^"-;KGT4=+_4E:F>DL$;
MTWRB&B<8K?YM=8JR-%1N<Y^LV31M:E9987917(U,G-U==K;NIH[[UV:;Q5<O
M;PM0V[1"*EDAYD_10C[B;<6?#4,3G)UQU)$TW(V.P1R(NR1HO\C#;E2&:D[W
MEI_$.H\YNT-*S?TD)@T92I26.%BMPN"%J)JWK6O>Z-KT]O>3_3L2"FCC8J81
M#HZ:O#1S=3;BN]+U]@ ,[7
M                          9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
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MZ>2=7TM$JTZ=_*NZ&WZ,X@6W4DBPO>D-2G2-4QDB+UMRB2:S#< 55O*N"A9
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M555PA\$KZ9/17/,+7K7\4D1,]'U!5$1S>9JHJ%"W5
M                        ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
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MTU2TK]GHB*IF#T[1
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M?..9:2H;NO(Y<8R99V^Z=#"RQMJ9F,W]%44S/JM1O<B'8[-M:<7Q-?-$;\E
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MU,]Q2N.M9WB%IM.SYJN>[!0 R*
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M;JJ?5=FJ(HE=%'+ERHG0D"1R.Y<>!3=4SA-O$\@W
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MS]Y55RN2@%'QJU['M7;)[<N^%*L>K?:>57*Y H@D_M( AZ5^41/ "B]5*
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MT\TK4DF7E:F2Z5,+MT(UULB_'6PJBKCM4V^LDV7'H]VP3L^8 "
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M47&7=#RA23:2#;Q  JO52@
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M\ZIWDA:$UQ+6R^979.2I;LO-MDIBSX\GX93:LPD<JU51<H5Y?11<[*40S*-
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MC)8FRQ+F-R914*FPQ@
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M'6->[LWL5K\=57J7*IA5138QY*Y*\5>BDQ,<I4 !=
M                     #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
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M.V6R"ECZ1M1,'V/2-,
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M,DLN,)NAD)'\_<=;L_%;'C^)@RVBT\G@ &\Q
M                ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
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M(B^P\H !5%:C>7D;CW%$PGJHB)X( !Z5V6X5-AEO+R\C<>X\@ FVR=
M                                       &0;ZJ>X!OJI[@!4M*GUT]
MQ=EI4^NGN ^(                                3<'OE5C5>[9J)E5
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M%<UY:.X0OE_4YMP,N FZ;8P
M                        JB*O087P H   !5$5>@%:I<6ZHS^HI %+Z>M
M9E[T>OWD]5R*EOGSE$Y5ZD!V]R+K:?E7/IK]Y@U'X);&F_'"4T]5/<:#Q3MW
M:6Y:EC?28F3?47*(8O4]*E59:AF,KR*<JD[3NZ]XWB81-P9J75>H.23JUR)G
MZSIYS5:Q$YLI@YQX1424NK)6O3#>;^IT=(UJ)Z*['9Q_AY.'D_%S?,!074
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MN$<J)XDUKU7H1IP4T?/8[,E15MY7R;HF$)+=U4!D9* "N1DH *Y&2@ KD9*
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M&2@ KD9* "N1DH *Y&2@ KD9* "N1DH *Y&2@ KD9* "N1DH *Y&2@ KD9*
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M.AJ>;'(Y,*B&?&R9PB)GP
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MD^\B-3F7VEPV5$5V$V4^:KE>H%
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M5=0PU<"Y9(W)]32>#%<^MT53-DW<QN#=CA[;=6<
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MEC5LB;*F#Z81,JBGS<[Q<G\3J0V>:-;W3.LMV2:),1N4W:VU#:FF8]JYRB&
MXAR1>:-553**A[T9+ST#<+E,&;%XPY>IKM?:&RJ5PF"@[C-#3L\KA.AY*^)0
MO##(IY*E"T,4O*GB6-LL;F/3+5/HH0M#%+#:8KIM):K@=&[%/,_&%Z8.DZ6J
M;6T<50Q45'M1=CF/53/1@ESAS'(J'0/#Z99M)43G=>S3<Y.LQQ3)O'BS4G>K
M/@JI0U%@                                            !D&^JGN
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M'20TT*8;&F#Z'#9P
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M8MXNC%1<HYB$WKMLGJIT.-J,O>WWCHSUKPQLH # D
M                          9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
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MQODRULM]+;*9(*.%K&-Z*B%S[SG9,ELD\5D\HY0  H
M                                            6]RH*:Z4;Z:KC:]C
MDQNA< " -=<-ZVRU<E;9'.='NY6M0UBWZD=!(D%TA=$]-N9=D.IG,9*Q62M1
MS5ZHII>J^'%JO;5=!"V.9>JF?%J+XN4<X-HGJC"GJH*EB.AE:Y/8I<)_(Q=[
MX;WJR.?)0/>K&K^CG!@6WB\6U>2MIW/1._!O4U>.W7D17;HW(](:O2ZPI7+R
MU#'QKWY:9."_VZ7&)T3WF:+1;I*\1LRQZ12T97TCDRDS?XGU;4TZM5>U;A/:
M-F6L*U=0RFIWR/5$1$(JO-!6:CKW.IT<K<[8W,QK74+)9$I*9^454RJ&9MT:
MVO3Z54+D[56Y.9K<\16:1/[MG%CM>\4K&^[$:1=46&I2EK<M:[9,[$BL<CVH
MY,84AR]W&LJY4J)'95JYV-XT9J".KI6Q3R8D:G>-%J8S5X/&&YGT>72SMDCJ
MV>J;S4[T]AK&BY/-]3O9GJ[^ILDM33]FY'2MW3Q-,H:J*GU4CHWHN7)T7VEM
M;7?#+#O&T)^;NU%*GRI']I2QO\4/J>7;3$:J7%FGS^JOW',4B\UZFWSN=,:T
M=RV*=5_57[CF%51EUE?S)CF,^.LS2=FQH+Q35TXFVZ3_ +\I/VT)IUII9;[:
MZ5.W;$B(G4A32KD^&J1RKMSH29Q0O<]-:J9M#4<NR(O*I.#AX;<3K=LUO;4X
MN[G:64MM-;]&6"5'UD<LJIT12$KS6>?W"HJ$3T7.7!XJ*RKJT_TFH?(G@JEI
M,Y(HESC<K>\6VK$-O1:"^FM?/FMO,MLT+(O9N:N<&Y^)INC'00T_-)(U,^TV
M:2Z44;?2F;_$];IZS7%6)\GA=9;CS6M'FNBAB)]2VV%%3M>9?88V?6$/2FA>
M]?<9IM%>LM*8;0O3<M:JNIJ1BNFE:GLR:S%/J*\/Y*.F?&QRXS@VZP\);I<'
MLGO,OY-=\*XPVU>.O3FI-6JUE]J:Z7S:SP/>YRXYT-\X?\+YYIVW"_JJNZHQ
MR$C::T39[#&G8TS'R)^DJ94V;.$PFR>!H9<]\O7H1M'1\Z>&.FA;# Q&,:F$
M1$P>P#"                                                ,@WU4
M]P#?53W "I:5/KI[B[+2I]=/<!\0                       "DD;)HG1R
M)EKDP5 &%I')9ZR2.I_L9-V*G<:KQRF:_243D7+.?^AOM?215E*YDJ9=CT5\
M#0-:VVHGL,]OJVN6)J98]4[PF.4L?PT1%TI3<OM+G5NIZ73]"]TCT=4*F&L]
MI%%DU#?-/T<EN@IWR-RJ,7?)L.D-"7C5-R2XW[M6TZ.1W+)T7W'-KI;6O/%T
M=.=56M.75;Z-TS7:ZOJW&Z,5E&B\R$X?%.T.HTI?-F(U$QG&YDK;04UMI&4]
M)$R-C$QZ*8+DZ%:Q6-H<VUIO.\M%N?"ZT5+5[!/27NZ&HW3@PU5<L&W_ #(3
M2BJG38<RKUW+;(B=G-]9PIK8%585=M[3&2Z$OU.B]DY^$]IU-SMQA8VK[T/'
MY->L,?V2T7M7I*8M+E5VG-2QIA%D_@92P: O5[K8DN2O;3YPY5.E%B@=U@B^
MII[8C(F<D<;43V(3.6\QM,IXY:E:^'UEM]-'&Z!LBM1/2<G4OY-(V>:)6-I6
M-7&RX0SJJJA%7Q**(/X@\.O6=11X7NP:'#IS4D3>RCY^5-D.K7<KTQ)&UW[2
M9/FE/3ILV&/'CREJVFOX96K>:]'+S-):EJ$PKI#X5_#&[U$2OGY\H=6-;$Q,
M-ACQ^R')%*U6/C9A?!!-K6ZRM.6T]9<IZ3N-PT=<VTU9S>;JY$7/@3G;*Z&X
MTK)Z9Z.:Y,EAQ%T5#<J:26GBPY$547!$UCO=?HZXK3U:/?39QOW&AJ-/O\56
MWIM1M\-DPZBC[6S5")NO*:QP;GY*ZIA[^T4N+GK&U5%BEDBG;VCF^KDL^"T#
MZFNJ*AK5QS\Q325F)G=;66B8Y)J5%3J4/3URNZ'E-SH.<'BHG931.>KDYD3H
MIYJJF*D8KI%^I##)!-=JE9'^C FR>T#U1-?6UOG$J>BFQG>["=$/G#"V&-&,
M3HA[                              !5JJBY0H /HKFO3$K4<GM,)=M+
M6N[,=VT+4<O@AERJ*J=% BJ]<'*:=7NI5Y/K-)N/":XTCU6E>[;P4Z,YW>.3
MUVB(F%8B^]"8F8Z)WERO-I34M$J\BR*B?66LD6J*9V.1R_4=8*D3TPZ&-?>T
M^$EMH'_VE.Q57V(9(SY(\4Q?9RC55&I5A<G9+NG@:;+'7TU<DU8Q4=G.5.VG
M66U.3"TS?X&MZBX>VB[QJD<+&/5.N#%GM?+7AF6SIM3&+)%[QO#F^MO\]QHH
MX)D:C&(B;&%JXXY8U;^EW8)IKN"4B2KV$R(W/1#,:>X/TM'*R2N5),;[H<[V
M7)-MYEZ:.W])BPSCQTZH,MDM\LM&LK(W=CUW+R#4%\N$+NQ;M[$.A=>:?HH]
M+2PT\$:(U.J-W([X9T%-*RHC>QJN:[&Z&[DU&3#2-I>=Q9)S7G;E"-].3UE)
MJ:.2M3E55ZK[SI.BE[6EC<G>B$2<1[5'15,=1"U$PY.B$C:,K4K+'"[.51,'
M.SW[S:\MK#'!,U9PU'B;*D>GWIWNV-N- XL3HV@@BSNKT^XPXXWM#)EG:LH2
MHM/7BI19H('.CSE%0R-OJJJT5K))&+'-&O13I?A?;:9NF(5F@8JKOE4/6JM!
M6J^12?D6,E5%PK6X.CGT_><XZH[,[9G2;X[QO27.^I]3U^HDB;68Y(^F#!JJ
M-3TEP2U6\&:N-R^;S>CU1#Z6/@O.^;GK9?11>BFK[-DM/-W\?;VAT^/;#$_L
MAUU#77).2@A<Y/'Q-@L]IU3!"D<-.YJ>XZ6TWI"UV6!K64\;I&IU5J&PM; B
M;4T2)[&H='35G3Q\,\WENT.TLFMR3>W3PAS!!IG6%6F['(BF3I.%6HZW"U$B
MHB]?2.BE9'G+6-3W(>D<K>BX,\YLD]9<^;S*$K5P31RYN%4K5\#<K-PPLMK<
MBO9VRI^L;VJJO5<E#'O,]4;K>AH:6@;RTD+6)X(A=*Y5]AY 0
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MI%5.FR%
M  9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
M AYJH8ZV+LJEO,P] #3JO3=-;ZQU0V!LK$7.,9P;+::Z"6%(VJR/")Z/0O6X
MW14RG@8JX69E0Y)X5[.1%SZ(&75N&HJYP48WF5<&/M3ZSFECJT:J,3T5[S7M
M>:EJ=//ADBA1T3E1%5?:!N!1#0OE&IH[K!3U$2-;(B9=GQ/I2<0(*V_24%)"
MDBHFRY WQC<YQG!Y4C.X:XK[3>8*:KI6L9._D15R2-2S)44[)4_23('U
M    ">]2J=3Y769:>VRRPLYY&IE$ ^RHDD;HWHBHJ8-!UKH:FN;'.B8BJOL,
M5;^)J]M5PU-,C5A=CJIE:[B3116UDT6.T<N.4"+%X:U"57(G-R9Z94FG06GF
MV.UM1C>5R]5,+=M:I0VJ&L;3-=VBIN;AIZZ?"MJCJ6M1O,U%P1$1"9M,\F15
M4:BN=LU.\Q=?>(4;V=)S.F7;")D^52E7552Q+^3AQU;N7MLM\5'W(YWBJ;DH
M65#;Y99FSURJY.O)TP9EB,B3$:(B>PJ]<J>0
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M:10,8G<@.JY"JN55RI57+[CR &0
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M@Z*?4.IEK)6KV?-S)_$Z&8SLHFQIT1#=P4X*[-+/?CON  S,
M                                                    #(-]5/<
MWU4]P J6E3ZZ>XNRTJ?73W ?$                             *Y7Q*
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MID3(4Y8F\K? #Z93DZ)D\
M              /C6T=-7P+#6PLDC5.CDR?8 8*@TA9*.=98:*)'=WHH:IQ0
MT<RX4SI*9B<S4V5J="2#VY&2QK&]J.:O7(V-]G**6B_N?YBKY>PSCOZ$U<+=
M+)9Z1))6)VCDW54-S^ K>DO:(Q.;.<%^B,8WEC:C4]A6M(KT6M>;=57+E5\#
MR 65
M                                          !5%Q[?>>E5JHGY-J*G
M>B'@ 8K45ECN]&^.1J+E.]"'JKA:YUQ5S6.1O-TY2>&N5O0KSJJYPF1MN1.S
M6-%Z8BLE&U%:B/\ =N;*Y<J5<]5ZGD
M                                     ,@WU4]P#?53W "I:5/KI[B[
M+2I]=/<!\0
M                                                           '
MS?5TK7]FLS>U7HT^GW      !$ST!\YZVEHFJ^KG9$U$ZN7!ZAGAJH^UII&R
M,7O0#T
M                                                   $W  ]\FV<
MH>
M       ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
M
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MU6032<WNW ZG>WE=@\EEI^N9=;13UD;VN1[4792][@
M
M                6EVN,5JH9*J?U&IG!?-1._)"7'?5"QQ);:&3,KU1%:!N
M>E>(E)J&XRTU+3O1&OY>93>%[_$BO@=I?X/M#:V9OY21$=N2JX#RB+X'M6*B
M97&#Q+*Z.GD<UN51"!Y-773X]MI73N6'M%;RYVZ@3PI5$SD^=)S24<4CE3*M
M0^B;;@1MJ;B(EBU!';YX7*DCL(]%V0W^UUD=?015,2Y1Z9V(LXXZ82JH//Z6
M->UB])7(?7@5JE*RW_!TRIVD28WZ@2NH/I(WOV^H^8
M                                           !D&^JGN ;ZJ>X 5+2
MI]=/<79:5/KI[@/B
M
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M'HF6]#I/35TCO-E@JXW9YFHJ@9(
M                                                          "J
M=X&.O]R9:[7-/(]K<(N,KCN.;;#3SZVUVZ>1%=%&JKXHN#<N.VJ')RVNF<O,
M]<>CXFR\%]+MM-H;4SLQ._?. A(=NI645''!&WE1K40N"J[JI0)?.J>J4DJ)
MX'-4F?E&;G_WR_>=)U?^RR^XYK<JKQ&9^^7[P.E[>F+=!Z&/03J>_<>:%[W6
M^'*ICD0] 6MYHF7*V3T\J[.8J=#F5KY]$\0'Y5S:5\N$[DZG4J=2(N.>EO/K
M:M? UJ21>EL"$K6BH9<;;#4PO:Y'IG9<GW5,$/\  C57G="M!52?E6*N$4F!
M0C=0 !(
M     ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!\0
M
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MS.5-D3('4KTP[;H>3%Z5O$-[L=-50N1RJQ.;"YPN#*
M
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MX#:H\XIG6RKDQ+%Z*(Y=P)D![<Q6G@
M                             ,@WU4]P#?53W "I:5/KI[B[+2I]=/<!
M\0
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MCG*GO-HOW&%M73VZFM\R=I)CG GQ2A9V:5T]JII7[JYB*JEX
M
M            ;#.$5? PL>K;8EQ?0S.Y9FJ![U9=HK-9IZB5>543"'/>A[;4
M:RUN^OG3GACESZ7>F38..6JG7"M99Z!<M>J9P;]PBTXEEL,;WQXE>F<^(&]4
M\#*6!D,;>5K4Q@]E555ZE    \53,TDN_<<TR+_[1FIC_?+]YTI5_P"RR^XY
MKD_Q%9A?]\OW@=*V[/P?#NGJ(?0\6Y/]7P[)ZB'L   /E7T[:VBEIWIEKTP<
MQ7BFFT-K^.:/+::23*JGO.HT(TXVZ76Z6)U5#'Z<**[*=0-\T]7-NMGIZJ-W
M-S,15P7ZD(<"=8)##):JZ1&+%MZ7L)1M6K:"XW*6B@=SR-[TZ 9T'IR;KL>0
M                                                        ,@WU
M4]P#?53W "I:5/KI[B[+2I]=/<!\0
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M@/F"J-54792GO
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M3W%V6E3ZZ>X#X@
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M^ZZM6X71BK3L?S-3QW)HY%:N4W0HLCEVRN"1;4-%2VZD93T421L8F,(?=2@
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M%VM=4,AC\7+@#ZX]YZ:ST5<[9$[R-K_Q9MU.]]/:X%K)4V1T:Y0U.2_:UO\
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M<79:5/KI[@/B
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MD5$/!J/"?4S=3:8ADJ)$6H@;R/3OR;<>V>=
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MOJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
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MZZ>X#X@
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MC;'$U&1M3"(B'LNS^RL.ACX><^;@:K6WU$\^BD<<<$+(8&HR)B<J(A4 ZC2
M                          /,TL5- Z>I>D<3$RKE[CVF$W=LWO4Y_P",
M>N)[A<W6FW3<E-$BME<QWK+G_P C'DR1CKQ2V]%I+ZS-&''XMRU/Q@ME"]\-
MM8M1(U<<Z=")=;ZVJM4T[HZBG:B*FWL/KPTTI%JJXU%+(]S.S9S93O-TEX<6
M%M0ZE==6QU#=E:YR(:7>Y[QQ5Z/2SH>RM);N<\S-HZM&X6:\JM.S^877+J)S
MMG+^B3RQUJU)0-D8YE5"J9QX$':YT'4:?B297=M2OSA^#5+#>KU8[BSX,GD=
M'W1JY<8,N'46XN#(Y?:?86*<7M6BMO7Q=)?$ZQX]*B9_ O;;9+=;5<M% V/F
MZX(\T]Q:@>K8+[3N@EZ*[&$)"ME^M5QC1U+6P+G]'G3)N[[O*VK,<I>H[+01
MUCJJ.!J3KU=@O9HF3Q+'*U',5,*BH>TPN[%1R>PKA4[E"K&4MBM](YSJ>G:Q
MSNN$*T=EH:2H=-3P-;*[JY$,B$4(VA\*ND@K(5BJ8T>Q>Y3X45IHJ)CF4T*,
M8[JB(7PR!A)]*V:>1TDM(Q7NZK@]TNF+/2RI)!2L:].BX,P-ANE&NNM)U]_O
M-*K57S2-4SOT3)OUFH66ZW0TL:;1MP7B>P](U5[E00?HMZJEAJHECJ&(]B]R
MF'72-C555:-F5]AFYIX8&JL\\<:>+G8-7OVO;+:&._+MJ)4_1C<B@B)GHR,.
ME+-3O22.D8U4[S#ZOUM0V2G=343VRUB[-8U,X-+K=7:BU9(M/9:.:&F<N.=&
MKG'O-OT3PPCHWMK;S(M34KOA^Z(1ONSUPS/.S&</]*5]VKTO=X8J-<[F8BJ3
M&QJ,8UC=D1#S!$R")(X6HUB;(B=#V&R      1<;@(!$7'[3RW&S/J$9E6H<
MA1TSEJ_-T;Z:OY<?6?H3J>WMNMEGIY$3"IX'(=/H^3Y1>P;&Y8DF\/:"$Z\
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M=EI4^NGN ^(
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MI4^NGN+LM*GUT]P'Q
M                            !YEB9-$Z.1$5J[;D#<5- SQ5#ZZ@C<Y.
MJM:TGLI)'%.Q63-1S5ZY*7I%XVEGT^HOI[QDQSSAQC3U53;I7-YY*9^<*G3(
MFJNU<KYI>9R]ZJ=1WOAW8;HYSEIVH]=S$4_"&Q12HZ9B.;X&E;1S,\I>IT_V
MFI2-[X_B_1S[:;;67>H;#0022<RX5R-V0Z+X;:+BL% R2=.:=41RJK=\FSV7
M3UKLL2LH:9C4\<;F45<^XSX=/&/G/5R.TNVLNN^'I7R%7J4 -EQ@
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M.Y ;E:Q6-H>7S9KYKSDO.\R  LQ@
M               "M22-T;O5<F%.<^+6B*BTW:2X4,+W4\F7.1&]3HP^5924
M]?3N@JV(^-4PN2EZ1DKPRV-+J<FERQEQSSAR-IC4MQTY72U%JE2-\B<KFJ6]
MUKY[E72U=6[FFD7+E)WU)P:MUR>^6WO; YR]3 P\#I5;R25R83ORIH6TN3I$
M\GK=-]H-'6ULMJ3%YZH<;S.<D<;5?(JX:U.JDY\&-"R4*I>+K$K)G-S'&YNZ
M(;-I+AC8K&K)9F)45#%14<[Q-X5&M1&L3#4Z)X&?!I>"=[=7-[5[?MK:]UBC
M:OC^JKU15RB80\@&V\X              *HAZ58XV*^1[6HGBN /*)GIN>TC
MRG7<TK4_$ZQ6'G9SK+4-VY6X5,D=7'BW>KNJLM%!RHO1^":Q-N58W)VCG*>'
M<L35=,J-:G554Q\M]LL;E;+<J>-4ZY>A #Y]:W7/G-SDAC7]#P/FW1U74>E5
MW-[G+UV,]=)EGPV8ISXX\4XU>MM.TBK_ *UI7JG@\Q4_%*P1*O+4POQX.(OI
M]%VUC<3M[5?%5/LS1]G:N?-6K]:F6-#;QM#'[53R;W)Q=LZ.RUC7>YQ1.,%I
M5?2A1O\ S&F,TQ:&)M1L*NTU:7)O2-+>P3\R/:Z^3>X>*UCE<BOEC9[W&5I.
M(6GJG&;C3,][R*7Z2L[^M*U/K4^;M&VGE7D@Y5\452/8;?-"?:J>2<(M36*7
M"MNM*[/@]"^IZBGJTYJ69DC?%%.<Y-$(CE=2UKXO!.I2.@U3:\_!UWD5J?HI
MWF*='ECIS7C48Y\72BQX3=4^H\(U53.%.?:/B!JJR8;74WG#4ZO7<W73G&"V
M5KFQ7-?-I%[D0P6K:GXHV9:S%HWK.Z3 6]!74MP@;-1S,>QR93<NE8J)E2J7
MDMKG0,N=%)328P]N-RY*HJITZ@B=IWAR_P 0]'UFGKM-)'"]]*K\HY&]##/U
M5<I+8M"VIQ!T5#K.NHJ2Y0.AKHFR,5-\D;Z@X-V:X2*^@>M.YWAT-&^DG?>D
MO3Z7M^G!&/5TXMNDN>DPUJJKO>I<6ZAJ+I4-@HXWORN%5J9)GH^!4,4F9ZQL
MC<],J;_IO1%IL,;>PA:LB=5*TT<[_%+:U7VGK;'P:>NT_JQ/"[2;+%;D?*Q.
MU7=<IN;VO4IW839 ;\1$1M#R%K3>TVMUD !*H   Z
M                            &0;ZJ>X!OJI[@!4M*GUT]Q=EI4^NGN ^
M(
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M$79$.A=,WB*^VF&LA5JJY/21%SN<K)CMCMPV;]+1>O%#)@ QK
M                                                JBJG>.9?$H
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M"'>%>M9XI_@F[N7F15Y7/4F16Y3F;A6KT.9,3$[2W8F)YP\CH 0*\R^)0
M                                                      #(-]5/
M< WU4]P J6E3ZZ>XNRTJ?73W ?$
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M1/:;'P$MLD-MFJI45.T<JHIH:Z8VK'BW-)$[3/@E=>J^\H5=ZRE#G-L
M
M            4>_D8YW@ASOKBH?>=:I#(N8V.Z?6=#R-5\3VMWRF#G/5T3[3
MKE9)TY6/<N%4S8-N\CB4R;\$[-LA8D<36-V1$/HK6[(JGF-Z21-<U45%3N'9
M-SNN5.TY4O2HUB9PJH1=Q8L];5(VKIF\Z,[D)3<[+=^AJ>H-74EEJDBKV(Z-
M>JXR5O$368LG',Q.\(XTSQ'GL\#:2OH_R;=L\I(>FM1V>_.YZ:)&3+U13!WV
M]:-N5OD>KF]LK5PB-QN:EH"B?)J%TE"UR4V=E]F3#2]Z6BN^\?ZMB:UM6;;;
M2D;B0B)97\K6=QA>$S&+#+E$5V3+\26_ZD7F:J=-S#\*)614T[^55Y3)/]6/
MV8X_I_RR?$>YNH[>L+%1%>N"-I=-/^"?A),([.2_X@UTU[OOFE&Y4<UV-BX=
MHO4CK9R+6?DL9Y<F')$Y+3RWV9:?].L<]MVY<,+@E5;/-Y%YE8F-S#<8F1MA
MCY$1%SW&O\/*J2QWWS2I>JJKN53/<8',=##(U>JY+Q;BPSNIP\.5D]!2I3:5
M?*C45Z9QL:/+='7J]/@N-8^"/F5-EQ@WSAV^)NF5?.F6;Y,%>;;I&[/F?Y[Y
MM4)GN[R;Q/!7:2LQ%YW9;3>FEI:AL]#<^VBZ\JOR2!$J\B9ZD":8[:WZA[*V
MU+IX.9$1?%,D\TRJL#%=UQN7Q6BU>4;*9*S%N<[OJ$Z[E"K>I=1IFI8/,+Q3
MUD&&NRF<$^:5N#KA9()'+Z7*F2 =7U25-S@I(=WY3H3WHJD=16&!DJ8=RI]Q
MRM9$=YR='3S/!S9D%5ZE#49@
M                      9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
M
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M,3&R'FRV6ALE$VGH(VM:U,9[R^.9>\WGBLWHK%8V@ !5(
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M+#1P-AIF(QC? ^IS)F;3O/5O;1'*  $
M                              ,@WU4]P#?53W "I:5/KI[B[+2I]=/<
M!\0
M                               @ %G>I.SM<[O^%3DS4<SZB_5;GKT>
MJ(=:W>/M;;,Q$RO*NQR?JZE6DU!5,>BMYG*N#2UL3M#T_P!E[5C/:)ZMJX09
M^&L(FZK_ $-@U_H"[WN]QS4L;.SSU5V,;F X.HOPWMU1=OX&5XI:NO=NNR4U
M'4+&S"]%-?'P]W\7FZ6M[_WA_P!"(F=O%M=Q?#I31245?.U9^7&$7.Y CG-F
MKT>J9:Y^3U77&NN4O:5]5)*[P55P4ML+JBO@A9NKG(4RY.\M&S?T6BMH\&2V
M:>=N<ISLW#VSZCL$;I(D9,K4])$3P-5O?!2ZT#G2V>M<J9V:CT0FC0],Z@L4
M,;V8=RIO]1FN;=5R=>F]8C9\[RS$VGR<MOI-<V!5;)2+,QO>Y<E8M?W&F7EN
M%N5JIUPTZBD1DK<21L<GM3)CZFP66K1?.+;3O7Q[-#8KJ<M?'=KSAQV\'/D'
M$FV2)RSQ2L7]@O8M=V1^$621J?LJ2U6\/-,U6<V^)JKX)@PU1P9T[-ES<L5>
MY$,L:V_E#%.EI^K2(]76!VRU3E7VH>G:IL"KZ5:Y/#"&S2\#;$Y?1G>GN0^3
M>!=ESO._ZRWMUO)'LE?.6M+JVP<BIYVY?J+:77EDIT5K7R.1._E4W2+@?86+
MO*]?J,E2\']-TRHYS.UQW*A$ZZ_DGV2GFBF?B51)E*:GED7NRPLOCK?:Y59;
M;8F%Z*J'0%'H735*B(VV0KCQ:AF::T6FE3_1J""-4\&(4MK,L]-H7KI\<>#F
MF#3NN-02)VL3Z>)W>CL8-NL7 Z5SF3WJL=)G=6\V2=&*C&X8Q$3V(455\5,%
MLE[_ (IW9:UK7\,-?T]HRR6)K5I*5BR-[W(BFP\V$PU.5/!#R"B0
M
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M\,;,/8-,6JP0\E!3L3&V53<S*N7&.B>!Y!1(
M                                       #(-]5/< WU4]P J6E3ZZ>
MXNRTJ?73W ?$
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M%$V-GJM3!4 W'G   !D "N5*  !D
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M
M             #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
M
M                     !-@
M
M
M                                        &0;ZJ>X!OJI[@!4M*GUT
M]Q=EI4^NGN ^(
M
M
M
M
M     #(-]5/< WU4]P J6E3ZZ>XNRTJ?73W ?$
M
M
M
M
M                              !D&^JGN ;ZJ>X 5+2I]=/<79:5/KI[
M@/B
M
M
M
M                                                        R#?5
M3W -]5/< *EI4^NGN+LM*GUT]P'Q
M
M
M
M
M                     9!OJI[@&^JGN %2TJ?73W%V6E3ZZ>X#X@
M
M
M
M
M                                              ,@WU4]P#?53W "
MI\Y(6O7*JH 'GS9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\
M7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'
MFS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F
M>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P
M#S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLS
MQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX
M>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V
M9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7
M /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS
M/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+
MAYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S
M9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<
M  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;
M,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9X
MN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /
M-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%
MP #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AY
MLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9G
MBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<
M\V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\
M7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'
MFS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F
M>+AYLSQ<  \V9XN'FS/%P #S9GBX>;,\7  /-F>+AYLSQ<  \V9XN'FS/%P
<#S9GBX>;,\7  /-F>+AYLSQ< !]D3"8  '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g98130g00t15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t15.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2:$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )F<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                    _^$_76AT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A
M9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-BXP+6,P
M,#(@-SDN,38T-#@X+" R,#(P+S W+S$P+3(R.C V.C4S(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,C4N," H
M5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#<F5A=&]R
M5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TQ,BTQ-E0P
M-SHQ,CHU-RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#(U+3$R+3$T5# T.C0X.C4Y*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-2TQ,BTQ
M-E0P-SHQ,CHU-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @
M/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R
M9" M($1A>6QI9VAT("T@1V%L96-T;R M(%)E<V%L92!3+3,@7T=$0R Q,BXQ
M,RXR,#(U7S4P,#0R.#8T.3 N,3E?+F1O8W@\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^<G(S.3,U,C<\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF
M;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.F8V-#0P934X+3=F,F,M.68T9"TY-6-D+38R
M93 X9C-C-#5D9#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F9A-F4R,&8V+6)C
M9#4M,C4T9BTY,S4U+31C-F1B-3,U8S$T,3PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D0V
M,#1#-#E".3)$.$8P,3%"048S144X-S,V-#,V-$1"/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$-C T0S0Y0CDR1#A&,#$Q0D%&
M,T5%.#<S-C0S-C1$0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R-2TQ,BTQ-%0P-SHU,#HP-"LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C0R,3 R,#@V+6%F,&(M-34T8BTX-C=D+6,R8V,Y-3 R.#9C
M,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R-2TQ,BTQ-E0P-SHQ,CHU-RLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F8V-#0P934X+3=F,F,M
M.68T9"TY-6-D+38R93 X9C-C-#5D9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TQ,BTQ-E0P-SHQ,CHU
M-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z-#(Q,#(P.#8M868P8BTU-31B+3@V-V0M8S)C8SDU
M,#(X-F,R/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.D0V,#1#-#E".3)$.$8P,3%"048S144X-S,V
M-#,V-$1"/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z1#8P-$,T.4(Y,D0X1C Q,4)!
M1C-%13@W,S8T,S8T1$(\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:
M'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H
M&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"C_P  1" 2\!+H# 2(  A$! Q$!_\0 '  !  (# 0$!
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M="LE;41PM1/XG9'#W;2A;Z=SF4,#ZAR;-95R12W'AOD_+#4U&NT^F_5O$?\
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M3.#3SS\9\O<S+G=:ZZ2K)7U#Y7+S*NSL,) #K1$1&T/&VO:\\5IWD !+$
M                $D                       D@    "          20
M        "0(                0                    @
M
M    ?N&1\,B20O5CTW.1<BP<&Z0ZFDD937EZS0*J(DG.TKL*5Y<-,L;6AMZ7
M69M)?CQ3M_:7J"BJH:RG9/3O1\;DS14/N4+@+%<UBKFQ3O5U%(J(Y%_AV[T+
MUI9XZF!DT+D>QZ9HJ<YP=1IYP6V\'T#HSI*FOQ\4<K1WP^H -=T@  #G\;WM
MMDL4\R.RG<FK&F?.IT!2.EJ[+6W]M(QZK%3M1,N;-39TF'K<D1/<YG2^L^Z:
M:UZ]\\H<5/-)43R33.5TDBJY55=^9\P#T+YM,[\Y  $ )(
M
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M9)WQT]\@ .H\B
M                         D@                         "2
M                   2!            $@0          )(
M                           !)!(2]+8<^K]K_E8O[$-@:_#GU?M?\K%_
M8AL#R]_S2^KX/TZ^Z  &*UJ<6?5NY?<.^1YM9R4/26+/JW<ON'?(\VLY*'8Z
M,_);WO%_:C]7'[O\I !TGE@
M               @                $D            @        !
M
M                                   )( 'I?#GU>M?\K%_8AL#7X<^K
MUK_E8O[$-@>7O^:7UC!^G7W0  Q6M3BSZMW+[AWR/-K.2AZ2Q9]6[E]P[Y'F
MUG)0['1GY+/%_:C]7'[O\I !TGE@                     "
M                               D"     ! 20!)  $D        $D
M   ) @     !)                          !
M                                              )() ]+8<^KUK_E
M8O[$-@:_#GU>M?\ *Q?V(; \O?\ -+ZQ@_3K[H  8K6IQ9]6[E]P[Y'FQG)0
M])XL^K=R^X=\CS:SDH=CHS\EO>\7]J/U<?N_RD '2>6
M                       "2                           ) @
M                              20              20
M (                                              (         )(
M)"7I;#GU>M?\K%_8AL#7X<^KUK_E8O[$-@>7O^:7U?!^G7W0  Q6M3BSZMW+
M[AWR/-K.2AZ2Q9]6[E]P[Y'FUG)0['1GY+/%_:C]7'[O\I !TGE@
M        &VPO97W^[LH(I4B<YJOUG)FFP[3P3UGK.'W%*<FHQXYX;SM+>T_1
MVIU-./%3>/X5J"RO!/6>LX?<4>">L]9P^XIA]\P^I?V+KO\ ]<_&/JK4'<8A
MT>5-FM<M=)71RMCRS:C<E4X=%V%V/+7)&])W:6HTN736X,U=I  9M<
M        #;8:L53?[BE+2JC,DS=(NYJ$6M%8WGN68\=LMHI2-YEJ0;+$=I?8
M[O-;Y)$E=&B9N:F2+F:T5M%HWA&2EL=II;O@ !+ !DVVBFN%;%2TS5=)(Y&I
M[/:;7%6'78>FBBEJXYY'IFK6IEJF,WK%HKOS75P9+8YRQ'X8\6A !DI =+@_
M"4V)HZE\-4R!(%1%UDSSS-)<Z-U!72TSGH]8UR54YS",E9M-(GG"^^FRTQUS
M6C\,]TL4'3X/P?48FAGEAJ60-B=JKK)GF='X)JSUG#[BE=]3BI/#:>;9P]%:
MO/2,F.F\3[E:@LE=$]8B*O=.'9_T*5[74ZT=9/3O<CEB>K5=TY&6//3+RI.Z
MO4Z'/I8B<U=M_<^ .GPS@JYWZ+AXD;#3*NR1_/\ @=$NB>MRV7*%5^PIC;4X
MJ3M:W-9BZ*U>:G'3',Q_[YJV!NL38:K\/3(VL:BQ.Y,K=J*:^U4C*ZOAIGSM
M@25VJDCMJ(I;%ZVKQ1/)JVP9*9.JM&UF*#<XGP]58?JTBJ%;+$],XYF[G&F)
MK:+QQ5[F.7%?#::7C:8  2K     $D      "KD@ '856!:BGP\V[+61JQS$
M=J:JY[3CS"F2N3G65^?39=/,1EC;>-_X $VJA8-OT8U=91Q5"7")B2-UD:K%
MV$9,M,?.\[,]-H\VJF8PUWV5\"RO!/6>LX?<4>">L]9P^XI5]\P^IM]BZ[_]
M<_&/JK4%E>">L]9P^XIQ^++!)ARY,HYIFS.<S7UFID9TU&/)/#6=Y4Y^C=3I
MJ=9EIM'\-* "YH!)   $@0         B*JY(BJJ]!VEAT=72Z4R3RR1TD;D1
M6Z^U7)U(89,E<<;WG9L:?2YM3;APUWEQ8+&ET4US8W+'<87N3<W5RS.&NUKJ
M[15NIZ^+@Y$_%%ZE,<>?'DY4G=9J-!J--'%FI,0P@ 6M, .EP[A&JO-OJ:UT
MS:6GA;GK/38XQO>M(WM*[#@R9[<&.-Y<T#+H:):NZQ44<B9R2\$DF6S?EF;3
M%^&9<-5$$,U0V=9FJY%:F61$Y*Q:*[\Y3&GR3CG+$?ACE,M #8X?M,UZND-%
M3JC%>N2O7<U.D[GP3UGK.'W%,,F?'CG:\[+M/T=J=57CPTWC^%:@LKP3UGK.
M'W%./Q98)<.7%E)+,V9SF:^LU,N=4_P,>HQY)X:SS3J.C=3IJ=9EIM'\-*#I
M+=A.:Y6&6XT%3'-)$F;Z?+)R(<WM3-%145-Z*65O6V\1X-?)@R8HK:\;1/.
M &2D      $"     "[,U  ZI,&S+A-;[QN/@T9K\%JKGORWG*IM3,QIDK??
MAGN7YM/DP[=9&V\;Q[@ &2@                                    D
M)>EL.?5ZU_RL7]B&P-?ASZO6O^5B_L0V!Y>_YI?5\'Z=?=  #%:U.+/JW<ON
M'?(\VLY"'I+%GU;N7W#OD>;6<E#L=&?DL\7]J/U<?N_RD '2>6
M      ?6EJ)J65)::9\,J)DCF+DO:9G=V[Y+_P!IU?Q5-<.92)K$]\+*Y;TC
M:LS"]-%U545>&$DJII)9,U\9[E5=ZE1UM\NS:VH1+E5HB2*B?I5Z2UM$GU23
MK7YJ4Q7?ZZI^\=\S0TU8G-DWAZ'I3)>-%IIB9YQ]&:VJO=TC?$V:NK&)RFHK
MGIV&NEBDAD='-&Z.1N]KDR5/P.GT:W5]MQ+#'EK15'B.15R1/:;G3':U@NM/
M711M;#*S5<YO.[VFQUO!EZK;E+F_=.NTDZJ+3,UG:85X9++?6O@X=E'.Z'SB
M,75[2+?2OKJV&EB3-\KD;_4MK'E2W#6#J>V4JY22(D:.3HWJ3ES<%JTK&\RQ
MT>BC/BR9KSM6L?&?)4L-#630+-#2SR0IO>UBJU,O:134575(JTM+-,B;UC8J
MY%OZ**:.KP3-!,GB22/8[J5-IBWG&%LPH]EMLU%%4.C35D<BHB(O7SJ4?>K3
M><=*[S#>CHG%7!349LG#68\N>_E"JJJCJJ3_ %=+- B[ED8K<SX%UX:Q-;,8
M(^CN%#%'/DN3'Y.S3V*5EC>R=PKY+3L3] [QH^HMPZB;6G'>-I:NLZ.KBQ1J
M,%^.D\OWCWM#F9L=IN4C=:.WU;D7G2)5+"T>X4I8;>MZOC6K'JZS&2IDC4Z5
M/W6Z48H*I\5!;624[5R:Y799IU&-M1:;37%7?99CZ,Q8\49=7DX.+NC;>595
M%-/3.U:F"6%R\TC50^1=-IN5IQ[;:BFJJ6.&K1,LMBN3VHI5&(K5)9;M444B
MZR,=XKLMZ=)GAS\<S2T;6A3K>C^HI7-BMQ4MX_5K0 ;#F-]A;"]=B&=6T[>#
M@;RIE38G5TERX8H;5842U4<C75:)KR+EXR]94-HQ?6VFQK;Z!J1O<JJLV]=I
MT6B*:6IOM7-42.EE<W:YRYJNXYVKIDO6UK3M6.Z'I^A\^FPY,=,4;WMWS/A^
MT-#I.^NM=U-^1RQU.D[ZZUW4WY'+<QN8/TJ^Z'$Z0_JLG_E/]P;D!]:2-9JN
M&)$5VL]$R3K+6I$;SM"S=&EM;:K'67VJ:B2*U5C1V[)$V=I7-WKI;E<JBKG<
MJOD>J[5SRV[BVM(TC;5@N*A@5&)(U&(B;%7+(IE$5<D1%55W(F]33TG_ "3;
M+/C_ &=OI>(T]<>CKW5C>??+]1QOED1D37/>NY&IFJF6EHN>JKNYU7JIS\$N
M1;&$+%;L,V#NI=D8L[FZSGR)M;T(F?.:IVE5O&%:EK:M-K99Z^U4Z2/O-[S,
M8J[Q"8Z+PX:5MJ\O#-O#;?XOKH214I[LCD5'(YN:+S;RO\5?M^M^T7MAI;;4
MT;Z^U1,C2J36D1FS:45BC;B"K3IDR*]+?CSWMMLV>E<'4:'#CWWVF>?S6=H]
MACM6!JFMUN#=*U9%<Y=F>15T^(+HL\JI<ZO)7+EE*[++,NNGH;73X+BI:Y[6
MT7!(KLWY9\^1S<.*L%P90MM[58WQ=986J5X<OXKVBLVWEM:W2_\ %BQ3EC'$
M1Y]\JV2_794_:=6O_JJ??"M$EVQ'2T]2KGMD?F]57-5+*OV#K3B&V=T+"D<4
MRIFW4Y*^S+I*D=QB@JWM1[X:B)5:JM7)44W,66N:LQ3E+BZK2Y='EI.>>*O?
M$[\IA<.D:^R8=M-/06QJ1NE;JHYNS41.@JJ*_P!VBG9,EQJ5<U4=DZ151?ZF
M'4U=35*BU51+/EN61RKD?FE@EJJB."!BODD5$1J$X=/7%3:W/S8ZWI')J\W%
M3>(Y;1Y+PMU4S&."7R5D3&R.16KFF>3DYRC9HUAGDCSUG1O5,^I2\8(XL'8&
M5LSDX1&K^+EYBC9)%EEDD=L5[E<4:+OOP_EWY-[IV?PX8R?J;<UKV](,;8&X
MO*__ (ZB;O1,LE1%R_H5.YJM>YJ[VKDIW^ANL?'>JFE5R<!+%FK>E<S1Z0[;
MW-Q/4L:UK8I,GL1N[(SPSU>6V+P[X4ZVOWG1X]7XQ^&?X[G-@'TI875-3% S
M/6D<C<TYLS<<2(F9VA$,4L[]2"-\CNAB*JF7W'NF6?<VKRZ>"4N&5+/@6Q0O
MDA9+4JF2.U4UGJ<['I7?PB:]I8D>>W)^U$-*NIR9.>.F\>]W;]&:;3[5U6;:
MT^$1OLK::":!VK41/B=T/144_,3'R/1D;5>]RY(UJ9JI>%XHK9BW"KZV")B2
M(Q7L<B9*CNA5*CPHU6XFM[7;TFR4LQ:CK*S.VTPUM7T;]VRTK%MZWVVE@5%'
M54TC65---"]_):]BHKNH^S;3<G)FVW5;DZ4B4O3%B6BW.CN]TB;)) U6Q-5,
M\UZCC8=*K4J$:^U-;!GEFC]J)TE5-5DRUWI3=N9^B=-I<DTSYMO+EO/\^2LY
M8I(7JR:-T;^AR9*?@N?'%JH+_ACNI0,C;*U$>UZ)EFG0I5>&[3)>KQ!0L56H
MY?'<B9ZJ%V'41DI-IY;=[0UG1M]/FKBK/%Q=T^>["IJ6IJ<^+4\LV6_@V*N1
M^JJWUM+$KZJCJ(6>4^-40N>]76TX%MD5/34T;ZI6IJQIDBN]JJ:>U:0*&]U#
M:&\6V..&7Q4<JZR9E,:K):..M/PMV_16FQ6ZG+FVR>6W+?WMM>/W91?=-^92
M2;B_,;PQ4^#9XH$1(FM1&HG04$W<-!.];3^[+[0UX,N.L^%829\=ZND;$9'<
M*IK$3)$25<D, &[-8GO<&M[4_+.SJ\%WBYS8IMT4UPJI(W29.:Z151?ZG:Z8
M*ZJHZ6B6DJ98%<Y458W*W,KS GUOMGWAW>FW_2T/VU-#+6/O-(V>BTF6\]%Y
MIF9WWC_"N%OUV]9U?Q5(J*>[5K>-5$%;4-U?UKVJY-7KZ#7KM0N/1=7MNV'*
MBW53T<^-%8C>=&*AL9[]17CK#G='X/OV3J<EYCER]ZG$/W%%)-(D<+'/>NYK
M4S5?P,V_T/<Z\UE+J*QD<BHW/HS.HT26SCF(%J7[8Z=JYIESF=\L4QS=K:?2
M6S:B-/X[[?5Q\]#5T[V,J*6>)[^0U[%17=0J:*KI&(^JI9X6+L19&*U%.ZQM
M<^.X]H8&9<'3R(U.O/:65>J>VK0Q5-W;&Z&!-=$?NSR-:^KFD5F:][JX>AJ9
MYRQ2_P"2=MY^:@&6JY/8CV6^J<Q=SDB7(Q)(WQ2+',QT<B;VN3)4+.FTILBG
M6.EM35IVKDBJ[+-.HW5SH+3C7#DE9011LJD3/61$1S7)S+D3]YO28ZVNT2PC
MHO!GBT:7+Q6CPVVW]RE3]PQ23OU((WR/\EB9J?:AHIJVX1T4*9S/?J)L+@;3
MVG -A9+/$R>M>F]436<[_"%V;/&/:(C>9\&GH=!.IXKWGAI7OE4CK/<VIFZV
MU>73P2F$J*USFN16N:N2HNQ4++9I7<LJ)):F)'GMR?M1#8XML%LQ%877FT<'
M'*QBO=J)RN=47+G*HU%Z3$9:[;MJ>C,.:EK:3+Q37G,3&W+]E1 )M0(;CB.M
MT8VN&YXD9QEKG1PIPB=&:=)T&DW%E5!<5M=MF="V),I%9L7/FR4KBFJJBE55
MI9Y(7+O6-RH?B:62>19)Y'22.WN<N:KUFO;3\67K+<X\G4Q](3ATDZ?'&UIG
M>9_;R;NQXJNMLKXYN-S3-1<G1R/547^I9ND*"GNN"UN2L;PC(T>U<MJ9\Q4N
M'K7/>+M!24[55SG9N7+8U/:6QI+KJ>UX22VY_I9F(QJ)[.<U]1$1FIP=_P#A
MT>C+WMHL\YI_!MRW\_V^2EDW )N!T'FF=8[>^ZW6FHXT5>$>B+ES)SJ6'I,K
M>X]EHK%0N1&*W*147)<DR^9C:&*%DM96UDC-L*(C'*AS.D"L6MQ36N5VLUCM
M1$1=B9&E,];J.'PKS_EW:5^Z='3EC\V2=OXAI;=--35U/-2-UJB-Z.8F6>:]
M1M<676[76IA?>X%AD8W)B+&K,TZC&PM]9+9N_7L^9V6FS)+K;^9.#7YEM[1U
MU:[<]IYM7#BM.BR9(M,1$QR\)?#0W2.EOL]2K56.)F6MT*8FD+$=?WT5<%-6
M3PQ0+JHD<BHB]AU.AJF;%:*Z>56IPC]BY\V1^Z^]X.M==,U].RJG<N;WZB/3
M/K534G)_\BT\.^W)V::?_P"FXZ]9%-YWF95@E^NJ_P#ZG5_%4Q*JJJ*N3A*N
M>2:1$R1TBJJY=9<M%2X5QA0RQT5/%%(G,C48YOMV<Q56)K%4V"Y/I:E=9J[8
MY$38Y#9PYJ7M-=MIAR==H<V#'&3CXZ3XQ/)M=&]\;9[^C)G94U5E&_9GMSV'
MUTF6%EGO7#4^?%ZKQT1>9W.<BR1T4C9&+D]BHY%]J%PXRIG7O1]3UB(Q]2QK
M7J]=Z=)CEGJLU;QW3RE=I*_>M%DP3WT_%'^84X FX&XX;(I:&KJFN=2TLTS6
MKDJQL540BFI*FI>YE-3S3/;L5&,5RH6MH4:CK/<$<B9+,GR%XQ-:<'/=0VJA
M9/4YJLJ[$R7K-*=5;K+8ZUWF'=IT3B^[TU.7)PUGOY?#95=305E*W6JJ2>%G
ME21JB'R@AEJ).#IXGRO\EB9J7;A3$%'C.EJ::LHHV2,3:Q?&V;LS7W&KLF (
M> HZ1M17/77R=OR7V\Q$:NV\TFOXF=NAL7!&>N6.J\]N?P57):;E$Q7RV^K8
MQ-ZNB7)#"3;N+LP?C>GQ'4NH*JC;#*Y%U6JN:.0K[259([-?UXLS4IITUVHF
MY%SVH68M1:U^KR5VEKZOHW'CP1J=/?BKOM/+;9RB;\DSS7<B&9':KC*FM';Z
MIR=+8E4L;1CAZC9:9KU<VLD1456LD;R$;O7\2;AI1AIZA\5MMK9*=JY(]7(F
M?X$6U%YO-,5=]F6/HW#3#7-JLG#Q=T;;RK6>@K*9%=44D\2<ZO8J(8R[E+QP
MKB>WXPCFI*NC9',B;8W9.14Z4*KQO:66;$-530)E!GK1IT9F6'43>\X[QM,*
M];T=3#AKJ,-^*D\O)8+?W,N^Y7^\J!O)0M]O[F7?<K_><KH]P;)>I&UM>BQV
M^)47)R9<+U>PIP9*XZY+6\Y;O2&FR:K)@QXXWF:0Y:&UW":))8:&JDB<F:/;
M&JHJ=9BJBHJHJ*BIL5%+1Q[C"*BA6SV'5CU$U'R1HF34Z$.+P?A^7$=W2G5R
MMA3QY9-^2%^/-,TG)DC:'.U&BI7/&GT]N.W=/EO^S44U)4U6?%:>:?+9^C8K
MCZS6NX01J^>@J8V(F:N=&J(6UB#$EKP8R&AMU#'-.UNUJ9)E[54U]JTETMPK
M&TMUM\<5-)XJOS1R)UHO,51J,MHXZTY-RW1FDQVZG+GVO[N6_O52BHJ; A8&
MDW"M/;&MNMN5K:65R-6-NY%7<J>PK\V<66,M>*KEZO2WTF6<63O@,BFH:RJ8
MY]+233L:N2NC8JHACEO:%T1</U^:)^M7Y&.HR]53CVW6]&Z.-9GC#,[;[JB5
MJM<K7HK7)L5%YC]P0RSRI'!&^25=S6)FJF3>?VM5_>*;K1I]<Z#K=\C.U^&D
MW_91AP1DSUQ;]\[?-SU32U%*_4JH)87<R2-5J_U/U#0U<U.L\-+/) W?(UBJ
MU/Q.[TS)_P!LTV6SQ#IM%E-'68"=!,GZ.221B]2Y&M;5<.&,NW>Z>+HF,FMO
MI(M^6)Y_!3U)0U=6BK24LTZ)O6-BJ154=52(G&Z::#/=PC5;F6I>,9VW"TC+
M;9*&*?@DU9'(J(B*GMYU-CAK$=KQFR2DN%#''4(BJC'Y+FG2BD3JLD1QS3\/
MS64Z*TU[=1&?_D]W+?RW4F#>8RLO<*^S4K4_0KXT:]*&C-NEHO6+1XN)EQ6P
MWG'?O@ !DK $            "2"0EZ6PY]7K7_*Q?V(; U^'/J_:_P"5B_L0
MV!Y>_P":7U?!^G7W0  Q6M3BSZMW+[AWR/-K.0AZ2Q9]6[E]P[Y'FUG)0['1
MGY+/%_:C];'[O\I !TGE@                <P',!=VB3ZI)UK\U*8KO]=4
M_>.^9<^B3ZI)UK\U*8KO]=4_>.^9H:;];(]%TK_1:;W?1\HWK'(V1JJBL5%1
M4+NNJIBG1ZZ6!C5FX)'-UN9R;RCRT=#5PC?!7VN;657^.F:[,E3)40SUE?PQ
MDCOJIZ#RQ.6VFOW9(V_EIM$UKXWB&2>5JZM*W//FSS/CI4NB7#$;HHI-:"!J
M-3+IVYE@45NAPC9KS4<EKW.<Q5Z%SR*0ED=-*^21<WN7-5Z3'!/799R^$<H6
M:^LZ+1TTD_FM,S/^%N:-IGP:/*Z:)=61BR.:OM1"HYY73SRRR+G(]RN<O2N9
M<NB6)*C!<T+MSY'M[4*OQ39JNSW6>.I@>V-SU6-VKL<@TUJ]=DKX[IZ2Q7G1
M:>\?EB#!\\E/B:WNB=JN=(C57V'>::H(U6WS9?I$\7//FS-!HQP]/<+W%6ST
M[^)0YN1ZIDBNYC*TQW"*IO5+3POS6G8J/1%V9YYB\Q;55BOA',PUG%T5DF__
M '3&RR'PT"X3@I[I(C*1\+6N579<W2<DF'L!<U6SXRFYMR0XJP"V!CFK*L.I
MEOU7)L*4K[=4VZH=3UE-)%*WF<TU]-BFTVKQS$Q/<Z/2FKKBKCR=56]9B-IG
M^RXK-1X-LU:E505T3)43+;*JG':5ZJWUUTIZB@GCF>K<GJQ<S7X*P=+B&=Z5
M#9J:E1,TE1FQ5Z-I@XNLM/8;JZCIJE:A&MS<Y41,EZ"_%CI7-^>9M#G:K4YL
MFA_1K3',^'G[FD !OO/!8FAG]K5/V/R*[+$T,?M:I^Q^1KZO]&SI]#_UN/WM
M)I.^NM=U-^1RR'4Z3OKK7=3?D<L9X/TZ^Z%'2']5D_\ *?[AN<'1MDQ+1->F
M::YIC8X<JVT-[I*A[=9&O1%3K,\D;UF(5::8KEK-N[>/[K&TV?Z2VMYD5?\
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MUG)0])8L^K=R^X=\CS:SDH=CHS\EGB_M1^KC]W^4@ Z3RP
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MN=DU,U7<B'TEIJB%NM/!+&U=RO8J(HW9169C=\@ &(
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MX\E<E>*LM'4Z;)I;]7EC:0 &;7
M   2]+X<^KUK_E8O[$-@:_#GU?M?\K%_8AL#R]_S2^KX/TZ^Z  &*UJ<6?5N
MY?<.^1YM9R4/26+/JW<ON'?(\VLY*'8Z,_);WO%_:C]7'[O\I !TGE@
M                               !9>A'_7W'["&GTIW*>JQ%)3+*JT\2
M9(Q%V9^TW&A'_7W'["'*8\^M%;]I?FIH4K$ZJTSY/0YLDUZ(QUCQM/\ EMM$
M=3)#BA86.5(I8UUDZ<E0V^F2XU#*NGHXY',@5F;FHN6MOWFAT4_6^+[M?FAL
M],_[:ION_P Q:L3JXW\F6*]HZ'MM/_<YK!%7+1XEHE@>Y$>_5<B+L5#O--,,
M;J.CF5J<)FK<_85WA3ZQT'WA9&FA%[FT:)O5Q.;EJ:,=%._1F>)\)C_#D\/8
MZFL]G6WQ4,;E5%:DB*K79KSFA6S7BJE61:"KD=(N>LK%7,M'"%BMMDPPESND
M$<DJLX1ZN;GDGLS-14Z4W-E>VCML?!(OBN<[:J&-<L\=NHIOYRSR:6L8<<:_
M-MRY1$=T-AHQL-ZM53+)7HZ.E>U,F.=GE^!R.E9C8\5S(Q,LVHJ]9V. ,67'
M$%[G94*C:=K45&-38GXG(:6?K9+]A/DACAX_O,\??MX+M;U/9<=1,S6+>/\
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M=NR)U\1U<3X[L?L]:?O%J3^68G=66&XTAQE1QMSU65.JF?L4L'35^S:+[?\
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M16NT^+1Z7P9<<TMDOQUF.4_L@ &VXP
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M9R4/26+/JW<ON'?(\VLY*=1V.C/R6>+^U'ZN/W?Y2 #I/+           !
M               2!                   '085Q14X<2?BD$3W2Y:SG[]A
MSX,;4B\<-NY;AS7P7B^.=IAT>)L7W+$$+8:IS8X$7-6,W*IS@ I2M(VK&T)S
M9\F>W'EG>0 &2D   !     WV%L45N'%FXFUCV2[7-=N-$08VI%XX;1R6X<U
M\-XOCG:8;_$N*[CB#4;5OU(6[>#9NS-  *4K2-JQM!ES7S6X\D[R  R5)(
MD@    )(     "2    $D     )(    "2    D@
M   D@                                       !
M     "7I?#GU>M?\K%_8AL#7X<^KUK_E8O[$-@>7O^:7U?!^G7W0  Q6M3BS
MZMW+[AWR/-K.2AZ2Q9]6[E]P[Y'FUG)0['1GY+/%_:C]7'[O\I !TGE@
M                 )(                                   D"   )
M(0  20        !((  $D "00    D@   @   !S D"    ) @  20
M
M                    !+TOASZO6O\ E8O[$-@:_#GU?M?\K%_8AL#R]_S2
M^KX/TZ^Z  &*UJ<6?5NY?<.^1YM9R4/26+/JW<ON'?(\VLY*'8Z,_)9XO[4?
MJX_=_E( .D\L
M         D@   !)                  D@ "2     $D$@0   )  @  2"
M             !                                            <P
M            "2                  !) "7I?#GU>M?\K%_8AL#7X<^KUK
M_E8O[$-@>7O^:7U?!^G7W0  Q6M3BSZMW+[AWR/-K.2AZ2Q9]6[E]P[Y'FUG
M)0['1GY+/%_:C]7'[O\ *0 =)Y8        !) $D                  "2
M  )(            2020                    $D           !((   D
M"$   $D 2020 "    !)            D"   )(
M                                                     D@D)>EL
M.?5ZU_RL7]B&P-?ASZO6O^5B_L0V!Y>_YI?5\'Z=?=  #%:U.+/JW<ON'?(\
MVLY*'I+%GU;N7W#OD>;6<E.H['1GY+/%_:C]7'[O\I !TGE@       !
M  D@       !                       "2         !)       !)
M   "0(         ) @ D 020    D@               $D
M    $
M          )"7I;#GU?M?\K%_8AL#7X<^KUK_E8O[$-@>7O^:7U?!^G7W0
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M(B;#]G'M.\S+V>.O#2*^0 "&:'\AW48*;C.?R'=1@\P0  D    "
M                            0
M         !   "       <P         !
M                        "            @
M     9S.2G420SDIU$D)  !#^0[J,$SG\AW48(0  D
M
M               !     !         $
M                                     !                  !G,Y
M*=1)#.2G420D  $/Y#NHP>8SG\AW48/,$  )            @
M                  $                  !     ($
M "    "      "            0        !
M                    !           0                       &<SD
MIU$D,Y*=1)"0  0_D.ZC!3<9S^0[J,%-PA  "0                  !
M      @ !                                   "
M         (          0     0        ( @
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M%58@MT4J;%:Z9$5 -\#&M]PHKE DUNJX:F%4V.B>CD,D      (
M$                    $                  (
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M2-7+53<B=IZJC8D<3(V\EC4:GX%0_1WTCMQ;8UM=PU&7:D1=;)NJCV]1;XA
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MU!3UE.JK#.Q)&JO0J!#[@ D         @                " $
M   !   0  @',             $  "0   (
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M>2FI?#DI^:'7PZ[3Y_T[Q+8@)M39NZ05MH
M                    @   (
M&<SDIU$D,Y*=1)"0  0_D.ZC!YC.?R'=1@IN"  $@
M      @  !    (                    Y@              @     ,LS
M6W:]T5K8JU,R:W,U-JG"WK&U54JZ.A3@H]VLJ;0+!K;E243'.J9V-RYL]IR5
MUQY&Q%9;X5<[RG;BOYYY:B1SYY'/<N]54^9"6XN&([E7*O"5#VM\EJ[#4/<Y
MZYO<KEZ57,@ !S     "    !A77EQ?9,$SKKRXOLF >CTOZ57S+I3^KR>\
M)+W/0 2 !"<Y($'T@FE@=K0R/C<G.U<CYDA,3MSAT]GQO=K>K6OF6>)%Y+SM
M[/I%M]2B,K8W02<[L]A4 5#6R:3%D[XV=33=,ZO3<HMO'E/-Z0HJVFK8D?2S
MLD:O0ID'G.W7*KMTJ24DSHU3FYBP,/:1^3%=V>SA&H<[+T?>G.G.'IM']HL.
M;\.:.&?DLP&';KG27*))*.9KT5-W.9AH3$Q.TN_6U;QQ5G>  !D
M           $    @                   (
M     !     SF<E.HDAG)3J)(2  "'\AW48/,9S^0[J,%-P0  D   Y@
M                       0         $       @              Y@20
M    !51$57*B(G.IR6(L804*O@H\I9D_B1=B =%<;E2VZ!TE5*UJ)MR5=JG!
M7[&TU1K16]NI'NU^=3EKA<*FX2K)52N>O0J[$,1"$OW-+),]7S/<]R\ZJ?@
M $          (     PKKRHOLF 9]UY47V3 /1Z7]*KYETK_ %>3W@!)>YZ
M        2 (!) &315U312I)2SOC<BY^*N699&&-(;9=6"[M1B[DD3G*N!3E
MT],L;6AO:/I'/H[;XIY>7@])TM1#51))3R-DC7G:N9]2@;!B2X6:5JP3.=%G
MMC5=BEKX7QA17IB,<J0U.6UKE3:<?/H[XN<<X>UZ/Z:PZO:EOPV\OHZ< (:C
ML@0
M                #.9R4ZB2&<E.HDA(  (?R'=1@\QG/Y#NHP>8(  2
M!                             !  Y@    !             (   0
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M2  ,@                       !
M              &<SDIU$D,Y*=1)"0  0_D.ZC!YC.?R'=1@\P0  D
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M  $ '2!A77EQ?9, S[KRHOLF >CTOZ57S+I7^KR>\!(+W/0  !(( D@  20
M!)     "2  !(&[PQB*JL54CHW.= N6LS/9D758KO37FC;/2/1?*;GM0\]&R
ML%ZJK)6MGI7KE_$WF5#3U6DC+'%7O=SHGIB^CGJ[\Z?V]ST*#5X>O-/>Z!M1
M3N\;9KMYT4VG6<.U9K.TO>X\E<E8O2=XD !#,"
M             $                          ($    9S.2G420SDIU$D
M)  !#^0[J,%-QG/Y#NHP>8(  2                 "        !
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M0&/0U<5;21U%.Y'1R(BHID'#VVY2][$Q:-X[@ !(        @
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M_NU_EZ_[/])__BY9]WT^CN$ !RWK0<P   $  "0
M         $     @                    9S.2G420SDIU$D)  !#^0[J,
M'F,Y_(=U&"FX(  A(                      0
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M&?=>5%]DP$/1Z7]*KYETI_5Y/>D @O<])!( $  2" !((    "2"0(    D
M 0  ) @RK572VVNBJH'*CF+GLYT,4"8B8VEE6TTF+5[X>B;'<HKK;8:J%4\9
MJ:R9[E,\I_1C?N(5_$:AWZ"=?%5>92X/ZH>=U.'J;S7P?2>C-=&MP1?QCE/O
M  4.B !                        $     @ (
M  !     ( ,YG)3J)(9R4ZB2$@  A_(=U&#S&<_D.ZC!0(  A(#F
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MTD4KLH)\F+GS+F:FLP]9CWCOAVN@];]UU$1:?PVY2NL!-VP'!?0@   @
M       (                     (       @               0  9S.2
MG420SDIU$D)  !#^0[J,'F,Y_(=U&#S"$  )        !
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MGGM5BZK),1W/I'1&K^]:6MI[XY3_  ($ -=TP           $
M            ',           0     Y@  Y@   &<SDIU$D,Y*=1)"0  0_
MD.ZC!3<9S^0[J,'F"  $@             (            0
M          ! @ (<=I8O263!E:]KT;+*U8V;>D[%#S_](^]K+<:2U1.\6-JN
M>B+SY[#9TF+K<L0RI&\J6>Y7O<]ZYN<N:K[2 #U#9             'ZC>Z-
MR.C<K7)M14V':8<Q>J:E-=,E9N27G3K.)!3FP4S5X;PB8B>]=D;V2L1\3T>Q
M=RM7-#](558<055IDR:Y9(%WQJNPL:T7:ENL.O3/1'IRHU7:AP-3HKX.<<X4
MVI,,\ &DP           '2$";@,*Z\J+[)@F==>7%]DP#T>E_2J^9=*_U>3W
M@)!>YX0    $@$  20  ) @ D" 20!)!( @$D       D@D#(ME4ZBKX*ABY
M*QV9Z'M]2VKH8*ABHK9&([8>;UW%QZ*[GQRR/IGJJO@7).HYW2./>L7CP>G^
MS6IX,ML$]UN[WP[4 ''>U         .8
M     $               !G,Y*=1)#.2G420D  $/Y#NHP>8SG\AW48*;@@
M!(                                    @              )3),U5<
MD0\A:5+FEUQI7S-5%:QRQHJ>Q5/4N++@VUX;N%4]<M2-=7K/&%5,ZHJ9IG<J
M1RN7\5.MT5CWFUUV*/%\P =M:        !        9MGN$MLK65,&6LWF7G
M0P@1:L6C:1;-BOU+=V91NU)T3-S';.PVO.4G#(^%Z/B<YKTW*U<CN,.XO1VI
M3W/).9)OS.)JNCIK^+%W>2FV/;N=H"&.:]B.C<CF+N5"3D]RLY@  "
M',!A77EQ?9, S[KRHOLF">CTOZ57S+I3^KR>] !)>YZ"0 ()()  @D" 20 )
M(  D@  "0 ( $D  202  (  D$ 2=YHCK>!NT],N7Z9J9?@<$;;"=7Q'$%%-
MGDB/1%_$JSTX\=JMWH[-U&IID\I>@@0U4<U'(N:*B*BDGFWT\ 0  $
M   !                             !                9S.2G420SD
MIU$D)  !#^0[J,'F,Y_(=U&#S!  "0
M       $   ( @       0 5KI]N2T6"70,7*2>1J?@>7R[_ *2U<KZRWT2+
MLC;K*G:4@AZ+HZG#AB?-L8XY  -]F              ()      -[A_$=3:I
M-5SG2TZKM8J[NHL6U7*FN=.DM*],\MK%7:A3I]Z.KFHYDEIY%8]JY[#1U.AI
MFYQREA:D2N<'-X?Q5!<,H:S*&HYEYG'29' RX;X;<-X4S$QW@ *D   #F Y@
M,*Z\J+[)@F==>7%]DP#T>E_2J^9=*?U>3W@ +W/"00 "$D  2 ( ) $  "2
M  ) @  "2"0(   D@    /U&Y8Y&O3>U44_(7<$QR>A,+U:5M@HID7:L:(O6
M;0XW175)/AS@U7-T3E[#LCS6:G!DM7]WU'0Y>NTU+^<0  K;0        .8
M                                              SF<E.HDAG)3J)(
M2  "'\AW48/,9S^0[J,$0@ !(   !TA                          0
M          " (    $H0?IG* \LZ>JY:O'L[47Q(HVM0KDZC294<9QK<WYYY
M2:O8<N>KTU>'%6/V;5>X !<D        "               !%5-J;%Z4.IP
M[BR:A1L%9G-3[LU7:TY8%>3%3+'#>-R8B>]=%'505D#9J61)&*G,NU.L^Q4%
MHNM5:YTDII%1.=F>Q2QK#B&ENT:-54BJ>=CEW]1P=5H+8?Q5YPHM28[FY W*
M#GL  <P&%=>7%]DP#/NO+B^R8)Z/2_I5?,NE?ZO)[T D%[GH ) $  "0 (
M$D (  ) @     )! $D  202 (!)    69H;J,UKZ=5W-1R=I9A3^B2;4O\
M+%YQA<!P==7;-+Z%T!?CT58\IF  &H[0$        "
M      (                     #G SF<E.HDAG)3J)(2  "'\AW48/,9S^
M0[J,%-P0  D         .8  @    $  !         @               "
M$ $ ) _$[M2GE?Y+%4_9BW5VI:JY_DPN7^@B-Y3#QEB>3A<07!^>>M,JFL,F
MY/X2X5+_ "GJIC'KZ1M$0VH  9              @D ""0         !^HWN
MC>CF.5KD7-%0_(&P[?#F+U16T]U7-/X943;^)VT;V2QH^)R/8NU%0I(W-AQ!
M56E^JUW"0*NUCE^1R]5T=6_XL?*5=J;]RU08%HNU)=8D=2R)PB)XT:[T,\X=
MZ6I/#:-I5;;,*Z\N+[)@&?=>7%]DP#T.E_2J^8]*_P!7D]Z2 27N>@   20
M ) @$D "2"0(     2  (             =3HTEX/%=-T.144N\H3!#]3$U&
MJ>47YSG&Z1C_ )(G]GN?LS;?36CRE  .>]&      "
M $                     .8        #.9R4ZB2&<E.HDA(  (?R'=1@IN
M,Y_(=U&"FX( @!(                   @      $            .D!
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M3YGH)=YR>DOSP]?]F/T;^]  .<].(                         $
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M&Y\CD:QJ9JY>9 /T# IKS;:J7@J>NAEE7<UKMIGDS$QWL:WK>-ZSN  AD
M  ,YG)3J)(9R4ZB2$@  A_(=U&#S&<_D.ZC!3<3" !
M           !       $      @0     Y@@!"6HBKDNU%WD!%R4#QOI#I%H
ML8W.+F657)^)SI8VGFAXICV=R)XDL;7(5R>KT]N+'6?V;5><  +D@
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M[J,'F"  $@                         @     @       "
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MD:QJ*KG*B(B=)UV,,"56%K325=?60+/4Y*E,WEM1>=3.V2M9BL]\IW<> #,
M               $WEB6.!:>V0QKOWG 4L:RU$<:;W.1"RH&ZD+&KO1,BN[R
MGVKS<."F+SG?X?\ ^OV20"MX, ) @ D 0 @$D!     D@ 20       "2 !)
M   DA"0( ) @ E$5SD:F]5R0)7!HFI>!P^^==\CCMS2X-H^)8;HHUY2L1SNL
MW1YO/;BR6L^G]'XNITN.G[0^-7&LM)/&W8KF*B*>>Y%6BOKEDWQ3[?P<>BBL
M-(N$)%J'7&U0JYKLW3,:F[VH;6@RUI::V\7*^T&DR9L=<N.-YJL>AG94T4,T
M+D=&]J9*ACW^Y1VFUS5<BIFQ/%1W\2]!35DQ==[$W@6N5\2)DD4J;&GPON([
MGB%[63*YT7-%&FS,RKT?;CYS^%3?[1XNH_#$]9Y?NL'">.I+S<VT<U(C5?N<
MQ=W696E*X<3PZZ!KD1]0Y&HO/_\ FPP]&>&9+=&MPKFHDLK<F-7>U#CM)5U=
M<,120M?G% B,1J+LSZ2:8L=]3MC[H8YM7J,/1DVU$_CORCW3_II;!=GV6Y1U
ML44<LC$7)K]QN[_CJKO=MDHJJEIVL?EXS=Z;3NL*X1M?<*FDKZ..6>1J/5R[
MT]AM^]&P^K(2S)J\''O-=YCQ4:;H?7Q@X*9(BMN<Q[_X5!@BZ=R<04\[LE8]
M>#=GT*N\M/22K781G<U<VJYJHJ%68WM;;-B*H@B1&Q9Z\>KN1%YCM;E<NZFB
M]L[E37:Y(U1%Z-AEGK%[X\U?'93H,ML.'4Z+)WQ$S_B6AT1?6A?N7%R(>>L-
MWN>Q5W&Z5K'R:JMR=NR.F\)MU\S3F.KTF3+DXJ]R[H?I?3:33=5EF=]YGN6^
M55IC_P!?1_8_R3:-(ERK+E!3R0P(Q[LE5-Y&F-4X]1>V/,JTV"^'/6+_ +MK
MI/7X=;H,EL,]TQ_=CX-P52WZS.JYJF6.765J-:B9'-8ALE38;CQ>J;K-WM=E
ML<A9^B?+O87HX13;XNL4=]M,D.JWC#=L3\MJ+T&?WNV//-;3^'=1V-CU&@ID
MQ1M?;?WM+HWN%IJZ1T=+314]8B)KMRS5?:AVQY[MM95X>O22;8IH7ZKV]*<Y
M?%HKXKG;H:N!R.9(W-<N9>="C6X)I;CCG$NAT'KHSXIPVC:U?X_]_=F )N!I
M.ZX33']7J/\ F/\ !J-#?^MK?N_\FVTQ_5ZC_F/\&HT-?ZVMR7_E_P"3IT_H
MY_\ ?%Y7-_UNONC^SM,;VE+OA^>-,^%C379ETH5[HLNO<^[5-/,OB2L78O,K
M2X%:CD5KMRIDI0V+:">QXCJ6,58T>JOB<GDJ8Z.8RTMAE;TW6=+GQZZD=W*?
M_?B_%=(Z_8LD5FLK)Y\DYU1N9=]; VFLDT$:YLB@5B+^!6NB&ULFN%173-S2
M%N4:JFS-5VEG77]F5?W:D:V\<=<<=T,N@\$QI\FIOWWW_P J(P\QLF*Z)KLM
M7C*;^?:>@UV.7),LCS? LZ71'4F?&&RZT>KOS12P?"3+34"05-&]+BQ-5SG;
M$Z\B_6X+Y9KP<W.Z"Z0PZ2F2,T[;SOO_ (][E](FJF,*[@\DR5O)-IC^:>6R
M6)9W*YRQ9KG\S366V5N)[\FNUZMD=K2R*BY-0LS'.&>Z6'XHJ)K>&HVYL3G<
MB)N,KY*XKXZ6GG'T58--EU>+4YL<<K=W[\]_[*ZPPW$B44BV)LO%U=XRLW:Q
MEW*V8OND38Z^GJ)F-7-$7F4^.#\45&%ZB6"IAD=3.Y4>Y47I.@K])\LDC.YE
M&Y&_Q(_:JF5^MC)O2D3^ZO3_ '.VGBN;-:)[IK_IL=%EJN-JX\VXP/A8]&ZB
M.YUYSO4--A6[5-XMW#U=*^G=GLUOXD-R<G/:ULDS;O>PZ/Q8\6FK7%,S7PW[
MPU6+/JM=OY=WR-J:G%OU6NW\N[Y&&/\ /'OA=J?T;^Z?[*BT:_6>F^S_ )+T
M7>I16C14[YZ;;S?Y0O5><W>D?U(]SB?9K^EM[T  T'H@   !S@9S.2G420SD
MIU$D)  !#^0[J,'F,Y_(=U&#S!  "0
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ME.HDAG)3J)(2  "'\AW48/,9S^0[J,%-P0  D            "  @
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M8I'B]/\ 9K2\>6V>>ZO+^9?< ''>U   0  $
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M^$;N]IF<'3QL\EJ(?0D%#X]DO-[3:?$! #    D@ 2  !
M!((     "0()(/U&Q9'M8W:YRHB($Q&[N=$]K6HN[ZU[<XX45$54V9ENFBP5
M:6VBQ0PJGZ5_CO7+G-Z>>U67K<DS'<^D]$Z3[II:TGOGG/\ ( #7=(
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MY.5TWFZK0Y)\XV^/)T( *GRU)  $D$D   !)  $D D 0             $D
M 2 (  !#KM&UF[IWI)I&YPP>,O7F<G&QTLC8XTS>Y<D3I+UP-9TM%BA:]N51
M(FM(IJ:S-U>/:.^7:Z#T7WG4Q-H_#7G/^'0^Q-R  X+Z$
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M*$\+Z>>2&5JMD8Y6N1>D])HM1UV/GWPV:6WA\P ;K(
M     !',6%8(%I[9$Q?XO&."@CX69C/*7(LJF9P=/%'SM:B%=Y>6^U6;AT],
M?G/]GU! YBMX$   D@ 20              D 0  !)     "0( ,RTT$MSKX
MJ6!%5SUZ-R$3,1&\LJ5F]HK7OEUNC'#_ !ZNX_4,_00KXN:;%4M_J3(P;+;8
MK5;8J6%J(C436RYU,X\]J,TYKS;P?2NC-%&BP13QGG/O  4.@   $
M           !                                       #.9R4ZB2&
M<E.HDA(  (?R'=1@F<_D.ZC!Y@@ !( !
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M/]&;?_*RQ[OK]  '+>L
M                       9S.2G420SDIU$D)  !#^0[J,'F,Y_(=U&"@0
M D           0
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M'W" X??SE[R(BL;1W  "0        <P
M                         !G,Y*=1)#.2G420D  $/Y#NHP>8SG\AW48*
M!  "0                            (
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M_&'K-3V6A;3TZ(KOXGY;54VB '#M:;3O/>][CQUQ5BE(VB  $,P
M                                                         9S.
M2G420SDIU$D)  !#^0[J,'F,Y_(=U&#S!  "0 "              !
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M*>VTC*:D8C(V)EUF6 <B9F9WE[&M8K$5K&T0  ,A
M                                 #I "  @     $      !G,Y*=1)
M#.2G420D  $/Y#NHP>8SG\AW48),(                          @
M$                       0        =(      !#VM>QS)&M<Q=BM5-BH
M59C_ $1T-[=+66;4I*M4Y")XKBU 68LM\4\5)V3$S#Q;B+#ERP_5.@N-.^/+
M<_5757\33H>VKU9J"]T;Z:Y0-EC<F6?.A16/-#551K+5X>7AZ=,W+$KMJ(=K
M3=(TR?AORE=7)$]ZF@?>KI)Z.98JJ%\4B<SDR/@=.)W6        (3<6!AN#
M@+5'_P!::QP<+.$E8SRG(A9-'%P-)%'Y+40KO+S'VJR\.FKC\Y_L^P *WS\
M) $$D  20 !)   D 0     D@  95OM]5<)4BI(72/5<MA96&-'<<&K/>%UY
M-_!M784YM13#'XI;^CZ.SZRVV..7GX.'P]AFOO4B)!&K(L]LCD7(M?"^$*&R
M,1ZM;-4JFU[DW=1T-/#%3Q)'"QK&(F2(A]$./GUE\O*.4/:=']"X-'M:WXK>
M?T$ !J.R (    ( $  (                         "
M                          SF<E.HDAG)3J)(2  "'\AW48/,9S^0[J,%
M"80     "   @
M        "      0  2A  T6(L)V?$,+F7"CC5R_\QK41W:4MC#0I64:23V&
M5:J)-O!JB(Y#T,$V;MYL8=5DP_EGDRB\P\0W*UUMLG=#7TTL+VKDNNU4,(]K
MWG#UJO,:MN5##-GSJW;VE98DT(6^J1TEEJ.+/5=C'(JH=7#TG2W*\;+8R1XO
M.P.UQ'HTQ#9%<Z2E6HB;_'$BJ<;+#) ]S)HW,<F]')ED=&F2MXWK.ZR)B7X
M!F,VRP\/<H&+NSS+%38B)[#BL(4Z2W!9%_Y:9G:])5?O>#^U>7BSTQ^4?W
M8/*    $@0@   D@    !](899G:L,;WNZ&IF$Q$SRA\QGTG5V; MUN&3GL2
M"->=Z;3M[-H\MU(C75KN,R)OV9)F:V368L?CNZNEZ%U>IYQ7:/.>2J[9::VY
M2:E%3OD]J)L0L##VCAJ:LUVE7/8O!M+"HJ*FHH]2D@9$W_I;D9!SLVOO?E3E
M#TNC^SV##M;-^*?DQ+=;Z6W0I'1PLC:FS-$VF6 :$S,\Y=^M8I'#6-H  &0
M
M               YP,YG)3J)(9R4ZB2$@  A_(=U&"AG/Y#NHP>8(  2 ',
M                                              $
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MJ&TT-"F5+31L_#,S@:E\U[_FEU\&BT^G_3I$'-ES  K;0
M                         @
M          #.9R4ZB2&<AO420D  $/Y#NHP4W&<_D.ZC!3<$  )
M      Y@        @                         (      (       @"
M               (       !S             0                  $
M                                                  $
M            9S.2G420SDIU$D)  !#^0[J,'F,Y_(=U&#S"$  )
M                                     @            @
M                   $ 0(         "                          $
M                                                0
M         !G,Y*=1)#.2G420D  $/Y#NHP>8SG\AW48*;@@ !(
M    0     "                                    "         (
M0             0           @      ";@                    !
M      @
M         !G,Y*=1)#.2G420D  $/Y#NHP>8SG\AW48/,$  )
M               (                                  0
M       (
M                                        !
M    9S.2G420SDIU$D)  !#^0[J,'F,Y_(=U&#S!  "0           #F
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M)5Q202<-#)P;6-3-9%]A^+?CF"6N;3W"BGH4?L:^1-BKT!+L $YE]@"  !(
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M2WRHM%O[R\7?>='M4MT        !TE9W']H5/WBEFISE97']H5/WB@8X
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M]F/TA_83WLQ^D/[ .8!T_>S'Z0_L'>S'Z0_L YE.<K*X_M"I^\4O/O9BV_\
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M[I2>0T#: U?=*3R&CNE)Y#21M :ONE)Y#1W2D\AH&T!J^Z4GD-'=*3R&D#:
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MCX"H=R5S\53"^CRTKQ3"[!TUH\]XQUMSGSC9V@',#6=4
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MTUVR>XLI+S::RSI)LCEJ45$?_07733;Z2MD9166NKZ&-^K)6Q(O!MV[5W;4
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MB]*J:Z_6&X6*6..Y1M8Z1,VZKM;,VL5XX:Q,\YAR-5AO.7)>L?AB9Y^'>U8
M+6D   9%M_:5']\SYF.9%M_:5']\SYD3W2SQ_GAZ17FZD()7FZD(/+0^LR
MD                     &<SDIU$D,Y*=1)"0  0_D.ZC!YC.?R'=1@\P0
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M.ZW&-NK'<*IK>A)5,::66>3A*B5\LF[6>N:EF^"V+UH[X?\ N/!;%ZT=\/\
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ML<BS)^GJ>:1R;OP,,FOQ16>&=Y7Z;[/ZN<D=9&T>^/\ #IN;\ $!Q'O
M                   &<SDIU$D,Y*=1)"0  0_D.ZC!3<9S^0[J,'F"  E&
MJNY%4D0#]:CO)=V#4=Y+NP#\@           ?I&JNYJ]@'Y!*IEO(    ?ET
MC&<IR(8M=5<$B-8J*[G-4][GJJN55(&\XU!YUHXS!YUIH<AD$M]QF#SK2.,P
M>=::( ;WC,'G6D\9@\ZTT(R]@&]XS!YUI/&8/.M-#D -]QF#SK2.,P>=::+(
ME&YYY)F!O.,P>=:.,P>=::+((F:Y(F:@;WC,'G6D\9@\ZTT.7:,@-]QF#SK1
MQF#SK30Y; B9KL0#?<9@\ZT<9@\ZTT2IDNU",@-]QF#SK1QF#SK30[!D!O>,
MP>=:3QF#SK30@#?<9@\ZT<9@\ZTT( WW&8/.M'&8/.M-#D2B9[DS WO&8/.M
M'&8/.M-#D -[QF#SK2>,P>=::'(9 ;[C,'G6CC4'G6FA&0&^XS!YUHXS!YUI
MH<AD!ON,P>=:.,P>=::$ ;WC,'G&CC4'G6G-7'92.5-BYH:76=Y2]H%A,EC?
MR7HI]-G2G:5TCW)N>Y/Q)X23SC_>4(V6)^*=H_%.TKOA)/./]X<))YQ_O V6
M'^*=H[.TKSA9/./]Y1PDGG'^\H-EB?BG:1^*=I7G"2><?[RA'RKN?)V@V6'^
M*=H_%.TKW6E\N3M4A9)4WR/[5!LL/L[1^*=I7?"2><?[RD\))YQ_O*#98?XI
MVC\4[2O.$D\X_P!Y24?*NY\G:#986SV=I/XIVE=\))YQ_O#A)/./]Y0;+#[.
MT?BG:5YPDGG'^\.$D\X_WE!LL3L[1V=I7?"2><?[RCA)/./]X&RQ.SM(V>SM
M*\X23SC_ 'E"22><?[P3LL3\4[2/Q3M*\X23SC_>"/ERSX1^7VE"-EB?BG:1
MV=I7G"2><?[PX23SC_>!LL/L[2?Q3M*[X23SC_>4<))YQ_O V6'^*=I.SI3M
M*[X23SC_ 'APDGG'^\-S98?9VC\4[2O.$D\X_P!X<))YQ_O*#98?XIVC\4[2
MO.$D\X_WAPDGG'^\#98>:<ZIVD9IY3?>0JW$,TK+!<G-ED1R0.R5'+LV'G'N
MA6KOK:KXKOS-W2:/[S$SOMLSK3B>X,V^6SWD&;?+9[R'A_NA6^FU7Q7#NA6^
MFU7Q7?F;?9,^OY?[9=4]P9M\MGO(,V^6SWD/#_="M]-JOBN_,=T*WTVJ^*[\
MQV3/K^7^T]4]P9M\MGO(,V^6SWD/#_="M]-JOBN'="M]-JOBN_,=DSZ_E_M'
M5/<&;?+9[R#-OEL]Y#P_W0K?3:KXKOS'="M]-JOBN_,=DSZOE_M/5/<&;?+9
M[R#-OEM]Y#P_W0K?3:KXKOS'="M]-JOBN_,=DSZ_E_LZI[@S;Y;?>09M\MGO
M(>'^Z%;SUM3\5WYD=T:WTVI^*[\QV3/K^7^T=4]PYM\MGO(,V^6SWD/#W=&M
M]-J?BN_,GNA6^FU/Q7?F.R9]?R.K>X,V^6SWD&;?+9[R'A_NC6^FU/Q7?F.Z
M%;Z;5?%=^8[)GU_+_9U3W!FWRV>\@S;Y;/>0\/\ ="M]-JOBN_,=T*WTVJ^*
M[\QV3/K^7^T]4]P9M\MGO(,V^6SWD/#W=&M]-J?BN_,E+C6^FU7Q7?F.RI]?
MR_VCJGN#-OEL]Y!FWRV>\AX?[H5OIM5\5WYCNA6^FU7Q7?F.R9]?R_VGJGN#
M-OEL]Y"<V^6SWD/#W="M]-JOBN'=&M]-J?BN_,=DSZ_E_LZI[@S;Y;?>09M\
MMOO(>'^Z%;Z;5?%=^8[H5OIM5\5WYCLF?7\O]G5/<&;?+9[R#-OEL]Y#P_W0
MK?3:KXKOS'="M]-JOBN_,=DSZOE_LZI[@S;Y;?>09M\MGO(>'^Z%;Z;5?%=^
M8[H5OIM5\5WYCLF?7\O]HZI[@S;Y;/>09M\MGO(>'^Z%;Z;5?%=^8[H5OIM5
M\5WYCLF?7\O]IZI[@S;Y;/>09M\MGO(>'^Z%;Z;5?%=^8[H5N?\ K:KXKOS'
M9,^OY?[.J>X,V^6SWD&;?+9[R'A_NA6^FU7Q7?F.Z%;Z;5?%<.R9]7R_V=4]
MP9M\MGO(,V^6SWD/#_="M]-JOBN_,=T*WTVJ^*[\QV3/J^7^T=4]P9M\MGO(
M,V^6SWD/#_="M]-JOBN_,=T*WTVJ^*[\QV3/K^7^SJGN#-OEL]Y!FWRV>\AX
M?[H5OIM5\5WYCNA6^FU7Q7#LF?5\O]G5/<&;?+;[R#-OEL]Y#P_W0K?3:KXK
MOS'="M]-JOBN_,=DSZ_E_M/5/<&;?+9[R#-OEL]Y#P_W0K?3:KXKOS'="M]-
MJOBN_,=DSZOE_M'5/<&;?+9[R#-OEM]Y#P_W0K?3:KXKOS);<:Y%S2MJD5/_
M )KOS'9,^KY?[3U3W"G_ .9$%":"<=7"HN[;%<YEJ(I&JL3WJJJU4YB^SG9\
M%L%^"RNU>&=@ %+%G,Y*=1)#.2G420D  $/Y#NHP4W&<_D.ZC!0("O-(^',<
MWBZT\V#L3,M%&V+5DB7^)_26& 1.SRWCB?2C@^ZVV@KL:OGDKG(UCHUV-S7+
M;FAW%#@C2VVIII9\>120(]KWLS7QFYYJF[H-=](WZZX3^\9\R_*==6.%>AC5
M_H8Q'.5DSM$2_$$L;TU&S122QHB2(QR*J+SYIS'[<YK&JZ1[6-3>KER1"AH'
MR8(^D+41R3N2@OC=9RYJJ:RY+E[-IT7TC+H^/#-#8:65\=7=:EC$X/E:J+MZ
MB=^3'AYK46>%&HY9X4:[DJKTR=U=)#ZFFC>C)*JG8]=S72-15_#,HC3]2R8<
MP7A>GH5?PU&K$9XR^,Y,DV])F6_0LR_V&"[7F]UZX@JHDJ&2,DRCB<J9HF71
MN&\]R>&-M]UX)THJ*G,J'XDEBA;G/-%$G3(]&_,J'01B.YI+><-8DJ4GJ[8Y
M71RKO<S?M4Y.S6^ITNXJNE?B"[K28?HYG4\=/%+J*[)5_IL'$<'F]$PSPSHJ
MT\\,R)OX-Z.R[#Z'G3%5B?HAK**^X*NLE5;I94CK*2:77R;T]1Z!M5;%<K;3
M5L&:1SL1Z(I,3NB8VYM?C3$--A3"]=>JQJNBIV9HU/XG+N3M*CL=+I.QW;4O
ME'B9EDHJE5?3T[47/5YE7V%TWBU4-[MTM!=:9E51RY:\3UV+EM/U&RBLMH1K
M4926VCCV>3&Q")C<B=E4:.L<8AH\;28)QRL<M?'&KXJMN^5-^:EQ%#8.DDT@
MZ;9\44D:I8Z")8&399+(N629=I?2KM45+('2!S+U&3%H)W*^9ZKTGS/T_E.Z
MU/R0D           J+Z1V)KSAFSV66P5\U'+/*]LBQ;WHB;$+>*7^DOEJ8.S
M3-.Z";%ZT [#1#C%F+L*PRSRYW*'Q*ACE\;-.?(^6G&\W"P:/*JOL]5)25C)
M6-;+'O1%7:<!C*DGT6Z2(<26YCEL-P1K*AJ[4:Y=^SH.I^D'505VA^>II)&R
MP2R1/8Y.=%5 .^PE4RUF%+/55,BR5$U*Q\CUWN<J;5-H:? K5=@FPZJ*J\3C
MW=1N^">F]JHG4!^%5K457O:QO2Y<D[3C=*UXGMF [G766N8RJB;FV6!Z.5J_
M@<+B>HN.D#2?/A*&X.H[)1,UY7PKD^39T_B:W29HW3!^#+E4X:N%7)22-RJH
M*EVLBITI[0+2T37*LO&CJS5]RG?45DT:K)*[>Y<UWG4/J*:-<I:JFC=T/E:U
M>Q5*6MV*9L)_1]L531:G&YV+##K)GM55&%=#D5]M,=SQG=*Z:YU":R)%)DUB
M<VX"[6JUR9M<US5W*U<T4_/"1Z^IPL?";]3636["F\ W&ZX-TA=X]TG=5T=2
MG"4<KUS<UNW)%7J1#2:2HKG5:=(Z"TUBTDM3 UCI,^2W),\O:!?S9Z=[M5E3
M3O?Y+96JO9F3)-#$J-FGAB<NYLDB-5>T\]Z3='D.CW#K,1V"ZUSJZ&9J2+-)
MFCU7V&YP]HT?CFS17W%UWK77&>/6A; _59&F6: 7:BHJ9M5'-7<J+FBGYDEB
MB3.:>&)/_F/1OS*<T$W2YL9BFSU,\E7);9-2D9)M5=_/V$6_1A>,65-57:0Z
M^K@:LF<--3R(C43V_P!0+DCDBE15AFBE3IC>COD<SCZW7VX4UO;AN^06>2.;
M6G?*]&\*SR4S*BN5L?HQTB6.'#USFGM=:]&RP22:ZIMRR.A^DM([N+A9[%<W
M7KFJN2Y;P+BUV1L8DTL;7*B)F]R)K+[,]Y^7U%/&[5EJJ>-_DOE:U>Q5*:^D
MG//36?"\M*]63I.U&+GEM5,CZKH8I+K:7W&^7>XU%YEAX379)DQ'99HB)T 7
M(F2IFBHJ+M14VHH*GT WRX5='=+)<Y73NM<JQLD?OU<UR0MD" 20   $D  8
MUQ_TCOP-*;JX_P"D=UH:5         !46F"^7^BQ':[=8;I)1<:=J>*NS-<M
MJENE(Z:JJ&BQM8:FJ?J012(Y[LL\D3(#:]YNDW_]Z1>]_L?.P8LQ#AK%L&'\
M93)6-J51L52WG7<=1X5L%*J?]L+N3_E*5]77-ND/2;:)++#(^AM[T>Z94R1<
MES_P!>ZIDJH#]JQ[E54:JIU&CQI=W8>PW6W%$;PL+/$1Z;%4#;.EAC7*6>&-
M>A[T3YE':7<7WZSXUI*.U72:GI7ZN;&*F2YJAG83P!WZ6AM]Q3=*Q:JJ77B9
M _)L:;]Q76DRVUMHQI0T57.ZHBA<UL$K^4K,TW^T#U3$N<$3E7:K&JJKU'X2
MHIE=J\:I]?R>%;GV9E9:5[]<VS6O#=BE2*KK6,5S_P")K<ND^7@:H66U9H[E
M7.O>KKI-PGB\)^68%KGX26)6N5)HE1O*5'IDG7T' Z(<1U]R2XV6\9.KK4O!
MOD3^)-J%=X/LE;BC%>(+6ZX34UK2=SITC=X[MV2(H'H*.2*7/@9HI?L/1WR(
MX:#75BU$&OSMX1,^PH'&-DK-'F);72X6N,^I<4U$29VMJKNS-[B'1A#1X;JK
MVEUKWWMD7#N?PGBJ[+-43V 7+D?-\\$:Y2U,$;NA\B-7^I7F$;Q?+OHJ@GMV
M55>G(Z/6=_#M5$4UUKT21W"C95XQN5:^YO1==K9-5K>C<!:[7-<W68]KV]+5
MS0YJX4%ZDQC25=->88;0QJ)+0*]$?(O3D5_HZGK<.:0:S#G'75EM<F<2N=K*
MB;>?\#+Q0KDT\V-J.=J\&FS/9S 6RLD>NK.$C1^_4UDULNK>?A*BG5VHVJIU
M?Y*2MS[,RE=(\=PJ--%-26JJ6FGGIFLX3/DIMSR0R,7:+:*Q6"IN]KN5P6ZT
MR<,CWOV*N]0+FW Y?1E>:B^X+M];6+K3ZNHYWE*FS,Z@       D@#78C^KU
MR^X=\CS8AZ3Q']7KE]P[Y'FQ#M]$_ELNQ  .NL     $$D$@  !T>!;E8K7=
MGS8FMCKE1K&K6Q)S.S3:6_@:;1UB^[]SZ/"/ 2:NMK2;OF>?2U/HY_7=?NE_
MR:.KQ1P6R1,[[><L+1XMYB*^:-;%?*VUSX.=)+2O6-SV[E7V;31X#PA;<7XA
MNEW6E?1X:I\WMB7J3Q?\G*Z5?WAW[^84U5MQ#=K90S4=!72P4LWZR-N63A3!
M;J]Z6G>8COF2*\N2T:7$6C"IKV6_O6?%&YW!I5.7^N\Y;2W@F+"-TIWT,BR6
MZL;KPJN]%Z.HT>!\-5V*+[!1T$2N1':TC^9K4WKF=MI^O='55]LLM Y96VR/
M4?)GFBNW9?T,:UZO-6M)F?/Q(Y3R506'HKP F)UEN5TG;36:F7](]VQ7KT(I
M7G-^)?F-H66C0%004.M$DTK'.5.?-55<RW59+5B*5G:;3LFTM+4XFT86^I?2
M1X4?6,B756HUN7[4VGTQ-@2Q8CPJ_$>!E2#@DUYJ-?X4R7-/8NPIDV5MOMSM
ME)/2V^ME@IY_UD;5V.ZR)TUJ[3CM._[R<.W<UJ[%7F5 '.3-55=J[3+LU&ZY
M76DHH4UGSR-9DW?DJ[3;FT1&\LGPBAEE_50RR?8:J_(MO1'A>TW;"M]J+O;F
M355.QRQND145F2&ZQCB:'18VBP_AFW0/J6QI)45%2W65^?\ DZ/ &)*;%&$+
M[7K314UR6%[9V1)DU4RV+D<S/J+WQ\41M$^.ZN9F8>9&(KMC45RKS(A]5I*E
M&ZSJ6H1O3P:Y%P:'+':;?A:X8OO,2SK3*J11KM3-$Z/Q0_%!IKJZB[I%<K;0
MI99'ZCF-B\9L:KEVY&Q.HO-IC'7?9/%/@ISF/KQ>?61O 2Z[DS1NHN:I[$._
MTU87H</7JDJ;2J\2N,:3L:O\.9:FD?$M+A"T6.X4UNIY[O)1L9#)(WQ6-R3/
M81;5<J\$;\2>+R>:Y(98OUL,D?VVJF?:?KBM3JZW%I]7IX-<CTCA*\VS'^"Z
MFXXHMD#I;8_7?P;=5'*B*J99=1H,$Z5*B^XNIK-5VRA;:ZARPL:V/:U.;,P^
M]Y/Q;4YU[^:.*5#GV92U+TUFTT[F]*1JJ%F5-HP[9-+5?%B/_A+/"]9(HD15
M1Z<R=ILKIICK(+E)387M=$MIB?JQYPYN>U"V=1:VW5UWY;^2>+R4ZYKHW*V1
MKF.\ER9*=*RNLJ8!?1.LTJWSAM9+CEXB-SY.?5L++TQ6VAO& [5BN.D2DKI=
M5)6M;JYYIN5/P-5 UO\ [-<[M5NMW0RULMO+0P^\1DI6VWCLCBW5+P4FHC^#
M?J*N2.U5R5>C,_;J6I8Q7/IIVM3>Y8U1.TOW!-3;K=H2I[C<J*.JXK*Z2)CD
M3:]%\7,Q]'NDJIQCB-;+?[?0=SJF-S48R/)<^9,R)U5_Q3%>5>_F<4J$!T6D
M.RP8?Q?<;;2.<Z")_BZV]$7;D<ZINTM%ZQ:/%G', !D      ""0   [C0I^
M\BU?^?\ M4]9KO4\F:%/WD6K_P _]JGK-=ZG Z4_5CW*,G>@ '-5LYG)3J)(
M9R4ZB2$@  A_(=U&"FXSG\AW48*;@@ !(H+Z1OUUPG]XSYE]Q?J8ONV_(K[2
M5HYFQG?+1<8KG'2-H'(JL='K:^2Y_@6$Q-5C&^2U&]B&,1SEE,\HA4/TB+?)
M!26'$M)&FO:ZMKIWIO5B\W]#66RX,TA:;Z:LIW-?9[91I(C=ZH]R+_E2S=)<
M=ODP+>&7B1D5*M.]45[D3-Z(N2%??1<P]W-P.^Z3Q(RJK97)FJ;7,14R7,C;
MFRB?PH^DO414M%A^IJ4S@BJFODV?PHY,RVK'5T]78*&MII&+2/IVO:_/Q43(
MJ/Z3<;)K;8HI$SCDJ&M<G2BN0QJ?0_B'N<V"RXVJ*.R5,2+Q)Z.=JM5-J(N8
MWYR;1-8W:S1ZWO@TL8TJZ-CGT4M,^))&[E=ENS.:T)Z/K'B]+W#<[A7TEPIJ
MMS$A@E1NLW;MRRVGH? 6#K;@JRMMUJ1RHJZTDK^5(Y>?,X[&6B".YWF2]87O
M$UANLBYO?%FC5_!!PG$YO%VBO 6%Z6"7$6(+O!%-(C&,?)K:R]61==CIZ>DL
M])3T3G.IHV(D:OV*J>TJJR:%ZB6^17+'.(Y<0+3Y+!$Y%1K51>=%7<7$B(B(
MB(B(B9(B$Q#&T[L:YU]-:[=45U?*D5+3M5\CUYD0H2:IQ%IIOTE-;N%H<%0R
MY/F3Q5F1-GXY[2U=*.$:S&N&W6FBNG<Y'KX[E151Z9[E1"L;7H/Q?::1*6UZ
M0I*2F1<TCA8YK<^I%(G>4UVB-UX6*R4=@M,-NM=,D%)"F2-1,L_:OM,TJG!>
MCG%MDQ!!7W?'4]SHXT5'4SD=DY5ZU+6SZ#*&,B#F_  E#GG\MW6?D^]7$L4[
MD5-B[4/@0D           ICZ3'(P;_\ 4$^:%SG$Z3\#28V2RI%71T?<ZHX=
M==BNX3:BY)T;@.AQ=8:7$V'JFU5K=:*9B*FQ-CDW*>7;_?*NPX O>!K_ *[:
MF&J;)2*Y%57,SZ>C8>N%VY=2(5GI;T5Q8^J*6IIZV*@JH6JU\CH];73\ /I6
MX?O>(-'F&8L/7IUIFCI8U>]JJFLFKNV&KPUH]QO;[U2U5QQH^JI(WHLD.L[Q
MTZ"SK#0K:[';[>Z1)%I86PJ]$R1V299F:!1N!Y$LVGN]T-<C(W3Q*YCW;UV)
ML0[W3764]%HSO;*N5(WSQ:D2._B7/F/GI&T=TV+G15=)5NMMXAR2.KCZ/;EM
M4Y"NT+WB]44L.)<8S7!S694WBKJQNZ7)S@<IB:DEG^CW@NIC8KHZ.;A9<N9N
M:GH#"5PI[UAZAK;<B+ ^-$1&KGJJG2:O#.$8+9@*FPO<WQUT$<2Q2/U<D>BJ
MNU$_$X!-#=[MLTT6%\:5%MM<CLTIE1RJWIVHH&+>G/O?TC+;);79MHH49,]%
MY.69DWC_ ,3-!GZ,GR:=S@' =OPA'/(R1U9<*AVM+5R[7N7K,>LP-+4:3X,7
M)7QMCBCX/BRL7678G/\ @!I_I)_NLJ_YF/YG5:-?J-:OY9O]I\])N%'XUPI+
M9HJME(Y\K9.%>W639S9&UPQ:W62PTEM?,DSH(DC61$R1V299Y 4SHLN#;3B#
M2%<9>13/=(NSHS/S@NSXITG1R7NMQ)44EL<]6MIJ5ZHJ9;E.^P?H[[A73$-3
M65L=93W=RJL*,RU47/8O2<MX&KS;:FH3"F,9K503+K+ B.V=B@<-CC"=!A/2
M/AJFH[E4UU3*]KYEG?K*U<_Z'<?24_8&$OYUG^#)ET)PI-;ZZ"]3R7>GE26:
MIJLWI)ES(G-SG4:3,#2XUMUGI8Z^.D=03-F<Y[%<C\N9.@#C?I(_LO"7\U&7
M(_\ T7_HI\CC=)>!I<:4MGABKXZ3B$K9%5[%=KY<R=!VCFYP<'GMU-3/\,@*
M9T!?6?&7\ROS4N@XC1[@67"5UO59+7LJDN,JR(QK%;P>U=B])VX ( @
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M\ULU^.RNUMY  5(9S.2G420SDIU$D)  !#^0[J,%-QG/Y#NHP>8(  2
M                         $
M                (        .8#F                    $
M                   ,P    #F            !F          !.9
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,.EQ]0 1,D1  !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g98130g00t16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t16.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2W\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +=\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)8*#)CA#5F*BPN$G1$5C\&2$H_$H9;-U_\0 &@$! 0$! 0$!
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MCU'I/S?0Z:^#)8W^X>UWH7)^RD-OU9?[?*DE)=ZN-R=DBDEZ0VY7&CDC@O\
M E5!T+*U</3SJ<,GV9EK&ZSM)QRLF#QM,:EMFI;>VKM52R5B\%:B^$U?.A[)
M\Z:S6=2Y@ (!X^J]04>F[//7U[T1C&KNMZW+V(>PO!/,56V]:M[^ZF6WT[U6
MDH'*SAT.?UGIX3A^ODY?A\6JUW+EM=:QN.K+G+/63.[FWOR4*<$:G4<QZ@#]
M/2E:1RUCL]$1H !H           !@R      #!D
M   P!D     !@R!@R         !@R       8,@            ,&0
M        8,@P!D     !@R         ,&3 &3!D
M   ( ,&0          , 9                        !@R     P!D
M                                              #!D       &#(
M  >WI/4]RTQ<655LG5F%\-G2UR=? MYH;55'JNRQUM([#T1$DC7I:[!2@[W8
MSJMVFM5PLE=BBJWI%(G4BKP1?[GS^.X6,M9M7S#%Z[A;P'YC>DD;7M5%:Y,H
MJ _.N#RM77)+3IRX5J],42JG'''H*1UM0ZKK)ZB3W<KU>J^E2W6VV=:?9K>'
MIT[K4^=R(4_/N?958Y+6_=VQ^  'UG0                ,&0
M       !@R     P!D     !@R 0               &#(
M          "      &#(        , 9         , 9  &#(  & !D
M, 9   PAD    !@R    &#(     @                    # &0
M    , #(     8,@ 8 &0                   , 9              8,@
M    , 9,&0         ,&0    _4;UBD;(SW3%1R>E#\CM NGLUNG??1=KJ5
M]WS*-=QSQ3@#FN3W.L^SNGS^Y*]GS*#\GGKRY+5CW>:WEN;>/V87?_@_S0J*
MG06ZV\?LPN__ "_\T*BIT'V?LK]*?Y=<?@ ,'TW1D     !@R     P!D
M       $                       !@&0                     P!DP
M9 &#(        , 9                      # &0  ,&0 ,&0      #!D
M                  8,@   !@R                  , 9
M 8!DP!D   8,@   ,&0    &#(
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M-%<B[R)T]!XY*VBT;K.P !1@R      P ,@  8,@
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MR<O?W_LF_P 3O=@'[-:#^I_^2D"[5Z:HJ]HUW;2P33O1R92-BN7H\Q/7)_\
MV:T']3_\E-+6^M-.;/[F]8+>E7>)US+N*B.1.U57U'CQ9;8^)OR1N9VS$ZM.
ME8ZFW5M*W>JJ*I@;VRQ.:G]SX1.5LC7-Z6JBH7 TQ?\ 3VTJSSKW*V5&?DY8
M9T\)JJG5^)7K:EHUNCM70PTSE6BJ7I+ G3NIO="J>_!QG4M..\:LW%M]I='3
M;5=<14+(8[,KHFLW4=W*_HQVD7<S5W:Z2*VGFEFEDS(V*-55N5X\"ZMH_5J#
MH_-_N*P:+UC'H[6]TJI:-]4DTJLW6N1N.*\>)PX7-%HO..FICZI6?.E@=(:<
MM]DT4QE!1MCG?29>Y6>&YRM7IZ\E4Z^FN%OO3JN2AJ8U9/O,62)4151>'470
MI;BV>R,N/-JUKH>>W,\>C."OFN=J$.K9:*T16V6F='6L=SCWHJ<%[$.' Y,G
M/;MO?EFDSMKU6U77$U!+!)9MV%T:L5W<S^"8Z<D1S.=)+(]_!SG*J^DN]>OU
M7J_BR^HIY8;#5:EU6ELHN$DLR[S\<&)GBJGJX'-2T6M%>735)AXU-2U%2[=I
MH)9G=D;%<O\ 8V7V>YQM5S[;6M:G2KH'(GJ+64UMTULNTPRHGB:WF\-=/NY?
M(]3PK%MHL-]O7>NLHI*>FF\".:945KE7J5.H1QV2^[8Z;K!SS/B%8NM?,?:E
MI:BJ>K*6GFG>G'=C8KE^9"Q.UW9715]K6[::ABIJF!JODB9P;*WIX><X[DT?
MKE6]G<Z\/E.T<;6^&<M?A\&N;<;134T-72JU*JDJ(%=P:DD:MWO1D^S;-='-
MWFVVN5O3E('8]1;S:$RP4-&R^ZF@2>&@XQ-5N<.5<=!SV@-K-IU/>7VF.AEH
MG*GY#>5%21/DZ#SQ]H9+4YZTWKRSSS,;58DC?$]62L=&].EKDPJ'Y+$\HO2M
MLAT\V^TU,R&L9,V-[F<-]'9Z2NW4>WAL\9Z<\-UMS0 =1,6P[9O#?G)>[VQ)
M+>QRI#"N?RCDZU\QO-FKAI-[$SJ$4PVJXSLWX;?62,7H<R%RIZCY5-'54F.Z
MZ:>#/!.=C5N?G+2ZQVGV#1$[[92TCIJJ-.,,*(UJ>95-S3EWTOM1M"K/11/G
MC;^4@E1-^)5X91?O/!]_R1'/:GX6.>?.E2H89)GI'#&^61>AC$RJ_(6AY.=M
M6CT1))4TCX*I]2]'+)&K7*B(F.GCCBI%VH; _91KNDN21K5VS>58$SAW1[E<
M]A/VSG5D>L]/]](J1]*WG71<V]R.7ACCP])SX_-.3%$TC\,_%+SN$;;2]I&J
M;'J.MHK9;-Z@B;PF= Y4Z.*YZ"OM94/JZJ:HEQORN5[L=JEB=JVU.&W2W;3;
MK9*^1\2Q<_SB(G%.G!6]$PF.P]/ 5U3<UU_VU2.ST+!7I:KU15[F+(VGE216
M(N-[!.[.4)0-8B=X*M<)CA.W\"O*!>A3OFX7'FG=X:FL3Y7:T-J6/5>GX+K#
M3OIF2Y_)O<CE3'G.+UMMAI-+7^6URVBHJ7L3QC94:B_)@W]@G[.+?Z7>L@W;
MQPV@U:IP7'5Z5/C</P]+\1;':.T.,5B9TZ':;KZIUK8(Z.FTS=*=&NYSG7,5
MS53'F0AQR*U5:Y%1R=**6XV*WME^T%2,>N_)3-[GDSTK@KEM3LRV/7%RI>",
M<_G8T3^%>@]_!Y:UM;!%=:;I/?3FJ6CJJM7)24T]0K>E(HU=CTX,U%!64SF-
MJ:2HA<_@QLD:M5WHSTEA^3':FQ:?N%SSE]3,D?T4_P#<Y;:WJ)+QM2M%#$K7
M0V^H:UKDXY<JIDZ1Q=K9IQQ':/BO-WTB66TW&*-TDMOK&1MXJ]T+D1$\ZX,0
M6NX3LWX*"KE9U.9"YR?V0N]<*"FN=H?25S4=32L1'IT<"+*S;!IW3=W99[?;
MWOHHE2.2>)41&XX='7T'#']H9,NXI3<I%YE6ZII9Z5Z-JH)8'*F4;(Q6JJ?*
M?(N!J335AVAZ;95111/?+%O4U2B8<W_\4JU[&;BFJO8\Z-.^"2\TK$7AZ<^@
M]/#\97-$[[3'EJMMO)IJ:>J>K*:&69Z?NQM5R_,AL2VFY0L5\UNK(V)TN="Y
M$3^Q:NAM&F]E^EW5T\+$?&U.=FW=Z21W8GRGDZ5VMV+5EWDM%;1.IF2^#"Z=
M45LN>&%[#A]_O;=L=-UCXISS/B%74]()IVZ[.:2Q4ZWZS-93TBO:R6!N<-5>
MM"%CVX,U<U.>K43N-AV.B-G=ZU:]CZ2)8:)V?]I>G@\#CDZR;M&;6+9I/9W;
M[?#!+572-7(Z-$W6LRJJBY7I,<3?+6O^E&YE+3.NR:M#Z4H-(V5E!;VY5<.E
ME5/"D=CI4K[RCOUWC\T2$J["M4W/5=LO%9=Y4>]M4C8T:F$8W&<$4\HW]=V?
M!'R^#K:O%3%YW+G7\W=%0':$4^Z[-B&AJYXGRT]+42Q,XN?'&KFIZ504M#5U
M:*M'2U%0B=*Q1J[U%A^3Q2QUV@[G23+B*9SHW*G3A45%/.N.TFR[/ZY;%INS
MMEAID1LDZ.3PUZ^)X)XN\WMCI7<PQS3O2!ZFDJ*1R-JZ>:!SNA)6*W/SGZI:
M&LJT5:2DJ)T3KCC5WJ+6TE/I[:OI**LJJ)(\JK=Y<(^)>O"H<5==I]DT35]Z
M-,VECXZ9.:DD3";RIYS-.-O?=:T_%'DYIGMI U51U5(J)5TT\&>CG8U;GYS\
MTU-/52<W2P2S2=.[&Q7+\R%HK@RV;4MF\E>ZF;3U6ZKF*[BZ)[5[4Z4(MY.S
M%CU]*Q5SNQN;GYS=.,FV.UIC4U^!%NR+ZFFGI9.;JH989/X9&*U?F4_,,4DT
MB1PQODD7H:QN57Y"3N45^O7_ "D.=V1\-H%K_J7U'>N:;8>KKX;:B>VW,3T-
M93/:RHI*B)[^#&R1JU7>A%Z2PFR:VR4^R*\\[0R15<D4R8=$J/=P7'!4R:7*
M,JUH;[IRJ1N]W._G=WMPJ*=[HK7$E]T/6WUU+S7<S'JD6>G=1?P/F\3GOEPU
MM$=IESFTS&U29Z.JHVM[LI9Z=7="2QJW/SDZ[&]GM%06OV5:GW-UC><BAE;X
M,;>G>7/7V'#:UUJ[:-=+-3STO<K6/W%5%SG),&VZMDL>S"*CHE:C96QT[LI^
MYA$4Z\1ER6K3'XFWE9F>T.*U?MQK4N$E-IFGABHHU5B2/XJ_SIV(>?8-N5[I
M:U%NT$592K[IK>#D\Z$1 ],<%ABO+RM<D+,;2--6;7.C6Z@LBT\52R/GN=:U
M,O3&5:XK0Y-USFKTHN#T*>^72FH74=/7U$=([W4378:OR'G*O2JEX;#;#$UF
M=Q\"L:2#L0TU'J+6D7=+=ZEI&\\],=?[O]RP,=ZHM77346FE9^1@B2)S\HN5
M7*+CT8.+V)6M-,: K[_6L2.:=KG-7/%6(G@_W(TV6:I=1[38Z^KE?'#73.;(
MU.ASGYQGY5/!FK/$7O:/]OC^6)C>W&:@MZVN^5]"K7HE/,Z--],*J(O!3S^M
M/2A,O*2L,-%>Z*[4['YKD5)7?NHJ(F"&DZ4]*'TN'R]7'%G2L[A9+;K^R>U>
MF#_%"MO462VZ_LGM/_(_Q0K;U'G^SOTI_F6<?@)IY+WZQ7CX!GK4A8FGDN_K
M%>/B[/6ITX[]"RW_ "MG:5M.U#8-7UUOH96)3QN\%')G!S";:-5(N>>AX>8_
M&V6TW&IU]<9:>WU<L:NX.9$Y47@<5'8+P][6MM5=ERX3\BXYX<."<=9F(\)$
M1I8_9-KQ=?45=;;_ $<#IV)AR?N2M5.Q2!]IUABTYK2X6^G5.91V^Q$3"-1W
M%$_N3'L+T/7Z;=57F^;M,BLPQBKT-QQ5>PB':Q>X+_KJY5E+QA1R1M=_%NIC
M/]CCPL5KQ-HQ?E_[2OGLX\R ?5=      !@R ,&0    P9, 6HY.'[.X_AY/
M6!R</V=Q_&)/6#\KQ?ZU_P"7FMY>GMX_9A=_^7_FA41.@MWMX_9A=_\ E_YH
M5$3H/K_97Z4_RZX_#( 0^FZ           $E<GS]H$7P:D:DE<GS]H$7P:GG
MXK]&W\);P]CE-?K;0?%_O(=0G'E%66Z7+5%%);[=55,:085T4:N3.2*6:2U$
M]R-;8[@JK_\ 94Y<'>L8*[E*S&FULUIUJ=<V>%%5%6=J\/,3%RI)&=Y['&B^
M&E0]<>;=/SL;V8S62J]D&I<0RPIOP1*N.;[7.^0C?;3J6+4FM*A]',Z2BIT2
M*/#LM=CI<APYHS\5$T\59_-9*.QO]B-V_JJ?\4.;Y-5ZC@NURL]1*]5JVHZ%
MB\6IC.?1TG2[&_V(W;*_O5/^*$'Z%O$ECU;;:V*5(FMG:V1R]",5WA?V,5Q]
M7K5_=(C>WM:LTH^':G/8VN=+S]2UV6IA4:_B=URB[FVCI+-INGQS4<;7O1.I
M6\$)5J=-4M?K2WZHC6%864SD<Y$3PE7W+L^@K!M+O:Z@UI7UJ.58TDYIF5X(
MC5QP+P]_O&2LS_MCZK'XD^:W_8@GQ-GJ(MY-_P"O4OQ=?62EK?\ 8@GQ-GJ(
MNY-WZ]28\F7UH<\/]-D_F4C\LI+VI[4:S1FHHK?!115$;X4EWG*J*G%>!YNC
M-N4-SNT='>Z1E)'*J-9,U<HB^<XSE+_KU3?%&^M2)4__ !3K@X+%EPQ,QWF%
MK6)A97;@NK8[))4VFM9+97JBO2!F[+&WMWDZ4*YVZG6NN%/3J]46>1&*]>/2
MO26*V"ZN34-CFT[=]V::F8J-<_CSD:\,?(1'M5TC-HW4[V1.7N2=5EIWM3&[
MQZ/D+P=NG:W#V[3'U*]NR08>3[SD3']_'>$U%QS*'DZOV*^QZP55S2\+-S"(
MY6+'C/$C)-1WM$1$O-P1$X82H=^)\ZF^7:JA=%4W2NEB=TL?.Y47Y,G:N'B(
MG<W[?PL1;W6$VQ4Z5FQ^@D21$YI(9/3PZ"M7G+):$>FO-CU59GS,=7Q-6)%5
M>+53W*D&5NC=04=P?1OM-8Z5K]Q%;$JH[CC*+V&."M&.+8[3WB2DZ[)KY,;%
M2Q721?<<YC)SNS.:/V[:[,C<ODD1O'W7!>@[C2]%%LQV75$UW<C*N9'/>UJ\
M=]R81$*_:)OCK'K"@NSORBQS9=OKC@[@JJOH...O6G+:OB>T,QWW+K>4)'S>
MT&;CG>B1Q&C(W2N2-B9>Y<(A8';OI&;4%-0ZDT] M:JQISO,^$KF=**B)TD;
M[/M 7J]ZBIV2T<U+3PO2222:-43"+T'HX;/2,$3,^&JS&DN[7XW4^P^DAEPD
MC4ID5,]:%:$)ZY2.HH60T6G:5S7*U$DE1%]RB>Y]1 I?L^LQBW/QG93PZ?9A
M^O\ 8OC+3N^4[^MUM^*_^I3A-F'Z_P!B^,M.[Y3OZW6WXK_ZE)?^KK_$D_F0
M[U  ][;M]DVM4T7?9)YXUDHZAN[-CI1$Z%0F:YVK9QKGF*R6KAAJ)EW_ ,G*
MD3W.=_$B]*D8;$=-6'55?745\A5TL;4=$J2*U7=J8/$UCH.]V'455!2VVJDI
MFO5\$L3%<B-SPXIUGS,M,>3-,1::VCZN<ZF4BZIV#<)9]-5RO;A%93S*G'_B
M(OT323T.T6STM4Q8YXJUK7-7J5%P3%R>Z74L,]=47GNSN![<-[J<N45.Q%.)
MO==37#;Q1346YS25D;%W.A7(JY,XLN3=\5IYM1Y(F?#V>5$Y5O-C:O0V!^/G
M0A:G<YE3$YCE:Y'MPJ=*<29^5!^F[+\"_P!:$+1>/C_K3UGIX+^GJM/RK#<H
M]<Z*LBKQ7?;_ (GIV^IJ+;R>HZBWKFH[ASP3.,KA?['F<HWCHJQ_UM_Q-W8Y
M<:'4VSFHTYSZ1U44*Q.:J\<+T*B=A\V(_P#QJV^$68^"M6>TDCD_ULU/M%I(
M(W8BJ&/1Z=N&K@\'4N@M06.Z34C[;53L:[#)HXU5KT\RDG; -#5E%<YK_>Z6
M6CYA%9 V9-Q>*<55%ZCZ/$YL<X+3OS#=IC3Q=L=4VV[9J.K:[FTB6"1SDX<,
M\<G1<I*C[NL%GOD"HL#5W55$Z=Y.!&NV2^4]^UU6U-'ET,6($=V[O#)-FSR-
M-;;*[935B1OYF=&O:]-[+6+P/+>)PTQ99^':6?$1+SM03LT%LOT^RB<]K'31
M32*JY7#N*^L\SE#6Z.YV?3MYAWGK)NPMQUH_"GC\I:O:M\M=MIYDYJF@\*%C
MN#>S*>A"2=GS8-8[/K(M9$W>I7-545,HBMRB*<8WBI3B)]YW_=/$;<[M-DCT
M;L<H+-21JY*E&PKO.XIG+E7YSA-B^T.ETDVHMMU8JVZI?ON>B95JJF/F/WRA
M[TVOUBENA?(D=!&D;F*O@[R\<HGRF]LAT38=8:7N+JR%4ND+U8S$F.K@N/2=
MZ4I7AN;+'YN_^6HUR]W<UVC=G.JZ^*:GJX65$B<(Z>9&;W_#VG$ZRV&5E!3S
MUEAJNZXVY>D+\-<UOIZR/:_2>H[+=)HVVZN9+!(K6S0L=A?.U4+!;$H[U;M'
MU,VIEFYI5=(Q:IZJY&]BYZ$,9.?AJQ>F3<>TI.X[Q*K3D5KE1R*CD7"HO4?D
M]+4=1%57ZX3TZ-2&2=[F;O1C)YQ]BL[C<NL+3<G+]06?"N]9%O*.<Y=<,17*
MJ) B(B]1*7)R_4%GPK_619RC/UY;\"A\;A_ZRW]W*OYI2AR<?U*?\(1CRCUS
MKEF55<0-P2=R<OU*?\(1CRCOUY;\"T8/ZVW]ROYDB<F']2J[XX[_ !0X;;BF
M]M:MK57"*L*+G^I#N>3%^I5=\<=_BA'G*$F6#:-#,SBZ.)CT]*+D8N_&7_ND
M?FE8K4\CJ72MQ?"[=<RF=NN3JX*4@5SI%<][E<YRY5RKE54N7HN[4VL=#0R;
MZ+S\*PS)G*M=C"E;M2;+M1VF]K1T]NFJH)'XBFB:KF[N>&\O4/LZ]<4WI>=2
MN.==I2'R697JR_1*Y5C18W(U>I>)YG*=IXH[_:)6)B66-=]>W"X0D;8SHY^C
M-/5,MT1D5=4+O3+O<$:F<<2%-N&JH=2:M1E&C74M'B-DK791_:,,]7C+7IX(
M[VW"SB2K#I-DB=+:-JI] I-<GNEN-6]ZJYSI7JJJOG4NK/\ J;_^R;_@A2>M
M_/:GX1WK4U]EQWN8_BL?R8XT32=?)UNJ53^R'N:_TEHF]7QM5J:M2"N2)&(W
MNE(_!ZN!P?)KU+2TLE78ZF5L<LSEEBWEPCE[$\YZ6WK9[<KW<X;W9VNJ7-BY
MJ2!K<JB)G"I\YQO68XN8M;EW\4F/Q.FT;:- Z1K)JJSW6!LTK4:Y9:M'<#@>
M4C<[9<V69]MK*>I>UST?S3T=A,<,GA:$V.7745+53W1TUH:Q=V)LL7A2+U\.
MI#E=?Z0FT==DHIZN"H5R(Y%8OA(B]J=1Z,.+'U]]3=H6L1ORY<Z+9S^OM@^.
M1^LYTZ+9S^OM@^.1^L^EE_3M_#I/A:+;+(Z/9Y==U?=,W5]!3I/<<"\VI[5#
M>K'66ZH5$94,5F5[>HJA4[+]40WYEL2VS.21^ZVH:U5C1,]*NZCY7V;EI6EJ
MVG3GCF(A8_8Y*^?9O95E=O.2'=RO'K4XG9G#&W;9K-(U3=8G@^?BA(%AI(-#
MZ#@IZRIC5E#3KORO5&HYR97_ -BOVSG6[*;:C476L1L-/<GJR3CP;GH^X\^*
MDY>K:GB?_;,1O;M^5#4S,H+/ R1S8GN<KFHO!WI*]<4XM545.M.HMKMFT9+K
M+3L:VYS5KJ5=^%J]#T7I3/H($TWLPU)=+OW//;)Z>"&1J3/F:K$5N>.ZO7P/
M;P&?'7!J9UINDQI9W0Z]UZ)M?="[^_3-1V>OA@@'8PQD>V:J9'[AKJAK?1E2
M==2WBWZ%TAESF(V"+FX(E=A7KC@B$ [!ZGNG:HE2]$8Z9LK\9ZUXX/)PT3./
M+?X2S7Q,I)Y37ZFT7QG[CG.2_1M6JNM9A-]&\WG'''!3M.4!9;A>M(P1VNFD
MJ98IT>YD:9=C'81?L4NTFC==36F^J^E2H8D:L?PW9%PJ9^0WA_'P<UKY(_*F
M;:-IO2M]EIG:JJN8=&F(_P OS>4R<[I[2>SBPWBFN=ONC$JJ==YBOK$<B=7%
M#:VX:(J=5VNGJK7A]73(N(_XV])#^A-DMYU%4U++FRHM,,*<'S1+X:YZ$0Q@
MK6<.YR3$>Q$=O*2=O]VL=VT4B4M?25-5%*CHVQR(Y4SP53M]D7Z@VKX)/45M
MVF[/Y]#SPI)6Q5<$W!JIP>BXZV]A9+9'^H-J^#3U$XBE:</6*3N-DQJJM&UU
MSG:_NV\Y7*DBIQ)RY.'ZAI\,[UD&;6_U^N_PJDY\G#]1$^&?ZSU<9_2U_LU;
M\J+^4:QK=<M<UJ(YT*;RIUDR[!_V;6WT.]9#G*._7>/X!"8=@SFKLWMJ(Y%5
M,Y1%Z.)QXG^CHS;\L*\[7L^V1?/A4]2''DE[8-*WE-:7RY+0S+0927NA&KN8
MPB=)&A]7AK1..NO:'6OANV+]-VWXU%_DA=35_P"JUT^+O]12NQ?INW?&8_\
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MK5MWN5=%S==<*NIC1<HV65SDSVX53MCP\1%HFU]Q_"Q%OC+24 P>UMD
M  &#(  P9, 6HY.'[.X_C$GK Y.'[.X_C$GK!^5XO]:_\O-;R]/;Q^S"[_\
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M0DN\[5ZFYZ-]C[[9$R/F4BYW?7/!,9P<WL]U;)HV].N,-*RI<L:Q[CEQ\IS
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MXO,=X3ECRFJAV]UM+1P4Z66%R11MCSSJ\<)C[C[IR@ZW^20_6J0<#A]PP?\
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M4MBU/66Z@F6:GA=AKU7.?E)&:LWG'\83??3P0@!U5A$3L0R
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M'#Q-,TZHD6B6@ #T*        !.  !<+U!.'4@  !  X=@          P9
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M1O@<J-2)<)T&\N6N*O-;P3.D6@VKK3-I+E54T:JK(I',15Z51%P:ITB=QM0
M%      ,&3 %J.3A^SN/XQ)ZP.3A^SN/XQ)ZP?E>+_6O_+S6\O3V\?LPN_\
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MW_GLFHF>S')H7>M5Z7M<J_V0A'5/ZQ7'X9WK4F[DRIBSWCH]TJ?V0A+52?\
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MU_T_B1ILI_:#9?AON),Y3Z8EM78J?B1GLHX[0;-\,>'AOZ3^TLU_*DWE1?\
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MC-RDKJJ!O\,4KFI_933,H28B?(V*NNJZQ6K654]0K>A99%?CYS7SPX@"(B/
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M<JJ]:]I@#4#:J;C754+8JNMJ9XF^Y9)*KFIZ$4U08$1$>!MTMRKZ1N[2UU5
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M9A=_^7_FA41.@MWMX_9A=_\ E_YH5$3H/K_97Z4_RZX_#(,&3Z;H
M                             !@R !@R  0         #!D
M        #!D  8,@ 8,@
M         #!D  8 R      P9               ,&0      #!D #!D
M                ,&0                !@R8 &0                8
MR                                8,@  8 M1R</V=Q_&)/6!R</V=Q
M_&)/6#\KQ?ZU_P"7FMY>GMX_9A=_^7_FA41.@MWMX_9A=_\ E_YH5$3H/K_9
M7Z4_RZX_#( /IN@      P9                            #!D 8,@
M                 ,&0               8,@   !@R  ,&0
M      !@#(,&0       8 R          !@R             & ,@     '4
M  ,&0            & ,@             !@#(               '4
M           #!D   !@R     P9       !@#(   & ,@& ,H  !@R ,&0
M          P#)@"U')P_9W'\8D]8')P_9W'\8D]8/RO%_K7_ )>:WEZ>WC]F
M%W_X/\T*B]2%Y-4V2BU#9*BVW1CGTDV-]K7;JKA<IQ.!38QHSR6L^O4]G!<9
MCP4FMM^6Z7BOE5D%IO:8T9Y+6?:%'M,:,\EK/M"GL]4P^TM=2%606F]IC1GD
MM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5
MD%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TSHSR6L^T*
M/5,/[G4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>T
MQHSR6L^T*/5,/[G4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#^YU(59!:;VF-&
M>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2
M%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[
M0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4
M>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:
M8T9Y+6?:%'M,:,\EK/M"CU3#^YU(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^T
MG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#^YU(59!:;VF-&>2UGVA1[3&C/):
MS[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]
MH4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%I
MO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,
M/M)U(59!:;VF-&>2UGVA1[3.C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,
M\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2
MUGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%6
M06F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H
M]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>T
MQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T
M9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U
M(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/
MM"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA
M1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]
MIC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^
MTG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR
M6L^T*/5,/M)U(59!:;VF=&>2UGVA1[3&C/):S[0H]4P_N=2%606F]IC1GDM9
M]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%
MIO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IG1GDM9]H4>TQHSR6L^T*/5
M,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:
M,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF=&>
M2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%
M606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0
MH]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>
MTQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8
MT9Y+6?:%'M,Z,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)
MU(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK
M/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGV
MA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F
M]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P
M^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHS
MR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+
M6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59
M!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"C
MU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3
M&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1
MGDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4
MA5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^
MT*/5,/[G4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4
M>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:
M8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M
M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\E
MK/M"CU3#[2=2%606F]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UG
MVA1[3&C/):S[0H]4P^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606
MF]IC1GDM9]H4>TQHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):S[0H]4
MP^TG4A5D%IO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1GDM9]H4>TQH
MSR6L^T*/5,/M)U(58,EIO:8T9Y+6?:%'M,:,\EK/M"CU3#[2=2%606F]IC1G
MDM9]H4>TSHSR6L^T*/5,/M)U(59!:;VF-&>2UGVA1[3&C/):O[0X>J8?:3J0
MSR</V=Q_&)/6#M]'Z=MVF+0EOM#)&4R.5^'O5RY5>T'Q,]XR9+6CXN4SN7L3
M>*<:?:;D_BG&F<X9      (  "             '4          ,F
M     !            "       9        0  $
M          !DP                       @             @      @
M  9,       &3  #J                       ,F     (9,
M                                                9,    !DP
M   #:IO%(!3>*!%?J;Q3C3[3<F\4XTP@ "@
M
M         (                             )T*        @  )Z
M    GG                    @
M            @ 0
M         VJ;Q0%-XH$5^IO%.-/M-R;Q3C3[2P@
M                    .H            "             "
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MGR( #"                                       $
M            (                                   0    0 #:IO%
M 4WB@17ZF\4XTS<F\4XTQ"  *                "
M
M             :]RJ>X[=5521ND6&-9$8WI=A.@V!C*87BGG$"#JS;9<%IYV
MLTS41NW51KUSX/G4@"KG?554T\JJLDKU>JKVJN2\\]OHYX98Y*:'=D:K7+N)
MUE/MH^D:W2FH*B&>)_<LCE?#+N^"J*O1D^QP.7',S6M=2Z5F/@Y1.!LVJMEM
MUQIZRG54EA>CVX-8[C9/HVJU3J*G587I;X7<Y+*K?!5$ZLGOO:*5F;>%2E2;
M;*Y[X(W:8J?"W6JY,_.3-22\_2Q3;JLWVH[=7I3*'Y91TK$:C*:%-Q$1%1B9
M/OYNH_.Y;TM^2NG.9CX!XFN/U.O'Q9_J/;/$USPT=>?BS_48Q_F@CRASDN?G
M>H/Z6>M2?NT@'DN<:O4'H9ZU)_PN5/1QOZTK;R\/7"-71MYWT\'N9V2%N3$K
MDO=W1ON-U/6=[MSU/3671M70I,WNVM;S;8T=X2)UJ>'R:+'+1V*MN=0Q4[K<
MWFE5,9:G2=,?X>%O,_%8[5<=J-<<H=JY_P#F6_XFSK1CM$[;*&YL3=IZEZ2K
MV>$N%-;4G_6&3XRW_$[GE'6-:S3$-V@:O/4+D5SD3CNJIZ>>(OCK/BU=*[_5
M]ZBM.D*^YN<B-2!58OG5O A;9E:)$V>ZFU!5)F>M:^-'+UHG6>?K+6"WS9OI
MBS4TF_63.2&H1%X]B$MU]G;8MDLEN:B(L5*J.\[N/$XQ6<%.6?-I^D$=G#\E
MO\RO/];3B=LDM1!M;DFHF[U5&^-T28SEW4=MR6_S*]?UM.6VC_MSI?C,/K0[
MT[<5?^/_ $?%Z<NN]J+&.>^VLPB97%.J_><[+M$UKJ>I[S-GA@GG7F\-3FE]
M&54M6JKYOF(2V\Z"8^E]DECB6&IITS.R%N,IGW7#K./#Y\5[<LTB")B7J;(]
ME\FF:E]VO<B2W)Z>"Q%RC.M5SUJ2177RUV^?F:^X4]/*O'<D>B+@CC83KQVH
M+:ZT727-PI&HC'/=X4C?Q-K:+LJ365]2XK=5I,1I'S>YGHZSCDB;9IC/.DGS
MW=HFJ;"JHB7>CRO1^4(-Y0DB2ZYLBM<CHG(Q6JG0J90]>+D_-9(QWL@SNN1?
M%=GRGG<H:U/M;]-U29D9"WFM_'3NX_ [<-7%7-'3MO>RNH3Y;$1+=3(G0C$(
M^Y0R(NSB?/2DS,?.=II"MCN6F+;50N1[9(4551<\2-^4G<HX-)P6]7ISU1(C
MT;GCA%/-P]9Z\1^Z1Y>!97N_T[3^F1/DRIT')H1$T=4*G2LJY/I9;!+[0DM(
MK%29U*^9K<<5RF4/*Y,5P8MLN=M>Y$GC?OHU5XX]!ZLD\V+)K_DU/B4V2^(E
M_H7U%<-C'@[6;LC.C+_\RPUXJX[?::RKG<C8XHG*JJOF(#Y/%,ZOUM>[FK56
M)&NP['#*N53CPW;#DF4KXE896MW]Y6M5R="JF<$,<J#]7K5Q_P"U<300ORG_
M -7K5\*XY\'^M5*^4@[,/V?6/XLTZ<YC9?\ L_L?Q9ITYQR_GM_*3Y  80
M                                                      0   $
M                                            @" ;5-XH"F\4"*_4
MWBG&F;DWBG&GVEA (
M                                0          $
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MX[Q>/@D3IS^S^CGM^B[125;-R>*G:U[>Q3WQUJ#-K<TS,_%)  0
M
M                                    @ &U3>* IO% BOU-XIQIFY-X
MIQIA  %
M
M      'I5$3S@ ,L]\C^D@RSWR/Z2  91,^YP[SIQ,     ,H!@'YYV'..?A
MSV;Z9/TGF  !   0      !                            3S  '.8Q/
MRDC&?U.1##'QO\7+$]>QKT50,@+P544(  X=:HB=JJ$5%3P7-<GF7(  91/=
M.:WTK@ !\J+Z   &6>^1_30 !EGOD?TD,IQSNJCOZ5R!@           !EO1
MO-SV93(    $5%]RYJ^A<@
M              0 #:IO% 4WB@17ZF\4[T&F;DWBG&F(0 !0
M
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M;=KS!)/1Y\-JY<UOI[ JTH.)V3;0*/:!I]:V!B05<*HR>#>SNKCI.V0J
M                                             0 #:IO% 4WB@17Z
MF\4XTS<F\4XTP@ "@
M
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M%5^5Q_<M&(0 !0                                           (
M " ;5-XL"F\6"*_4WBG&F;DWBG>@TP@ "@
M
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M\^;BI8\>D@\C2FG+;I>S0VRST[8:>-.*HG%Z]JGK@%
M                        (        !M4WB@*;Q0(K]3>*<:?:;DWBG&F
M6$
M                                           !
M                  @
M           G0               $
M                               @ &U3>* IO% BOU-XIQIFY-XIQIA
M %
M                                                        (
M
M
M                           ;5-XH"F\4"*_4WBG&GVFY-XIQIA  %
M
M                                                 !
M
M                                             0
M                      @&U3>* IO% BOU-XIQIFY-XIQI]H0 !0
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M-+-@^=/-%401ST[VR0R-1S7MXHJ'T*                            !
M               @
M
M                                                   #;IO% Q3>
M*!%?J;Q3C3-R;Q3C3"  *
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MG*+T;[W7_5*=ML[V@V?7L-7)9$F1*941_.)@#KP 4
M           (   0           @                       ''L  (
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M=88:ICV-K$3$T2=*+CBICB>$G#'-$[@FKJ@ >-D
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M>QQVO5]%5/JJ9-ULK$1,M3J5.TY+7NKKOMKU106FQ4<T5LCEQ&UR=&>"N<J
M2WR2Z%U-LYEJ'HJ+-4.5,ITH2K=M-66\5"5%TMM/53(FZCY&HJX/EHC3T.EM
M+4%GI\*E-&C7.3]YW6>V5')W/0^EV6NL>RQT2.;"Y45(TX<%(IY*,;(ZK5[(
MVHUC:C"(G4F2>+M^B:[X%WJ()Y*OY[K'XS]Y%6  !4         @
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M*=?G.7&\36*3CCO,DRE\! ?&<P           @
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M!/)5_/=8_&?O)VNWZ(KO@7>H@GDJ_GNL?C/WD%@3 !0
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M)]-*]=YRTZ[N5)% '':/V:Z9TE(DUJH6K4IP2:7"N0[)5R8
M                                                   0       (
M !M4WB@*;Q0(K]3>*<:?:;DWBG&GVA  %
M           [3G-2/TO8**6XWRFHH8NE7/8F\]?-VG1JJ-:YSO<M17+Z$*?:
MD2\;:-K4MLIYE9;J9RL16KX,;$5?"QVD(2#<=N>SJ"=S*6RNG:U<;W<Z)D]+
M3FV+9M=JEE/-;VTDK^"++ B-^?)Z5FY/NB:&E:RLAJ:N;"(Z19,(J]?#!X>M
MN3E8*RW32:8DJ*6M:F\V-[]YK_,%33;**UM8VKM5/3-;(F6RPITIZ3?*W<EO
M5-?2W>OT9>'.5\;G+$CU558K>E/1P+(E0                  &K=OT17?
MN]1!/)5_/=8_&?O)VNWZ(KO@7>H@GDJ_GNL?C/WD%@3 !0
M                                   .7U]K*@TE9IYYIXUKMS,$#NEZ
M]7#L-5K-YY:^5B-O>K[E16YF_7U4-.WI3G'(F35M^HK/<9.;HKE2RR?PM>F2
MF>H]07#45QFJ[E4/D<]RJC,^"WS(AYM/-+32I)3R.BD3H<Q<*?3K]FQKO;NU
MRPOEU@AW8IM+9=:-;5J&JC97QJC('OX+*F.CTDN5=5!14SZBKF9# Q,J]ZX1
M$/G9<5L5N6S,QI]C5N5QH[73.J+C4QT\2<=Y[L9(GU5M@?+5K;-#TCKC5JN.
M>W55$]':>;:MEU^U75]\==W&2-CERE-&Y%RGW':O#<L<V6>6/JL5UY>EJ+;3
M"^=]%I&@GKJM55B2;G!%[<=9Y,.B==ZV1*C4UU[BHI.*PMX93LW4Z"7M-Z6M
M&G*9D%JHV1[J>,<F7K\I[2].>OM+]XKC[8:Z_>>\KS1'APVFMEFE[$C7LHDJ
M:A.*OG57<?,AV\,;((DB@8V.-J81K4PB'Z!YKY+7G=IVSN9,<57K" &4
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M%C7>E$-H\+0UTN=YTQ25U]H>X+A*BK)3_P /$]TJ             !\X
M            0
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M43>=7?;T87.%^4M:O2I'^Q[9O2[/K$^#>;/<9UWIYD]2>8[\J
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M,[RGY 'ZWE[1O+VGY &555Z3                           !
M                $
M          @" ;5-XH"F\4"*_4WBG>@TS<F\4XT^T(  H
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MS]Y.UV_1%=\"[U$$\E7\]UC\9^\@L"I@R8*
M                       '6>3J?4-NTU;)*ZZSI%&U/!;^\]>Q$-#76LK=
MH^UNJ:][7SNX10-<F\]?P(HTYIF^;3KNR^ZK?)3V>-V8J5R*B/3I1$3L/1BP
MQ:.?).J_^?X:B/C+XOFU+M@NKHXD?0::B?Q7HWD^]29='Z5MFD[:E):H43/N
MY7)ESU\ZGJ6VAI;;1QTE!"R"GC:C6L8F$X&R3+GF\<E8U7V)D]( .#(
M           ?F61D$+YIWI'%&F\][N"-0^==5T]!22U5;/'!31IO/DD7"(GR
ME;]6:PU!M?OJZ;T2R:EL;7;E16-5</3/%55.K@0>MM%VL7'45T=I79I&ZIJ'
MNYN>L:G1U+A>PZC9-L>H])O2ZWR3OC?Y$57ODPYK%7L.GV;;/[3H6TMIZ&)D
ME<Y$Y^K5J;\CO2=CZ>(&555, %                      0
M
M                     @&U3>* IO% BOU-XIWH-,W)O%.-,0@ "@
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MN>E5)^Z3AM$;4]-ZTN;K?8ZB22I1N]A\:M3'RG<]94
M!JW;]$5WP+O403R5?SW6/QG[R=KM^B*[X%WJ()Y*OY[K'XS]Y!8$P%!0
M                                         #E-H>MJ'1MJ=-4+SE9(
MBI!"G%7+V^@^FT#6-#HZSNJJIR.JG)^0AZWK^!&>S_2%QUK?EU9K%KN8<Y'T
MU.ON7)GAP[#TX<,3'4R?E_\ +41\9?G0NC+CKB[^RC6N74SEWJ>F=PSV<.PG
M2-C(HFQQM1D;4PUK>"(@:UK&(QC4:UJ81$Z$,G/+FG+.Y[1\(]DF=@ .2
M         #I1R=J8 *YJ=+VHOG4QO,]\9\Y!%]V,:KN%YK*JGUE-'%-(KV,5
M5\%%7H(UVJ:2U%H"@I9Y=9/JY9YDB6%DBHYGG5""X.^S^-GSGPN%=2VZAGK:
MR=D=-"U7/>J]"(5NH-D^H*JQMNJ[0-VD2-)9'[[E2-,9PO$X'2E@U+KK4M3I
M^BO576V*&5$J*E7*C5:B]*9^4#N;]>K]MQU.^RZ<<^CTO3N1997)A'XZ<K]Q
M8#1.D[7HVR1VVS0-C8B9D?UO=UJJG[T;IBW:1L4-JM$>Y#'Q<Y?=/7M53VP
M *
M                                     $                    $
M0#:IO% 4WB@17ZF\4[T&F;DWBG&F$  4
M       /(U7I^CU18JFTW/?[EG3==N+A3UP!QNSW9S9=!LJF61952H3#UD=D
MY>Y; -(7*X5%9/W7SL[E>[#\)E26T3*].$[2LVVC:Y>JS4C]*Z(61KD7FY7Q
MMR][NM$["#JI]@NSRG>K*BN?$[L?.B*?6GY/F@ZE,TM1/,WMCF12+*+8EM(O
M$*5=;7MC=(F]B6H7>X^;J-2[Z)VH;.6]\X*R62&+CF"59$1.GBWL"K$:"V3Z
M>T1=G7&S<_W0YJM_*.RF#OR+=A6T]NOK5+!<&I'>*;"2(B(B2)VH2D5
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M;.FS>7GL\WW0NYGLX@32@ *@
M
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MZ(KO@7>H@GDJ_GNL?C/WD%@  4
M       JHB*KEPU$RJKU($(DVU:RFCYO2NGU?)=*S#9%B7BQ%7HX'3%BG+;E
MA8C;G];W>MVEZOBTS8=[O52R8J9F\$5,X55_N31IJR4>G;-!;;<S=@B3IZW+
MUJIX.R_1D&D+$UBX?<*AJ/J)53CO=GR'8G3/EB=8Z?ECZ_NLS\(.@ 'G9
M      !U       )Y@<SM&UA1Z(TO4W6L5'/:F[#%G"O>O1@"$^5Q!::N6RP
MP*LFHG.5C8HTSEB]OGR5OO6G[K8Y4BN]!/2/X821N"3+'5:SGU@[6,VE:N\/
MF<LM/SS55C./!4/:VFWG7VOJ"EIJ[1$U,ZGF25)8XU5SO,O#H(K@MGNR_4.L
M+E!'!12PT+G)SE2]-UJ-\Q>'2&GZ72^G**T4*?DJ:-&J[K<O6I EJVF;2+;;
MH*.FT"YD<3$9X+7)O83I7"$D;)=8ZLU-65L>J=..M,,346*147PE5>CB!)8
M*@
M               @
M$ 0#:IO% 4WB@17ZF\4XTS<F\4[T&GVA  %
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MLD:M1=WHRAI\DBH2J=JJ=J*U)9D>B+TIE2*L.I@ J         "
M                    !\*ZKAH**>KJGHR"%BO>Y>Q .<VCZNI]'Z>DK)%W
MJJ3P((TZ5<O6<3L4TC42RRZMU#F2XU3E="C^EK5Z_P"YS]FIZO:SKY]TJV.9
MI^@=^2;T(N.CAY^LG]C&QL:R-J-8U,-1.I#V7GH4Z<?FGS_Z;GM&F>T 'C8
M                 B97 'SJ:B&DI9JFI>D<$35>]SNI"LL:UFW+::JJLC-*
M6M^%:[@CL+YNM<'O\H#5]5>KI3:!TL_G*NH>WNI[/W4[,]A+.SC2%)HG2U-:
M:1,R(B.F>N,N?CB0=#14\-#1PTM*Q&00L2-C4ZD3@?;)@%&44953
M                                                   (
M       $     @                                          !  -
MJF\4!3>*!%?J;Q3C3[3<F\4XTRP@
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M(U*C"(GI)WNWZ)KO@7>H@GDJ_GNL?C/WD58 &3!4
M                 #CU$)[9=1U%^O%)HS3SGODDDQ5/C7*)YE]&>)(&TW5<
M>DM+5-8CD[L>FY SK5W:<GL-TG-3P3ZGO*\Y<;E^48KNEK57.?E/7@B,=9S6
M^'C^6J]N\N^T=IZFTOI^FME(U,1IE[T3W3EZ5/:0 \LVFT[GRR  @
M        ZE '%;6];T^A]*3UCU1U=,U8Z:+>PJOQTG8U-1%2T\U14O1D,+5>
M]R]2)TE:*".?;3M<EJ9]Y=-V>3P&N3".POF[< =;R=-$3TU//J_4,:ON]Q5S
MH^=;ES&+U\>TFX_,<;(HVQ1-1D3$W6M3H1$/T
M                @                                    $
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MB">2K^>ZQ^,_>3M=OT17? N]1!/)5_/=8_&?O(+ *#)@H
M         (          !^99&11/EE<C8V(KG*O4B'Z(GV[:JEI*&#3MH>JW
M&N<B/YM>+6+Z.TZ8L4Y;Q2%B-RY:G27:OM-2=Z.]C]N7=RG!%QT?.3_%&R&)
MD4+4;&Q$:U$ZD0YC9KI6+26F(:)J-6ID_*3OQQ5R]1U)TXC+%[<M?RQX6T@
M/.R                ($!X>M=2T>DM-U=WKY&M9$W#&N7&\Y>A (HY1NKZE
MW<NA[ Y'W&YJB3*WI:BKT?*2/LMTA!HK2-';8D3NE6(^H?UJ]>*D3\GO3=3J
M._5^OM11.=/+(J4C94SA/-GJXEA%XD  %            $
M                                            (  "
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M                  ! @
M
M;5-XH"F\4"*_4WBG&F;DWBG&F$  4
M  @ ! #YSS14\2R3R-CC3I<Y<(@'[=E&/5%PJ-54])1G:A)J*^ZPK9:V2:1U
M/*K8GMB<BM;U85$+K]_+5C](TOUK?Q/BMPL"JJNGMJJO2JJS*D%):*^:ZHH6
MQ4]VN+6-3")X:_<;'LIV@?SBX_,[\"Z/=^G_ '^V?^0=WZ?]_MG_ ) J!.3E
M>M47'64L5^N%544R1JNY*BXSCSEDC0H*FUS2[M!)1NDZ^9W=['R&^$  4
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MS=KM^5<]WND:JYP2\0  4
M                                    "
M                                &U3>* IO% BOU-XIWH-,W)O%.-/M
M$(  H                                   <IM2T]5ZHT5<+3;Y$CJ9
MV;K7*N$.K"?W J$G)QU=Y= G_&H_TXZN\O@^FI;[)C)!4+_3CJ[R^#Z:_B/]
M.6K_ "^#Z:EOLJ./:! ^PW9-?=#ZJ=<KO4QRP+&K=UKE7BJ$[]IG)@H
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M.I$X'Z *
M   @                          !                          "
M                      ! -JF\4!3>*!%?J;Q3C3-R;Q3C3"  *
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MA=WJ+,KV)T(F$]!P>Q71Z:-T+24DS42NF3G:A>M57H.[(  *
M                                             "
M
M$ 0#:IO% 4WB@17ZF\4XT^TW)O%.-00C  *
M            #\5#E;2U#F^Z;$Y4]."H6Q'35'K+:Q=I]0-2H;2O=,L4G'?7
M*IQ0N N-UV\F6X7*>8IQJ'5-#L^VNSWG2DW/TKWKW33.X<>M"$+8LTQI]C=U
MEBMJ-1,(G<[3/L:L/\CMOV=I$]!RE-(2T[75=-7Q38\)K8T5,^;B;'^H[1/\
M%Q^K3\0)8HK1:Z&19*&VTE-(O#?BB1J_.AN^LX#0.UG3NN+LZW65M6E0UJO_
M "K$1,'?E                   :MV_1%=\"[U$$\E7\]UC\9^\G:[?HBN^
M!=ZB">2K^>ZQ^,_>06  !0      @"                     ")GAT <=M
M7U.S3&D*N=%_VJ=.:A:BX7*\,GB;"-,OM&G9+G6L_P!NN2I*Y7)Q1.KC\IQ]
M^DDVD[6*:V0JJVFVKX>>A<*N?43S!$R"".&)$;'&U&-1.I$/7D_T<48_C/>?
M^FY[1I^_E !Y&        #M      #*)E> 'CZR_4Z^_$Y/\5(DY)'ZCU?PS
MO6='M:VHZ9T]:+G::FJ=/73P/A2.!$=NN5%3PN/ B?DV[3=.Z9L\MGO,LL%1
M-*KFR*G@85>M2*M'//'34TM14/:R&)JO<YRX1$0K;HFGFVK;9:Z_5J.[SV>7
M_9VKQ;E%X)_8Z_E':T91Z.@L]FJ$EK;PB-8L:YS&J\3L=CFDHM(:(H:5K$2K
MGC;+4/ZW.5,\?G".W7BO!$1.PP 4
M$
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MUS\<-Y4X)DN%TJOI"  *
M                 0
M                           0       !  -JF\4!3>*!%?J;Q3O0:9N3
M>*<:80 !0                                     ?BISW'4XZ>:?CT
MX4JYR8F4\FU"_OKD1:]N\L6]TYRN<?(6G3ATIE.LJEM@T3?]!ZX]F&DV2NI7
MOYU7,X[CE7BBHG40A:WKX])EN%7#T16+[I%Z,><J]:N4[5PTS8[S9FR5#4PY
M8O!15^4\G5G*"U!J2CDMNG+:E,DZ;JN:U728\V -K8^D47*.KV6O\T59][=Z
M.LM8O20AR;MFU9IBDJ+[?V.CNE6N8V.7*M:O6OG7)-P  %   #F=IMR2U:!O
ME2JX7N9[$7SJBG3$4\I>6K]K6>EH()9GU#T1R1M551/D CGDBVJG<EZN]R;!
MN*B,8Z;&,YX])8JG2R5#MVG[VRNZ-UNXJJ5$V8[+-8ZMLG-=U2VJR[ZJG.+N
M[[L\>'2;^LMBFJ=$43[S9+F^L93IOO6%RHYB=I%6Z@I8('+S$$<2NZ=QJ-R5
M3Y4]XJ+QKN@T["]>9@W45G5OKU_,I(G)QVH5&KJ>2R7Q6K<Z1B+&_KD:G;YR
M)]I2]T<I9S).+>Z8TQ_P@6IT3IZBTQIJAMUOA9&QD35<J)Q<JHF<D-<K#2=)
M-I^DU!20LBK:=ZI+(U,;S>HG]J88Q.I&HG]B-^43&U^R:\JJ>Y:BH$8Y.^H)
M=0;,J%]0]7S4JK YR]*X4DH@;D@R.71=?&J^"E0Y21-:;3],:-NK;=?JQT-4
MYB2;K8U=X*]'04=7=OT17? N]1!/)5_/=8_&?O.FKMO&A)K?5Q-N4F^^)S6_
MD7=*H<KR3)F5,NK)HES').CVKCJ52"P@,F"@
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ME'06CK7HFQ,MMGBPW@LLJ\72.[5.C *@
M                       Z@
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MW6HG4F2>;M^B*[X%WJ()Y*OY[K'XS]Y!8  %
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MZ]>\K5X+\YSW)(_4BL^&=ZR*G( %0
M                                   #J
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M(Z5R<6Y3I7[B>8HF0PLBB:C8V-1J(G0F#UY/]'#&/XV[S_TWXA^@ >1@ Z@
M              !U ?B:6.G@EGG<C8HFJ]ZKU(G25LT=%-M7VTU%_J45UEM+
MMR+L=A5P=QRD=82V'2T5HMKE[YW21(FHU?":U?Q.DV+:/;HS0])1N3_:Y\3S
MN5,.WE3H4@Z/6?ZG7WL[BD_Q(DY)'ZCU?PSO62WK+]3K[\3D_P 5(DY)'ZCU
M?PSO6%3D "H
M                                     "                (
M                              0#:IO% 4WB@17ZF\4XT^TW)O%.-,(
M H                                     "N1K7.=[EJ*Y?0A3O7NJ-
M5[3-H<]CT[43,I8WK%%&Q=U,)GPE5"X%2F:.J1.E87HGS*5CY+;8H-HVI(JC
M"5>';F>GI4A",-9Z.U9I"^6ZUW:Y.2:M5K8WLG<K455QQ7Y3U]6[*-?Z<MCJ
M^>IDJZ9J;RK33N<J)VDI<K^E6.CTW<HV^'#.[*^C&":= U;+OHBSS/Q)'/3(
MCT7CGM"H'Y)VGN?J*C4K[BDTS,PO@5V7-X=*_.65*Q['WI8.4#=K+1N_V*H6
M1ZM3H14SP+.=80 !0         0      &K=OT17? N]1!/)5_/=8_&?O)VN
MWZ(KO@7>H@GDJ_GNL?C/WD%@3!E3!0                     #D]I^I4TO
MI*KJFNQ4RM6*#SN5#K$Z>/00)K&5^T/:I26.G<K[9;7ISRMZ%PO%?N._#8XO
M?=O$=Y:K&W5;!=-/MNGY+U6IFON*J[+NE&9Z%)10^=/#'3PL@A:C8XVHUJ)V
M(?0QER3EO-Y^*3.P '-                 _,LK((9)I51(XFJ]RKV)Q4_1
M$7*1U>MCTHRST,G^\[J[F6-:OA(B]?\ <#AM(0.VK;;J^\5GY6RVM/R*+T+C
M@GRY+!WC45HLSV,NUP@I'N3P6R.PJH<ML4T@S1^A*&E<Q6UL[>=J%7IWEZC]
M[0-E]BUU6PU=X6=LT3=U%C=C*$#5NN-,3:4O,4-[HWR24DC6M1_2NZI%_)>U
M-9;1HZJANESIJ:59G*C9'87&3I/].>CNN6L^D/\ 3IH[WRL^D%2-2:STW5U+
M*>EO5)+/(NZQC7\7*>^A%%DV#:3M%UIKA3OJW34[T>Q'.X90E=$1&HB=")A"
MH                                                       0
M                 0                  .H
M                      -JF\4!3>*!%?J;Q3O0:9N3>*<:9800
M                               &4\Z93K3M*K[6M ZGT9K:75FBTJ'P
M2KSKEITXQJO2BXZBTLSMRGFD1,JR-ST^1"L>QO7NIK]M<GMM;<G/MLDLBOII
M43"(F<(B$(2!JS3USVC;$J1U<S=O:TZ3M;CBKNM/2I!>EMJVM-!V:73RT#W+
M$JM8L[';T7HX%T\;N41$1$[."'G5EDM5=.DU9;Z>:5/WG,0"O')CTG=ZO4]9
MK*^13,5=Y&+,U4617=*IDLOVF(V-B8UD;48QJ81K4PB&4XE
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MD:;O2C57I.IV-:/9HW1%'2.1.[)VI-4*G6Y2#N5Z>'1U& "@9,
M                 @  (
M
M              -JF\4!3>*!%?J;Q3C3-R;Q3C3[0@ "@
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MO*                      @
M  @
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M:B\,+ZR4]G>F8-(Z0H+13IQB9F15Z5<O%2#I%7*J8 *         0
M
M
M        !  -JF\4!3>*!%?J;Q3C3[3<F\4XT^T(  H              0
M          "        &A?+S;[%0.K;O4QTU*WID>N$0WR*>4S1SU>S"I=3M
M5R0N5\F.I )*L]VH+S1,K;35Q5=*[W,L2Y:I"NVS8ZNI;@Z_:3J(H+LQ,R0,
M<B*]4_>RG0IS&PG;!IW3>B6V:]<]%41*[#VHBM<B]!X6R;:9;;)M$OMQO%=4
MNM]1GF45RJG2O5DBN.U19-I%4ZDIKW;[K4I0K^05[%<C?.BGM1V/:IKEE/;J
MV.Y1T3$1J<ZBLC1$[2?7;>]$.]W4RN]*(H3;YHA$PVIF1.Q$0#U=CVSBEV>V
M)\&^VHN%0N]/-C'R)YCOSBM&;3M.:QN3J"RS2/J&M5RHY.I#M?-UE0
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MN];L<5/4*                               @
M                           "
M                      "               !  -JF\4!3>*!%?J;Q3C3-
MR;Q3C3"  *                 0                  ?.IIXJRFEIZF-L
ML,K5:]CDRBHI]#E-J=SN=HT1<:RQ,?)<(V9C:Q%5<^A .,NO)ZT;65,U0Q*J
MFWLJD<:IA/[$3;.=B;;KK2[4.H*2MIK7!GF)4PF]Q)9V!ZHU1J*&YNU3!-&L
M356+G&*W*_*1?J;:1M*I+_<*>AH:E:>.56L5L+E14ZN."*D?_3=H_C_M%?\
MV'^FW1_E%?\ V(F]M':GY#6_4N'MH[4_(:SZEP%@- ;([#H6[.N5HEJ7SN:K
M<2XQ@D @?85K/6E_U3)2ZHIJB*C2-5S)&K4SCSD\]I48     $ /*U5?Z+3-
MAJ[K<I$;! Q78SA7+U-0#UD:J]"*IG=<B="IZ4*GS;4]H>T&[30Z*HIJ:G:N
M6\PBY1/.O1D^=QU3M>T&K*Z_LJJFD1<KSV7,^4@MD$0X39'M%HMH5D=41,2"
MO@PE1#G.%[4\Q^]M&J*C2&A*FY43D;5*Y(XU7M*.YW7=B_,-U>Q?F*>6S:MM
M.N=+W1;Z:HJ(57&^R-513:7:-M9PO^[ZSH]Z<0TMST=*&#D]EEQNMUT715>H
M(G17%Z+SC7HJ+TG6%&K=OT17? N]1!/)5_/=8_&?O)VNWZ(KO@7>H@GDJ_GN
ML?C/WD%@  4              =8/$UGJ"FTSIZKN-4]&JQBI&W/%SL<,%K6;
M3J/)",MN=_J;E6TNC+,F_55#FNG5O4A)^CK##IK3M);*=,<VU%>O\3NM2,=A
MVGY[I75>L[VCWU-2YR0(].A.U"9SU<1,4B,-?$>?Y:MV["<  >1D
M         #G-8QSWN1K&IESEZ$0#E-J&KJ?16D:NYSO1)U3FX&KTN>O01QR:
M](3QTU9K"^-<MTN#W+%O_NL7K_N<QJBIGVQ[6X++0*Y=.VMV](].+'*G3GTE
ME:6GAI*:*FIF(R")J,8U$Z$0@^@ *
M
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MG@.!@ 9X><<#  SP\XX& !G@.!@ 9X#@8 &>'G'#L4P ,\!P, #/#SCAYS
MSP\XX& !G@.'G, #/#L' P ' SP, #/ <#  SP' P ,\!P\Y@ 9X#@8 &> X
M& !G@.!@ 9X><<#" #/#L4<.PP ,\.P<#  SP' P ,\!P, #/ <#  SP'#L,
M #/ <#  R.!@ 9X#AYS  SP' P ' SP, #/ <#  SP\X3!@ ;=-XL&*;Q0(K
M]3>*<:?:;DWBG&F(0 !0                                     9:F
M5*V[<]K5TDOKM*:*YSG_ '$LT.5>YW8F"QM2JMI*ES?=)$]4^92K?)IHZ:Y;
M5+]77%&R5L"N?%O=*+E>)!Y%!L6VC7J!*NOKIHG2)OHDLSE=Q[>)I7K0NTS9
M^U+E!55LD$2Y5T$KG<.GBG87-5555SUF%B9.QT,K$?%(FZYJ]"IV 19L&VF>
MSRS2P7)&QW:DPV1$7QB=N"4RJ>QN-EJY1-?16Q<4:K-EK>CK+6]?F P "@
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M1+R46-CJM7LC:C6-J,(B)C"9)WNWZ(KO@7>H@GDJ_GNL?C/WA5@ 9,%0
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MQ75\?!\"(N\GR&OJC;IK2WTCZ6NL2V^>I:L<;GHJ+QX<$(/7VRWZLV@:XHM
MZ;EWJ/>1:N5BY151>*+CLP3MI2Q4NFM/45IH6M;%31HQ5:F-]W6Y2..3QH)=
M.V%]ZO$>]?+@[G'/?G>8U>K^ZDN]8&3 !0      $
M
M
M    " (!M4WB@*;Q8(K]3>*<:9N3>*<:?:$  4            Z@
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MTG\8^\GT@+E6>-TG\8^\A"<;'^@K;\79ZC<-.R?H*V_%V>HW"@
M,HJIT+@_;'N5[>/6?,RCFQHLCW(UC/"<Y>A$[0*Q4E[I-/\ *%U;=+C*D5/3
MM<]57K\Q]]G-FK]K>O:G6.HT>EEIG8I(E]RJIT)@X2_V/VQ=N]UH[14HM)-4
M_E9F\4W$7B6_TY9:33UDI;5;V-93T[4:F$QGM4BO2X=70B83S& @*@
M                                                      0
M
M                             VJ;Q0%-XH$5^IO%.-,W)O%.-/M"  *
M                                    ##D:L<B/XM5JH[T8XE([_J"C
MT%M4DN^CY7/9%*[G(94Z^M/07/NUWMUH@62Z5L--&J8\-V%7Y"*X=';*=27.
M9\,M+/5S.5SLOQE?E(L/!MW*=L3H&]\;36MFQX7-[N[GYS;_ -3>E/Y9<OF;
M^)U:;$-#8X6M%SV*/:0T-_*T^<(SLXVPV37MY=;+71U<$R,5^]-C&$]!))R.
MDMG6G-)W!:ZR4?,5"M5N]GJ.N*                   U;M^B*[X%WJ()Y*
MOY[K'XS]Y.UV_1%=\"[U$$\E7\]UC\9^\"P ,F        $X955PB)QR!\ZB
M:*FIY)YWHR&-N\YSEQA" :J:LVOZX9!$DD>FZ!V']2.Q]ZF_M0U-6:ROC-':
M7WGQ[Z=TS,Z%[>/82MHO3-'I2QPVZ@3H1%D>O2]W6I[*Q]VISS^:?'[?NW'X
M8>K;Z."W44-'1L2.G@8C&-3J1#80 \?E@   @+E6>-TG\8^\GU" N59XW2?Q
MC[R$)QL?Z"MOQ=GJ-PT[)^@K;\79ZC<*          0 0CM^U]4PO@T;I=ZR
M7BX8CE='Q6-%7&/2=5MFVC4^A+$YM.YDMYJ? IX.E4S^\IS.P#9U/0/?JS5+
M%EO=8[G(FOXK&U>.?3Q((XV$6&HTSMIK+562))4PQHDCD_B7"KZRV2]*E=-)
M(O\ J@U%P7.]^!8M>E<B!@ (4
M
M             0
M&U3>* IO% BOU-XIQI]IN3>*<:94
M      \O5%WCL.G+C=9L*VEA=)A>M<+@]0CSE R.CV47W=7&]"J*!6&UVS5N
MVG5E7*RIEYI%5SGO55CA;U(B'N:PV":FTG:7W6WW)*WN=-]Z4Z.:YOG)0Y(,
M,;=!U\S6HDCJE45W7@FZXQI+;JR-R9:^%R*G;P(J%>3#M K-36NLLUYF=+64
M#6JR1ZY<YO1CY"<2I?)V_P!CVSW:EA\&)7N;A.Q'*6T+" [0        @
M $       -6[?HBN^!=ZB">2K^>ZQ^,_>3M=OT17? N]1!/)5_/=8_&?O(+
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MX3VO4MNJZ1ZLE9.S"IYUP!_1X'X@DYVGAD5,*]C78]*'[*@
M             "
M             @
M                      #:IO% 4WB@17ZF\4XTS<F\4XTP@ "@
M                      =H    1SRA?V47OX)21CF-I6FI-6Z.K[-!,D,E
M0W"/5,H@$/\ )9U+9;/H2J@NESIJ69U2KD9(_"X)@J=<Z6=2SM;?J!7+&Y$_
M*>8KXG)ANB?_ %J+ZO\ ]S/^F&Z_SN+ZO_W(KQ=B5XMU!MHN=96UL,%*Z1ZM
ME>[#5XKUEH/9WI7^?4'UA7A.3#=$_P#K47U?_N9_TQ77^=Q?5_\ N!9.TZEL
MMXJ%@M=SIJJ9$RK(GY7!ZQ"NQC8Y6Z!U*^YU5Q94L6-6;C6XZ4)JZU*@
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M=;*9^8XE7@G06HL]IM]EHFT=II(:6G;T-C:C<^<BMW@B(U.AJ(B)Z  5
M
M                                                    $
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M%C%Z2N>DO^M!J'^K\"QB]*D&  4
M
M
M@" ;5-XH"F\4"*_4WBG&GVFY-XIQI]:A  %
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M=I'C_L=P^@030#SM.WFFU!9J:YT.\E/4-WFH],*GI/1*
M
M     0                        (
M                   $ VJ;Q0%-XH$5^IO%.-/M-R;Q3C3[0@ "@
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M2QOXHWJ3T$\:8TU:-,43:6RT,5-&G2J-3>7TJ;ED_0=MZ_\ 9V>HW @ "@
M     #7KZ*EN%,ZGKH&3P.Z6/3*'CIHG3./T+2?0.@ '/^PK37\EI/HCV$Z9
M_DM)] Z  ?.F@BI8&0TT;8HF)AK6IA$0^@
M                                   @
M
M          !M4WB@*;Q0(K]3>*<:9N3>*<:80 !0
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MM5LCJ*EFB6BEWW(]JIE,^<"W%C_0=M^+L]1N$!6_E&6&FME) Z@J5DBB:Q?
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M=QQ!.H(*_P!2=@W\=[ZG=[=QQAO*3L&5S;ZG'5X#@)V!!+>4G8,+FWU*+U>
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M_P!2=@W/T?4[W9N.*)V!!*\I*P(U,6^I5>S<<%Y2=@3&+?4JG7X#@)V!!/\
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MJ'45+:*:CFCDJ%W6N<U>DF-0,
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M'WMIHVM>JKQ141?Q)B4@P "@
M               0! -JF\4!3>*!%?J;Q3C3-R;Q3C3*@
M                      $2\I^62/9C,D6</>J/QV8):.4VJ:>74^@[O;HT
MS4.A<Z+AGPD0#C^2Y3P0;+H'P(F_+(KI%3M);*J\F[:'3Z5JZK2NIG]R1.D5
M8Y)5W48_^%<EIX)H:AB.IYXIFNXHL;T=P^0@_?:8=&R:.2*5,QO:K79ZT/TJ
M;J*KE1$[5X$>[6MI-IT9I^J5*N&:YRM5D,$;T5R*J=)1 ^PQO</*$K*:D7\A
MOSIPZ,<2W2]95WDGV"JK]1W'558QR-:YS6/<BX<YW3A?E+0IUB 0
M  #*+CH, #SJZQVJO?O5ENI97_Q+&F?GP;5'1TM#%S=%30P,[(V(W/S'W
M :MV_1%=\"[U$$\E7\^UC\9^\G:[?HBN^!=ZB">2K^>ZQ^,_>06 "&>LYC:'
MK&@T1IR:Z7%R.=A4ABSA9'8Z"CD^4PB^U76?"(>[L31?:MT_PX<P5$VC;7-1
M:UYZFJINY[:YV4I8U\$W]FNVK4&D%IJ2:1:VU1>#S$B^Y;YB*O"#Q](ZBH=4
MV&ENMLD1T,[456YRK%[%/8*@        /2 !IOM5M>]7/MU(YR]*K$W*_P!C
M'>BV==NH_J6_@;H TN]%L_EM']2W\#[TU+34J*E-30PHO3S;$;GYCQ-9:RLF
MCZ)*B^5L<*N\7&KDWG^A"-H.4?I*2IYIU+5,9G'..5,$$U \K36H;7J6W-KK
M)6Q55.O!58[*M7L4]4HSDP  ,X\X1,G -VJV.37OL4IF23U>.,['(K$7L [X
M&<854,                    '5@RB97@<)M$VGV30M32TUQ1U155"HB11.
M3+$7K4#N@?.EF;44D%0Q%1DS&R-SV*F3Z                       ',Z_
MUK:]#65;C=W;R*N&0M=A[_0AOZ0O]/JC3M%>:&-\=/5,WVM?TH![&5[3"!#B
M]=[3--Z+7F[K6,?5JF4IXW)O8 [0$.6GE$:0KZML,T=11M<N.=E5,(2W;:ZE
MN=%'5V^>.HII$RR1BY10-@                 T+_=Z.Q6BIN5RE;%30-5R
MJY<9QU(!O@Y'9QKVWZ]ML];:Z>6&.)ZQJDBYSCK.N #CC&3Q-6:JL^E+>M9?
M*V.FC7W#7+X3U[$0B].4AI+NE8EI:O<SCG<I@":P>+I35-GU5;^[+'6Q5,:<
M'(UV5:O8J'M  </KK:CIK1DBPW*K;+6)C-/$Y-Y#E;+RAM(7*L9!.V>A1RXY
MR94W4 F('PH:NGKZ2*JHIF3T\K4<R1BY14/N         "   ?F61D,3Y9GM
MCB8F\Y[EPC4.%T5M1LVK]15MHM44N_3*J+,JHK7XSQ3Y@.\ -.[W2BL]!)6W
M2IBI:6/BZ21R(@&X"&*_E&:1I:M88X*FI8BXYV-4W5.ZT-M#T]K2-W>:M8M2
MU,NIW.3?0#KLF <WK36MCT=1\_>ZV.)[DRR'>3>?Z$ Z0$+4_*.TE+5)$^FJ
MHF*N.<<J8])*^GK];-16YE=9JR*JIG?O,=G"^<#T@$3*\$.#UUM7TQHV9:>O
MJFSUB>Z@A<BN;Z0.\!$%BY0>D+I6-@GYZ@1RX229>!+5+40U=/'/2S,F@D3>
M8]BY14 ^H                                             $ 0#:I
MO% 4WB@17ZF\4XTS<F\4XTP@ "@
M    A+;%L,I=654EVT^^.CNKUS(UV=R3S^DA5VG]JNC7K#3.N$,;>A8G;S5^
M="ZYG/H5/.F2"E3:_:]>$[F2INCT7P=W")G^QTFC>3[J&]US*W6-7W/!G+XW
M/59'%L<^9OS(,YZ0/.T_9:#3]J@MMH@;3TD*81J=:]JGH %
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M]U121/WG,<OC'+QQZ"9.5%5.I]E\S&KPFF:U?G-'DETK8=FD\J)X4M6Y57Y
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M]S1+AKZI[53S94"X@,O]T[TF"H                                (
M          0! -JF\4!3>*!%?J;Q3C3-R;Q3C3$(  H
M                        BS;#M<IM"RQ6VAIW5MXF3*1MZ&=F2*?;GVG[
MW/)9I.YNG'<G''IP06I!%6Q_:_2ZXG?:[A3.H;S'G\FO0_'22J4
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MUR*KW8X80K;R<K74:JVIU^I:F->YHM][E7^)W0!;5_NE/R97CE3!4
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M[0+IJBI9B*%RO:Y>MSG='S%K0  *        -#47ZNW3XN_U%7>2A^T"[?\
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M)CD5SG+GJ(%Y*5@GN>J+IJ>I8O,1N5&.7^-V5^\$+4.]TOI,&5Z3!4
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M:-C,=OVDS:L2ZN>KY'2<PK,8SU9)= &57*KZC Z@              $   (
M 0BC:GL?CU[J*GNKKH^D6%$3<1F<X)7!!\:*#N6AIJ=%WDAB;&B]N$QD^P!0
M                     <%M=V=MVAVJFHWURT?,/WT<C<Y/>T'IUNE-)V^R
M-G6H;2,W$E5,;Q[X (N"'-IFPJTZKN+[I;*E]NN+N+MQ$W7KGI\Q,8 K11\F
M^XU=3&V^:@F?2L7*)E7+CS9Z"?-':7MND;'%:[-#S<#.*N7W3U[54]L $
M             .?U]IQNK=*5UE=.M,E2W=YU$SNG0 #A-D6SYNSVSST+*Y:S
MG9%?O*W&,G=IP  X/:CLPL^T&F9W<KJ>NB14CJ(^GY>TA_\ TX7E%[E]D4O<
M&>C>7&/Z>@LX .#V7;,+/L^I7]Q*ZIKI4_*5,G3Z$[$.\ZE[.P "%]I.P6UZ
MFN<EUL]4^VUSUWGM9[A5[4[#DK?R;J^KJX_9!?YI*9B]&\KE5/EZ"RH \?2>
MG+=I:R06NSQ<W3Q(G'K<O:I[            (!\+A3)66^II5<K>>C6/>[,D
M8[*]D,>@K_5W-MT=5+/GP%8B8SG\250 [3GM=:/M6M;*ZVWF+>9G>9(WW3%\
MRG0@"L\_)ONE+-)'9]0S-I'KQ3>5O#SHAWVRS8C:-%UJ7*LG=<+FG%KWIX+%
M[40EH$&<D:;5=D5GU\Y*I\CJ*YL;NI-&G!WI0DH%%9&<F^\2N;3U6HI5H&KP
M3>54QZ";-FVSZT:"M2TMK:LD[_&U#_=/.PR8(&,HJ.3>1>"D([0]@%LU!=)+
MK8ZR2VUDCE>]C?<J[M3L)N0%%:[;R;JRKK&/U'?YY8&+[G*N5?-QZ"P.F[%0
M:<L\%LM,*14T2(B)UN\ZGIA
M          $  VJ;Q0%-XH$5^IO%.-,W)O%.-3M",  H
M                   :]PK:>W4%16ULJ14T#%?(]>I$-@BSE++5ILPK.X][
M<S^6Q_"!Q.HN4I#%72PZ<LTE7$Q<;\B=/GX'[T[RBZ"YU+*#5ME6GIYEW%7=
MRU,]J*=/R?Y='-T!;FT3J%:_<7NE)D3>WL^<T^4=)HYV@ZY)W47?7"=S)"B;
MV]GS$5G66P[3^I8&7?2$_>RMF;SL<D;EW)%7BB^;JZ#BZ76>T3914)1ZKIG7
M2T,5&ME1-Y,>9>TEGD^K5^U;:>[M[.XG-;W\'42#54\-73NAJHF31.X*V1J.
M3^X1QV@]INF]:Q-[V52Q5:]---A'_,=KVH1?[2]BH]846H;&^6AE@?O/IV+X
M#R47<54#  *                -6[?HBN^!=ZB">2K^>ZQ^,_>3M=OT17?
MN]1!/)5_/=8_&?O(+   H
M
M@                                           (
M                                    0#:IO% 4WB@17ZF\4XT^TW)O
M%.-/M$(  H   @                     @          &M<J&FN=OJ*&OA
M9-2SL5CV.3**BFR *\:@Y-L<E;+-IN^OHH7KGFG\$;YDPI]=,\G"GIZ^&HU+
M>I*^.-V]S2)EKL=2Y4L$$(/C1TT%%20TM)&V*GA:C&,:F$:B'V *"
M              -6[?HBN^!=ZB">2K^>ZQ^,_>3M=OT17? N]1!/)5_/=8_&
M?O(+  R8*
M
M
M                      0! -JF\4!3>*!%?J;Q3C3-R;Q3C3[0@ "@
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M%=\"[U$$\E7\]UC\9^\@L"8 *                       @
M                    0
M
M                                        $ VJ;Q0%-XH$5^IO%.-,
MW)O%.-/M"  *                               $
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MT@J   (
M                            $                       0
M                             '4                           "
M                    0 #:IO% 4WB@17ZF\4XTS<F\4XU"PC
M                                         RBX4KYK/D]2ZBU1<KLE
M[6%*N7G.;W$\'AC!8( 5HI>3)-!4Q3=_U=S;T?C<3J4L-SU-I_3S'U]0UE-1
M0(CY'KC*-0])"O\ RL;Q=$M=NLEKBG=#4;SJA8VJN\B="$'!;0]H&H=J^HO8
M]I&&H;;-_"-A5?#3K<Y4ZB<-C^R6VZ#HVU%0UE9>7IET[F)^3\S2LFSK5VI=
M"4\[+/9EYZ9?#F?"JN5.SH.Q]O+:$O\ ]-7ZE?P"K;X55XH1EJO;/8],ZN73
MU=352U2/:QTB8W./0IR>Q7:9JS5>K'4%^H^9I4B5^\L:MXF>4;LJJM3*S4&G
MF(ZXPIB:)%\)Z)UIYPB=F.1\;'M7+7M1R8ZT4CCE$5E/3;*;NRJ<W>G9N1M5
M>*N\Q#6D]N^H],6YMJU#:):J6G3<;(YF'83@B*>1>Z[6VW"]TM,RC?2VN)_!
MJM5K(T7K7MX!4@\CVDF9IVYU3MY('R*QN>A5)^EIJ:9V]/302N[7QHJGAZ T
MM2Z.TO26>BPJ1)F1Z?ONZU.A*C7[@H?(:7ZIOX'TA@@@14@@BBST\VQ&Y^8^
M@ (                                            0
M"#T                     'J     B           .CT  9PJYPA@
M         !
M                                 0 #:IO% 4WB@17ZF\4XTS<F\4XT
M^T(  H                                                   8<Q
MC_=Q1O7JWFHID ?GFH?>(?JT'-0^\0?5H?H 8:R-JY9%&Q>UK413*<  ->>B
MI*AV]/24\BIUNC:OW'VBCCA9NPQ1QM[&-1OJ/T
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M#">?(1:5 95,+A>E#!0                                     $
M                                         (            R8 &U3
M>+ IO% BOU-XIQIFY-XIWH-,(  H
M
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M;94?T]RL/;                             @
M                                             ( $ VJ;Q0%-XH$5
M^IO%.-/M-R;Q3C3"  *
M
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M3I*[<JS2LJ);-66^/PZ5Z-G5.G"<47YT(0L6U=YZ+U.PI3W:NJ?Z@Z#X:/\
MR4LOLNU+'JO1%LND;D65S-V5/X7(?*Z[.-+W74$=\K[>Z2YQJCFRH]43*='
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ML5U+#,Z2/?X957<,>C 6%G;;2=P6VEI$Z((T9\QL#BN57IZP5
M
M                       "  ;5-XH"F\4"*_4WBG>@TS<F\4XT^T(  H
M         $"
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MW51N>HZ?0&EZ71^EZ.TT;4S$U.=?_&_K4Z+)CT@
M
M                 !M4WB@*;Q0(K]3>*<:9N3>*<:80 !0
M                                                          @
M               !              !
M
M
M            @&U3>* IO% BOU-XIQIFY-XIQIEA               "
M
M              !                 @         !
M        @                                          !
M
M         ( @&U3>* IO% BOU-XIQIFY-XIQIA  %
M                  @
M                         (  0    "
M              !   " $ "
M
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MA0,!#.%[%,8  SA1@# ,X& , 84S@# ,HBC & 9PHP!@&<+V# & 9P, 8!G
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M@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8
M PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,
M)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=
M@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,
M)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=
M@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8
M PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,
M)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=
M@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,
M)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=
L@ #"=@PG8  PG8,)V  ,)V#"=@ #"=@PG8  PG8,)V  ,)V#"=@    ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g98130g00t17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t17.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2&"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (64
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$! 0$            '" $$!@4# @G_Q !<$  ! P(# P0+#04%!00* P$
M 0(#! 4&!Q$2(3$($T%1%!<B,U)A<9&2L>$5&#(U-U5F<W2!E*'!%B,V0G(T
M4V*RT214@I/P)3A#HB8G1$5&5F.#A/$H=<)D_\0 &@$! 0$! 0$!
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M2J]/6$7J, ^@Z,F
M
M
M        R8                               ,F
M                                 ,ZF$W+KTH !W. \R;UA>IB:M0^H
MMZ+H^!^_=XBT6#L4V_%5L2LMLFJ)N>Q>+%ZE*2^4ZC+W%]7A&]1U5.NM.YR)
M-'T.3K/GZO15RQ-J1M9SM3?LN@#4L]?#=+935M,Y'13L1[5\IMGY^8VZ2X!"
MW*3Q!)1VFCM--+LNJE5TJ([>K4Z":2J&?]8^IQ[/$YRJD#=A$ZD/;^GX^>:-
M_1O'&\HV,#H!^C>@
M
M
M
M                                     !T* !8[DU8@DJ[76VFIEVW4
MRHZ)%7>C>HFLJAR?ZQU-CV&)KE1)V["IUEKS\Y^H8XIFG;U>>\;2%.\Y7*N9
M5\U77271/,7$*=9R?*5??KOT.OZ5_+/T7%W<6 #[SN
M
M
M                   "
M
M      #M<F7*F95CT736;1?,I<0IUDU\I5B^N_12XI\']4_ECZ.&3N%.<Y/E
M+OOUWZ%QBG.<GREWWZ[]!^E?RS]#%W<8 #[SN              ,Z&     R
M@T P   ,^0 8!G0P  ,@8   !#(& 9TW#0# '09T P#)@  AE$U P
M #*)J8
M !D#          0 #.XP  0SH!@      0SHO4!@   $,HGEU P#.F\ 8
M&=#   ST 8!D: 8                 "  9T,  9T,     1
M      @ &=#  &=#                ,Z 8!E$"(!@        &=-Q@
M,F  &@                   #L\FOE*L7UWZ*7&*<Y-?*78OKOT4N,?!_5/
MY8^CAE[A3K.7Y2K[]=^A<4IUG)\I=]^N_0?I7\L_0Q=W%@ ^\[@
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M]EY.OGJF(DZPQN3:XHY=#=O$TV6L<MXMTZG6LJL@= /INH
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M@;434T>VV-==';_$/U".-Z4K'3Y>BW[[*Z6NWYF4F)6WGW,N;ZA\B/D:_P"
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M[SN         (;E);*ZKA=-24=1-$WB^.-7(GWH29B.XTP 4
M       !EJ*YR(B*JJNB(G2;E3:KA2P<]54-3#$O\[XU1OG),Q!NT@ 4
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M'>);E7HQ*B1$148FB'D@YUPTK:;Q'64BL1.X #HH
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MZKJ>+C#$M;BN\+<[FD:5"QMCTC31-$X'B YQAI6W.(ZIQC?< !T4
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M7PY0WREU7V>+U$O8@^0O_P#!;ZB(>4-\I55]GB]1+N(/D+__  6^H9/X\/\
M@](59;\% @;\% ?8=EA<@YEI\ML1S(JHK'O5%3BB[!7^H>^2>5\CG/>YRJKG
M+JJKKQU+"\GBE[-R_OU+TS2N8GE5A!6(['76*\55!7PN9-$]4U1-47IU13P:
M::^/DCUZ.=>\I*Y-=;)#BRIIFK^[GC57)KU)J:^8M'#1YWT:0-1J25<,CM.E
MRNWG0\F_#-7!4U5\K8'14^SL0N?NUW;U.-Q5>6WS.6GJ(TT9'7QPM7K1K^)S
MB8MJ;S7Y=4_J=GRHYG\[984<J,T>Y4UW*I'63UN6Y9AVEB/1G,R<\JKT[/02
M#RH_[;9?Z7$89:W1+1C6UU;T3FTE1KU5>"*:TT3Y3:ORE:_"D/E.U+GW^T4^
MV[8CA>NST:Z\2%^A2P_*,PW4W:@M]]ML3IXZ:-R2HS?HQ=^T0!1T536U,=-2
M02232KLL:UO%3IH+5G!']EI/[5E\ 2K=,E)H:Y'2L;"Z/N^E$WH<;R8$1,2X
MA1-R) U-/^-3M*M)< Y*N@JTC6N2'9YMR[E>Y>'F.*Y+KMO$-_<O\U.Q?_.>
M&.N'-:.TRY^DN'QI\K]?_P#V;?\ ,A(W*D^%9/(XCG&OROU__P#9M_S(2-RI
M/A63R./3/\N'Z?\ PUZPQR6O_B/_ .U__HBBY4K*W,"JI9N]RU[F+Y%<2OR6
MO_B/_P"U_P#Z(DO=3V'CBNJ=_P"ZKG/W<=SC6+?S&3;^Q'>5I<?80?B?"M-9
MZ>L[$A;L:KX2-3<A&:9 ]5Z9YCJ\TJ"KQAEU2UV'9I))8T9+LQOV5<FG=)Y2
MM+JBY-D6-T]:DB+LJW;=JB]1YM'3+:DQ2^W7MLE8GTE;/ .$I,+X;JK155S*
MRG=M;&N[814X$2Y#4K:/,FY4[';38VO1%\6JGTPOE7456$9+SB6]7"WNV%D9
M$V3@WHVM>E31Y.'\<5/=;7[IR;2[]1%8BF68MO\ /H;=)>/GS4NJ,PJM'INB
M383?T'&X>NUPLEUBK+/*Z*M1-ECFMVEW[M-#J\[_ )0[E_4I[?)QME)78PJ)
MJIC9'T\.U&CM.*KQT/;6\8]-%IC>-F]]JOU79=8\QI4Q7.[O@6=\:-19EV-&
MIPW(A[V$\D:VWW"BKKQ<J:-]/.V5(XU54=HNNFJH?/.W&>*;5B=U#1/DHZ%(
MT5BL;KSGCU..P##B7%N+K=*LE7/!2U#9)GJJHUK==^IYHG-;%RY16NS/79(?
M*>7_ ++MFG!9%/GR8_B2_?6I_E/IRGTTM=LZN<4_')B15LM^1/[Y/\IQC_H_
M^_-/Z$%UGQ]4?:W?YU+!YS?)+;O%L>I2 +G!+3XBJ63QN8]*MVJ.3_&6 SF^
M2:W>5GJ4]6I^/%]5GO#:RGA]P\H*FLIF(DTC7S:HNJZZ(5HJYY*FJFGG=M2R
M/5SG+TJJEA<@JZ.[X!NED?5-6L1ST;$[BUCFHB+Y-2#,38>N.'[O44%SIWLE
M8Y='(FJ/;KN<GB&DVKFR1;ONM>\NGR,K5H<PZ)VVK6R,=&[?QU.DY3=%3PXG
MHJJ-FD\\")([7CIN0TN3_AFLK\6MN;XG,H:5BZO<FFT[H1!RC+W3W+%L5+2N
M;(E)$C7/;PVEXI]PG]VLCCZ1U2?B=SG+.^+)VRLC<YJ21P([1=-4V$W%<>C<
M6)SJ^2&P_P!$'^1"NW0;_3X_XI^LKC[+&OGEJ>3A+),_:?V/IKI_B*XIP0L3
M#_W:Y/J%_P Y79. T/\ 7_\ VE:>HOP5++54[K#R?6ST;&,DDIVJ[3I5RHBJ
M5IXHJ)TEG,+1P8UR4?;(7))+%%S2L3<NVW>A-?TBDSVWC=+JR='B.AL.,[]8
M;?-06JO6"EEUVF;*+QX\>!Y-PMM9;:J2FKJ66&=BZ*QS=Z$S94Y<VN7"M5>\
M84J\R]-N-)%5NPQ.G[SMJ,N.E-[]869C9T64E4MHR:N%WBC:ZJ19I57I>J<-
M2N-94OK*NHJI/AS2+([RJNI9#)*KH+K@^\62EG;NFD2-B]#'<%(&Q?AZX6"^
MU5)7T[V*DCE8Y$W.;JNBH>?23$9LD3WW_P!)7O+V\EKG);,P;:L6B)4NYAZ_
MX5__ $=9RDH8X\<VE[&HCI*=%<O6NVJ'DY#86J;OC&&X21RQTE!^]YS9[ES]
M=S3<Y0USIKACVBBI96R+21)%+L_RNVE706F)U<<?2.J3\71(.;U7)3Y2T;(U
M5.>B8U51=-VB%;+?_;Z7ZUOK+%9T?)5;/Z&?Y4*Z6_\ M]+]:WUET$?\4_65
MQ]EFL]II&97-:UZHC^;1VG3P*T6G==*/3^];ZRRF?/R8Q>6/]"M=J^,Z3ZUO
MK)^G_P ,_63'V6$S_77+:U+Q7;C_ ,IG*:N]S,E[E6:N;S*2.U;Q0QG]\FUJ
M_KC_ ,ILY*6YEWRFJ[?)\"H=)&OWGCZ1I8W[<F/Z5;:F9:BIFG<JN=(]7JJ\
M5U4E[DR5L[<65](DB]CR4RO5G1M(J;R+;[::JT7>LH*JGDBD@D<W9<WH1=WY
M$U<F[#-5225F(JV-\5-)"L42N33;37553Q;CZ&LM7R\_W;M/[7%YH25.&LU:
MJNL\SHZM7\[&Y&Z[*JBIN0]*KP+CW':TMRNSXE<L:)&LZ[&RU=_!$/7P144>
M+L[:VX3:2P0JYU.UVFF[=P7B;V>F,,36:]Q45M<^DH%9W,C&Z\XIY_$O%JXJ
M1'+;O*;^D-"P9%7"">&HO-RI85BE:]$B551=%UZ4.DY2>B85HD:NJ;::*1)A
MEN*,98AI(F2U=0D,S99':JUK6HJ:JI+?*4;L86HFIKHC]#%HO&HQQ>V\_A.O
M*-V<AIE@RRN,K>+-MR>92NMTD66Y5<CN+I7.7[U+#9'?)7=?Z9/4I7:N_MM1
M_6IZ-+'_ #9?JU3O*RO)UMT4&!:FH@[F>JE7:<O6B:(>%6Y%/JZVHJ9;XCI)
MI'/<J[UWJ;O)SN\=PPO<++*K&2Q/7FT1='.:J;U\Y#N-K3?,.8AJZ.NEJVZR
M.=&]LCE:]JKN5-YYZ4R3J+Q6W&68B>4IKP3D^[#6)*2Z,O&VD*KM,;NVTZE\
M1XV<EL94YKX=FE1CZ:9C&.:CMZJCE]A'V6>%+MC*]=COK*Z"AC;M33I([5$Z
MDUZ3]8ZM4."<<T4%%=:BM2#8D?+,NJL77>GF-UQSXW[K[VV^2Q'7JD?E-UTD
M-ILMOA561/<Y7M3@J(B:(5[7X/460SNLM5B_!UHO%D1M5%3L6:1&<7,5$WIY
M-Y7JWVZKN-9'2T=/)+/(NRUJ-7B=OT^:QAV^7=:=EEHJV2NR)FEF^&VFV-?$
MFA5Y.!:RXV66P9,5=!4JBS,IU5_B5>@JFG S^GS$\YKVW,?JRG$L%R9?X?OW
MUJ?Y2OJ%@^3(BK8+ZB)KK,B?^4Z?J'\$_P"%OV0[8:)MQQY3TLB(K9*Y45%W
M:]V31RE:V:EPY:[?!W$$DO=HG2B(NB$&2NGM>*GS/1\$D-8KE54^#W>_\BP.
M<MGJ,:X#M=RP\K:QD"\^NQQ>S95%T\ARSS$9L5K=F9[PK1KN+(\GV9M=E_<[
M?4JLD;5>U6JO\KFJBH5Q2*57;*12;6NFFRNI9O*JV/P7EI65UY5L+IF.GV5Z
M$V>Y3RJ:_4)CPMO7>-EOV5OOU/%27JNIZ=NS#%*YC&JNNB(IHH;-UJNSKE55
M2-V4FD5^G5J:R'OKVC=N.R?^3"Y663$KT_E>Q?\ RN(-ODCYKS7R2.5SUF?J
MJKJO%2<.3+\08H_J9_D<09=OC6M^N?ZU/#I_^QD_PQ7XI67R"MC(,NY'TR[$
MU8]SG.7KTTU.:J,AWU%3-/+?$=)(]7N54WZJIZF0-QBNV!ZZS<^K*F-SFHFN
MBHBIQ0A'%=LON'KW4T-PDK&/1[E8[G'*CVZ[E1=3S8Z9)SY(K;:68WWE/& <
MJ9\(XABN5/=VR-1JMDCT^&BG <I6BBBQ;3U<3FZS4Z-<U/$J[SQLKL%W?&EQ
M?S];74ULB362=)%U5>A&ZGD9I6*GPYB62V4ERJ+A''&BNDF=JYKM^K3KBI,:
MC]U]YV^2Q'5,N86_D_V[[/3^I#DN3-00S8GK:UZ+SL$*L9XD7B=;F%_W?[=]
MGI_4APO)UO,-NQA+2U,FPVJB5K57@KN@Y4B9TV3;YRD?#*1,?Y3RXLQ+-<YK
MLD2.:C&1KOV40\*DR)DI*N&II[XULL3T>QR)P5%.<SXL-YM>*9;G%)5.MM2C
M=E['KHUW2BZ<#@\-6V^8AN\%NMTU8Z65R(KED<B,3I53>&F2<46C)TV^2Q$[
M=T^<H*WMGR_I9)I&+44LS5VD5-7;E0\WD[/6/+N_/3BV=Z_^1#BLV\!4V#K/
M1R,O=;65<[]ET$S]6Z:;U1/*=GR?/DWQ!]<__(ARM6(TG2=XW_\ E/Z5?JQ[
MI*NH?(Y7/=(Y5<J[UWJ6HR=M+8LK((J)ZQ2U;'N5ZKP5V[4JM4_VB?\ K=ZR
MRV3E;%B'+":TPSN95PL?$N_16Z\%\AZ?U&)\*-OG#5^SG5R"5SG.?>VN<Y=5
M54WJ=5EQEE48,OCJV*[-FAD8K98N".ZE^XKO?**^6*XRT-QDK8JB-=Z<X[1R
M=:'8Y68#NN,YYIJVOKZ2UQ)ISS9%VGNZFZF,N/)X<S?+^WZ,S$[=WK9MT,5+
MG%13PN14J'Q.5J<$5--3J.4K5R,P_;:5JJC)%1RZ+QT(MO%J@L>9T%MI*Z:N
MA@GC1)I5U<J]*?<23RF?BVT^0D5B,F&-]^B^L("@[]'_ %-]99+-][GY0T#G
M+JJHS7S*5L@[_'_4GK+(YN?(_;_(SU*=M7_)C^JV[P^N45+[D90UM7 UK9)F
MOEU1>*Z:%:IW*^>5[U5SG/555>*[RQV1%?[NY>7"SS/8DT2NC8W@NRJ)HJ_>
M0)B6PW"PWBHH;C3OCE8Y=%TU1R:KHJ&=).V;)6W?<IWE]L,XLO.&))WV2M6G
M=.B-?W*.U3[R6^32Q*V[WVXU6S)5ZM7G%3?J[B>3DIEY3WJ*MN&)*-RVY&?N
M5<NSO3BODT.@R<O-FH\PKW:[2QD%)4+I BNUVMCI1?&8U62MZY*TCK'>4M,3
MO$/0Q?E!/B6_U5RJ;RC5E<NRQ=^RG4:5ER0=;+K2UK+TFU ]'Z)NUT.%SDPY
M=L/XGJJJ&2K[ JWK*Q[9'*B*J[T\1S.#[5>,27^FMM--7Z2.3G'M>[N&=+MY
M*4R3BY1DZ;?(B)V[IGY3-)$ZP6^LT8LL<B1H[7?HI70DC-[!M)@^6DIH;S65
MTTR;2Q5#M=$ZR-SU:&L5PQ$3O#5.S[6_XPI/KF?YD+ <IJ>1M@LL#7.1CY%5
MR(NYV[I0@"W_ !A2_7,_S$]<ISXIL?\ 6OJ,:B/_ ",?^4M\2$,,N5,26E6J
MJ+V7$FJ+_B0G3E1U,S+79Z=KU2"65RO9T.5$W$%8:_B.U?;(O\R$W\J;^R6+
MZU_J,YX_\G'_ )+?%"%\&?Q99_M+/62URI/[9A[ZJ3UH1+@W^++1]I9ZR6N5
M)_;</?52^M#67_M4_P D_%#KLDODH?Y)/U*QU?\ :ZCZQWK4LIR?JEM=E]5T
M+%:LD+G,5$XHJZZ:E=KW;JRW7:KI:RFEBG9*NK')OWJNAC23MFRQ/S2O>4Z\
MF#XIO?\ 6WU*1%C#Y1J[[:WUH3KR>L/5UFPU65-PB6%:Q4?$UW%6Z<2"L8?*
M-7?;6^M#."T6U&28(^*4M<IGX@P]_6O^5#1Y+*IV9B%-4UV(O6IZ?*5@EEPW
M8I(XW.9&]=MR)\'5J<2,,H<4_LMB^GEJ'O915*I%,B)U[D5?(IC%2<FBFM>_
M_P!I$;UV:F:M ^W8]N\,DBR*Z7G4<O4O0<D3YGE@"JNU6F)[!M5C96-26%FF
MY$3<YOZD#O@E8Y6NBD1R;E16KJA[=+EKDQ1M/5TI.\%/!)4SLA@8KY9%1K&I
MQ53=NEEN5J1%N5'-3;6Y%D;IJ2/D=@.KNM^I[O<*66.VTZ\Y%(N[;>G#0WN4
M;B:&XWBGLE(YKFTJHZ5R=#UX)K]YF=3OFC%3K\_[)RZ[0_?)IL3ZJ]5EY>R-
M:>G;S357X2/7J^X]W-'+/$^,,4RU\+[?'2L3FX4<]4<K?'N/7M](N6^3=14P
MLC2XR1I*_5VY[W::?D0:N86)U55]U9DUWZ=1XZ1DSYK9L<QTZ=68WF=X3GDY
M@;$F#*ZJ9<IJ.6WSL^#$]55KM>/ B[/W#<=CQBM321[%+6MYU=__ (FJ[1X-
M+F)B6.J@?+=9EC;(USDZT1=Y.F<%JI\79;LNU*QKZB%C9X7(O!%TVOR&V33Y
MXODGXNG0ZUG>7$<F#XZNWU;?U.-SL^4BZ?\ #ZCLN3!\=7?ZMOZG'YU1O=F/
M=%;&]4[G>C5ZCMC_ .Y;Z$?$X0_4/?8_ZD]9GF9?[J3T5,QL<V6/;:YO=)Q3
M3I/H;NJX,UVIK)EO3U]=3I44T5.U7QZ(NJ>12/(LXL'J]J28?5K%XJD#-4.H
MQU\B<GV5A51.!\?1Z6F:+3;YN-*[KD-N+:C#C;M@>AH)Y)&;2L5$C54TUV=W
M3XBK^/,57S$=VF2^O<Q87JC:;31(O$>]DKC:3"^(64M2[6VUKFQR;2K^[77<
MJ'>\H+!"55.S$EIBVI$T2I1O2W3<Y#>&E=+GX7COVE8CC.TJ^J8,\4,=!]9U
M69R0F=3Y4U,S/A,YQ4_,K;72.EK:F1ZJKG2.555=5XJ6-R:^2&M\DOZE;ZCO
M\W]:^L^?I(_Y<OU<Z=Y6@RB>^/*%[F.5'-A?IXMRE8*MROJIW/57.<]RJJ].
M]2SN4WR/R_4/]2E8:G^T3?U+ZR:+^3)]2G>5DLLU5<EJ_557N7^I"M\4+JBK
M;!'IMRR;#=>&JKHA9#+/Y%J_^E_J0BS)/#*8BQLQ\[&R4E"[GI6JO3KW/YF<
M%XQSEO/I*5G;=/4&'+G1970V2T,I6W%T'-O5ZJC-5UVE(<AR+Q; ]DD-3;FR
M,5'-7G%W+YCUL\\=W:@Q=[F6FI['AIXVN<YG%SE3>B^0CE,P<3I_[VF,:;#J
M.'.LQ^[J5BW=9/%F&I[WEK);[RR*2XP4VTU8G+ISC6[E^\J]A"-T6+[;'(G=
MLJ$:[RZDS\G[&=;=;E<;;>JQ:B61J/A1_4FY40Y'&N'6X?SAI6T\>Q25,[)8
MTUZ5^%^8TW+#:^"_U*])F)=-RF[FYGN3;$>]$DCYY6I\%=%5-Y J*J=TG%%U
M3Q%CN4=AN:X6>CO-+ ^62C1(Y-G?LL5===/*I7RVVVKN5?#14=/+)43.1C6H
MW>NIZ-!:O@1MZ+3LL?LR7_("):V55E6FU5_3JBKHI60LMCN1,#Y,TMH?*K:N
M1B4[5XJKN*E:O+Q,Z#M>8[3,[&/U8 !]!T     ':9-?*58_KOT4N*4ZR:^4
MNQ_7?H7%/@_JG\L?1PR]PISG)\I=]^N_0N,4YSD^4N^_7?H/TK^6?H8N[C
M?>=P     .RRZQ]<<&5CUI_W]#*NLE,]R[.O6GC.-"&+TKDKQM&\$QNG_MT8
M7>]*B;#+W5:]TYVRQ>Z\NA^(,^*::GN$=?:Y])4<R%(G)HUJIIOUZ2 S.O\
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M']4_ECZ.&7N%.<Y/E+OOUWZ%QBG6<ORE7WZ[]!^E?RS]#%W<6 #[SN
M          SJO6OG,
M    &=5ZU^Y1J8
M              $,ZKUKYS
M
M                                        [3)KY2[%]=^BEQ2G637R
ME6+Z[]%+BGP?U3^6/HX9>X4ZSD^4J^_7?H7%*=9R?*7??KOT'Z5_+/T,7=Q8
M /O.X
M
M
M
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M^*OF2K]$>-C]T?<Y0Y<'4=K_ !5\R5?HCM?XJ^9*OT1XV/W1]SE#EP=1VO\
M%7S)5^B.U_BKYDJ_1'C8_='W.4.7!U':_P 5?,E7Z([7^*OF2K]$>-C]T?<Y
M0Y<'4=K_ !5\R5?HCM?XJ^9*OT1XV/W1]SE#EP=1VO\ %7S)5^B.U_BKYDJ_
M1'C8_='W.4.7!U':_P 5?,E7Z([7^*OF2K]$>-C]T?<Y0Y<'4=K_ !5\R5?H
MCM?XJ^9*OT1XV/W1]SE#EP=1VO\ %7S)5^B.U_BKYDJ_1'C8_=!RARX.H[7^
M*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'
M+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q
M^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,
ME7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1
M':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^
M*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'
M+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q
M^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,
ME7Z(\;'[H^YRARX.H[7^*?F2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1
M':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^
M*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'
M+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q
M^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,
ME7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1
M':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^
M*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'
M+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q
M^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,
ME7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1
M':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^
M*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'
M+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q
M^Z/N<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,
ME7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J>U_BKYDJ_1
M,=K_ !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT3/:_Q5\R5?HCQL?NC[G*'+ ZC
MM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N
M<H<N#J.U_BKYDJ_1':_Q5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(
M\;'[H^YRARX.H[7^*OF2K]$=K_%7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_Q
M5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\5?,E7Z(\;'[H^YRARX.I[7^*OF2
MK]$QVO\ %7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_P 5?,E7Z(\;'[H^YRAR
MX.H[7^*OF2K]$=K_ !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\ %7S)5^B/
M&Q^Z/N<H<N#J.U_BKYDJ_1':_P 5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_
M !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\ %7S)5^B/&Q^Z/N<H<N#J.U_B
MKYDJ_1':_P 5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_ !5\R5?HCQL?NC[G
M*'+@ZCM?XJ^9*OT1VO\ %7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_P 5?,E7
MZ(\;'[H^YRARX.H[7^*OF2K]$=K_ !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1
MVO\ %7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_P 5?,E7Z(\;'[H^YRARX.H[
M7^*OF2K]$=K_ !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\ %7S)5^B/&Q^Z
M/N<H<N#J.U_BKYDJ_1':_P 5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_ !5\
MR5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\ %7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ
M_1':_P 5?,E7Z(\;'[H^YRARX.H[7^*OF2K]$=K_ !5\R5?HCQL?NC[G*'+@
MZCM?XJ^9*OT1VO\ %7S)5^B/&Q^Z/N<H<N#J.U_BKYDJ_1':_P 5?,E7Z(\;
M'[H^YRARX.H[7^*OF2K]$=K_ !5\R5?HCQL?NC[G*'+@ZCM?XJ^9*OT1VO\
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MXVG>$I@$&=IWA*-IWA*8 &=IW6HVG=:F !G:=UKYQM.\)3  SM.\)1M.ZU,
M#.T[K4;3NM?.8 &=IWA*-IW6OG, #.T[PE&T[K4P"C.T[PE&T[K4P ,[3NM?
M.-IWA+YS (,[3NM1M.ZU, #.T[K4;3O"4P ,[3NM1M.ZU\Y@ 9VG>$HVG=:^
M<P"C.T[K4;3NM?.8 &=IW6HVG=:F !G:=UJ-IW6OG, @SM.\)?.-IW6ICH &
M=IW6HVG>$I@ 9VG=:C:=X2F !G:=UJ-IW6OG, #.T[PE&T[K4P ,[3NM1M.Z
MU, ;#.T[PE&T[K4P ,[3O"4;3O"7SF !G:=UJ-IW6I@ 9VG>$HVG=:^<P ,[
M3O"4;3O"7SF 49VG=:C:=UKYS (,[3NM1M.\)3  SM.\)1M.ZU, HSM.ZU\X
MVG=:F 09VG>$OG&T[K7SF !G:=UJ-IW6OG, #.T[K7SC:=UKYS  SM.\)1M.
MZU, #.T[K7SC:=UKYS  SM.ZU&T[K4P ,[3NM?.-IWA*8 &=IW6HVG=:F !G
M:=UJ-IWA*8 &=IW6HVG=:F !G:=UJ9VG=:GY!1G:=UJ-IW6I@ 9VG=:C:=UK
MYS (,[3NM?.-IW6I@ 9VG=:^<;3NM?.8 &=IW6OG&T[K4P!L,[3NM1M.ZU,
M#.T[PE&T[K7SF !G:=UJ-IWA*8 &=IW6HVG=:F !^MIW6IC:=X2F 4?2%561
M$555#;-2#OJ&V18#4G[ZXVS4G[ZX(^8 *               $    @
M
M
M         "                 (
M
M^D'?4-LU(.^H;9%@-2?OKC;-2?OK@CY@ H
M            0
M                                                           $
M
M                                                           /
MI!WU#;-2#OJ&V18#4G[ZXVS4G[ZX(^8 *
M                                              "
M   (
M
M                (                                          /
MI!WU#;-2#OJ&V18#4G[ZXVS4G[ZX(^8 *              @
M                                          @
M                 !                           0
M                                            @
M                                        "
M /I!WU#;-2#OJ&V18#4G[ZXVS4F[ZX(^8 *                    (
M             "
M
M   "
M
M /I!WU#;-2#OJ&V18#4G[ZXVS4G[ZX0CY@ H                     "
M
M  !                           0
M                                                          !
M
M  #Z0=]0VS4@[ZAMD6 U)^^N-LU)^^N"/F "@                    0
M                             (     =8
M
M                          @
M
M  0 #Z0=]0VS4@[ZAMD6 U)N^N-LU)N^N"/F "@         $
M               (
M                              !G0# ,Z>0*FG0H& !T  %W   ."  9
M&@& 91#"[N*     "=(!    ,Z+OU P
M     "               0         @
M                                      ^D'?4-LU(.^H;9%@-2?OKC
M;-2?OK@CY@ H                      "
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M4ZY<>.NG_P"/KU[K,1%>B2N@ 'SG,
M                      $           (
M         0           $      !](.^H;9J0=]0VR+ :D_?7&V:D_?7"$?
M, %                !
M               (                           &'[7-OV--K3=KUD)W
MFXYHLNE8VC9"E,CG;'<HO<DVF453KBR^'WK$_58G91G$+ZZ2\5;KKKV:KUYW
M=IO//ZR=L[\MZN:X27RRPNG25?WT;>*>-$(.DIYHI%CDB>UZ;ME4T4^_@RUR
MTBU76.KYHJHJ:<2:L.W',YECHVVUL:TB-3FE<Q-=/&<KEGEW<\1W:":>G?#;
MHW(Y\CTTVDUX(6OHX&4E)%30)I%$U&M\AY-9J:TVK$1,I,[-'#3[B^S4[KRU
MK:Y6_O-GAJ>F ?'F=YW<GSJO[)4?5N]16[(_Y5*O^J3UJ61JO['4?5N]16W)
M)R-S3JU<Y$3:DX_>>W2_Q9/HW7M*RW2?&N5$HJA7<$C74_2U$*:JLT:)UZD?
MYJX]MUBL%13TU3'+7S-V$C:NNFJ'DQX[9+16(9B-T3Y/(LV:<TD7P$?)KH>C
MGS\HUI_K3_,AZ_)QP],WLN^U+%:DBJUBNZ?&>1GQOS$M/]2?YD/K\HMJ]H](
M==_W-W/>UNI8['?Z=O[QJ,:YWD3=ZB5K?B2*7 "7I7HJ,@U77KT-3'EE2^Y=
MOIM-7LA21OE1"OU'BY\>7-1AE%=V4^?1$Z=G7@<,>/S.*M?6L_Z2(Y0[K)>@
M=<9\38BJ6JKI&OYMR_>>;D-\HMT\CO\ ,2O@6RI8\MV4^FDCZ97OUXZJU2*,
MAOE$NGD=_F->)XE<TQV-]]VURFD5;M;$3BK-WYFA9\#YB5%JIIJ*Y.;3/C1T
M;>>TT3HZ#T>4O\<VO^DF;!/\)VOZAOJ).:V+3TF(C_)OM6%7,5/Q?8ZUM#?:
M^KB:Y=-M'JK5^\E_*;+>T4C8;ZZK9<IG=TQ4X,7Q^,[C,+"M-BRP2TDS?W[$
MVHG]**03E+BBKP5BQ]DNZK'222*QZ._E=P1349;:C#/#I,=XCU-]XZ)[Q=B^
MUX2AADN[WL;*NC$:W4YCMSX3W_OJA?\ [9TN+<(VG&--3I=$D?''W4;HW:<3
MF%R6PGIWNI_YGL/'B\OQ_P"3?=B./JXK/F[TM^L-IN-N<YU,]VB*J:$MY;*B
MX*M6SPYEOJ. SCPE!;<NF06B-RQ4CT=HN]=-3WLC+Y3W/!L-,V5JU-,B,>SI
M0[9=K::.':):GK7H]W,]43 UTVN&Q_J1+DDCER]Q,K=>"^I#NL^+[!:\'2TJ
MR-[(J7(UK.DT,C[!)!EW5)*U4=6[2HB]*:;B8_V::9GUF".E7-\FS3W4O"?S
M:H3XWB5PR>KF8:S'N=MN#DBYZ18V[7#75="P]=5PT%'+55,C60QM55<J[C&O
MB?&W^>R7[JY+H[/6/9_O?]2RB<$\A6[+*)^),VJFZQ(KJ:)[G:^HLDO%=#6N
MZ6K7Y071SGY_ $_]:'QY/?\  #?KE/MGY\G\_P#6A\N3W_ "?7*(_P"I_D_I
M24!T \+
M
M     ^D'?4-LU(.^H;9%@-2?OKC;-2?OK@CY@ H
M
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M7!#7BVX>'Z+OTV $!S0            (                    #K
M 0
M                  !](.^H;9J0=]0VR+ :D_?7&V:DW?7!'S !0
M            (                                            !
M                          "          #(&      &437<13CS.JT8.
MOS[56TDLLS6[6TU=WJ E4$$>^3L/S;5?]?<?6FY2&'9)$;+13Q-ZW+[""<@<
M[@W&=EQ?1K/9:R.79W.8B]TGW'1%    "),P\\+-A*Z/ML-.^X5;-SVQ.3N0
M);!P&5.8\>/Z>IDBMTU'S#M%V^"G?@
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MLM732235.FCVKN34"1 ?BGD2>GCE;P>U'(?LH        (
M                !                      #Z0=]0VS4@[ZAMD6 U)^^
MN-LU)^^N$(^8 *
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M'+IUF\5               "
M      !](.^H;9J0=]0VR+ :DW?7&V:D_?7"$?, %
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M$W<5(0LI!@_#4U#$DEAMZ[<::_NDZBNN=^7$F![G#BG";71TVVFU&UNZ-?\
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M.BHH*:!$2.)B,33Q'V*@
M  "                ^D'?4-LU(.^H;9%@-2?OKC;-2;OJA'S !0 "
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M7<R]$;JOE_T FX&1IY/.5& -
M )U@ !T     -:6WT4LZ32T=.^9.$CF(KD^\V0 1$1-P  UJJWT58Y'5='!.
MY-R.D8CE/O#''!&V.!C8XV[FM:FB(?H :%=9;77N5U;;J6=Z\7/C154_=OM=
MOMW]@HJ>G7KC8B*;@ <===^IKQ4-'#.Z:"D@CF=Q>UB(Y?O-@ 9U5%U0\^NL
MULKW*ZMM]+.]>+GQHJF^ -.@M5OMW]@HJ>G7KC8B*;;VMD:K7M1S%XM7@ID
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M]'#S5)!%!&G\L;=$/J           0
M                     /I!WU#;-2#OJ&V18#4F[ZXVS4G[ZX0CY@ H
M                                $  Y3&68&'<(:-O5>R*9W"--ZG%+
MR@\'HJ_O9%3H[E0)@!#WOA,'_P![)Z*G18'S5L.,KF^AM+W+.UNUO33<!WX
M   "J'*;^5*S>5/\R%G\/?$-!]2WU%8>4W\J5F_J3_,A9_#OQ%;_ *EOJ(*_
M<L1J\Q9W=")O\ZDNY..1^7-F5J\(40XOE2V&2YX%[-A8KGTCD543JU/KR8\2
M4UUP0VW+,WLRDT:YFN_0*EVL5&T-2J\$B=ZBI')];SF=M0YOP4>]?664S,O]
M-AS!]?5U<S8G*Q61HJ[W*J*0-R3K1-67^Y8@D8J1HY6HY>E5_P#V"'/8Z3F>
M41&Y^Y%JFJGI%P(5188U3P4*H\I.VR6',:UWQC5YF1Z/5_1N5%++8*O--?\
M#-!744K96/C371>"]('(\H=Z,RJNNO%=$0X[DB1N3"EQ<OP><3]1RK<2T])A
MN*RQ3-=55"HKF(N]$U.HY.5BDLN7E.Z=JM?5(DFBA&MFE:,PZZ^MEP=<V4U!
MLZ;"]?F.+GL&<T$$LK[]%LQM5R\/]"Q_G-*]*ON/6[U[T[U 0_R;L47[$#K[
M!B*M=524DFPBJB)HJ:ZDV=)7_DM_&N,/M3O6I8 0  * 0
M
M           0
M               !                       $               "
M /I!WU#;-2#OB&V18#4G[ZXVS4G[ZX0CY@ H
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M]:E@"O\ R6OC7%_VI?6I8 D  "@             (        @
M!           0                                     "
M                 @                             $
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M?Q/6_5+Z@(,Y+7QKB_[4OK4L 5_Y+7QKB_[4OK4L 2  !0
M             !
M                                   @
M               0
M  'T@[ZAMFI!WU#;(L!J3]]<;9J3]]<$?, %
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M
M
M    0  @
M $              !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !0
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M^-<7_:E]:E@"O_):^-<7_:E]:E@"0  *
M
M                               $               0
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M
M
M           /G4SQTT+IIWMCB:FJN=P0^AIWF@I[G;9Z2LUYA[5V]..A8VWZ
MD/)?C;#K&.<ZZ0Z-X[SG9<XL)1U"QI6JYJ+HKT8NGJ*U8RAHJ3$%536ATG8D
M;MENVNJJIX>A]BGZ?CVWF9=.,+GTN/,-U5.V:*Z0[#N&NY3W+=7TMRITGH9F
M31<-IJ[BCE Z/LN%*E7<QM(CT:O07+P!:+=:,.4\=H5ZTTJ))W:ZKJ>35:6F
M"(F)GJEJQ$.B !X6                 !                        $
M           ?2#OJ&V:D'?4-LBP&I/WUQMFI/WUP1\P 4$"
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MU2FZ:5[^)ZWZI?4!!G):^-<7_:E]:E@"O_):^-<7_:E]:E@.LD  "@
M                        (
M
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M#;-2#OJ&V18#4G[ZXVS4G[ZX(^8 *
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MU;]4OJ-TTKU\3UOU2@09R6OC7%_VI?6I8 K_ ,EKXUQ?]J7UJ6 )   H
M                                     !
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MV=B.^_0YLMX($!0          !          @            @
M        ! !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !0
M                   ',9DX=GQ5A&KM%)+S,TVFR_7330K^G)NQ!IONZ?\
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M9R6OC7%_VI?6I8 K_P EOXUQA]J7UJ6 )   H
M      "                            @
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M+A.K9<K[+'65[4[AB-[EB]9-BA&  4            "         $
M                        !](.^(;9J0=]0VR+ :D_?7&V:D_?7!'S "%
M                                ( !^7L9(U6R,:]J]#DU0_,-/#"BI
M##'&B\=AJ)J?0^=3*E/2S3NWMB8KU^Y /+O-98[3&LUT["A1>E[6ZJ<R[,3
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MJ7UJ6 $  "@
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M.^H;9J0=]0VR+ :DW?7&V:D_?7!'S !0
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M K_R6OC7%_VI?6I8 D  "@                          "
M
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MM1RHOBU) :B-:C6M1K4W(B)HB %                         (
M                          !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !
M0                                   QLIU(9/C6S+34-3.B:K%&YZ?
M<@'-8RQ[AW"*:7FL9'-_=-WN\QQ*\H3!"*NDM0O_ -I2$K%AJLS:S5N;*VK?
M'!&]7/<O=;+4731";8N3UA!C$:])'JF[:ZR*Q[X7!/\ >5'_ "5.DP-FKAS&
M=S?069\JSM;M+ML5NXY[WOF#O[N0Z/ ^5E@P;<GUUI8])G-V55>H#O% !4
M@       "       TKW\3UOU2^HW32O?Q-6_5+Z@(,Y+7QKB_P"U+ZU+ %?^
M2U\:XO\ M2^M2P!(  %                      "
M                                              !        #\331
MP0NEGD;'&U-5>Y=$1 /WTZ'+XTQQ9\)TSG5\[75"IW$+=ZN4X7'&:4U16NLN
M"H'UE8Y=ET\?=(WR:'[P7E.]U6V[8SJ'5U:J[20OWHWRGKK@K2.>:=H^7K+<
M5VZRY]TN,<TZG9C8ZVV/7X2=RKF_KN).P7EY9<+0HM/%V15JG=3R;U5?$=;!
M#%30MBIXV10L31&L1$1#Z:^-/.8R:FUHXUZ5^23;Y" ?>GG'_7$\[(
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M9CUDL43UVVTC7?IT$]6&Q6VPT;:6TTL=/$U-.Y3>OE/3U75=3   %
M          (           0                                 ?2#O
MJ&V:D'?4-LBP&I/WUQMFI-WUPA'S !0
M      _%1&V:GEA?\&1JM7R*?L_,S%?#(Q-RN:K44"JMIN+<H\XZ]UP5'6NN
M5422-==E%W[RQ5'CC#=;"DM/=8'1NWHJN0@W%')ZO%ZOM96K=6K%-(KV-?)K
ML^<\QG)IO+$T9=F-3J21$(JQ:8ML7SG3^FAM6^^6VXRK%0UD4TB;]EKM5*V>
M]KOGSRW_ )AW>3V4%RP/B&2X5U>E0QT>PC4?J!-0 *@                :
M5[^)JWZI?4;II7OXFK?JE]0$&<EKXUQ?]J7UJ6 *_P#):^-<7_:E]:E@"0
M*                           !                      !
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M@>M??)=)'+(J.2-W$EU5\P&I:K=1VFA91VVG93TS$T1C$T-H("@    0 $
M                                                          #Z
M0=]0VS4@[ZAMD6 U)^^N-LU)^^N"/F "@
M       .:S&Q(_">$ZN[QP\\Z'3N.L@5.4S5:?$R>D65N=NH[K1OI+E3MJ*5
M_P *-W!3G$RTP9P_9ZE\ZD$'>^9JOF?_ ,P]\S5?,_\ YB<>UK@S_P"7J7SJ
M.UK@S_Y>I?.H5!WOF:KYG_\ ,=SE%G%/CK$$ENEM_8Z-9M[>NO2=QVM<&?\
MR]2^=3T+)A##UBJ75%GM4-).Y-%>S770(]Y=VI@ H                &E>
M_B:M^J7U&Z:=[^)JWZI?4!!?):^-<7_:5]:E@"O_ "6OC7%_VI?6I8 D  "@
M                    0
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MH862UJ[Y:IS>Z<O3O/9PCAFV84M$5NLU.V*%B:*Y$[IWC53V0@ "@
M
M  ^D'?4-LU(.^H;9%@-2?OKC;-2?OK@CY@ H               0
M          @ !   /E4U,%)&LE5/'"SPI'(B'F_M/8DW>Z]#_P YO^H'K@\C
M]I[%\[T/_.;_ *FS0WFV5\JQT-?35$B;U;'(BJ!O                   :
M5[^)JWZI3=-*]_$U;]4H$&<EKXUQ?]J7UJ6 *_\ ):^-<7_:E]:E@"0  * "
M
M                        !^9)&0Q.EE<UD;$VG.=P1!+(R")TL[VQQL35
MSG+HB(09C;%URQS>?V:PBDB4B/V*BI9P5-=%WIT'7#AG+.T=O66JQN^F.L;7
M+%]W=AK!6KHM=)JAN[=P7?U'?Y<X$HL'T'<Z37"3NI9W;UUZD-C &"Z'"%L;
M#3M;)5N3][.J=TY?*=4=,N:-O#Q=*_DF?2  'F9     'SF@AG1$FB9(B<-I
MNI\?<ZB_W6'T$-H#>1J^Y]%_NL/H(?IE#2,>CF4T*.3@NPAL ;R;@
M   <$5>I-2",9Y]U&&+[4T-3A^7FXG;+)7IHC_&FI*N.L76W!MDFN%SE8BM:
MO-Q;6CGNZD0@7#&&KQG-BA<08EC?26"-=88%;\/3UD$99AXJQ3F#<&U=30U/
M8*:<U"R-=C34E'"V<]PP_A^BME-@ZI:VGC1BJV-4VE3I+&4-JH*&DBIJ6B@C
MAC39:U(T/MV)3?[M!_RT"HUROS.K<9W>:BJ[#/0-8S:YR1JHB^(E _$4446O
M-11LUX[+40_?E*@           '6                         "
M              @              /I!WU#;-2#OJ&V18#4G[ZXVS4G[ZX(^
M8 *                                   'XGE;!!+,_X$;5<OW'[/C7
M0K44%5 WC+&YB?>@%/L:7S%&9V8M39[)42MIHW[$<35V6M1-VJGM1\G/$[F:
MRW6-']*;:FSDS/%@[.:\VZ]IS$E1M)$Y_!55>LM(FB_!<BIUZD557WN.)/G:
M/TE.]R:REN^"<0RW"Y5S)XG,V$:CE4F[3QH--/8-DW%XJ8 *
M    !IWOXGK?JE]1N&E>_B:M^J7U 09R6OC7%_VI?6I8#K*_\EKXUQ?]J7UJ
M6 )   H                                !
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MI*>WT<5)11-AIHF[+(V[D1!0TD%!1PTE)&V.GA:C&-:FB(B'W   H
M
M       #Z0=]0VS4@[ZAMD6 U)^^J;9J3]]<$?, %
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MZU+ $@  4
M                             !JB;UW)UKT&434B#.C,5;7 ^RV)ZON$
MK?WDC$UV$_U.F+%;+;C58C=YN<F9'[[]G[#4M:YZ\W45+7;F="IJ,M<08,P?
M2)$ZMBGN,J:S52Z=/1J5]E>^25\DKE=(Y=7*O2I^--VA]ORE/#\/?I^73:-M
MEZ+5=*&[4R5%MJHJB)>ECM3=*;9?8VK\(71DT#W24J]\@Z'(6QPE>DQ!8J>Y
M) ^!)D1=AZ:*?*U.EG!._HQ-=GL  \K( $         (      ! !Y]_O%%8
M;547"Y3,B@A8KE5SM-K3H0V;A64]NH9JRME2*GA;M/<J]!6>YUMYSQQDZW6Y
M[J?"U%)I(Y=VVW7\^! ME'=<\<:R5E<Z6#"]&[6)BHNR_3=Y.LLK;+?26NBC
MI+?!'!3QIHC6-T0UL-6*APY9X+;:X6Q4\*:;OYEZU/3   H    @
M0    "                                   $
M       ^D'?4-LU(.^H;9%@-2?OKC;-2?OKA"/F "@
M                !\ZF9*>EGG5-4B8K]/(?0^%="M1054"<9(W,3[T J/;+
M'49OYOW%*^=Z4%.Y5=LKP:F[1-2R5JRXPK:Z=L--:HM&IIM/WJOC*\98X@AR
MZS?N]%>_W,%2]6<X_<C=5W*6KI;A0U4224M93RQNWHK9$4BN QMD]AC$-KJ&
M0T:4E9L.6.6-=-^G211R;[C6X<Q[<\)5CU=$W7915U1%UXH6#Q/BJT8>M-56
M7"N@8D<;E1G.)JY=."%=<AN?Q1G#=<11Q.;2HBJBKPXIT@6G7=JA@RO$P5
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M>1%7@:5Z1?<>M^J=ZBH@ODM?&N+_ +4OK4L 5_Y+7QKB_P"U+ZU+ $@  4
M                                                     (
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M,8^M?W4T^B;3EZM3M"  "@                                    Z
M                 "                         #Z0=]0VS4@[ZAMD6
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M!.26DW/XF[*_M'/?O/ZM5U+#\"O_ "6_C7&'VIWK4L   !0
M                                 @
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MSWVK3:EE=O5NJ\#G<BLO:F6KFQEBQJR7*L5)88W[]A%WZZ$Z^4@P "@
M
M                 /I!WU#;-2#OJ&V18#4G[ZXVS4G[ZX(^8 *
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M2^H"#.2U\:XO^U.]:E@.LK_R6OC7%_VIWK4L 2  !0
M                                                       "<=.L
M##W-8QSWN1K&IJJKP1.L@C'U]K\P<2IA?#JO;01/19YV+JCNO[CV<X,:3R3Q
MX6PXKG5]2O-RO9_*B[M#K,K\%P81LK$>U'W&9-9Y>E5ZCV8ZQ@IXMOBGM'_R
MW$<8WE[>%,/T>&[-#;Z!C6M:G=N1-%<O2JGL 'DF9M.\L;@ (
M     &NRCG*NB(FJKU$+9IYXV2PLK+301^Z%6YJQO5CNY;JG6=+GSB67#> :
MN2E<YD]0Q8VN3HU*)S2OFE=)*Y7/<NJN7BJD$SY(9N4N"7UE-<*-[Z>KF61T
MK7? U\1;7#.(;?B2UQU]IJ6302(BZ(NJM\2G\X":N31C9V';]54E;.K;;+'M
MO15W)IU!5J\;8HH<(V">YW&1J(Q.X8JZ*]V_1$(*RPPS<,S,728RQ9$_W/B=
MI34\B:HO5Q\IIS+<,\,P%9&CXL*T#]>ZW(_3<66ME!36JABHJ&)(J>)J-:U
MC88QD<;8XFHQC$V6M1-R(AD H                             "
M                       $                         =   ^D'?4-L
MU(.^H;9%@-2;OKC;-2?OKA"/F "@                           0
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M7UJ6 *_\EKXUQ?\ :E]:E@"  "@
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M?TN=TGO %0                                          !
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M7U 09R6OC7%_VI?6I8 K_P EKXUQ?]J7UJ6 )   H    $
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MX2P_28:LD%NH&:,8WNG=+EZU4]@F?+%YXUZ5CLEK;@ .#(
M     3B !&^;-ZQI:I*5,'6Q*N)^O.KIJJ$.8OS6S%L=,M-?K=%3=E-YMJ*F
M]=2R6+\2T>%+#572X3(QD355K57X;NH@7+>P7+-/&LN,<3L<EJC7_9(57N5T
MW)N4BN R_P .XZP[<DOEMPXM1+-J^-\C>&O2A*EFQ=FU-=J6.ML6S3.D1)'*
MU-S==Y/[>X:C(^Y8U-$1.A#.V[PE"/G&KEB8KTT>K45R=2GZ * "
M
M                   ^D'?4-LU(.^H;9%@-2?OKC;-2?OK@CY@ H
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M-<7_ &I?6I8 K_R6OC7%_P!J7UJ6 ZR0  *        "   @
M                   "                      Z%  B'E'_%5G^O_4DO
M"W\.V_ZII&G*/^*;.J_WZ'L8HQI#@_ = ]%VJ^>%&0L3>NJIQ/;-)OAQUKWW
MEO;>(>;G'C:6F1,-V!7272K1&JL2ZJQ%\AT&5."X\*69))VH^YU2(^:1R=TB
MKT:_><WDY@N?G'8HQ#K+<:A5='M\6HO22YUF<UZXZ^#3_,_.29VC:  'D8
M          0         #XUU7!04<U562-CIXF[3G.71$0^R=>NFA77.'&%;
MC;$D6!L(O=S;W(E5,WAQWIJ!YESJKEG=CYM'2)+%ABW2_O')O;(FOFZ"R-GM
ME+9K9!06^)L5- W9:UJ:)Y3Q<N\(46"\-T]MH6(DFRBS/Z7NZ3IB  "@
M               0
M                           ^D'?4-LU(.^H;9%@-2?OKC;-2?OKA"/F
M"@                                   !\+A*L%NJIF_"CB<Y/N0"*\
MX<XZ3!4GN=;&-J[LO%F]48A!];FWC^2OI'U_^RPSO1&_NE:BIKY3WLFK'38W
MS<O5POC4J$IG.>V.1-I%5%W<3H.55%%!7X<CIXF1,1[41K&HB)W1%>UF]F#B
M+"5HPS76IC9(YX6OJE5BJB[DW'=93YB46/K-S\2)%7Q)I-#U>,]:VVFBO."*
M.DN=-%40OI$31[==.YZ"O.2T"X=STNEGHWKV(J.393AIN M2#*\5,%0
M    0       TKU\35OU2FZ:5Z^)ZWZI?4!!G):^-<7_ &I?6I8#K*_\EKXU
MQ?\ :E]:E@"0  *
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M8#J[A<),;XO:LU?5ZNABF37837<N\GG7KXD&  4    0     "
M
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MUQA]J7UJ6 ZR ^2]#+'=,7<Y&]NM2JIJFFN]2?=..XD# ,Z*-%*, SHHT4#
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MRHEFTD6-O%-23,"V2WVNP4;J*CCBD=$BN=L]TJ^4]M];$8XO$=VIF-MV,O\
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M&=%&B@8 T4:*  WF= , :&= , :+U&= , SIXC&B]0! AG13&B@ -#.B]0&
M-#.@& 9T7J&@& 9T7J&B@8!G13&B]0 &=!OZ@, :*9T P#.@T4# ,Z#0#]P=
M]0VS4@1><0VR+ :D_?'&V:DW?7!'S !0
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M_):^-<7_ &I?6I8 D  "@                   0
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M=%ZAY04
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M2(4S;S.^;:C\.XD3)''6,L1XFFI<24<D5*D>TCG1.;OU\8$\=8&[5= 5
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M,Y7013)KL(O3O\I![>1N6JX?IG8@O^LM]K421VVJ+S>N\EY1^7B   %
M
M(                                 !](.^H;9J0=]0VR+ :D_?7&V:D
M_?7!'S !0                                  !414T5$5/&?E(H_[J
M/T4/T?B>5L%--,_>V-BN7[@.<QMC"Q8-M_95Z?&Q%W-C:U%<[[B%[ARF+='.
MYM%8GR,3@Y4:FIQJVJNSCS<KX9YW-H*=RZZ+\%J;M$+"V?*3!]JIFPPVU)43
M<KI=%52*CS#O*/L-;4MBNEL?2-<J)M[+51/,3C9KA0W:WQ5UL?%)3RIJUS$0
MC/'&1V&;W;*A;? ZCKFL<L;F+HW73@1[R:;Q76'&%SPA<'*YD>NRU>A=>@"S
M8&FBJ"H     !S./<:VK!5IDK;K+W>RJQPM^$]3&8N+Z3!>&:FZ52HLC4TBC
M7^9Q5S"EAO.<V+9KG?*KF;7%)M/57:(UJK\%J+XB []IL],8+IM16J-VJ(J:
M,C:F[HZ2U^#,,4&$K'#;+9&C6,3NW)Q<O2I^,+VNQX8M,5NM#H(H8TTUU35W
MC53V8:FGE?LQSQO7J1=X$;YD90T&.;Q!<*RJ?&Z/<K=5T5.HZW#>#K'A^VQ4
M=OMT+6L;LJ]6ZN=Y2%LV,TL48/S!@H=(8[0YZ*FTS57,UW[_ "$\X>NM->[/
M2U]'*R6*9B+JU>D*A7E*9=VF7"LU^MU+%35=-IMJQ-$>FIM<E/$%1<L)5%!5
M/<_L1R)&JKP3J_(W>4SBNBM>")[3SS'5M7HB1HN]$U-'DHV&:W82J:^I8K.R
MG(YFO2@'KYI6/,*X7YLN#ZR."@V=-ERZ;SB*S"V<C:.=9KI!S2,7:3:XIYBR
M*+N-.]_$];]4H1 G)+9-'/B=E2NL[9M)%ZW:KJ6'*_\ ):^-<7_:E]:E@!
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M9#"Q&11ILM:G!$/V4
M
M ?2#OJ&V:D'?4-LBP&I/WUQMFI/WUP1\P 4
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MI[;0PT='$V*GA:C&-:FY$0V  -*]_$];]4OJ-TTKW\3UOU2^H"#.2U\:XO\
MM2^M2P!7_DM?&N+_ +4OK4L!UD@  4
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MJW95$\AB'!>&X(61,LU)L,3935FJGLTM+3T<#8:2%D,34T1C$T1 C[F "@
M
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M4OJ @SDM?&N+_M2^M2P!7_DM?&N+_M2^M2P!(  %  =
M           #2N]JHKQ2.I;E V>!W%JFZ!$S'6#LX]N6>$MI-;4SSD0X?PQ9
MY\X:RUS4;74#$72+7<BZ%D&?"30@?#'R[UW]*^H]VFRWF+[S/9TK,]4C=K3"
M6OQ2SSG44%'3V^DCIJ.-(X(TT:U.@V53>I@\=LEK?%.[$S,]P &4
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MNV8ZA[NZ8O0A:=%1R(YJHK535%\14                         @
M                                                     (
M                 ?2#OJ&V:D'?4-LBP&I-WUQMFI/WUPA'S !0
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MKT8NBG999YB8JQ%?TH[UA]U)3*BJLNSIL@2^ NY5!0
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MV-C8UC$T8Q$:B)U(!D %0
M
M    !](.^H;9J0=]0VR+ :D_?'&V:D_?7!'S !0
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MQ-DWWE'G)P_AZN^M7UJ2WUD1\G'^'J[ZW]5)<+J_YK%^X #SL@
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M1,1D3&,C;N1K4T1#)\75E,CE1:F'TCZM<CFZM5'(O!44HR
M
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MO_G"N])29<$V!V&L/4ULDK)*UT2)K-)Q4]P%                 (
M
M                       !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !0
M         !                       :-ZNM'9;=+77*9(:6/X3UZ#D4S>
MP3I\<P^<]['.&H<78;J;/4RNBBGTU>WBFA#:<F"SZ;[Q5JO]*$$C=M[!/SU#
MYQVWL$_/4/G(Z][!9_GBK\R&/>P6?YXJ_,@$C=M[!/SS#YSU<-X[P[B2K=2V
M:X1U$[4U5K>HB3WL%G^>*OS(=?EGDU;\!WJ2Y4E?/42.9L:/1 )37B "@
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M-7*OWG=*OC\1@%      0
M                    $       '6                   "
M                    'T@[ZAMFI!WU#;(L!J3]]<;9J3]]<$?, %
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MLJJ(OF Z !/*B^0(                            !     !
M     (              $
M                      ?2#OJ&V:D'?4-LBP&I/WUQMFI/WUPA'S !0
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MJWPF^< @&K?";YQJWPD\X #5OA)YQJWPF^< !JWPD\XU;T.3S@   "
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MKT+J6BP/BNW8PL4-SM<B.:].[9TM=U!70& "H        'ZC^&GE/R93<OD
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M$KL;U.&(L0*E;!Q<KMWJ+BL^$A6S"BI[X^[)T[7ZJ%?5<M<U]-E<1LT3_%[
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M^T;-4_Q>P=K;-C:U_:-FO]7L+& ;"N:9;YL([5,1LU_J]@3+;-A%54Q&S?\
MXO86, %<TRVS81%1,1L]+V&$RVS7V=/VC9I_5["QH KEVMLUU;HN(V:?U>PS
MVMLV%XXC9Z7L+& ;"N?:VS85=5Q&S7^KV'B6J?&N%\U[/9L0WAU0D[TU1JZH
MJ:EITXE=<R53WQ6'_P"I/6@58MR:*8,NXJ8*@ @
M                                 /I!WU#;-2#OJ&V18#4G[ZXVS4G[
MZX(^8 *                                  0"/<^+Y)8\N;C)3O5DT
MK4:UR+HJ:D8<F# -!5T,^([S3LJJA[D6%LK=43IU._Y2-NDKLM*U\2:\RJ*O
MG/*Y+-WAKL#OHVN1)Z9R(YNN\BIF8QC&[,;&L:FY&M31$/TF[@IA/$"HY+,C
M!=LQ?AVLIZNEB6J2-SHIMA-M%TZR >3+<:JQ9@W/#DKW+$J*W95=VJ*F_0M'
M<JF.BME753N1L443G.5>K12JF1;EN^>-SN,#=8-7.U3RHGZ$6%M%ZC!E>*F"
MH          #P,;85MV+['-;;I&BM<B[#]-58O6A7V3(W&V'JJ5,+WQ4I'KH
MB(]6[O)KH6A %>\!9!U4-[CNV-+AV;+&[:2+7:VE\:J6"BC9#$V*)J,C8FRU
MJ<$3J/T !IWKXGK?JE]1N&E>OB:M^J4"#.2U\:XO^U.]:E@"O_):^-<7_:E]
M:E@$W*2!X]=B>R6^H6"LN=-#*G%CI$14([SLQ)9KC@J6&CN5+42JNYC'HJFQ
MBW)*Q8FO<USJJNIBEEXM:Y=#@LPLF;)A/#DMSHJNIDGC7<CW*J'?3?RU^K5>
MZ1\JL4V.AP!:Z>JNM+#,UFCF.D1%3>=M;<16>YS+#;[C33R^ Q^JD&X*R.L.
M(<,45UJJRJ9-4-VG(URHAW>!<GK+@^\)<J*IJ)9FIHB/>NAG-_);ZD]Y26!T
MZ@YL@        0 "O_*I[[AO[4TG.Q?$M%]4WU$&<JGON&_M32<[%\2T7U3?
M40;H,Z*8*,/:CV.:[@Y-%.=PW@NS8<N=;7VNGYNIK%VI7=:G1@    ,Z;C
M  :MQM=#=Z=::YTD-3"O\LC$=IY"KV%<)V.7/RNMDM!&Z@C17-A7@B[RUL?P
MD*W80_[R=R_I7U*0A8FBHZ:@IVP4-/%!"U-$9&U&H?8RO%3!0
M\+'G\%WCZA3W4.(S4Q19K1A:YTMPKX8JB:%49'KO52"-.2C9:+W/N=T6/6M6
M56[>O1JI8-2N?)?Q59:*TUE!65T4-7+-JQCUTU352Q;51S4<U4<U=Z*BZZE@
M                       (!E%WG,TF"+)2XFFOT-/LW*7X4FITO  .L!#.
MB@8    (               #/ # 0! .:DP399,4)B%U.ONFG_B:G3#13
MRB=0& 9T4P               9W])@  9T4#"'-W/!5EN6)::_55/M7&G[W)
MKP_ZT.DX #*J8"&=E0,    B:F=% P
M                    /I!WU#;-2#OJ&V18#4G[ZXVS4G[ZX0CY@ H
M                             #3O%N@NUKJ:"J;K#.Q6.*>W2EQ-DIC>
M:KH8G.M\LBJU7)JR1FO!="YR*:-XM%OO5&^ENU)#50N3>V1NI!#.'N4AA^KB
M:EU@DI)M.Z5$U37Q'JUO*"P?!"KXIGSN\%K5U/C>^3QA.XS/EII)J-7+KL1H
MFRAH47)KPW%(CJBOJI&]2(@5&F8^<UXQZB63#E&^&EF785&HNW)KNT4F7D]Y
M=28-L2UES;LW.K3NVK_(WJ.OPCE[AK"K6K:[;!SZ:?OG,17'5A  %
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MDY7&3#^9URLSW*D#]IB,5=$U1=Q;14T70(P "@
M          $            #Z0=]0VS4@[ZAMD6 U)^^N-LU)^^N"/F "@
M                                    'QJZF"C@=/5S,AA;Q<]=$ ^P
M.:_;S"Z3<U[M4FWKI\)-#WZ.JIZV!LU),R:%W!S%U0#[
M   :5[^)ZWZI3=-*]_$];]4H$&<EKXUQ?]J7UJ6 ZRO_ "6_C7%_VI?6I8#I
M(,HBD=Y\(O[!U.J=)Y.,+;F+/?)GV-T/8"_ U<B'+7O"&9M\H'4=P;"^G=Q1
M)$/?@PUK:MYO'W;K7;KNE3*%%[7=HW?^&=?HJ$ VK#&:-JM\-%1\RVGB31B+
M(FXZ_ -OQ]37I'XD=#V!IW6CD5=3.;#7>UXO'W)KZ[I. ZP>-@
M%<^6%\56KZS]%-3D<L14N[OYD7]$-OEA)K:[5]9^BGA\D*XLBO-PH7*FW*FT
MB=/ BK4)Q*D\J!J,S'M[F\=8_P!"VZ)W2)TZE0<^9O=G.*EH8.[=')&BHGW!
M(6OL"JMAMRKQYAOJ-XUK9$L%MI(EW*R)K3:*/RJ(J*CD147H4(B,C<UC4:FR
MNYJ:)P,A?@N_I7U 4_PC_P!XFJ^V+ZRX*\5*?81_[Q-5]L7UEP5XJ2!@ %
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MNKJN--IC'.=JGE3_ $+?NWN7RB!@ %
M               !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !0
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MM(4Y+UJM]=ANODK:&FJ)&U"JU\C-53>I/C&M8U&L:C6IP1.@@R "@     !
M            $!<KQCWX7MNPQSOWW0FNG$GTU:^W45Q9S=PI8:EB+N;*W5$4
M#B\B&N;EC;&O:K5W[E33H0Z^_P!KBO5EK+?4HFQ/&YFJIKIKTFU34\-+"D5-
M$R*)O!C$T1#Z@4YMU5B'(_&]7SE%-46N1RMX*C'M7I1>LZW&W*$6[V62W8:M
MDS:NJ;L*_>JMUZD+'7*V4-TBYJY4D-5'T)(W4\J@P5AN@GYZEL]*V5%W.5FN
MBD5$W)LR]J[0RHQ%?HG,K:K1T;)&Z.37?J3R$31$1$T1$T1.H%0
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M/6V9)J*T4L<J+JC]C>B^(BHUY.&7M1A:TONMV8K+C5I\%R:.:FO23. 5
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MJ&.1O!S86HJ?D!Z2;T1>A4 !0           (             !
M          "
M                                      !       ?2#OJ&V:D'?4-L
MBP&I-WUQMFI-WUP1\P 4                                  !Q&<>%
M)<88(K+?2Z+5IHZ-%Z50@G">;^(<!4+;!?K/-*E)^[8Y&;]$W%K34KK90W!/
M]LHX)M.ES$U\Y!5G%^:N(\R*1,/6*T2PQU#D1ZJSBA87*W##L)8.H[;*J+.U
M-J33K.BH;=14#=*.D@A3K:Q$4V@!^9&1R*BR,:]4X*Y-50_0*"
M         :5Z^)ZWZI3=-.]_$];]4OJ @ODM?&N+_M2^M2P!7_DM?&N+_M2^
MM2P!(  %              0@SE%963XGA2]V1C75\#566/7>]/$3F90#^:M?
M05=!4.@K:>6&5J[*M>U4WG79<Y<WG&5VAAIZ:2.DVOWDSVJB(A._*I@@2HPZ
MY(8VN=4M1RHU$5?*3IAV..&QT388V1MYINYC43H\1%?+"MDI\.V"CME(U$C@
MC1BJG2J)Q/5Z "H             "
M                                    !T
M            $
M           ^D'?4-LU(.^H;9%@-2?OKC;-2?OK@CY@ H
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M )5/?<-_:FDYV/XEHOJF^H@SE4]]PW]J:3G8OB6B^J;ZB#= !0
M                                  (                       @
M                         (                              (
M                                             !](.^H;9J0=]0VR
M+ :D_?7&V:DW?7!'S !0
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M]T[^9.HH@[DM?&N+_M2^M2P!7_DM?&N+_M2^M2P'02 0 %
M"  5_P"53WW#?VII.=B^):+ZIOJ(,Y5/?<-_:FDYV+XEHOJF^H@W0 4
M!                                                $
M
M                                                 !](.^H;9J0=
M]0VR+ :D_?7&V:D_?7!'S !0        "          $
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M6*5:K78LJ%:J:*BR+O+$ (C3)G+:?+^.X)4UC:E]4Y%54)+ *   !
M        #@LT\O6XY6VJZJYA:.5)/*B';T<"4M)# U=4C8C47R'V
M                    $
M        @                !                      (       $
M                                                    !](.^H;9
MJ0=]0VR+ :DW?7&V:D_?7"$?, %
M                )QW@ 13G-E=69A5-(^&XMIH8&Z;#N!'+.31<6-TCOR,;
MU-W(6<!!63WM=T_^8%])3M,ILG:W!&)DNE3=5JV(U6\WJI,X YG'^";3C:TN
MHKK&FVW7FID35S%(*?R>\36Z=[;!B58J55W)MJW=Y$70LV ("P3R>XZ*ZLN.
M*[DMQF8[:2->Z1R^-5)Z@ACIX(X:=C8X8VHUC6IHB(G1H?L%
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MAA::N>ONG1+S<B+N541$WDI%    $        0
M                                              "   $
M     !](.^H;9J0=]0VR+ :D_?7&V:D_?7!'S !0
M
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M\J"'L#,:V7"/<]6M7S.+.82J'5>%K54/75TE.Q=?N0*]4 %0
M            0  .@
M                         !^X.^H;AJ0=]0VR+ :D_?7&V:D_?7!'S !0
M                 "
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M)^2%7\8J['6?M-34W=QPO1KM.A$UU+;4T+:>EAA8FC8V(S3R(('T !4
M
M                            !  !](.^H;9J0=]0VR+ :D_?7&V:D_?7
M"$?, %
M                                                  'EXK_A6\?9
M7^I2HF0^,[3@[%]TJKS(K(I$<UJITKJ7*JJ>.KI9J>=NU#*U6/;UHI'LF2.
MI7O?)9U5SEU7]ZO$@ZO"6(;9BRUI<K7L2P;6SM*F_4]Q-R;N!Y&%\.6S"UL]
MS[)3]CTB+M;&NN\]<H  #\\W'KKS;->O9WC89KKS;-KKTWGZ  PK&.7NF-=Y
M4U,@!HB)HB:(?B:"&=$Y^&.73@KVZG[ 'Y2.-K-A(V(SP=-WF,M:UJ:,:B)U
M(AD 8:QB.VFL:CNM$WGQEH:2=^W/202R>$YB*I]P :B-:C6HB-3@B)HB  #\
MR,9+&K)F,D8O\KDU0^,%#1P/VZ>DIXG^$QB(IL #*KUF$  ^%11TE2[:J:2"
M9R=+V(JGV;'&V/8;&QL:?R(F[S&0!^=&QL<K6HU$371J$08SSVP_98[A1Q-F
M=<H=8T9ITDPH1I>LE<)7B^RW2MI7NEE=M/:CU1'*!&')GPY57K$E=BZZQ.TV
MW<TYZ<57J+-*OPG+T;S3M%LH[/01T5LIV4]-&FC6--Q=Z*B].X@AG-'-C#3+
M/>;$Z=W9R-5FST:G'\CS>EY\OZ(2Q=<G\$W:XSUU?:EDJ9G;3W<XJ:KUGM8/
MP/8,'I-^S]&M-SR]WW2NU Z0( 41'RC<%.Q+A-UPHF:W"AT<U6IJY413;Y/6
M+F8CP7'23O1*ZWHD4C'+W6[<2@YC9&.8]$<UR:*B])QV&LN[/AO$59=[0CX9
M*I=9(T5=E5XD'8K&Q55RL;M=:IO,@(48<UCOA,:[RIJ91$1-$1$1.A.  &$C
M8BJJ1L1W6B:&0 ,(QB*JHQB+UHFAD #\M8Q%U:QB+UHF\Y7-+%,&$L'UM?-(
MB2JU61-VM%5RH=8<GCK MMQHE(R\.>Z&F>CTC:NB*J$$5\F/"$^S68LNT:]D
MU3W<SMIO1%Z2P!\*"D@H*2*EI(TB@B:C6-3H0^X  %
M
M                  'T@[ZAMFI!WU#;(L!J3]]<;9J3]]<$?, %
M
M
M  (                @
M                                            $
M                  'T@[ZAMFI!WU#;(L!J3]]<;9J3]]<!\P 5
M           $
M
M
M                                                      $
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M(=CKX7Y&P -?L=?"3S#L=?"_(V !K]CKX0['7POR-@ :_8Z^%^0['7PD\QL
M#7['7POR'8Z^%^1L #7['7POR'8Z^%^1L #72G7POR'8Z^%^1L #7['7POR'
M8Z^%^1L #7['7POR'8Z^%^1L #7['7POR'8Z^%^1L #7['7POR'8Z^%^1L #
M7['7POR'8Z^%^1L #7['7POR'8Z^$GF-@ :_8Z^%^0['7POR-@ :_8Z^%^0[
M'7POR-@ :_8Z^%^0['7POR-@ :_8Z^$GF'8Z^%^1L #7['7PD\P['7POR-@
M:_8Z^%^0['7POR-@ :_8Z^%^0['7POR-@ :_8Z^%^0['7POR-@ ?#L=?"3S&
M.QU\+\C8 &OV.OA)YAV.OA?D;  U^QU\+\AV.OA?D;  U^QU\+\AV.OA?D;
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1=?"_(V !\8X=ER+M'V  _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g98130g00t18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t18.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2'&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (:D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     /_A0#%H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC
M,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E
M<CY!8W)O8F%T($1I<W1I;&QE<B R-2XP("A7:6YD;W=S*3PO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-2TQ
M,BTQ-%0P-SHU.3HU-2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871E1&%T93XR,#(U+3$R+3$T5# T.C0X.C4Y*S U.C,P/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R
M-2TQ,BTQ-%0P-SHU.3HU-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!$87EL:6=H
M=" M($=A;&5C=&\@+2!297-A;&4@4RTS(%]'1$,@,3(N,3,N,C R-5\U,# T
M,C@V-#DP+C$Y7RYD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/G)R,SDS-3(W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E
M+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM
M<"YI:60Z.35".31&03(Y-$0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+WAM<$U-
M.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD
M:60Z.31$0D,Q0S@X140X1C Q,4)!1C-%13@W,S8T,S8T1$(\+WAM<$U-.D1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M>&UP+F1I9#HY-$1"0S%#.#A%1#A&,#$Q0D%&,T5%.#<S-C0S-C1$0CPO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.31$0D,Q0S@X
M140X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3(M,314,#<Z,C4Z
M,30K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HY-$(Y-$9!,CDT1#A&,#$Q0D%&,T5%.#<S
M-C0S-C1$0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-2TQ,BTQ-%0P-SHU.3HU-2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.35".31&03(Y
M-$0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3(M,314,#<Z-3DZ
M-34K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z.31".31&03(Y-$0X1C Q,4)!1C-%13@W,S8T,S8T
M1$(\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z.31$0D,Q0S@X140X1C Q,4)!1C-%13@W,S8T,S8T
M1$(\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^>&UP+F1I9#HY-$1"0S%#.#A%1#A&,#$Q0D%&,T5%
M.#<S-C0S-C1$0CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^
M-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$
M!08%! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@
M(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1
M" 2K!E\# 2(  A$! Q$!_\0 '0 !  (" P$!              <( 08#! 4"
M"?_$ %H0  $# @,#!@<," ,%!@8!!0 ! @,$!08'$1(A,0@305%5<18B89&2
ML=$4%Q@R,S8W4G-T@9,5(T)RH;+!X34X5"0T4V*4)29#1(*#)U9C=<+P1:)&
M9?&C_\0 &@$! 0$! 0$!              $" P0%!O_$ #81 0 " 0($!0(%
M P0" P$    ! @,$$1(3(3$505%2H3)Q!10B,V&!D? C-$*QP=$D1.&"_]H
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M+A8WX05J['K/30?""M78]9Z:%<@/#L'H<N%C?A!6KL>L]-!\(*U=CUGIH5R
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M0U#60H/U5*12.&O9Z8C8 !H # &0     &#(  P!D   8,@
M  P!D  #!D                   !@R           0               &
M#( P9          P9       ,&0                  , 9     8,@
M   P#(             !@R
M          @   P!D                       &#(
M   #!D .A2=,A,P9(ZJ+#MTD5T3]>8D7H7ZI!9RTE3+1U,=13/5DL:[37)T*
M<-1@KFI-92T;POH#7\ WI+_A6@K]45[HT1^GUD1-38#\M:LUF:SY/,%0,ZJU
M];F!<=MZN2%W-IOX:%ORE&8[G.QY?MI==*N1/XGTOPJ/]29_ATQ]VN@ ^\[
M       ,&0       8,@      P9
M  &#(          & ,@                       &#(  & ,@& ,@    !
M@R  ,&0,&0        8 R  !@R !@R          ,&0
M     #!D       & ,@P9               !@#(     8,@
M        !@#(              8 R         8 R            0"RW)GK
M7S89KJ9SE5L,J*B:\-4)C(%Y+#E6"_M5=R/C5/,I/1^8UL;9[//;N%*,QOGW
M?OODGK+KE*,QOGW?OO<GK/5^%?7;[-XN[73!D'W74!@R         !@R
MP9 &#(0P!D P!D  8,@               P9
M &#(                        , #(    #!D   !@R       #!D
M        , 9   P9          &#(     !@R  ,&0        !@R8,@
M    8,@                       &#(    8,@
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MD]3))+)L.2545-/P0B928<U<U>.O8B=XW  =5   !@R           &#(
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M,C>*=2+UG7S2PW285Q7);+?)+) V-K]9--=5UZCE&>DY.7'=-XWV:B #LH
M!@R                  !@#(,&0!@R         !@R
M       $ G[DK_)8@_>C]2D]D"<E?Y/$'[T?J4GL_,Z_]^W^>3SV[A2C,;Y]
MW[[Y)ZRZY2?,7Y]W_P"^2>L]/X5]=OLUB[M> ,'W78,@ #!D  # &0
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M.BM1^UKJWJ-"/H8;7M2)O&TMU[=0 '56 9               ,&0    P9
M    !@R  " (!/W)7^2Q!^]'ZE)[($Y*_P EB#]Z/U*3V?F=?^_;_/)Y[=PI
M/F+\^[_]\D]9=@I/F+\^[]]\D]9Z?PKZ[?9K%W:\ #[KL
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MOY.\;W9DTSVM<K&P2ZJB;DW'SGU%)/F?4Q0L<^5\4;6L:FJN7?N0EC+^RV#
M5<RU15D-=B"K7QG-<B*C.[H(MSMK'T&;3JR+>^!L4C=%ZB8\O-U4VK'3;H1.
M]MW-A7,?$^!*6*AO%OGEI53]2RJU8[1.I5Z#>[-G+AN^QMI\16]L#I%V=E[>
M<;QZ5T.]4Q8>S=PM1ZU;(+E$W=M.3;C=IHN[7@IKUMR'IZ:NBFNMVCDHHUUD
M8C=G:3JUUW'&UM/?><L<-OX3IYNCGE@"VVRW1WVQ1I$R5VLL:*FSHO!6IT$(
M$TY]8RMMQHZ*PV2?G8Z9=9'L=JW=N1NO3P(6Z#WZ'CY4<;=-]NH #V-
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MQ.#7R*J)^!\T]3/3JJTT\L2KQYMRMU\QP@<,=A]S2R3/5\TCY'KQ<]=5\Y\
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MRHISNN5>Y%1U=5*G4LSO:=0P.&!GK !0        !@R "     !@R   &#(
M             @$_<E?Y+$'[T?J4GL@3DK_)8@_>C]2D]GYG7_OV_P \GGMW
M"D^8OS[OWWR3UJ78*3YB_/N_??)/6>G\*^NWV:Q=VO  ^Z[   P9
M!@#(     $        !@#)@R  ,&0           &#(       !@#(!@#(
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M_#BI[L>2,E8M7M+<3O&[(,:I]9#)L         # &0   , 9     8,@
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MFK).:7]4DSE<Q%T_94Z:>*\<3BR;QYQ)7OTEK  /IPZ   &#(
M         #!D                   ,&0         ,&0 !@R     ! )^Y
M*_R>(/WH_4I/9 G)7^3Q!^]'ZE)[/S.O_?M_GD\]NX4GS%^?=_\ ODGK+L%)
M\Q?GW?\ [Y)ZST_A7UV^S6+NUX 'W79@R       8,@
M           ,&0                 !@R      #!E!IZP+&Y]_1?9^^'^4
MKM3O2.IC>O!KVN\RDM9I9@V7$N"K?:[:LRU4"Q[6VQ43Q4T7>1%[#Q:*EJ8M
MK1MUEFD=%J<<1UF)LL*.NPY4S131L;,WF7[*N1$T5"M[\48@C>YDEWKVO:NB
MHLJ[C;,L<SJK!T+Z&>#W7;Y';6RYZ_J^[R$A.S(RXJ94J:JU)[H7>[_9==YY
MJ5OIIFG!Q1Y,Q$U\FM8&PIB;$V&:B\5&)*^BB9M+&CGKXZ(FJKW&MY4Z^^E2
MHZ99W<X[65=^WY3W\R,VF7BUOLN':9:2W.9LK(WQ':?51.A#1LN;S28?Q91W
M&OV_<T6NUL)JIVI3);'>;1MOVA8B=I23RG_\8M7V:FT9%U#+OEE6VFFE='51
M(]BN:NBM5R;EU(SSJQE:\85]#-:%E5L+%:_G&;)K&!<65F#[RE?1)SB*FS)"
MKM&R)Y3G&GM?2Q3M,)%=ZN?$5QQ/8;O46^MNMPC?$Y6IK*N].A3W<M:/$N-K
MO)2QWVX04\;%<^?;541>KO) ]]?!-Z@9)B*THE4G%.9YS^)UKSG)8K5:Y(,&
M6QC)I%WJL?-HGE\JDG)EM7AC'M;U\C>>VR,\=6RIL^,X:"MNC[E-#*Q%D>NJ
MM\9-Q*7*5^:M@^U__ @9:Q\]U2LJGND>Z9)7N<NJKXVJDG9QX]L^+;%:Z2TK
M,LU-)M/VV*U--G0ZWQ7C)B\]M]UF)WA%]LF;3W&EF?\ %CE:Y>Y%+.YLT]QO
MF!:*[8<JJB-\+.?TA?L[;51-=>LJSZB3\LLU9\*T*6ROIUK+>KM45SM71IU(
MG5Y#6KPVM-<E(WF/(M'G#278IOS55KKQ7HJ;E195W$FX7PCB2\X-DOU9B:NH
MF(CG-C>Y=[4Z?Q-B7,;+:65:F6U)S[DU<BTNN\TS,_-5<24#[/9J?W+:_%U>
MB[+G:=&G0ARFV7+,5I3A]9E.L^3[Y.^OOCSZOYQ>8DU?];?Q->SL^DV]?OM]
M1G)_$]!A/%3KA=%D2G6%T?B-VEU7R'F9CWFEQ#C.XW2@5ZTT[D5FVFB[DTX'
M:M+1J9MMTV6(_4[>3WTF8?\ M_\ \5-SY14B19@6J1W!D;7+^#R/,OKM3V+&
M5JN==M>YJ:7;?LIJNFBH>]G)BJW8NQ%35MI6188X>;=SC=E==1?':=3%MNFQ
M,?J2YG!;_"S+"@N5 U\[H$;.Q(^G5-%W%9G-5'JS1=O739TWZ]1)66.:53A&
ME_1U7![KM[G;2;3UUCUZ$\AOB9D9<<][L6T_[4J[2_[-^UWZ'#%S=+O3AWCR
MV2-Z]'B466%EH<LY;UB)9HKBL+I8_P!8J(BJGBHJ=>IO&7%;/B7)_P!ST#E@
MN$4+X&[+]%1R:HU=?*0[F=F55XQ5M)% E-;(G+LL1VNWU*O4>5E[CJX8+N$D
M](U*BGD322![M&N\I+:;-EQ3-Y_5OO$?^#AF8ZNE7WW$MMK):2MNE?%41*K7
ML=*NY4-QRRLV*<;RU+FWZNI:.!-%F615U=U(AN[\T< W9B3WFU?[6]$VUYC;
M77OZ3S<49R6RFM$U!@V@; LC5:DNQS>QY=.LLWRWCAKCVGU\CK/39%&.Z.>W
M8HK:&JKWW"2G<C/=#EUVMQX!]SRR3S/EF>KY7JKG.=Q53X/I4K-:Q$ND)<Y-
M7SPJ_L37\\/I'N?[R&<G,56["6()ZR[<XD+X]E.;;M+KO/*S+O=)B+&%;<K=
MM^YY5U;MIHIXZTM&JFVW39B(_4W_ ),?SBN'V1JV>7TB7#N3UJ<^2^+[9A"[
M5=1=UE2.5FRWFV[2GAYF7RDQ%BZKN5NV_<\NFSMIHOF)3':-5:^W38B/U-[Y
M,GSFKOL#P<<U#:3.-]1)IL1SL<NO ^,F,76W"-YJJJ[+*D<D>PWFV[2ZFO9@
MW>EOV*ZVX4&TM/,J*W:311&.TZFTS'28-OU)NY1E-+5X-ME7!&Y\;'(YZM35
M&HJ)O7R%?;)05-UN=/24$2S3O>FC4ZM>)-&"<Y:!+ EKQ?3+*C&)$CVMVDD9
MITH<E9FGA"S12SX4LK75SFJU'K%S>R<<$YL%9Q<&_I/DE=XZ-NSH@=2Y3R0/
M75T;8VKWD?<F#YPW?[!OK4XL59FT%_RR;::F2>2\O1%D<K%V==I5X]VAI^5>
M,UP7?753X>=IIVHR9.E$ZT)CP9/RU\<QUW2*SM,.EF:US<P+^U[515JG*B+U
M$VY.WJ+%^7]7ARMJ$2OB8Z)/%TTC7XJIUZ&M9BXUP/BFR5;*>*6"Z2Z.;/[G
MWZIT*I$>'KS6V&Z0U]NF='/&NNY=SDZE.O+MJ,,5F.&8[-;<4.YC#"URPK=)
M:.YPJC6N78F3XKV]"HIXD+'32MBB:KY'KLM:U-ZKU%@:#.7#MWM4<6++6BSI
MN<U(^<;WH<U-F5ES;EYZ@M?^T-WM7W-HJ+WZ;BQJ<U8VMCG<XICR>QE!AZ+!
M>!ZFYWQJP32ZR3-?OV&IN3<09;8/#/,B-C8MF*LJ]51FY$9K[$/1S$S.NN,$
M=3(GN.VZHO,,=JK].ER_T,Y.8CLN%[W47&^.EU1FS"C&;6B]9G'BR8ZWRV^J
M?)(B8B92KG3BVIP7:[1;,/S-@J$XHJ:_JT33UD4>^YB]/_/Q_EH=#-/%,>+,
M5SUU-M>Y&HC(=K<NSW=!J!TTVDI7'''7JM:QMU3GE#F;>[KB^"VWJ5L\-2BM
M:J-V=A=%/'Y1F'([7B2&Z0;+8[AKM,1/VT3>OXD6VRLEM]?3U<#G-DAD1Z;*
MZ*NBZZ:DQY@YAX:QG@F.CJ>?@NK&M>U>:VD:]$WIKU+UG.^&<.>M\<=)Z3LD
MQM/1O-2NF1;U7A[E*L(Y-.)8G"F;.%*'"E':[FVHD<R)&2,6%7-4Y4S&RS[*
M;_T9RP7R8)M'!,[RD3,>2N6J=9*')V^?[/L7&^+F-EIHNEJ9_P!&1U@3%UHL
M.8E5>)VOCMST<D;8V;TU\AWOEOFQVKP3'1K>9A['*8^>-#]V_J1)#))#*V6%
M[F2,5'-<W<J*AOF<N*[=B[$%+6VE9%ACAV'<XW9774C\[Z6LUPUK:%K'1:7+
M/$5)F+@J>TWEK7U<3>;F:O[2=#RO>.L-5.%<155OJ6*D:/58'_79KN4Y<OL5
M5&$,0PW"!-N+XLT>OQFD@9M8SPEC6V0OIY:J*Y4R*L>L.YVO0JGFICOI\\Q6
M/T6^$B)K*&C"\#)C35%0^CY-K%YZ_198?W8?Y$*\0?+Q?OM]9+.9V/[-B/ ]
MKM5N6=:JG2-'[;%1-S41=_X$2QJC96.7@UR*OG/'HJ6IBVM&W66*1T6+Y1GS
M!L_VT?\ (I7NU_XG1_;,]:$JYNY@V7%6%;?;[4LRSP2,<_;8K4T1JHI%%%(V
M&NIY7Z[,<C7.TZD74FBI:F'AM&T]2D=$^<I;YI8:^U7^1#O9)V1,+X#KL0U<
M:I5SL<]$VM46-OQ>XTG-W'ECQ=:;%1V]9U]RS;4^TS9\791%T/0QUF/A^MR\
M3#V'7U4<C48Q%<U6^*G%-3R1BR3AKBVGK/7[;L[3MLU:IS>Q9)4ROBJXXXW.
M56LV$7937@<7OMXO7_S[/RT-""=)]*--BV^F'3AA:O$]/!F#E(E0W]9.D23,
M5JZ?K&\?XZD8<FQCF8YK&/31[:96N3RZF<F,R;?A6UUEOOKIG4[G[<*-:KMG
MK33RJ=;!6+\.8;S&NMU@6H;::ABI%XBJY'*NJ[CYT8LE*9,,1T\G/:8WAY&=
MUEJ;3CRX3S1JVFJW\Y"_77:30Z^4-CJ+WC6@2&)SJ:%^W,].#4T)&AS?L-PK
M*NFQ%;FU5O1_^SROBVG(WN.Q69PX8LML>S"-K3W0_H6+FT[UZSIS,\8^5P==
MMM_)=YVV>7RG+M%+76NU1ZJ^!JRN7OW?T(04[MZNE9>;E/77&9TM1,Y7.55X
M>1/(=(]NFQ<G'%&ZQM#U\'_.FT_>6>LEWE2_[[8?LW^LAO#]5'0WR@JI]>:A
MF;(_3CHBF^YVXUM6,JBUOLZRJE,UR/YQBMX\#CEI:=12T1TC=F8_4D?)KZ(*
MW]V3^I6ZH_WF;]]?63!EWF)9+#@&HL]P6?W6]'HFPQ53?KIO(?E5'S2.371S
ME5":6EJY,DS'>5K'64]<F+_#[]WIZB&\9_.JZ?;N-ZR7QU:,(4ETCNZS(ZI5
M%9S;-KH(]Q'5Q5]]KJNGUYJ:57-UXZ%PTM&HO:8Z3LE8ZR\XWW(KZ3+5_P"O
M^530C:<L;Y28<QG0W.XJ]*:':VMA-5WHJ<#OJ(FV.T1Z-6[-EY1?TC2_=H_4
M:9@S$55AB_T]RHWJFPNCV\4<U>*'LYN8DH<58O?<K6LBTZPMC\=NRNJ>0TM#
M&#'_ *$4O'DE8Z;2N90TEJQ9/9L3T<BK- S]6YJ[M'<45.LAWE/_ ./6K[%_
M]#Q\G,RHL'\_0W5KWVV5=MKF;UC7N\IU,ZL8VS&%SH*BT+*K(6*U_.-V=ZGS
M\&FR8M1'G6.TL168LEG)SZ)).Z0K)5_[W/\ :.]:DS9>YE6&PX!?:*]9_=:H
M_<UBJF_AO(7G<CYY7MX.>JIYSU:2EJY,DVCO+5(VF7&O M+E']$<_P"Y+ZBK
M?0I-V LS+#8\ R6>M=.E6YKT\6-53>F[>77TM>D16-^I>-X1+A?YTVK[Y'_.
MA/\ RF_FU0?;+ZBO5EJ8Z.]T-5-KS4%0R1^G4CM5)4SGS#LN+[-2TMI6=98I
M%>[;8K4TT)GI:V?':(Z03'6$.&0#WMN2F:R2HC9,[8C<Y&N<B:Z:KQ)*QKEY
M7X'M%->K;<IIDET1[HDV58BIKJI&*<=W$F; N<,5-:FVC%E&E51HW9Y[3:54
MZ&JWI/+J>;&UL?6/.&;;^34L(YE8IM51'3T=<ZI;-*W5LS><5=_!-29<\_<U
MPRRAK*R-6U2;+XD<FBHY4WGCMS'RYI)?==%:O]J9XT>E-IO\Q&>9V8=9C6JC
MC1GN>W0*JQPHNJJO6IXXQVS9:WBG#MWEF(WG=HH'1Q!]:'0      8 &0
M         &#(  &#(  P!D (            P9, 9
M (!/W)7^3Q!^]'ZE)[($Y*_R6(/WH_4I/9^9U_[]O\\GGMW"D^8OS[O_ -\D
M]9=@I/F+\^[_ /?)/6>G\*^NWV:Q]VO  ^Z[    & ,@               P
M9     #!D   ,&0              # ,@       !            P9"
M ,&0             #!D       !                        #!D   !@
MR                    P9   & ,@                    !@R
M                          !@R                  !@#(
M            8,@       ! )^Y*_P EB#]Z/U*3V0)R5_DL0?O1^I2>S\SK
M_P!^W^>3SV[A2?,7Y]W_ .^2>LNP4GS%^?=_^^2>L]/X5]=OLUB[M>!@R?==
M@           8,@              P9     # &0                 !@R
M         !@R@       ,&0      #!D       &#(      0          8
M,@ 8,@     , 9,&0      8,@       P9       0            @&#(
M  P!D             ,&0      8,@     , 9                !@R "
M          8,@                           !@R       8,@8,@  @"
M 3]R5_D\0?O1^I2>R!.2O\GB#]Z/U*3V?F=?^_;_ #R>>W<*3YB_/N_??)/6
M78*3YB_/N_\ WR3UGI_"OKM]FL7=KQ@R#[KL
M            8  R ,&0                                8 &0
M                     !@R
M     , R                     P9      !@R            &#(
M                 !@R8 &0            &#(     8 R
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MX.7OLBO_ "'^P>#E[[(K_P AWL+L<X_K'./ZR>*V]OR<U2?P<O?9%?\ D/\
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MOR<U2?P<O?9%?^0_V#P<O?9%?^0_V%V.<=UA)'=:E\5M[?DYJD_@Y>^R*_\
M(?[!X.7OLBO_ "'^PNQSCNL<X[K'BMO;\G-4G\'+WV17_D/]@\'+WV17_D.]
MA=CG'?6'..ZQXK;V_)S5)_!R]]D5_P"0[V#P<O?9%?\ D.]A=CG'=8YQWUAX
MK;V_)S5)_!R]]D5_Y#_8/!R]]D5_Y#O878YQW6.<=UCQ6WM^3FJ3^#E[[(K_
M /IW>P>#E[[(K_R'^PNQSCNL<X_K)XK;V_)S5)_!R]]D5_\ T[_8/!R]]D5_
MY#_878YQW6.<=UE\5M[?DYJD_@Y>^R*_\A_L'@Y>^R*_\A_L+L)([K'..ZR>
M*V]OR<U2?P<O?9%?_P!.[V#P<O?9%?\ D/\ 878YQ_6.<=UCQ6WM^3FJ3^#E
M[[(K_P AWL'@Y>^R*_\ (?["['..ZQSCNLOBMO;\G-4G\'+WV17_ )#_ &#P
M<O?9%?\ D.]A=CG']8YQW63Q6WM^3FJ3^#E[[(K_ ,A_L'@Y>^R*_P#(?["[
M'..ZQSCNLOBMO;\G-4G\'+WV17_D/]@\'+WV17_D/]A=CG'=8YQW63Q6WM^3
MFJ3^#E[[(K_R'^P>#E[[(K_R'^PNQSCNL<X_K+XK;V_)S5)_!R]]D5__ $[O
M8/!R]]D5_P"0_P!A=CG'=8YQW63Q6WM^3FJ3^#E[[(K_ ,A_L'@Y>^R*_P#(
M=["['..ZQSCNLOBMO;\G-4G\'+WV17_D/]@\'+WV17_D.]A=CG'=8YQW6/%;
M>WY.:I/X.7OLBO\ R'^P>#E[[(K_ ,A_L+L<X[K'..ZR>*V]OR<U2?P<O?9%
M?^0[V#P<O?9%?^0[V%V.<=UCG'=8\5M[3FJ3^#E[[(K_ ,A_L'@Y>^R*_P#(
M?["['..ZQSCNL>*V]OR<U2?P<O?9%?\ D.]@\'+WV17_ )#O878YQW6.<=UE
M\5M[?DYJD_@Y>^R*_P#(?[!X.7OLBO\ R'>PNQSCNL<X[K)XK;V_)S5)_!R]
M]D7#\A_L'@Y>^R*_\AWL+L<X[K'..ZQXK;V_)S5)_!R]]D5_Y#_8/!R]]D5_
MY#_878YQW6$D=UCQ6WM^3FJ3^#E[[(K_ ,A_L'@Y>^R*_P#Z=WL+L<X[K'..
MZR^*V]OR<U2?P<O?9%?^0_V!,.7OLBO_ "'>PNQSCNL<X[K)XK;V_)S4-<F6
MW5M!'??=U)44VTZ/9YV-6Z[EX:DXG#3.54=JNN\YCYV?+.:\WF-MV)G>=PZ<
MORCN\[ATY?E'=YRAE\  H
M
M
M
M                                             [%+P?WG.<%+P?WG
M.18#IR_*.[SN'3E^4=WA'P "@
M                                                       "
M            !                                              (
M               $
M                                                   .Q2\']YSG
M!2<']YSD6 Z<ORCN\[ATY?E'=X1\  H       0
M
M
M
M $         (                                            3I [
M%)P=WG.<%+P?WG.18#IR_*.[SN'3E^4=WA'P "@
M              0
M           (                                          0
M                        0
M
M     .Q2<'=YSG!2\'=YSD6 Z<ORCN\[ATY?E']XA'P "@
M        (:KC7'MAPA3.DNE=$DR)JV)KM7*!M1E4T35=-.\JWB//W$%YE?!A
M.T2)"OBI(B.5365ES<O:K*QMP:UV_1-40ALN2W1>"HO<IE4T*:?H[-ZA_6?]
MI)IOXJ>E:,W<P,+R(R]VV>HA1?'61KM=.D&RW (LP#G7AW%&S!4RLM]:J?)R
MKHFI*37->U'L<CFJFJ*BZHI1D
M
M         (
M                                               @
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M1[;.M5;Z:H<FCI6(]4ZM3L:Z].I  !0      @
M                   !         $      @
M
M
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M( $  Z=3=+?2OV)ZVG8[J5Z(=BGFBJ(]N"6.1J]+%10.0
M                            $
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MB/J9XX6*NB*]R-15_$Y&.:]J.:J*U>"H!D
M                 $
M    @'8I.#N\YS@I>#^\YR+ =.7Y1W>=PZ<ORCN\(^  4            0
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M&<[;9=61T=T=\3QO%?IU$RJ48                '0
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ML[:.T[M4-VS RV7&>)*:LJZ]T-#"Q&K$U/C+Y.HX9<..F>:VG:J3$;H1S+S
MJL97B%L2.BML+TYJ--VJ]:EHL-?X!0?8M]1 &>=BM^'ZJS4=JIV0Q-:FJHF]
MR]:E@,-?-^@^Q;ZCKJYK.&DTC:.JV[/1 !\]S
M                                                  $
M !   '0!V*3@_O.<X*7@_O.<BP'2E^4=WG=.G+\H[O"/@ %
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MJ$19D=P8[J0U$1M,R)3 !$           "
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M<I3_ !JT_NIZR;<-?-^W_8M]1O-_M\?]5GZ8>B #Q,  0
M                (
M         !.D! .Q2<'=YSG!2\'=YSD6 Z<ORCN\[ATY?E'=X1\  H
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M<Q,]P,GD:J.29>,1:QOT@A<S@#/2N\P1
M                                       9153@N@VM%UZ>LP &NO$
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M:F]IK%9GI"[]-@ &4  @                        !
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M$/;8J.35BHY.MJA'!;H/<MOIZ?:VN:8C=>O0YP"@
M &6[E7?T& @%"\\5MC\=5SK/4RU+><=SKI$^*_7>B$>EKN4W@2FAL'Z6LMNB
MCV7+)52,31>\JB6TS,[RKZ9_4W_)G$,&&\94-=,]R,;(B/1.E%ZR/CL4*R>Z
M&-AWO<Y&M[U-8KQ2V\K'1^D=IN5+=J".MH)$DIY$U:X[9I63-OK;9EW:Z>YL
M1E0C-=/(O W4S:(WG9F0 $                     @
M                                    >/BW$=#A6RS72ZOV*6+1'*B:
M\5(\3E X*_U+_07V 2V")$Y0&"M?]YD]!?8;'A?-7"&)*EM-;[M$E2[A&_Q=
M?.0;P F]$5. *    \C%6)+7A:U/N-ZJF4].W<FU^TO4A&EJY06&[E=X:""E
MFVIGHQC^@"8@8:NK45.E-3(                                    =
M.Z76@M-/S]SJX::+71%D=IJO4AVH9&S0MDC=JQZ(YJ]: ?0.M<KA26RC?57&
MIBIJ=B:J^1R(15?.4#@^W5#XJ5[Z[97171ZHGJ EX$48;SZPA>*EM//.Z@D>
MNC5EX><E.GGBJ8&34\K)8GIJU[%U14[P.0 U7'>/+)@F*%]\GYM9OB-3>JH!
MM0/!P9BNUXOM7N^RS)+#KLKUHOE/>3> !I6-,S+!@^[06Z\2N953-1[41%X*
MIN-/*V>GCFCWQR-1S5ZT5 .0 \C%F(:'"UCFNUU?L4D2HCE1.L#UP1(G*!P5
M_J9/07V!.4#@K7_>I/07V 2V#1L,9KX/Q'4-IJ"[1-J7<(Y/%]9O/<NJ=
M        ZUSK8+;;YZVK>C*>%NT]R]" =D&@83S:POB>\_HRVU>M2[781V[:
M[B0.O4# /%Q=B2@PI9I+I=GJRFC5$543K,8/Q/;\66A+C:'J^F5=-5ZP/;
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MITM7B?3RZ&EJ?IC:6MMUU$!T[/<J:\6V"OHG;4$S4<U=#N'Q=ICI+F
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MECYS=SCD15W)UGI<IKZ*Z[]YOK(0R0ROJ,P:):B^5D\=CI7(R.)CM-I=.C^
M%I[-C'#]YDYJW76FDEUT1G.(BK^![VFG$J[FSDC!A"T)?\%U-2QU*[61CY%5
MR)QU1?P)5Y/^-Y<98,8^O<BU]*Y8Y%3]I$X*$2: "@
M          ZP.Q2<']YSG!2\']YSD6 Z<ORCN\[ATY?E'=XA'P "@
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M3@FY  41;RE_HGN?>SUFB\FC!F'[]@2:IN]MAJ:A)U:CWM15T-ZY2_T3W/\
M>9ZSQ>25]'<_WA?417WFAD98[Q9)IL.TR45RA17,:Q$TDT3XNAH7)ZS#3#]Y
M7"F(:2"E>KU8RH5FRYKOJJI:9%T7<5@Y4& 'T%;'BZR1K&BJU)TC1=6NUW.
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M#L4O!_><YP4G!W><Y%@.G+\H_O.X=.7Y1W>(1\  H
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MVWZ  .#( $  RB+U#1>I0, SHO4I@
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MXGM #7;#@G#E@E66U6N"*3ZRIM:=QL7'>$
M     '6 !V*3@_O.<X*3@[O.<BP'3E^4=WG<.G+\H[O"/@ %
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MIJ]:*>'61-/TS6/O#%GV8 / P
M
M                                                       "
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MH"6X3+;L#VV>>I<NRDBMU_$WG).P8HH8J^[8QK'35==HK(57Y- J3P.@%0
M                   99\9.\K=:_P#-;=^[^B%D6?&3O*W6O_-;=^[^B$(6
M1=\9>\P9=\9>\P4$->Q=<</^X:BTX@KJ:!M5&K59*Y$5$7IT-A*Y<KFR4#*&
MEO;Y)&W&39B8B.7391=X(1QA+,RHRMO-_MMIV;C;I)E2%5=N:B*NBH;79>4U
M7,JFI<;8QT"KHJM=O1"N2\017Z!8=S-PM>[;#5Q72GA63<L<CT147J-SC<U[
M&O8Y',<FJ*BZHJ'Y\946NDOF.+9;+E)(VGJ)-GQ%5-_0?H'24[*.DAIHM5CA
M8D;=>I$T".54U1R:Z:IIKU$.7K*:[U]UJ:J+$=0QDK]I&ZKN\G$F,';%FOBG
M>JQ,QV0559)7.K9LU=_DF;U/15_J?5/DK=J:/FZ?$,L4:<&MU1/63F#M^>S>
MOPO'**<'98W2QW^"OJ;_ #U$4>NL2JNCOXDK+Q7=H <,F6V6>*Z3,SW$''BB
M+^&H!S1YERP_:;DQS:RW4TBNXN5B:D>8PRBL#[9655 V2FGC8YZ(SAN125CY
MD8V2-\;TU8]JM=W*=<>:^.?TRU%IA0S?JNO7H#?,U,"5F%KW,^.%S[=,NW'(
MQ%5&HO0IH>G1TGZ*EXO6+5[-L+Y"Y&65WIJ[!]M;[LBDG9$C7-VTU31"L>7V
M"Z_%MWC@@C<VE:J++*Y%T1NN\ERY9-7&VNY["MXDB>F]&*JHAXM9RK[8[6VD
MF([2FX$!,Q-F#A"167>D?7TS.+FMUW)Y=#:</YTV6M<V&YPS4<_!VVFY#Y]M
M'DB-Z]8_AG@E*@//M=ZMUTC22AJX96KU.15/0TT/+,3'26'%-54\"Z3U$42]
M3W:'%^D:'_6T_P"8AH>8&7-5BF\)74]XEI6HQ&<TBKIW[C1+]EBMEH)YZW%:
MQO8Q7-8YZHJKU<3U8\.*\1O?KZ;-Q6)\T[_I&AZ:VG_,0RVX43ET;60*J]3T
M*MY<X?7%3*A*G$;J.9CMEC'R+J[R\21*?)BNCGCD\(IE:UR.W*N\Z9-+BQSP
MVOU^R\,>J:4W[T75 <=+%S%-%"KE?S;$;M+TZ'(>%S
M
M
M            !            '8I.#N\YS@I.#N\YR+ =.7Y1W>=PZ<ORC^\
M(^  4                      Z-ZM%!>Z-]+=*:.HA<FGC)O3N.\ ($Q?R
M<;36RR5-@JI*29554C5VJ:D?5N1>.[>Y4HZUSV)P5LRH6\,HH%.Z?)G,2K>C
M):J1$7I6=3:\.\FRHFF;+B:Y.7315:Q^NI9G53!!JV#L!8?PE3M9::)B2(FB
MROWN53:EW[UXF 4         #".155$<BJG4H&0   54;\9S4[U'XHJ>0
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M@1[[[V%_]4IL>%,6VK%#9EM,W.+%\9.HEL.2L;VK,0G#,/? !R0
M
M                                        $
M                 RG2!STG!_><YP4G!_><Y%#IR_*/[SN'2E^4?WA'R "@
M              (        $ !$U-'S.S)M. *.-U>Y9*N9%6*%N]50AF7E,
MU+WJL%J;L=&[^X%G]#&FA5[X2]=V6WT5]IS47*1KJBLIX5M;4221K/B]:Z=8
M%FP=>W3K54%/4*FRLK$>J=1V       $37<#1LY\073#F"JBLL,7.5RN:QJ:
M:Z:KQ ^LTLP[9@6QS35$K9*][%2"!KD5=K3<JH1'R:,87K%&-KN^ZULDT3H^
M<;&[@U=>@UFT92XBQ727+$F-II8F1T[YV,<[QG*C57AT'8Y(:(W&=V1."0Z)
MYR*MB:!G%F)3X P^DVSSEPJ$5*>-.OK4D!-ZE/<\JN3%6=]'9G.5U/%.RG8G
M>N\)#M61F:N8$;[K25TU-22*JQHOBI^!]VK,?&V6V)8:'&?.U-&]?&V_J]:*
M6JL]%%;+3245,Q(XH(VM1J;N@BWE/6&&ZY;55>Z-/=%"J2-?TZ:Z:!4H6:XT
M]WM5+<*%Z/IZF-)&+KKQ-#SJS*@P!9F) U);I4+I$S7XOE4UKDEWV2YX'J:"
MH=M+12M8SR,T(DS0EDQGGXMM>[:BAJ&0(G1HW34(]*RT>:^-J9;K!<)Z>GDW
MQH[5J*GF.?#F9^,,OL3QVK&_.STDCT8YSTWHW735%4M92T\5'2PTU*U(X8FH
MUK4W:;B%^5;A^&XX#9=N;3W30O31Z;ET7B%3);ZR"X4$%92O1\$[$>Q47H4Y
MR(>2]?'W7+6*EF=M2T;W-U_Y==Q+Q499\9.\K=:_\UUW[OZ(619\9.\K=:_\
MUMW[OZ(0A9%WQE[S!EWQE[S!0   SKU[S  @'E<8G=;\/4=AC1%=6_K7*J:Z
M-1530J.I:+EBV2>9MHO,3%6GA9S,B]2JJJ5=7B11"R/))QC5)=JC#=5*Y]-(
MU9(45==EQ6Y"=.279)ZO'3[FC')3TD:JK^A57H N$#*\=Q@J
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MJ=*&+8[4^J-DF)A]  R@
M                                 $
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M38;KKO.=]/6E9GCB4FNWFD<!. /,R
M                    @                 0           "
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MH!] ^.=B_P"(SSF6O8[<U[7+Y% ^@
M
M  (!U@=BEX/[SG."EX/[SG(L!TY?E'=YW#IR_*.[PCX !0
M       #+?C(8,MX@5-Q_3+C3E'P66O>JT4-0D6PJ_L\51"U-LM]+::-E';X
M6001)LHUC=$*N9^4-=@G->WXQHXU=#+(DJNZ$<B\/,33A#-W"^([?#,M<RGJ
M7-19(I-RM7I(J0W+M-5'(BM7H5"KG*BPU18<O]@Q%:8VT\U1/^L;'N\9JHNI
M/5RS PQ;H'35-V@1C4Z%U*RYEXMFS<S M-HL<+Y*"GG1K%TTUU7>[S!(6NPG
M6/N.%[563+K)/3M>Y?*>H=2ST+;9::.A8NK:>)(T7N.V4
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M[$VGL;M5T !Y&
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MDY=8*I,#VA]!0SRSM>]7*Z1=5U*-J
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MKIVRSMVG(B[D-RP[E!;++=X+A'73R/A75&JNXE\6"N\<4[Q_!M5)O2!J#R,
M                          (                          "
M     $  [%)P?WG.<%+P?WG.18#IR_*.[SN'3D^4=WA'P "@
M         +IHNO Z;;C;D=I[HIVNUT7140[J=.O#@5JS&R=Q54XIJ:G#%RG6
M@G7;1JO5-E>E.)!MM_S2J:+-ZWX:BCI9+=42HQ\RIJJ)UZDN.N%M1RHD]-HG
M<42NF"L24N/Z2Q5,TKKO-(C(Y-5W+WF_+DOF-JJ?I"?\Q?:%6N_2-M_X]-_
MAC/#-:KPG>[90X?6CE294YU5:BJB:D;^\OF-VA/^8OM/1PQR?\055^I:K$M:
MO,Q2->Y7;U<B+KIO LWA^K?7V*@K)=$DGA1[D3K4[YQTT$=+314\*:11-1C4
M\B'(5                        'PZG@E>CI8(I%UXN8BJ5QM#&LY5=V;&
MQK&HGQ6IHG!I9)GQD[RMUK_S6W?N_HA"%D7?&7O,&7?&7O,%
M     (N@ $>YL98VW'5N<]$2GNT35=!.S<JNZE(OR[S%NV7UY\$\P6N93,7F
MX:E4UZ=V_J+)&HYD8#M..+-)3W&-L<\;5='4HB;3=$ZR#:J>I@GIV5,,S'T[
MDVDD1=RH5IQ'74B\IVVSI4Q\RC6HLFNY..XB&ZXSQ%8J2LPO2WF66A@F5K9&
M/754\B]1I+JRH?4^Z'3R+/KKSBN7:U[PK]+6/9*Q)(7M>Q=Z.1==3)2S)K.&
MZ89O,%)=JA]7:Y7(QR2O7]7JO$NA!-'401S0.1\4C4>UR=*+TE1]@
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M1-VFN_U%XLJ,:V3%>'*6.SRI')3QI&ZG7<YNB ;N!P!4              !
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M-UD@="EO%MJO]WK(7(O#QCNLDC=\61J]RGQIB8[N>SZ!E&KIP &
M     !  -?S"^9EV^P=ZE-@-?S"^9EV^P=ZE-X_KC[K7NTODV?1^[[R_UDJ$
M5\FSZ/W?>7^LE0Z:G]VWW)[@ ."                      $
M        [%+P?WG.<%)P?WG.18#IR_*.[SN'3E^4=WB$?  *    !
M          !EO%.\P$X[@*IXLF9ACE.4]PN/ZJDGJ6O21VY-GAJ6$S%AAOV
M;Q%22,GCFA5R*Q=I%315-2SPRUI<>P4[Z6I@I[U3M7FMI=%>G48R"PQ?</6"
MYT&)Y'2(Z18XVN<KO$5/*16G\C^\1?H&ZV:25J3LG65&*N_31$X'SROJJG;2
M89CC>Q:^.H<Y$1?&:F[34T['>6>*L#8KGN>#EE6DE57L=#KJW7H5#JX0R[QC
MCS%E+78I69M-"]KWR3:IJB+KHB 6HP/))+@VRR3*JR.IFJY5XZGMG'2P1TM-
M%3P-V8HFHQJ=2(<A4                   "    !H&.<J;%C2[,K[KSB3-
M39\5>@A? &'Z3#'*/K;3;MKW+3MT9KW(6H9\9.\K=:O\UUW[OZ-(L+(N^,O>
M8,N^,O>8*@                   Z  .&LHZ:O@6"NIXIX7;E9(W:0JYB'#
M-FBY1]!:XZ&-*"1$<Z%$395=Y:IO%.\K9B7_ #2VS]UO]2$+"T]FME-0NH8*
M&G92.;LNC1B:.3RH5_S&RNNN#;FN*\O))&I&NU-1Q[N_\"QSOC*8XHJ*B*BI
MO1>D",<I<U[?C*F2BKU;17J%$8^&1VBO7ITU).(/S:R>6JJ5Q'@IWN&[P:RN
M8Q51)%3?N,Y19P>[*E,.8S1U)>8?$223Q4>H$W@)HJ;E147@J+N4(4 1%FIC
MC&&'K^VDP[9GU=&L:.YU&Z[^HTJ7-O,>&*263#CVL8FTY=G@G7P(+) J_9L\
M<<WJ.1]KLB5#(UT<YC==%\QZU)FIF1)51,DPX_8<Y$7Q>C7N L4#BHWOEHX)
M)F[$KV(Y[>I>E#E*  0
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MYNUN%,B:/7]MO6=-9I9KOECK!-4I@(#YK           "             "
M             Z .L#L4O!_><YP4G!_><Y%@.G+\H[O.X=.7Y1W>$?  *
M                   9;Q0P9;Q0"H.:UVND6?C8IJR:DI4J6,C<BJB;&I;J
MF5'4L"M?MIS;='=>[B58Y3E=5U^)EM\%C>]\":QUD3%VO.:EAG,S,*PTD=-'
M!65$4::-21CMR$5=C?HJ*FJ=2A$T393<G45%3.[,+LJ3T'>PYZ#.K,":NIHI
M+7(C'R-:Y=AW!5T7H";+9 Z]LE?/;:6:9-F22-'.3J4[!0
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M%T6Q7W5J+^OZO*3ZB-3@UNJ=2$!\D1%_05]^W_J3X0  4
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MSXR=Y6ZU?YKKOW?T0LBSXR=Y6ZU_YK;OW?T0A"R+OC+WF#+N*]Y@H
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M0
M^9%5(GJQ-7HU5:GE/H 0?<L4YDQ7"H9!;DYIKU1GBZ[N@UG%\N/L5VYM%<[<
M[F4<CO%;TEE_P0Q^">8]E=7%>L4C=OB_A7RUW_,BVVZGHJ>W?JH&)&S5G0AM
M^7U_QO7X@;#?Z)(Z!6KM.V=-%)4_!/,9,WU-;1,<$=2;1Z,=8 /*P
M            AH.>GT;7/\/6;\AH.>GT;7/\/6==/^[7[K7NY\E?HWM/V9NY
MI&2OT;VG[,W<9OW+?<GN  Y(              "    "&I9F6FWUF%+E/54D
M4DS(7*U^F]%T7I-M-?S"^9EV^P=ZE-XIF+QLM>Z/N3C:J";!JUTE+$^L2H>W
MG7)JNA,)%?)L^C]WWE_K)4.FJF9RVW)  <$
M       $       G2!V*3@_O.<X*7@[O.<BP'3E^4=WG<.G+\H[O"/@ %
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M?N_HA9%GQD*W6K_-;=^[^B$(61=\9>\P9=\9>\P4
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MO4-E>I?,!\@^ME>I?,85%3B!@
M       .@    0  4                     !  !DT#/3Z-KE^'K-^0T'/
M3Z-KG^'K.NG_ ':_=:]W/DK]&]I^S-W-(R5^C>T_9F[C-^Y;[D]P ')
M  "            ->S!^9EV^P=ZE-A-?S!^9EV^P=ZE-X_KC[K7NTODV?1^[
M[R_UDJ$5\FSZ/W?>7^LE0Z:G]VWW)[@ ."
M              .Q2<'=YSG!2<'=YSD6 Z<ORCN\[ATY?E'=X1\  H
M               !EO%-3!E/*!5G-&CEP5GY;,45D;OT;4U*2K(B:HW?HI9N
MWW.CN=-'5T53%+#*FTU6NZRNW*"P_C7$6(9J2V4DE59^+-&ZZ$=6C!F:%ICY
MNABN$4:;D:CET0BKK[3?KM\XVF_6:4Y_0N;O_P#D/.ISV^SYLI<*59OTAS22
MM5V]>&N\(N!^.H.M:TD;;*5*C7GDC3;UZSLE           #HW6TT5VCBCN-
M.R>.)Z/:UZ:IJ=X :YF!&R+ %YBA8UD;:=R-:U-$0K_R._\ &+U^XO\ 0L#F
M+\Q;W]W<5^Y'G^,WK]U?4A%6C5=ECW)T(JE-\,)[LY2TRR;]:USOX(7(V=I'
M-ZTT*<6G6U<IB=)?%1*UR;_*B!(7(=Q4CKE!1)+E5=T=O1$1WF)%7C^!&O*(
MJ6TV5-U5RHBNT:FOE*-#Y',KG6"\QJNYCD5/.3=?L2VC#[HTO-;'2K*FK$?T
MD+<CVD=%A>Z5+D5&RR(B+UZ*27F+ES:L=R4;[L][74S=EFSWD'8;F5A'5/\
MMJG\Y".%[C277E/W*LMTS9Z:1NK)&\%W(;HG)UPKM(G.RZ:D?9>X>I,+\HVL
MM%O55IJ=NC%=QZ JU+OC.[S!EWQE[S!4
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M?73^8E#)UN-?<]6N-^:_^EL$C,55C9^Z@UZP@ "@
M          (                                         !H.>GT;7
M+\/6;\AH.>OT;7+\/6==/^[7[K7NY\E?HWM/V9NYI&2OT;VG[,W<9OW+?<GN
M #H.2                   &O9@_,R[?8.]2FPFO9A?,R[?8.]2F\?UQ]UK
MW:9R;/H_=]Y>2H17R;/H_=]Y>2H=-3^[;[D]P '!              0
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MF-[->K#,]E%43HYB*N]JHJ*J=P%P =*Q5_Z4LE#7Z(GNB%LFG>=TJ
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M '5_J A?DB?X%??M_P"I/A 7)$_P&^_;_P!2?0   !S6O8YCVHYCMRM7>B@
M0_F7DG;K\]URPVK;9=V:O1T:JB/=^!I.%\TL1Y>W!MDS!IIIJ1J[#*I$_KW%
MED/(Q1AJU8GM[J.\TS9XUW(O[3?Q(.6P7RWX@H65EIJ8YX7[]R[T/2*QW[+[
M%F5EP?>,#U$E9:VKM/IW.UT_ D?+/.:T8IV:&Z.2@N[=&NB>FRBNZ?X@2J5P
MSZ^F[!G<G\Q8N>HAIH%GGF9'"B:J]R[M"K6=F*+-7YP87K*2L9+34B(DSV\&
M^,"%J&?)L_=0R>;8KY;;W2LEM57%4,V4UV5WH>D4
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M^9EV^P=ZE-X_KC[K7NTODV?1^[[R\E0BODV?1^[[R_UDJ'34_NV^Y/< "'!
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M1<U1P-T8SJW(15HW?&7O,&7?&7O,%0                   !
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MRGM7/Z[+D<K$7JU DT %0
M            !
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MQS9KK%<6X6S"CDIZAB[,55+NU3HUU+!02QSQ-E@D;)$]-6N:NJ*GD*C[
M
M           (                       #7\POF9=OL'>I38#7\P?F9=OL
M'>I3>/ZX^ZU[M+Y-GT?N^\O]9*A%?)L^C]WWE_K)4.FI_=M]R>X #@@
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M)9EI8(EW;G)M._$*]BBIHZ*C@I8$TBA8C&IY$.8(J*FJ:*B[]05
M    @           >+=\)V2]U;9[K;X:F9-R.>W5="O^&K?26SE07.DM\+8*
M:-NC8V\$W(6;9\9.\K=:_P#-==^[^B$(61=\9>\P9=Q7O,%
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M
M                         &OYA?,R[?8.]2FP&OYA?,R[?8.]2F\?UQ]U
MKW:7R;/H_=]Y>2H17R;/H_=]Y>2H=-3^[;[D]P '!
M                   " =8'8I>#N\YS@I.#N\YR+ =.7Y1W>=PZ<ORCN\(^
M  4                      RF_<8/IGQD[P*V<H[,FZ4U]APMAJ1\<WQ9G
M1*NTYR[D::5;<I,Q+G3,J9JRKA=(FULOE<B^L];%U,RV<J"CJ;LQ/<D]8V1C
MG\%0MDKMI=6KJU=Z:=1%5"]Y/'_:51^<[VG-09+X]AKJ:5]RG5C)6N=K,O!%
MW]);;5?*-5ZPCJVR)\%MI895VI8XT:Y5Z5.R 4
M =8&6?&0K=:_\UMW[OZ-+$S5U)32(VIJ8HW=3G(BE<[-+'-RJ;J^%[7L5-SF
MKJB[D(0LH[XR]Y@R[XR]Y@H                   @
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MWW=_\JD/<D+YFW;[X[U(03SJO68 *       $
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M;G(L;6KLJ![EMG?4VZFGD31\L:.<G4IV##6HUJ-:B(U$T1$Z#)4
M             ( !$^9^4LN-K[%7QW:>D1K=G8C?HA$V5V'EPMR@ZFSNJ'5*
MT[-.=<NJNUT4MDWXR=Y6ZU?YK;OW?T0@LB[XRF#Z=Q7O/DH
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M"R__ ,U2>F@&T@U;WPL*Z?XU2>FAZ5EQ+9KW(^.U7""JD9O<V-VJZ >N
M
M     !     Z57:J"LDYRII(I'\-5:FIP>#]I_T$/HH>H"Q:8\UW>7X/VG_0
M0^BA]Q6.V12(^.AA:]JZHNRFX]$#BMZF\@ (@   "
M                 .Q2\']YSG!2<'=YSD6 Z<ORCN\[ATY?E'=X1\  H
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M:V[]W]$+(L^,G>5NM?\ FNN_=_1"$+(NXKWF#+OC+WF"@
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MTSI941J[;E7<;G:_\,I/LF^I#L@.L %
M
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M&0K=:_\ -==^[^C2$+(N^,O>8,N^,O>8*
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MP'>"@5ZY6W'"GWU"PI7KE;<<*??4!"?+7_A=)]DWU'9.M:_\+I/LF^H[(
M                                                $  !
M                                                           "
M )T@=BDX/[SG."DX.[SG(L!TY?E'=YW#IR_*.[PCX !0
M     <55414E+-4U#MF*)JO<[J1"F6*+MB'.?'[[=:]KW&QRL8Q%T:UB*OC*
M6CS>J)*7+>^R0ZH[W.Y-4Z").1O04_Z$O=P5K5JDG1B.TWHW3@027DYEVW+R
MS5%+[J6>:J5KY47@UR)IN) 1=Z>0P"B&,U<CJ3&%7576BJY([F]-S57Q5\A#
M^5&++SECCY,/7W;;12S)#(QV]&[]$5OD+C_B5=Y7-!#28BL%S@1K:F5=ERHF
MBKLJBHI%6B:YKFHYBZM<FJ+U@\3 \SZC!EEFE761],U7*O2>V5       Z
M         -/S/QW1X!L<5PKHEE=,Y8XF(N]7 >OB_$-#A:PU-TN4K8XHF^*B
M\7.Z$0TC)',N?,5UY6>E;3QT;F\WL]*+UE=<7W7&&:3:NZ3030V:D;M;&](T
M]JDC\C#=3XE3JYLBK)A @*C+/C(5NM7^:Z[]W]$+(L^,A6ZU?YK;OW?T0A"R
M+OC+WF#+OC+WF"@                                   "
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M/LF^H[)I^!<>8>Q)1T\%KN$+JAD:-6)7IM:HAN!0           !
M       $  #H
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M>EXONDEU<B*QFNJ1=?XA4OV2A_1EFH:%%U2GB;'YD.X9XF"H
M    (:]C+!]JQ?#10WN'GH:2196LZU-A" :)F;;:.TY5WJEMM/'30-BW,8FA
M$_(Q^0Q-_P"V3'G!]&M[^R(<Y&/^[XF_]LBK)I_0X:BKIZ;3W1/'%KPVUT.8
MCC-W+FHQY-024USEH?<S%:J,=IM:KJ$;XVZV_:36N@X_70KO9Y&2\JF[/B>U
M[%3<YJZIP0[*<G>X*J)X257YIK&5N'GX7Y0=3:):EU4^G;HLKEU5W *MD[XR
M]Y@R[XR]Y@J              $
M                \C&'S4NWW=_\JD/\D+YFW;[X[U(3!C#YJ7;[N_\ E4A[
MDA?,V[??'>I"">  4   0\7%>%K5BRVR4-ZI63L<FYRIO:>T9:FNJ=>X"@^8
M[*C!V(;MAJTW2>2VMD5'1H[=W&@*NO$W;.BCGHLRK]'4-5'+4.<BKTH:217>
MLMUK+-7Q5ENG?!41KJUS5T+ZY08N3&F"*.Y/_P!Y8B13>5Z)O4_/Q"QW)MS(
ML&%K)4VN^5#J>6:7;8Y479W@6H!YUHOELN\39+;6PSHJ:^*X]+1?P*C
M            !\R[7,R<W\ILKL]_0!]HG<-.XKG=[9G&^Z53J58E@61=C1>C
MHZ35L87;-;"-M2OO4K(Z9SD9JBZ[U73K(+:Z=WG&A5ZUP9R7.W4];2NC6"H8
MDC%5>A?Q-XRNH<S*?$T;\5K$ELV%V]^_7H F@&5XJ8*
M                                                         0
M                 .Q2\']YSG!2\'=YSD6 Z<GRCN\[ATY?E'=X1\  H
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M5HG?&7O,&7?&7O,%0                             $
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M@
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MMAR'"G*(J[-33.FBIFZ(]_%==%(JUKOC+WF#+OC+WF"H
M                                                \C&'S4NWW=_\
MJD/<D+YFW;[Z[U(3#C#YJ7;[N_\ E4A[DA?,V[??'>I"">  4
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M:YEM\P;%]T9ZC8R@
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M$5L<C7JG.<41=0+2L<CVHYJZM5-44R=>VP+2V^FIW+M.B8C%7K4[!4
M                (#* &_&3O*W6O_-==^[^B$U8BQ[AS#5<REO=QCIYW>,C
M7=1 V$;M0WSE-W&X6J=)Z.9NK)$X+N0A"T#OC+WF#+OC+WF"@
M                                                    #R,8?-2[
M?=W_ ,JD/\D+YFW;[X[U(3!C#YJ7;[N_^52'N2%\S;M]]=ZD()X !0
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M1,NC$5J[U D<&5U34P                   !
M     "                   !U@=BDX/[SG."EX.[SG(L!TY?E'=YW#IR_*
M.[PCX !0                     #+=RHO48"<=X%6LT**7!>?=LQ161.=;
M*BI29TFGBMZ%+,VZ\4%UIHZJAK8)8Y6HY%:]"OF?N%L;XGQ#+3VR%9[-Q8S3
M@1Y:LO<SK5'S=O2JA8G!$<NGJ(JZ"21Z?*,])!SC/^*STD*?^"^;W^HJ_2_L
M=BWX9S:;7TRS3U:QI*U7>-T:[^@&RW7%-V@.M;&RMME*VH769(T1Z^4[)4
M                    ( !H^,LK[!C"YLK;O$KIVILZHG00E@2PT>&^4E76
MJV-V:6G;HQ/P0M,SXR%;K5_FNN_=_1I"%D7?&7O,&7?&7O,%
M                                                    'D8P^:EV
M^[O_ )5(>Y(7S-NWWQWJ0F'&'S4NWW=_\JD/<D+YFW;[X[U(03P "@
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M:%&3
M           =8 '8I>#N\YS@I.#N\YR+ =.7Y1W>=PZ4ORC^\(^0 4
M                )Y $\@$<8TSAL&$+S):[D^3W0SCLH>%\(K"?UYO14V/&
M.4>&\6WA]RNK9/=+^.RB'A?!\P9]6?S(17#\(K"?UY?14^Z?E"85GJ(H6/FV
MI'(Q/%7BJZ'Q5\G?",L+FP.GC>J;G:(0U6X,H\L<RJ*DQ'3)7VBKD;S,VFFS
MXVY?XH!<2DG94TL51'O9*U'-[CE.&AYGW%![E5'4^PG-JG!4.8J
M               ,L^,A6ZU?YKKOW?T:60:YJ.3:<U.]2M]K_P UUWWHN[H[
MD(0LB[XR]Y@R[BO>8*
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M1GRC_HEN_<GK!#L\G[Z)[)]F2&1YR?OHGLGV9(9 " %
M RFFJ:@$15X)J9V5ZE\Q"F9%3F='B.5N&846VZ>(J:]9IERO.<5MH)JRJBV8
M(6JYR[]R(!9W97J4;*]15/">,,U\4VO](69O/4NVK-I->*<39K%5YP.O-$E=
M3_[*LK>=UU^+KO(+"@Q'M<VS;^/HFUWF2@
M      @       .Q2<'=YSG!2<'=YSD6 Z<ORCN\[ATY?E'=X1\  H
M                !E-R@<,E33Q.5LL\3'=3G(A\>[J/_5P?F(0!G'EUBO$>
M-9JJQU[8X)&ZMCY[97S&E>\GF1_JW_G_ -R"V;KA1-:JK5P(B<?'0K!RJ<2V
M^]WJPVJU3-GJ::55>]BZHBJNB(>7[R.8[O%=5/T^W_N;CEGR?9K?>XKIBR?G
M)('I(V)JZ[3D7I"IRP5'+#@^S15&O/,IFH[7K/9&[31J:(B:(@*@
M            0 $X@ 1!FMA''-\Q!%485NJ4E&C516:Z;R*\J;;=;5R@*BCQ
M#4)4W*-GZV7ZW MJS7:3O*VVK_-;=N[^B$59%WQE[S!EW%>\P5
M                                                     " >1C#Y
MJ7;[N_\ E4A_DA?,V[??7>I"8,8?-2[?=W_RJ0]R0OF;=OOCO4A!/  *
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MBB.7N;N(,'^YZ>GE;-;XU1%A>FN[R%Q\NL8T.-L.0W.WN3:5-)8^ECNH#9P
M4    0              &44UC,Y53 -Z^[O_ )5-F-8S/^8%Z^[O_E4"/^24
MJ^]<[J]UR>LFC5="%N25]%SOO<GK)H$ $
M              ZP.Q2<']YSG!2<']YSD6 Z<ORCN\[ATY?E'=X1\  H
M                 !EOQD[S!E/*!4/-BZW6+/EL,]=4T5%[I8R-R/5K=C4M
MQ2JCJ2!S'I(U8VZ.1=4=NXE5^4[7U5?B9;?'9G2.@3]75QL77CUH:?AO,G,*
MQTL=-%[JF@C31K7Q*JHA%7<WC12H'OTY@?Z.7\K^QST&<N/I:ZFCDI)48^5K
M7?JNA5TZBILMN#K6R5\]MI994TD?&CG)U*=D
M#+/C)WE;K5_FNN_=_1"R+/C)WE;K5_FNN_=_1I"%D7<5[S!EWQE[S!0
M                                   "                      -:
MQ#CK#N'JQ*6[W"."H5-=A5W@=[&'S4NWW=_\JD/\D+YFW;[Z[U(;7B?-+!]5
MAVY00W:)TDD#VM37BNBD8\F;&V'\.85N4%YKV4\TE4KFM=TMTXD%F@:3!FI@
M^>=D,=WB61[D:U-4WJ;JQ[9(VO8J*QR:HJ=*%&0       $
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M O7W=_\ *ILYK&9_S!O7W=_\J@1]R2_HN=][D]9-!"_)+^BYWWN3UDT=
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MUW[OZ-+(L^,G>5NM?^:Z[]W]&D(61=\9>\P9=\9>\P4             !
M                              $               UT7B:'C/*K#F+[
MFE?=8GK4:;*JU>)O@ B1,@,&I_X4OI?V,KD#@U>,,NO?_8EH 1329#8/IJJ*
M=D,JNC<CT3:Z474E.")L$+(HTTC8U&M3R(?8                      "
M                                   @ ^9(V2QNCE:CXW)HYJIJBH1-
MBK(3"M\K'U,7/43W;U2-=VO<2V (FPGD/A;#]:RJ?SM9*Q45J2\$7N)8C8V.
M-L<;49&U-&M3@B&0   'TCG)P53BDBBE^5BC?^\W4^P!Y%QPQ9+BBI5VRG<B
M\=&(AJ=UR;P7<&NUMB1/7]IJDA@"#J_DX8>?M.M]QK*9_%$:[<>#)D1B>VR*
M^PXCFT3@DDI8\ 5H?8LXK$__ &6J;6L;P35%U3SGW[Y>:-D39NN'6RL;Q5$W
M^LLJBJG!5_ ^'QLD^5C8_P#>34@K]1<HF2G1$O5AJ(EX.5&+N-EM6?\ @^L3
M2JFDIE_YF*FA)E;8;37-5*JVTCT7_P"DGL-:N>56#;@UW.V6G:]?VFM0#L6S
M,K"5ST]R7B%=?K+H;'37:W5*(M/6P2:_5<1+<.3QABH5SJ2IJ*1Z\$CX(:Y4
M<GV[TDBOL>*:F+3@CGKIZP+$MWIJU45/(9T*T2X(S9L;O]@ODM8QNY&ZKHO\
M3*8SS;L*:5UDDJF)Q710+&W&MI[;0SUE;*V*FA:KWO=T(A6+-7E ,N--76C#
M].V2DD1T3IGHJ*Y---4-;S9S<Q!B##T=FK[9-:U>OZW75.<3J(2"ICR;SFFP
M+;6VBHI&2VY9'2*Y/C(JENL(XEMN*[-%<K/.DL+]-I.EJ]2GYQ(3OR3<2U%#
MC.2S.>JTE8Q7*W7<CD0"WX&FGX J
M        .Q2\'=YSG!2\']YSD6 Z<ORCN\[ATY?E'=X1\  H
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M?&3O*W6O_-;=^[^B$(61=\9>\P9=\9>\P4                      (
M
M $
M       &454X+H8=H[XZ([O34 "OO*VPM+76&WWBA@;I1JJ3[#=/%7@5+/TO
MKZ2GN%%-25D;9*>9JL>UR<4*Z8XY-T=36RU6&JOFXWNVN9>J;M>HBJMITD\<
MDS#-178QDO+F+[DHF*U7+TN5#U\-\FBMDJVNO=:D5.BZN:Q4U4L?A3#ENPO9
MXK;:84C@C3>O2Y>M0/8UU5?* "H
M      ZP.Q2\']YSG!2<'=YSD6 Z<ORCN\[ATY?E'=X1\  H
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M>[A?LO75=UJ'5$_NE[=MW'1%)6*
M          [%+P?WG.<%)P=WG.18#IR_*.[SN'2E^4?WA'R$ *
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MS7H,7^ZE:VE318NO<J?U)+UWJJ& !G4:F !G4:F !G7<$4P ,ZC4P ,ZC4P
M,HI@ "&^5A]%L?WQG]3=LHE_^'-E^R.QF)@ZDQQ8$M-?,L,*2I+M(FN]#U,-
MVB*PV2EME.Y714[=EJKTD'I&3 *,ZC4P ,ZC4P ,ZC4P ,ZF-0 ,ZC4P ..I
M9SU+-%KIML5NO>1YE7ER_!-XO=:ZJYY+A)M(WZJ:JO\ 4D< -3.I@ 9U,:@
M9U&I@ 9U&I@ 9U&I@ 9U&I@ "MV>7TZX2_\ 1_,61Z#1L6Y;V_$N+K=B"JG<
MRHH=-AJ)N71=2$-[=Q_!/48U"[_48*,ZC4P ,ZC4P ,Z[AJ8 &=3&H &=1KN
M, #.IK&9&&78OPA6V9LO-+4(B;75O-F &MY=X<7">$J*SNEYU:=NSM=9LI@
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MBHL.S1*NNULKP(+0 T3+#,RT8]I'^XW<S6Q_'IUXZ=:&]E
M                 "JC6N<]41K4U557<B  A!V)\[FP9B4^'[$R.II><;%+
M,OUO(3DJ</*B*!@'Q-(R&&265R,CC17.<J[D1"!L;\H."CNDMNPM1K7RQNV5
M?LKHJ^0"? 5JM'*)N-'6QQXGLRP0NW;2-75"P>'+Y0XBM$%QM4S9J>5J*BIT
M+U*!Z0          !                 >)C#%%LPE:'W&\3I%"FYJ=+UZD
M ]L%:+CRB;I75+FX<LJS1)N1=E5.UA[E%R0U\=-BJUNI6O=HKT:OB^4@L:#I
M66Z4=YMD%PMTS9J69NTQ[3KXGO\ ;\,V::YW>=L--$G%>*KU(4>J"M-SY1-S
MK:R1N&K,L].Q=-I6KO0]S G*"I;A<X[;B>E]P3O5&H_95$1=>"D$] PQS9&-
M?&Y',<FK7(O%#)0                "         ( !H.:&9]GP%3M;5/2>
MOD;JR!J:K^)#R\H+$LKUJ*:PJZBUUVME> %GP19E?G+:,:5"4$W^QW->$3DT
MVNXE33>!@&CYG9D6C 5$UU<_G*R7Y.!N]5[R&'\H3$DCUJ*:P[5$G[6PO "S
MX(PRKS?M..)%HI-*2YM3=$Y%3:[B3^D                            0
M!  (ZSES*ILOK3$YNS-<I_DH5ZNM3NY.XRJ,<82;=:N%L4BO<S1O#<H&\ RB
M;R&\S<\;9A>O=:[3&E?<6^*Y$151KNH"8P5BI^4-?Z.9LMYL7-TCE^-L*FXG
M? &-;3C>S^[K1,BJU=)(E^,Q0-F           !
M               '8I>#^\YS@I.#^\YR+ =.7Y1W>=PZ<ORCN\(^  4
M        !                $                        //Q%<V6:PW
M"Y2:;-+$LBZGH&AYZSNI\K+ZK55%?%L[N\"O.2=A3,C-&ON]]5U3302+.J/\
M9'+JNC?,6RJ+%::BA6BEMM*M*J;.QS:;D\Q /(S@;^B\15"IXW.QHB_@6.Z.
MD@IMB"DDRCSNIGVY[FT,CTD:SXJ*QV[12XM-,VHIHIXUU;*QKT5/*FI5?E@1
M(S&=DJ$31WN9$5?_ %*6.P!,M1@BQRN75SJ5FOF ]X( 4
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MQ'E[''5O5]512+"JJNJJU."DK=!6CD;3N5+[3JOBM:COQW%EP  *
M              -=$<J<41=.\#K JC#E_B'%V<JU>*:*9EN6H5ZJ]%5JQHJZ
M)O+04UDM5+1MHZ>WTK:9J;"-YM%U3S'?1$5>":]9".9&>T&%+]<+-2VV:HJJ
M5=E9-/%UT((DS\LU-@G-:AJ,/K[F69C)]B/Q=AVN_@6XM->LV&Z6XU";*^YD
MFD3N3>5!P/3SYMYCI<\2U\,4<;D_5/7151.#4+:8L5*+!=W2!-ED5%(UB=2;
M*H%50H*:3-?/6>.ME<ZB9,JHB[T2-J[D_$MQ3V*T4U"E%#;J5*5J;.QS:</,
M5=Y(D23XXN]0_17LA1VJ^5RELPBH&>>&VY;9C6J]V+6""H?S[6,\5&JCMZ;B
MUF%[HV]X=MUR8J+[HA:]VGUM-Y!G+%@1UDLLZ_&C<Y$\Y(G)]G=491V-[EU5
M$<W7N4*D( %0                        0\O$]]H\-6.JNEQD:R"!NNBK
MIM+T(AZFJ(BN<J(UJ:JJ]"%6<V,15N:>/J;!^''N6VQ.3G7)P<J<573J((WQ
MQ)>L=Q7?&=;SC+=!*D4*.UTT5=R)YRQ?)4^C%GVK_P"93R<]\.T>%,C([3;F
M-9'%)&CU3]MVJ:J>MR4OHQ9]J_UJ%;MFQB%V%\!72Y1.TG:S9B773QE(#Y+V
M#:?$MRNF);Y$E3S$NC&R)M(KEWZ[R0N5E4+%E@V-NOZRK8B]V\YN2O3MARVY
MQJ;Y9=5 DB_X6L]]M<M!76^F6)[58W2-$5JZ:(I5;*^KJ,N,[Y;')*[W#)*Z
M%Z*NB*BIJBEPV[G)WE-L\V^X<\H)H]SG.C<JIUZA(7)71=Z<%WF#X@7:IX7=
M<;5_@?90                                           =8" =BEX.
M[SG."EX.[SG(L!TI?E'=YW3IR_*.[PCX !0
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MUXKN.GGAE#A_!^!Y;I;%D]T-D:U-KJ51D/E-8,6X.ANUSYSW2DJIXO#<N[U
M;URK&)5Y505,.^-:B-Z+_P JHIW.2U,V7+5&(N^.313:LU\-?I[+2X6FF9M2
M10IS+=-=5;P(3Y*V,::RU%SPU>)FTTDLJ.B65=/&3=L@6B9\9-.LIOGLY*S/
M&"*/15:Z-NB=Y;:\WVVV:W35]?6P1PQM5VJO3>J)KHA4S+V";,?/:2[I$[W"
MR59GJJ:HUJ)H@1<&!-FGA;U1M3^"'V9\B<$31#!0
M                     "  @ '8I.#N\YS@I.#N\YR+ =.3Y1W>=PZ<ORCN
M\(^ $!0                                      $
M "  1-FUDU;\:S_I&A>VCNJ)JK]Z(]?*1DN1V/Y8THY[[K0INTYQ>!:8$$=9
M2Y5VS -.^5NS4723XTZZ^*G4A(H0%      0
MRU='(O48 $(XCR:K+KF:[$[*R-L*S))S:ZZ[M";U7AY$1#  XJJGBJJ:6GJ&
M))#*U6/:O2B]!7K&')\J6W>2XX+KTHW2.VDCVE38_'O+% "L-%D%BB\5L:XL
MO/.4S5W^,JJ6&PEARWX6LD%LM,+8H(D1%5.+EZU/8!  !0
M         !ENY47J*Z8\R%NF*,67"[NN,>S42;34=KJUO0A8H 5;^#=>>"7A
MJ(G#QE]@3DVWGMA/27V%I 01/DIEA6X!K*V:MK4J4G;LHB*JZ&^XRPQ;L76.
M:UW:%)(9-Z.Z6KUH>V"BK]5D%BNSU<R85O7-TSUUW.5%T\I[6"N3],V\,N6-
M:[W8]BH[FT<J[2IPU4L, /F&*.")D4+$9$Q$:UJ<$0^@
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MM);F;<[]\LZ[U?\ V-O !
M        =8'8I.#N\YS@I>#N\YR+ =.7Y1W>=PZ<ORCN\(^  4
M                            !
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MH&                          @
M      @                      '0 G2!V*3@_O.<X*7@_O.<BP'3E^4=W
MG<.G+\H[O"/@ %
M"                                                    !]1_&_!
M?44FP!_F%;_]Q?\ S*79C^-^"^HI-@#_ #"M_P#N+_YE(L+LR?*.[S"*J+JB
MZ&9/E'=Y\E15;E<8:AMMWM=_HF)$^I562;.Y%<F_7O)PR/O3[[EG9ZB9VU+'
M&D;W+TJA'?+%<Q,'V5JZ;:U#M/,A[O)@B?+E&D3E5O.2/:CNI%UWH16OYI9Y
M5-!?7V'!M.VKK&+L/D5%7QNE$-6DK\YIXEK$I'M8J;6RG_\ LD?"V4]AP3BQ
MV(;E<X97[U:E0J;E7IWFZ7+,K"=N8O/7BE5$3>UKT @S V>M^M>(HK1C2E1L
M:N2-SE14<Q57B3+G'>[Q9,"2WG#.P^6%6R.5W3'UE8.4#B>PXGQ?35V'=E=$
M1)9&)IM+N+?6VBBN^!*2AJTVXZFB8Q^N_P#9 T7D^9B5..[-7)=5C2X4KT31
MJ:;353B2PFBKHO!/44[R>KYL 9UU%FJ]60U,[J947<FBJNBEI<?7V+#6$KG=
M)%32*)R-WZ:JJ*$0MB'-7$-=FXS#&&.:=3I*D2JO3IO53;\ZLUFX#AI[?0QM
MJ+U4,148J;F>;RD:<E&P27;$URQ37-5Z1N<UCW)^VN_B>7RF:"NM&9E!?)('
MST?B2-5456ZM=KLA7=I[QG%?(DN%+1N9"]-I$TTW><[N$L\,0V+$45HQW1I'
M&JHUSE14<W7I[C><'Y_87N-)!%7:6Z;91JL5=&HIZN*,&X*S0KJ:M=70/GC9
ML_J%;M.3R[P),IYHZFGBG@<CX96(]CDZ47@?9UK911VZW4U# JK%3QI&Q5XZ
M)P.R5'AX[^9=Y^P4K-R1]??"O'V*^M2S.._F7>?L%*.Y=8HON%L05U5AJG=/
M42(K'M:U7>+JO4187_T7J4X:V2."CJ):ER-A:Q5<KN&FA4U,Y<R>BUS?E.]A
MY=YQ7F=C2!:!:2NBBD\5R,:YJ*@1Y^72)79^1OM>^%U>]S%;]752VN8>,[;@
MBQ.N-R>FJ^+%'TO=H1QR?,I9<(+)>;ZB.N<J(D<:MWQ(1GRH+I/><S*.P-D<
ME-#S;6MUU1'/T370*[3<SLQL=5<G@Q0(RE:NB*Q/ZZAV9>8^!:N)<3T*.I7.
M\;;1>'?J62P-AZBPSAJAH*&".-6QHKU:U$5SNE3ZQIA^CQ+ANX6ZN@CDYV)R
M,<YJ*K7:<4 Z.76-;=CBPQW"W2(CT1$EBZ6.ZC2<[<W/ F6.U6B)M1>)6HNB
MHNC/[D1\F>Y3V#-.OLKY'+3/1\2L5=VTCM$4X^4)2UV'<X([[/3.GI';,C-I
M-6+IJF@'K177.2YQ?I""C<V)R;:-1--W'K/0P1GG>K7B)EEQW2-B17)&K]E4
M<U54WO"6?6%;G3015<B4$VRC58Y41NIW<0X&P5F/=X+LE;!)4,:FZ!6ZNTZP
M/K/"[XHH+-2NP=3-J8IVNY]W4Q47>58RPNF*+?BFJJ,+TJ3W)=><8O1Q+RUE
M*RCPU54T?C,AIG,:KN.B(59Y,._-2YHJ:IJ[H\K@+'Y9UMZN&$*:HQ1 D%T<
MY=MB="=!M!Y5_P 06NP1QR76JBI62+HQ7KIJ>-[Y.$^V*7TT"-O;Q0IARA_I
MM?\ :Q>M"W&'<26G$"RK:*R.J2)41^PNNA4?E$?3:_[6+UH%A<5KUCL\;V_&
M92M<G>C2L>'>4%<Z2OO;+XR.98MIE)$QJZN?M*B)ZBS3O\#3[HG\A3+)&P4U
M]SB<VMC;+!3U+Y58Y-4=XR@;74XLS:OL3KC1V]\-*OC,:U.CSGJ989Z71,0Q
M63&4+6)(_F^<T5',=T%F&L9&FQ''&UB;D:UJ(A4+E-V^GMN;5!-0QMA66.)[
MD8FFKM>($U9WWG&%KCH6X-I$J8)HW^Z'<=$Z"KF7=TQ10X\JJK#E*DMZ=SG.
M1Z<-5\8O#0/67!U/(_>YU$BJJ_NE7.3NO_QWN7!=T_1_S 2?18PQE095WR\X
MBI64]SIE3F6JFY4._P G3'5VQS9[O47I8U?32L8Q6=2H>UGWHF5=[T1$\3H[
MR.^1I\VL0_;L]0%ANA>XKO:<UL05.=C<,R<U^CEJ5BTZ=-G4L0G!>Y2G.'_\
MSS?OJ_RA(6=S)QE18'PY/<ZQ=I^](8_KNZBO5/CO-#'#GU.'Z'8H]5V%8FB:
M><WKE;V6MN>$K?5T3'R14<CG3-:FNB+HFIK63&=UCL>&**R7FF2E?3-V.>;N
MVO*H5Y#LTLP\"5T+,54".IWKOVTXIY%U+)8(Q-18NP[37:W/UBE;XS?JNTWH
M:M?*K!6:%B6W3W*D<CWHYKD5NVFG5J;)@+"%NP9:%M]H>Y],Y5?J[K AF7-C
M$3<YDPVBQ?H]:I(E3IV=2><1WBBP_:ZJXW.5(J2!-7.7U%1Y_P#,LGWYOK0D
M#EBWR:GMMNLT3W-CJ5YYZ(O'150#P+OG3B[%]XEH<$4'ZA':(J(NTO4J[SJU
M>+\V<'M2MNU$KZ;B[:35$3\%)CY/F%*/#^7]#4L@C]VUK$DED5J:^<D>LHZ>
MX4TE-61,FAE:K'->U%W+N C_ "@S1H,?T3HUV8+I$FLD*[M4ZT/-Y0^.+K@:
MR6NILJL1]1(YKU?U)H0-1L?EUGXV"A>YM,VHV4:BZ(YCDX$H<L9=<+6%=$WR
MN7SH@'B5.>&([];K?;<)4'NFZ+"U:J5&KHCEZ$-?N>.<T\)/;77BF<V#7]I/
M%]9+O)BP]1V[+JGKT@B=6U;E<Z56^-LZ[D-_S!H*:Y8+O$%7#'(SW.Y4VFHN
MB@:]DUF+!F#8I9E:V*OIM&SQHF[54XH2#UE4N2&]\.+KO3M<O-JW>G7IJ6M*
M@
M                         3I [%)P=WG.<%)P=WG.18#IR_*.[SN'3E^4
M=WA'P "@
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M,6HKL*W=&IJY:=V@167DE?/F[]SOZEKRJW)0I9X,<79TT,D;51=[FZ=9:E
M *                           !
M                       #K  [%+P=WG.<%+P=WG.18#IR_*.[SN'3E^4=
MWA'P "@                                      !
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MR1K7L<FBM<FJ*9!1X=1A'#E1)MS62A<_CKS2;ST+?:K=;45+=0T]+]DQ$.X
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M:&C>Y]'104[UXNC8B*IV@  "  @
M                                0               #K [%+P=WG.<
M%+P=WG.18#IR_*.[SN'3E^4=WA'P "@
M                                                   $
M                                                     @
M                                            (        $
M                  "                                       [%
M+P?WG.<%)P=WG.18#IR_*.[SN'2D^4?WB$?( * ,F.@ #)@       (  ,F
M    R@ P!UA.(          (     (         !GH,   @ &3  #H,@8
M   9 &  @ #H'0    &3'0     =             !T    !D 8 "  .LR!@
M&3"       !   '6 !DP  0   @ #I"<0 '69 P   "     ,F  "   9 P
M  '2$     .L  G   !T    !DQT        ST 8 '0    #I   (  ,@8 Z
MP@ #H  #H'0  Z0 !DP  '0       !T  9,)T@   !DQT  $  &4,    !D
MP@ !#(&$ '0    !.!D#  0  9 P   '09 P   ,F.D   .Q2<'=YSG!2<''
%.18?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g98130g00t19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00t19.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1^24&AO=&]S:&]P(#,N,  X0DE-! 0
M    'W4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_A0#%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B R-2XP
M("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C R-2TQ,BTQ-%0P-SHU.3HS,2LP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(U+3$R
M+3$T5# T.C0X.C4Y*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C R-2TQ,BTQ-%0P-SHU.3HS,2LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC
M<F]S;V9T(%=O<F0@+2!$87EL:6=H=" M($=A;&5C=&\@+2!297-A;&4@4RTS
M(%]'1$,@,3(N,3,N,C R-5\U,# T,C@V-#DP+C$Y7RYD;V-X/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/G)R,SDS-3(W/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @
M(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V
M=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.3)".31&03(Y-$0X1C Q,4)!
M1C-%13@W,S8T,S8T1$(\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z.4%$,3$U1C,X1D0X1C Q,4)!1C-%
M13@W,S8T,S8T1$(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HY040Q,35&,SA&1#A&,#$Q
M0D%&,T5%.#<S-C0S-C1$0CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.4%$,3$U1C,X1D0X1C Q,4)!1C-%13@W,S8T,S8T1$(\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C4M,3(M,314,#<Z,C8Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY,4(Y
M-$9!,CDT1#A&,#$Q0D%&,T5%.#<S-C0S-C1$0CPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TQ,BTQ-%0P
M-SHU.3HS,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.3)".31&03(Y-$0X1C Q,4)!1C-%13@W,S8T,S8T1$(\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C4M,3(M,314,#<Z-3DZ,S$K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX
M;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.3%".31&03(Y
M-$0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.4%$,3$U1C,X
M1D0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HY
M040Q,35&,SA&1#A&,#$Q0D%&,T5%.#<S-C0S-C1$0CPO<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @
M/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A
M8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.#PP0
M%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'
M!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"C_P  1" 3(!EL# 2(  A$! Q$!_\0 '  !  (#
M 0$!              <(! 4& 0(#_\0 6Q   0,# 0,%"0P( P8% P$)  $"
M P0%$08'$B$($S%!418B,E)587&1L105&#8W9G2!DY2AX1<C0G)SDL'1,V2R
M)#0U4V*#)2=#5((X1%9CA/ F177Q1J+"_\0 &@$!  ,! 0$
M  $" P0%!O_$ #01 0 " @ % P(%! (# 0 #   ! @,1!!(3(3$445)!L04R
M,W&1(F%B@4+P%32A(T-RP?_:  P# 0 "$0,1 #\ M2   !B7&Y4=M@=-7U,-
M/$G2Z1R((C?:!E@C*_;9M-6UVY3ROK).R/H]9RU3R@Z=CE2GLCY$[5FQ_0Z:
M\'FMWBJW)*=AD@+X0WS>7[Q^0^$-\WE^\?D7]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
MOA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^
M/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS
M>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-
MY?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64
M^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^
M0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y
M#X0WS>7[Q^0]!G^/V.64^Y&2 OA#?-Y?O'Y#X0WS>7[Q^0]!G^/V.64^Y&2
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M1D !D9  9&0 &1D !D9  9&0 &1D !D9  9&0 &1D !D9  9&0 &1D !D9
M9&0 &1D !D9  9&0 &1D !D9  9&0 &1D !D9  9&0 &1D !D9  9&0 &1D
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M=U5>:^=ZJKI)GN55]*GJ?A>.)O-Y^C3'#" ![K8
M
M
M
M
M#]*>:2GGCFA<K)8W(YKD7BBH?F>H!=+9O>O?[1]NK'*BR+$C7KG/?)P4Z8A;
MDR5CY;!7TKG*K87HJ(O5E5)I/E>)Q]/+:L.:T:EK-3JJ:=N:HO%*:3_2I1IR
MY<Y5Z<K[2\NJ/BY=/HTG^E2C2]*^E?:>G^$^+?Z:8G@ /7:@
M
M
M
M
M         >IUGAZ@$]<EA55VH$SP3F^'K)^( Y+'^)J#_M?U)_/FN/\ U[?]
M^CGMY:S5'Q<NGT:3_2I1I>E?2OM+RZH^+ET^C2?Z5*-+TKZ5]IW?A/BW^E\3
MP 'KM0        'N!@#P#                                   'N /
M          @ 'N#P  $0                            /<'@    !@ !
M@]P!X $  ]P>  #W '@/<!4 \ "    ![@8 \ /< > !     ]P>8  8
M #W '@&  ![@8 \ P>X \![@8 \ /40#P#'                 ]QP \![@
M\    #W!X    'N!@#P ( ![@\P  /<< /    P  /43TG@
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M0JR5O.*WK;GBBDW\HN@BN6E[5J"&7#6*UJ-\9']!%9OP^6M+6W6WNB-UE7K
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M5*-+TKZ5]IW?A/BW^E\3P 'KM0
M   /UI9G4U3%/'C?C<CVY[44_( =EK#:)>=5VV&BN;*=(8ERWFVX4XU0"E,=
M<<:K&H(C0 "X                           #+I+;75D;I*.CJ)V-\)T<
M:N1#%<U6N5KD5')P5%Z4(W$CP ^HV.D>UC&JY[EPC43*JI(^09E7:ZZBC22L
MHZBG8JX1TL:M15^LPR(F)\  "0    ^FM5[FM:BJYRX1$3BH'R#9,L-W?X%K
MK7>B%R_T,>LM]91)FLI)X$SC,C%;Q^LK%HGQ)MB@ L !ETMMK:J!\U+25$T+
M/">R-51/2I$S$>1B ^F1ND>C(VJY[EW4:B955[$,JLME=0L1U;1U%.U>"+)&
MK47UC<&V&#W!E45MK:]KUH:2>H1G!RQ1J[=].!,Q'D8@/UJ*>6FF=#41/BE;
MX3'IA4]*'Y$@#-;:;BZE2I;052TRIO)*D:[N.W)A8(B8GP  )    #]J6EGJ
MY5BI(9)Y$3.[&W>7 F=#\0;-=/WA$RMJKD3SPN,&IIYJ67FZF*2&3&=U[512
M(M$^)-OR P.K.>!( S:6TW&J8CZ6@JIF+T*R)513ZJ+-<Z:-TE3;ZN*-O%7/
MB5$0KS1XV;8 "<>CB"P    95%;ZRN5R45+-4*SPDB8KL>H3,1Y&*#ZD8Z.1
MS)&N:]JX<UR85%[#Y       "&114-57/5M%335#F]*1,5RIZA,Z\C'!^D\$
MM/*Z*>-\4C>ECTPJ?4?F/(         !$R !F4=KKZV/G*.BJ9V=&]'&KD_
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MJ\%12(M$^)-OD $@#)AH*N:G?40TTTD$?A2-8JM;Z5,8;
M    /J'H  (;;2^H*_35UCN%JE6.9O!4_9>G8J&I!$UBT:DTD2^[7M2WBUU%
M!(M/3QSMW7O@:K78[,D>9RN5XJ> ICQ4QQJD:1$:  :)
M              ]0\/4 GGDL?XFH/^U_4G\@#DL?XFH/^U_4G\^:X_\ 7M_W
MZ.>WEK-4?%RZ?1I/]*E&EZ5]*^TO+JCXN73Z-)_I4HTO2OI7VG=^$^+?Z7Q/
M  >NU
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M\GRKJ*N9\T\E/*YSWNRJKO*5M;X*>@Y_P^)K%XF=SM%'H /17
M                                             #U#P]0">>2Q_B:@
M_P"U_4G\@#DL?XFH/^U_4G\^:X_]>W_?HY[>6LU1\7+I]&D_TJ4:7I7TK[2\
MNJ/BY=/HTG^E2C2]*^E?:=WX3XM_I?$\ !Z[4
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M\%/06-TY_P#3E/\ 19?]2E<F^"GH.+@OS9/W4I]7H .]<
M                                         /4/#U )YY+'^)J#_M?U
M)_( Y+'^)J#_ +7]2?SYKC_U[?\ ?HY[>6LU1\7+I]&D_P!*E&EZ5]*^TO+J
MCXN73Z-)_I4HTO2OI7VG=^$^+?Z7Q/  >NU
M                               #[@EDAE9+"]S)&+EKFKA44^ !.^F=
ML-KN5J;:M;6]LL2,1'3*F^U^.C+3:4^L-EMME=5T-# M2WBQ$I\*B^;/05T/
M<G#/ 8YF=3,1[1*O([S:CM"JM9UK8XVNI[9"N8X=[.\O:IU&R/75BT[HROM]
MUJ'Q54SG*UJ,545%3"$-'N36W"TG'TH[0<L:T_>OD;-7U,L:Y8^1SD7S9),V
M&:OM&E*FXOO4[HDE1$9AN<D5@TR8HRTFEO"9C<:==4:I=;]H#[]9Y'.8V?G&
MIX.^WCP7S$O_ *3]#ZGML/=30M94-3P)(^<W5\RE<\]H,LG"4R:WYCZHFNT\
M5^TC1NF:=TFC+/#-7R=[SNYN;J?U/QUYM(L>JMF[Z2:16WIS&N2)&+A'YXID
M@P%(X''$Q;ON/JCDA,.Q[7=HTKI>Z4]=4.BKI-YT*;BJBNPN/QP;>U;0M%ZA
MM\<NM;9 R[(FY)-S6\K\="Y1"",@FW!4M:;=]RGE3YJ+:Y8[)9UMVA:)C><:
MOZUC>;;$O;CK4A6TUZ,U)2W"N>Y42I2:9_2J]]E5-;D&F+AJ8HF*_5,5B$S[
M:M=V'5&G*.DL]0^6>.5'.168PF#AMF^MZO15U=40M?/22)B6G1^&N\_I.1R!
M3AJ4Q]+S"(K$1I8F?7FSC4#655[H(HZSI<CH=Y?6AC7G:QIK3]I?2Z)M\?.2
MJJ*K&<VC>'A>=2OX,8X#']9F8]MHY'Z5-1-55$D]3*Z6:1RN<]ZY557SGY '
M=$:7"4-G6UNOTU3I0W2-]QH$7#=Y_?1IYE7J\Q%X0SRXJ9:\MXVB8VL35:QV
M7794J;A10,J7<7I[GXJOG5.D_6IVPZ6T[:XZ?2]O=.U'82%GZM&IVE<L@Y/_
M !^.?,S,>VU>2%BKW=M&[4+8QU;<%MU= Q=ULC\(U>GKZ2O=;%'!63Q02I-$
MQZM;)C&\B+TGX*B+T@WP8.CN(GM[)B-/4)AV6:XLFG] 76U7.H='63K+N,1B
MKG>;A.)#J'J+P+YL,9J\MDS&Q5[Y5[5R?K25$E)515-.N)H7(]GI0_$(::[:
M2L?J7:W8:[0U72T]9(MUFI4CPC%3#U3CQ]97%55557*JJO2J@\,,'#UP1,5^
MJ*UTW>B;E#:-56VX5+G-@IY4<]6]."7]KVU"RWS2<ELL<SYI:AR))EJMPU.L
M@5#W(R<-3)>,EO,(FNYV\" '0L]151,(JIZ%/     _6EJ)J2HCJ*:5T4\;D
M<Q[%PK53K)XT=MNI9J1E#JVDRK68=4IWR/7]T@(&&;AZ9HU>$36)6,35FR=R
MK(MOI-]>*HM+UFLU;MCMU%9UMVBJ1L.\BL;(C4:D:=J)VD#GAA7@,>]VF9_>
M58I#])YI*B:2:HD?+-(N\Y[URKE[54ZC9_KBXZ-N//4JNFI7?XE,KL-=^9R8
M.NV.MZ\MH[+Z6-JMH6SO4,,,U]HHTJMU%=O0[RM7K3/6?,&T'9UIR)]58*")
M]:UJHWFX=QSO-O*5UX><''_X_'XW.O;:G(ZW7^O+IK*J8ZL7F:2/_#IF+WJ<
M>E>U3D0#LI2M(Y:QJ%XC0AV.S?75;HNZ<[$CIZ"5?UU/O81?.GG..""]*Y*S
M6T=B8VL14ZVV9WN1*V[T4;:QR=^CX=Y57SJG2;*T[9M+05CZ*.-:2UP,1(9&
MLX.7LW4Z"LV1DXY_#\<QJ9G^5.2&SO\ 6MJ-1W"NHI'(R2I?+$]."X5RJBDP
MZ-VOVZJLL=JUK2).V-$8LSDWT>B=J=I!9X=&3AZ9:Q6WT6FNUBJ;6.RVVU'N
MFBH8%J&KO,<E/Q:OFR1AM-VB56M9XX^9]S4$*KN1;V=Y<]*G"GA3%PE,=N?O
M,_W1%8A(^RG:3+H]9:*MB6JMDRIWN<+&O:GF\Q(%1JK957R+4U5' V:3B]/<
M_2OG*\'I&3@Z7MSQ,Q/]B:IJUYM;HGV=]CTA2)!1NCW.>3O41O8B'/;#]56O
M2MXKZB]3.BCEC1K51N<KDC8$QPF.,<XX^IRQK3HMHMSI;UJRX5UO>LE-*[+%
M5,9)#VDZ[L5[V<4%HM]0]]="V%',5BIC=1$4AK(SPP6GAZSR_P"/@Y3M)CM^
MN+'#L7[GI)WI<^:<WF]Q<95RKTD.9"%LN&,NN;Z3M,QMO-'UMYM5VBN5@@J9
M9J=45R1,5R*G8['436[:/HG4E'%W7V](*V+PF21[RHO6<)L'U73:>U%+2W*1
M(Z.M;N;RIP1WG7L.ZU9L7COUVGNECN<,<52[?5BIO(F>Q4.'B9Q]767M[3"D
MZWW;#2^O=/)J*VV'1=#&R"H<Y9I&LW>A,]!P?*4JI'ZWIZ9518XZ5KDQVJJG
M>:)T-9]FLDMWU!<J>2JW%;&J\-U.M&IUJ0CM*U,W5FJJFY1M5L'^'%E,+NHO
M!5*\+2ML_-C[Q$>9^LE8[]G+&;9)XZ6[T<\ZJD4<K7.5.Q%,((>K,;C31-6V
M?7EAU-IJEI+14OEG8]%5%8J<$(FL%XK+%=8+A;9713PN1R87@Y.Q>U#7Y/#'
M%@KBITX\(BNHTL13[4]':EH&-U;;F1SM;_ZD?.87S+U!-I&@]-4<\^F+=&^N
M1N&[L6XK_2I7@9,/_'X_&YU[;[*\D-WK+4=9JJ]3W&N7#W\&,1<HQO8A(VH]
M<6.MV.TE@IYW.N4;(T='N+A%1>/$AX9-[</6W+'Q\+<KP &Z3J++63:?HQ-*
MTMLNE0LC4@;'+$^)51>'%"M)Z<^?AZYXB+?16:[6+35&R7&$H:1/_P!E4^_T
MHZ$T]1S2:<MT;JCJ9%$D:N^O!7 ]SYS#_P ?2?-IG_:.1U.O]:W'65S]T5KE
MBIF<(:=KLM8G;YU/=EUXH[#K6@N-RD6.EBSO.1,XX'*!#JZ->3IQVA;7;3NM
MLVH;?J?62W"TRNEIO<[(]Y6XXIG)O=ANNK?I1;C!>ZF1E+-NNC:B*Y$<F<\"
M*<@I/#5MBZ4^#E[:2'MJUE2ZMOT"VQ[GT-,S$;EX95>G@;+89K"SZ3FN*WF=
MT23(FYAN<D4GHGAJ3BZ/T1R]M.CUU=*6[:RK+A0O5]+)*CFN5,+C/82=M+V@
MZ?ONA8+9;JE\E6QK$5JL5.AN"#<GHMPU;<N_^)RO$X)A3]Z*JFHJJ*IIGK'-
M$Y'L<G4J'X!#?79985VTS3&IM#I;=33K!6R1;DB\VKD1Z)X2%?ZJ..*HDC@E
MYZ)KL-DQC>3MP?GD\,</#UP[Y?$HB-!F6BXU-JN,%;0RNCJ(7(YJHO9U&&$-
MIC<:E*PU)M3TAJ:VQ1:PM[&3L3]MG.)GM3L/SK=JFE-,6J2#15O:Z>9>*M;S
M:(OC+VE?LC)Q>@Q?WU[;[*<D,N[7">ZW*IKJQZOGG>KWKYSO=E.TN72/.4-P
MC?56N3H;O<8U[?01L#IR8:9*<EH[+3&^RQ/==LK=4MKG44"5*+O[J4_[7:<#
MM3VG2ZMB2W4-.M+:XG\$WN,G8OF]!&N3PQQ\'2EHMWF8]T16( G6 AUK)ELV
MNK%3;&I=/S5#TN:P/8C$8N,JY53C]9#2)AJ9/44\,<6&N*9F/K.T1&@ &R0
M                                                       ]0\/4
M GGDL?XFH/\ M?U)_( Y+'^)J#_M?U)_/FN/_7M_WZ.>WEK-4?%RZ?1I/]*E
M&EZ5]*^TO+JCXN73Z-)_I4HTO2OI7VG=^$^+?Z7Q/  >NU
M
M
M             ZC/@O-SIV(R"XU<;$Z&LE5$]1@ B8B?(R:RNJJW'NRJGJ-W
MHYUZNQZS&Z@!$1'@  2
M
M      'J'AZ@$\\EC_$U!_VOZD_D <EC_$U!_P!K^I/Y\UQ_Z]O^_1SV\M9J
MCXN73Z-)_I4HTO2OI7VEY=4?%RZ?1I/]*E&EZ5]*^T[OPGQ;_2^)X #UVH
M
M
M
M
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MJ  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J
M ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,
MIVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IV
MH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,
MIVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IV
MH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH
M RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  R
MG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:
M@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@R
MG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:
M@ #*=J#*=J  ,IVH,IVH  RG:@RG:@ #*=J#*=J  ,IVH,IVH  RG:@RG:@
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MY
M
M
M
M                          !.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ O
MH->                                                  Z@
M
M
M
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M45EBUE;)*:X4+$=[I5%1)DSA/K DP#J0
M
M
M
M  G6 G6!DTG2\R#'I.EYD >/\!?0:\V#_ 7T&O
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M3*5,  $XF/5UM)1JB5=5# J]"2.QD#(!\02QSQ))!(R6-?VF+E#[
M
M
M
M        $ZP$ZP,FDZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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M@]P,+V >
M
M
M                    !.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
M                                           :S4UYIM/6&MNM:N(*
M5BO5.WS%8)=L&T?5MQJ5TC1*E*QW!L,>]A.K*JI/&W"VU-TV8WB"B:Y\S8]_
M=;TJB+T'+\EJ>W.V?\Q2I"VXPR*VJ;PW\YX9ZP(U[IMN*YQ0U?V*?W/%U+MP
MPO\ L-7T=4*?W+8=_P"?U#OTZE_$#G- 3W6IT=:YM1,<R[/B1:A')A4<= >K
MG*YZ3P#U$RN.M2N6W;:)=*_4C-$:7:Q5F<D,[G-RKU=PQQZ"QT:X>BKVE/[U
M)W+<HSW5=VJV"6K1Z/?T(UR\%^H#N[%R9[4EL8M[N=3[O>F9$C1-UB^8XRZ4
M-]V ZI@GH'LK+-5+E7O8F7-Z%15ZE+;1R1U#$EIY&RQ/3>:]BY14*]\KJ\T/
MO#06ALD<E>^1)-UJHKFIGH Z[:_=(=0;$*NZ42[T-13<YPZLIQ3UFHY)+D79
M]58Z4G7)MM,:<J*OD\-L]0QWNF:@<K6JG'BF4."Y)=]AH:B[Z;K9&PU&^LC&
MR+C*IPPF0++1^&GI*BV=.=Y4\W-\<7!V<%KKS<(+3:ZJNKI60PPQJY7/<B)T
M<$*O; J.75&V2\:B1CO<\$KIM]4X+E<=/U 8_*/:K-M]M>[P5;3X]9;&)46"
M->UB+^!6OE;6B6FNMFU%&Q7,1[6.5$Z%;Q3*_43QH&]TVHM)VZOHYF2HZ)J2
M;JY5KL<44#E>4,Y&;++GO=:HGM.<Y)K'-V>R.=T+,['K/PY5VHZ>CTA3V6.5
MCJRLEWEC:[*HB=J?6==R?[')8ME]LAJ&JR>7>F<BIA<.7@!I-HE?M0@U-.S2
M--"^THB<VYR)E5Z^LY"[:DVSVJUU5PK:6F934S%DD=NIP3UECT<J)P54.5VL
M*J[,]2<57_9' :W8IJ:OU;H6GNEV<UU4]RHJM3"=)W:D4\F/Y*Z+]]WM)6
M
M
M
M         3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
M                        # PO8     )U@:K5-YIM/Z>K[I7)O4]/&KG-
M\;S%+;3<M4WC6%SN^SZBJ*%)9%<K*5."(J\,YX9+7;;K94W;9E>*>B8KYFQ\
MXC6]+D3J.6Y+-=02:!]PTZQMN--(J5#%1-_.> $8>^FW).AU=];&A;KMR1%7
M-=]3&EM=V3Q5]0W9$_97U <WL^DNLNCK6_46][ZNB1:C>Z=[SG0'KLHO'I/
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MO+OVO.=>3>DTGEMY  %0
M
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MNUQ=2VV:FLT#/U,\J8YUV0)$                .5VK_)IJ3Z(XZHY7:O\
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M>0AR8O\ A]Y_C_T)O'&_K61;R  Y4
M
M                                                   $ZP$ZP,FD
MZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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MPGKZI%1_,H_*(O8J]9.EOHJ:VT<=)001T].Q,-C8F$0R#P
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M].Z2;+4<F,ICI)8-^,F+9K3";>0 ',@
M
M                                                     G6 G6!D
MTG2\R#'I.EYD >/\!?0:\V#_  %]!KP
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M)\F/Y*J+]]WM)6(IY,?R547[[O:2L 0U>IK+#J"RSVVI>K(I>E4-H":S-9W
MB!-@]C_][.I[^@>Q_P#O)_Q)>/<G1ZO-\D[E$'Z!['_[R?\ $?H'L?\ [V="
M7\G@]7F^1N6CT;INFTK9FVZCD=)&U<[SNDW@!SVM-IW* ]WE1,(JG@('UON[
M5/%55/  /4<J="JAX ![E<8SP/ ![G'0%55Z5/ !ZCE1,9X'@ !#U'*B=)X
M   ]1>.3WG'>,OK/D   !](]R=#E/%557*G@ !.D #U55>E3P
M
M
M               $ZP$ZP,FDZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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M::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M
M
M 3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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MGM?PN:"K^P4"V:^<\.>V?55RK-&VNHOK%CN<D2+.U4PJ.]!T(
M      Y7:O\ )IJ3Z(XZHY7:O\FFI/HC@.3Y,?R547[[O:2L13R8_DJHOWW>
MTE8
M
M
M             !.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
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MF/Y*J+]]WM)6(IY,?R547[[O:2L
M
M
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ME=J_R::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M
M
M      3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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MASK%_P#69_..=9_S6?S <_L^I+E0Z-M5-?'*ZY1Q(DRJN>^.@&<\47.>M%
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M@/#E=J_R::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M
M
M         3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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M*_<FJ[SZ=U_>=)54BN@<]61L7H1R+T^HM&SB["KTJ5%L"^Y.5-.D?0ZX.14
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M:2L
M
M
M              G6 G6!DTG2\R#'I.EYD >/\!?0:\V#_ 7T&O
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M2;-=,:BNDEQNU DU4]$1SUZSB]HFR;2%LT+?*ZBMK65,%,Y\;_%4F4Y7:O\
M)IJ3Z(X#D^3'\E=&O_6[VDK$4\F/Y*J+]]WM)6
M
M
M                                                 3K 3K R:3I>
M9!CTG2\R /'^ OH->;!_@+Z#7@
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MKM7^334GT1QU1RNU?Y--2?1' <GR8_DJHOWW>TE8BGDQ_)51?ON]I*P
M
M
M
M     "=8"=8&32=+S(,>DZ7F0!X_P%]!KS8/\!?0:\
M                >MZ0")E.E./G(_NNT&U.U^[0];02SRR-3>>Y$6-<H<%M
M7T?M#?J=]5HZOJ9;?4=]S:/1.;7LXD(U=FUPS:0VAGEF74V$7>5R;V,<.(%G
M+UL*T1<9WR,H%IGN7ON;D7"KZ#ZL>P[1%JF;.MO]T2,7>:LDBX14\Q#BZ0VT
M97,]6J_Q&GBZ.VS.:K5GJ\+P7]8@$Q:9VH4-PVA5&CJ&WK RDRQKVHF.'9CJ
MXDG8PJD#;!]D]XTUJ&>_ZH>B5+FJD<:+EV\J\552>0!I-4:4LFJ888=04+:R
M.%<L1RJF%^HW8 X--C^@U_\ \?A_G<<=>+-L@M>HZ6QRVN"6X5$J1<W&]5W'
M+V\20-K-]ETYL_N]PIEW:AL6[&[L<O60OR?=EM->Z6/66H999:F2;G:=F>&4
M7.5^L"5JC9'H&G@EEDT_%N1M5R]^[H3ZS@M%0['-77!U!1V9E-6(]6MBG>J*
M_"]7$GF>)DT+X96HZ-R;KFKUH5MV[;)K=INT.U5I7G*26D>CY8D=WO3TIU@6
M*M5MI+/;H*"W0I!1P-W8XT7.ZAEG(;)+_)J79_:+A4KFI="U)5[53@=>
M             .5VK_)IJ3Z(XZHY7:O\FFI/HC@.3Y,?R547[[O:2L13R8_D
MJHOWW>TE8
M
M
M                   !.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
M                               'J*J="X]!JWZ?M$EY2[R6^!UT1,>Z
M53O\>DV8 ^MY>U?6-Y?&7UGR /57)X    ');6;)+J'9]=Z"G173K$KXVHF=
MYR=1#O)[VGVVR6E^E=3RI0S4LBMB?+P15SQ1>PL@G#H(JVA;#M/ZNJ9*^G8Z
M@N#URY\>=UR]JH!W2:LT\L7.>_5!N=/^,WH]9"'*%VHVJZ6!^E]-S)7U-8J-
ME?%Q1J9Z$3K->O)=N'.X;J"#FL]"L=GV$A;.]A5@TG61U]4CJ^X1KO-<_*L:
MO:B =)L=L<NGMG5GHJE%;4<RUTC5ZE7C@[,]7@N,8QPP>
M  #E=J_R::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M
M
M         3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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MJCE=J_R::D^B. Y/DQ_)51?ON]I*Q%/)C^2JB_?=[25@
M
M
M                                                      $ZP$ZP
M,FDZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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M(XZHY7:O\FFI/HC@.3Y,?R547[[O:2L13R8_DJHOWW>TE8
M
M
M                                                        !.L!
M.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
M        !.DK?M\O]YU1KNET%I^62)J.;S[HW*F\JITKCJXED6])6#4MPCT?
MREY;C=45M'5(U&RJG!$5$X_@!IMKVQZVZ"T'3U\=7)57!T[6/>Y,(F<91"5Z
MC9_!M"V.:<H9:I]--3T_.0N:F45V,84Q>5;+'4;-:66"1DD;JICFN:N45,H=
M[LWJH*#9E9*JKE;%#%2(]SG+C@B 0QR=[Q==-:ZN6AKU*^1D:+S;7JJ[KT[/
MJ+*KP54*O[.:YNKN4?<;Q;45U%#O.1V.E."9+0+TJ!X  .4VK7V33>@;M<:=
M<5#8E;&Y%QAR]9#7)_V86Z_VN75>J8_=\U6]7PLEXHBYXJO:3#M=LDNH-GEX
MH:=-Z?FE?&WM5")N3EM)MEOLKM*W^;W'5TCU;"Z3@CN/% ,#9?2P4/*1OM-1
MQ,A@CA>C8V)A$3#39<I#9I;:>QSZLLK/<M;3.1\Z,Z'\?"])J]GM;2IRDK_4
M.J(DIUB>J2*Y$:O!O6;+E&[3;966*32]AG2LJJI4;,YB9:B9Z/2!*6Q>]2WW
M9O9JJJ575"0HR1RKQ54.U.+V-622P;.+-25#=VH6%'2-[%7B=H
M       .5VK_ "::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]
MWM)6
M
M                      'N / ,
M                  $ZP$ZP,FDZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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MGDQ_)51?ON]I*P
M
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M,V567W3GOHD5F>PD0YS9S63UVA[/45=(E',Z!-Z!&[NYCJP=&
M      .5VK_)IJ3Z(XZHY7:O\FFI/HC@.3Y,?R547[[O:2L13R8_DJHOWW>T
ME8
M
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MH$MMGAIDJ?=+&M3=D3H5#3'$Q:>VFN*+1>>VH;, &[H
M  "=8"=8&32=+S(,>DZ7F0!X_P !?0:\V#_ 7T&O
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M$<=4<KM7^334GT1P')\F/Y*J+]]WM)6(IY,?R547[[O:2L
M
M
M##O/_!KA_ ?[#,/%1'-5KD16JF%1>M 2C'8EQEO'3^S[23S\:>EIZ97+3P1Q
M;W3N-QD_8ICKR5Y5,=.2O*(<SKW3Z7ZSN2)52J@[^/"9WO,=,"UHBT:E-JQ:
M-2B'3VKKAI>#W#=J&5T3.#5?E,*?I?\ 6U;J2C?:[3;Y&\]WKG-RJKYB5)Z6
MGJ%S/!%*O_6U%/(*.E@?O04T,;NUC413'I6UR\W9CTKZY>;LYW1.G%M&G9(9
M7N]U54:[Z+^PJHO CNS5ERT)>:GGZ-\L+N]?E,(Y.I44FT_.>GAJ$Q40LE3_
M *TR6MB[1RSK2UL/:.6=:1W/M)FJHN;M5LD=4NX-7IQ]1R,D=;;-7T=3>68F
MEE;*['4B\2;XJ*EA<CH::&-R="M8B8/9J2FGDWYZ>*1_C.:BJ5G%:WF5;8;6
M_-+2:ZM+M0:??%2\9-Y)&+V^8X73VLZW35&MNNUOE=S;L,WLM5J$MM1&XPF$
M3HQU'XSTE-4.WIZ>*5W:]N5+VQS,\U9U*]L<S/-6=2B?4VK*O5-.R@M=!)N.
M7OU1-[B=7265]BT!4TTRYF<S>>B)T+DZV"DIJ=<P4\42]K&X/T>QLC5:]J.:
MO2BIE%(C'.YFT[E%<4[F;3N4=;&?]SKNG_$-5M/@DJ=:4T4"JV98F[B^?A@E
M>GIX*=%2GACB1>*HQN,GCZ6GDF262")\B=#W-RJ?61TOZ(IM'1WCBFT=4FT"
MKM,7N.\VV19X>]YQ55-\TSUNNOKY"KH7PT3%Z53+6H2[-1TL[MZ>FAD=VN;D
M_2&&*!BLAC9&U>IB80=*9[6GL3AM;M:W9JKW3LI-(5U/&B;D=*K4PF,X0X[8
ME_PZXX_YB>Q"2'M:]KFO:CF.X*B\45#\Z>F@ID5*:&.%%Z=QN,EYI_5%O9>:
M;O%O9'6T73=;[YLO5H21\J+ER1IWR*B]*'S1[3'T].R&X6YZU$;<.<JJF5]!
M)J+A5QDQ7V^BD<KI*.G<Y>M6(5G',3NLZ5G%,3-J3K:(ZRINNOKM R.F?3TC
M.*)Q5J><EVWTK:&A@I6*JMB:C45>L_2&&*!N[!$R-O8Q,(?H32G+N9GNMCQ\
MNYF=R  T:                   !.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^
M OH->                                    _-\\$;E;)-&UW8YR(I^
MJ>C.""-K6R+4^KM8U-UL][;24DC6HV-9'-QA/,H$X^ZZ;_W,/\Z'Y5-UM]'
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MCOW7(IZ       ?+GL8N'R,:O_4Y$/H
M       3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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M ]SZQE3P >Y7M/,@ >Y494\ #)[G'6> #W(RO:>  BXZ#W*]IX /<K@(N#P
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MO,@QZ3I>9 'C_ 7T&O-@_P !?0:\
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M[25@
M
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MQ/4[SW6K$]3=I[M^ #=T@                  !.L!.L#)I.EYD&/2=+S(
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MW>TE8BGDQ_)51?ON]I*P
M
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MVK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M
M                                                   3K 3K R:3
MI>9!CTG2\R /'^ OH->;!_@+Z#7@
M  !ZTKMMXT/K;5NIYFVN-T]F:C5A;C@U<<>)8@]WEQP54 I_;-F^U:V1<W0U
M%="Q.A&R+@SNXO;'Y0N'VBELMY>U?6,KVKZP()V,:=VA6S5;I]7557+;^:5-
MV5V4WLD[+_\ NH557K4\ )Q-=J*\T>G[-57.Y2)'3P-WERN-Y>I$\YL4*_\
M*[N\\-CM%H@>J)5R[[T3KQT 1W>-5:XVQ7Z2CT^RJI[8CMWFX7*C&IXSE3K.
MCM_)HNTL2/N5^B25R95K4551?K)OV1:6H])Z)M]-21-2:>-LTLB=+E5$ZSLN
MD"J5YY.NIK5"ZIL=X2HD9Q2-BN:]?0:"':WK+3MCN>E;U',^ND;S4<LRJDD7
M5A"XU=5-H:"HJGHYS86*_#4XKA"CFJZ&]ZNAOFMJW,45/4\VC7MW53L]H%EN
M3UHE^E-)>[*Y56XW-$FDSTM1>HE,XK8O>)+YLULM3.Y73-@1CW=JH=J
M            .5VK_)IJ3Z(XZHY7:O\ )IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y
M*J+]]WM)6
M                                         #U$5>@;J]B^H#P'NZO8
MHW5[% \![NKV*-U>Q0/ >[J]BC=7L4#P'NZO8HW5[% \![NKV*-U>Q0/ >[J
M]BC=7L4#P'NZO8HW5[% \![NKV*-U>Q0/ >[J]BC=7L7U > ]PO8OJ/
M
M      $ZP$ZP,FDZ7F08])TO,@#Q_@+Z#7FP?X"^@UX
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MY*J+]]WM)6(IY,?R547[[O:2L
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M3!9MWA+Z2FNRKX_V?^-_12Y3_"=Z3R?Q"E:WCEC79%G@ //5
M                                                       "=8"=
M8&32=+S(,>DZ7F0!X_P%]!KS8/\  7T&O
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MDD <%9=D&B;1*DM-9VRO3H6=RO.[ACC@B;%#&V.-B8:QJ81#Z
M         #E=J_R::D^B..J.5VK_ "::D^B. Y/DQ_)51?ON]I*Q%/)C^2JB
M_?=[25@
M                                    0! (FY27Q/A_B)[2LB%F^4E\
M3X?XB>TK(A[O ?H_RO'@ !V@                     ZO95\?[/_&_HI<I
M_A.])3795\?[/_&_HI<I_A.])X_XE^>/V19X #S50
M                                                G6 G6!DTG2\R
M#'I.EYD >/\  7T&O-@_P%]!KP
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MJ.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M            ! $ B;E)?$^'^(GM*R(6;Y27Q/A_B)[2LB'N\!^C_*\>  ':
M                     #J]E7Q_L_\ &_HI<I_A.])3795\?[/_ !OZ*7*?
MX3O2>/\ B7YX_9%G@ /-5
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M\FFI/HC@.3Y,?R547[[O:2L13R8_DJHOWW>TE8
M
M       $ 0")N4E\3X?XB>TK(A9OE)?$^'^(GM*R(>[P'Z/\KQX  =H
M                .KV5?'^S_P ;^BERG^$[TE-=E7Q_L_\ &_HI<I_A.])X
M_P")?GC]D6>  \U4
M                       )U@)U@9-)TO,@QZ3I>9 'C_ 7T&O-@_P%]!KP
M                                   ]3BI6WE"ZFN]_UA3:$T](]F5;
MS^ZN-]5\_862;TE8+Y70Z7Y3T]9=EYNEJ=UK)7="91.('4Z;Y-NGJ:B9[_U,
M]56JB;ZQ/PU%[#\=4\FVQS4$K]-U4]/6M:JL25V6JN."$^-5)6))&J/C<F6N
M3H5#R61E-"^>=[8X8T5SWNZ$1.D"N_)PU3=;=J"X:'U%(YTM(BK#O<5:N>A/
M,6(ZU*QZ$K(]2\I>XW.U?K**+><LC>A4PB9+.KQ50/$.$VIZ"MVNHK=%=ZU*
M6FIGJY>_W5?YD.[(PV[Z+O>LK9;X-/S+') ]7/1'[N4 W>D]#:+TLUOO73T*
M3M_]>21'/7UJ=<E=1XQ[LI43L21$_J5/_01K]$_WU?MOS'Z"-?\ _O7?;?F!
M:_W;2?\ O*;[5![MH_\ WE-]JA5#]!&O_P#WKOMOS'Z"-?\ _O5^V_,"VK7-
M>U',<U[5Z'-7**>G/;/;166+1EJMMR?OUE/$C)'9SE3H0!R^T#7%HT-:O=MX
MD57ORD4+/">J'4MZ>/05FVJ:0U#K+;#1>[*&9;%'(QB/3P49E-Y0/VFY1-WJ
MWNEL^FJEU)THJQ[W#TH=ALZVZVG4URCM5UI9K;7R+NM63P7+V>8EBTVJAL]#
M'0VVFBBIHF[K6HU./I*T<K#3EOM-=:[U;6-I:R1._2/AO*B]/I M$G3PX^<B
MG:AMHM6C*];92P27&ZIA',BQAGI-Q:]2S4VQ=E]J53GX;?O<>M4;A%(9Y,>G
M(=3ZBNNI[TSW4Z-ZHSG.*;Z\<_4!M*+E%W"EJ6.U!IVIBI'KX2,W,)]9/&D]
M1V[55E@NEHFYRGD1,IUL7L4^=7Z=M^IK!5VZXT\;V21JC%1J(K5ZL%=>3;=)
MM-[1KUI2=ZK#(]6,:O4Y%Z?4!9B[W*DL]MGK[C,V&EA3><]2 KMRBYZFMDBT
MO8JFI@8N.<5F_O>?AT'QRMK_ #<W:M-TCU;STB/E1/VL]!+6RC2=#I/1U#3T
MU.Q*B6-))WN:F\YRIQ XC9[MYMM_NK+3?*.:V5TBHQCGIAKG+U8ZB:/K12O7
M*IT?2Q6FEU/;H4@K()4;*Z-,;V>A?22=L4U"[4NS>UUTSD=.UJPO]+5QD#MS
ME=J_R::D^B..J.5VK_)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M
M                        ! $ B;E)?$^'^(GM*R(6;Y27Q/A_B)[2LB'N
M\!^C_*\>  ':                     #J]E7Q_L_\ &_HI<I_A.])3795\
M?[/_ !OZ*7*?X3O2>/\ B7YX_9%G@ /-5
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MOZ*7*?X3O2>/^)?GC]D6>  \U4
M                                 )U@)U@9-)TO,@QZ3I>9 'C_  %]
M!KS8/\!?0:\                                 ."HJ*F47J  P?>6U
M.>KG6NB5RKE56%N57M*X[1Z*+7&VJGT?%!!26JBPZ188T8YW!%7VEG$Z2L.W
M"CNVA=JD&M[9 ^6EG<W?W47=RB85JKY\ 6%LFD[%9*)E);[72MCC3&71HKE\
MZJ?-]TE8[[02T5PMM,L<K5;O,C1'-SUHIP6G]O>C[I2MDJZA:&?'?LF7H7S'
MXZHV_:4M5%*ZV2^^%6K52-L:IC>ZLJ!Q6QY\FB-L]UT<Q6S4$F>9<Y.^3H7.
M2RB\.'85LY/MFNVJ->7#7=ZB?%&_/-*Y.#G+V?4637I \ " :36];<+=I6XU
M=EA6>X11*Z&-$RKG%7';?=>-K5HO<\"U:.W5BYO*HO86,VPWN?3^SJ[UM&JM
MJ.;W&/3]E5ZS@^31I"W)I3NDKH8JRYW!ZO625J.5G%>C('#+M8VK)%SJV-W-
M].]S/ T\?* UT^K2E;3P+4JN$BYM<Y+>\U%N[O-1[GB[J8('Y3FEZ"BLM+JB
MVPQ4=SI943>B:C=],^8#EZ#E!ZIM%5$FIK'&E.YV'.5JHY$ZU0L5I#4=OU78
MH+M:)><II4XYZ6KUHIRUGH+=KS9)1U%WH:=TM50[SG\VF\CD;THOI0C?DHU4
MU+=-26%TCG4]*JO8BKPSO8 L4U,N1%7!2GE!:VEU+KN6BD5_O7;95B2-N415
M1>*EUNA>LTTNEK!-*^6:ST+Y7KO.<Z%JJJ]O0!7#26WVT:6L<%KM&GV,@B;Q
M7*Y>O6JJ;CX3T2IA+&SUJ3IW(Z<\B6_[!O\ 8=R.G/(EO^P;_8#\M/7"'66B
MHJJ:'FX;C J.C[,H5EME9>-A.T.M2LI'S66I56[Z^"YJ\45,=:%MJ6"&E@9!
M31MBA8F&L:F$1/,ACW2U6^[0<S<Z*"JCZDE8CL>C($%:VY1-GFL4U-I2"HFN
M52S<:LL:HC,\%QV]9F<F70E;:(:[4E]B='67!$YIK^E&JN<DGVW0.EK;4I/1
MV2C;*BY171HN%^LZ9J(UJ-:B(U."(B81 (HY16A:C6.E(Y[9&K[E0OYQC$Z7
MMZT.#V7[=Z2Q61EEUM3U$-31_JV/C8JJK4ZE3M+)IP.>O&B=-7B99;C9J.65
M>ER1HBKZ0*T;0=77+;5J2AL>F:.1+7#)A78PN%7PG9["T.D+'#IO35#::?P*
M:-&JO:[K4_6RV&TV.-66FWTU*BIA5CC1%7ZS9 %.5VK_ "::D^B..J.5VK_)
MIJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
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M_HI<I_A.])3795\?[/\ QOZ*7*?X3O2>/^)?GC]D6>  \U4
M                                                      )U@)U@
M9-)TO,@QZ3I>9 'C_ 7T&O-@_P !?0:\
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MD^B. Y/DQ_)51?ON]I*Q%/)C^2JB_?=[25@
M                        0! *W<IWXUVSZ.OM(<0F/E._&NV?1U]I#B'T
M7"?HU7@ !T                      F+DQ?&NY?1D]J%DUZ5*V<F+XUW+Z
M,GM0LFO2IX7'_K2K;R\ !Q(      ( @$3<I+XGP_P 1/:5D0LWRDOB?#_$3
MVE9$/=X#]'^5X\  .T                     '5[*OC_9_XW]%+E/\)WI*
M:[*OC_9_XW]%+E/\)WI/'_$OSQ^R+/  >:J
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MFFI/HCCJCE=J_P FFI/HC@.3Y,?R547[[O:2L13R8_DJHOWW>TE8
M                                         $ 0"MW*=^-=L^CK[2'$
M)CY3OQKMGT=?:0XA]%PGZ-5X  =                      )BY,7QKN7T9
M/:A9->E2MG)B^-=R^C)[4+)KTJ>%Q_ZTJV\O  <2      " (!$W*2^)\/\
M$3VE9$+-\I+XGP_Q$]I61#W> _1_E>/  #M                     !U>R
MKX_V?^-_12Y3_"=Z2FNRKX_V?^-_12Y3_"=Z3Q_Q+\\?LBSP 'FJ@
M                                                           !
M.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
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M2?1''5'*[5_DTU)]$<!R?)C^2JB_?=[25B*>3'\E5%^^[VDK
M                                      @" 5NY3OQKMGT=?:0XA,?*
M=^-=L^CK[2'$/HN$_1JO  #H                     !,7)B^-=R^C)[4+
M)KTJ5LY,7QKN7T9/:A9->E3PN/\ UI5MY>  XD      $ 0")N4E\3X?XB>T
MK(A9OE)?$^'^(GM*R(>[P'Z/\KQX  =H                     .KV5?'^
MS_QOZ*7*?X3O24UV5?'^S_QOZ*7*?X3O2>/^)?GC]D6>  \U4
M                                                        )U@)
MU@9-)TO,@QZ3I>9 'C_ 7T&O-@_P%]!KP
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M4]SMU-743TDIJAB2,<G6BF2                 .5VK_)IJ3Z(XZHY7:O\
M)IJ3Z(X#D^3'\E5%^^[VDK$4\F/Y*J+]]WM)6
M                          ! $ K=RG?C7;/HZ^TAQ"8^4[\:[9]'7VD.
M(?1<)^C5>  '0                     "8N3%\:[E]&3VH637I4K9R8OC7
M<OHR>U"R:]*GA<?^M*MO+P '$@      @" 1-RDOB?#_ !$]I61"S?*2^)\/
M\1/:5D0]W@/T?Y7CP  [0                     =7LJ^/]G_C?T4N4_PG
M>DIKLJ^/]G_C?T4N4_PG>D\?\2_/'[(L\ !YJH
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M/:A9->E2MG)B^-=R^C)[4+)KTJ>%Q_ZTJV\O  <2      " (!$W*2^)\/\
M$3VE9$+-\I+XGP_Q$]I61#W> _1_E>/  #M                     !U>R
MKX_V?^-_12Y3_"=Z2FNRKX_V?^-_12Y3_"=Z3Q_Q+\\?LBSP 'FJ@
M                                                           !
M.L!.L#)I.EYD&/2=+S( \?X"^@UYL'^ OH->
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M=5SPQTKT=+'E45G'I1>P"T@.5V6ZA?JC0EIN<W^\20M27C^TG ZH
M         <KM7^334GT1QU1RNU?Y--2?1' <GR8_DJHOWW>TE8BGDQ_)51?O
MN]I*P         ^F=)\GTSI I9M'5>[B\\5_WAW7YSG./C+ZSH]I'QXO/TAW
MM.</I\?Y(:''QE]8X^,OK +AQ\9?6./C+ZP ''QE]8X^,OK  <?&7UCCXR^L
M !Q\9?6./C+ZP ''QE]8X^,OK  <?&7UCCXR^L !Q\9?6./C+ZP ''QE]8RO
MC+ZP> 6DY.7'9\W*JOZY_M)1ZU(NY./R?-_C/]I*)\[Q7ZMOW4GR  YT
M  $ 0"MW*=^-=L^CK[2'$)CY3OQKMGT=?:0XA]%PGZ-5X  =
M          )BY,7QKN7T9/:A9->E2MG)B^-=R^C)[4+)KTJ>%Q_ZTJV\O  <
M2      " (!$W*2^)\/\1/:5D0LWRDOB?#_$3VE9$/=X#]'^5X\  .T
M                '5[*OC_9_P"-_12Y3_"=Z2FNRKX_V?\ C?T4N4_PG>D\
M?\2_/'[(L\ !YJH
M                      3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
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MG2?)],Z0*6;2/CQ>?I#O:<X='M(^/%Y^D.]ISA]/C_)#0 !=
M       !X>G@%I.3C\GS?XS_ &DHD7<G'Y/F_P 9_M)1/G>*_5M^ZL^0 '.@
M      @" 5NY3OQKMGT=?:0XA,?*=^-=L^CK[2'$/HN$_1JO  #H
M             !,7)B^-=R^C)[4+)KTJ5LY,7QKN7T9/:A9->E3PN/\ UI5M
MY>  XD      $ 0")N4E\3X?XB>TK(A9OE)?$^'^(GM*R(>[P'Z/\KQX  =H
M                     .KV5?'^S_QOZ*7*?X3O24UV5?'^S_QOZ*7*?X3O
M2>/^)?GC]D6>  \U4
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MRN@N=MIJZC>CZ>H8DC'(N<HIDD;\GF>:?95:.?55W(T:Q5["25 \
M    P;A>+9;GHROKZ>!R]"/>B 9P/QHJNFKH>=HJB.>/M8Y%/V '*[5_DTU)
M]$<=4<KM7^334GT1P')\F/Y*J+]]WM)6(IY,?R547[[O:2L         /IG2
M?)],Z0*6;2/CQ>?I#O:<X='M(^/%Y^D.]ISA]/C_ "0T  70
M       >'IX!:3DX_)\W^,_VDHD7<G'Y/F_QG^TE$^=XK]6W[JSY  <Z
M  " (!6[E._&NV?1U]I#B$Q\IWXUVSZ.OM(<0^BX3]&J\  .@
M          $Q<F+XUW+Z,GM0LFO2I6SDQ?&NY?1D]J%DUZ5/"X_]:5;>7@ .
M)      ! $ B;E)?$^'^(GM*R(6;Y27Q/A_B)[2LB'N\!^C_ "O'@ !V@
M                  ZO95\?[/\ QOZ*7*?X3O24UV5?'^S_ ,;^BERG^$[T
MGC_B7YX_9%G@ /-5
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MM.<.DVCHO=Q>>'_W#O:<W@^GQ_DAH 8&"Z # P  P,  ,   ,  ,#  # P
MP, #P]P, 6CY./R?-_C/]I*)%_)Q15V?-X+_ (S^KSDI;J]B^H^=XK]6W[JS
MY?(/K=7L7U#=7L7U'.A\@^MU>Q?4-U>Q?4!\@^MU>Q?4-U>Q?4!\A#ZW5[%]
M01KNQ?4!6SE._&NV?1U]I#B$R<IY%[J[9P7_ '9?:0VB'T7"?HU7@ P,'0 &
M!@ !@8  8&     8&  &!@ !@8  8& )BY,7QKN7T9/:A9->E2MO)A1>ZNY<
M%_W;^J%DU:[*\%]1X7'_ *TJV\OD'UNKV+ZANKV+ZCB0^0?6ZO8OJ&ZO8OJ
M^0?6ZO8OJ&ZO8OJ ^0A];J]B^H(UW8OJ B3E)?$^'^(GM*R(6<Y235[CH5PO
M^(GM*QHA[O ?HKQX ,#!V@!@8  8&  &     # P  P,  ,#  # PH'5[*OC
M_9_XW]%+E/\ "=Z2FNRI%77]GX?^M_12YCFNWG<%Z>P\?\2_/'[(L^ ?6ZO8
MOJ&ZO8OJ/-5?(/K=7L7U#=7L7U ?(/K=7L7U#=7L7U ?(/K=7L7U#=7L7U ?
M(/=U>Q?4>
M       G6 G6!DTG2\R#'I.EYD >/\!?0:\V#_ 7T&O
M                           0[RH=3U=BT1#1V^1T<]PE2-7MZ=WK0F).
MA>T@OE:VJ>ITE;+E3M5S**H3>QU9R!^6S+8+84TW35FIHO===5,23&5W6(J<
M/K.:VG[#ZK3*+J'0D\J)3+SKX<KOLQQRWM3S$Q[*]>V74^EZ#F*Z&.KAB;#)
M"]VZ[>1$Z,])W:85%X(YJIZ45 (@V#[56:PHDM%Y=S=]IV]\KL)SJ)U^DUW*
MZ^3VC^E(<OMUV<5FFKRW6NCFO8ULB/GCCZ(U[43L-!M6VGT.O=E%%%(Y(;S!
M.G/0HB\<(G?(!8#8?\E.G?HR';G$;#_DIT[]&0[<         >ITG@0"I?*.
M:L>VRUR/\%4I\>LME"N]!$Y.A6)["M_*VLLT-59]1PQN>UCVL>O4W'%";MF^
MHJ35.D;?6T,S97<VUDK4Z6O1.*8 YOE#O1FRRYJ[K5$_ YWDFQJW9Z][O!69
MV/68'*NU/2P:9IM/P3-?654N\^-JY5J)V^L[K8/8GZ?V96NEJ&*V>1'2N1?^
MI<H!H-HE%M0FU/._25;'%:E:G-M7J7KZCC[MIW;-=K956^NKX)*6H8L<C<]*
M+]18_(RO:H%9=+Z,VO:8M3+;9ZN"&D8N6LST?@;;WMVW^4H?6G]BPF5ZU49\
MZ^L"OGO;MO\ *,/K3^P][=M_E&'UI_8L'GSKZQGSKZP*^>]NV_RC#ZT_L/>W
M;?Y1A]:?V+!Y\Z^L9\Z^L"OGO;MO\HP^M/[#WMVW^48?6G]BP>?.OK&?.OK
MKY[V[;_*,/K3^P2V[;T__F4'X?V+!Y\Z^L97J50*C7+8]M%N-=-65;Z=\\SE
M>]V]TJ8WZ$-?_P"7_F4N%O+VJ,KVJ:QGR1_RDW*GOZ$-?_Y?^91^A#7_ /E_
MYE+A97M497M4=?+\I_DW*GOZ$-?_ .7_ )E'Z$-?_P"7_F4N%O+VJ,KVJ.OE
M^4_R;E3W]"&O_P#+_P RC]"&O_\ +_S*7"RO:HRO:HZ^7Y3_ ";E3W]"&O\
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MF'?YF-)5S(C4WU3HWL<3[SYU/
M                       3K 3K R:3I>9!CTG2\R /'^ OH->;!_@+Z#7@
M                                           ,6Z6^ENMOGHKA R>F
MF:K7,>F4])E "OTG)W][]4TMSL-X6*BCF21U.YJ[V,]&44L!&W<B8SIW6HT]
M 'S-%'/"^*>-LD3TP]CDRCD]!73:=R=TK:J:X:0G9$K^*T;F\,^9>PL:$ YG
M9C:*JP:#L]KN+4;54T*,D1%SA3I@          Z@ -7J:PT&I;-46RZPMEII
M4Z%3.ZO:A7Z;8=K#3E9-W&:FFBI9%RC8U5JHGGX\2RH0"!=#["*AE^9>];W1
M;E4,<DB1.15RY.U57B3RUK6M1K&HQB)AK4X(B=AZ
M   #W=7"KU)UGRQS'NPQ[7+V(H'H/514SGJ/ !^=3 RIIIJ>9,Q2L5CD[44_
M0^^;=U(!SVD-*6O2='-36:)8XI7;[D7M-\>JBITH&M5W@ID#P!45%X@ #[YM
MV,XX'P !ZB97"=(<U6]/ #P                     !ZC57H/E7,1VZKV;
MW9D#T'JM5.D\ 'J+@\ '.T&C;/0ZIJ]0T\*I<JI,2/ZE.B/K==NYQP/$157A
MQ \!ZYJM7"I@\  ^FL<Y,HG ^53   ^E8Y$RJ< /D
M   3BN$#U;'X;VM7SJ ![C+<HJ*G:AYU@ @/4:J]'$#G-0:-M%^O5ONMQB5]
M90NWH7)U*=&JYXGJL<B=!\HF0 /I6.:G%,'R !ZUJNZ$#FJU<*G$#P ^D8Y4
MRB< /D
M                     G6 G6!DTG2\R#'I.EYD >/\!?0:\V#_  %]!KP
M
M                           !Q^T[7MOT%875M8J253TQ!!UR+_8[%B9=
MCM*?[4:N7:'MOI;,CW>XXY$IT8BY1J(J[W #]J:OVG;7:J2:W.?2VW>[U6.Y
MIB-[,YXFQJ-BFT6AA]T4-YEEJ&\=SW4J?U+-V.UTMCM--;:")D5/3L2-$8W&
M<=9G9 JYH?;'J+2-^CL.T&!W,;VXLCVJCXTZ,^="SM%4PUM)!54DC9:>9J/C
M>G0Y%(AY3>CJ:\Z*GO4<+$K[>W>61&\7,ST*8W)4U--=M&5%MJI%=);W(R+>
M7*HP#\-N.UNNL=T;IK23&R75^$DDW=[=S^RARE+LRVKW*E]W5-Y?!4R)OMBY
M_'3V\>!(E'L<9#M0?J^JN7NM'2K+[G?'T+C"<?,2XJJJJN,@5@T5M/U3HC5T
M>FM?LWZ=[TB21W%S<KC.>M#L>5%/<Z325OO%DKIX(V2(U[HG81R.SA3@^5?5
M4U9K.R45"K7W"-4216>%E53=0F;6-@?>=C"VZJ:JU$5$V3#DX[S4]H'[;#K^
M_4>SF@K)Y5EJ&JL<CE7CE,=)UNH+@RTV&X7"1<-IH72+]2$$\D"[;UFO-HF=
MW\$J.8Q?Q]AUW*8ORV;9Q/3QOQ+7NYC&<9:J 5KH]H.IXM0PW>6X53J%:KH5
MZ[JIGHQGL+RT-3'64--41.1S)8VO14\Z%5;YHE8>3A;*YL*I6LJ/=$C]WBC5
M54)JY/E]]_MFE YSMZ:E_4R*JYX]0&-RBM2S:;V?2K1S.AJJIW-QO:N%3'8?
MER;FW*;9\ROO%5-4S5,KG-=*[/>]1'?*SN#JZ_:=T_$[/?(]6IVNX=!/^B[2
MVQ:3M=M:B)[GA1JX3''I W(                  &!?KO1V&T5-SN<J0TM.
MW><Y3/0KCRN-1SL6UZ;IGJU)TYV1J+X>5X(J <]?-IFMMIE[FM6B:=T- CL(
ML>47'1ESNHR8]B&T.2'GI[U(VJ5,[ONI>GTY)JV*:2I-*Z%MZ0Q-2LJHFRU$
MF[ARJO5D[W(%2*?6&T39+=8:?4L;JFWN7CSB[Z.3S/+,Z)U3;M7V"GNMJE1T
M<C4WV=<;NM%/RV@Z:I-6:4K[960L>Y\:K$Y6Y5CNI4*Z<F&\SV'7]UTU4O=S
M$JN;A5X(]JXX(!:W!I]7ZAH]*Z=K+O<7HR&!BJB+TN=U(AN'N;&USI'(UK45
M7*J\$0K)K*YU>V3:53:<M#Y&Z=H7XJ)&95KL+Q<H&CV7[0+YJG;32RU5;*E)
M4SY2G1RHQ&]28+*;2Z2KK=%7:*W2OAJT8KV/C7"ICB5DT/;:>T<I!+?1,1E/
M357-L1$[$0M]-&DS)HG85)$<Q<^?@!7WDJ:LK[NEXMEVJY*B>)><8LCE54ZL
M?@6$1,KQ*E;+%72'*#J;5(NY!/,^/CP14XX+1:FN#+3IZYU[W(U(*=[T7..*
M)P J9MLUQ?JW:+=(K%75,5)2M1BMA<J(F.E2PVPW4C]3[/**KGEYRIC58I%5
M>.4QQ4A'85IY=6TFLKO6Q+(ZIA>V)7)GOE7J4WG)*NRTM5?-.5+EYQDJN8U5
MZ,9WL)]0%@-1U[;7I^XU[E1$IX'/ROF12O?)IN5ZU)K6ZW"X5]3-01,<B,<Y
M5:CE7AP)&Y1UZ6S[,ZQC78?6+[GQG"JBH:ODLV+WLV=I7O;B2OD<_*IQPBX
MF(                  #QSFQL<][D:UJ*JN7J0](TY0^HY-/;-:Y:9ZLJ*O
M]0U6KA4SUH!'.T[;7=;A?'Z=V?P\X]'K"Z=K=YSUZ.">DTU%L?VDWJ/W7=;M
M)3R2=\C%J5RGU9X'5<E+2%/!9*C4E9$V6KJ78A>],JU,\51>W)8'*]:J!4:X
M46U'91(VO?/)54#%RYZOYUN/.F>!.NQ_:;0[0;6Y%W8+K U.?@SP]*>8[ZKI
M(*^DEHZR-LM/,U6/8],HJ+YBG3F2[+]NJ1T;E91R5*(C$X(L;EZ%]8%PKE74
M]LM]16ULB14\#%>]R^8K#6:XUSM7U#/;=&-]QVN)RMYQJ[N$RO%7=JDB<J>]
MOMVSEM/3R*U:V5J9:O2B+E3S8U)8-GVS"CJ;Q6TM'-6_KW.D5&ND143" 1KJ
M*P;4=G%.V])<Y*VFC7,F9-]&]:Y3/03ALCUW%M$TD^=^(;A&BQU#&?LKU*A^
M,>TG0^JJ>IL\EVID95,6)S97HB.1>' VV@- V/123NL+7HVIXN57Y10(&V2Z
MGO5KVTSV2\U\\T,LLD38Y7JN.*X+4*F'*GG*G;;*9=)[<[3>HTW(YY&SHJ<$
MX+C^I:NCJ$GH:>JWLL?$V7/I3(%=^4_J^ZTE[MECL-5-%/N<\_F55%7IX&WY
M+.K:V\VJZVR[U,D]93R;Z.D7+D3&,?@<AI]J:[Y2%94/1)J*D5>'2FZB8_J?
MAL_D=HKE$5=KD_54E9,Z-,\$5O' %K&X1<N\%.*^9"K-/J&]:LY0#[?0W&H9
M0PRKF-CU1N&=/ LAJ^X,M>E[M6O<B-CIGJU57''"X*\<D^V/N6H[SJ.I:N\B
M*UBJG2JKQX@6==C/ \':
M                                  3K 3K R:3I>9!CTG2\R /'^ OH
M->;!_@+Z#7@
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M9+>VU6>BH&)AM/$D:?4!F =0
M                                     !.L!.L#)I.EYD&/2=+S( \?
MX"^@UYL'^ OH->
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M>?' V0 JMLBV/ZAM>T:GK;Y;Y(K;2R*]LC^*.X\,%JE7B%5>M<H>
M
M        "=8"=8&32=+S(,>DZ7F0!X_P%]!KS8/\!?0:\
M
M                               8E1=+;2RK'57"DAE3]B25&J!E@P%O
MEGZKM0?;M/UI[C0U+MVEKJ:9W9'(BJ!E ]PJ=1X         !CU==1T:M2LK
M*>G5W!J2O1N?1D_=CFO:CF.1S5XHJ="H!Z           /SJ)X::)TM3-'#$
MWI?([")]9AI?;-Y6H/MD V ,#W]LWE:@^W:?4=YM4LC8X;G1/D<N&M;,BJJ^
M8#-
M
M         G6 G6!DTG2\R#'I.EYD >/\!?0:\V#_  %]!KP
M
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MBGAMM*RLDYVI2-O./QC*XXF2
M                                                     "=8"=8&
M32=+S(,>DZ7F0!X_P%]!KS8/\!?0:\
M
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M0GZ2T3IV:ZU]IHG;JHUD2,;O/=Z#6;,KY;M?:.O*VFS):V2L6!51J-21<=6
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M8MGD%9,S=JK@Y97*O2B="(!+2]*]AX
M
M"=8"=8&32=+S(,>DZ7F0!X_P%]!KS8/\!?0:\
M
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M7:NU7$]*^J3]4R9.^XKG>X]!/:](
M
MG6 G6!DTG2\R#'I.EYD >/\  7T&O-@_P%]!KP
M
M                                            >HN.CU'@ \W6*N5C
MC5>W=0^L_P#[H>                  $  ]SYD]..)X
M  /%1JJBJUJX[6HIZ '_ ._
M                                                         "=8
M"=8&32=+S(,>DZ7F0!X_P%]!KS8/\!?0:\
M
M
M
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M.KD=<JZAGIE8B,9!2NB<UV>*JY9'(J8ZL)Z0 -F
M  #5W."\R2YME=0T\7#O9Z1TJ]/'BDC>KS>LVB9QQZ0 !\S(]8GI"YK9%1=U
MSF[R(O4JIE,^L #7VR&[QU,KKE6T4].K41C(*5T3FNSQ57+([*>;"&R
M                                8MP96R1-2WSP029XNFA61%3T(YOM
M  ]MK*N.BC;<9H9ZI,[\D,2QL=Q7&&JYRIPQUJ9(              !J*VGO
MCZK>HKA;XJ??1=R6B>]VYUIO)(G'SX^HVX
M       &)<8ZZ1C$MU13P/1>^6:%9$5/,B.;@^[<RKCHHFW&:&>K1/UDD,2Q
ML<N>IJN<J<,=:@ 9                !KKU#=9H6)9:RCI947OG55,Z=%3S
M(U[,>L #*H&5+*.)M?+%-5(GZR2&-8V.7M1JJY4]:G[@
M                                      &!=8KG(UOO75TE.["Y6HIW
M2Y7JZ'M,JD;.VEB;5R1RU"-1)'QL5C7.ZU1JJN$\V5  _4  #\ZA)702)3O8
MR96KN.>W>:B]2JF4SZT  P[7%=(Y9UNE91U$:[O-)3TSHE9V[RJ]V]GACHQY
MS8          85SCN$C&);*FFIW)G>6>!TJ+V8P]N#];>RJCHXFW":&>J1/U
MDD,:QL<OF:KG*GK4 #(             :NXP7F2HS;J^@@ARWO9J1TCL=?%)
?&]/HX><VB9PF>*@                      '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g98130g00z03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00z03.jpg
M_]C_X  02D9)1@ ! 0$ HP"C  #_[15B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %44
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(S(S0G*RP=(6-%)35%5C)&*BL_ F-4-$=(/A)62"DY3B_\0 &@$!  ,! 0$
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MV.*W:W7*CN47E:&IBGC_ +3'9_ZZ*#BUV6QG&73/MR@*P/'=&KPD91$0!$1
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M-56S/]^U>=5UE35EIJIY)2T;<Y)73&]T3@^-Q:YNX(ZY6B,=L<&&=FZ>\NE
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MA;'4Q-+I6QL YF@.).P] W5T+<\2,MNF2]T#'";B)^$N6UWB5HJ1M'(X@<P
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M+)N"R8**HVMIE;1H'4O^5R?3;]Z'0&I.UKD^FW[U:\80 %5>LS3^I'[*G_T
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M=-VYM)01AO0O<,^<[ !.Y.,X"]EC&L:&L: T= %RPJ)V.1LJHC7UV%@]5E%
MN/EN-)'744U+.,Q2MY7#T*K6O=(UFFKK(R2-SZ5Y)9(!MV/B?%6O7P7>UT=V
MI'TU? R:)W9PRIUSV,INI5B_I4K3E^K;!7MJ[?*6.'4 #SAD'&X/@I=LG&J
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8B( F$1 ,(B( F$1 ",HB( B(@"(B __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g98130g00z10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g00z10.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1U84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '3L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$            ! @,$!08'_\0 .1$!  $"! 4"! 0$!@,! 0
M  $"$0,2$U$5(3%AD01!!2-2H10R0G$S8H&Q!A8B4^'P0W+!--'_V@ , P$
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M#,'OY-.'4WCTM+Z_P/F/'I:7U_@?,Y9 X9@]_)IPZF\>EI?7^!\QX]+2^O\
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M]?X'S.64V WPS![FG#J;QZ6E]?X'S'CTM+Z_P/F<L@<,P>_DTX=3>/2TOK_
M^8\>EI?7^!\SED#AF#W\FG#J;QZ6E]?X'S'CTM+Z_P #YG+('#,'OY-.'4WC
MTM+Z_P #YCQZ6E]?X'S.60.&8/?R:<.IO'I:7U_@?,>/2TOK_ ^9RR!PS![^
M33AU-X]+2^O\#YCQZ6E]?X'S.60.&8/?R:<.IO'I:7U_@?,>/2TOK_ ^9RR!
MPS![^33AU-X]+2^O\#YCQZ6E]?X'S.60.&8/?R:<.IO'I:7U_@?,>/2TOK_
M^9RR!PS![^33AU-X]+2^O\#YCQZ6E]?X'S.60.&8/?R:<.IO'I:7U_@?,>/2
MTOK_  /F<L@<,P>_DTX=3>/2TOK_  /F/'I:7U_@?,Y9 X9@]_)IPZF\>EI?
M7^!\QX]+2^O\#YG+('#,'OY-.'4WCTM+Z_P/F/'I:7U_@?,Y9 X9@]_)IPZF
M\>EI?7^!\QX]+2^O\#YG+('#,'OY-.'4WCTM+Z_P/F/'I:7U_@?,Y9*H.&8/
M<TX=I63>M+O&6F(]'2.L. Y&/Y5FCK),AI+P7?Q?J_[PW[#=K=A\;U.'&%BS
M13TARF+2UQC[^($U_J3^IR:=98^_B!-?ZD_J<FGV/A?\*?W=L/H  ^DV
M                          [% [% F&&_]ZK'[A%_E4AZ;"88;_WJL?N$
M7^52'IL.5'YZOZ)'4 !U4
M                                           $OIOY,ZM^^P_Y5(AV
M$OIOY,ZM^^P_Y5(AV'+"ZU?NE( #JH
M                           %  N\WC(S26#%1NW2T5R+29*FH7 %=FW4
M *
M           "$QPQ_P 3K'_2IG^0AR$QPQ_Q.L?]*F?Y#EC?DE)Z(<WR0&^2
M#JH                                        50H50#HOP7?Q?JW[P
MW[#=J;#27@N_B_5OWAOV&[4V'YCUO\>IYZNK7&/OX@37^I/ZG)IUEC[^($U_
MJ3^IR:?5^%_PI_=UP^@ #Z38                             #L4#L4"
M88;_ -ZK'[A%_E4AZ;"88;_WJL?N$7^52'IL.5'YZOZ)'4 !U4
M
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MR@ ]30
M  A,<,?\3K'_ $J9_D(<A,<,?\3K'_2IG^0Y8WY)2>B'-\D!OD@ZJ
M       /4-CHCD;#:Y[EV(U,U4]Q8$6"J)&A1(:KLTVJF8N+0/<.&^*Y&PFN
M>Y=C6IFJE8L&)!=HQH;X;NY[511<6P      =Z               JA0J@'1
M?@N_B_5OWAOV&[4V&DO!=_%^K?O#?L-VIL/S'K?X]3SU=6N,??Q FO\ 4G]3
MDTZRQ]_$":_U)_4Y-/J_"_X4_NZX?0 !])L
M    !V*!V*!,,-_[U6/W"+_*I#TV$PPW_O58_<(O\JD/38<J/SU?T2.H #JH
M
M                      )?3?R9U;]]A_RJ1#L)?3?R9U;]]A_RJ1#L.6%U
MJ_=*0 '50
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MI[?28,T3-55,1?9NF+*  ]K8
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MJ1#L)?3?R9U;]]A_RJ1#L.6%UJ_=*0 '50
M                                        22S;TK-HS+XE(F5;"B9+
M$@OUL=ELU$UC8[7-$A.8R7DH3U3RT;FJ>\U,#A7Z;"KG-53$RS-,2^^MU>?K
M=0B3M6FHDU-/U*]_8G8B=R'P ':(B(M#4<@ %
M                                    $)CAC_B=8_Z5,_R$.0F.&/\
MB=8_Z5,_R'+&_)*3T0YOD@-\D'50            !-L&?RB4K_63#PEXCX5W
M4U\)SF1&P$5KD7)47-35%"JTW1*G!GZ>]&3,)<VN5,\C[;KNBJ73.0YJL1FQ
M8L-N@U6MRR0\M6#5./&)[1#,QSNZAPENR!>-L0(D?1?49+19,([)51^6IZ>O
M(UQBY4V4?&2B3\7\'!;#5WJ74:EM2YZI:T[%F:+'Y&+$9H/S3-%3U'FZ;DJ-
MSSZ3E7BMB1VMT$5K<DR/-A^AR8TU1^668HM+IK%6?NN4D92?LU.<P<O[5D-B
M/<J+L5-6PC\'QB+:<:LU.N2=.:V"Z*Z6C0$1R(B+J5<MJ]QJ:UL5+FMR2;)R
MLS"CRS$R8R89I:/H36?+>.(UPW9+I+5.88R51<U@P6Z+7+Z>\YT>BQ*;46BV
M_N13,,IA#9L2];H?-3J*E.EW\M&?DJ)$=GJ:AT.M>H-<JT_:*N9%>R!HQ&9_
M15,O)3TH<Q6WB'<%N4E*=28\*!+HJN_!HKE5>W,P--K$_3JPRJRDPYD\UZQ.
M5[U7;F=<;TE>/5-54VB.A-,SU2VN6I&L[$RGR<;/F;IQCY>*J9(YFDGV;#<'
MA$T:HUJW:6VDRD6;?"F%<]L)NDJ(K=IHFZKYK=T0I9E8C0XG-GZ<)S69.:OK
M)-(XUW7*24*61TE%T&Z*1(D+-R^M<Q7@8\S1B<IJI,L]6LW-5KG-<F2M7)4]
M*'D]Q'K$B/>[RGN5R^M5S/!]*'2           "J%"J =%^"[^+]6_>&_8;M
M38:2\%W\7ZM^\-^PW:FP_,>M_CU//5U:XQ]_$":_U)_4Y-.LL??Q FO]2?U.
M33ZOPO\ A3^[KA]  'TFPE&&/X]4C]LA%R3X9*C;YI"N<C42,FM5R0YXO\.K
M]DGHZ:Q&G+.E8DJEXPH#W*G]CRD/2U$89B=8=LT^*E A-6(K5T84O!T=)>Q%
M7N(SX3D:%&F*0L*)#B(C79Z+D7+6IHL^7Z7T=.+A1-4S^SG31>&R[(KTU<N,
M<K5IS)L6/%S1B+J8U,D1$]AL;'^\ZK0(].DJ-,NEG1$6+$B,7Z2Z]2?P-0X/
M.:S$*E.>YK6H_6KER0FGA,18<6X*8Z%$9$;R"^2Y%RUKW'7$PZ9]513;E$+;
M_4EW@^JZ;I%=N&<<L:HS4;^T>NM5T4S_ *FC[GNRK5.YYJJ/G9B'&;%7DT:]
M42&B+J1$)_X/EYR=%FINC5>,D&7FW(Z#$>J(Q'ZT5%7TZB0UW!"6JEQQY^1K
M$&!3([N5=#1-)4[T1=F1B*J,#'KG%]^B=)F[,8@.2Y<#.E)YC4F6RT.9143/
M)V:)_4^FWG.MS KGM/R;,<Q6.BHFQSDVD<QONRF4JUX=HT1['O>QK(G)N16P
MX:=B^E<B[@M=5)K=FQK5KDQ#AQF,6"UL5Z-2)#7]'TH>?3JT,UO].:]NR6Y-
M;X/W#4X&(4@JSDQ$;.1-".U[U5'HO>3GPI?PE'_T.^TS%K8?6U9-TRL_,5EL
M['BO6')2VK-KE[=2Z\D,+X4CDY:C-[=!R_Q.\8E&)ZJBJCI8ZRG]=K<>WL'(
M%0D\DF8=/@MAJO8JM1,SGNG7;=57KU)Y*/$J50EHBK+,B)I_27MR-T8BS$%^
M!D&&V-"=$23E_HH]%78WL-1X'U21I&(,I&J;F,A/8Z$V(_4C'*FH>DIB,*NO
M+>;RM/26S*O8=VW9'@3UXUV7I:06HUL.57)J:\\U^DB9DCQ9E&2^$<S+K'6;
M2#"8U(SES5^7:6,3;"F;MJ<&>;<O,J8R&C8D%7?13+-=),ERU^DK?R2$;!Z8
MEJ-.0IJ! ED1KTB(JN1NI5V^@\M->:<.;^_2(M9F)Z&#DR^4P=9,PLN4A,C/
M;GWIGD:OP'JT_-XIM=-3<>+SB%&6(CWJJ.7)50V-A5'@MP6<QT>$UZP8WT5>
MB+V]AJG "(R'B;*NB/:QJ08V:N7)-BGHHIB8QYM_WFNZ0^$779UMVR-/@3$6
M% EV-BHUCU1%<J[=7J)UB,KI[!!L:8<KHG(PHBN7:JFKO"&B,B8A,=">Q[>;
MP];79]JFS;UF(+L#4AMCPEB)*P_HH],_<2:8BC!MNOM#F%/)0#L0'VG6 =B@
M=B@3##?^]5C]PB_RJ0]-A,,-_P"]5C]PB_RJ0]-ARH_/5_1(Z@ .J@
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M=!67GX?TTAN152(FU5]:9&J#[.!B:N'%>[K3-X  =5
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M4"88;_WJL?N$7^52'IL)AAO_ 'JL?N$7^52'IL.5'YZOZ)'4 !U4
M
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M+KK5$Q&D9&F3SX$J^!"<YB)VJN2@;Z!;EG*Z4EW.UN="8JKWJJ%P
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MU=6)G_XN7G=T+1<3;6NVW&TF^(*08K(:-?$B)FU[DU:3536BEZ)B!9%BT.)
MLR"R:FHF:(D//;WO<[7EZ#G34$.7X##OUFVWLF1+;,N1LKB#*5VMQ7Q$Y98L
M9^U5S)%CE>%*NZ=ID2COB.; 8]'J],MJZC6 .\X%,XD8GO#67G=O3##$>@T#
M#WHFH18R3?\ :_1:U%3Z6SM(?A%B#U,J,Q"G(;XU*FW9Q&MRS8[L<G]37A0Q
M^$P_]43^KJF2'24*MX52M6=<,%\OTCKBZ"-=GI>AODYFH,4KR2\J\DQ+R_-Y
M& W0@L5$TE3M5<B&:NX#"])3AU9[S,]R*;  /4T   50H50#HOP7?Q?JW[PW
M[#=J;#27@N_B_5OWAOV&[4V'YCUO\>IYZNK7&/OX@37^I/ZG)IUEC[^($U_J
M3^IR:?5^%_PI_=UP^@ #Z38                             #L4#L4"8
M8;_WJL?N$7^52'IL)AAO_>JQ^X1?Y5(>FPY4?GJ_HD=0 '50
M
M        ( @&[L!/Q<KO[>']BFPC7N GXN5W]O#^Q381^9]=_'J_[[//7U
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MLO%J"K#=^DFO6=9/\M?6!Y  'W4S\'-_Z#X4/NIGX.;_ -!\*
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MQD3])$RUF1\)#\JU._=X/\R =(RG]QE?V+/Y4+I:E/[C*_L6?RH70
M "%JJ?BY7O\ I\;["ZA:JGXN5[_I\;[#>'^>/WA8ZN5$\D!/)!^N>F
M                                   JA0J@'1?@N_B_5OWAOV&[4V&D
MO!=_%^K?O#?L-VIL/S'K?X]3SU=6N,??Q FO]2?U.33K+'W\0)K_ %)_4Y-/
MJ_"_X4_NZX?0 !])L                             !V*!V*!,,-_P"]
M5C]PB_RJ0]-A,,-_[U6/W"+_ "J0]-ARH_/5_1(Z@ .J@
M
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MGQOL+J%JJ?BY7O\ I\;[#>'^>/WA8ZN5$\D!/)!^N>F
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MW(/$!2]Z37N0<1P-_L9X<X@Z.\0%+WI->Y!X@*7O2:]R#B.!O]C/#G$'1WB
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M0>("E[TFO<@XC@;_ &,\.<0='>("E[TFO<@\0%+WI->Y!Q' W^QGASB#H[Q
M4O>DU[D'B I>])KW(.(X&_V,\.<0='>("E[TFO<@\0%+WI->Y!Q' W^QGASB
M#H[Q 4O>DU[D'B I>])KW(.(X&_V,\.<0='>("E[TFO<@\0%+WI->Y!Q' W^
MQGASB#H[Q 4O>DU[D'B I>])KW(.(X&_V,\.<0='>("E[TFO<@\0%+WI->Y!
MQ' W^QGASB#H[Q 4O>DU[D'B I>])KW(.(X&_P!C/#G$'1WB I>])KW(/$!2
M]Z37N0<1P-_L9X<X@Z.\0%+WI->Y!X@*7O2:]R#B.!O]C/#G$'1WB I>])KW
M(/$!2]YS7N0<1P-_L9X1_ /\6Z[^WA_8IL(^VR,.96U9"=E9>;BQ63+VO57Y
M:LDR,]U<A>>>?$]5B4XF+553TERJF\HH"5]7(7GG#JY"\\X\[** E?5R%YYP
MZN0O/. B@)7U<A>><.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B
M@)7U<A>><.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>>
M<.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>><.KD+SS@
M(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>><.KD+SS@(H"5]7(7
MGG#JY"\\X"*(?=*_X5/?_;]IG>KD+SSB]#H4-DO&@I%=E$RS4"' E?5R%YYX
MZN0O/. B@)7U<A>><.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B
M@)7U<A>><.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>>
M<.KD+SS@(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>><.KD+SS@
M(H"5]7(7GG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>><.KD+SS@(H"5]7(7
MGG#JY"\\X"* E?5R%YYPZN0O/. B@)7U<A>><.KD+SS@,%3/P<W_ *#X28R]
M#AP6Q42*Y>43)2SU<A>><!% 2OJY"\\X=7(7GG 10$KZN0O/.'5R%YYP$4!*
M^KD+SSAU<A>><!% 2OJY"\\X=7(7GG 10$KZN0O/.'5R%YYP$4!*^KD+SSAU
M<A>><!% 2OJY"\\X=7(7GG 10$KZN0O/.'5R%YYP$4!*^KD+SSAU<A>><!%
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MW(/$!2]Z37N0<1P-_L9X<X@Z.\0%+WI->Y!X@*7O2:]R#B.!O]C/#G$'1WB
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MI$57]BY9$P0^'ZG$C$Q:JJ>DN,SS  <$
M
M
M
M
M
M
M
M
M
M                      #,  $7,        9@ !F  *9@5 S  #,9@ ,P
M
M
M
M
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M$@TIAM2I/$&/=DK%CPIR,GTX3'9,<J[55/23A$R4L7]V9M[*@ J
M
M
M
M          8:9N&4E:]#I<RY(<:+#TX;G+DCE[O66FF:NC%>)3AQ$U3;V9D%
M$4J1L
M                           $%QO_ "8U[]W4QG@V?D;M_P#9N_F4D>*-
M(FZ[8U6IU-8D2;CP5;#:JY9KZSX<%:!/VQAO2*35X;84[+L<D1J.S1/I*NTG
MNU^E!/"'EEHU?M.[X$-=*2FFPH[T[6JNI/>IBJG*0\1L6J^QK>5D:;270,VK
MGE$>W-/4NPVSBQ;<2Z[%J=+EV-=-/8CX&EJ^FBYIK["(^#W8M4M&EU6/<4-K
M:G/14TE1^DJL:F29K_\ FPDQS:B>34TM<T:!@ RVV15;4ND5I[8.O26$CE^1
M*L>*4^A89VM26(B2,&+";%R35I)EM+TOA%5DQHBU5\&&EN),K-0_IY_2[M$W
M!B%:,E>MLS-(GET$?DZ'%3;#>FQ4):\2N:(F&7HC(,.C2#)712 V!#1FCLT=
M%,C1-Q(UGA44U9/+E'2R<NC>[13:9*CR.+-JR"T619(5:5A)H2\W%?DYC=B;
M?ZYF<PLPVG:-79RZ+LG6S]PSC=%51,TA)W(O?J+U9CE>6USG3PK)9L[6[,E'
MN<QDQ,+"<YNU$5<LT])T6AI['.RJU=5>M2:HTNR+!D)GE(ZN>C=%,Q5T2CE+
MX/\ 9SH.7^.UW_\ V%)E8>%%M69-).4Z ^-/HF7.8ZZ3_>3Y$U)F"V@S3+G;
MPCH3J5B%8]P1=)).%,HR(]$U-1'(NO\ @=!RLS#FI>%,2[T?"BM1[')VHI@[
M[M20O*WIFDU)GT(B?V<1$^E#=V.0U!29?%##F"ZF2<M#N.DPM4!ZJNDU.[O]
MY.DK^:&]*S/P*;2IN<FWMAR\"&KWN=L1$-">#E3HU0I]]5-6NY*I/=#AKEY6
MI^SXD+]4I&).)G)R%:AP[>HCOP[&JN<1$U^LW1:=OR5L4&4I5.AHV!+L1N:)
MDKU[7+Z5'63\L6:6\%:;22?<MOS2<E/2TRY[H;ER545R]GM0Z!S-*8C8:5N6
MNM]X8>3;92JQ,DF)9-21>]=>KL/EB7ABQ,,=(PK5@P9I6Z/.<UR1>_7J$3;D
M3&;G">S.)%,@8@P;12#&B3T3).49K:W-.TG*&J<(L-)BWIV:N"YIE)ZX9WZ3
MWKKY'/6J(O>;6+%_=F;>P "H
M               "CG(U%5RHB)VJ>61&O3-CD<FS4N8'L!/2   S  IF>'16
M,=HN>U'=B*N0%P%,RH         !0B@ %/@FZS3I-^A-S\K!?LT7Q410/O!:
MEYB%,0DB0(K(L-VQS%S12Z@ 'B)$9#\M[6IZ5R/3'(Y$5JHJ=BIV@5!15RSS
M5,D/+(K7^0]KO4N8'L!#R][6)F]R-3O5<@/0+23,'ST/XD*LBL>N3'L<OH7,
M"X @       !;2-#5^ARC-+]'-,P+@*9GA\5C%R>]K5[E5$ N HBYE0
M
M                          &F<97*VX916KDJ0<T5-J:S<QIC&?\ &"6_
M8?U/;\/_ (SXG^(/_P 4_O']V?PYO=)Y&4RK1,IO9"BKL>G<OI-CYKF<M-56
M.1S55JIK147+(V_AU>[9UD.FU6(ULRU$;"B*OX3T+Z3MZST=OF8?]8>'X-\9
MSV]/ZB>?M._:>[8X*(JYE3YC]2
M                                              9!-0 #(9(  R*9
M(5 #(9 9@!D8R3K]+G:G'ITI/R\:>@)G%@,=FYGK0R8   ,BF2%0 R&1XY1J
M/1BO:CUUHW/6I[ 9#( !D
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M+(P/@Q7!/4B\ZG:D]'=$@*JM8S:C(C%5%5/1ED6)W3+%ILZE 0&F
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M[(45=2/3N7TGRO6>CM?$P_ZP_7?!?C6>WI_43S]IW[3W_NV0"C57,J?+?J@
M
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M]<D5%S1,\]@M*9HF\2@_A4V9.PJM+W938+WP<FLF'0TS6&Y/)<OHU(2NQ_"
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MJ-<O?EGM)]9-H4BSJ4DA1)5D%BY+$?M=$=WN7M+:9GFEXB.20IM !I@
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MS,/^L/V/P7XUGMZ?U$\_:=^T]VQ@4;GGK*GS'ZH
M                                                     '/MGJG^
MU#="9IGR+?L4EWA$VM.7-8R+2X*QYV1C),-A(FMS<M9/X% I,O6(U5@4^694
MHVJ),M;]-WK4RF2;#-N5FLW.\-%V=B'AO.4"$^NR].I=1@0T;'EYB6R=FB;4
MU>@^C"JY9J[+XGYBB4&0E+3E&JR#-\U1D2([7DJ.RS-DU"QK7J,TLQ.T&GQH
MZZU>^"F:F;ITA*4V59+2$M"EI=B9-APFHU$]@B)69CV<NTE] 9C/<S\5G:,9
M'+S/G2*L#+N3;V=Q]&.%UVI,65,T2QY.7CP])(LS-2LOE#@M1=>;LMNPZ*KE
MK4.NO:^L4F3G'MV.C0D5?>>(-I6_!ID>G0:/(LD8R918+82:+_6,IFCJTS>]
MLSER8#VK.T6&LQ-TN!"FVPF[8B-R543T_1)-:N-UI1K8@1ZO4$D*C!AHR-)Q
M6N2(CTU9(F7:;2I\A*TZ2AR<C+PX$K#319"8F36IW(AAIFQ[8FIY9R8H-.B3
M2KI+$=!3-5[Q:?9+Q/5I/ NNON7&&Y:E'A.A<XEU5D-Z9.1F::.:+Z#Q;=7?
MA#B=7Y6YH46%0JQ&6/+SB,56-S<JZU3UF_I&@4F1J,6>DJ=+0)R*W0?&APT:
MYR=R^XNU:D4ZKR_(522EYN$OYD9B.3^(RKF:7Q@Q5I%5MJ-0;,F$K-6J&4)&
M2['.1K5[5U%F]+(J%(\'.#1X4)T>=E.3CQ8;$S7RD5WN-OT:S[>HL?EJ51I&
M4C99:<.$B+[S.O8U[5:]J.:NI45,T46W,UNC3-G8U6C+65(,G)YT*I2LNV"Z
M35CEB.>UN6BB>PB& ]2F*MC;=,]/2[Y29F8/*K ?J<UJJF6:>K6;T99%LLJ"
M3S:%3DFT=I\KR*9Y]Y]\K0:5*568J<M(2\*H1VZ,688S)[T[E46DS1SLT)7:
MU)6AX2:U&X(O-9*+)JC8JIFGTDU$HOO$J<MN[*2^HRD"9L>HPD<DTV%IY9[5
M7N1,T76;.KMLT6O.8ZLTN4G7,3)JQH:.5#Z(]%IDQ362$>1EHDDQN@V"YB*U
MJ=R(+29H]W..,4_A75+8BOH7-IBN1ESEFR$-4>K^]4R-KX?SDU:.#\I.W5RR
M/DY=(D5%UO1NK)"1R%BVO3YELQ)4&G08Z+FCVP4S13[KLA\I;=0AI(-J"NA*
MB2JIJB+V(HB/<O$\GR6+=DA>5!AU:E)&26>YS$2*W1=FGH)"0[">W(UL6?+R
M<RQD./$>Z.^$S9#5RYZ*>HF)89GKR  5              .7?##_ ,5H?[)W
M]3J(YS\*>VZS7*I1GTBFS$XR'#<CW0FYY+FIFKHW1U;KP\3_ .":-^ZL^PY[
M\,.<AQJO09%BHL:'#>]43N74GVF(D+FQDDI&#)RLE,,@0F)#8G-=:(FI.T^V
MR,(KLNZ[65J_4C2\LV*V,](SM)\;7GHHG8A+WBT-1&6;RDV(TI$DO!AI<",B
MMB-Y)51?2KE-;K1FS/@[PZE#;_:R53=[G99J;_\ "%H\W4<+8TA1Y-\>*V-"
MT(,),U1J9I]Q$K LZI1/!_K5&GY*+"GH[HD2%!<GTL]2I]@F.9$\KM5]-NQ#
MO>P:<Y7/9+-@P(R._214S7W(A]E3;H>$_HM;HM2IM1J>C17(S?@Y6%6I&_75
M"M4N/+2\K#71=%3)%>N:)D7*O:E?B>$:VILI4PZG\_:_G"-^AHZ*ZS-N2WYO
MI\,3_%+=_8Q/YC!1L"IF9P[D[BHT\LQ-191LT^5>W+-%;FJ-7O)EX55NUBN5
M&@OH].CSC8<*(CUA-ST5S[3<F&TI&D[ M^5G(3H4>%(PF1(;MJ*C=:*:M>6;
MVIARYX.O5*/=4*2N.GN6K9JLK&B.7DU<B^2YO>AT1C-==6M&V8<[097G$RZ*
MD-6Z"NR3U&D<=<*ZM3KO2NVA)QXLO-Q$BJR FN#%3M3+L7(Z#PSK-0KEIRD>
MN2,23J+$Y.-"BIK543RO:(V*MVC+?QDO>K5J2I\U2$; FHB07N2 J9([5M(Y
M@4B2V/$S"B*C7:4PU$7M72.P%8W)?HI[CE+%:QKELS$.)=EIRL:/*Q(G*M?"
M;I+#>J?2:J)V+D)B86F8F\,IX841J35"A?G<FYWLS4QN/,M%AX3X?Z;530A.
MTO1FQ,C#RM%O3&.]9.:K\C&EI&%E#BQ'0UALA,1<U1$7:JG0&+%@I=.'W1$B
MNC-2<-JRN?YRM34U?7D2U[R7M:'G!R(SQ)TAR.149)Q<\NSZ3S1/@JPWOQ-G
MXJ)]!L.-FOK<[(P\A7,1[6H$S9T*ES<.'$<K=4%SG,SVHUR:LE-V>#9AU/6C
M2)NHUV%R-3G5U05UK#AILS7O4L<[$\HEMVHPV,ID\K&HBNA/551-JY*<G^"_
M^5ZI?NT7^8ZSJ37/ITTUB9N="<B)WKDIS+X.MK5VD8HS\W5*7,RTLZ7BM2)$
M;DF:N+/6&:>DNHT 0&F         $.Q$O-+7EI67D9=)^MS\1(,G)([)7KVJ
MO<U#"XKX@U"Q+6ITVDC*S57FHC(2RVFJ,S541<NU=I+K$3+9>0R0TBR^<6WL
M:]F'TDK7(BHO.5V*3+#JO7I5YF:;>%MR]'@L8BPGPXRO5[L]F0NN5/,@$!60
M9(      HY4:U578B9J!7(&N\/,0)B[*_<\LZ2@P:?2HO)P8[7*KHO>JEW">
M^9N^&UB8C2,&6DY696! >QRJL5$VJN?L)>%RRG^0R 4J&0-?TN^YBI8J3]K2
MTI!=(2<ND5\TCUTM/]'+9M4GZ$CFLQ94 %0R!A;SK;;<M>IU9R,<LI =%:UZ
MY(YR)J3VJ1NT[[BSV%D*\*])LDU=!=&6!"553)%5$37WY$NMD^&1J3#?$&\;
MMGY.8CVG"E;=FT5T.=2*JN1O8JHIMI/6(FY,65R0&NX5_P U,XPQ[-DY.7B2
MLO*I,1IE7KIM7NRV&:95;D=?KJ:M$A-MML#32I+%^FL3+R='N%RR5#)#3=P8
MJ7#&N^H4.QK:965IRZ,U$B1%;HKGDJ(;8H\>9F:7*QY^7YM-Q(:.BP<\]!R[
M4S$3<F+/L !4     #(!=2*0VS+X@77<%=D*? <DM2HB071W+^$?KSR3NU L
MF60  9  !D 478!4&OK7ON9KN)E?MR')P4D*7#1><HY=)SERU9;.W^!L!HB;
MK,65  0!&\1KDZHV95:XD)D9\G"TVPW+DCUSRR(G5,0ZO3L,*1=<2DRSHDRL
M-\S!Y1=&%"<NMR+Z$)=8B9;0!\].FX4_(P)N7<CX,9B/:Y%S144^@J
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M3T?G:JLTS+^E8.'I411>]O>>H #+H
M                                                  &OL7,0(ECR
M]+26DTF9F?FF2[=-<FM15R5?6+V6(OT;!!1BJK&JJ9*J:RH0   9&O<<KBJ=
MKV#,5*BQFP9QL:&U'.;I)DJZ]1*+-GIBI6M2YV<<CYB/ :^(Y$R15]1+^RVY
M79K( %0   $7Q(B7!"M&==:$-(E9R3D6JB;?:9"T'U-]MTUU>;H518+><M35
MD_M S "[#55F7;6*EC%=-"G(['TR28BP8:,R5NM.TEUB+MJ@HA4J
M   !41=J(H %-%OZ*>XJ  5$7:F81$1-2  $1$V(B%-%,\\DS*@ J(NU$4
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MCPXPL*/^0 ')Z@
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M6M; @9ZUB.7++WD.I-N8GW13V5N;NM*5%CIRTM)LAZH:+K1':O4:WN^GSD'
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MW2*O1+;A25Q5!E1GVN571VYY*G9M1#42Q,=TE !4
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M+T?I,/T>'&%A1R_OWD !R>H
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MO8BYZC.8683OL2ZZE48=26;E)F"C&I$3^TTLT555?7F;8!,L+FE1I4 TR
M
M
M
M            :9QE:KKAE4:BJJP41$3:NLW,8:9M^4FJ[#JDPU8D:%#T(;7)
M]%OI]9Z/38L8->>7SOB?I*O68&C3-KS"(8>60DDUE1JT-%FEUPH:KFC$[U])
ML9$R4(FO8>CGBXM6+5FJ=_2>DP_28<8>''+^_P"X #F]0
M
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M^DL24K"DI6%+2S$9!A-1C&IV(A?-,
M
M
M
M
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M0F(QOJ1,C7NSTA> !60
M
M
M
M
M                 >(D-C_+8UV6S-,SRDO!\S#^%"Z +;83&*JLAL:OH3(]
M.8CDR<U')W*F9Z 'AD-K$R8UK4]"9%'0F/\ +8UR^E,RX +?-X/F8?PH&0F,
M7Z#&M]+4R+@ \NAM<J*YK55-BJFP]
M
M
M
M
M
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M-$5#+IJ,59?THMQ_(]I\;O*7UGV1_(]I\;O*7UF10
M
M
M
M
M                                                 !<@>4OK0^T^
M*!Y2^M#[0+<?R/:?&[RE]9]D?R/:?&[RE]8%
M
M
M
M
M                                             %R!Y2^M#[3XH'E+
MZT/M MQ_(]I\;O*7UGV1_(]I\;O*7U@4
M
M
M
M
M                                         7('E+ZT/M/B@>4OK0^T
M"W'\CVGQN\I?6?9'\CVGQN\I?6!0
M
M
M                                  5['>I37=J7JC:G,4NKQ$:U(KFP
M8[E]/DJ;$['>I3G&K?XK.?M7?:>_T6#3C1534^!\:];B>CJPL3#GWF\;]'1O
MV UEA[>BHL.EUB+FBKE"F'+L_P"539OI36AY<;!JP:LM3Z?HO6X?K<+4P_ZQ
M[P  Y/8
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M:'VGQ0/*7UH?:!;C^1[3XW>4OK/LC^1[3XW>4OK H
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M=51L.(N;DR[PEN5V> -9XAXP4JR*ZE+GJ=-3$71T].&Y$3+W!8B_1LP&C?\
M:2M_LH\_\:?<2NQ\8K9NR?AR$%\23G8NJ'"C_GKZ]A+P99;'!5=2Y*41,U*@
M# R]X4*:N1M!E*A"CU-6*]8</6C43;FNPSP            -I@I2[:'.7*M
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M$R@QW=O_ "N^\V8?G\;!JP:LM3^A>B];A>MPHQ,.?WC8 !R>P
M
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M2SY6<D_HQX*KFF>6:*B]RFEI_%*XZS:T:E6G::2EOI!5B.>S21C.W7GK/O\
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M/0^MP_6X6IA_UC8 !R>P
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M/P8GURGT6HT.O4N=DX<!R199\>&K6Y+M:F9NLKFJ[5S*%CD3-Y  $
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M:T[VIV(JF9/SE499F(F[^F85<XE$5S%IGVGV  9=
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MYDQ:0 %1Z:]43)'*GM**Y576N?M*
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MS_+HZ/VOP7X-HV]1ZB/]7M&W_/\ 8 !\Y^F
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ML-,@       +D#RE]:'VGQ0/*7UH?:!;C^1[3XW>4OK/LC^1[3XW>4OK H
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M:P62N@Y4V:1NXU#X.],F8\G6[PJ#5;'KL=SX:*F2\FBY(N79FB(;>+3T2KJ
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MZMZ#I6[I7X E$I6[I7X!Q.GZ69]/,^[E5&N_0=\*E6M=^@[X5.JNA:7NZ5^
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M/69[X>'T?LO@WP71MC^HC_5[1M_S_8 !\U^F
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M6A]H%N/Y'M/C=Y2^L^R/Y'M/C=Y2^L"@
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M#/O5?>++$V6926@24I!E92&V%+06HR&QJ9(C4+H 0
M
M                                !7L=ZE.<:M_BDY^U=]IT=V.]2G.=
M1AOBUB:APF.?$='<C6M3-57,^I\,ZU/RO^)ORX?[R^:%#B1HC(4%BOB/7)K4
MVJIN"P;/91H*3L\U'S\1$5&JF:0O5Z2MAV=#H\)LY/M;$GW:VHJ:H?S)F8]7
MZS/\O#Z.OP;X-HV]1CQ_J]HV_P"?['M !\Y^E
M
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M;C^1[3XW>4OK/LC^1[3XW>4OK H
M
M
M                                 "['9=RD5M2T8-*FYBH3:-BST9[E
M:O8Q%7L])*BJ;%[S=.)53$TQ/5QQ/3X>)7377%YIZ*  P[
M
M            5;M3/84 '-EZ6QB#5,3IBOOMV#4)27?HR<&-%1&-:FQ<N\E"
M7)C(B9):M/1$3)$2*FHW6.XEES-<W1(W-=&"]6D:E3X4*X9N K$EF/3)5S[S
M+X0TB>H.'=)IM6@\A/0473AYYY>TE_?M!2_LQ%WR<>H6M5)239RDQ'@.9#;G
MEI*03".@W#:>%4[)19)(=;1CUEX*N1<W9+DN9M)/2I7/VBQ$VY.7++MS$ZV:
MS.UE+7E9VKSBYOF9B*BJWT-3L)W+W'C$Z8AI%M>02&KDTEY5-AN<JB^DD09K
MM>8J6!%O:E4V:DX[)&XZ?E&EXRK]%(F6MJ^TBDQ.8S3<@M$6F4^%&<WDGU1'
MI]).U<C=I7,6+H9A58T"P[<60;$Y>=C/6-,Q_P!)Z[<O03( J
M  "Y \I?6A]I\4#RE]:'V@6X_D>T^-WE+ZS[(_D>T^-WE+ZP*
M
M
M
M
M                                                          +D
M#RE]:'VGQ0/*7UH?:!;C^1[3XW>4OK/LC^1[3XW>4OK H
M
M
M
M
M                                                      N0/*7U
MH?:?% \I?6A]H%N/Y'M/C=Y2^L^R/Y'M/C=Y2Y@4 U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
M U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4  U#4
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M#IV?D'RR.3E&LA9.5OHU$N38,@8JJS  #*
M
M
M
M
M
M
M
M
M
M
M
M
M                             868N&4EKBAT>8<L./%A\I#<ODN]'K+3
M3-71BO$IHM-4V]F: 38"-@
M
M
M
M
M                               :5QF>YETRKF*K7)+HJ*FKM4W4:3QJ
M_&:6_=T^U3V^@_C?TE\?XY_^2?WA),.;X;/,ATVJQ$;--1&PHB_^9Z%])LA-
MARO">Z&YKF.5KT7-%1<LC<.'-[I4&,IM4B9334R9&>NJ)Z/6=O5^CM?$P_ZO
M'\)^+9K8&///VG?M+8X"; ?,?I
M
M
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MMD  ^8_3@
M
M   !0 ,/'N2D2]<A4>-/PF5.(F;)=5^D[M/-P7-1[>2#TU/P9-(ZZ,/E%7Z1
MI>ZT3_:=HJ__ $F_R%OPL9-U0BVM)PU:CX\PZ&U7;$544SFZMQ3SB'04O$9&
M@LB0G(Z&]J.:Y-BHNQ4/AKU;IU!DN>5>;ARLMI(SE(FS-=B&G_!]O&:@Q9JQ
MKG58-6IBZ$ORF><5FO5Z3(>%/^3+L_O</^HORNF7G9M"?K5.D*2M4G)J'"IZ
M-1_+N7Z.2[%(ZF*5F9?C!)_Q^XB>+'^7R-^Z0OZ'QX08;VI5L.:'/5"CR\>:
MC0=*)$<W6Y<U%YO8B(M>6RZ'>=O5V.L&DU>5F8N6>@UV2^Y20IL-'8E8+4F'
M1X]5M"'%I]7E$Y:&V"[)KD;K5,B78&WC&O*RH4U/JG/I>(L"-EVJB)DOM+$^
MTDQ%KPV& FPC]W7?0K1E63%P5"#)LB+HL1R_2<OH0K*0 @-O8MV=7)^'(RM6
M9#FXBY0X49JL5_JS)/=%?D+:HDQ5:K%6')P$S>Y$S)=;2RX->S6,%ERLU+R\
M:K-Y2,C7?18JHS2\E'9;%4G\-[8D-CV+FQR(J+WH6]R8F'LA]S8CVO;<5T&J
M56$V8;EI08?TW)[B+^$/>DU;%LRLA27*VIU>(LM"<FUJ=JIZ=8PSPAH5'HDO
M,5F594ZO,,2)'C3*:>3EUY)GL,WV6(BUY2FUL1;8N>,D&DU.&^8=GE"?]%R^
M\R]PW)2+=@PHM;GX,G#BKHL6(OE*:OQ9PCDYJENJMF27-*_**CH39;)B1=>M
M,N\F%+MY+KLRDPK]I4)\_!AIRD-^O)V6T<RT=5SQI69_^X)/_P!7W#QI69_^
MX)/WK]QI[PEK'MVVK"EINBTR!*3+IZ'#6(Q,E5JYYH;!M'"ZSYRUZ9,3%$EG
MQHDNUSW*W6Y53:+RMHM=LJGSLO49&#.2,5L:5C-1\.(W8Y%[3&4V[*'4ZQ'I
M4A4X$>H0,^4@-7Z29;3&WK492R,.ZA'E6-@P)*4<R Q-B:LD1#F20I\_9-)L
M[$2*US8\[-/;.M?W/=J=ZLD$S9(IN[)0J69*8A3<K"F9=R.A16(]CD[45,T+
MQID              #5N,>*#;!G)" L"+%69:KLV-:NS/O\ 429LL1?E#:0.
M:&>$E#TDTI.9RSUY-8;)PYQEMZ\YMM/A.C2=15$T8<PB)RB]NBJ"*HE9IF&S
M@1#%.[>I=HQJPL-\30B,9DQ$5=>??ZC7^&N-T&Z[ME:1$@1H21VNT7/:U$TD
M3-$U"Y%,S%V[P1V_KE@VG:D_5YA'.2!#56M;EFKNS::@M#'QM=N6F4M928:L
MW&2%FK6Y)FGR$S8BF9YN@0:NQDQ.2P)JFPE@Q8O.F.=]!J+L7+M-<+X2;/U2
M9S_TL&:((HF>;I@&C[,\(2@56>@2-4AS4I%C.T6QWM;R:+V(N1NYKD<B*U45
MJZT5.U!$W28F.KT NPUIBEBY1;&BI(QN6F*F],TA041>33L5V9;V(B_1LL&F
M<.,=J+<M3@TJ>9,2L['54A1(C41CE[$S3M-LU>IRM(IDS4*A&;"E8#%B/>O8
MB$B;DQ,/M!SS/^$G2F594E).=?(M=EY+<W)WH;FLF[:7>5$95*)&6) 5=%[7
M)DYCNUJH(F))IF$@!K+%#%ZB61&YA%Y:9J3FY\G!1%Y/NTLS!X>X]4.X*G"I
MM1;,2DS&7*'%BM1(;E[&YIVB\+EFUVZ0$!60     /+E1J*JKJ1,ST0?&>Y.
MK.']5FV1%AS$2$L&"J(BJCW(J9Y B+N=[DBNQ+QY27AO:^GP8S6)I.^BD)F6
MDOVGC&Z12Q<6Y*O4=S$EXJLFF\FN2-<FIS=7H^PPN&V%MTWC3XM9H<]+2;4B
M+#5\5[D<Y>W+(RMYX*WE2:!-5:K5.3GH$DS3<QKW*Y&YZ\LT.7-WY1-G65)J
M<&LVS+U*6<CH4U+)%147O:<<VC2JK<6*-1H],J<Q(LFGQ&3$5CESY+-%<B:^
MW4;=\%BZG5.SZE1)F*KHM.3."BHB?V:HN2)VKD07 [5CM.__ ,WVH:GG9FF,
MMV*QOPU3#EU/GJ+4IA[(V::3OHN8]-BHN9+L4Z)$NW!^@WA-U&,R:I\BV&^"
MJ9I'55\I5[S,>&#_ (#2?VBE:WG_ +*[,OU9G\Q-UB>42C?@V8>LJT67NA:K
M&@K)QU;S5K-3^S6N9\7A O>W&F0:V(]$5L+-$<J)M)]X)]0DX=G34M$F8+)C
MG*Y0W/1'+VZDVJ:_\(+\M5/[\H7VB?RD7S.GYJNTNB4Z1=5Y^!)I%AM1BQ79
M:2HB9ENGW;;]4F>:TZKRDS,O:JMAPXF:KD1O$+#BG8@4RD-J;GMYHS-FC$<W
M:U.XPMCX)46T;A@UB2?$6/!:Y&YQ7JFM.Y5-\W.+6<\8?4:I75B#-4"2JDQ(
MP9J)%YQ$AN7/DVJJJGMR,AC/8WBNKE'CT2I3"K,(KV/ST7L>WTF5\'1?_P!;
M9C_3,?\ <2/PQO\ $+5__D,6Y7=;SFL^";PEF*UAM&O&N5N:CUR- YUDY,VH
MB;&[>Y"2^"C6IR<MRNTZ:F'Q8,LYKX*/<JJW21<T3T:D)[-?D+=_TU?L-7^"
M(U7PKE:U-:HQ$]REB+2S>\3=',#XCW8ZSS71'JU(L7)%<JIM4GGA>N<RV:,K
M'N:O.E\E53L-;845&5HF.\YTG%2"U\U$@H]RY(CM)=N>S:2OPL;FIU0ATND2
M,W"F8T*(L:(D)R.1NK5K0D=%G\T/5>M)+@P%I54?/Q8#J9!<_DT322+FJ:E7
M/TD7\'K#EMVSCJRZJQI/HJ:A/Y%C,TB[5UKGZ#9\DF?@R1^U>;?]R&$\$2I2
M4M2Z]+S,U!@QHD>$K&1'HU7:E35GMVH(CG"7FTH'CQ%=.XZ/EYIRN@,B2\-$
M78C5RS0[&E8;(4K!APT1&-8C6Y;,D0Y@\*FTIJ3KLI==/A908B-AQHC<U5L1
MODN5.Q-2$\L+'6V9JW99M>GHDI483$9%1\+-'JB;4T2QRF;I,7IBS:52MRC5
M2<9-5*F2DU,L;H-B182.<B9YY9E^L3\M1*--3T=$9+RD)7JB:D1$38<N7'BK
M<EW8F24M8T],2\HL5L""Q8:9.1532<Y.[UDY\*2Y(]*LBGT9)G_?IYZ)'5B;
M6M36OH15+F3+/*&O,#)!U[8HSU?K/)QI2%IQ(BQE3)7.S1NWN/EM.=7#?':+
M*NB(M/BS:R[GZ635AN74[NU9E+,P5O.JT&6JE*J<I(R\VQ'I#>]S79=F>2&&
MQ+PON>RY&!5J[.RTXU\1&)$A.55:Y-:9Y^DQS=.4S:[L"_%1UEU=6JBHLLY4
M5.W4<[>"+^,M6_9FS[0N?K5@5%G(D57S4*5? CJJ(BZ;=6Q/1D:3\&^ZZ+:M
M<J4>O3K92'$9HL56J[-<_0:F><,4QRF'8YI'PMOR=RO[XS[%)5XY[%R7.NP^
M$_[B$^$]4Y2L844Z?IT9(TI'FV.AQ$14TDU]Y9GDE,3$PU!A_BS<=F6RE/I=
M.2-),B*_EG0W*B*NW7ED7ZM<=ZXT3,M3($O#=!@/1RLAZFMSU:3N_(W5X-4C
M+5'"/FT] AQX$2/$:YCVYYIJ-+XD46I82XCMG: Y\I)Q8G+2JM57(K,];%SV
M^HS;DW$Q=U-AA:O4RRZ?15B\M$@HKHD1$RS<JYKD26/"9'@Q(49B/AO31<U=
MBIW&#L&Y9:[+4D*O*/TDC,33S3)6O34Y,O62#,W#E/7FY#Q#HU4PAQ)E:Y27
M1GTJ/&6+":BKHZ.?TH2KZBQ)-J^.6*#HKG1Y6D0D:Y[=)=&##3+Z.K\Y5,]X
M1MX1KGN64L^WW<NV%%Y.,U&HNE&5<D1';=1'\(+DG<+<0X]%N1'0)2.J0IAB
M-1=%Z^2[->S7V&/>SK%[7]W7E-DH%.D8$G)PTAR\%B,8U.Q$(YBO'B2V'%Q1
M8+E;$;)OR5-J:B5L>CVHYKD<UR(J*G:?!<5,A5FA3].CMTH<S!=#5,\MJ*;<
MHZN<? ^EX3JG7IAR(L=L)C6KVHBKK^PZ=BL9%A/AQ&HYCDR<U4S14[CC'#BX
M9K"'$:=DZ\R*R45%@S#(;47-,_HN3/L-UWOCM;,K;,R^@5"),U.(S1@L9"5%
M8Y>U=+49IF(ANJF9GDV=2;=H]'>Z)2J9*2CW)DKH,)&JJ>LY0J?^8U_[ZG]#
M8_@QUN[KA?5)NN5!\S2(:(V&D5NMT15S547N-77-/2U,Q_F)R>BI"EH,XCGO
MRSR3425IBTR[/.,;M1M,\(YW,FHQJ52$NBU,D^D[7]IT%4<<+&E)6)&AU59E
M[4S2'"A.TG+W:T0T%AE*36(V-;ZU%@O?*PYGGD1R_1T&HN;$7+5F6J;]$HB8
MO,NP9B3EIA6OF):#%<SZ35>Q%5%3NS./\:[MN6X:HDE7Y29IUO0YG18]L%<G
M(B^5GW^@V9BYBE<5EW_+R290Z,]8;\^18Y7L_.R54SSVE_';$"U:OAG,RTI.
MPIR9FT:L"$U,W-7//->[(3-RF)AL7"*!1):PJ5 MF:9-R#(2(D5%UN=VZ7<I
M,317@BRLU!L>?BQFN;+1IG2@YIY6W-4]!O4U'1BKJX<N.GS]6QRJ%/H\PZ6G
MYFH+#AQFKDK,T3-?<3[$G GJ]:<:MTJKQX\[),Y:9Y7-%B=ZHN>I<R&3M9@6
M_P"$)'JLXJMEY:IJZ(J)GDW)$.@\9[XH<'#*H\A4($:+49=8<NR&]'*JKEM3
MLU&(B+2ZS,WBR$88X@UB=P4KJL?'FJM28:M9%76Y6N74OK1#5.&]+M*YGS3[
MVN2/*5&)$_L^57-'HJ;<\S9'@Y1X5KX=W!<%7@1(E,BO1BM8W25R)FBZNX\4
M6TL*L0X<[,4?E:3,L>NE"F9E835SUYHF>P=2]KLYA!AQ4[;O%T_0KLE9ZWU7
MZ<&%$TEB,79I)GJ5#:>*=R,M6QZG4U_")#6%"1%R73=FB9?:<I4!\[8^,DM3
M+6J:QI=9N'!<L%RQ&1(:KK:N>>>1/?"RN-\U5:;;4K%5S8>4:+#:GYZZFIGZ
ME0L3R28O+&>#_9D&Y*)<T_5HD%%FV.EH+HV6DCUUJ],_26/!LK[K5Q%J%MSS
MUY&<>Z BN=DB1&+DB^M3U2\!;\9(PG2E:D9>'$:D3DTB/3+-,]>K:0F^;,N#
M#&OTF>JLS C33XO.(,>"JN32:NM%SVJ9YPO*;Q=T5X5'Y,%_>X?_ '&J<&<*
M'WY;CYZLU:9@TZ%%="@2T/6F>29NV^DGF.=<@W'@13JM ?ILF8L)ZKEEKR5%
M_CF4\%N[:3#LZ8I,Y.P9><@1W1-&*Y&(K%1,E15-<IE(O%+6,@E7P=Q?E:<V
M?B1:?%CL:]N:HV+!<NK-.]#LF$]L2&U[-;7)FAQUBE5(%[8YTZ!1U68ALCPY
M9KVIJ54=FJIEV>D[#EH?)2\.&OYC4;[BT^[-?LN  TP   :-D/\ ,M/?L/\
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M1\M^J
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ME6)RF2<K%5-<1>\S9^<QZJ*JYG#BT/Z9\/P\;"]/31CU7J  <7L
M
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M$6)4Z5*Q8JKFL3DT1R^M>TD>946.C V[:%"MU$6D4R6EWI_YC6)I>_:9[(!
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MKG[=H,@ >-]L
M
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M$MSZEXM>8;7;L*@&V
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M3+,W:FPPUHT"4MFWI*DT]B,@2S$;J_.7+6IF2Q%H9F;R  J
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M?ROVGPKX53Z.G/7SKG[=H,D !XWV0
M
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M/A18/),EM'6S5EM-CM+"3*H *R
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MS@ )L
M            TGC5^,TM^[I]JF[#4^(]$FZ]?$G*2;%7.733B9+HL3-=:J>S
MT,Q3BWG:7R?C5%5?ILM,7F9C^Z VY1)JN3S):48KM::;NQB=ZF_+9H,K;].;
M+2R9OVOB*FMRBUZ!*4"GMEY5J*]43E(F6MZF:[!ZKU4XTVCHGPSX93Z2G/7S
MKG[&2  \;ZX
M
M      R  9  !D0O%"PY:_*5*R4U,Q)=L",D9'0TS551=A- ")L^>GRR2<C+
MRS55R0838:*O:C4R/H  9      R  #( !D,@       ,D  9  !D,@ &0V
M
M
M                                 #PD-J1'/1J:2IDJ]I[
M
M
M
M
M
M
M
M
M
M
M
M
M
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M CO7>V=^T_C(.N]L[]I_&0:5>TEI2($=Z[VSOVG\9!UWMG?M/XR#2KVDM*1
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M?&[RE]9!0
M
M
M
M
M                 !<@>4OK0^T^*!Y2^M#[0+<?R/:?&[RE]9]D?R/:?&[R
ME]8%
M
M
M
M
M             %R!Y2^M#[3XH'E+ZT/M MQ_(]I\;O*7UGV1_(]I\;O*7U@4
M
M
M
M       L.FX#9ULH^*ULPYNDUBKDJIZ"^:NQ<CQ9:L4V-+Q%AQF-S:YO8=O3
MX6M7D>+XAZO\'@SC6O:8_NVB")V-=T*O0$EYI4AU%B:VKJ1Z)VH2PQB8=6'5
M--75V]/ZC#]3AQBX4WB0 &'<
M
M                  %R!Y2^M#[3XH'E+ZT/M MQ_(]I\;O*7UGV1_(]I\;O
M*7U@4
M
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M?+3O0E9\#$PZL.K+5U?T'T_J,/U.'&+A3>)  8=P
M                                                       ,BH%
M!Z@                            =@   "Y \I?6A]I\4#RE]:'V@6X_D
M>T^-WE+ZS[(_D>T^-WE+ZP*
M
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M#N
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M<C-GY^NF:*IIGV?T;!Q:<;#C$IZ3S  9=
M                                      ?FO_TK]@'8Y.]%0#0O@X?C
ME>W[R[^AYD_\U4_^RA_U)5@]8U9M2X;EG:NDND&?C*^#R4327+TE)>Q:S#QS
MF[L<DOT1$AL1J\I]/5G^:9MR;OSEC\?[1FGPY>\K;1\.M4QZ+%Y)-<6&G;J[
MLO<0*H7;*WKB]8%6E5RB+**R.S/6R(CM9T^]C8C'LBM:Z&]%:YJ_G(NU#0,I
M@K4Z-BO+5FB\V6@LBK%R?%R>S/:B)VB8*9BW-]'A2?X_8G[]_4WI+(O-9?\
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MYGK/69?EX?7WE^H^"_!=2WJ/41R]HW[SV&HC6HUB(C43)$3L*@'R'[,
M
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M7"GFQ)RMS$>41V:P49HJJ=V9M>K652YRR(MK23%D*8]J-1(2KFF2Y[>]<B3
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M3+>W7+_"@ZFV_NN7^%"<3H^F69PI<KM<WO3WGM'-_23WG4R6=;^ZX'PH.I]
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MA4 ^._9@
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M2DG/?F]OR-G&F<%[EK$G=%5L>YIA9N9DE5TO'<N;G-3L5?8;F[RPS5U  5
M         7('E+ZT/M/B@>4OK0^T"W'\CVGQN\I?6?9'\CVGQN\I?6!0
M
M
M
M  #56,G^)2'^A3:IJO&9<JC(+_R*>ST'\:'Q?C__ .&K]X_NUXJIEK)[A]9K
MI]S*C5&.;*M5'0X3D_">E?0></[-=47,J549E)M7-D-=2Q%[U]!MMK6L8UC$
M1K&HB-1.Q.X]?K/5Y;X>'U]Y?'^#?!M2WJ/41R]HW[SV&M:QJ-8B-:B9(B:D
MR*@'R'[(
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M('E+ZT/M/B@>4OK0^T"W'\CVGQN\I?6?9'\CVGQN\I?6!0
M
M
M                                                    "/5RVH-:
MK4K-SJYR\NW5#3\YWI)"#5%<T3>ERQL&C&IR8D7C_P#BC4:QJ-:B(U$R1$38
M5 ,NH
M
M  N0/*7UH?:?% \I?6A]H%N/Y'M/C=Y2^L^R/Y'M/C=Y2^L"@
M
M
M
M
M                                                         "Y
M\I?6A]I\4#RE]:'V@6X_D>T^-WE+ZS[(_D>T^-WE+ZP*
M
M
M
M
M                                                     +D#RE]:
M'VGQ0/*7UH?:!;C^1[3XW>4OK/LC^1[3XW>4OK H
M
M
M
M
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M)&^C43)-1BJG+[I:P #(
M
M
M
M
:                                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g98130g01t21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g01t21.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1CB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-&)U)3A#5&.D@N'B\"8G9(/Q*$:BL\+_Q  : 0$  P$! 0
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M^ER_F4N\I2#-?I=>?2Y?S*=_TGUV7Q>[2@ ]MJ
M             !S(272;%<LJJ2&HB;1<G*QLC=9DUT5-4,\F6F/USHB9B$:
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MZNJ<YG;+2L;TST1O0XP'W-&Z&:6)_P ^-ZL=IUHNBGSH::I8 ,@8!E$U,
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MV7*"JF3_ ,.1-S\2(;I;ZJU7">BN$+X*J%VZ]CDXH4Q;1CS>B=2+1+R  V2
M&=/*!@&=.<P !G0P !D: 8!E$&@& 9T"IH!@ SH!@&43543[#L[[LVO]DQM+
MY7-IO@.ZQWQ)-7:.YN!2V2M)B+3W1,Q#BP#.A=+    SH8
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M5RZO71>?K.H[I]J)DUJ<G.M,OYE-\=\F/:(QVMK$PM$S$H7 !Z+0
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M'HNJ+IY25:C&L%RV[P7*SW1E-=$^5Y2CJ-V15ZU15YS3:<V2N3O,5TZ3'_\
M29E N?X9787>FT58[E8)/C05")HCTUZNA?(=_G>*W^@V;,N%=E%36T*LB5*-
MS%1O'F377H\QJ-MN/7ZR5M Z\7J6[T$KU2F?+P=&O2BIYNDDW:SXCX?JJ?\
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M:YT?,B[R\")O/Q'!.9#2=GB<L9=>L)W>NHH .A8
M              LQW,OT/KO2E]B%9RS'<R_0^N]*7V(<'U+[$_F%,G9,( /G
M6        "OO=1_\79/],A!!._=1_P#%V3_3(00?2[!]BO\ WW=%.P #L6
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M[TDADJ7N8Y.94UYS4+QY^(+4P13);)KW(KI.H #=8
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M:['IO4IM;/:*"SP.AME,RGB<[>5K.95ZSFVK;ZY\>Y$*VOK#W@ \QF
M  KYW4:_[78_],A!/ O+>+!:[RZ-;I1Q5*QZ[F^G-J:_O%QKL>F]2GJ[-]0K
MAQQ28[-*WTC12K@.!=7O%QKL>F]2CO%QKL>F]2F_-:?&5N)"E7 <"ZO>+C78
M]-ZE'>+C78]-ZE'-:?&3B0I5P' NKWBXUV/3>I1WBXUV/3>I1S6GQDXD*5<!
MP+J]XN-=CTWJ4=XN-=CTWJ4<UI\9.)"E7 <"ZO>+C78]-ZE'>+C78]-ZE'-:
M?&3B0I5P' NKWBXUV/3>I1WBXUV/3>I1S6GQDXD*5<!P+J]XN-=CTWJ4=XN-
M=CTWJ4<UI\9.)"E7 <"ZO>+C78]-ZE'>+C78]-ZE'-:?&3B0I5P' NKWBXUV
M/3>I1WBXUV/3>I1S6GQDXD*5<!P+J]XN-=CTWJ4=XN-=CTWJ4<UI\9.)"E7
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MT=OQ*Q6ZLCJJ*VP0U$?S7M3BAO#S=KVB-HO%HC3HSM;60 '*J
M
M
M
M
M
M          'Q-*R&-\DKVLC8F\YSET1$ZU4#[!S%BSS'+]?ZJS6>YPU=?2MW
MY6Q<41//S=)^^6YC8\3IVRWROC@5_P R-/C2.\S4XJ!T .8IL[QZ?&),@2XQ
MQVN/7>EE16<4Z-%XZ^0QA^>8]EZRML5P9/+&FKHG(K'HG7HO'0#J <5==J.(
MVJ^-M-;>(65:N1BJB*K&.5>".<G!%.SBD;+&V2-S7L<B.:YJZHJ+S*@'T
M
M
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M>8Y$Y^.I,"%7<7KLBNG=*6R;*Z"EMUR2A76"GDWT:WRKUEHD
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MC4R ,:C4R -'#DU!+EM1CK7._2,,#:AR:<-U>8WA%%N_[Q=V_P"E1$K@
M                     %YCQW*YT=LIEJ+C50TT*<-^5R-0#V _)E1$^F2H
M;(U85;OH_7@K=-=36VS([3=*IU-;Z^&HF:BJK6+KS ;<
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M82WH- (QV7;,YL:N]PR')+E^F,DN&BR5"MT;%SZM9Y"3F\PT"
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MMI/J6>Q#T@         #\:JIAI87S54T<,+.+GR.1J)]J@?L#3]]%A[9M_\
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M3;8MR_X2KADWXE=I\UVO,H$K )Q
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M8_Z&SV'3@
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M*\6L_I<'YR32,NZ*\6L_I<'YP)$MGZMI/J6>Q#TGFMGZMI/J6>Q#T@
M  #DMI^&Q9UBT]FGJYJ1'N1[9(UXHJ=:=*<3K0!65.Y7@T^DE5]Q G<L4^O'
M):K3_0A9H: ?S6RJP36+);G:HHJJH923.B;+R2_'T7G4]6!8M+E&5T-HG2II
M(JA^ZLW)+\4_HL^WT4CW/DHZ=SW<5<Z)JJOX"*WT<3T?%24['IS.;&B*GVZ
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M5YB>^39N[JM;NKT:< UC6)HUJ-3R)H!EO!-.HR
M           !%%N_[QEV_P"E1$KD46[_ +QEV_Z5$2N
M             #19[]";]Z%-^13>FBSWZ$W[T*;\B@>79?XO<?\ 0V>PZ<YC
M9?XO<?\ 0V>PZ<
M                     --F?T2O7H<OY%-;LK\76/\ HC/8;+,_HE>O0Y?R
M*:W97XNL?]$9[ .K
M                                       C+NBO%K/Z7!^<DTC+NBO%
MK/Z7!^<"1+9^K:3ZEGL0])YK9^K:3ZEGL0](
M    #'$#(                              %  =          #0 !H-
M%\@#0&.)E ")H                                     'P^1K&ZO>U
MJ=:KH?1 ?=?7.>BPRW,HJYT$RU;=YL;]'*G6!TENDC_Q$7=_*1[OZ*BX[R$K
M,D:]-6.:Y.MJZH?S-2]W1*EU0EPJ$J'-W5DWN*IU%H>XTNE?<*3(XZ^LFJ(X
MWQJQLBZ[J\0+*                             !HL]^A-^]"F_(IO319
M[]";]Z%-^10/+LO\7N/^AL]ATYS&R_Q>X_Z&SV'3@
M                                               !ILS^B5Z]#E_(
MIK=E?BZQ_P!$9[#99G]$KUZ'+^136[*_%UC_ *(SV =6
M
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M +Y--30R2LIG;KW,17)YE/9LSH:2FPZU24U+!"^2G9ONCC1JNX=.G.!U2
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M;H(5[HB[,6*/<_14?#=30EB**.)ND4;6(O0U- /L
M         -%GOT)OWH4WY%-Z:+/?H3?O0IOR*!Y=E_B]Q_T-GL.G.8V7^+W'
M_0V>PZ<
M              --F?T2O7H<OY%-;LK\76/^B,]ALLS^B5Z]#E_(IK=E?BZQ
M_P!$9[ .K
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M&Q(R[HKQ:S^EP?G)-(R[HKQ:S^E0?G D2V?JVD^I9[$/2>:V?JVD^J9[#T@
M.(0         -$  :   -  &@     <7EVS/&<KN3;A=J23X:C=Q989%8Y[>
MI>M#M !S./X-CF/ST\]IM<$$\#%CCD357(U><Z8: #G<RPZRYC1Q4]^I>72%
MV_$]KE:Z->M%/!BVS;%\:J65-LMK5K&:Z5$SE?)Q\JG8C1 &@
M             T0 !H-$  #0 !H@T     -  &AA3( XC+MF.,97=/TE=:21
M*_=2-T\$BQN>U.A?(;*QX-CECK*:JM=J@IZFGBY&*1NNK6]*'2Z  ASN:899
M,RHH:6_4G+LA?RD3FN5KHW=:*=$ .+L.S'$[+#N4MK:]W*I,LDSE>]7IS*JG
M9HAD                 <CM;\7-_P#1G'LV=_0FS>C,]AX]K?BZO_HSCV;.
M_H39O1F>P#H@   /B61D,;I)7M9&U-5<Y=$1 /LP1;G6W+#L4:Z/X>VX5O1#
M3+O(B^5>@A>Y;7-I&T6H6CPFT34=)(J-22%%WDUZ5>!9?+,VQ_%*5\U[N<,&
MZBJD:+O/73H1$(#R_NEYZ^5U#@-JFEF<J(V>:/>7[O0?EB/<UUUTG2OS^[SO
MD<N^Z"-^^JJO%=7<2>\/P'',1@Y.R6R")VFBR.8BO=]H%:J#9?M,VGS1U^87
M)]'2.U1&RNT<U/(Q"9L$V$8?BZ0SOHUKZZ/1>5J':HCNE40EE$&@'Q#%'%&C
M(F-8Q.9K4T0^]     BBW?\ >,NW_2HB5R*+=_WC+M_TJ(E<
M                  &BSWZ$W[T*;\BF]-%GOT)OWH4WY% \NR_Q>X_Z&SV'
M3G,;+_%[C_H;/8=.    !>8X=:K*4S?X%\-M_P"C%594;R/RG)Z_-UZ_*!W
M,(9
M  #39G]$KUZ'+^136[*_%UC_ *(SV&RS/Z)7KT.7\BFMV5^+K'_1&>P#JP
M
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M $4V[3_$5=M?G?HJ+U$K$46[_O&7;_I41*X
M     -%GOT)OWH4WY%-Z:+/?H3?O0IOR*!Y=E_B]Q_T-GL.G.8V7^+W'_0V>
MPZ<   !RZ_3YOHW]SJ#EW?3YOHW]P.H0!.@
M                                  !ILS^B5Z]#E_(IK=E?BZQ_T1GL
M-EF?T2O7H<OY%-;LK\76/^B,]@'5@
M                                  #P7]:=MDKUK6JZF2!ZRHG.K=U=
M4]17+"+_ +38<<@;C.%T%19-YWP-]2B,DY/7AJG]RREQA=44%3#&YK7R1N8B
MN35$54TU4K/1V'([%')04FV6U4<;)'.Y#?1>355XHFO,GD GS9]5WVMQR&;*
M;;#;;DKE1T$*ZM1.A3I#D]EZ5B8G EQR&#(:A'+K70Z*UWD.L       T
M  1EW17BUG]+@_.2:1EW17BUG]+@_.!(EL_5M)]2SV(>D\UL_5M)]2SV(>D
M
M                                  _.>6.")\L\C(XF)JY[W:(B=:J1
M'M$V^8MB2N@I)/TO7)_X=,]-U/.X"7W*C457+HB<5U(RVA;:<2P^*2.6NCKJ
M]$5&T].N]Q3H54YB!:C)MJFV"K=36>&IMEHEX+R:*R-$UYU=IJI(V =S;9[9
M(VLRZI6\5B_&6-=48B^7I50*I99>&W[([A=(XUA95RK(C%77=13RVF)E1<::
M*9-Z-\B(Y/)J6EVF=S[CM#:KW?J.LJH>28Z9E,WYC=.A/(9PWN<K!6VNUW5]
MUKT>]C)E9IPUY].<";,%QBRX_8Z-MGMU/3[T+'.<UB;RJJ=*\YTZ<Q^5) VF
MI88&:[D3$8FO4B:'Z@-              PJZ(JKP,GFN%)'74<]+/O<E*U6.
MW55%T7RH!&%L<UW=%796N:J+:HN9=26#C\.V>6+$Z^>NM<4SJR9NX^::17N5
MO5JO0=@@                              -%GOT)OWH4WY%-Z:+/?H3?
MO0IOR*!Y=E_B]Q_T-GL.G.8V7^+W'_0V>PZ<   !R[OI\WT;^YU!R[OI\WT;
M^X'4)T )T
M         --F?T2O7H<OY%-;LK\76/\ HC/8;+,_HE>O0Y?R*:W97XNL?]$9
M[ .K     :7(\GL^-QQOO=:RD9)KNN>BZ<#VVBYTEWH8ZRW3)-32<6O1.<X[
M;E303;,KX^>"*5S(F[JO:BZ?'3F.IQ6*.+&K4V)C6,^"Q?%:FB?,0#:@
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MJ6>Q#TGFMGZMI/J6>Q#T@
M                                       'S)JK7(U='*G!>I2"+\W:
M119C:[+'E-+I<UE>QW(?[MK..GJ GD'Y4C9&4L39WH^9K$1[T31'.TXJ?J
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MVM^+F_\ HSCV[._H39O1F>P\>UOQ<W_T9Q[-G?T)LWHS/8!T0
M                                       &BSWZ$W[T*;\BF]-%GOT)
MOWH4WY% \NR_Q>X_Z&SV'3G,;+_%[C_H;/8=.    Y=WT^;Z-_<Z@Y=WT^;Z
M-_<#J$Z $Z
M          &FS/Z)7KT.7\BFMV5^+K'_ $1GL-EF?T2O7H<OY%-;LK\76/\
MHC/8!U8    #AMMOBOO_ -4W\[3J,9^CEJ]$B_(AR^VWQ7W_ .J;^=IU&,_1
MRU>B1?D0#8@
M      &%,@".=HN,9C<;G!<<,R5+>]C-Q]+,U71O\OG.06MVTP,6A^!VV=WS
M?AJ+I]N[H3HY4:U5<J(B)JJJ1];=KF*W+)W6.AJIIJAJ/59&QKR>K-=Y$7IY
M@-;@^*9ZR_PW/,LJ9401)\6BIF*UBK_S$J)TFOL5WHKY;8Z^VS)-32:[KM-.
M9=%147F-@            C+NBO%K/Z7!^<DTC+NBO%K/Z7!^<"1+9^K:3ZEG
ML0])YK9^K:3ZEGL0](
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MO,A/. ['L3PZ.-]+;XJNM:B:U-0S><JITHB\Q(R>4 8:B-31$1$3H0R
M  <AM<\7-_\ 1G'MV=_0FS>C,]ARVV[*K;;,5N=IJ75'PVKIG)$R.!ST5?.A
M[-D.4VR]8Y24-O?.M11T[$F;+ Z/1=.C7G [\!.8
M                             #19[]";]Z%-^13>FBSWZ$W[T*;\B@>7
M9?XO<?\ 0V>PZ=3F-E_B]Q_T-GL.G X;*=JF)8M=I+;>KFRGK&(CG,TYD7F-
M1X=\ [;9ZBM7=6(B[6:K5$_W3?8A#VZG4@%]O#O@';;/5_\ ,TJ[9L$[Z6UW
MZ;9R20;GS>G7SE(]U.I!HG4@%]O#O@';;/4/#O@';;/44)W4ZD&ZG4@']#\3
MVHXIE=U2W62YMJ*M6JY&(G0AVS2D7<E(B;58]$3_ '#_ &*7>
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MFYVZK=%^TWX
M    !X[Q2+76JLI&R+&Z>%\:/3H545-2K3(<SQG(+%''@SI:BT,EA9+3HFY4
M[VJ->Y4Z>/$M/=73LMM6ZC1%J4B<L6O[VBZ?B5>LEC6^43JZ];6JNWW%\CDG
MIDD1$B=KS)JH$[;(,?KL>PV&"[(C:^HD=4S1(O")SUUW4\QVIR6RZWQVW$X*
M>"_27]B.54K7NWE=Y-3K0           $9=T5XM9_2X/SDFD9=T5XM9_2X/S
M@2);/U;2?4L]B'I/-;/U;2?4L]B'I
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M4SV'I
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M9]54?E X[N?]D%]V?Y%6U]XJ:*6&:+DVM@5574GM
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M$/$P=U7XV*KZIOL0A\      FCN2_&I']0_V*7=*1=R7XU(_J'^Q2[H
M                                                   &FS/Z)7KT
M.7\BFMV5^+K'_1&>PV69_1*]>AR_D4UNROQ=8_Z(SV =650[M7]<8[]1)^8M
M>50[M7]<8[]1)^8"M(     $ 0"XO<9?0"Y^F?V+ %?^XR^@%S],_L6
M                     X2+QQS_ /3&_F.[.$B\<<__ $QOYCNP
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M:#0R ,:#0R ,:#0R ,:#0R ,:#0R ,:#0R ,:#0R ,:#0R ,:#0R ")H
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M%+NE(NY+\:D?U#_8I=T
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M2X;%01KG*VWX.BJL?PM$5=?)TE9<IJ;#/<95V.4N0LNCG:(ZB5R4^G2J)JJ
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M34T1L;$:B>H]B<X               ,:>1#(
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M]B$/@     $T=R7XU(_J'^Q2[I2+N2_&I']0_P!BEW0
M                                       --F?T2O7H<OY%-;LK\76/
M^B,]ALLS^B5Z]#E_(IK=E?BZQ_T1GL ZLJAW:OZXQWZB3\Q:\JAW:OZXQWZB
M3\P%:0     ( @%Q>XR^@%S],_L6 *_]QE] +GZ9_8L
M        !PD7CCG_ .F-_,=V<)%XXY_^F-_,=V
M   "@ <OE6"X_E=;2U-_H6UCZ9%Y-KU7=3[#<6BSV^STS:>V4<-+"W@C8VZ'
MZW;>_1=9N/>Q_(OT=&FKD71>*)UE>]G>U&_X_8Y;??,=O=SF9,]T56]J[TC%
M7AJG$"QS3)HL*R!<EL45Q=0ST*O546&=-')H;T           !&7=%>+6?TN
M#\Y)I&7=%>+6?TN#\X$B6S]6TGU+/8AZ3S6S]6TGU+/8AZ0
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M1+"&BM&(V&T5WPRV6NEIJE&JWE(XT1=%YS>IS@9
M                                                          !^
M-73Q5=)-35#$?#,Q8WM7I14T5" +EL9S"PNFBV=Y;+0VR29TC:.1W"-%Y^.G
M'B3AD]PJK5C]?74%"^OJJ>)7QTS%T65>I"$O#KDZ7IMG=L_J_P!)NCY9*;E/
MCJS][3J Z;9GLLN-FR9,GS"]2WF^MAY"%[EX1-5-%3FXDN$/81M;NUZSZEQB
M^8K/9JB>!T[732<=U$545$Z=280      :+/?H3?O0IOR*;TT6>_0F_>A3?D
M4#R[+_%[C_H;/8=.<QLO\7N/^AL]ATX%&NZK\;%5]4WV(0^3!W5?C8JOJF^Q
M"'P     ":.Y+\:D?U#_ &*7=*1=R7XU(_J'^Q2[H
M                                     &FS/Z)7KT.7\BFMV5^+K'_1
M&>PV69_1*]>AR_D4UNROQ=8_Z(SV =650[M7]<8[]1)^8M>50[M7]<8[]1)^
M8"M(     $ 0"XO<9?0"Y^F?V+ %?^XR^@%S],_L6
M       X2+QQS_\ 3&_F.[.$B\<<_P#TQOYCNP
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MIN#9JA[*;5BM315W5UXDQV"Z17FU4]?3PSPQ3)JC)V;CTZ.*= &Q
M
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MD7<E^-2/ZA_L4NZ
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MT5XM9_2X/SDFD9=T5XM9_2X/S@2);/U;2?4L]B'I/-;/U;2?4L]B'I
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MWF9&U&HGV(>@#3X]C5HQZE;!9[?!2QM31-QB(OKYS<       &-$Z4"&0
M
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M?8A#Y,'=5^-BJ^J;[$(?      )H[DOQJ1_4/]BEW2D7<E^-2/ZA_L4NZ
M                                                     !ILS^B5
MZ]#E_(IK=E?BZQ_T1GL-EF?T2O7H<OY%-;LK\76/^B,]@'5E4.[5_7&._42?
MF+7E4.[5_7&._42?F K2     ! $ N+W&7T N?IG]BP!7_N,OH!<_3/[%@
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M'*-Z_P  /L'QRC>O\!RC>O\  #[!\<HWK_ <HWK_   ^P?'*-Z_P'*-Z_P
M/L'QRC>O\!RC>O\  #[!\<HWK_ <HWK_   ^P?'*-Z_P'*-Z_P  /L'QRC>O
M\!RC>O\  #[!\<HWK_ <HWK_   ^P?'*-Z_P'*-Z_P  /L'QRC>O\!RC>O\
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MJU:*2^43:M'\GR2R?&WM>;0Z-JZ@9
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MD,/^8[S&3#_F.\QJLM]LQ^@%A]%8=.<QLP\7]A]%8=.?+Y?7;\O+MZI  45
M    '"1>..?_ *8W\QW9PD7CCG_Z8W\QW8
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MW^TW)K5H;C2S:IJB-D37U&S:J+S*B^8YYB8[LYB8[L@ A
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MUZN5Q?=;@]-&OEA:Q&+UHB=/E.^3F+;7M49HBM8,N;B1'03F !PL
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M:/K%]BE<WV[?A6_IE;% $!\R\P
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M)@A;[9AXO[#Z*PZ<YC9CXO[#Z*PZ<^7R^NWY>7;U2  HJ    % X2+QQS_\
M3&_F.[.%A\<=1_TQOYCN@
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MC*8F.[[!Y:RNIJ+DDJZB*'E7;K-]VF\O4AZ4*H9
M                           !@UMYOMLLT#YKG6P4[&)JN\[CZN<F(F9T
M@B->S9F%(CR3;7;*7>BL5-)73?LO>BM8O]SEI+AM$SQCFTL$M)1*Y$56?)(G
MVJNJG379+S&M_P"F/W;1AMWGHF;(<OL>/Q[USKXF+S(QB[SO4A&60;;FN?R&
M-V^2615TWYDUU\J-0^L?V(L<J3Y'<III575T<2\_G<O$DW'\4LMAA;%;J"%B
MMYI'-1S_ %KQ+?\ CXO_ &G^T)_TZ?NA1EGVB9VZ.:LJ'4M(Y/BK(O)M1/\
M2G%3K\<V*6FD1LEZJ)*V;1-YC5W6:^TEI.8%;;7DF-*_TQ^R)S6[1T1]DNRJ
MQ7I*=&-?1-IV;C&P<$\Z]9L,#P.APZ2J?05%1*M0C=])':IJG3H=B#&<MYKN
MS/1EK,QH)S  S0                                     !5O;_  4*
M;3ZV7-V5K\=?:E;;E8J\DVKW>&NG-Q+2+S$3;5J#-UN4E?9WV2NL$,;56V7%
MC='O3G7>7F7J BK8_7TN0[1<"=9&RROM-KEBKZE6JC6JN]HSSZ*A:Y"%-E&T
M6"7)X,5N.-4=EO55&ZH5*!S'Q*U$U356].B$U@%YB+-IS77G/L4QJKEG9:JU
MDTL[(GJQ9%:GQ4U3CP)3Z#FLPPZV98VE6Y<O'-2N5T,U/)N/9KSZ+Y0.(V-7
M&LK\'O%MFJG.DIZB>CHG2O\ C*U-41->G3K-/LTBAQ3-**S9!;Z^._UL4CXZ
MQU7RL4J(NNF[T+H2&S9W88Z2UT\,<\3+<DB0JR1455>FCG.7I7RF,8V=67'[
MRZZTRU=37<GR3)*J99%C;U-UY@.QZS@=K-\N%NL-PI*.Q55P@J**7E*B)[4;
M%P5.*+ZSOS19[]";]Z%-^10/-LS3=P&P(BZI\#C]ATRG,;+_ !?8_P"AL]AT
MX%'.ZMX;6*GH^19]O!"'28>ZK\;%5]4WV(0\      31W)7C4C]'?[%+NH4B
M[DOQJ1_4/]BEW0   %8-O7C E^H86?7F4K!M[^G\OU##O^G?=_AT;-ZD=F#*
MF#VW<   =EL>73:+9TT5=9%X]7!3C3L]COC$M'UB^Q3/-]NWXE2_IE;% $!\
MR\P                             83B9    "NV6S/Q?:GFU3=:>J=!>
MK4D-"^&)9$>_1$W5TYN)T.'5E/CF$T.&Y50US^4MCJFIEBC5S&L<J_$U3]HF
M=S6NTWD1=.M#.B+T 0?LMK53._@.&SW*;$FTNM1'7L5$AD151$C5>/,3@8:U
MK?FHB>9#(' ;3['>*^V7"KM^15%OI(J23?IF1-<C]&KKQ7K-GLN1R[.\=^.O
M"C9JOV&SS/Z)7KT.7\BFMV5^+K'_ $1GL ZC<=_F+ZBJG=I:_I;'45RK\A)P
M_P#B+7%4.[5_7&._42?F K2     !.< "XO<;:KL_N:(Y4_VSU<"?=QW^8OJ
M("[C+Z 7/TS^Q8 #XW'?YB^H;CO\Q?4?8 ^-QW[ZE6=MJ*FT2X:KK\2/V*6I
MZ"K&V_QAU_\ H9[#O^G?=G\.C9O5+@@ >V[@  ##_F.\RF3#_F.\Q(MYLS15
MP"P:.T_V1ITVX[_,7U'-[,?%_8?16'3GR^7UV_+R[^J7QN._S%]0W'?YB^H^
MP45?&ZY.=ZJ5DKMK&5PUM3$VM9NLD<U/DF\$U4L\O,I26Z_K2L^M=[5/1^GX
MZWFV]&O9T[-6)UU=KX7<M_\ .L_E-]P3:[EFO_&L_E-]QP /3_3XOC#JX=?#
MIF;3\F[\)*WX6SE_@O):\FW334W/A=RS_P \S^4WW$7L^D$GU/\ <V16FSXN
MO],(KCKUZ.^\+N6_^=9_*;[CVV3:KE-7>*&GEK6+'+,UCDY)O%%4C,V>,_2*
MV>D,]I-MGQ:3_3"9QU\+FM:Y41=]>9#.X[_,7U&8_FIYD/H^<>8^-QW^8OJ&
MX[_,7U'V /C<=_F+ZAN._P Q?4?8 ^-QW^8OJ&X[_,7U'V /C<=_F+ZAN._S
M%]1]@#XW'?YB^H;CO\Q?4?8 ^-QW^8OJ,;COWU/T !.;B
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M\+5<YRKT(5B)GHKH]8-%B.46W*:!:NU2*Y&JK7,?P<WSH;TF:S6=)3,3$Z2
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M^)UK&M8W1K4:B=")H9!RVO:\ZVG5C-IGN  J@
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MK+7<GR2.I?@[=&-8W7=1W/Q)2([S#QK87_IJ?R 2(G2 G2
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M\8^D5L](9[2UO3*9[+GQ_-3S(?1\Q_-3S(?1\L\H
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M3]Z-3TQ[6,1>U%6Y;J^5BGXKLAQ1>:DD3S2*?F[8[BRZZ03I_P#N#_Q?W/\
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M_"E_3*V* (#YEY@     $=YAXUL+_P!-3^0D0CO,/&MA?^FI_(!(B=("=(
M                            --F?T2O7H<OY%-;LK\76/^B,]ALLS^B5
MZ]#E_(IK=E?BZQ_T1GL ZLJAW:OZXQWZB3\Q:\JAW:OZXQWZB3\P%:0
M( @%Q>XR^@%S],_L6 *_]QE] +GZ9_8L    #H*L;;_&'7_Z&>PM/T%6-M_C
M#K_]#/8=_P!.^[/X=&S>J7!  ]MW   &'_,=YC)A_P QWF)@A;[9AXO[#Z*P
MZ<YC9AXO[#Z*PZ<^7R^NWY>7;U2  HJ+S*4ENOZTK/K7>U2[2\RE);K^M*SZ
MUWM4]3Z9WM_#KV7W>4 'K.MKF?2"3ZG^YLE-:SZ02?4_W-DI2GO^5:^[!L\8
M^D5L](9[36&SQCZ16STAGM+6],IGLN?'\U/,A]'S'\U/,A]'RSR@
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M]Y_@*_\ \M?<!)0(U\(]Y_@*_P#\M?</"/>?X"O_ /+7W 24"-?"/>?X"O\
M_+7W#PCWG^ K_P#RU]P$E C5-H]Y5=$P*_Z_5_\ R-?:]K\]W6J2UX=>ZIU+
M)R,Z,C7Y-Z?LKP EH$:^$>\_P%?_ .6ON'A'O/\  5__ ):^X"2@1KX1[S_
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MV65[GGZ".]*?[$.O;L%*8XM$=M(;;16-W>2> #R7$
M        :+/?H3?O0IOR*;TT6>_0F_>A3?D4#R[+_%[C_H;/8=.<QLO\7N/^
MAL]ATX%&NZK\;%5]4WV(0^3!W5?C8JOJF^Q"'P     ":.Y+\:D?U#_8I=TI
M%W)?C4C^H?[%+N@   7F4K!M[^G\OU#"SZ\RE8-O?T_E^H8=_P!.^[_#HV;U
M([4P94P>V[@  #L]COC$M'UB^Q3C#L]COC$M'UB^Q3/-]NWX4OZ96Q0! ?,O
M,      CO,/&MA?^FI_(2(1WF'C6PO\ TU/Y )$3I 3I
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M(K9Z0SVEK>F4SV7/C^:GF0^CYC^:GF0^CY9Y0
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M=4+JW?XZIJFO0FB$E1M1C6M:FC6IHB'T";Y+7]4ZIFTV[R  HJ
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MO?VT._P_&:+%K4MOMSI'0J]9%5ZZKJO_ /!O@:7S9+QI:=86G):T:3( #)0
M                          T6>_0F_>A3?D4WIHL]^A-^]"F_(H'EV7^+
MW'_0V>PZ<YC9?XO<?]#9[#IP*-=U7XV*KZIOL0A\F#NJ_&Q5?5-]B$/@
M $T=R7XU(_J'^Q2[I2+N2_&I']0_V*7=    O,I6#;W]/Y?J&%GUYE*P;>_I
M_+]0P[_IWW?X=&S>I':F#*F#VW<   =GL=\8EH^L7V*<8=GL=\8EH^L7V*9Y
MOMV_"E_3*V* (#YEY@     $=YAXUL+_ --3^0D0CO,/&OA?^FI_(!(B=("=
M(                              --F?T2O7H<OY%-;LK\76/^B,]ALLS
M^B5Z]#E_(IK=E?BZQ_T1GL ZLJAW:OZXQWZB3\Q:\JAW:OZXQWZB3\P%:0
M   ( @%Q>XR^@%S],_L6 *_]QE] +GZ9_8L    #H*L;;_&'7_Z&>PM/T%6-
MM_C#K_\ 0SV'?].^[/X=&S>J7!  ]MW   &'_,=YC)A_S'>8F"%OMF'B_L/H
MK#ISF-F'B_L/HK#ISY?+Z[?EY=O5( "BHO,I26Z_K2L^M=[5+M+S*4ENOZTK
M/K7>U3U/IG>W\.O9?=Y0 >LZVN9]()/J?[FR4UK/I!)]3_<V2E*>_P"5:^[!
ML\8^D5L](9[36&SQCZ16STAGM+6],IGLN?'\U/,A]'S'\U/,A]'RSR@
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MB3+K2V2HF<U:ANJ<HO'CYRX)Q[3L_ F(UUU8Y<?#G34 !S,@
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M9Z0SVEK>F4SV7/C^:GF0^CYC^:GF0^CY9Y0
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MT6ZIACAJ*"EEBBX,8^)%1OF3H/> /SIX8X(DCAC;'&WF:U-$0_0
M      'FKJ&EKF(RMIH:AB<4;*Q')^)Z0!YH*&E@IEIX::*.!4T6-K$1OJ/(
M_'[.]V\^U43E3I6!ON-H /F-C8V-8QJ-:U-$1$T1$/H               ^7
ML:]JM>U'-<FBHO2AXZ.T6ZBE62CH::"1>=T<2-7UH>X ?*MWFJUR:HO!4/B"
M"*GCY.")D;$X[K6Z(?J                               :+/?H3?O0I
MOR*;TT6>_0F_>A3?D4#R[+_%[C_H;/8=.<QLO\7N/^AL]ATX%&NZK\;%5]4W
MV(0^3!W5?C8JOJF^Q"'P     ":.Y+\:D?U#_8I=TI%W)?C4C^H?[%+N@
M7F4K!M[^G\OU#"SZ\RE8-O?T_E^H8=_T[[O\.C9O4CM3!E3![;N   .SV.^,
M2T?6+[%.,.SV.^,2T?6+[%,\WV[?A2_IE;% $!\R\P"@*!63N@?&$_T6,C8D
MGN@?&$_T6,C8^DV;[5?P]/%Z(.HU];^M[;YGFPZC7UOZWMOF>6R=OYC_ )3;
MLV'6!U@T6;[ OIA:?2&^TN,4YP+Z86GTAOM+C'C_ %+UU_#CVGO  #S7*
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MSTAGM-8;/&/I%;/2&>TM;TRF>RY\?S4\R'T?,?S4\R'T?+/*
M
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M+FT5KMEAHZ6@UBK);EQJ)W]#H^E )?VH;4K9@U):YG)%6OKI6M8QDJ)I&O\
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M<HQ$YEZ_.6)3I R
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M](;[2XQ3G OIA:?2&^TN,>/]2]=?PX]I[P  \UR@
M   --F?T2O7H<OY%-;LK\76/^B,]ALLS^B5Z]#E_(IK=E?BZQ_T1GL ZLJAW
M:OZXQWZB3\Q:\JAW:OZXQWZB3\P%:0     ( @%Q>XR^@%S],_L6 *_]QE]
M+GZ9_8L    #H*L;;_&'7_Z&>PM/T%6-M_C#K_\ 0SV'?].^[/X=&S>J7!
M]MW   &'_,=YC)A_S'>8F"%OMF'B_L/HK#ISF-F'B_L/HK#ISY?+Z[?EY=O5
M( "BHO,I26Z_K2L^M=[5+M+S*4ENOZTK/K7>U3U/IG>W\.O9?=Y0 >LZVN9]
M()/J?[FR4UK/I!)]3_<V2E*>_P"5:^[!L\8^D5L](9[36&SQCZ16STAGM+6]
M,IGLN?'\U/,A]'S'\U/,A]'RSR@
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ML5O-IH;T :6X8S:;A=+=<*RC9)64'_#R+_X9N6])D
M                                                         -%G
MOT)OWH4WY%-Z:+/?H3?O0IOR*!Y=E_B]Q_T-GL.G.8V7^+W'_0V>PZ<"C7=5
M^-BJ^J;[$(?)@[JOQL57U3?8A#X     !-'<E^-2/ZA_L4NZ4B[DOQJ1_4/]
MBEW0   +S*5@V]_3^7ZAA9]>92L&WOZ?R_4,._Z=]W^'1LWJ1VI@RI@]MW
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MZ0SVFL-GC'TBMGI#/:6MZ93/9<^/YJ>9#Z/F/YJ>9#Z/EGE
M
M
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M:BHNJ$WH
M           #C]KEVKK)L_NU?:I^0K(H]8Y--=U=0.P!'6P"_P!SR79E;KG>
MZE:FME<]'2JFBJB+P)%
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MJ7(W1473GY@.D6-BIQ8U?L,<C'_EQ_=%-/%4P1S4TK)89$WF/8[5')UHJ'Z
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M\_,<YAN?_I22CH[S1_ :V:@_23W;R<E'$YVC=55>?310.\Y-B_L-]1CD8_\
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M>VU4-3"BZ;\3D<FO4>Q -;566BJKU0W6>#>KJ)KVPR:K\5')H[\#8\VID+S
M8U"?_>IPN4[0%LV41V"AL=;=;@^'E]('-:C6_:?&0[16VBHMU!%9*ZMO57"M
M0M!"Y-^%B:ZJY>;H [TSQ\AS^)Y509%C,5\AWJ:F<URR-G5$6)6KHY'>;0_;
MOKL&Z]WZ8H-UC4<Y>7;P1>GG W7'R#B:RJO]II:.&JJ+C2QTTW^[D=*FZ_S+
MTFKRO+Z&S857Y!3RQU4$,2NBY-=Y)'\S4X>70#IM?,9(QQ+:'75N3NL]_I*>
MBY&TQW&>;?T2-7:?%77FX*AVU9DUEHG1)672DA65B2,1\B)O-7F7S ;CF,'S
M#*R:)DD3D?&]$<UR<RHO2?8&NI;-14UYK;K#!NUM8UC9I-5^,C4T3\#8:F36
M9)=H[)9JFX20S5'(L5R0PIJ]^G0@&R!'5MVL6BKV>2Y=+25=-2LD6%*>1$Y1
MTB+HC4\JJ>--L5!30UT=XLU?;[E3MC=%12:.?4;_ ,U&J@$H^LRAQF"YU'E%
MPN%NGM=9:KE1-8^2GJ=%56NYE14-[5Y'9J*H=!5W2CAF:[=5CY6HJ+Y4U VO
M_P!\!ZS7TE]M58R=]+<:25D":RN9*U48G6O'@?%LO]INLSXK=<*:IDCXN;%(
MCE0#9^L>8B"^;5+C1U%ZFH;?3SVVCN4-MBE5RZR/=KO+S]&BDG.OEKC@J9I+
MA2MCIG(R9RR)I&Y?V57K\@&RX]1C[#Q6J[T%VC?);:N&J8Q=USHGHY$7RGN
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M/$Y:?]<GYB6")^Y<\3EI_P!<GYB6
M
MY_/K(W(<,O%K>CE6>G>D>[S[Z)JW\40A7!+/E=\LF1W66EFH[NRWMM=%RO!W
MQ$1'JFO7I^)8HPB=2:>8"JW>E([$JV6B6YS5\5"VGJJ-*;DX]]9&Z[Z_MNYU
MU.FJ,;J:!,YI;?;9HJ2HM%)N1L:J)))HW>T\O.6"1C4UT:U->?ASF=U.I (
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M9=W7*IML,D[W(^1JI\21R<SG-YE5.LW=OH*6W4_P>@IHJ>!%549$U&IJO.O
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M5/I/4_RD+-@#GL"Q2BPO&*2R6S?6G@155SUU5SEYU.A
M
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MO5]Q=M1O-%"EWJXH[0DL$-%+N-@D_P QWD3G+('"95LOLF1Y#+>JF>X4U?+
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M*IBIG5BUZ.9+H]LR_M(NAN\4PZU8PM1);HI'U51IRU3.[?EDTZW =$G2 @
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MZF$0R
M
M
M
M
M  1           ,:=>AD 8374R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7535[$Z6MMV0YE17&MDK*AE3&^1[G:M1[FZJC>I ): 0
M
M
M
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M>@] 0
M
M
$  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g98130g02t21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98130g02t21.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1N(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &VL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      #_X4 Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K
M970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_
M/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K
M/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O
M,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,C4N
M," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,C4M,3(M,314,#<Z-3<Z,CDK,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R-2TQ
M,BTQ-%0P-#HT.#HU.2LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C4M,3(M,314,#<Z-3<Z,CDK,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@
M(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI
M8W)O<V]F="!7;W)D("T@1&%Y;&EG:'0@+2!'86QE8W1O("T@4F5S86QE(%,M
M,R!?1T1#(#$R+C$S+C(P,C5?-3 P-#(X-C0Y,"XQ.5\N9&]C>#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^
M"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3YR<C,Y,S4R-SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @
M(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C@P,48W,49%.3-$.$8P,3%"
M048S144X-S,V-#,V-$1"/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D$P1#$Q-48S.$9$.$8P,3%"048S
M144X-S,V-#,V-$1"/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z03!$,3$U1C,X1D0X1C Q
M,4)!1C-%13@W,S8T,S8T1$(\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.D$P1#$Q-48S.$9$.$8P,3%"048S144X-S,V-#,V-$1"
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(U+3$R+3$T5# W.C0S.C0X*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-T8Q
M1C<Q1D4Y,T0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,3(M,314
M,#<Z-3<Z,CDK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C@P,48W,49%.3-$.$8P,3%"048S144X-S,V-#,V-$1"
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(U+3$R+3$T5# W.C4W.C(Y*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C=&,48W,49%
M.3-$.$8P,3%"048S144X-S,V-#,V-$1"/"]S=%)E9CII;G-T86YC94E$/@H@
M(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D$P1#$Q-48S
M.$9$.$8P,3%"048S144X-S,V-#,V-$1"/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M03!$,3$U1C,X1D0X1C Q,4)!1C-%13@W,S8T,S8T1$(\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,
M$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'
M!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@#Q0=? P$B  (1 0,1 ?_$ !T  0 "
M @,! 0             &!P0% @,( 0G_Q !<$  ! P," @0&"PP) @0$!04
M 0(#! 4&!Q$2(1,Q05$(%1<B89(4,E)35%5Q@9&QT3,T-C="5G)S=).ALA88
M(S4X=93!PJ*S)"5BE2>"X? F0T178X32167Q_\0 &0$!  ,! 0
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M@GC[6G\8]X_6'=_2O]V?T7Q]T' ![S8
M
M
M
M
M                                     'UO6>T],_Q?X]^Q1?RH>+&]
M9[3TS_%_CW[%%_*AY7]5^Y7]6>3LDIX^UI_&/>/UA[!/'VM/XQ[Q^L.;^E?[
ML_HKC[H. #WFP                 6WI#I='D='XZOLG1VM-^CC1=E?LO-5
M7L0RS9JX:[K(F=%2 ]#5E7H_27!:-]OIWN1R-61C7.9ZW$8>JFEEK2P/R#$6
MM9%'&DSH(E5S'Q[>V:<]>-K-HBU9C7RK%U"@M[P?<9L^25-V;>J"*K;$QJQI
M)OYO/T$NO:Z3V6Y3T-=:8FU$*[/1K'+_ ,B;\9%;SCBLS,>#?UT><P>C[QIU
MAV58O+<<26*EECB61CH554WVWX7IN4OI]B<^69/':FNZ%K45\[UZVM1=EV])
M;%Q=,E9MVT[ZIBT2C V/3CL2TUM5QI\>K8:9]RE9NCY7KQ>C==^2J5+K%@D>
M&7BF]@/?+05J*Z)'=;'(O-N_;UE<7&4RVVZ3&O;7ZD7U5Z$YGH#!],\<M&+0
M7W-7,>Z>/C6.=58R/?FB;<MW;&;<=.\/S+&Y;CAW1TLK&KP=%NJ<2=CF[J5G
MC\<6TTG3S]$;X><A\Y8&EFG\N77VI@K7/@HZ%VU0NVSE7?VOHZBW(\8TRDO#
ML;93TJW-&<*NXEXN+NWW]MZ"V7C*8[;=)F?\)F^CS&-B;ZK80["K[%3PR.GH
MJEG' YWMN2\T4L/!-+[):\;CR#-WM<Q\23=!(JM:QNVZ(O5NI>_%XZTB_?7L
M;HTU4*#T'E.F^.91B27K!$B@D8U7-8Q5X9-NMJ\UV<>?=MM]^M%VV+8.(KFB
M=.\%;:O@!]1JJG)%7YC=9\!]V7M14+YT8P['[Y@-577:UP5-6R21$D?ONB(W
MEU*89\\8*[I1-M%"@[)6;2RHUJ[(]439/2=>QO$IB=0'U&JO4BK\B#94ZT5/
ME0#X!L?>%W/=KOH4#X!L?>%=]MEW^10/@.7 [W+OH4^; ? ?>%=M]EV[]@C5
M7?9%7;N0#X#ZJ*G6BI\J'S8 /G0[8&;S1HYJJU7M1=T7;;<O?63#,?LFG$-P
MM5K@IJQTT+5E9ONJ*B[]:^@PR9XQVK2?^2LVT4&#Z3O27 OZ<7&J;+5^QJ6C
M5CI41N[I$=OR1>SJ-,F2N.LVMVA,SI"!@WF<6V"SY;=;?1HY*>GF6-G%U[&D
M1%7J15^1":VBT1,)B7P'U45.M%3Y4/A8!\Z&]P:DIZ_,;-25D22TTU2UDD:]
M3FKV%B^$'B]FQQ++XCM\5(LZR=)T>_G;;;=:F%L\5R1BF.LJ[NNBG0?514ZT
M5/E38^;&ZP#[PN]R[Z#X  /J-5=]D5=NY /@/JM5.M%3Y4-_@V-39;DD%HIY
MVP/E1SUD<W=$1J;KR*VO%8FT]H-4?V!.M7,3H\/O=#;Z%TDB.I4?(]_Y3]]E
M4@R(J]2*OR(1CR1DK%X[2B)U?!L?>%R<U:NW>J$ITYQ)^8Y"VWLJ$IXVIQR/
M5N_+N3TDWO%*S:W:$S.B*[ DVHUA@QK+:VU42R/@I^%$>_K7=$5>9+<SK< E
MP?HK!0I%?.&+^TZ-R<^7'SWV[S+X_2LQ$S$HU58#ZB*N^R*OS!6JG6BI\J&Z
M7S8;&WQ.QS9)D-':::1L4M0[9'N3=&^E22ZM89385<+;14LTL[I:?I)7N3EQ
M;[<NY#*<U8O&/ZRC6-=$#!:MAKM/V8 V&YT"/R'V.]%EZ-R_VFZ\*[[[=Q5:
M>UY]8QY)O,QI,:$3J^ ^\+O<N^A3X:I A]1KEZFJOS#94ZT5/E&H^?.@+LT6
MQ.QWS#KQ5W:W0U-3 ]Z,D?ONB(W?L4U>@^.6G(<AO%/>*&*KAACWC:_?S5XO
M0<MN+K7?T^ZKN5."7:JVRDM6>W6AME.D%+"YJ,C9NJ-Y$25%3K-Z7B]8M'U3
M$ZP^ ^\*]R_0-BZ7P'U$55V1%7Y!PNVWX7?0!\ V/JM5.M%3Y4 ^ ^HU5ZD5
M?D0(U5ZD5?F ^ ^[+W+] V7MY?*!\!]1%7J"HJ=:*GRH!\!]1%7J"-7?J7Z
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M@/0DN%8ZFBGCA+3 ER\6I-T^Z\7'LGG=9Y\1%X=U1WR[%,&>,VNGTG1$6U?
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MI78;3)3T:0[2HC5;N_=>]>XAFR[=2_01COOK%M-$1.KX#[PNVW5JI\J'PND
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M547E]!I<BN\]]N]3<:MC&33NXG(Q-D0UH-8QUBVZ(ZIT^H #1(
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MU$,T#=/D87BFW_ J?U$'BFW_  *G]1#- W3Y&%XIM_P*G]1!XIM_P*G]1#-
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M=/D87BF@^!T_[M#+BC;%&C&-1K&ILB(FR(<@)F9[@ "
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MRW"E9;W;(E0LB<"\]NL#9@QK?74UPI&55#/'44[TW;)&[='?(9(
M
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M]4^FKKS005#/;1OF1%3Y0-Z#JIJB*IIXYZ>1DL,B(YCV+NCD[T4[4
M
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MK;A7.C>]>U&\]_\ J)CX0UZ2R:771ZL5SJKAI&[=BNW^PV.BECEQ_32R4-3
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M;.57<^3OF["H]"T2V^$?=J"R2O\ %;DG1R,YM<B;*F_S[@>O@
M
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M[*FEM6Z4\B-1NR-?P;)MV+UGH9
M
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MU;*3S0O2;R>LKJZXU;:R\5O*21OM6MWWV3EU[EM;#8
M
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MEWBL^^:C?EMOOPIZ"S$ZAL
M                                       ^+ON1+4G/+5@5@DN-UDXI
M%:O04[5\^9W<GV@2X&HQ&\_T@QJW7;HNA]EPI+T>^_#OV$(RS55MOR]N+8W:
M*B]WK@1\B1.1L<._8YR\@+.!7>G>I\&5WJOL==;*JT7NB3>2GGYH].I5:O:A
MVY_J33XS<Z:SVVWU%XOM1S2DIU1%C;[IR]B=0$_!6N)ZHMN.5MQG(;/566]/
M:KXF2JCF3(GN7(64                 ")L
M
M                                               7D<7.X6JJJB(G
M/=>I .0-'BV56G*(ZR2R5/LB.DF6GD>C51O$G7LO:GI.65Y/:<5M,EQOE8RF
MIF)OSYN=Z&IV@;H$)PG5'%,SJY:6Q7))*EB;]'*U6.<GHWZR1Y#?+?CUJGN5
MXJHZ6CA3=SWK_!$[5] &S!7V)ZPX;E-V9;;3=.*L>GF,EC5G&O<BKV^@L%
M
M
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M-Z-[$WV-Z><_!?\ PBO'/_\ 2I_.AZ,*<5AC#DFD(M&DZ  .=4
M                            =--.V=KE9OYKE:N_>AW
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M?ZEQ$M%_[LKOUB?42[,_P6N?ZEQ$=%_[LKOUB?4!8X
M                        &HR_\%+S^QS?R*;<U.7_ (*7G]CF_D4M3[T)
MA1/@O?A%>?V5/YT/1AYS\%[\(KS^RI_.AZ,.S^H_[\_]+7[@ .%0
M                             8%G^XS_ *Y_UF>8%G^XS_KG_69X
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MBOS_ %&_7J4T%I_O%?G^H#?@
M          [0/,F-?XA?_P"KD_E4]-GF3&?\0O\ _5R?RJ>FSOX_[U/TA>X
M#@4
M       ?$_W*R\'W\$KK_F]3_,A9J?[E9>#[^"5U_P WJ?YD LX
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MJ>FLTTKY86(]Z/C5O)5V[2+8,M8UM6=$;9A*P$[08H
M              8%G^XS_KG_ %F>8%G^XS_KG_69X
M      K72O\ "[.?VY/^1916NE?X79S^W)_R LH
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M])K)\;T'[]OVG92WVU54S8::Y4DTKO:L9,USE^9%&VW@T;, %4
M                                                 ^)_N5EX/OX)
M77_-ZG^9"S4_W*R\'W\$KK_F]3_,@%G
M,*]6REO-LJ+?<(DEI:AO!(Q?RD*]30K3_;^XX]OTU+/ %8^0K3_XCC]=1Y"M
M/_B./UU+. %$:H:/839M/[[<+?9V1U=/3J^-Z.7=J[IS(EX$G-N4KV[P_4I=
MVM?XJ\F_9%_F0I#P(_N>4?+#]2@>GZRFBJZ:2GG:CXI$X7-[T(\F"V#X$GK*
M2< 1G^@M@^!)ZRC^@M@^!)ZRDF $9_H+8/@2>LIK,EPZR4E@N$\%(C98X7.:
M[B7DNQ.33YC^"UU_9W_4!7^B7WS<OU;?K4M@J?1+[YN7ZMOUJ6P
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M/ZH_1JOJ<!ZOLJN]FHUSE=LY?J4D1';-]_\ _P SOJ4D0
M                              !1.3Z*5]WR"NN,5U@C942K(C5C7=-_
MG-9Y KG\<P_NU^T]$@[*\?GK&D3_  O%Y>=O(#<_CF']VOVCR W/XYA_=K]I
MZ)!/^H9_/\'Q)>=O(#<_CF']VOVF]P71ZOQS*:*Z3W.&:.!556(Q45>7REV
MBW'9K1-9GO\ X-\@ .-0
M ,2[5T5LMM775'%T-/$Z5_"FZ[(F_(#+!3">$5B*IOT-S_TS_L']8G$?>+G_
M *9_V 7."OL U6L6;W6:WVF.L;-''TB]-"YB;;^DL%.H           /B?[E
M9>#[^"5U_P WJ?YD+-3_ '*R\'W\$KK_ )O4_P R 6<
M                 (3K7^*O)OV1?K0I#P(ON>4?I0_4I=^M?XJ\F_9%^M"D
M/ B^YY1^E#]2@>I0     T^8_@M=?V=_U&X-/F/X+77]G?\ 4!7^B7WS<OU;
M?K4M@J?1+[YN7ZMOUJ6P
M                                        !@6?[C/^N?\ 69Y@6?[C
M/^N?]9G@       +U<P ([+FV,0ROCER"V,D8NSFK4MW1?I./].\5_.*U_ZE
MOV@20&AHLPQVNJHZ:COENGJ)%V9''4-5SE[D3<WJ=8'T          "M=*_P
MNSG]N3_D645KI7^%V<_MR?\ ("R@
M !UU/WM+^@OU'C+P;OQ_5'Z-5]3CV;4_>TOZ"_4>,O!N_']4?HU7U. ]7V;[
M_P#_ )G?4I(B.V;[_P#_ )G?4I(@
M
M    !QD8V1CF2-1S')LK7)NBH<@!7&JM\QS3_'67&IL='42S2I## RG;N]R_
M,52NKU9[.]A)I8GLM8^F2%:9.-8_=;;=1/\ PB'/MU)C.0.I'UE%:;BDU3$B
M;[,5/;;>C8CVHN1TM+GF!ZA0U4C<96)]+/,UBHJ(Y7;;MZ]N: ;31;/JK+LI
MN5*F)4UEAHXD29Z1\$J.5>353;J+K*1LV56W)=<J2;#)DG@;0.;<Y&M5J.\[
M=JKOUJ7<           #8K+P?N'^B5TX>+;QO4]?Z2%FE8^#Y^"-T_S>I^M
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M4E_E5@^ N]8DG] L>^ )ZZC^@6._ $]=0(WY58/@+O6'E5@^ N]8DG] L=^
M)ZZFMR/"[%26.NG@HD;+'$KFKQKR4#=X=D;,CHYZB.%8DB?P;;[[\C?E=Z*?
MW%7?M'^Q8@
M                         8%G^XS[>_.^LSS L_W&?]<[ZS/       <B
M*U47J7D !5]YT=T[B;57&YVJGACW66:625S6INNZJJ[E832:!13/C=%$JL<K
M55%?LNWSEK^$.DKM*+RUBMZ%48D^_O?&G$5UJ-:L4L>+X#?K%14<U-1UD$2R
M-1'(^-R)Q(_O^<#NPBHT77++6F.0-6[K,B4VW%R?V+UGH?8I+-;)9,.S_%<F
MQ^"FAJ;E5-HYX6-1R2QN3V[6]BIMUH7:            K;2SA_I;G/#Q;^SD
MWW_^8LDK72O\+LY_;D_Y 64                                  .NI
M^]I?T%^H\4:$W>U676ZHK+E5>Q($2I:Z69R(Q%7?D>V9&H^-S%ZG(J'G^O\
M!@Q^LK)ZA]WN*+*]7JGF\E5=^X";VK43$&5VZWZD:G$O-ST1.I3=^4W#?SAH
M/WA4O]5;'/C>X_\ 3]@_JK8Y\;W'_I^P"VO*;AOYPT'[P>4W#?SAH/WA4O\
M56QSXWN/_3]@_JK8Y\;W'_I^P"VO*;AOYPT'[PS+3G6-7>M;26V\TE14N152
M-C]U78I>7P6,=9$]_C>X>:U5_)^PJOP;K=%3ZZ,HV.7@@;4,:Y4YJC47K^@#
MVO[.IO?F?2/9U-[\SZ3$\3L]\7U4'BAGOB^J@&7[.IO?F?2/9U-[\SZ3$\4,
M]\7U4'BAGOB^J@&=%50RNX8Y&N=W(IW$=M2<%S1FZJB;DB
M
M            (=JC7Y%;['')C%DIKTY9-JJGG7ET6W/9.U?00BU:M8?=J5+)
MEMHDL*O5&1T=PI]F*WW2+MLU-RR\QRRSX?:TN%_JFTU,YZ1M54W5SE[$3M*5
MR'/7ZA.DH<6T[6\1NW:E;<(D9$^-/<NVW3F!<>%6?&;;0K)BD-"D#^N6FX7<
M7HXD)(4UHEI9=L-NU9=+I<6,AJ8_[.V4[WNBI]UW5.?<7*     I&XX#JK/<
M*F6EU!ABIWR*Z./HU\QO8GM0+N!YKTTJL^N&J\UIDR];K:K1(BU\K&?V;UZE
MC1=NO<D^K=RRFZ:D6?%\*OOBZ9],^:J5$W1B=BNY+V 7:"FL;P?4VCO='4W/
M/8:R@C>BS0(Q?/;W>U0N5.H 5CX/GX(W3_-ZGZT+.*Q\'S\$;I_F]3]: 6<
M                                         (=K'^+#)/V1WUE&^!%]
MPR?].+ZE+RUC_%ADG[([ZRC? B^X9/\ IQ?4H'J,  #49=^#5Q_4N-N:C+OP
M:N/ZEP$2T4_N.N_:/]BQ"N]%/[CKOVC_ &+$
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M_P!9%]IKO!T>^3"KA)+$L,CKK4JZ)R[JQ=TY;EI%8^#Y^"-T_P WJ?K0"S@
M                                        !#M8_P 6&2?LCOK*-\"+
M[AD_Z<7U*7CK&NVE^2[_  1WUH>1] -5[=IK%=F5]%-5NK7,5O1OVX>%.WDH
M'NH%::1:MT&I-7<*>@M\](ZC8U[ED=NCD5=NY"RP!J,N_!JX_J7&W-1EWX-7
M']2X"):*?W'7?M'^Q8A7>BG]QUW[1_L6(
M           0G-/PVPS]HF_D)L0G-?PVPO\ :)OY";
M                 !@6?[C/^N=]9GF!9_N,_P"N=]9G@      .5&HJKU)S
M 7FFR@5EDF9XIEN#Y1&R\5-/0T/##6U$#'-?"JN[/G38KC#LFT/Q5>EHGK/6
M.:U)*FIA=(][DY\7/DB[\^1=.56KQ;BMY=C-@M];7SHC_8<D;6QU#M_RN_EN
MI4MHSO!8)G4F<8=!C=8U49O/1HL4C]]G<*\/5_L!/;!K3A%[NU):[9<GOJZE
MZ1Q,Z%R(J]B%D$4QJTX=5/9<,=I+/,Z)=VS4K&*K%^5.I25@   .BNJHJ*BG
MJJAR-AAC=(]5[$1-U.\JWPD;UXKTRKJ9C7=)<W-HF.1VW KEZP(YHY2RY]G%
MVU%N:*ZB:]U':HG+NC&MY*[;L7T^D^^$8V]UF18=0V>U+=(/9"SOIW)M&][?
M:HYW8G:6AIM94Q[![-;.!C7P4[4?P-V17+S4B6J&HEPP3+K"E=24_P#16L=P
M55<YKE= [GW<NX"-W_--2\(AIKMDMHME18E>WV0RBW5]*SM3KY_*6@_-;0W$
M*7)6NGDME2QKXUBB5[E1?_2GR$"UJU$QV3 ZVU6RX07*Y7>%:>DIZ5R2.<YV
MW7MU=?:3+2"S5=ATTQZUW./HZRGI6MEC5=^%VZKL!I_+-B_O=V_T+S7Z(W.G
MO-[S*OHNE2GFK4<WI6*QWY76BEK\#?<I]!6VE?X79S^W)_R LH
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M_P#U3O\ N(3(ALWXVJ?_ "IW_<0"9
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MEWX-7']2X"):*?W'7?M'^Q8A7>BG]QUW[1_L6(
M                0G-?PVPO]HF_D)L0G-?PVPO]HF_D)L
M                     &!9_N,_ZYWUF>8%G^XS_KG?69X        &'=[E
M26>VU%PN4[8*2!O')([J:A264ZM6+)I'6W&<1DRR=4X8Y7P(L#'NY;*NVZ?P
M4F^O[:IVD]^2BB25_1M5S=MUX4<BJJ)VC3+(\9CPRURQW&UT]1+3QK4)QLB<
MLB-1%XF\N>X%;Z9Z2Y'2YC29'4.I\;M[7\<EFHY7N:Y4[]^6RGHHU=+D5FJI
MV0TUVH)IGKLUC*AKG*OH1%-H    PKM::"[P,ANE)#51,>DC6RMXD1R=2F:
M"(B)LG)$,.ZVRAN]&ZDNE)!5TSNN.9B.3^)F "&X[IEB&/5ZUMJL5)%4[[I(
MK>)6KZ-^HF0  K72O\+LY_;D_P"1916NE?X79S^W)_R LH
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M)D0V;\;5/_E3O^X@$R
M   075V_Q8_8Z6HFQM^0(^=&) V%).#DOG;*BE4>4VD__:6?_0M__M+\R*_6
MJP4L=1>ZR&D@>_@:Z5=D5W<:#RDX5\>V_P!9 (AH_GUOR?)JZ@HL.\2STT6\
MLO0-8J<_:KLB%QE&8[E%NR379LN%.1]$RB5MSECY,E=Q>:OI5.K<O,
M     !6/@^?@C=/\WJ?K0LXK'P?/P1NG^;U/UH!9P
M                       $1U>_%CDW[#)]1+B(ZO?BQR;]AD^H#SYX$G]Z
M9'^SQ?S'K$\G>!)_>F1_L\7\QZQ &HR[\&KC^I<;<U&7?@U<?U+@(EHI_<==
M^T?[%B%=Z*?W'7?M'^Q8@                                     !"
M<U_#;"_VB;^0FQ"<U_#;"_VB;^0FP
M    8%G^XS_KG?69Y@6?[C/^N=]9G@        1W4-UG9AMT7)99(K1T?_B'
MQJJ.1NZ=6W/KV/.WL?07X95_1)]AZDK:2GKJ62FK8(YZ>1-GQR-1S7)Z44TO
M]"\7_-^U?Z5GV 4E@<6C"9A:UQVKG?=TF3V.U_'MQ]G6AZ.*(SJRV/"-4,2N
MN/4=+#6W&I]BU%)%&B\;%3V[4_)5.]-B]P           %:Z5_A=G/[<G_(L
MHK72O\+LY_;D_P"0%E
M <)ON,GZ*G,X3?<9/T5 \0^#K_B&C_65GU./<)X>\'7_ !#1_K*SZG'N$
M        "]1';7_>OSK_ +DB7J([:_[U^=?]P)$
M        $-F_&U3_ .5._P"XA,B&S?C:I_\ *G?]Q )D
M                          !\<Y&M5SE1&HFZJO8?2':Q7&HM6F>1U=(U
M73,I'HFWI39?X*!&;G?,"U5R&7#JJ)]T?0[U#G-XFQM<G)41R=?65OJ%9=(\
M/OL=ECQ&KN]V5O&^FHWN56-]*[[%J:*6*T8MI;;*ZGCB?(M(M3/5(QJR/WW<
MY.)$W7;;J(;X,E%'>KAE68U$#W2UE:Z.EGE7=W1]J)OZ0)9H5=\)N-GEAPR@
M2VST_F5-+*W:9B]SE7FI:)2;J2DLWA(PNLC(^DN-"KK@QB;(Q47DO+M7K+L
M           5CX/GX(W3_-ZGZT+.*Q\'S\$;I_F]3]: 6<
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M+4<JO5.>Z[=A)"I]$?OJY_JV_66P
M   $)S7\-L+_ &B;^0FQ"<U_#;"_VB;^0FP
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MPNSG]N3_ )%E%:Z5_A=G/[<G_("R@
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MTGU&W-1E_P""]V_9I/J K[1+[ZN?ZMOUEL%3Z)??5S_5M^LM@
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M*[4-;6U5)2U,<M12KM,QJ\V+Z3.      ,"S_<9_USOK,\P+/]QG_7.^LSP
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M(XR_<G_HJ!XGT"_Q"O\ TJG_ &/;1XET"_Q"O_2J?]CVT
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M,Z=>&-)';*Y?1](&S :J.1%3FBF#;KO07*>KAH:J.:6E?T<S6KNK'=R@9P
M           :'.\>9E.(W6RR2+&E9 Z-'IV+V?Q-\ /'6H%OU0M6/X]9;O1Q
M3T=!7L915%/MQ2.3VO$B+R3Y2QG7;7)5_N2W?,]OVE@ZRYD[#<=IIZ.VI<[I
M5U+:>CIU3?>1>WYB%4V+ZSUL#:F3,+91.E3C6G="JK%O^3NC>P"1:8UVI%3?
M)V9Q;J6FMZ1;L?$Y%57[]7)2T2IM+LUR),EJL/SVE;'=H(^DIZUG)E6Q%V54
M3["V0           %8^#Y^"-T_S>I^M"SBL?!\_!&Z?YO4_6@%G
M                                    !"]:/Q5Y/^Q/)H0O6C\5>3_L
M3P*9\"O[RR+]*/\ Y'IH\R^!7]Y9%^E'_P CTT -1E_X+W;]FD^HVYJ,O_!>
MZ_LS_J K[1+[ZN?ZMOUEL'GO$,GJ<:DJ'T]-',LS41>-53;;Y"2KJI<43G;Z
M;UG 6^")X!E%1DL-4^I@CAZ%R(G JKOO\I+
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MJ(];O[V3_P";_<D*]1&Z.1L5S1S]T1-^SY0)(#'BK(97(UCN:^@R
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M;M13I;8;4R>BF;;J5):)O!3.Z--X4[F]P&PA:K(F-<O$YK415[SD
M       5AKO9+W6VFTWG%XV2W.R5:5:1+UR,V\Y$3J5>1&(_"4QZ)C8KC9KS
M2URI][N@57*OH+V,&JL]MJJME54V^DFJ6>UEDA:YR?.J;@5#@-7<M1]1VY=5
M6J>V66V4ZT]"V?S9)7.7=55.XNP(B(FR(B)Z     BF3:A8QC-P]@WNZQ4M5
MPH_@<BJNR]1*SRS67C"KKK/D][S!\/L&!K+?#!*Q7ODD:FRJC4Y[ 7K8=2\3
MOUSBM]JO$-15R>TC:B[J;/+\NLF(T"5=_KXZ6)5V:B\W.^1$YD)TP9IG>J^2
MNPF.C?6T:IQ<+5:]F_;LI&[3:J?.M?[_ %EVA966JR0-IX(9?.:V5=MUV7K[
M0+0PO/<=S-DRX]<8ZET*[/9MPN3T[+V$H*!UJM%'@F2XQF6.TT-+4QU+:.:G
MB;T<<S'+^4C=N\OUB\3&N[TW ^E8^#Y^"-T_S>I^M"SBL?!\14Q*ZHO7XWJO
MYD LX                                             (7K1^*O)_V
M)Y-"%ZT?BKR?]B>!3/@5_>61?I1_\CTT>9? K^\LB_2C_P"1Z: '&1C98W,D
M:CF.396JFZ*AR &!XEMGP"E_=(:G*[3;XL;N3XZ&F:]L+E14C1%0DII\P_!>
MY_J' 0S17[VN?Z;2RRM-%?O:Y_IM++
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M5$7LW W)6NE?X79S^W)_R+**UTK_  NSG]N3_D!90
M                          <9?N3_ -%3D<9?N3_T5 \3Z!?XA7_I5/\
ML>VCQ+H%_B%?^E4_['MH                 8;K;3.7=6+O\JF8 (Y;&HRY
MM1O5NO\ N2,CMO\ [U3Y5_W)$                    ALWXVJ?_*G?]Q"9
M$-F_&U3_ .5._P"X@$R  %+WS2B\5^N<&:15U$VVQK&JPN1W2>:Q&KV;=:%T
M    !\<U'M5KD16JFRHO:1RV81C]KR26^VZW14UQEBZ)[XO-16[[^UZMR2
M>>L[T3OU-G*Y/IK<X[=42[OFCD>N_2*J[JG9LN_4IZ% %)Z'Z/5^'7VXY!D]
M?#77BKZEBW5&[\W*NZ=9L;SI]E%9K/39137UD5BC6/BHN-VZHUNRIMMMS4ML
M 4KK=H[4Y?>:7),6K6T&0P<+72/<J(]&]2IW*G4:'!M%<EESZFRG4"[P5D]*
MY)(XXU5RN<G)$7EML>B !5NNFE3-1;;32T50VDO-&N\$SU7A5.UJ[>G8K:S:
M$Y=?,GME;J'>H:N@H$1C8V/57N:WJ1%VV3F>FP!"M5\ H\_Q&2T3O6&5GGTT
MJ+R8]$Y;^@H9F@>?W.CM]AOV0TK\>H9.)C$>J\M^>R;;[_*>K@!@V&UT]DL]
M);:)JMIJ:-(F(J[KLB%6ZZ:7W7/[SCE7:JRDIX[:]72)/Q;NW<U>6R>A2X !
MPIV+'!&Q5W5K415.8                 $1U)N>3VJU4U3AUKBNE6DR)+3R
M.X=V;+S1?EV(79]=;8RH=2YC:J_':B-NSY*F-5B5_:UJE@9QF=FPJULKK_4.
MAAD?T<:-8KE>[;?9$0J:XYQD6H\:4N*84Q:%=V.JKRQ$Z-Z]3FMWYIM\H%UV
M>]6R\P)-:J^EJXU:CMX94<J(O5NB+R^<V!YTQ?P?+K;VU%=4Y5/1765ZR*EO
M3ABWWW3DJ$]T1R'([K#>K9E;5EJ;74K RK6/@Z=-UY^GJZP+.  !5V15[BM,
M#QK3ZONMYNF/TM)6UBU*I5.E;QNBD[4V=U%EE,7W2N_VC)*V]:9WYEIDN#N*
MKIJE.DC5W:YJ*B\P-!J#:J+&=?,"DQV!M ^Y/<RKCI_,;*U-^MJ<C>:5.9:M
M9\^L\ZK[)G<VL8G>Q=O_ .Y#<X!II7T.0NR;-KJEYR!6\,;FMVB@_039-EV.
M6HVF]==\@AR?$+IXIR.)B1K(Y-XY6]SDV7L0"/\ A2.;/9\<H85Z2LEN43F0
ML3=[D1>:HA9N5X[)D-MIJ>.YU=N6)R/5].[97<NI2"X7IG>G9=3Y1J'>8[M=
MZ)JLHVTZ<$42+V[;)S+< K9-,*A%_"R\_O%^TQ/!O@6FP6N@61TJQW6I;TC^
MMWG)S4M0K'P?/P1NG^;U/UH!9P
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MV)?>#C54ZV[=:)V)L6WIYJ-6W?(ZG%\KM7BS)(&=,L<3N.)\?8J+NO/K LL
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M\347SFMV7J4NVPVNFLEGH[;0L2.FI8TCC:G8B 1)*C4;X)C/K3&ET76M=?\
M-%NK:=M;[-;TB4ZKP;^=U;\RU2M=*_PNSG]N3_D!90
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M;]7468            K'P?/P1NG^;U/UH6<5CX/GX(W3_-ZGZT LX
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MUO)$W)(                 (;-^-JG_ ,J=_P!Q"9$-F_&U3_Y4[_N(!,@
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M\_!&Z?YO4_6@%G
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M5_A=G/[<G_(LHK72O\+LY_;D_P"0%E
M                  'B303_ !%,_65/\JGML\2:"?XBF?K*G^50/;8
M             !>H!>H".T7]])\Y(B.T7]])\Y(@                !#9O
MQM4_^5._[B$R(;-^-JG_ ,J=_P!Q )D
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M_!&Z?YO4_6@%G
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MM%!B"1+>;K5I3QJ]-^%-MU4J^XP:E4.=V_&:W,::.LN-,ZH@DX5X7.15W9_
MM;6W&+O?K';ZW&9$9>K15-JZ=JI]TVZV[^DBVH%GR>L_HEG=+96R9):D5)[:
MQ^Z*Q=]T1>_FH'5I/1Y3;-3KA1Y[>)9JY*1'44;'+T,\>_G/3THO(O0H_!9\
MESS4BBR:]V&>Q6^W4KH8&O5>*95=S1=R\            %8^#Y^"-T_S>I^M
M"SBL?!\_!&Z?YO4_6@%G
M        A^L'XK\G_89/J*!\"3[_ ,C_ %,?UH7]K!^*_)_V&3ZB@? D^_\
M(_U,?UH!ZN               !J\I_!RY?L[_J4A.BOWC</TV_43;*?P<N7[
M._ZE(3HK]XW#]-OU 64                     A.:_AMA?[1-_(38A.:_A
MMA?[1-_(38                                   ,"S_<9_USOK,\P+
M/]QG_7.^LSP        -#G6108EBMQO=3"LS*2/BZ-O6]=]D1/G4HZ?6'4AD
MMH3^@U&QEX=M0]),J=)OS1%[EVVZRU-;[-57O3BZT]O@?45D:,FBA;UR*UR+
MM]&Y6F=7^NRW2.S9):K55TD]DKHY9X',V>Q(]N-6IW 9N+:G9]<-1J'&+WBM
M%;'NVEF>LJ[]%VJU5Y*OR%\GGO)-0K+GV4X/!B"/GNS*QM1+,UG.FBV\YKU3
ML4]"            *UTK_"[.?VY/^1916NE?X79S^W)_R LH
M                                    \2:"?XBF?K*G^53VV>)-!/\
M$4S]94_RJ![;                   +U +U 1VB_OI/G)$1VB_OI/G)$
M              (;-^-JG_RIW_<0F1#9OQM4_P#E3O\ N(!,@
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ML?!\_!&Z?YO4_6A9Q6/@^?@C=/\ -ZGZT LX
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MG^;U/UH9R:O8BJ_?=7_HY?L-9X.4\=5A%?40JJQ2W6I<U53953=.P"TP
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MC&3VC)Z>:>QUC*N*%_ ]S$7DH&Y
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M'-6N3947=/R@+,
M  / 6!Y9285K#-?;A#+/302SM5D6W$JN143K/?I!)]),*GGDFEL<#I)'*YRJ
MJ\U4"N?ZTF+_ !1=/^C[21Z>Z[V+-\HI[';[?7P5$S'/1\O#PIPIOV*;V;2'
M"&02.;8J?=&JJ<U[CS)X/,3(/""2*)J-CC=5-:U.Q$W1$ ]N
M    !>H ",Q2]!<UE<USFIOU&S\;Q^\R?2AE.H:=SE5T:*JGSQ?3>](!C>-X
M_>9/I0>-X_>9/I0R?%]-[T@\7TWO2 8WC>/WF3Z4.RFN<<\J,:QR*J[<U0[?
M%]-[TAIK<U&W14:FR<?V@2,          "&S?C:I_P#*G?\ <0DMZNM'9;;/
M<+G,D%)"G%)(J<FH55)J5B3M2(*]+U![%2VNC5^R[<7&B[ 7$#4XWD5LR2B=
M5V6J;4T[7<"O:BHF_P YM@
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M<\2NO^;U7\R%G%8^#Y^"-T_S>I^M +.
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M_E=I:Y6NE?X79S^W)_R LH
M            ==3][2_H+]1XJT _Q$/_ %E7_P CVK4_>TOZ"_4>*M /\1#_
M -95_P#(#VR                        1V@_O5WZ?VDB([0?WJ[]/[0)$
M          ,*]VV"[VBLM]6Q'P5,3HG(J;\E3;<_/'+<)KK)J#58K#%))4I.
MD<"=:N8[VKN7H/T;(E78%:*W/:/*YHT]GTT*Q-1&[(Y5_*5>U43D@'?IOBM/
MAN'T%FIFHBPLWE5%WXI%]LN_RDF
M         &DSBH?2X;?)XG*V2.BF5KFKLJ+P+LJ&[-)G%+/78?>J6DC66HFI
M)&1L3K<Y6JB(!47@X87CUVTMHKE=+53UE=622/GGG;QN>O%MUJ<O!Y@98,PS
M?&Z7=*&&KZ:%NZJC$ZMD(QII?=3<'P^BL4&GLU2RG5R]*]^RKNN_NC%Q2X:F
M8_EE\OD6GTLLET=Q.B5VR1_)S ]3@K73?+LUOUYFI\HQ!;-1-BXFSJ_?=V_5
MUJ64            K'P?/P1NG^;U/UH6<5CX/GX(W3_-ZGZT LX
M                                         1'5W\6F1_L;RC_ E^\<
MD_3C^I2]=4J>:KT\R""FC=+-)2N:UC4W5R^@\<8!5ZFX)!51XY::F%E4J.EZ
M2F1^ZIU=?4![P!X[\I6MGP*3_1-'E*UL^!2?Z)H'L0'C:JU2UGI::6HJ:5T4
M$35>][J)NS43M4L_P9-1\BSNIO+,BJ89V4S&+'T<2,V55] %]
M  -9E'X.W/\ 9W_4I -$NJX?(TL'(XWRV"XLC:KGN@>B(G6J[*4K8:G),<AJ
M'T-++'&Y.)ZOB141$^4"^P5_IED]RO\ 55C+C(Q[(V(K>%B-Y[^@L
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M=G/[<G_("R@
M!UU/WM+^@OU'BK0#_$0_]95_\CVK4_>TWZ"_4>!]/LNH,)UBJ[W=&224T,U2
MQ6Q<W;N540#WX"@/ZT>(_ KAZ@_K1XC\"N'J 7^"@/ZTF(_ KAZA(\!UWQ_-
M,GI;';J2MCJ:A'*UTC=FIPHJ\_H MP                  ".T']ZN_3^TD
M1&H).@N#I',>K>/?DGR@24&#37**>9(VM>CE[S.
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M^#]Q_9W_ ,J@5MHA]^W#]6TMLJ31#[]N'ZMI;8
M                             8%G^XS_ *YWUF>8%G^XS_KG?69X
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M"
M              *Q\'S\$;I_F]3]:%G%8^#Y^"-T_P WJ?K0"S@
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M_P JFR-;DOX/W']G?_*H%;:(??MP_5M+;*DT0^_;A^K:6V
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MO^(YGZ^I_E<![:                     1Z@_OAWZ3B0D>H/[X=^DXD(
M
M           K'P?/P1NG^;U/UH6<5CX/GX(W3_-ZGZT LX          0[2^
M^7"_6N[S721DDE/=)Z:-6L1NT;>'A3^*\R8E&Z>X%19)#?Z^KN-XI95O%2SH
MZ6K=$S9%;SX4[25^2*U?'>1_^X. L<%<>2*U?'>1_P#N#AY(K5\=Y'_[@X"Q
MP5QY(K5\=Y'_ .X.'DBM7QWD?_N#@+'!7'DBM7QWD?\ [@X>2*U?'>1_^X.
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MT(!V
M '"::."-9)Y&1QIUN>Y$1/G4#F#JIJB"JCZ2FFCF9U<4;D<G\#M %8^#Y^"-
MT_S>I^M"SBL?!\_!&Z?YO4_6@%G          #II*2GI&/;2PQPM>]9'(QNV
M[EZU7TG<                       #I924[*J2I9#&VHD:C7R(WSG(G4BJ
M=P                      (IJO^+?(_P!C>4CX%']U9!^LC_W+NU7_ !;Y
M'^QO*1\"C^ZL@_61_P"X'ID                       &#?O[DK_U#_J4K
MC17[XN7R(6/?O[DK_P!0_P"I2N-%?OBY?(@%J@
M                 P+/]QG_ %SOK,\P+/\ <9_USOK,\
M          5KI7^%V<_MR?\ (LHK72O\+LY_;D_Y 64          -!EV.-R
M)EK:^I=![!KHJU.%N_&K-_-^?<WX                       (ZN,,7.$R
M/V4_C2F]C=!PIM\NY(@                      <*C[WE_17ZCQ-H7_B,=
M^OJ_K4]LU'WO+^BOU'B;0O\ Q&._7U?UJ![<
M
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MD77\P<E_=(9&&ZE4N1Y75XY+:+C;+G30>R'Q5;439NZ;=7R@3\
M                                              I//,>RK%M1I<XP
MRF;=(JZ)M-6V_J<J(B><GJIVEV "B;/8\KU(SFVWO-+4RSV*SJJQ6Z7SG3R;
M>V7KY(7LG5RZ@ ':5?X/:H[$;IPJB_\ F]5U?I(6@8=NM]);87PT%/%3Q/>L
MCFQM1J*Y>M?E4#,          &KRKEC-VW^"R_RJ:#1M473''5;U>QNS])28
M31LEB?'*U',>BM<U>I4[CJH:2"AI8Z:CBCA@B3A9&Q-FM3T(!D
M#!O_ /<5R_9I/Y5(CH4J+I58%145.C?U?K'$ZE8V2-S'M1S'(K7(O4J'3;Z.
MFM]+'2T4$<%/&FS(XV[-;SWY)\X&0          .JK^]9OT'?40'0-473BC5
MJHJ=+)U?I%A.1'(J.YHO9WF/;J&EMU,E/0P1T\#5549&U$1-_0@&2
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M(U1X9:J3.*W*X6S>-:N!M/(JOW9PIMU)W\@)*
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MEHXZC2FHG>JI)25,=1$N_P"4F^WUEBX;/+58M:IZA=Y7TT:N7O7A0#<@
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M6>6GAR^PJ[BI;3='QP=^SE55 NT
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MK8Z%MML]%1,:UJ01-CV;U;HGVH8]GQRRV6222TVNCHWR>V=#"C57YT-NG4
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MJNFE<ROGB@D21E--4N="FR[HG#U;>@M**-D,;8XF-CC:FS6M39$3T=P'8
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MWVX.K8M*@HZ>@HX:2BA9!30M1D<;&[(UJ=2(@&0
M                                                      .FMD=%
M1SR,VXF1N<F_>B*>?-.;[J?GMGJ;G;[W;::"*IDIT8^F15\U>L#T2"BKUDNI
M^!]'<\G9;;M8(WHVH=3QHQ\;/=KL7/9;G2WBU4MRM\B24E3&DD;^]% S@:YU
M]M39$8ZY42/7L6=N_P!9ER5=/' V>2>)L+MMI'/1&KOU<P.X'QKD<U'-5%1>
M:*G:=<=3!(^1D<T;G1KL]&N15;\O<!V@U[;U:W2]$VXT:R]7 DS=_HW-@ !%
M-5;U5X[I[?;O;7-;64D'21JYO$B+Q(G5\Y6V)+JOD>,VV\09!:XXJV%)DC=3
M)NW?L O0%&TN;9QA^=6FRYU[ KK?=7=%3U%,Q&.:].U40NRHJ8*6/CJ9HX8]
M]N*1R-3Z5 [@8M'<:*NW]AU=/4;<UZ*1';?0=E554])'TE5/'"S?;BD<C4W^
M<#N!B4=RH:YVU'64]0J)OM%(COJ*YO&H\]+K#;\28E)'0.A=+/.]Z<2KRV;U
M\@+1!\8J*U%1=T7FBD'U6SMF&6N!M'"E9>ZU_145'SWD=OS7Y$ G(*8IL.U(
MOU,VY7K+?%5?MQ1T=)$G1)VHCN??UF1IAGF1NS.LPK/*-C;Q!&LT%7 S:.:/
MT[<DY 6^#'JZVEHH^.KJ(8&+U.D>C4_B?**OI*YJNHJJ"=J=:Q/1VWT 9(*M
MJLQNS-?*?%FR1^*'VY:A6<"<7'RY[_.=N 9==;SJ5F-FKI(W4-M>U*=K6;*F
M^_6O:!9H/A5.GN9WB]:MYI8:Z2)UNMBHE.UK-E;[7K7MZU M<&*^X4<395DJ
MH&)"J)(KI$3@5>_N/M'<*.M1RT=5!4(WKZ*1';?0!D@Z)*NFBD=')41,D:WB
M5KGHBHG?MW'5272@K)%CI*VFG>GY,<J.7^"@9@.$\T<$;I)Y&1QMZW/79$^<
MQJ2ZV^LDZ.DKJ:>3W,<K7+_!0,P'QSFM:KG*B-3FJKV&##>;;-/T,-PI'R[[
M<#9FJN_=MN!G@ZI:F"%[&2S1L<]=FHYR(KE]'>?9YXJ>-9)Y611IUN>Y$1/G
M [ 5EK?EUTQ2UV2HL<L375=:R&17MXD5BJG5])8C*AC*-D]0]D;5:BN<Y=D0
M#)!KXKW:YINBBN-(^3?;A;,U5W^3<B>LV9383A-9<J#H'U[41L3)5[UVXMNW
M8"> @=]NE\N.GE-6XQ<+=%>)&Q.?+.YJ1)O[9.Y%)E2/D9;X'ULD?2I$U97H
MNS>+;FJ>C<#*!@07FV5$W0P7"DDEWVX&3-5=_DW,N>>*GCXZB5D3-]N)[D1-
MP.P&#-=[=!-T,U?2QR^X=*U%^C<S6N1S45JHJ*FZ*G:!]
M                                   &!9_N,_ZY_P!9GF!9_N,_ZY_U
MF>                                          -+5Y38:.HD@J[M10
MS1KPN8^5$5J]R@;H&IH<CLM<JMH[K13+OMLR9JKO])M@         "JB(JJO
M)#0OS#'8WJR2]4#7)R5%F3= -\#66Z_6FY*C:"Y4E0Y5V1(Y45=_DW-F
M X2RQPMXI7M8W?;=R[(!S W0+U  1W(\UQO&W,;?+S24;W+PHV1VZ[_(FZF;
MC^0VG(*5*FR7"GK8%_*B?OM\W6!M0!U@ 8E;<:.BD@965,4+YW<$2/=LKU[D
M/DERHHJ^*ADJHFUDK>)D*N1'.3O1 ,P'PQ*FYT5+60TM150QU,J;QQ.=LY_R
M(!F (             X3RQPQ/EF>UD;$XG.5>2)WG70U=/74S:BCFCGA?[5[
M%W10.\   =*U4'L=\Z31K"Q%5ST<BHFW7S.%OK::OI6U%%/'/ _JDC=NB@9(
M
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M^HMUZM:)*V1LSMGL3VR+\IQU+?6X/J?8LYDHI*NR/IDHZOH&\3XMTY.V^?\
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MNX>%W'XI:G#MSWZ).6Q&O!N:]FF%$DC'L7I9.3V[+U@6B
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M/Q(SLW56\_X@7ZG4 G4
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MR2,B1'.7Y=C/<QKVJU[45J]BIN<@!QV[DY!C48FS41$[D38Y
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M%TM16OJ&=$[=.%=MMRQ@ *WU@P&KRMMJNEAJFTF06>7IJ5[D\R1?<N]'(L@
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MWV-4US'<;Y(U397-;OR78V&D^G%TQ; KYC=SGA>VH=(RFE8N_FN1417?P+<
M%(Z:8GFMEPV[X9>*.@]@)22LHZV.3F][TV1%3N-QBVF+W:,IAF2/1LKF.:LD
M#M^!V^Z*G>6L$ HVST.K^.VEM@H8;/74\35CIKA,_9T;$ZN)N_-208/IK48U
M@=]H)*I*J]WELDM3*[DSI7-VV3T%I "%Z08U78E@-OLUT=$ZK@1W$L:[MYN5
M4-%IG@MUQO/\MO->ZG6DNCT= D;MW=G7]!:( (
M
M
M
M     # L_P!QG_7/^LSS L_W&?\ 7/\ K,\
M
M
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MZ+?GP\>^VVX$^!QCD9*QKXW(]CDW1S5W14]!R
M
M                      P+/]QG_7/^LSS L_W&?]<_ZS/
M                       !N-P &X    !N  &X
M
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MYR*NZDY-3B=AI,9Q^CM%OXUIZ9G"CGN5SG+VJJKVJ;8
M
M                           # L_W&?\ 7/\ K,\P+/\ <9_US_K,\
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MSU2G4
M
M
M
M                           8%G^XS_KG_69Y@6?[C/\ KG_69X
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MEPSS),PI[A<+/3X_C=.Q6RTLK6NFEDV7947;JWV+@&P
M
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M' [Q5RUL-L:V:BJ9O;.C=U)\Q<P
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M<4RBT97;&U]BK&55.O)W#UL7N5.Q3=
M
M     JVZZ=7&LN5541US6LED<]J*J\D5=]BT@!47DQNGQ@S^)\;I?<6[\-=&
MBKU[;EO "HO)C=/C!G\2<8-8)\?M\T%3,DSY'\>Z*24; # O],ZKL=PIXT5S
MY8'L:B=:JK50SP!37@S7&)F(UEBJY&PW:W5DL<]*[D]GG+MNG;R0CNLF*Y)8
M+;?LE@SNX1,:KIX:-%1J)S]JGR%AYQI1:LDNGC>AJJJRWM&KM64+N!7.['.1
M/;*GI[S2VG1&EDK(:K,,@NF22PNW8RKD5(]NY6[\T B5VJIZW+M%JBJE=-/*
MB.?(Y=U<O#UJ26Q?C>U(W3EXN9_*I/+Q@MINE_Q^ZR-?%+9%WI8XEX6)Z%0[
M[?B%NHLGN]]9TCZJYQ-BG:]=V<*=R 41@J2/\&/)FTJ*Z?V34\H_;;=(G=Z-
MSOTYQB_W# +956O41M/;$IT184C:C8DVYM7_ .I:^(Z763%;_7W*U/J6QUC7
M-?1NDW@1'+NNS>HCM?H#BM15U$E//<J*GF>KW4U-4N9%NO<U (=-9[;:M!KS
M36J^1WNEEK=WS1LX6HY7IQ-V)[JU2P46@MVIJ6-L4$5O1K&(FR(FR$CFT\L3
ML-3&::G]BVU.%=H>2JJ;<U7M5=C:9)C='D&,5-BK5D2CJ(NA<K%V=L!2F3*U
M-&]/U7A1/9E+S=MMUFTUBV76#2;AVX?9CMMNKL)W?M-++>L(HL7JWU*4-)P+
M$]C]GHK>I=SY)IM:IJG%*B>>KEFQSG2O>_=7_I+V]0$,TEIX7:T:EU#XF+,R
MI:QLBIS:B]:(IVP,:SPE;CP-1N]H8J[<MUV7K+!Q[#;?8LCOMZHW2K57B1))
MT<[=J*G<$PZWIFTV4(Z;QA+3)2N;Q>9PIZ.\"D:+@30[/>EVZ)+E/Q[^YXTW
M_AN6O2U^*II3&]LU$W'O8'))%3@1O#VIW[_Q.^+3>SQXM=K CIUHKE.^>;=V
MZ[N7=43T$9J= \2GK^E5U>VD5R.6B;4.2%=NSAZM@,SP<(:R+2NWI7(Y$=)(
MZ!'>]*OF_-UDDRW-[3C%XLMLNRS-DN\JP0R-;YC5_P#4O9UDEI*6&CIHJ>EB
M9#!$U&,C8FR-1.Q#3YGB=JS"S26V]0)+$J\3)$Y/B=[IJ]B@4WKK9[+AE%09
M9BKV6_(FUK(FN@<CO9#7JO$CDZU3DG,S:N=:+PE[-77-6T\-;9N".1Z\*.DV
MYM0DV,Z*8U8[U!<GR5UQEI_N3*V996,7L5$7M0DF?X%9<XHH8+Q$]LL#N*&I
MA=P2Q]Z(Y.I% @FL%6RKU+TUH:1S9I6W+IY&QJCE8UJMW5>Y"Y>T@>!:66+#
M;E-<:1U565\C48D]9*LCHTY[\._5OV_(3Q$ I/0UC5U'U(DV3C]GHG%V[;'5
MH@QOE=U5<C6\27!$1=NS=>19F+89;<;O%ZN5"Z99[K-TTW&[=$7T''%\)MV.
M9#?[Q0NF6IO,R35"/=NU'<^KZ0*&F9([(-;T@3S^'\E.>V_/^&Y;.G=?86Z.
MVY\<U/';&T*<:3*FR<N?$AG+B-+B];E626>CEN%SNC5DEI7N\V14_)3Y3SM[
M)TY?#-655GR6EK7.59;(SC6'C7?=J)U*W?T 27"KE[%T#NU-1M626Z7.2AIT
MCY<WJB)M\RF_\(NTMLNAMGM=*G1)35=+$WGOPKNO/Z3;Z2Z;(N$XX^]I4TDE
M+6+<XJ-KN%$5516->G;LB(6'G^&V_-[(RUW9TK8&3LJ$6)=EXFKR IS2J.;3
M[4E]HR]S*NJOL+)J&\2)NZ1>'G"KNSY#<:=RMH]>\_9?)(8ZV?HW4*2KYSH=
MUVX=_E+&S3![7E=NHJ:MZ2&:BD9)354*\,L2M[G>GM*BUF=CB9;34V9V>\4W
M0PM2BO=M55=.G)'-DVV5-O\ <#>W::V3>$M9/83N.O;;9/9"M5%;P\MNKM+F
MF9QPR,3K<U4/,^BMEHJS5J.[8G0W-MAHZ-\<M7<FJDDDKMN6Z]:<CTVG- */
M\'&LAM%1E>*5[TBN])<I)EC<O)['KR5O?U$ESS5'&[9:LAH'U[([M2QO@2EF
M8YKI'N;LB-Y<]]S/S[3"T9=6P7))I[9>($7HZVC=P/WZTXMO;;+WD+G\'VFN
MC7U.29/=;I=FI_85DB[+$O8NW:!$LUM%79O!:M5-<H'T]6ZL@FDB?R5BN>J_
M4>B+%4P0X[;72S1L:VEB55<Y$3VB$3JM.YL@P!,9S2\273AE:]*J-G1/5&^U
M1=NM>OF1]= K&]B1S7J^R0HFR,6K=MMV=H&%IW61Y3KQE=\HO[2VT5,RCAJ8
MUW9*Y-D<F_;ML7>:3$,7M6)6>.V6.E934S.:\*<WN[7*O:INP
M
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MV-[57FU.S?8O)"D-/%JM0-4:O,YZ6IIK-;XO8UL69G Z7?VSMN[FI=Z
M
M
M         !4,9U!2NDZ1::%9/=*Q-S) !   VYG5/3Q3MX9XV2(G4CVHIV@#
MKAACA9PQ,:QO<U-D.Q
M                                        ,"S_ '&?]<_ZS/,"S_<9
M_P!<_P"LSP                                   ZYX8YXW1S,;)&Y-
MG-<FZ*1&DTNPJDN25]/C=OCK$=QI*D?/?O)D ,>IHJ>IHW4M1"R2F<G"L:IY
MJIW;'='&V.-K(T1K&ILB)V'( 8#;/;VW7QDE)"E?P<'3HWS^'NW-=689CE;5
M2U-79J.:>5RN>]T>ZN5>TD  U]ILMNM$716RBIZ6/NB8C3D^T4#[JRYOI(G7
M!C.C;.K?.1O=N9P ^*U%147FB\EW[3!M=HH+4R1EMI8J9DCN)R1ILBKWF> /
MFQJ68S967);@VV4B5JKNLW1IQ;]YMP!\5NZ*B[*B\E0U=%CEGH:Y]91VVEAJ
MGKNZ5D:(Y3:@!L85+:J&DKJFLIJ6**JJ=NFE:W9S]N\S0!B7.VT=TIG4UQIH
MJF!W6R1NZ'RV6RBM=,E/;:6&FA3J9$WA0S  ,1;;1K<FW!::):U&=&DW#YR-
M[MS+ #8U-5C=GJZ]M=4VRDEJV]4KHT5QM@!\1NR;)R0QKA;Z6XT_05\$=1#N
MCN!Z;ING4IE ##N-KHKE1^Q*^FBJ*;=%Z-Z;MY=1\N-KHKC0+15U-%/2KM_9
M/3=O+J,T 5OJ+;LKCKJ.?'*:@N=D;"L55::E$3=$ZG,7;KVY$>QC$,@OV5VF
MXY!:J"R8_:=Y:.WTZ[O69>6[E1.KM+I1-@B 8MNMU);8'0T%/%3Q.<KU;&W9
M%<O6IQI;714E;4U=-311U-3LLTK4V<_;JW,P 1^]6!'4]SJ[$V&BOM5%PI5H
MWFKD]KQ=Z<D*=N5KU$K[;4T#\6L;<AJ(EADO#7-1JL7DNR;<E5#T$-@(UIQC
MKL4PRUV:21))::)$D<G4KEYK_%3;W:TT%WIT@NE+%50HO$C)&[HB]YG ".P8
M/C,$S98;'0-D8N[7)$G)3>R4T,E,^G?&Q8'L5CH]N2M7DJ;': -8E@M:6A+5
M[!@\7)U4_#YB<]^KY371X+C$;T>RQ4"/1=T7HDZR2 #A%$R*-L<36L8U-D:U
M-D1#F@
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M<O<ZTM52U$BO;&_EL_B7JZP/0B )U
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M2)T].RHAYU#.Q&_^I>Q#:8=JU0Y!E*6"JM-RM5?*Q9J=*N/A22-$WWW[%7N
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MENUGJG4KWOY/>Q/:N5"U
M
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MO M+,=PRJDK*&&2IN+N25=4Y9)6IW(J]2 3J-J-8C4ZD38^@
M
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MSN#DA1.;7M;RXD7Z"ZS"LUJH;+;H*"U4L5+1PIPQQ1-V:TS0
M
M
M    !Q>QLC%8]$<U>2HJ;HIR &/!14U.]7P4\4;E[6,1%,@  %0 #&FH*6=_
M'-30R/\ =.8BJ=[&-8U&L1&M3DB(FVQR
M
M
M  !T5%%35"HM1!%*J=2O8BG;'&R-B,C:C&)U(U-D0Y    .+F->U6O:CFKR5
M%3=%.FGHJ6G?QP4\4;N]C$13( !$
M
M
M
M
M
M
M
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M_P!L<KIK;:([C!(Q?_R^E17*GRM,/5ZN9EE7#70R-FM5L6BEB;OSCJ)'HO\
M(!?]%<:2MJ:N"EJ(Y9J5Z,F8U=UC<J;HB_,997VG*(F99ZJ)_P#KH?\ ME@(
MJ\P/H"<P
M
M
M
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MMV;5;]7$GH)9L-@"
M
M
M
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M8E@==1WZ"\Y'<*6LK*-CHZ1*.G2!C4?[97(B><JD_EABG9PSQLD;OOLY-TW
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M6.-&[_0=M+24](QS:6"*%KEXE2-J-15[^0'< ?$ ^@
M
M
M
M
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MS^RFR3[.CBDY-1'*GG<*<@+?[3Z?$ZSZ
M
M
M
M
M             V                V     -@          V
M
M
M
1                   '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
